{
  "category": "Anatomic Pathology",
  "subject": {
    "name": "Hematopathology",
    "url": "https://app.pathprimer.com/curriculum/f534cbd3-a700-4198-a455-0f5cda11d3c5",
    "lessons": {
      "Bone Marrow: Nonneoplastic Lesions": {
        "name": "Bone Marrow: Nonneoplastic Lesions",
        "url": "https://app.pathprimer.com/lesson/92495282-ce4a-41b9-a2f4-c2339cb2cc79",
        "topics": {
          "Overview of Anemia": {
            "name": "Overview of Anemia",
            "url": "https://app.pathprimer.com/document/1a86f912-8cd9-426c-b831-7e114f935caa/lesson/92495282-ce4a-41b9-a2f4-c2339cb2cc79",
            "content": {
              "TERMINOLOGY": {
                "Definitions": [
                  {
                    "text": "Decreased RBC count, hemoglobin, and hematocrit levels compared to age- and sex-defined normal rangesRBC parameters normally highest at birthRBC count, hemoglobin, hematocrit levels higher in males after pubertyDefinition of anemia in advanced-aged adults problematicKey issue is distinction between normal physiologic age-related declines in RBC parameters vs. pathologic anemiaRBC count, hemoglobin, and hematocrit decline with age, while mean corpuscular volume (MCV) and RDW increase with ageAging-related declines in RBC parameters likely linked to stem cell factors ranging from decline in number of stem cells to possible clonal hematopoiesis as well as other factorsAnemias can generally be categorized into decreased proliferation, impaired maturation, or decreased RBC survival mechanisms",
                    "sub_points": [
                      "RBC parameters normally highest at birth",
                      "RBC count, hemoglobin, hematocrit levels higher in males after puberty",
                      "Definition of anemia in advanced-aged adults problematicKey issue is distinction between normal physiologic age-related declines in RBC parameters vs. pathologic anemiaRBC count, hemoglobin, and hematocrit decline with age, while mean corpuscular volume (MCV) and RDW increase with ageAging-related declines in RBC parameters likely linked to stem cell factors ranging from decline in number of stem cells to possible clonal hematopoiesis as well as other factorsAnemias can generally be categorized into decreased proliferation, impaired maturation, or decreased RBC survival mechanisms",
                      "Key issue is distinction between normal physiologic age-related declines in RBC parameters vs. pathologic anemia",
                      "RBC count, hemoglobin, and hematocrit decline with age, while mean corpuscular volume (MCV) and RDW increase with age",
                      "Aging-related declines in RBC parameters likely linked to stem cell factors ranging from decline in number of stem cells to possible clonal hematopoiesis as well as other factors",
                      "Anemias can generally be categorized into decreased proliferation, impaired maturation, or decreased RBC survival mechanisms"
                    ]
                  }
                ]
              },
              "EPIDEMIOLOGY": {
                "Incidence": [
                  {
                    "text": "Worldwide incidence of both iron deficiency anemia and hemoglobinopathies conferring resistance to falciparum malaria is very high, affecting billions of people1/4-1/3 of world's population suffers from anemia, 1/2 of which is iron deficiency anemia",
                    "sub_points": [
                      "1/4-1/3 of world's population suffers from anemia, 1/2 of which is iron deficiency anemia"
                    ]
                  },
                  {
                    "text": "Acquired anemia is generally more common than constitutional anemias (malaria resistance is exception)Most common acquired anemia by far is iron deficiency anemiaOther common acquired anemias include anemia of inflammation (AI), anemia of chronic kidney disease",
                    "sub_points": [
                      "Most common acquired anemia by far is iron deficiency anemia",
                      "Other common acquired anemias include anemia of inflammation (AI), anemia of chronic kidney disease"
                    ]
                  }
                ],
                "Age Range": [
                  {
                    "text": "Constitutional (familial) anemias generally manifest in neonatal period or early infancyMilder forms of constitutional disorders may not manifest clinically until after early childhood",
                    "sub_points": [
                      "Milder forms of constitutional disorders may not manifest clinically until after early childhood"
                    ]
                  },
                  {
                    "text": "Iron deficiency anemia is very common in women of reproductive age and childrenAffects patients of all ages but predominates in children and adult females living in poor socioeconomic conditions",
                    "sub_points": [
                      "Affects patients of all ages but predominates in children and adult females living in poor socioeconomic conditions"
                    ]
                  },
                  {
                    "text": "Other acquired anemias can occur any time throughout life, although they predominate in adults in resource-rich countries"
                  },
                  {
                    "text": "AI can occur in wide age range of patients but generally predominates in adults"
                  },
                  {
                    "text": "Anemia is common in advanced-aged adults"
                  }
                ],
                "Ethnicity Relationship": [
                  {
                    "text": "Constitutional (familial) anemias that confer resistance to malaria infection show striking ethnic and geographic disease distributionMarkedly increased incidence in those areas in which falciparum malaria is endemicSickle cell trait confers resistance to RBC invasion by falciparum malariaSimilar malarial resistance mechanisms described in other germline anemias, including thalassemia, glucose-6-phosphate dehydrogenase (G6PD) deficiency, and other hemoglobinopathies",
                    "sub_points": [
                      "Markedly increased incidence in those areas in which falciparum malaria is endemic",
                      "Sickle cell trait confers resistance to RBC invasion by falciparum malaria",
                      "Similar malarial resistance mechanisms described in other germline anemias, including thalassemia, glucose-6-phosphate dehydrogenase (G6PD) deficiency, and other hemoglobinopathies"
                    ]
                  }
                ],
                "Sex": [
                  {
                    "text": "Typically, constitutional anemias do not manifest strong sex associationExcept for G6PD deficiency, which is X-linked autosomal recessive disorder",
                    "sub_points": [
                      "Except for G6PD deficiency, which is X-linked autosomal recessive disorder"
                    ]
                  },
                  {
                    "text": "Acquired iron deficiency anemia is more common in female patients of reproductive age due to increased iron requirements during pregnancy and iron loss with menses or childbirth"
                  },
                  {
                    "text": "Acquired VEXAS syndrome is X-linked disorder affecting middle-aged to older male patients who manifest with autoinflammatory symptoms and anemia (vacuoles,enzyme,X-linked,autoinflammatory,somatic)"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Constitutional (Familial) Anemias": [
                  {
                    "text": "May result fromBone marrow failure to produce adequate RBCsIsolated erythroblastopenia in Diamond-Blackfan anemiaEventual multilineage bone marrow failure in Fanconi anemiaDefective hemoglobin productionDefects in hemoglobin synthesisHemoglobinopathies, such as sickle cell anemiaDefects in globin chain synthesis rate in thalassemiasDefects in porphyrin ring synthesisSideroblastic anemias both germline and acquiredIntrinsic erythrocyte survival defectsHereditary spherocytosisG6PD deficiencyPyruvate kinase deficiencyHereditary microangiopathic anemias, such as germline ADAMTS13 deficiency, linked to extrinsic defect reducing RBC survival",
                    "sub_points": [
                      "Bone marrow failure to produce adequate RBCsIsolated erythroblastopenia in Diamond-Blackfan anemiaEventual multilineage bone marrow failure in Fanconi anemia",
                      "Isolated erythroblastopenia in Diamond-Blackfan anemia",
                      "Eventual multilineage bone marrow failure in Fanconi anemia",
                      "Defective hemoglobin productionDefects in hemoglobin synthesisHemoglobinopathies, such as sickle cell anemiaDefects in globin chain synthesis rate in thalassemiasDefects in porphyrin ring synthesisSideroblastic anemias both germline and acquired",
                      "Defects in hemoglobin synthesisHemoglobinopathies, such as sickle cell anemiaDefects in globin chain synthesis rate in thalassemias",
                      "Hemoglobinopathies, such as sickle cell anemia",
                      "Defects in globin chain synthesis rate in thalassemias",
                      "Defects in porphyrin ring synthesisSideroblastic anemias both germline and acquired",
                      "Sideroblastic anemias both germline and acquired",
                      "Intrinsic erythrocyte survival defectsHereditary spherocytosisG6PD deficiencyPyruvate kinase deficiency",
                      "Hereditary spherocytosis",
                      "G6PD deficiency",
                      "Pyruvate kinase deficiency",
                      "Hereditary microangiopathic anemias, such as germline ADAMTS13 deficiency, linked to extrinsic defect reducing RBC survival"
                    ]
                  }
                ],
                "Acquired Anemias": [
                  {
                    "text": "Includes anemias caused by production, maturation, and survival defects of erythrocytesIron deficiency anemia and AI most common worldwide",
                    "sub_points": [
                      "Iron deficiency anemia and AI most common worldwide"
                    ]
                  }
                ],
                "Mechanistic Classification of Anemias": [
                  {
                    "text": "Production defectFailure of bone marrow to produce adequate erythrocytes may result fromDiverse bone marrow failure disordersDefective erythropoietin production by kidneyBone marrow effacement by infiltrative or fibrotic processAplastic anemiaRed cell aplasiaParoxysmal nocturnal hemoglobinuria (PNH), some types",
                    "sub_points": [
                      "Failure of bone marrow to produce adequate erythrocytes may result fromDiverse bone marrow failure disordersDefective erythropoietin production by kidneyBone marrow effacement by infiltrative or fibrotic processAplastic anemiaRed cell aplasiaParoxysmal nocturnal hemoglobinuria (PNH), some types",
                      "Diverse bone marrow failure disorders",
                      "Defective erythropoietin production by kidney",
                      "Bone marrow effacement by infiltrative or fibrotic process",
                      "Aplastic anemia",
                      "Red cell aplasia",
                      "Paroxysmal nocturnal hemoglobinuria (PNH), some types"
                    ]
                  },
                  {
                    "text": "Maturation disorders affecting erythrocytesNuclearImpaired DNA synthesis and mitosisDeficiencies of vitamin B12 or folateChemotherapeutic agentsCytoplasmicDefective production of hemoglobinIron deficiencyGlobin chain production disorders, such as thalassemiaHeme biosynthetic disorders, such as sideroblastic anemia",
                    "sub_points": [
                      "NuclearImpaired DNA synthesis and mitosisDeficiencies of vitamin B12 or folateChemotherapeutic agents",
                      "Impaired DNA synthesis and mitosis",
                      "Deficiencies of vitamin B12 or folate",
                      "Chemotherapeutic agents",
                      "CytoplasmicDefective production of hemoglobinIron deficiencyGlobin chain production disorders, such as thalassemiaHeme biosynthetic disorders, such as sideroblastic anemia",
                      "Defective production of hemoglobin",
                      "Iron deficiency",
                      "Globin chain production disorders, such as thalassemia",
                      "Heme biosynthetic disorders, such as sideroblastic anemia"
                    ]
                  },
                  {
                    "text": "Erythrocyte survival defects includeIntrinsic defects in erythrocytesMembrane defects: Hereditary spherocytosisHemoglobin defects: Sickle cell anemiaEnzyme deficiencies: G6PD deficiencyExtrinsic factorsTurbulent blood flowMicroangiopathiesDiverse immune-mediated hemolytic anemias",
                    "sub_points": [
                      "Intrinsic defects in erythrocytesMembrane defects: Hereditary spherocytosisHemoglobin defects: Sickle cell anemiaEnzyme deficiencies: G6PD deficiency",
                      "Membrane defects: Hereditary spherocytosis",
                      "Hemoglobin defects: Sickle cell anemia",
                      "Enzyme deficiencies: G6PD deficiency",
                      "Extrinsic factorsTurbulent blood flowMicroangiopathiesDiverse immune-mediated hemolytic anemias",
                      "Turbulent blood flow",
                      "Microangiopathies",
                      "Diverse immune-mediated hemolytic anemias"
                    ]
                  }
                ]
              },
              "CLINICAL IMPLICATIONS": {
                "Clinical Approach": [
                  {
                    "text": "Assess age at onset and duration of anemia"
                  },
                  {
                    "text": "Assess severity of symptoms, sudden vs. gradual onset of symptoms, and episodic vs. sustained symptomatology"
                  },
                  {
                    "text": "Clinical history should include evaluation for blood loss, menstrual and GI symptomatology"
                  },
                  {
                    "text": "Dietary history, including homeopathic remedies and dietary supplements"
                  },
                  {
                    "text": "Exposures, including medications, possible hobby and occupational exposures, alcohol ingestion"
                  },
                  {
                    "text": "Family history of anemia or other disorders"
                  },
                  {
                    "text": "Racial/ethnic background"
                  },
                  {
                    "text": "Evaluate for underlying chronic disease, including liver and renal abnormalities, collagen vascular disease, endocrine abnormalities, and chronic infectionsSome underlying chronic illnesses linked to AI may be clinically occult",
                    "sub_points": [
                      "Some underlying chronic illnesses linked to AI may be clinically occult"
                    ]
                  },
                  {
                    "text": "Evaluate for underlying neoplasms, including plasma cell neoplasms, myelodysplasia, lymphomas, solid tumorsAlthough AI predominates, incidence of folate deficiency in hospitalized cancer patients is up to 7% in recent studies",
                    "sub_points": [
                      "Although AI predominates, incidence of folate deficiency in hospitalized cancer patients is up to 7% in recent studies"
                    ]
                  },
                  {
                    "text": "Prevalence of anemia increases with agingDetermining cause of anemia in older adults is problematicUp to 1/3 have been designated as \"unexplained\" anemiaClonal cytopenia of uncertain significance (CCUS) &/or myelodysplasia are considerations in these patientsReduced health-related quality of life and increased overall mortality for older adult patients with \"all-cause\" anemia",
                    "sub_points": [
                      "Determining cause of anemia in older adults is problematicUp to 1/3 have been designated as \"unexplained\" anemiaClonal cytopenia of uncertain significance (CCUS) &/or myelodysplasia are considerations in these patients",
                      "Up to 1/3 have been designated as \"unexplained\" anemiaClonal cytopenia of uncertain significance (CCUS) &/or myelodysplasia are considerations in these patients",
                      "Clonal cytopenia of uncertain significance (CCUS) &/or myelodysplasia are considerations in these patients",
                      "Reduced health-related quality of life and increased overall mortality for older adult patients with \"all-cause\" anemia"
                    ]
                  }
                ],
                "Physical Exam": [
                  {
                    "text": "Evaluate for stigmata of constitutional disorders"
                  },
                  {
                    "text": "Evaluate for jaundice, spleen size, mucosa, nails, fingers, neurologic features, features of underlying chronic diseases"
                  }
                ],
                "Laboratory Tests": [
                  {
                    "text": "CBC and differential cell counts and blood smear review"
                  },
                  {
                    "text": "Evaluate size, shape, hemoglobin content, and uniformity of RBCs"
                  },
                  {
                    "text": "Assess for polychromasia and nucleated RBCs"
                  },
                  {
                    "text": "Assess for any abnormalities of RBC form, RBC inclusions, organisms, agglutination, rouleaux"
                  },
                  {
                    "text": "Assess all WBC lineages and platelets"
                  },
                  {
                    "text": "Reticulocyte count: Determine whether there is appropriate bone marrow response to anemiaLow: Production or maturation disorderNormal: Some cases of AIElevated: Hemolytic anemias",
                    "sub_points": [
                      "Low: Production or maturation disorder",
                      "Normal: Some cases of AI",
                      "Elevated: Hemolytic anemias"
                    ]
                  },
                  {
                    "text": "Customize further laboratory testing based on whether anemia is microcytic, normocytic, or macrocytic"
                  },
                  {
                    "text": "Key to distinguish iron deficiency anemia for AI by laboratory testing"
                  },
                  {
                    "text": "Assessment of iron levels and stores as well as folate, vitamin B12, and methylmalonic acid levels are commonly used in work-up of anemias"
                  },
                  {
                    "text": "Assess serum copper and ceruloplasmin levels in patients who have undergone bariatric surgery, patients taking zinc or homeopathic remedies, and patients with celiac disease"
                  },
                  {
                    "text": "Hemoglobin electrophoresis for various hemoglobinopathies, including sickle cell anemia/trait, thalassemias, hemoglobin C disease, and others"
                  },
                  {
                    "text": "Bone marrow examination necessary only in minority of anemic patients in whom cause cannot be determined after clinical, hematologic, and other laboratory testing are completeAlso needed in patients with possible CCUS, myelodysplastic syndrome, or germline disorder",
                    "sub_points": [
                      "Also needed in patients with possible CCUS, myelodysplastic syndrome, or germline disorder"
                    ]
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "Molecular/genetic testingFor selected constitutional (familial) disorders (germline mutation gene panel)Evaluation of fibroblasts recommendedAssessment for underlying CCUS, much more prevalent in older patients (myeloid gene panel)Assessment forUBA1mutations in rare male patient with possible VEXAS syndrome",
                    "sub_points": [
                      "For selected constitutional (familial) disorders (germline mutation gene panel)Evaluation of fibroblasts recommended",
                      "Evaluation of fibroblasts recommended",
                      "Assessment for underlying CCUS, much more prevalent in older patients (myeloid gene panel)",
                      "Assessment forUBA1mutations in rare male patient with possible VEXAS syndrome"
                    ]
                  },
                  {
                    "text": "Flow cytometry of bloodPNHReticulocyte count",
                    "sub_points": [
                      "PNH",
                      "Reticulocyte count"
                    ]
                  }
                ],
                "Electron Microscopy": [
                  {
                    "text": "Transmission electron microscopy of some utility in diagnosis of congenital dyserythropoietic anemia"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Microcytic Anemia": [
                  {
                    "text": "Consider iron deficiency, AI, thalassemia, hemoglobin E, and, rarely, heme biosynthetic defects"
                  }
                ],
                "Normocytic Anemia": [
                  {
                    "text": "Assess uniformity of erythrocytes"
                  },
                  {
                    "text": "Assess reticulocyte count"
                  },
                  {
                    "text": "Assess all lineages"
                  },
                  {
                    "text": "Suspect AI"
                  },
                  {
                    "text": "Bone marrow examination may be necessary to exclude other considerations"
                  }
                ],
                "Macrocytic Anemias": [
                  {
                    "text": "Evaluate erythrocytesOval macrocytesFragmented formsAgglutinationTargetsPolychromasia",
                    "sub_points": [
                      "Oval macrocytes",
                      "Fragmented forms",
                      "Agglutination",
                      "Targets",
                      "Polychromasia"
                    ]
                  },
                  {
                    "text": "Evaluate all lineages for evidence of myelodysplasia or evidence of megaloblastic anemia"
                  },
                  {
                    "text": "Rare cases of VEXAS syndrome manifest with macrocytic anemia and severe autoinflammatory conditionsVacuoles in myeloid and erythroid lineage precursor cells are bone marrow morphologic clue to VEXAS syndromeSimilar vacuoles seen in copper deficiency",
                    "sub_points": [
                      "Vacuoles in myeloid and erythroid lineage precursor cells are bone marrow morphologic clue to VEXAS syndromeSimilar vacuoles seen in copper deficiency",
                      "Similar vacuoles seen in copper deficiency"
                    ]
                  },
                  {
                    "text": "Some cases of megaloblastic anemia lack macrocytosisElevated RDW and oval macrocytes presentNeutrophil hypersegmentation present",
                    "sub_points": [
                      "Elevated RDW and oval macrocytes present",
                      "Neutrophil hypersegmentation present"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Anemias of Inflammation, Chronic Kidney Disease, and Cancer": {
            "name": "Anemias of Inflammation, Chronic Kidney Disease, and Cancer",
            "url": "https://app.pathprimer.com/document/d901914c-3e23-487b-bcc5-ffa3dc9a8eba/lesson/92495282-ce4a-41b9-a2f4-c2339cb2cc79",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Anemia of inflammation (AI) is form of anemia seen in acute or chronic inflammatory conditions, infections"
                  },
                  {
                    "text": "Anemia of chronic kidney disease (CKD) is anemia secondary to chronic renal failure, often with significant AI component"
                  },
                  {
                    "text": "Anemia of cancer is anemia associated with cancer and its treatment, often with significant AI component"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "AI is usually mild to moderate and nonprogressive"
                  },
                  {
                    "text": "Anemia of CKD exhibits gradual onset of fatigue and tiredness in majority of patients; pruritus, anorexia, pain, and depression are also common"
                  },
                  {
                    "text": "Anemia of cancer is most common cancer-associated morbidity"
                  },
                  {
                    "text": "Cancer-associated anemia is independent risk factor for survival regardless of tumor type"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "AINormochromic, normocytic anemia with low reticulocyte count in peripheral bloodNormal number of erythroid progenitors in bone marrowIncreased storage iron and decreased sideroblasts",
                    "sub_points": [
                      "Normochromic, normocytic anemia with low reticulocyte count in peripheral blood",
                      "Normal number of erythroid progenitors in bone marrow",
                      "Increased storage iron and decreased sideroblasts"
                    ]
                  },
                  {
                    "text": "Anemia of chronic kidney diseaseNormochromic, normocytic anemia, indistinguishable from AIOften show erythroid hypoplasia in bone marrow",
                    "sub_points": [
                      "Normochromic, normocytic anemia, indistinguishable from AI",
                      "Often show erythroid hypoplasia in bone marrow"
                    ]
                  },
                  {
                    "text": "Anemia of cancerBlood and bone marrow findings similar to AI, except hypocellular post chemotherapy",
                    "sub_points": [
                      "Blood and bone marrow findings similar to AI, except hypocellular post chemotherapy"
                    ]
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "Iron deficiency anemia"
                  },
                  {
                    "text": "Multifactorial anemia"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Anemia of inflammation (AI)/anemia of chronic disease (ACD)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Chronic renal disease (CRD)"
                  },
                  {
                    "text": "ACD for AI"
                  }
                ],
                "Definitions": [
                  {
                    "text": "AI is anemia associated with acute or chronic inflammatory conditions, infections, chronic kidney disease, and cancer"
                  },
                  {
                    "text": "Anemia of CKD is anemia secondary to chronic renal failure and includes substantial AI component in many patients"
                  },
                  {
                    "text": "Anemia of cancer is anemia associated with cancer and its treatment and includes substantial AI component"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Anemia of Inflammation": [
                  {
                    "text": "Proinflammatory cytokines cause following abnormalitiesIncreased hepcidin production, which causes iron metabolic disturbancesDecreased iron absorption in GI tractAccumulation/shunting of iron to macrophagesInability to release stored iron to plasma, i.e., hypoferremiaDiminished iron available to erythroid progenitors for hemoglobin synthesisFunctional iron deficiencyInhibition of erythroid cell differentiationReduced response of erythroid progenitors to erythropoietin (EPO)Shortened RBC life due to destruction by activated macrophages in marrow",
                    "sub_points": [
                      "Increased hepcidin production, which causes iron metabolic disturbancesDecreased iron absorption in GI tractAccumulation/shunting of iron to macrophagesInability to release stored iron to plasma, i.e., hypoferremiaDiminished iron available to erythroid progenitors for hemoglobin synthesisFunctional iron deficiency",
                      "Decreased iron absorption in GI tract",
                      "Accumulation/shunting of iron to macrophages",
                      "Inability to release stored iron to plasma, i.e., hypoferremia",
                      "Diminished iron available to erythroid progenitors for hemoglobin synthesisFunctional iron deficiency",
                      "Functional iron deficiency",
                      "Inhibition of erythroid cell differentiation",
                      "Reduced response of erythroid progenitors to erythropoietin (EPO)",
                      "Shortened RBC life due to destruction by activated macrophages in marrow"
                    ]
                  },
                  {
                    "text": "EPO level inappropriately low for degree of anemia due to blunted response to tissue hypoxia"
                  }
                ],
                "Anemia of Chronic Kidney Disease": [
                  {
                    "text": "Impaired renal function results in decreased EPO production leading to decreased erythropoiesis"
                  },
                  {
                    "text": "AI is often significant contributing factorCytokines damage or destroy erythroid precursors directlyReduced iron availability for erythropoiesis due to shunting of iron into macrophages",
                    "sub_points": [
                      "Cytokines damage or destroy erythroid precursors directly",
                      "Reduced iron availability for erythropoiesis due to shunting of iron into macrophages"
                    ]
                  },
                  {
                    "text": "Azotemia suppresses hematopoiesis directly and decreases RBC survival"
                  },
                  {
                    "text": "Long-term dialysis may additionally contribute to anemia through nutritional deficiency, toxin, and fluid imbalance"
                  },
                  {
                    "text": "Bone marrow fibrosis, variable bone changes, advanced osteitis fibrosa cystica in long-term chronic kidney diseaseRenal osteodystrophySecondary hyperparathyroidism",
                    "sub_points": [
                      "Renal osteodystrophy",
                      "Secondary hyperparathyroidism"
                    ]
                  }
                ],
                "Anemia of Cancer": [
                  {
                    "text": "Usually multifactorial with substantial AI component"
                  },
                  {
                    "text": "Inflammatory inhibitory cytokines suppress erythropoiesis"
                  },
                  {
                    "text": "Suppression of EPO production secondary to blunted response to tissue hypoxia"
                  },
                  {
                    "text": "Chemotherapy-induced myelosuppression; tumor effacement of bone marrow"
                  },
                  {
                    "text": "Tumor-induced autoantibody formation leads to autoimmune hemolytic anemia or red cell aplasia"
                  },
                  {
                    "text": "Mechanical interferences, such as hemorrhage, hemolysis, or bone marrow necrosis"
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Presentation": [
                  {
                    "text": "AIUsually presents with mild to moderate anemia",
                    "sub_points": [
                      "Usually presents with mild to moderate anemia"
                    ]
                  },
                  {
                    "text": "Anemia of chronic kidney disease occurs in 20-60% of patientsGradual onset of anemia in majority of patients, roughly correlates with disease severityPruritus, anorexia, pain, depression are also common",
                    "sub_points": [
                      "Gradual onset of anemia in majority of patients, roughly correlates with disease severity",
                      "Pruritus, anorexia, pain, depression are also common"
                    ]
                  },
                  {
                    "text": "Anemia of cancer~ 40-80% of people with cancer have anemiaAnemia is most common cancer-associated morbidityCancer-associated anemia is independent risk factor for survival regardless of tumor type",
                    "sub_points": [
                      "~ 40-80% of people with cancer have anemia",
                      "Anemia is most common cancer-associated morbidity",
                      "Cancer-associated anemia is independent risk factor for survival regardless of tumor type"
                    ]
                  }
                ],
                "Laboratory Tests": [
                  {
                    "text": "AIDecreased serum ironDecreased serum transferrin or total iron-binding capacity (TIBC)Decreased serum transferrin saturation with ironNormal or increased serum ferritinNormal serum transferrin receptor concentrationIncreased plasma/serum and urine hepcidin levels",
                    "sub_points": [
                      "Decreased serum iron",
                      "Decreased serum transferrin or total iron-binding capacity (TIBC)",
                      "Decreased serum transferrin saturation with iron",
                      "Normal or increased serum ferritin",
                      "Normal serum transferrin receptor concentration",
                      "Increased plasma/serum and urine hepcidin levels"
                    ]
                  },
                  {
                    "text": "Anemia of chronic kidney diseaseDecreased serum ironDecreased serum transferrin or TIBCDecreased EPO levelAbnormal renal function tests",
                    "sub_points": [
                      "Decreased serum iron",
                      "Decreased serum transferrin or TIBC",
                      "Decreased EPO level",
                      "Abnormal renal function tests"
                    ]
                  },
                  {
                    "text": "Anemia of cancerDecreased serum ironDecreased serum transferrin or TIBCDecreased serum transferrin saturation with ironNormal or increased serum ferritin level",
                    "sub_points": [
                      "Decreased serum iron",
                      "Decreased serum transferrin or TIBC",
                      "Decreased serum transferrin saturation with iron",
                      "Normal or increased serum ferritin level"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "AITreat underlying disease(s)If not feasible, treat with EPO/other erythropoiesis-stimulating agentIron therapy; RBC transfusion for acute severely anemic patientNewer erythropoiesis-stimulating agents, anticytokine/antihepcidin drugs, and agents targeting hepcidin-ferroportin (FPN) pathway",
                    "sub_points": [
                      "Treat underlying disease(s)",
                      "If not feasible, treat with EPO/other erythropoiesis-stimulating agent",
                      "Iron therapy; RBC transfusion for acute severely anemic patient",
                      "Newer erythropoiesis-stimulating agents, anticytokine/antihepcidin drugs, and agents targeting hepcidin-ferroportin (FPN) pathway"
                    ]
                  },
                  {
                    "text": "Anemia of CKDErythropoiesis-stimulating agent therapy; some patients may become refractory; other complications commonOral hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor therapyStabilize HIF and stimulate EPO and RBC productionAgents targeting IL-6, hepcidin, TNF-α, FPN-in trialsDialysisPacked RBC transfusionDietary supplementation of iron and folate",
                    "sub_points": [
                      "Erythropoiesis-stimulating agent therapy; some patients may become refractory; other complications common",
                      "Oral hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor therapyStabilize HIF and stimulate EPO and RBC production",
                      "Stabilize HIF and stimulate EPO and RBC production",
                      "Agents targeting IL-6, hepcidin, TNF-α, FPN-in trials",
                      "Dialysis",
                      "Packed RBC transfusion",
                      "Dietary supplementation of iron and folate"
                    ]
                  },
                  {
                    "text": "Anemia of cancerTreat underlying neoplasmWhen reversal of underlying neoplasm is not possible, treatment of anemia becomes primary goalStimulate erythropoiesis with EPO; other erythropoiesis-stimulating agentLactoferrin and ALD518 for advanced cancer in clinical trials",
                    "sub_points": [
                      "Treat underlying neoplasm",
                      "When reversal of underlying neoplasm is not possible, treatment of anemia becomes primary goal",
                      "Stimulate erythropoiesis with EPO; other erythropoiesis-stimulating agent",
                      "Lactoferrin and ALD518 for advanced cancer in clinical trials"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "AIAnemia itself is mild to moderate and typically nonprogressivePatient outcome depends on underlying disease",
                    "sub_points": [
                      "Anemia itself is mild to moderate and typically nonprogressive",
                      "Patient outcome depends on underlying disease"
                    ]
                  },
                  {
                    "text": "Anemia of chronic kidney diseaseDepends on underlying kidney diseaseEnd-stage kidney disease eventually leads to death without transplant",
                    "sub_points": [
                      "Depends on underlying kidney disease",
                      "End-stage kidney disease eventually leads to death without transplant"
                    ]
                  },
                  {
                    "text": "Anemia of cancerEntirely depends on underlying diseaseReversible with successful treatment of disease",
                    "sub_points": [
                      "Entirely depends on underlying disease",
                      "Reversible with successful treatment of disease"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Predominant Pattern/Injury Type": [
                  {
                    "text": "Proliferation defect in all 3 types of anemia"
                  }
                ],
                "Predominant Cell/Compartment Type": [
                  {
                    "text": "Erythrocyte"
                  }
                ],
                "Histologic Features": [
                  {
                    "text": "Peripheral bloodAINormochromic/normocytic anemia, hemoglobin rarely below 8 gm/dLLow reticulocyte count (reduced polychromasia)Normal mean corpuscular volume (MCV)Normal mean corpuscular hemoglobin concentration (MCHC)Normal RBC distribution width (RDW)Anemia of chronic kidney diseaseNormochromic/normocytic anemia with variable numbers of burr cellsMorphology may be indistinguishable from AILow reticulocyte countAnemia of cancerNormochromic/normocytic anemia but can be hypochromicLow reticulocyte count",
                    "sub_points": [
                      "AINormochromic/normocytic anemia, hemoglobin rarely below 8 gm/dLLow reticulocyte count (reduced polychromasia)Normal mean corpuscular volume (MCV)Normal mean corpuscular hemoglobin concentration (MCHC)Normal RBC distribution width (RDW)",
                      "Normochromic/normocytic anemia, hemoglobin rarely below 8 gm/dL",
                      "Low reticulocyte count (reduced polychromasia)",
                      "Normal mean corpuscular volume (MCV)",
                      "Normal mean corpuscular hemoglobin concentration (MCHC)",
                      "Normal RBC distribution width (RDW)",
                      "Anemia of chronic kidney diseaseNormochromic/normocytic anemia with variable numbers of burr cellsMorphology may be indistinguishable from AILow reticulocyte count",
                      "Normochromic/normocytic anemia with variable numbers of burr cells",
                      "Morphology may be indistinguishable from AI",
                      "Low reticulocyte count",
                      "Anemia of cancerNormochromic/normocytic anemia but can be hypochromicLow reticulocyte count",
                      "Normochromic/normocytic anemia but can be hypochromic",
                      "Low reticulocyte count"
                    ]
                  },
                  {
                    "text": "Bone marrowAINormal number of erythroid progenitorsIncreased storage iron in macrophages/histiocytesDecreased number of sideroblasts (iron-containing erythroid progenitors)Anemia of chronic kidney diseaseUsually erythroid hypoplasiaVariable bone changes depending on duration of renal failure and development of secondary hyperparathyroidismSignificant myelofibrosis in late stageAnemia of cancerAdequate to increased storage ironNormocellular marrow but can be hypocellular post chemotherapyMetastatic cancer can reduce number of hematopoietic cells",
                    "sub_points": [
                      "AINormal number of erythroid progenitorsIncreased storage iron in macrophages/histiocytesDecreased number of sideroblasts (iron-containing erythroid progenitors)",
                      "Normal number of erythroid progenitors",
                      "Increased storage iron in macrophages/histiocytes",
                      "Decreased number of sideroblasts (iron-containing erythroid progenitors)",
                      "Anemia of chronic kidney diseaseUsually erythroid hypoplasiaVariable bone changes depending on duration of renal failure and development of secondary hyperparathyroidismSignificant myelofibrosis in late stage",
                      "Usually erythroid hypoplasia",
                      "Variable bone changes depending on duration of renal failure and development of secondary hyperparathyroidism",
                      "Significant myelofibrosis in late stage",
                      "Anemia of cancerAdequate to increased storage ironNormocellular marrow but can be hypocellular post chemotherapyMetastatic cancer can reduce number of hematopoietic cells",
                      "Adequate to increased storage iron",
                      "Normocellular marrow but can be hypocellular post chemotherapy",
                      "Metastatic cancer can reduce number of hematopoietic cells"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Iron Deficiency Anemia": [
                  {
                    "text": "Hypochromic microcytic anemia with abnormal RBC shapes, especially elliptocytes"
                  },
                  {
                    "text": "Decreased serum iron, serum ferritin, and reticulocyte hemoglobin levels"
                  },
                  {
                    "text": "Increased TIBC and soluble transferrin receptor level"
                  },
                  {
                    "text": "Decreased serum transferrin saturation with iron"
                  },
                  {
                    "text": "Decreased serum hepcidin level"
                  },
                  {
                    "text": "Diminished storage iron and sideroblasts in bone marrow"
                  }
                ],
                "Multifactorial Anemia": [
                  {
                    "text": "Patients typically have multiple comorbidities"
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Clinically Relevant Pathologic Features": [
                  {
                    "text": "AIMost common type of anemia in hospitalized patientsUsually mild to moderate, normochromic/normocytic; develops 1-2 months after onset of illnessMay develop within days in critical illnessIncreased plasma/serum and urine hepcidin levels",
                    "sub_points": [
                      "Most common type of anemia in hospitalized patients",
                      "Usually mild to moderate, normochromic/normocytic; develops 1-2 months after onset of illness",
                      "May develop within days in critical illness",
                      "Increased plasma/serum and urine hepcidin levels"
                    ]
                  },
                  {
                    "text": "Anemia of chronic kidney diseaseHistory of chronic renal failure and abnormal renal function testsDecreased EPO level",
                    "sub_points": [
                      "History of chronic renal failure and abnormal renal function tests",
                      "Decreased EPO level"
                    ]
                  },
                  {
                    "text": "Anemia of cancerHistory of cancer",
                    "sub_points": [
                      "History of cancer"
                    ]
                  }
                ],
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "Peripheral blood findings are generally similar in all 3 types of anemia"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Iron Deficiency Anemia": {
            "name": "Iron Deficiency Anemia",
            "url": "https://app.pathprimer.com/document/2600c59b-2aea-4415-8812-840901de60d8/lesson/92495282-ce4a-41b9-a2f4-c2339cb2cc79",
            "content": {
              "KEY FACTS": {
                "Clinical Issues": [
                  {
                    "text": "Estimated global anemia prevalence is ~ 30%, affecting > 1.9 billion people"
                  },
                  {
                    "text": "Iron deficiency anemia (IDA) accounts for > 60% of global anemias"
                  },
                  {
                    "text": "Highest rates of IDA in children < 10 years and female patients"
                  },
                  {
                    "text": "IDA is common delayed consequence of bariatric surgery"
                  },
                  {
                    "text": "Insidious onset, chronic, often asymptomatic"
                  },
                  {
                    "text": "Symptoms may include fatigue, pallor, weakness, tachycardia, dyspnea on exertion"
                  },
                  {
                    "text": "Diagnosis of IDA should be based on panel of tests, not on any single test"
                  },
                  {
                    "text": "Low serum ferritin is generally indicative of IDA"
                  },
                  {
                    "text": "Serum transferrin saturation < 16% supports diagnosis of iron deficiency"
                  },
                  {
                    "text": "Oral ferrous iron salt (ferrous sulfate) supplementation to all patients with iron deficiency"
                  },
                  {
                    "text": "Parenteral iron should be given to patients who cannot take, or are refractory to, oral iron supplement"
                  },
                  {
                    "text": "Give RBC transfusion to patients with symptomatic severe IDA to rapidly correct hypoxia and iron deficiency"
                  },
                  {
                    "text": "Excellent prognosis, except in patients with significant underlying disease"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Mild to marked anemia with marked anisopoikilocytosis"
                  },
                  {
                    "text": "Hypochromic, microcytic"
                  },
                  {
                    "text": "Increased RBC distribution width"
                  },
                  {
                    "text": "Frequent elliptocytes, target cells, and rare prekeratocytes"
                  },
                  {
                    "text": "Erythroid hyperplasia in bone marrow"
                  },
                  {
                    "text": "Diminished bone marrow storage iron and sideroblasts"
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "Anemia of inflammation/chronic disease"
                  },
                  {
                    "text": "Thalassemia minor"
                  },
                  {
                    "text": "Lead poisoning"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Iron deficiency anemia (IDA)"
                  },
                  {
                    "text": "Anemia of inflammation (AI)/anemia of chronic disease (ACD)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Hypochromic microcytic anemia"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Iron deficiency: Reduction of body iron stores, which may lead to IDA if left untreated"
                  },
                  {
                    "text": "IDA is severe form, resulting from decreased hemoglobin production secondary to decreased iron availabilityHypochromic microcytic anemia",
                    "sub_points": [
                      "Hypochromic microcytic anemia"
                    ]
                  },
                  {
                    "text": "Iron-refractory IDA (IRIDA) is rare autosomal recessive disorder; mutation ofTMPRSS6gene leads to IDARareOther mutations reported",
                    "sub_points": [
                      "Rare",
                      "Other mutations reported"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Iron Homeostasis": [
                  {
                    "text": "Total body iron store is ~ 30-40 mg/kg of body weight"
                  },
                  {
                    "text": "Daily requirement is ~ 25 mg"
                  },
                  {
                    "text": "Major source of daily required iron is provided through recycling of phagocytosed senescent RBCsHeme complex is degraded in liver and spleen by monocytes and macrophagesMacrophages and hepatocytes store iron as ferritin and release it into plasma through ferroportin when serum iron drops",
                    "sub_points": [
                      "Heme complex is degraded in liver and spleen by monocytes and macrophages",
                      "Macrophages and hepatocytes store iron as ferritin and release it into plasma through ferroportin when serum iron drops"
                    ]
                  },
                  {
                    "text": "~ 1-2 mg of ferrous-form iron (Fe²⁺) is absorbed daily from small intestinal tract, specifically duodenum and jejunum"
                  },
                  {
                    "text": "Factors impacting iron absorptionIron from food is generally ferric iron (Fe³⁺); it needs to be reduced to ferrous form (Fe²⁺) for absorptionFerric iron is reduced to ferrous iron by reductase duodenal cytochrome B on brush border of enterocytesFerrous iron crosses apical brush border through divalent metal ion transporter 1pH of intestinal lumen, vitamin C enhance iron absorptionMeat protein also increases iron absorptionPresence of chelating or other agents in food will reduce iron absorption, such as calcium, fiber, and teaExpression level of iron transporters of enterocytes",
                    "sub_points": [
                      "Iron from food is generally ferric iron (Fe³⁺); it needs to be reduced to ferrous form (Fe²⁺) for absorptionFerric iron is reduced to ferrous iron by reductase duodenal cytochrome B on brush border of enterocytesFerrous iron crosses apical brush border through divalent metal ion transporter 1",
                      "Ferric iron is reduced to ferrous iron by reductase duodenal cytochrome B on brush border of enterocytes",
                      "Ferrous iron crosses apical brush border through divalent metal ion transporter 1",
                      "pH of intestinal lumen, vitamin C enhance iron absorption",
                      "Meat protein also increases iron absorption",
                      "Presence of chelating or other agents in food will reduce iron absorption, such as calcium, fiber, and tea",
                      "Expression level of iron transporters of enterocytes"
                    ]
                  },
                  {
                    "text": "Body iron is mostly contained in hemoglobin, ferritin, and other proteins"
                  },
                  {
                    "text": "Iron plays critical role as oxygen carrier; it also plays important roles in many other key proteins, such as cytochromes and myoglobin"
                  },
                  {
                    "text": "Iron homeostasis is tightly controlled by iron regulatory hormone hepcidin, which is produced in liver"
                  },
                  {
                    "text": "Hepcidin level fluctuates with plasma iron level; it increases when plasma iron level increasesHigh-level hepcidin reduces iron absorption from gutHepcidin binds to and internalizes ferroportin for degradation; thus, high-level hepcidin limits iron exporting from enterocytes and macrophages to plasmaExcess hepcidin causes ACD in inflammatory diseases through IL-6 and other cytokinesHepcidin deficiency causes iron overload in hereditary hemochromatosis and iron-loading anemia",
                    "sub_points": [
                      "High-level hepcidin reduces iron absorption from gut",
                      "Hepcidin binds to and internalizes ferroportin for degradation; thus, high-level hepcidin limits iron exporting from enterocytes and macrophages to plasma",
                      "Excess hepcidin causes ACD in inflammatory diseases through IL-6 and other cytokines",
                      "Hepcidin deficiency causes iron overload in hereditary hemochromatosis and iron-loading anemia"
                    ]
                  }
                ],
                "Erythropoiesis": [
                  {
                    "text": "Erythropoiesis is regulated by erythroid growth factors, such as erythropoietin and erythroferrone"
                  },
                  {
                    "text": "Hemoglobin is iron-containing oxygen transport metalloprotein in RBCs of vertebrates"
                  },
                  {
                    "text": "Hemoglobin molecule is assembly of 2 α- and 2 β-globin subunits with associated heme group"
                  },
                  {
                    "text": "Each heme group contains 1 iron atom that can bind 1 oxygen molecule"
                  }
                ],
                "Iron Deficiency Anemia": [
                  {
                    "text": "Hemoglobin synthesis is impaired in IDA"
                  },
                  {
                    "text": "Anemia develops despite increased erythroid lineage in bone marrow"
                  },
                  {
                    "text": "Hypochromia and microcytosis of circulating RBCs due to inadequate hemoglobin production"
                  },
                  {
                    "text": "Menstruation is most common cause in teenage girls and women of child-bearing age"
                  },
                  {
                    "text": "Increased need for iron in growing children and during pregnancy is most common cause of IDA worldwide"
                  },
                  {
                    "text": "Malnutrition due to reduced intake in vegetarians/vegans and older adult populations"
                  },
                  {
                    "text": "Malabsorption secondary to parasitic infections, gastric bypass or duodenal surgeries, chronic inflammatory diseases of intestines, and celiac disease"
                  },
                  {
                    "text": "Chronic blood loss from gastrointestinal tract, such as neoplasms and dialysis; medication, such as aspirin and NSAIDs"
                  },
                  {
                    "text": "Blood donation may also contribute to IDA"
                  }
                ],
                "Iron-Refractory Iron Deficiency Anemia": [
                  {
                    "text": "Autosomal recessive disorder due to mutation inTMPRSS6gene, which codes for transmembrane protease, serine 6, a.k.a. matriptase-2"
                  },
                  {
                    "text": "Matriptase-2 inhibits signaling pathway that activates hepcidin and leads to high hepcidin level"
                  },
                  {
                    "text": "Loss-of-function mutation leads to constitutively high level of hepcidin, thus blocking intestinal iron absorption and also limiting iron release from hepatocytes and macrophages"
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "Estimated global anemia prevalence is ~ 30%, affecting > 1.9 billion peopleIDA accounts for > 60% of global anemiasHighest rates of IDA in children < 10 years and female patientsSome published estimates of ~ 1.24 billion individuals with IDA worldwide",
                    "sub_points": [
                      "IDA accounts for > 60% of global anemiasHighest rates of IDA in children < 10 years and female patientsSome published estimates of ~ 1.24 billion individuals with IDA worldwide",
                      "Highest rates of IDA in children < 10 years and female patients",
                      "Some published estimates of ~ 1.24 billion individuals with IDA worldwide"
                    ]
                  },
                  {
                    "text": "Globally, estimated prevalence is 50% in preschool children, 42% in pregnant women, 30% in nonpregnant women"
                  },
                  {
                    "text": "Prevalence in resource-rich countries is 2-5% in adult men and postmenopausal women, ~ 10% in women of child-bearing age, much higher in hospitalized patients"
                  },
                  {
                    "text": "IDA is common delayed consequence of bariatric surgery"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Insidious onset, chronic, often asymptomatic"
                  },
                  {
                    "text": "Fatigue, pallor, weakness, tachycardia, dyspnea on exertion"
                  },
                  {
                    "text": "Difficulty in concentrating"
                  },
                  {
                    "text": "May cause decreased cognitive performance and developmental delay in childrenImpairments may be persistent after resolution of IDA",
                    "sub_points": [
                      "Impairments may be persistent after resolution of IDA"
                    ]
                  },
                  {
                    "text": "May predispose patient to infections"
                  },
                  {
                    "text": "May precipitate heart failure"
                  },
                  {
                    "text": "May result in longer hospital stay and poorer clinical outcome"
                  },
                  {
                    "text": "Severe anemia in pregnant women may result in preterm labor, low birth weight, and increased mother and baby fatality rate"
                  },
                  {
                    "text": "Pica (craving and consumption of ice and nonfood items), restless leg syndrome, esophageal webs, deterioration of cognitive function can occur"
                  },
                  {
                    "text": "Other classic symptoms, such as koilonychia (spoon nails), glossitis, or dysphagia, are not common in resource-rich countries"
                  },
                  {
                    "text": "IDA often coexists with other types of anemiaAI due to autoimmune disorders, chronic infections, malignancy, and other chronic systemic diseasesChronic kidney disease-associated anemia secondary to blood loss through dialysis, reduced hepcidin clearance, inflammation, &/or certain medicationsMultifactorial anemia In older adult patients with advanced age and other comorbiditiesBlood loss in intestinal parasitic infectionsMultifactorial anemia in patients with obesity due to decreased absorption and chronic inflammation (AI)",
                    "sub_points": [
                      "AI due to autoimmune disorders, chronic infections, malignancy, and other chronic systemic diseases",
                      "Chronic kidney disease-associated anemia secondary to blood loss through dialysis, reduced hepcidin clearance, inflammation, &/or certain medications",
                      "Multifactorial anemia In older adult patients with advanced age and other comorbidities",
                      "Blood loss in intestinal parasitic infections",
                      "Multifactorial anemia in patients with obesity due to decreased absorption and chronic inflammation (AI)"
                    ]
                  }
                ],
                "Laboratory Tests": [
                  {
                    "text": "Classic laboratory testing in IDACBC and morphologic review of blood smearBone marrow is still gold standard for assessing storage iron and erythroid iron incorporation, but procedure is invasive and not usually neededSerum ferritin: Measures total body iron store, single best noninvasive test for assessing iron deficiencySerum iron: Measure of transferrin-bound ironTotal iron-binding capacity (TIBC): Measure of transferrin concentrationHepcidin and reticulocyte hemoglobin levels: Measure of iron regulation and iron availability in newly formed RBCs",
                    "sub_points": [
                      "CBC and morphologic review of blood smear",
                      "Bone marrow is still gold standard for assessing storage iron and erythroid iron incorporation, but procedure is invasive and not usually needed",
                      "Serum ferritin: Measures total body iron store, single best noninvasive test for assessing iron deficiency",
                      "Serum iron: Measure of transferrin-bound iron",
                      "Total iron-binding capacity (TIBC): Measure of transferrin concentration",
                      "Hepcidin and reticulocyte hemoglobin levels: Measure of iron regulation and iron availability in newly formed RBCs"
                    ]
                  },
                  {
                    "text": "Laboratory findings in IDADecreased RBC countDecreased hemoglobin and hematocrit levelsDecreased mean corpuscular volumeDecreased mean corpuscular hemoglobin concentrationIncreased RBC distribution width (RDW)Decreased serum ferritin levelDecreased serum iron levelIncreased TIBC levelDecreased serum hepcidin levels; decreased reticulocyte hemoglobin",
                    "sub_points": [
                      "Decreased RBC count",
                      "Decreased hemoglobin and hematocrit levels",
                      "Decreased mean corpuscular volume",
                      "Decreased mean corpuscular hemoglobin concentration",
                      "Increased RBC distribution width (RDW)",
                      "Decreased serum ferritin level",
                      "Decreased serum iron level",
                      "Increased TIBC level",
                      "Decreased serum hepcidin levels; decreased reticulocyte hemoglobin"
                    ]
                  },
                  {
                    "text": "Diagnosis of IDA should be based on panel of tests, not on any single test"
                  },
                  {
                    "text": "Serum ferritin is single best test for IDAFerritin level of < 30 µg/L is generally indicative of iron deficiencyIn older patient population, sensitivity of serum ferritin is low due to concurrent medical complications; therefore, cutoff of ferritin is higherIn patient with chronic inflammatory conditions, recommended ferritin cutoff is < 100 µg/LIn patient with heart failure, recommended ferritin cutoff is < 300 µg/L",
                    "sub_points": [
                      "Ferritin level of < 30 µg/L is generally indicative of iron deficiency",
                      "In older patient population, sensitivity of serum ferritin is low due to concurrent medical complications; therefore, cutoff of ferritin is higherIn patient with chronic inflammatory conditions, recommended ferritin cutoff is < 100 µg/LIn patient with heart failure, recommended ferritin cutoff is < 300 µg/L",
                      "In patient with chronic inflammatory conditions, recommended ferritin cutoff is < 100 µg/L",
                      "In patient with heart failure, recommended ferritin cutoff is < 300 µg/L"
                    ]
                  },
                  {
                    "text": "Serum transferrin saturation < 16% supports diagnosis of iron deficiency but greater specificity if < 10%"
                  },
                  {
                    "text": "Hepcidin < 6 ng/ml distinguishes IDA from AI"
                  },
                  {
                    "text": "Screening for IDA during pregnancy has no proven benefits, although routine iron supplement during pregnancy does improve maternal hematologic indices"
                  },
                  {
                    "text": "IRIDAHypochromic microcytic anemia, indistinguishable from other IDALow transferrin saturationInappropriately high serum hepcidin level",
                    "sub_points": [
                      "Hypochromic microcytic anemia, indistinguishable from other IDA",
                      "Low transferrin saturation",
                      "Inappropriately high serum hepcidin level"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "Oral ferrous iron salt (ferrous sulfate) supplementationRecommended daily dose for adult is 100-200 mg of elementary iron or 3-6 mg/kg of body weight of liquid preparationTaking vitamin C concurrently will enhance iron absorptionExpected response in IDA patient with oral iron treatmentIncrease in reticulocyte count and increased hemoglobin level in reticulocytes in 1 week (reticulated hemoglobin)Increase in transferrin saturation in 1 weekSerum iron level starts to rise in 1 weekIncrease in hemoglobin level in 2 weeks (gradual normalization of hemoglobin level)Iron therapy should continue until iron stores are repleted, which may take monthsCaution against use in malaria endemic region due to possible increased risk of hospitalization and death, although conclusion is still controversialNonabsorbed iron could alter gut microbiota, leading to increased intestinal pathogen concentration and potential infection",
                    "sub_points": [
                      "Recommended daily dose for adult is 100-200 mg of elementary iron or 3-6 mg/kg of body weight of liquid preparation",
                      "Taking vitamin C concurrently will enhance iron absorption",
                      "Expected response in IDA patient with oral iron treatmentIncrease in reticulocyte count and increased hemoglobin level in reticulocytes in 1 week (reticulated hemoglobin)Increase in transferrin saturation in 1 weekSerum iron level starts to rise in 1 weekIncrease in hemoglobin level in 2 weeks (gradual normalization of hemoglobin level)",
                      "Increase in reticulocyte count and increased hemoglobin level in reticulocytes in 1 week (reticulated hemoglobin)",
                      "Increase in transferrin saturation in 1 week",
                      "Serum iron level starts to rise in 1 week",
                      "Increase in hemoglobin level in 2 weeks (gradual normalization of hemoglobin level)",
                      "Iron therapy should continue until iron stores are repleted, which may take months",
                      "Caution against use in malaria endemic region due to possible increased risk of hospitalization and death, although conclusion is still controversial",
                      "Nonabsorbed iron could alter gut microbiota, leading to increased intestinal pathogen concentration and potential infection"
                    ]
                  },
                  {
                    "text": "Parenteral iron indicationsIron refractory defined as absence of response after 4-6 weeks of oral iron treatmentIron intoleranceSevere &/or symptomatic anemiaGastric or duodenal surgery leads to malabsorption of ironIRIDA, which is unresponsive to oral iron treatmentChronic blood loss that cannot be compensated by oral ironActive inflammatory bowel diseaseEnd-stage kidney disease receiving daily dialysis and erythropoietin treatmentCaution against hypersensitivity, rare life-threatening iron infusion-related reaction",
                    "sub_points": [
                      "Iron refractory defined as absence of response after 4-6 weeks of oral iron treatment",
                      "Iron intolerance",
                      "Severe &/or symptomatic anemia",
                      "Gastric or duodenal surgery leads to malabsorption of iron",
                      "IRIDA, which is unresponsive to oral iron treatment",
                      "Chronic blood loss that cannot be compensated by oral iron",
                      "Active inflammatory bowel disease",
                      "End-stage kidney disease receiving daily dialysis and erythropoietin treatment",
                      "Caution against hypersensitivity, rare life-threatening iron infusion-related reaction"
                    ]
                  },
                  {
                    "text": "RBC transfusionSymptomatic severe IDA patients should receive RBC transfusion to rapidly correct hypoxia and iron deficiency",
                    "sub_points": [
                      "Symptomatic severe IDA patients should receive RBC transfusion to rapidly correct hypoxia and iron deficiency"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Excellent, except in patients with underlying disease"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Predominant Pattern/Injury Type": [
                  {
                    "text": "Decrease in hemoglobin synthesis"
                  }
                ],
                "Predominant Cell/Compartment Type": [
                  {
                    "text": "Erythrocyte"
                  }
                ],
                "Histologic Features": [
                  {
                    "text": "Peripheral bloodMild to marked anemia with marked anisopoikilocytosisHypochromic, microcyticFrequent elliptocytes, target cells, and rare prekeratocytes",
                    "sub_points": [
                      "Mild to marked anemia with marked anisopoikilocytosis",
                      "Hypochromic, microcytic",
                      "Frequent elliptocytes, target cells, and rare prekeratocytes"
                    ]
                  },
                  {
                    "text": "Bone marrowErythroid hyperplasiaDiminished bone marrow storage iron and sideroblasts",
                    "sub_points": [
                      "Erythroid hyperplasia",
                      "Diminished bone marrow storage iron and sideroblasts"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Anemia of Inflammation/Anemia of Chronic Disease": [
                  {
                    "text": "Normochromic, normocytic anemia; less commonly hypochromic, microcytic"
                  },
                  {
                    "text": "Decreased serum iron"
                  },
                  {
                    "text": "Increased serum ferritin"
                  },
                  {
                    "text": "Decreased TIBC"
                  },
                  {
                    "text": "Increased bone marrow storage iron and decreased erythroid iron incorporationDesignated by some authors and functional iron deficiency; iron-restricted erythropoiesis",
                    "sub_points": [
                      "Designated by some authors and functional iron deficiency; iron-restricted erythropoiesis"
                    ]
                  },
                  {
                    "text": "Increased hepcidin level; normal reticulocyte hemoglobin level"
                  }
                ],
                "Thalassemia Minor": [
                  {
                    "text": "Normal or increased RBC count"
                  },
                  {
                    "text": "Mild anemia with minimal anisopoikilocytosis since birth"
                  },
                  {
                    "text": "Hypochromic, microcytic"
                  },
                  {
                    "text": "Normal RDW"
                  },
                  {
                    "text": "Target cells prominent"
                  }
                ],
                "Lead Poisoning": [
                  {
                    "text": "Hypochromic, microcytic anemia"
                  },
                  {
                    "text": "Coarse basophilic stippling"
                  },
                  {
                    "text": "Ring sideroblasts in marrow"
                  },
                  {
                    "text": "Blood lead level test diagnostic"
                  }
                ],
                "Sideroblastic Anemia": [
                  {
                    "text": "Normochromic, normocytic"
                  },
                  {
                    "text": "Erythroid hyperplasia in bone marrow"
                  },
                  {
                    "text": "Accumulation of iron in mitochondria"
                  },
                  {
                    "text": "Ring sideroblasts > 10% erythroid precursors in bone marrow"
                  },
                  {
                    "text": "Increased storage iron"
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "Hypochromic, microcytic anemia"
                  },
                  {
                    "text": "Decreased serum iron, decreased ferritin, decreased hepcidin, decreased reticulocyte hemoglobin"
                  },
                  {
                    "text": "Increased TIBC a.k.a. serum transferrin level"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Megaloblastic Anemia": {
            "name": "Megaloblastic Anemia",
            "url": "https://app.pathprimer.com/document/1357a99b-33b4-4e90-9b92-09701044e1b9/lesson/92495282-ce4a-41b9-a2f4-c2339cb2cc79",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Ineffective hematopoiesis resulting from disorders of DNA synthesisMost commonly manifests as macrocytic anemiaUsually deficiency of vitamin B12 or folate",
                    "sub_points": [
                      "Most commonly manifests as macrocytic anemia",
                      "Usually deficiency of vitamin B12 or folate"
                    ]
                  },
                  {
                    "text": "Nuclear maturation defect results in distinct morphologic features"
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "Vitamin B12 or folate deficiencyInadequate dietary intake (folate) or absorption defects (vitamin B12)",
                    "sub_points": [
                      "Inadequate dietary intake (folate) or absorption defects (vitamin B12)"
                    ]
                  },
                  {
                    "text": "Certain medications, toxins can impair DNA synthesis"
                  },
                  {
                    "text": "Rare inherited abnormalities of nucleic acid synthesis"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Supplementation with only folate can improve anemia in patients with vitamin B12 deficiency, while neurologic symptoms will progress"
                  },
                  {
                    "text": "Pernicious anemia (PA) (vitamin B12 deficiency caused by lack of intrinsic factor) more commonly seen in people of Northern European/Hispanic descent"
                  },
                  {
                    "text": "Symptoms can include anemia, neurologic impairment (usually only seen with vitamin B12 deficiency), glossitis"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Peripheral blood shows macrocytic anemia with oval macrocytes"
                  },
                  {
                    "text": "Hypersegmented neutrophils may be 1 of earliest signs"
                  },
                  {
                    "text": "Anisopoikilocytosis worsens with severity of deficiency"
                  },
                  {
                    "text": "Some cases may exhibit pancytopenia"
                  }
                ],
                "Diagnostic Checklist": [
                  {
                    "text": "Macrocytic anemia with no known clinical explanation should prompt evaluation of serum vitamin B12, folate, methylmalonic acid"
                  },
                  {
                    "text": "Bone marrow biopsy is generally not necessary in cases of megaloblastic anemia and may be misdiagnosed as neoplastic (especially as myelodysplastic syndrome)"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Definitions": [
                  {
                    "text": "Ineffective hematopoiesis resulting from disorders of DNA synthesisMost commonly manifests as macrocytic anemiaUsually deficiency of vitamin B12 or folate",
                    "sub_points": [
                      "Most commonly manifests as macrocytic anemia",
                      "Usually deficiency of vitamin B12 or folate"
                    ]
                  },
                  {
                    "text": "Nuclear maturation defect results in distinct morphologic features"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Vitamin B12 or Folate Deficiency": [
                  {
                    "text": "Inadequate dietary intakeMore common with folatePopulations at riskOlder, indigent, patients with chronic alcohol abuse disorder and pregnant women and their infantsRisk of vitamin B12 deficiency in infants when mothers on highly restricted dietsCancer patients, especially hospitalized cancer patientsExcessive cooking can rapidly degrade folateCereals and grains in USA are supplemented with folate",
                    "sub_points": [
                      "More common with folate",
                      "Populations at riskOlder, indigent, patients with chronic alcohol abuse disorder and pregnant women and their infantsRisk of vitamin B12 deficiency in infants when mothers on highly restricted dietsCancer patients, especially hospitalized cancer patients",
                      "Older, indigent, patients with chronic alcohol abuse disorder and pregnant women and their infants",
                      "Risk of vitamin B12 deficiency in infants when mothers on highly restricted diets",
                      "Cancer patients, especially hospitalized cancer patients",
                      "Excessive cooking can rapidly degrade folate",
                      "Cereals and grains in USA are supplemented with folate"
                    ]
                  },
                  {
                    "text": "Absorption defectsMost common cause of vitamin B12 deficiencyIncludes deficiencies of and antibodies against intrinsic factor (IF)Autoimmune disorder termed pernicious anemia (PA)Medications that may impair absorptionAminosalicylates, neomycin, metforminMore common in older adults but can occur in younger patients",
                    "sub_points": [
                      "Most common cause of vitamin B12 deficiency",
                      "Includes deficiencies of and antibodies against intrinsic factor (IF)Autoimmune disorder termed pernicious anemia (PA)",
                      "Autoimmune disorder termed pernicious anemia (PA)",
                      "Medications that may impair absorptionAminosalicylates, neomycin, metformin",
                      "Aminosalicylates, neomycin, metformin",
                      "More common in older adults but can occur in younger patients"
                    ]
                  }
                ],
                "Medications That Impair DNA Synthesis": [
                  {
                    "text": "Pyrimidine analogues5-fluorouracil, cytarabine, zidovudine",
                    "sub_points": [
                      "5-fluorouracil, cytarabine, zidovudine"
                    ]
                  },
                  {
                    "text": "Anticonvulsant therapyPhenytoin, phenobarbital, carbamazepine",
                    "sub_points": [
                      "Phenytoin, phenobarbital, carbamazepine"
                    ]
                  },
                  {
                    "text": "Purine analoguesAzathioprine, 6-mercaptopurine, 6-thioguanine, acyclovir",
                    "sub_points": [
                      "Azathioprine, 6-mercaptopurine, 6-thioguanine, acyclovir"
                    ]
                  },
                  {
                    "text": "Dihydrofolate reductase inhibitorsMethotrexate, pyrimethamine, triamterene, trimethoprim",
                    "sub_points": [
                      "Methotrexate, pyrimethamine, triamterene, trimethoprim"
                    ]
                  },
                  {
                    "text": "Ribonuclease reductase inhibitorHydroxyurea",
                    "sub_points": [
                      "Hydroxyurea"
                    ]
                  }
                ],
                "Inherited Abnormalities of Nucleic Acid Synthesis": [
                  {
                    "text": "Lesch-Nyhan syndrome, orotic aciduria, dihydrofolate reductase deficiency"
                  }
                ],
                "Pathophysiology": [
                  {
                    "text": "Vitamin B12 and folate are intricately related in DNA synthesis pathwaysIn vitamin B12 deficiency, conversion of homocysteine to methionine is impairedLeads to both megaloblastic anemia and neurologic complicationsIn folate deficiency, conversion of deoxyuridine monophosphate to deoxythymidine monophosphate is impairedRate-limiting step in DNA synthesis",
                    "sub_points": [
                      "In vitamin B12 deficiency, conversion of homocysteine to methionine is impairedLeads to both megaloblastic anemia and neurologic complications",
                      "Leads to both megaloblastic anemia and neurologic complications",
                      "In folate deficiency, conversion of deoxyuridine monophosphate to deoxythymidine monophosphate is impairedRate-limiting step in DNA synthesis",
                      "Rate-limiting step in DNA synthesis"
                    ]
                  },
                  {
                    "text": "Deficiencies result in defective DNA synthesisImpaired mitosisAffects all mitotically active cells in body",
                    "sub_points": [
                      "Impaired mitosis",
                      "Affects all mitotically active cells in body"
                    ]
                  },
                  {
                    "text": "RNA synthesis is not affectedCytoplasmic maturation continues unaffected",
                    "sub_points": [
                      "Cytoplasmic maturation continues unaffected"
                    ]
                  },
                  {
                    "text": "Results in characteristic megaloblastic featuresGiantism of proliferating cellsAsynchronous nuclear and cytoplasmic maturationImmature nuclear features, including sieve-like chromatin",
                    "sub_points": [
                      "Giantism of proliferating cells",
                      "Asynchronous nuclear and cytoplasmic maturation",
                      "Immature nuclear features, including sieve-like chromatin"
                    ]
                  },
                  {
                    "text": "Ineffective hematopoiesis"
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "Folate deficiencyPopulations with inadequate nutritional status (indigent, older adults, severe chronic alcohol abuse disorder, cancer patient)Populations with increased requirement, such as pregnant women and infantsMalabsorption in jejunum, seen in celiac disease, tropical sprue, gastric or jejunal resection, Crohn disease, use of sulfasalazinePatients taking dihydrofolate reductase inhibitorsCongenital disorders of folate metabolism (rare)",
                    "sub_points": [
                      "Populations with inadequate nutritional status (indigent, older adults, severe chronic alcohol abuse disorder, cancer patient)",
                      "Populations with increased requirement, such as pregnant women and infants",
                      "Malabsorption in jejunum, seen in celiac disease, tropical sprue, gastric or jejunal resection, Crohn disease, use of sulfasalazine",
                      "Patients taking dihydrofolate reductase inhibitors",
                      "Congenital disorders of folate metabolism (rare)"
                    ]
                  },
                  {
                    "text": "Vitamin B12 deficiencyPA with reduced IF secretion or antibody to IF &/or parietal cellsDietary deficiency in strict vegansCobalamin malabsorption seen in atrophic gastritis,Helicobacter pyloriinfection (chronic gastritis), bacterial overgrowth, gastric surgery, long-term use of acid-suppressing medicationsMalabsorption at terminal ileum, including Crohn disease, tropical sprue, and ileal resectionMedications that may impair absorption include aminosalicylates, neomycin, colchicine, metforminHIV infection, unknown mechanismChronic abuse of nitrous oxideRarely, inherited defects in metabolic pathway, such as congenital transcobalamin II deficiency",
                    "sub_points": [
                      "PA with reduced IF secretion or antibody to IF &/or parietal cells",
                      "Dietary deficiency in strict vegans",
                      "Cobalamin malabsorption seen in atrophic gastritis,Helicobacter pyloriinfection (chronic gastritis), bacterial overgrowth, gastric surgery, long-term use of acid-suppressing medications",
                      "Malabsorption at terminal ileum, including Crohn disease, tropical sprue, and ileal resection",
                      "Medications that may impair absorption include aminosalicylates, neomycin, colchicine, metformin",
                      "HIV infection, unknown mechanism",
                      "Chronic abuse of nitrous oxide",
                      "Rarely, inherited defects in metabolic pathway, such as congenital transcobalamin II deficiency"
                    ]
                  }
                ],
                "Age": [
                  {
                    "text": "Both vitamin B12 and folate deficiency are more common in older adult patients"
                  },
                  {
                    "text": "Severe dietary restrictions in pregnancy linked to folate or vitamin B12 deficiency in infant"
                  }
                ],
                "Ethnicity": [
                  {
                    "text": "All ethnicities affected"
                  },
                  {
                    "text": "PA is more common in people of Northern European, Hispanic descent"
                  },
                  {
                    "text": "Socioeconomic factors more significant than ethnicity for folate deficiency"
                  }
                ],
                "Presentation": [
                  {
                    "text": "AnemiaIn more severe cases, all lineages may be decreased (pancytopenia)",
                    "sub_points": [
                      "In more severe cases, all lineages may be decreased (pancytopenia)"
                    ]
                  },
                  {
                    "text": "Neurologic impairmentGenerally limited to vitamin B12 deficiencyPathologic featuresPeripheral neuropathySubacute combined degeneration of spinal cordFocal demyelinization of white matter of brainSigns/symptomsParesthesiasAtaxia (difficulty walking)Muscle weaknessMemory impairment/personality changesSymmetrical loss of position and vibratory sense in extremities",
                    "sub_points": [
                      "Generally limited to vitamin B12 deficiency",
                      "Pathologic featuresPeripheral neuropathySubacute combined degeneration of spinal cordFocal demyelinization of white matter of brain",
                      "Peripheral neuropathy",
                      "Subacute combined degeneration of spinal cord",
                      "Focal demyelinization of white matter of brain",
                      "Signs/symptomsParesthesiasAtaxia (difficulty walking)Muscle weaknessMemory impairment/personality changesSymmetrical loss of position and vibratory sense in extremities",
                      "Paresthesias",
                      "Ataxia (difficulty walking)",
                      "Muscle weakness",
                      "Memory impairment/personality changes",
                      "Symmetrical loss of position and vibratory sense in extremities"
                    ]
                  },
                  {
                    "text": "Thrombotic thrombocytopenic purpura (TTP)-like presentationClinical and blood features in PA can closely mimic TTPMean corpuscular volume (MCV) may be normalNeurologic symptoms of PA mimic TTP",
                    "sub_points": [
                      "Clinical and blood features in PA can closely mimic TTP",
                      "Mean corpuscular volume (MCV) may be normal",
                      "Neurologic symptoms of PA mimic TTP"
                    ]
                  },
                  {
                    "text": "Glossitis"
                  },
                  {
                    "text": "Gastrointestinal disturbances"
                  },
                  {
                    "text": "Weight loss"
                  },
                  {
                    "text": "Problems with fertility"
                  },
                  {
                    "text": "HyperhomocysteinemiaMay lead to vascular occlusive lesions, including stroke",
                    "sub_points": [
                      "May lead to vascular occlusive lesions, including stroke"
                    ]
                  }
                ],
                "Laboratory Tests": [
                  {
                    "text": "CBCMacrocytic anemia; increased MCV in most cases but can be normalVery high RDW due to marked anisopoikilocytosis in severe casesBroken macrocytes can mimic schistocytesPancytopenia in moderate number of casesReticulocyte count decreased",
                    "sub_points": [
                      "Macrocytic anemia; increased MCV in most cases but can be normal",
                      "Very high RDW due to marked anisopoikilocytosis in severe casesBroken macrocytes can mimic schistocytes",
                      "Broken macrocytes can mimic schistocytes",
                      "Pancytopenia in moderate number of cases",
                      "Reticulocyte count decreased"
                    ]
                  },
                  {
                    "text": "ScreeningSerum vitamin B12 (decreased in PA)Measurement can have interference by autoantibodies, including IF antibodiesSerum folate (decreased in folate deficiency)Can fluctuate with dietRBC folateMore representative of long-term folate status than serum folateMethylmalonic acid (markedly increased in vitamin B12 deficiency)Equal sensitivity to serum vitamin B12; more robust quantitative assay than vitamin B12More specific than serum vitamin B12 (only other cause is impaired renal function)Elevated in vitamin B12 deficiency, not in folate deficiency",
                    "sub_points": [
                      "Serum vitamin B12 (decreased in PA)Measurement can have interference by autoantibodies, including IF antibodies",
                      "Measurement can have interference by autoantibodies, including IF antibodies",
                      "Serum folate (decreased in folate deficiency)Can fluctuate with diet",
                      "Can fluctuate with diet",
                      "RBC folateMore representative of long-term folate status than serum folate",
                      "More representative of long-term folate status than serum folate",
                      "Methylmalonic acid (markedly increased in vitamin B12 deficiency)Equal sensitivity to serum vitamin B12; more robust quantitative assay than vitamin B12More specific than serum vitamin B12 (only other cause is impaired renal function)Elevated in vitamin B12 deficiency, not in folate deficiency",
                      "Equal sensitivity to serum vitamin B12; more robust quantitative assay than vitamin B12",
                      "More specific than serum vitamin B12 (only other cause is impaired renal function)",
                      "Elevated in vitamin B12 deficiency, not in folate deficiency"
                    ]
                  },
                  {
                    "text": "Additional testing if screening tests are equivocalTotal homocysteineElevated in both vitamin B12 and folate deficiencyPoor specificityAlso elevated in renal failure, alcohol abuse, hypothyroidism, isoniazid therapy, inborn errors of homocysteine metabolismLactate dehydrogenase (LDH)Often elevatedResults from rapid cell turnover due to ineffective hematopoiesisHaptoglobinDecreasedDue to hemolysisIndirect bilirubinMildly elevatedDue to hemolysisIF antibodiesSpecific for PAParietal cell antibodiesVery sensitive for PA (93%)Low specificityAlso seen in unaffected family members and other autoimmune diseases",
                    "sub_points": [
                      "Total homocysteineElevated in both vitamin B12 and folate deficiencyPoor specificityAlso elevated in renal failure, alcohol abuse, hypothyroidism, isoniazid therapy, inborn errors of homocysteine metabolism",
                      "Elevated in both vitamin B12 and folate deficiency",
                      "Poor specificity",
                      "Also elevated in renal failure, alcohol abuse, hypothyroidism, isoniazid therapy, inborn errors of homocysteine metabolism",
                      "Lactate dehydrogenase (LDH)Often elevatedResults from rapid cell turnover due to ineffective hematopoiesis",
                      "Often elevated",
                      "Results from rapid cell turnover due to ineffective hematopoiesis",
                      "HaptoglobinDecreasedDue to hemolysis",
                      "Decreased",
                      "Due to hemolysis",
                      "Indirect bilirubinMildly elevatedDue to hemolysis",
                      "Mildly elevated",
                      "Due to hemolysis",
                      "IF antibodiesSpecific for PA",
                      "Specific for PA",
                      "Parietal cell antibodiesVery sensitive for PA (93%)Low specificityAlso seen in unaffected family members and other autoimmune diseases",
                      "Very sensitive for PA (93%)",
                      "Low specificity",
                      "Also seen in unaffected family members and other autoimmune diseases"
                    ]
                  }
                ],
                "Natural History": [
                  {
                    "text": "Anemia may not be present initially"
                  },
                  {
                    "text": "As deficiency worsens, pancytopenia may result"
                  },
                  {
                    "text": "Paradoxical inverse correlation between hemoglobin/hematocrit and severity of neurologic symptoms in vitamin B12 deficiencyAnemia may disappear with worsening neurologic symptoms",
                    "sub_points": [
                      "Anemia may disappear with worsening neurologic symptoms"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "Expected response with appropriate treatmentErythroid precursors lose megaloblastic features within 2-3 days; changes persist longer in granulocytic lineage in bone marrowHypersegmented neutrophils resolve within ~ 1 week; WBC normalizes very quickly in neutropenic patientsMarked reticulocytosis peaks within 4-10 days after therapy is startedNormal CBC parameters within 1-2 months (RBC normalization follows neutrophil and platelet recovery in pancytopenic PA patients)",
                    "sub_points": [
                      "Erythroid precursors lose megaloblastic features within 2-3 days; changes persist longer in granulocytic lineage in bone marrow",
                      "Hypersegmented neutrophils resolve within ~ 1 week; WBC normalizes very quickly in neutropenic patients",
                      "Marked reticulocytosis peaks within 4-10 days after therapy is started",
                      "Normal CBC parameters within 1-2 months (RBC normalization follows neutrophil and platelet recovery in pancytopenic PA patients)"
                    ]
                  }
                ],
                "Drugs": [
                  {
                    "text": "Vitamin B12 or folate replacementCan be replaced orally or intramuscularlyIntramuscular vehicle necessary for people with absorption problems",
                    "sub_points": [
                      "Can be replaced orally or intramuscularly",
                      "Intramuscular vehicle necessary for people with absorption problems"
                    ]
                  },
                  {
                    "text": "Supplementation with only folate may improve anemia in patients with vitamin B12 deficiency, while neurologic symptoms will progress"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Excellent, if treated"
                  },
                  {
                    "text": "Some neurologic symptoms can be irreversible"
                  },
                  {
                    "text": "Autoimmune disorder in PA may be linked to other adverse manifestations"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Peripheral bloodMacrocytic anemia with oval macrocytesAnisopoikilocytosis worsens with severity of deficiencyHowell-Jolly bodies, basophilic stippling, or Cabot rings in erythrocytes (severe)Schistocytes may be presentHypersegmented neutrophils may be early signSevere cases may exhibit pancytopenia",
                    "sub_points": [
                      "Macrocytic anemia with oval macrocytes",
                      "Anisopoikilocytosis worsens with severity of deficiency",
                      "Howell-Jolly bodies, basophilic stippling, or Cabot rings in erythrocytes (severe)",
                      "Schistocytes may be present",
                      "Hypersegmented neutrophils may be early sign",
                      "Severe cases may exhibit pancytopenia"
                    ]
                  },
                  {
                    "text": "Bone marrowHypercellularity of all lineages, but erythroid lineage is often most prominentMyeloblasts shouldnotbe significantly increasedReversed myeloid:erythroid ratio (frequently)Megaloblastic changes in multiple lineagesErythroid cells have enlarged nuclei with fine, sieve-like chromatinGiant metamyelocytes and bandsDissociation in nuclear vs. cytoplasmic maturation (nuclear stage less mature than cytoplasm) due to defects in DNA synthesisMild erythroid dysplasia may include nuclear budding and binucleate forms due to stress erythropoiesisIncreased sideroblastic ironStorage iron may also be increased if no concurrent iron deficiency",
                    "sub_points": [
                      "Hypercellularity of all lineages, but erythroid lineage is often most prominent",
                      "Myeloblasts shouldnotbe significantly increased",
                      "Reversed myeloid:erythroid ratio (frequently)",
                      "Megaloblastic changes in multiple lineagesErythroid cells have enlarged nuclei with fine, sieve-like chromatinGiant metamyelocytes and bandsDissociation in nuclear vs. cytoplasmic maturation (nuclear stage less mature than cytoplasm) due to defects in DNA synthesis",
                      "Erythroid cells have enlarged nuclei with fine, sieve-like chromatin",
                      "Giant metamyelocytes and bands",
                      "Dissociation in nuclear vs. cytoplasmic maturation (nuclear stage less mature than cytoplasm) due to defects in DNA synthesis",
                      "Mild erythroid dysplasia may include nuclear budding and binucleate forms due to stress erythropoiesis",
                      "Increased sideroblastic iron",
                      "Storage iron may also be increased if no concurrent iron deficiency"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "Generally not indicated"
                  },
                  {
                    "text": "Stains for CD71 will demonstrate prominent erythroid hyperplasia in marrow"
                  },
                  {
                    "text": "CD34 showsnoincrease in blastsMegakaryocytes may be CD34(+)",
                    "sub_points": [
                      "Megakaryocytes may be CD34(+)"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Myelodysplastic Syndromes With Erythroid Lineage Predominance": [
                  {
                    "text": "Clonal neoplasm of hematopoietic stem cellsChromosomal abnormalities seen in ~ 30% myelodysplastic syndromes (MDS)",
                    "sub_points": [
                      "Chromosomal abnormalities seen in ~ 30% myelodysplastic syndromes (MDS)"
                    ]
                  },
                  {
                    "text": "DysplasiaMust be present in ≥ 10% of cells of given lineageErythroid dysplasia can overlap with megaloblastic anemia morphology but usually shows other dysplastic featuresIf multilineage dysplasia is present, this disfavors megaloblastic anemiaDysgranulopoiesis includes nuclear hypolobation and hypogranular cytoplasmDysmegakaryopoiesis includes micromegakaryocytes with hypolobation of nuclei",
                    "sub_points": [
                      "Must be present in ≥ 10% of cells of given lineage",
                      "Erythroid dysplasia can overlap with megaloblastic anemia morphology but usually shows other dysplastic features",
                      "If multilineage dysplasia is present, this disfavors megaloblastic anemiaDysgranulopoiesis includes nuclear hypolobation and hypogranular cytoplasmDysmegakaryopoiesis includes micromegakaryocytes with hypolobation of nuclei",
                      "Dysgranulopoiesis includes nuclear hypolobation and hypogranular cytoplasm",
                      "Dysmegakaryopoiesis includes micromegakaryocytes with hypolobation of nuclei"
                    ]
                  },
                  {
                    "text": "Blast percent variable; must be < 20%"
                  },
                  {
                    "text": "Ring sideroblastsNot always present in MDS butnotfeature of megaloblastic anemia",
                    "sub_points": [
                      "Not always present in MDS butnotfeature of megaloblastic anemia"
                    ]
                  }
                ],
                "Pure Erythroid Leukemia (Subtype of Acute Myeloid Leukemia With MutatedTP53)": [
                  {
                    "text": "Cytogenetic abnormalities;TP53mutations virtually all casesComplex karyotype with multiple structural abnormalities most common",
                    "sub_points": [
                      "Complex karyotype with multiple structural abnormalities most common"
                    ]
                  },
                  {
                    "text": "Increased pronormoblasts; ≥ 30% of erythroid lineage cells (80% of total cells are in erythroid lineage)"
                  }
                ],
                "Thrombotic Thrombocytopenic Purpura": [
                  {
                    "text": "Close clinical and hematologic overlap with PA"
                  },
                  {
                    "text": "Disrupted oval macrocytes of PA produce schistocytes"
                  },
                  {
                    "text": "Both TTP and PA can exhibit neurologic symptoms"
                  }
                ],
                "Medications and Toxins": [
                  {
                    "text": "Agents that interfere with DNA synthesis"
                  },
                  {
                    "text": "Clinical history essential"
                  }
                ],
                "Collagen Vascular Disease": [
                  {
                    "text": "May see megaloblastoid changes in erythroid nuclei"
                  },
                  {
                    "text": "Often present with cytopenias"
                  },
                  {
                    "text": "Bone marrow is variably cellular but can be hypercellular"
                  },
                  {
                    "text": "Exclude with laboratory testing and clinical history"
                  }
                ],
                "Idiopathic Cytopenia of Undetermined Significance": [
                  {
                    "text": "Persistent unexplained cytopenia(s) clinically"
                  },
                  {
                    "text": "No dysplasia; normal blast percentage"
                  },
                  {
                    "text": "No cytogenetic abnormalities, no gene mutations"
                  },
                  {
                    "text": "No detectable vitamin deficiencies"
                  },
                  {
                    "text": "Clinical history to exclude medications or toxins as cause of cytopenia"
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Clinically Relevant Pathologic Features": [
                  {
                    "text": "Peripheral blood smearMacrocytic anemia with anisopoikilocytosis; oval macrocytesHypersegmented neutrophils",
                    "sub_points": [
                      "Macrocytic anemia with anisopoikilocytosis; oval macrocytes",
                      "Hypersegmented neutrophils"
                    ]
                  },
                  {
                    "text": "Hypercellular bone marrowNormal blast percentageProminence of erythroid lineage",
                    "sub_points": [
                      "Normal blast percentage",
                      "Prominence of erythroid lineage"
                    ]
                  },
                  {
                    "text": "Nuclear featuresMegaloblastic changesErythroid cells with fine, sieve-like chromatinGranulocytes also have enlarged nuclei, fine chromatin, giant bands",
                    "sub_points": [
                      "Megaloblastic changesErythroid cells with fine, sieve-like chromatinGranulocytes also have enlarged nuclei, fine chromatin, giant bands",
                      "Erythroid cells with fine, sieve-like chromatin",
                      "Granulocytes also have enlarged nuclei, fine chromatin, giant bands"
                    ]
                  }
                ],
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "Macrocytic anemia with no clear cut clinical explanation should prompt evaluation of serum vitamin B12, folate, and methylmalonic acidBone marrow biopsy is generally not necessary in cases of megaloblastic anemiaRisk of misinterpretation as leukemia or MDSBe aware of clinical and hematologic overlap between PA and TTPBe aware that PA may be associated with normal MCV &/or pancytopenia",
                    "sub_points": [
                      "Bone marrow biopsy is generally not necessary in cases of megaloblastic anemiaRisk of misinterpretation as leukemia or MDS",
                      "Risk of misinterpretation as leukemia or MDS",
                      "Be aware of clinical and hematologic overlap between PA and TTP",
                      "Be aware that PA may be associated with normal MCV &/or pancytopenia"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Granulomas in Bone Marrow": {
            "name": "Granulomas in Bone Marrow",
            "url": "https://app.pathprimer.com/document/e0aca703-c115-47c0-a615-e42f39ffd7e5/lesson/92495282-ce4a-41b9-a2f4-c2339cb2cc79",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Loose or discrete aggregate of histiocytes/macrophages with variable numbers of admixed lymphocytes, plasma cells, eosinophils, and neutrophils"
                  },
                  {
                    "text": "LipogranulomaHistiocytic/macrophage reaction to lipid-like materialMost common type of BM granuloma",
                    "sub_points": [
                      "Histiocytic/macrophage reaction to lipid-like material",
                      "Most common type of BM granuloma"
                    ]
                  },
                  {
                    "text": "Epithelioid granulomaCohesive aggregate of eosinophilic histiocytes/macrophagesMany subtypesCaseatingSarcoid typeForeign body type",
                    "sub_points": [
                      "Cohesive aggregate of eosinophilic histiocytes/macrophages",
                      "Many subtypes",
                      "Caseating",
                      "Sarcoid type",
                      "Foreign body type"
                    ]
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "Histiocytic/macrophage reaction to diverse inciting agents"
                  },
                  {
                    "text": "Common tissue response to many types of infections"
                  },
                  {
                    "text": "Bacteria, fungi, viruses,Rickettsia,Leishmania, others"
                  },
                  {
                    "text": "Response to foreign material (e.g., crystals or other foreign material)"
                  },
                  {
                    "text": "Ring granulomas characteristic of Q fever but also seen in other disorders"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Fever or cytopenias common in patients with infectious BM"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Granulomas most frequently detected on good-quality core biopsy sections"
                  },
                  {
                    "text": "Caseating granulomasVery likely to be infectiousPositive stains for bacteria, mycobacteria, fungi common",
                    "sub_points": [
                      "Very likely to be infectious",
                      "Positive stains for bacteria, mycobacteria, fungi common"
                    ]
                  },
                  {
                    "text": "Granulomas may be poorly formed/absent in patients with underlying immunodeficiency despite secondary infectionPerform organism stains",
                    "sub_points": [
                      "Perform organism stains"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Definitions": [
                  {
                    "text": "Loose or discrete aggregate of histiocytes/macrophages with variable numbers of admixed lymphocytes, plasma cells, eosinophils, and neutrophilsAdditional features that may be noted includeMultinucleated giant cells or lymphoid aggregatesCentral necrosis or lipid vacuolesBacteria or fungiMay be rare or confluent",
                    "sub_points": [
                      "Additional features that may be noted includeMultinucleated giant cells or lymphoid aggregatesCentral necrosis or lipid vacuolesBacteria or fungi",
                      "Multinucleated giant cells or lymphoid aggregates",
                      "Central necrosis or lipid vacuoles",
                      "Bacteria or fungi",
                      "May be rare or confluent"
                    ]
                  },
                  {
                    "text": "LipogranulomaHistiocytic/macrophage reaction to lipid-like materialMost common type of BM granulomaIncreased frequency in older adultsMay become epithelioid as lipid is resorbed",
                    "sub_points": [
                      "Histiocytic/macrophage reaction to lipid-like material",
                      "Most common type of BM granuloma",
                      "Increased frequency in older adults",
                      "May become epithelioid as lipid is resorbed"
                    ]
                  },
                  {
                    "text": "Epithelioid granulomaCohesive aggregate of eosinophilic histiocytes/macrophagesMany subtypesCaseatingRing granulomaSarcoid typeForeign body type",
                    "sub_points": [
                      "Cohesive aggregate of eosinophilic histiocytes/macrophages",
                      "Many subtypes",
                      "Caseating",
                      "Ring granuloma",
                      "Sarcoid type",
                      "Foreign body type"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Pathophysiology": [
                  {
                    "text": "Histiocytic/macrophage reaction to diverse inciting agentsMay be idiopathicHistiocytes nonneoplasticDistinctive immune responseCommon tissue response to many types of infectionsBacteria, fungi, viruses,Rickettsia,Leishmania, othersFormation of cohesive granulomas impaired in HIV(+) patients with reduced numbers of helper T cellsMay be associated with neoplastic infiltrates in BMPresumed immune response to neoplasmsGenerally admixed with neoplastic cellsMay develop following bacille Calmette-Guérin (BCG) therapyMay be idiosyncratic reaction to drug therapyReaction to foreign material introduced into BMMultinucleated giant cells described in association with long-term oral bisphosphonatesProposed to be giant osteoclasts",
                    "sub_points": [
                      "May be idiopathic",
                      "Histiocytes nonneoplastic",
                      "Distinctive immune response",
                      "Common tissue response to many types of infectionsBacteria, fungi, viruses,Rickettsia,Leishmania, others",
                      "Bacteria, fungi, viruses,Rickettsia,Leishmania, others",
                      "Formation of cohesive granulomas impaired in HIV(+) patients with reduced numbers of helper T cells",
                      "May be associated with neoplastic infiltrates in BMPresumed immune response to neoplasmsGenerally admixed with neoplastic cells",
                      "Presumed immune response to neoplasms",
                      "Generally admixed with neoplastic cells",
                      "May develop following bacille Calmette-Guérin (BCG) therapy",
                      "May be idiosyncratic reaction to drug therapy",
                      "Reaction to foreign material introduced into BM",
                      "Multinucleated giant cells described in association with long-term oral bisphosphonatesProposed to be giant osteoclasts",
                      "Proposed to be giant osteoclasts"
                    ]
                  },
                  {
                    "text": "Multifactorial causesMay find isolated epithelioid granulomas in negative staging BMs in Hodgkin lymphoma (HL) patientsPresumed remote immune response to neoplasmLipogranulomas are incidental finding linked to ageEpithelioid granulomasBacterial/fungal infectionsOther infectionsCaseating granulomas in mycobacterial infectionsRing granulomas in Q fever (not specific)Response to immune aberrations (e.g., sarcoidosis, neoplasms)Response to foreign material (e.g., crystals or other foreign material)Ring granulomas characteristic of Q fever but also seen in other disorders",
                    "sub_points": [
                      "May find isolated epithelioid granulomas in negative staging BMs in Hodgkin lymphoma (HL) patientsPresumed remote immune response to neoplasm",
                      "Presumed remote immune response to neoplasm",
                      "Lipogranulomas are incidental finding linked to age",
                      "Epithelioid granulomasBacterial/fungal infectionsOther infectionsCaseating granulomas in mycobacterial infectionsRing granulomas in Q fever (not specific)Response to immune aberrations (e.g., sarcoidosis, neoplasms)Response to foreign material (e.g., crystals or other foreign material)",
                      "Bacterial/fungal infections",
                      "Other infections",
                      "Caseating granulomas in mycobacterial infections",
                      "Ring granulomas in Q fever (not specific)",
                      "Response to immune aberrations (e.g., sarcoidosis, neoplasms)",
                      "Response to foreign material (e.g., crystals or other foreign material)",
                      "Ring granulomas characteristic of Q fever but also seen in other disorders"
                    ]
                  }
                ],
                "Diseases Associated With Bone Marrow Granulomas": [
                  {
                    "text": "Noncaseating granulomas (found in ~ 1-2% of BM core biopsy specimensViral infectionsMycobacterium avium-intracellulareOther infections: Brucellosis, rickettsial infections, Q-fever, typhoid fever, leprosy, tularemiaSarcoidosisGranulomas may show striking multinucleationGranulomas may resolve, at least partially, after therapyAnemia common; some patients also have eosinophiliaNeoplasm associatedHLNon-HL (NHL)MyelomaCarcinomas/melanomaAutoimmune disordersPosttherapy reactionsMedication associatedIdiopathic",
                    "sub_points": [
                      "Viral infections",
                      "Mycobacterium avium-intracellulare",
                      "Other infections: Brucellosis, rickettsial infections, Q-fever, typhoid fever, leprosy, tularemia",
                      "SarcoidosisGranulomas may show striking multinucleationGranulomas may resolve, at least partially, after therapyAnemia common; some patients also have eosinophilia",
                      "Granulomas may show striking multinucleation",
                      "Granulomas may resolve, at least partially, after therapy",
                      "Anemia common; some patients also have eosinophilia",
                      "Neoplasm associatedHLNon-HL (NHL)MyelomaCarcinomas/melanoma",
                      "HL",
                      "Non-HL (NHL)",
                      "Myeloma",
                      "Carcinomas/melanoma",
                      "Autoimmune disorders",
                      "Posttherapy reactions",
                      "Medication associated",
                      "Idiopathic"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Presentation": [
                  {
                    "text": "No symptoms related to lipogranulomasIncidental finding",
                    "sub_points": [
                      "Incidental finding"
                    ]
                  },
                  {
                    "text": "Fever or cytopenias common in patients with infectious BM granulomasEspecially likely in patients with underlying immunodeficiency disorders",
                    "sub_points": [
                      "Especially likely in patients with underlying immunodeficiency disorders"
                    ]
                  },
                  {
                    "text": "Some patients with BM granulomas have stage IV lymphomas or other neoplasmsFever and weight loss common symptomsVariable lymphadenopathy, splenomegaly, other organ pathology depending on type of neoplasm",
                    "sub_points": [
                      "Fever and weight loss common symptoms",
                      "Variable lymphadenopathy, splenomegaly, other organ pathology depending on type of neoplasm"
                    ]
                  },
                  {
                    "text": "Patients with constitutional crystal deposition disorders may exhibit prominent granulomatous response in BMVery rareCrystals elicit granulomatosis responseOxalosisCystinosis",
                    "sub_points": [
                      "Very rare",
                      "Crystals elicit granulomatosis response",
                      "Oxalosis",
                      "Cystinosis"
                    ]
                  },
                  {
                    "text": "Foreign body granulomas may occur in patients with antecedent surgical procedurese.g., foreign body reaction to squamous cells in sternal BM specimen in patient with previous cardiac surgerye.g., foreign body reaction to hydrophilic polymer-coated medical devices",
                    "sub_points": [
                      "e.g., foreign body reaction to squamous cells in sternal BM specimen in patient with previous cardiac surgery",
                      "e.g., foreign body reaction to hydrophilic polymer-coated medical devices"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "Variable depending upon underlying cause of granulomas"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Variable depending on underlying cause"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Blood": [
                  {
                    "text": "Nonspecific findings linked to underlying disordersMay see toxic neutrophilia &/or monocytosis in fungal or bacterial infections",
                    "sub_points": [
                      "May see toxic neutrophilia &/or monocytosis in fungal or bacterial infections"
                    ]
                  },
                  {
                    "text": "Fungi may be present on blood smear"
                  },
                  {
                    "text": "Variable cytopenias &/or cytoses depending on underlying conditions"
                  }
                ],
                "Bone Marrow Aspirate Smears": [
                  {
                    "text": "May see granulomas on aspirate smears but is uncommonClumps of histiocytes seen on scanning of aspirate smears",
                    "sub_points": [
                      "Clumps of histiocytes seen on scanning of aspirate smears"
                    ]
                  },
                  {
                    "text": "May see negative image of organisms within histiocyte cytoplasm on Wright stain"
                  },
                  {
                    "text": "Fungi may be apparent on Wright stain"
                  }
                ],
                "Bone Marrow Core Biopsy": [
                  {
                    "text": "Granulomas most frequently detected on good-quality core biopsy sections of at least 1-2 cm in length"
                  },
                  {
                    "text": "Loose or discrete collections of eosinophilic histiocytesLipid-like material gives foamy appearance to lipogranulomasVariable necrosisVariable giant cell formationVariable caseation",
                    "sub_points": [
                      "Lipid-like material gives foamy appearance to lipogranulomas",
                      "Variable necrosis",
                      "Variable giant cell formation",
                      "Variable caseation"
                    ]
                  },
                  {
                    "text": "Caseating granulomasVery likely to be infectiousPositive stains for bacteria, mycobacteria, fungi common",
                    "sub_points": [
                      "Very likely to be infectious",
                      "Positive stains for bacteria, mycobacteria, fungi common"
                    ]
                  },
                  {
                    "text": "Granulomas may be poorly formed/absent in patients with underlying immunodeficiency despite secondary infectionAlways perform organism stainsAssess for diffuse increase in histiocytesMay be subtle on H&E stains",
                    "sub_points": [
                      "Always perform organism stains",
                      "Assess for diffuse increase in histiocytesMay be subtle on H&E stains",
                      "May be subtle on H&E stains"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "In Situ Hybridization": [
                  {
                    "text": "EBER relevant in occasional cases"
                  }
                ],
                "PCR": [
                  {
                    "text": "Relevant in selected types of infections"
                  }
                ],
                "Blood and Bone Marrow Cultures for Various Organisms": [
                  {
                    "text": "Specimens for culture cannot be placed in either fixative or heparinized syringe"
                  },
                  {
                    "text": "Specimens for culture should be transported promptly to laboratory"
                  },
                  {
                    "text": "Request that specimen be cultured for bacteria, fungi, acid-fast bacteria, and viruses"
                  },
                  {
                    "text": "Request that Gram stains be performed on culture specimens to expedite identification of some infectious agents"
                  }
                ],
                "Organism Stains on Clot or Core Biopsy Sections": [
                  {
                    "text": "GMS stain for fungiGMS with diastase easier to interpret on BM sections since few normal structures stain",
                    "sub_points": [
                      "GMS with diastase easier to interpret on BM sections since few normal structures stain"
                    ]
                  },
                  {
                    "text": "Acid-fast stain for mycobacteriaAtypical mycobacteria (Mycobacterium aviumcomplex) are typically abundant within granulomas and interspersed histiocytesMycobacterium tuberculosisare typically very rare, and lengthy review is required",
                    "sub_points": [
                      "Atypical mycobacteria (Mycobacterium aviumcomplex) are typically abundant within granulomas and interspersed histiocytes",
                      "Mycobacterium tuberculosisare typically very rare, and lengthy review is required"
                    ]
                  },
                  {
                    "text": "Gram stain for bacteriaBacteria may be evident in circulating neutrophils in septic patientsFoamy histiocytes in BM contain bacteria in Whipple disease",
                    "sub_points": [
                      "Bacteria may be evident in circulating neutrophils in septic patients",
                      "Foamy histiocytes in BM contain bacteria in Whipple disease"
                    ]
                  }
                ],
                "Histochemical Stains": [
                  {
                    "text": "CD68, CD14, or CD163 to highlight histiocytes"
                  },
                  {
                    "text": "B- and T-cell markers for lymphoid infiltrates (needed occasionally)"
                  },
                  {
                    "text": "Stains for various infectious agents, as needed, if available"
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Underlying Cause of Granulomas": [
                  {
                    "text": "Infections (many types)"
                  },
                  {
                    "text": "Neoplasm associated"
                  },
                  {
                    "text": "Immune disorders"
                  },
                  {
                    "text": "Sarcoidosis"
                  },
                  {
                    "text": "BCG therapy"
                  },
                  {
                    "text": "Drug reactions"
                  },
                  {
                    "text": "Idiopathic/unexplained"
                  }
                ],
                "Disorders Mimicking Granulomas": [
                  {
                    "text": "Discrete aggregates of mast cells may mimic granulomas on BM core biopsy sections"
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "Integrate clinical, hemogram, blood, and BM findings"
                  },
                  {
                    "text": "Review blood smears for infectious agents: Fungi, bacteria, or CMV (scan feather edge)"
                  },
                  {
                    "text": "Maintain high index of suspicion for secondary infections in febrile immunosuppressed patients"
                  },
                  {
                    "text": "Plan for cultures that will need to be obtained on fresh, unfixed BM aspirate or core biopsy specimens"
                  },
                  {
                    "text": "BM aspirates may be difficult to obtain due to reticulin fibrosis"
                  },
                  {
                    "text": "Assess histiocytes/macrophages for negative images of bacteria on aspirate smears"
                  },
                  {
                    "text": "Review blood and BM aspirate smears for fungi"
                  },
                  {
                    "text": "Core biopsy specimens should be free of significant aspiration artifact and 1-2 cm longExtra biopsy can be obtained for cultures if aspirates are unsuccessful",
                    "sub_points": [
                      "Extra biopsy can be obtained for cultures if aspirates are unsuccessful"
                    ]
                  },
                  {
                    "text": "Assess core biopsy and clot sections for granulomas &/or diffuse increase in histiocytes"
                  },
                  {
                    "text": "Generously use organism stains/cultures in febrile or immunosuppressed patients"
                  },
                  {
                    "text": "Note that organism stains are typically negative whenOnly tiny clusters of epithelioid histiocytes are noted in healthy, afebrile patientGranulomas are cut through during subsequent sectioning",
                    "sub_points": [
                      "Only tiny clusters of epithelioid histiocytes are noted in healthy, afebrile patient",
                      "Granulomas are cut through during subsequent sectioning"
                    ]
                  },
                  {
                    "text": "Epithelioid granulomas in cases of sarcoidosis are very discrete, tight, and distinctiveGiant cells are commonOrganism stains are negativeCultures are negativeClinical and laboratory evaluation for possible sarcoidosis warranted",
                    "sub_points": [
                      "Giant cells are common",
                      "Organism stains are negative",
                      "Cultures are negative",
                      "Clinical and laboratory evaluation for possible sarcoidosis warranted"
                    ]
                  },
                  {
                    "text": "Foreign body-type giant cells very rarely encounteredView with polarized lightConsider exogenous material that is inadvertently introduced from prior procedureReaction to squamous cells introduced from surgical procedure near BM siteReaction to hydrophilic polymer-like material seen rarely in BM vessels following use of polymer-coated intravascular medical devicesConstitutional crystal deposition disorders are typically readily evident clinicallyMay see multinucleated giant cells in patients on oral bisphosphonate therapy",
                    "sub_points": [
                      "View with polarized light",
                      "Consider exogenous material that is inadvertently introduced from prior procedureReaction to squamous cells introduced from surgical procedure near BM siteReaction to hydrophilic polymer-like material seen rarely in BM vessels following use of polymer-coated intravascular medical devices",
                      "Reaction to squamous cells introduced from surgical procedure near BM site",
                      "Reaction to hydrophilic polymer-like material seen rarely in BM vessels following use of polymer-coated intravascular medical devices",
                      "Constitutional crystal deposition disorders are typically readily evident clinically",
                      "May see multinucleated giant cells in patients on oral bisphosphonate therapy"
                    ]
                  }
                ],
                "Neoplasm-Associated Granulomas": [
                  {
                    "text": "High index of suspicion if cytologically atypical cells noted in conjunction with histiocytes"
                  },
                  {
                    "text": "Lymphoma-associated granulomas may be present in both HL and NHL"
                  },
                  {
                    "text": "IHC assessment of atypical cells essentialIHC panel must include B-, T-, HL-associated antigens, CD45, and EBER ISHMetastatic lesion can be excluded by IHC",
                    "sub_points": [
                      "IHC panel must include B-, T-, HL-associated antigens, CD45, and EBER ISH",
                      "Metastatic lesion can be excluded by IHC"
                    ]
                  },
                  {
                    "text": "Clinical correlation essential"
                  },
                  {
                    "text": "Biopsy of extramedullary site may be required for definite diagnosis"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Parvovirus B19 Infection": {
            "name": "Parvovirus B19 Infection",
            "url": "https://app.pathprimer.com/document/e53dcd03-38e2-49b8-b35b-9b456a650ee7/lesson/92495282-ce4a-41b9-a2f4-c2339cb2cc79",
            "content": {
              "KEY FACTS": {
                "Etiology/Pathogenesis": [
                  {
                    "text": "Parvovirus B19 (B19V) propagates efficiently only in human erythroid progenitor cellsVirus is cytotoxic to these cells",
                    "sub_points": [
                      "Virus is cytotoxic to these cells"
                    ]
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Clinical manifestations of B19V depend on patient age, underlying hematologic disorders, immune stratus"
                  },
                  {
                    "text": "Erythema infectiosumMost common form of B19V infectionAcute disease of primarily children (fifth disease)",
                    "sub_points": [
                      "Most common form of B19V infection",
                      "Acute disease of primarily children (fifth disease)"
                    ]
                  },
                  {
                    "text": "Transient aplastic crisisPatients with underlying decreased erythroid production or increased red cell lossPrecipitous drop in hemoglobin",
                    "sub_points": [
                      "Patients with underlying decreased erythroid production or increased red cell loss",
                      "Precipitous drop in hemoglobin"
                    ]
                  },
                  {
                    "text": "Chronic infection with persistent anemia in immunocompromised individualsPrimary infection, reinfection or reactivation",
                    "sub_points": [
                      "Primary infection, reinfection or reactivation"
                    ]
                  },
                  {
                    "text": "Arthralgias and arthritis"
                  },
                  {
                    "text": "Fetal anemia, hydrops fetalis, intrauterine fetal death"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Normochromic normocytic anemiaReticulocytopeniaEvaluate for underlying hematologic disorder",
                    "sub_points": [
                      "Reticulocytopenia",
                      "Evaluate for underlying hematologic disorder"
                    ]
                  },
                  {
                    "text": "Possible neutropenia, thrombocytopenia"
                  },
                  {
                    "text": "Bone marrow with red cell aplasiaMinimal erythroid maturation beyond proerythroblast stage unless immunosuppressedGiant proerythroblasts or \"lantern cells\" are hallmark of infection",
                    "sub_points": [
                      "Minimal erythroid maturation beyond proerythroblast stage unless immunosuppressed",
                      "Giant proerythroblasts or \"lantern cells\" are hallmark of infection"
                    ]
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "Immunohistochemistry or in situ hybridization for virus in biopsy sections confirms infection"
                  },
                  {
                    "text": "Real-time PCR helpful in diagnosis of acute or chronic infection"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Parvovirus B19 (B19V)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Erythema infectiosum"
                  },
                  {
                    "text": "Fifth disease"
                  }
                ],
                "Definitions": [
                  {
                    "text": "At least 4 different parvoviruses infect humansSmall, single-stranded, nonenveloped DNA virusesB19V is best characterizedMember of Parvoviridae family; genusErythrovirus",
                    "sub_points": [
                      "Small, single-stranded, nonenveloped DNA viruses",
                      "B19V is best characterizedMember of Parvoviridae family; genusErythrovirus",
                      "Member of Parvoviridae family; genusErythrovirus"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "B19V Pathogenesis": [
                  {
                    "text": "TransmissionPrimarily through respiratory dropletsVertically from 30-50% of infected mothers to fetusStem cell and organ transplantsBlood transfusion products",
                    "sub_points": [
                      "Primarily through respiratory droplets",
                      "Vertically from 30-50% of infected mothers to fetus",
                      "Stem cell and organ transplants",
                      "Blood transfusion products"
                    ]
                  },
                  {
                    "text": "Selective tropism for erythroid lineage cells in bone marrowViral capsid binds globoside on erythroid progenitor cellsSpecific uncharacterized cell receptor allows viral entryProductive viral replication in CFU-E to erythroblastsDependent on erythropoietin stimulation; enhanced in hypoxic conditionsInduces DNA damage response, cell cycle arrest, apoptosis, cytolysisTransient or persistent cessation of red cell productionHemoglobin drops ~ 1g/dL in normal individuals",
                    "sub_points": [
                      "Viral capsid binds globoside on erythroid progenitor cells",
                      "Specific uncharacterized cell receptor allows viral entry",
                      "Productive viral replication in CFU-E to erythroblastsDependent on erythropoietin stimulation; enhanced in hypoxic conditionsInduces DNA damage response, cell cycle arrest, apoptosis, cytolysisTransient or persistent cessation of red cell productionHemoglobin drops ~ 1g/dL in normal individuals",
                      "Dependent on erythropoietin stimulation; enhanced in hypoxic conditions",
                      "Induces DNA damage response, cell cycle arrest, apoptosis, cytolysis",
                      "Transient or persistent cessation of red cell production",
                      "Hemoglobin drops ~ 1g/dL in normal individuals"
                    ]
                  },
                  {
                    "text": "Secondary viremic phase after productive viral replication in bone marrowInfection of other cells types during high viral loadsB-lymphocytes in tonsils, placental trophoblasts, endothelial and stromal cellsDetectable B19V DNA can persist in infected tissues lifelong",
                    "sub_points": [
                      "Infection of other cells types during high viral loadsB-lymphocytes in tonsils, placental trophoblasts, endothelial and stromal cellsDetectable B19V DNA can persist in infected tissues lifelong",
                      "B-lymphocytes in tonsils, placental trophoblasts, endothelial and stromal cells",
                      "Detectable B19V DNA can persist in infected tissues lifelong"
                    ]
                  },
                  {
                    "text": "Immune response develops against virusAnemia resolves in 10-19 days",
                    "sub_points": [
                      "Anemia resolves in 10-19 days"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "Common in childhood≥ 50% have lifelong immunity",
                    "sub_points": [
                      "≥ 50% have lifelong immunity"
                    ]
                  },
                  {
                    "text": "Yearly seroconversion rate of ~ 1% in women of childbearing age"
                  },
                  {
                    "text": "Detectable antibody in 85% of older individuals"
                  },
                  {
                    "text": "More common during winter and early spring"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Self-limiting disease in healthy individualsIncubation period is 3 days to 3 weeksAsymptomatic in 25-50% of casesFever, coryza, headache, mild gastrointestinal distressSubclinical erythroid aplasia followed by rash or arthralgias",
                    "sub_points": [
                      "Incubation period is 3 days to 3 weeks",
                      "Asymptomatic in 25-50% of cases",
                      "Fever, coryza, headache, mild gastrointestinal distress",
                      "Subclinical erythroid aplasia followed by rash or arthralgias"
                    ]
                  },
                  {
                    "text": "Erythema infectiosum (fifth disease)Most common form of B19V infectionMainly children but some adults\"Slapped cheek\" rash develops 4-14 days after infectionBright red eruption with surrounding pallorPossible 2nd rash follows with erythematous maculopapular exanthem on trunk and limbs",
                    "sub_points": [
                      "Most common form of B19V infection",
                      "Mainly children but some adults",
                      "\"Slapped cheek\" rash develops 4-14 days after infectionBright red eruption with surrounding pallorPossible 2nd rash follows with erythematous maculopapular exanthem on trunk and limbs",
                      "Bright red eruption with surrounding pallor",
                      "Possible 2nd rash follows with erythematous maculopapular exanthem on trunk and limbs"
                    ]
                  },
                  {
                    "text": "Transient aplastic crisisMain cause for community-acquired aplastic crisisPrecipitous drop in hemoglobinMarked erythroid hypoplasia in marrowAffects individuals with concurrent conditionsHemolytic disordersHereditary spherocytosisThalassemia, sickle cell diseaseRed cell enzyme deficienciesAutoimmune hemolytic anemiaRBC production problemsHemorrhage, iron deficiency anemiaMalaria, hookworm, or other infectionsRenal or stem cell transplantsImmunosuppressed with insufficient B19V antibody production (acute, chronic infections)AIDS or congenital immunodeficiencyReceiving immunosuppressive or chemotherapyHematopoietic neoplasmsSymptoms relate to worsening anemiaDyspnea, lassitudeCardiovascular complications, congestive heart failureBone marrow necrosis in sickle cell diseaseCan be fatalUsually recover in 1 week unless persistent infectionPure red cell aplasia in chronic infectionMay develop neutropenia, thrombocytopenia, and, rarely, bone marrow failureMultiorgan complications in patients with hereditary hemolytic anemias",
                    "sub_points": [
                      "Main cause for community-acquired aplastic crisis",
                      "Precipitous drop in hemoglobinMarked erythroid hypoplasia in marrow",
                      "Marked erythroid hypoplasia in marrow",
                      "Affects individuals with concurrent conditionsHemolytic disordersHereditary spherocytosisThalassemia, sickle cell diseaseRed cell enzyme deficienciesAutoimmune hemolytic anemiaRBC production problemsHemorrhage, iron deficiency anemiaMalaria, hookworm, or other infectionsRenal or stem cell transplantsImmunosuppressed with insufficient B19V antibody production (acute, chronic infections)AIDS or congenital immunodeficiencyReceiving immunosuppressive or chemotherapyHematopoietic neoplasms",
                      "Hemolytic disordersHereditary spherocytosisThalassemia, sickle cell diseaseRed cell enzyme deficienciesAutoimmune hemolytic anemia",
                      "Hereditary spherocytosis",
                      "Thalassemia, sickle cell disease",
                      "Red cell enzyme deficiencies",
                      "Autoimmune hemolytic anemia",
                      "RBC production problemsHemorrhage, iron deficiency anemiaMalaria, hookworm, or other infectionsRenal or stem cell transplants",
                      "Hemorrhage, iron deficiency anemia",
                      "Malaria, hookworm, or other infections",
                      "Renal or stem cell transplants",
                      "Immunosuppressed with insufficient B19V antibody production (acute, chronic infections)AIDS or congenital immunodeficiencyReceiving immunosuppressive or chemotherapyHematopoietic neoplasms",
                      "AIDS or congenital immunodeficiency",
                      "Receiving immunosuppressive or chemotherapy",
                      "Hematopoietic neoplasms",
                      "Symptoms relate to worsening anemiaDyspnea, lassitudeCardiovascular complications, congestive heart failureBone marrow necrosis in sickle cell diseaseCan be fatal",
                      "Dyspnea, lassitude",
                      "Cardiovascular complications, congestive heart failure",
                      "Bone marrow necrosis in sickle cell diseaseCan be fatal",
                      "Can be fatal",
                      "Usually recover in 1 week unless persistent infectionPure red cell aplasia in chronic infectionMay develop neutropenia, thrombocytopenia, and, rarely, bone marrow failureMultiorgan complications in patients with hereditary hemolytic anemias",
                      "Pure red cell aplasia in chronic infection",
                      "May develop neutropenia, thrombocytopenia, and, rarely, bone marrow failure",
                      "Multiorgan complications in patients with hereditary hemolytic anemias"
                    ]
                  },
                  {
                    "text": "Arthralgias and arthritis (polyarthropathy syndrome)More common in adolescents and adults60% females, 30% malesSymmetrical arthralgias, mainly hands and feetLast 1-3 weeks, may persist or recurAssociation of B19V with juvenile rheumatic disease",
                    "sub_points": [
                      "More common in adolescents and adults60% females, 30% males",
                      "60% females, 30% males",
                      "Symmetrical arthralgias, mainly hands and feetLast 1-3 weeks, may persist or recurAssociation of B19V with juvenile rheumatic disease",
                      "Last 1-3 weeks, may persist or recur",
                      "Association of B19V with juvenile rheumatic disease"
                    ]
                  },
                  {
                    "text": "Fetal infection in 17-35% of exposed seronegative pregnant womenHighest risk in 11th-20th week of gestationNonimmune hydrops fetalis or fetal death in ~ 10%Occurs in healthy and immunosuppressed individuals",
                    "sub_points": [
                      "Highest risk in 11th-20th week of gestation",
                      "Nonimmune hydrops fetalis or fetal death in ~ 10%",
                      "Occurs in healthy and immunosuppressed individuals"
                    ]
                  },
                  {
                    "text": "Rare cause of hemophagocytic syndrome"
                  }
                ],
                "Treatment": [
                  {
                    "text": "Immunocompetent patients with transient aplastic crisisRBC transfusions, supportive therapy",
                    "sub_points": [
                      "RBC transfusions, supportive therapy"
                    ]
                  },
                  {
                    "text": "Immunosuppressed patients with persistent infectionTemporary cessation of immunosuppression if feasibleAdminister intravenous immunoglobulin (also for acute, severe infection)",
                    "sub_points": [
                      "Temporary cessation of immunosuppression if feasible",
                      "Administer intravenous immunoglobulin (also for acute, severe infection)"
                    ]
                  },
                  {
                    "text": "Arthralgias and arthritisRespond to NSAIDs",
                    "sub_points": [
                      "Respond to NSAIDs"
                    ]
                  },
                  {
                    "text": "Maternal B19V infectionIntrauterine blood transfusionsTreatment of hydrops fetalis, severe fetal anemia",
                    "sub_points": [
                      "Intrauterine blood transfusionsTreatment of hydrops fetalis, severe fetal anemia",
                      "Treatment of hydrops fetalis, severe fetal anemia"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Benign and self-limiting infectionMajority of children and adults",
                    "sub_points": [
                      "Majority of children and adults"
                    ]
                  },
                  {
                    "text": "Immunosuppressed patientsMay be fatal if severely immunosuppressed",
                    "sub_points": [
                      "May be fatal if severely immunosuppressed"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Peripheral Blood": [
                  {
                    "text": "Normochromic normocytic anemiaReticulocytopeniaResistant to erythropoietin therapyNonspecific anisopoikilocytosisImmunocompromised patientsCirculating nRBCs may have rare nuclear inclusions",
                    "sub_points": [
                      "ReticulocytopeniaResistant to erythropoietin therapy",
                      "Resistant to erythropoietin therapy",
                      "Nonspecific anisopoikilocytosisImmunocompromised patientsCirculating nRBCs may have rare nuclear inclusions",
                      "Immunocompromised patients",
                      "Circulating nRBCs may have rare nuclear inclusions"
                    ]
                  },
                  {
                    "text": "Evaluate for underlying hematologic disorderRed cell shapesSpherocytes in hereditary spherocytosisSickle cells in sickle cell anemiaRed cell sizeHypochromic microcytes in thalassemia and iron deficiency",
                    "sub_points": [
                      "Red cell shapesSpherocytes in hereditary spherocytosisSickle cells in sickle cell anemia",
                      "Spherocytes in hereditary spherocytosis",
                      "Sickle cells in sickle cell anemia",
                      "Red cell sizeHypochromic microcytes in thalassemia and iron deficiency",
                      "Hypochromic microcytes in thalassemia and iron deficiency"
                    ]
                  },
                  {
                    "text": "Normal or slightly decreased WBC countMild lymphopenia or neutropenia",
                    "sub_points": [
                      "Mild lymphopenia or neutropenia"
                    ]
                  },
                  {
                    "text": "Normal or decreased platelets"
                  },
                  {
                    "text": "Possible plasmacytosis 6-10 days after initial infection"
                  }
                ],
                "Bone Marrow": [
                  {
                    "text": "Giant proerythroblasts are hallmark of B19V infectionAlso referred to as \"lantern cells\"Nuclei have fine megaloblastoid chromatinNuclear viral inclusions may be subtleDark blue, often vacuolated cytoplasm in earliest cellsBecome larger in size, lose cytoplasmic basophilia, and develop pseudopodia over timeBroad-based or \"dog ear\" cytoplasmic projections",
                    "sub_points": [
                      "Also referred to as \"lantern cells\"Nuclei have fine megaloblastoid chromatinNuclear viral inclusions may be subtleDark blue, often vacuolated cytoplasm in earliest cellsBecome larger in size, lose cytoplasmic basophilia, and develop pseudopodia over timeBroad-based or \"dog ear\" cytoplasmic projections",
                      "Nuclei have fine megaloblastoid chromatin",
                      "Nuclear viral inclusions may be subtle",
                      "Dark blue, often vacuolated cytoplasm in earliest cells",
                      "Become larger in size, lose cytoplasmic basophilia, and develop pseudopodia over time",
                      "Broad-based or \"dog ear\" cytoplasmic projections"
                    ]
                  },
                  {
                    "text": "Immunocompetent patientsRed cell aplasia with minimal erythroid maturation beyond proerythroblast stage due to viral cytopathic effectsVariably increased megakaryocytes and hematogonesMay see wave of regenerating erythroid precursors",
                    "sub_points": [
                      "Red cell aplasia with minimal erythroid maturation beyond proerythroblast stage due to viral cytopathic effects",
                      "Variably increased megakaryocytes and hematogones",
                      "May see wave of regenerating erythroid precursors"
                    ]
                  },
                  {
                    "text": "Immunosuppressed patientsOften hypercellular bone marrowErythroid lineage present in normal numberViral tolerance with maturation of infected erythroid cells",
                    "sub_points": [
                      "Often hypercellular bone marrowErythroid lineage present in normal numberViral tolerance with maturation of infected erythroid cells",
                      "Erythroid lineage present in normal number",
                      "Viral tolerance with maturation of infected erythroid cells"
                    ]
                  },
                  {
                    "text": "Viral-associated suppression of myeloid or megakaryocytic lineages possible"
                  },
                  {
                    "text": "Severe bone marrow necrosis (rare)"
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Bone Marrow Paraffin Tissue": [
                  {
                    "text": "Immunohistochemical stain for B19V capsid proteins"
                  },
                  {
                    "text": "In situ hybridization for B19V DNA"
                  }
                ],
                "Serology": [
                  {
                    "text": "IgM assay, preferably by capture technique90% of cases positiveBy 3rd day of transient aplastic crisisorAt time of rash in erythema infectiosumIgM antibody present 7-12 days after infection and up to 4 months or moreMay be negative in immunosuppressed patients or pregnant women",
                    "sub_points": [
                      "90% of cases positiveBy 3rd day of transient aplastic crisisorAt time of rash in erythema infectiosum",
                      "By 3rd day of transient aplastic crisisor",
                      "At time of rash in erythema infectiosum",
                      "IgM antibody present 7-12 days after infection and up to 4 months or moreMay be negative in immunosuppressed patients or pregnant women",
                      "May be negative in immunosuppressed patients or pregnant women"
                    ]
                  },
                  {
                    "text": "IgG antibody appears after decline of IgM productionPersists lifelong, but titers slowly decrease unless boosted by B19V encounter",
                    "sub_points": [
                      "Persists lifelong, but titers slowly decrease unless boosted by B19V encounter"
                    ]
                  }
                ],
                "PCR for B19V DNA": [
                  {
                    "text": "Detectable in serum for > 4 months after acute infection"
                  },
                  {
                    "text": "Real-time PCR helpful in diagnosis of acute or chronic infection, including in immunocompromised individuals"
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Pure Red Cell Aplasia": [
                  {
                    "text": "Transient erythroblastopenia of childhoodHigh platelet counts unlike B19V infection",
                    "sub_points": [
                      "High platelet counts unlike B19V infection"
                    ]
                  },
                  {
                    "text": "Other viral infections, medication effect"
                  },
                  {
                    "text": "Diamond-Blackfan anemiaMacrocytic anemia, < 1 year of age",
                    "sub_points": [
                      "Macrocytic anemia, < 1 year of age"
                    ]
                  },
                  {
                    "text": "Immune-mediated disorders"
                  },
                  {
                    "text": "MalignancyThymoma, T-cell large granular lymphocytic leukemia",
                    "sub_points": [
                      "Thymoma, T-cell large granular lymphocytic leukemia"
                    ]
                  }
                ],
                "Aplastic Anemia": [
                  {
                    "text": "Bone marrow failure disorder"
                  },
                  {
                    "text": "Hypocellular bone marrow with trilineage hypoplasiaNo viral inclusions",
                    "sub_points": [
                      "No viral inclusions"
                    ]
                  }
                ],
                "Rheumatoid Arthritis": [
                  {
                    "text": "Exclude B19V infection if acute presentation"
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Clinically Relevant Pathologic Features": [
                  {
                    "text": "Serologic assays for B19V infection may be negative in immunosuppressed individuals"
                  }
                ],
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "Perform immunohistochemical or in situ hybridization stains for B19VOn bone marrows from immunocompromised patients with persistent anemia (especially HIV infected)May show erythroid maturation",
                    "sub_points": [
                      "On bone marrows from immunocompromised patients with persistent anemia (especially HIV infected)May show erythroid maturation",
                      "May show erythroid maturation"
                    ]
                  },
                  {
                    "text": "Presence or absence of viral inclusionsNeed ancillary tests for diagnosis of B19V infection",
                    "sub_points": [
                      "Need ancillary tests for diagnosis of B19V infection"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Neutrophilia": {
            "name": "Neutrophilia",
            "url": "https://app.pathprimer.com/document/319a6121-3603-491a-9b38-6a9cf6e9ea85/lesson/92495282-ce4a-41b9-a2f4-c2339cb2cc79",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Absolute neutrophil count (ANC) that exceeds age-related normal rangesNewborn > 28.0 x 10⁹/LInfant > 10.0 x 10⁹/LChild > 8.0 x 10⁹/LAdult > 7.0 x 10⁹/L",
                    "sub_points": [
                      "Newborn > 28.0 x 10⁹/L",
                      "Infant > 10.0 x 10⁹/L",
                      "Child > 8.0 x 10⁹/L",
                      "Adult > 7.0 x 10⁹/L"
                    ]
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "Many causes of secondary neutrophiliasInfections most commonOther causes: Inflammation, metabolic disorders, medicationsRare constitutional neutrophilias",
                    "sub_points": [
                      "Infections most common",
                      "Other causes: Inflammation, metabolic disorders, medications",
                      "Rare constitutional neutrophilias"
                    ]
                  },
                  {
                    "text": "PathogenesisDemarginationRelease of BM reserve compartmentIncreased neutrophil production in BM",
                    "sub_points": [
                      "Demargination",
                      "Release of BM reserve compartment",
                      "Increased neutrophil production in BM"
                    ]
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Absolute neutrophilia"
                  },
                  {
                    "text": "Variable degree of left shift of neutrophil lineage"
                  },
                  {
                    "text": "Toxic changes usually presentNeutrophil vacuolization suggests sepsis",
                    "sub_points": [
                      "Neutrophil vacuolization suggests sepsis"
                    ]
                  },
                  {
                    "text": "Other lineages generally unremarkable"
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "Chronic myeloid leukemia"
                  },
                  {
                    "text": "Chronic neutrophilic leukemia"
                  },
                  {
                    "text": "Other myeloproliferative neoplasm"
                  },
                  {
                    "text": "Myelodysplastic/myeloproliferative neoplasm"
                  }
                ],
                "Diagnostic Checklist": [
                  {
                    "text": "Careful history for possible cytokine therapy"
                  },
                  {
                    "text": "Consider myeloproliferative neoplasmIf splenomegaly or basophilia presentIf leukoerythroblastic picture present",
                    "sub_points": [
                      "If splenomegaly or basophilia present",
                      "If leukoerythroblastic picture present"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Synonyms": [
                  {
                    "text": "Granulocytosis"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Absolute neutrophil count (ANC) that exceeds age-related normal rangesNewborn > 28.0 x 10⁹/LInfant > 10.0 x 10⁹/LChild > 8.0 x 10⁹/LAdult > 7.0 x 10⁹/L",
                    "sub_points": [
                      "Newborn > 28.0 x 10⁹/L",
                      "Infant > 10.0 x 10⁹/L",
                      "Child > 8.0 x 10⁹/L",
                      "Adult > 7.0 x 10⁹/L"
                    ]
                  },
                  {
                    "text": "Leukemoid reactionExaggerated leukocytosis usually > 50 x 10⁹/LUsually includes marked neutrophilia with left shift",
                    "sub_points": [
                      "Exaggerated leukocytosis usually > 50 x 10⁹/L",
                      "Usually includes marked neutrophilia with left shift"
                    ]
                  },
                  {
                    "text": "Leukoerythroblastic reactionCaused by myelophthisis (BM disruption)BM microenvironment disrupted by metastatic tumor &/or fibrosisVariable degree of leukocytosisLeft shift with circulating immature granulocytic lineage cellsNucleated RBCs",
                    "sub_points": [
                      "Caused by myelophthisis (BM disruption)",
                      "BM microenvironment disrupted by metastatic tumor &/or fibrosis",
                      "Variable degree of leukocytosisLeft shift with circulating immature granulocytic lineage cells",
                      "Left shift with circulating immature granulocytic lineage cells",
                      "Nucleated RBCs"
                    ]
                  },
                  {
                    "text": "Chronic idiopathic neutrophiliaSuggested designation for cases with sustained neutrophilia with no cause found in otherwise asymptomatic patient",
                    "sub_points": [
                      "Suggested designation for cases with sustained neutrophilia with no cause found in otherwise asymptomatic patient"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Diverse Etiologies for Secondary Neutrophilias": [
                  {
                    "text": "Infections (usually bacterial)"
                  },
                  {
                    "text": "Occasional viral infections (SARS, hantavirus)"
                  },
                  {
                    "text": "Medications/hormones/endogenous overproductionRecombinant colony-stimulating factor (CSF) therapyChemokine therapyGranulocyte CSF (G-CSF)-producing tumorsLungKidneyBladderTongue (squamous cell)Chemokine-producing tumorsBladderEpinephrineCorticosteroidsLithiumβ-agonists",
                    "sub_points": [
                      "Recombinant colony-stimulating factor (CSF) therapy",
                      "Chemokine therapy",
                      "Granulocyte CSF (G-CSF)-producing tumorsLungKidneyBladderTongue (squamous cell)",
                      "Lung",
                      "Kidney",
                      "Bladder",
                      "Tongue (squamous cell)",
                      "Chemokine-producing tumorsBladder",
                      "Bladder",
                      "Epinephrine",
                      "Corticosteroids",
                      "Lithium",
                      "β-agonists"
                    ]
                  },
                  {
                    "text": "Inflammatory and metabolic disordersObesityBurnsTraumaInfarctionGoutCollagen vascular diseaseKetoacidosisInflammatory bowel diseaseChronic hepatitisEclampsiaOther chronic inflammatory disorders",
                    "sub_points": [
                      "Obesity",
                      "Burns",
                      "Trauma",
                      "Infarction",
                      "Gout",
                      "Collagen vascular disease",
                      "Ketoacidosis",
                      "Inflammatory bowel disease",
                      "Chronic hepatitis",
                      "Eclampsia",
                      "Other chronic inflammatory disorders"
                    ]
                  },
                  {
                    "text": "OtherStressSmokingObstructive sleep apneaAsphyxiaPregnancyToxinsVenomsPostsplenectomyNonhematologic neoplasmsLinked to liver metastasis or paraneoplastic syndromes",
                    "sub_points": [
                      "Stress",
                      "Smoking",
                      "Obstructive sleep apnea",
                      "Asphyxia",
                      "Pregnancy",
                      "Toxins",
                      "Venoms",
                      "Postsplenectomy",
                      "Nonhematologic neoplasmsLinked to liver metastasis or paraneoplastic syndromes",
                      "Linked to liver metastasis or paraneoplastic syndromes"
                    ]
                  },
                  {
                    "text": "Leukemoid reactionInfection most common causeParaneoplastic leukemoid reaction also common",
                    "sub_points": [
                      "Infection most common cause",
                      "Paraneoplastic leukemoid reaction also common"
                    ]
                  },
                  {
                    "text": "Leukoerythroblastic reactionCommon in myeloproliferative neoplasm (MPN) and other hematopoietic neoplasmsAlso seen with BM involvement by solid tumors",
                    "sub_points": [
                      "Common in myeloproliferative neoplasm (MPN) and other hematopoietic neoplasms",
                      "Also seen with BM involvement by solid tumors"
                    ]
                  }
                ],
                "Constitutional Neutrophilic Disorders": [
                  {
                    "text": "Leukocyte adhesion deficiency (LAD)Neutrophil production increasedMarked neutrophilia in bloodNeutrophils unable to migrate to sites of infectionMultiple genetic types",
                    "sub_points": [
                      "Neutrophil production increased",
                      "Marked neutrophilia in blood",
                      "Neutrophils unable to migrate to sites of infection",
                      "Multiple genetic types"
                    ]
                  },
                  {
                    "text": "Hereditary neutrophilia"
                  },
                  {
                    "text": "Familial cold urticaria"
                  },
                  {
                    "text": "Down syndrome"
                  }
                ],
                "Pathophysiology": [
                  {
                    "text": "Astronomic daily production rates of neutrophils in BM"
                  },
                  {
                    "text": "Earliest myeloid precursor cells reside adjacent to bony trabeculae and around small blood vessels"
                  },
                  {
                    "text": "Maturing granulocytic lineage cells reside more centrally with ready access to BM sinusoids and systemic circulation"
                  },
                  {
                    "text": "Large reserve of neutrophils, bands, and neutrophilic myelocytes is present in central medullary regions of BMRepresents ~ 1-week supply",
                    "sub_points": [
                      "Represents ~ 1-week supply"
                    ]
                  },
                  {
                    "text": "Reserve pool can be released into blood in response to acute stress or medication"
                  },
                  {
                    "text": "Neutrophils circulate for only few hours before migrating to tissue"
                  },
                  {
                    "text": "Neutrophils migrate by attaching to endothelium and passing through vessel wall"
                  },
                  {
                    "text": "Estimated total lifespan of neutrophils is 11-16 days (mostly within BM)"
                  },
                  {
                    "text": "ANC highest normal range at birthShould decline rapidly after birthLymphocytes outnumber neutrophils by 1 week of age",
                    "sub_points": [
                      "Should decline rapidly after birth",
                      "Lymphocytes outnumber neutrophils by 1 week of age"
                    ]
                  },
                  {
                    "text": "Neutrophil homeostasis maintained largely via steady BM production"
                  },
                  {
                    "text": "In most clinical situations, ANC reflects total body neutrophil reservesException LAD in which neutrophils markedly increased in blood but cannot migrate to tissues",
                    "sub_points": [
                      "Exception LAD in which neutrophils markedly increased in blood but cannot migrate to tissues"
                    ]
                  }
                ],
                "Mechanisms of Neutrophilia": [
                  {
                    "text": "DemarginationNeutrophils attached to endothelium are released back into circulationCaused by epinephrineRapid processDoubles ANC within few minutes",
                    "sub_points": [
                      "Neutrophils attached to endothelium are released back into circulation",
                      "Caused by epinephrine",
                      "Rapid process",
                      "Doubles ANC within few minutes"
                    ]
                  },
                  {
                    "text": "Release of BM reserve compartmentCaused by G-CSF, adhesion molecule mediatorsTakes several hoursLeft shift in blood (limited)Prominent increase in ANCMyeloblasts not typically present in circulationTransient circulating blasts present early on with recombinant G-CSF therapy",
                    "sub_points": [
                      "Caused by G-CSF, adhesion molecule mediators",
                      "Takes several hours",
                      "Left shift in blood (limited)",
                      "Prominent increase in ANC",
                      "Myeloblasts not typically present in circulationTransient circulating blasts present early on with recombinant G-CSF therapy",
                      "Transient circulating blasts present early on with recombinant G-CSF therapy"
                    ]
                  },
                  {
                    "text": "Increased productionCaused by sustained stimulus to BM myeloid stem cellsG-CSF mediatedIncreased granulopoiesis in BMRequires days to several weeksPrimary mechanism in sustained neutrophilias",
                    "sub_points": [
                      "Caused by sustained stimulus to BM myeloid stem cells",
                      "G-CSF mediated",
                      "Increased granulopoiesis in BM",
                      "Requires days to several weeks",
                      "Primary mechanism in sustained neutrophilias"
                    ]
                  },
                  {
                    "text": "Corticosteroid therapy-associated neutrophiliaDemarginationReduced release from BMReduced egression from blood to tissue",
                    "sub_points": [
                      "Demargination",
                      "Reduced release from BM",
                      "Reduced egression from blood to tissue"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "AdultsMore frequent in inpatient hospital settingLinked to numerous acute stressful events, especially acute &/or chronic bacterial or fungal infectionsLinked to smoking, obesity, other acute and chronic inflammatory disorders",
                    "sub_points": [
                      "More frequent in inpatient hospital setting",
                      "Linked to numerous acute stressful events, especially acute &/or chronic bacterial or fungal infections",
                      "Linked to smoking, obesity, other acute and chronic inflammatory disorders"
                    ]
                  },
                  {
                    "text": "ChildrenLinked to acute infections, other acute stressful events",
                    "sub_points": [
                      "Linked to acute infections, other acute stressful events"
                    ]
                  },
                  {
                    "text": "NeonatesLinked to infection, acute stress (many causes), congenital anomalies, and rare constitutional neutrophiliasMay be seen as component of transient abnormal myelopoiesis in newborns with Down syndrome",
                    "sub_points": [
                      "Linked to infection, acute stress (many causes), congenital anomalies, and rare constitutional neutrophilias",
                      "May be seen as component of transient abnormal myelopoiesis in newborns with Down syndrome"
                    ]
                  }
                ],
                "Presentation": [
                  {
                    "text": "Abnormal CBC with leukocytosis"
                  },
                  {
                    "text": "Neutrophilia"
                  },
                  {
                    "text": "Clinical features highly variable due to many diverse causes of neutrophilia"
                  },
                  {
                    "text": "Many patients present with symptoms of acute or chronic infection"
                  },
                  {
                    "text": "Paradox of severe recurrent infections in setting of striking blood neutrophilia in rare patients with neutrophil migratory defect LAD"
                  }
                ],
                "Treatment and Prognosis": [
                  {
                    "text": "Dependent upon underlying cause"
                  },
                  {
                    "text": "Potential risk of recombinant G-CSF treatment in healthy donors for allogeneic transplantation"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Predominant Pattern/Injury Type": [
                  {
                    "text": "Hyperplasia"
                  }
                ],
                "Predominant Cell/Compartment Type": [
                  {
                    "text": "Neutrophil"
                  }
                ],
                "Histologic Features": [
                  {
                    "text": "BloodVariable toxic features of neutrophilsToxic granulationDöhle bodiesVacuolization, if prominent suggests sepsisGranulocytic fragments mimicking platelets also found in severe sepsis and systemic inflammatory response syndrome (SIRS)Neutrophils with botryoid nuclear hypersegmentation in hyperthermiaVariable degree of left shift of neutrophil lineageLimited left shift in adults with infectionsMay see circulating blasts in infected neonates, infantsMonocytes may show toxic changes in infection and with recombinant granulocyte-macrophage CSF (GM-CSF) therapyOther lineages generally unremarkable",
                    "sub_points": [
                      "Variable toxic features of neutrophilsToxic granulationDöhle bodiesVacuolization, if prominent suggests sepsisGranulocytic fragments mimicking platelets also found in severe sepsis and systemic inflammatory response syndrome (SIRS)",
                      "Toxic granulation",
                      "Döhle bodies",
                      "Vacuolization, if prominent suggests sepsisGranulocytic fragments mimicking platelets also found in severe sepsis and systemic inflammatory response syndrome (SIRS)",
                      "Granulocytic fragments mimicking platelets also found in severe sepsis and systemic inflammatory response syndrome (SIRS)",
                      "Neutrophils with botryoid nuclear hypersegmentation in hyperthermia",
                      "Variable degree of left shift of neutrophil lineageLimited left shift in adults with infectionsMay see circulating blasts in infected neonates, infants",
                      "Limited left shift in adults with infections",
                      "May see circulating blasts in infected neonates, infants",
                      "Monocytes may show toxic changes in infection and with recombinant granulocyte-macrophage CSF (GM-CSF) therapy",
                      "Other lineages generally unremarkable"
                    ]
                  },
                  {
                    "text": "BMIncreased granulocytic lineage with intact maturation (if neutrophilia sustained)May see mild left shift if neutrophils released rapidly due to demandOther lineages and bone generally unremarkable",
                    "sub_points": [
                      "Increased granulocytic lineage with intact maturation (if neutrophilia sustained)",
                      "May see mild left shift if neutrophils released rapidly due to demand",
                      "Other lineages and bone generally unremarkable"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Molecular Genetics/Cytogenetics": [
                  {
                    "text": "Rule out chronic myeloid leukemia (CML)"
                  },
                  {
                    "text": "Rule out other MPNs or myelodysplastic/MPN (MDS/MPN)"
                  },
                  {
                    "text": "Assessment for rare germline constitutional disorders or Down syndrome"
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Iatrogenic Cytokine-Mediated Neutrophilia": [
                  {
                    "text": "Recombinant G-CSF or GM-CSF therapy"
                  },
                  {
                    "text": "Used to induce rapid neutrophil recovery after profound myelosuppressive therapy"
                  },
                  {
                    "text": "Widely used in healthy donors for collection of peripheral blood progenitor cells for allogeneic transplantation"
                  },
                  {
                    "text": "Used to treat some constitutional (germline) neutropenias"
                  },
                  {
                    "text": "Used to treat other sustained, refractory neutropenias"
                  },
                  {
                    "text": "May see increased blasts in blood and BM during early response"
                  },
                  {
                    "text": "At peak response, marked neutrophilia with left shift, including circulating myeloblasts"
                  },
                  {
                    "text": "Marked toxic changes"
                  },
                  {
                    "text": "Rare binucleated neutrophils/neutrophil precursors"
                  },
                  {
                    "text": "Acquired tetraploidy may be factor in leukemia risk in healthy stem cell donors who receive G-CSF"
                  }
                ],
                "Chronic Myeloid Leukemia; Subtype of MPN": [
                  {
                    "text": "WBC often > 100 x 10⁹/L"
                  },
                  {
                    "text": "Absence of toxic changes"
                  },
                  {
                    "text": "Left shift includes blasts"
                  },
                  {
                    "text": "Basophilia, often striking"
                  },
                  {
                    "text": "Eosinophilia common"
                  },
                  {
                    "text": "Normoblasts"
                  },
                  {
                    "text": "Splenomegaly"
                  },
                  {
                    "text": "BCR::ABL1by cytogenetics/molecular"
                  },
                  {
                    "text": "Hypercellular BM"
                  },
                  {
                    "text": "Abnormal, hypolobated dwarf megakaryocytes"
                  }
                ],
                "Chronic Neutrophilic Leukemia (International Consensus Classification) (MPN Subtype)": [
                  {
                    "text": "WBC ≥ 25 x 10⁹/L for cases lackingCSF3Rmutation"
                  },
                  {
                    "text": "WBC ≥ 13 x 10⁹/L forCSF3R-mutated cases"
                  },
                  {
                    "text": "Neutrophils + bands constitute ≥ 80% of WBC; may see toxic changes"
                  },
                  {
                    "text": "Limited left shift"
                  },
                  {
                    "text": "BM hypercellular with increased granulocytic lineage; blasts < 10% for chronic phase"
                  },
                  {
                    "text": "Additional International Consensus Classification (ICC) criteria"
                  },
                  {
                    "text": "Megakaryocytes may show morphologic abnormalities"
                  },
                  {
                    "text": "Splenomegaly common"
                  }
                ],
                "Other MPNs": [
                  {
                    "text": "WBC variable but may exhibit nontoxic neutrophilia"
                  },
                  {
                    "text": "Left shift may include blasts"
                  },
                  {
                    "text": "Normoblasts common"
                  },
                  {
                    "text": "Basophilia variable"
                  },
                  {
                    "text": "Erythrocytosis or thrombocytosis may be present"
                  },
                  {
                    "text": "JAK2,CALR, orMPLmutations in most cases"
                  },
                  {
                    "text": "Hypercellular BM"
                  },
                  {
                    "text": "Abnormal megakaryocytes with hyperlobation and clustering"
                  },
                  {
                    "text": "Variable fibrosis"
                  },
                  {
                    "text": "Variable osteosclerosis"
                  },
                  {
                    "text": "Splenomegaly present"
                  }
                ],
                "MDS/MPN": [
                  {
                    "text": "Neutrophilia required in atypical chronic myeloid leukemia (aCML)"
                  },
                  {
                    "text": "Variable degree of neutrophiliaHigh in aCML, may be elevated in chronic myelomonocytic leukemia (CMML) but not required by ICC",
                    "sub_points": [
                      "High in aCML, may be elevated in chronic myelomonocytic leukemia (CMML) but not required by ICC"
                    ]
                  },
                  {
                    "text": "At least 1 cytopenia must also be present"
                  },
                  {
                    "text": "Dysplasia of neutrophils typical"
                  },
                  {
                    "text": "Variable percent circulating blasts; < 20%"
                  },
                  {
                    "text": "Monocytosis (> 10% WBC) in CMML; monocyte dysplasia common"
                  },
                  {
                    "text": "Molecular genetic testing essential for diagnosis; additional ICC criteria"
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Clinically Relevant Pathologic Features": [
                  {
                    "text": "Cause of secondary neutrophilia usually clinically apparent"
                  },
                  {
                    "text": "Careful history for possible cytokine therapy"
                  },
                  {
                    "text": "Elevation of WBC and ANC usually ≤ 30 x 10⁹/L"
                  },
                  {
                    "text": "Left shift doesnotgenerally include blasts in adults,exceptpatients receiving recombinant G-CSF"
                  },
                  {
                    "text": "Left shift may include blasts in septic neonates/young infants"
                  },
                  {
                    "text": "Assess for toxic changes in neutrophils"
                  },
                  {
                    "text": "If blasts, basophilia, marked leukocytosis, &/or normoblasts present, consider MPN"
                  },
                  {
                    "text": "Significant splenomegaly more suggestive of MPN"
                  },
                  {
                    "text": "Molecular genetic testing may be warranted to exclude neoplastic neutrophilias"
                  },
                  {
                    "text": "In rare patients, sustained neutrophilia may be consequence of G-CSF or chemokine-producing neoplasmsMyelomas, sarcomas, carcinomas, and mesotheliomas may aberrantly produce neutrophilia-inducing chemokines or cytokinesNeutrophils may show toxic changes",
                    "sub_points": [
                      "Myelomas, sarcomas, carcinomas, and mesotheliomas may aberrantly produce neutrophilia-inducing chemokines or cytokines",
                      "Neutrophils may show toxic changes"
                    ]
                  },
                  {
                    "text": "Constitutional neutrophilias restricted to rare family kindredsNot usually encountered in routine clinical practice",
                    "sub_points": [
                      "Not usually encountered in routine clinical practice"
                    ]
                  }
                ],
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "Spectrum of morphologic features in reactive processesToxic granulationDöhle bodiesCytoplasmic vacuolesLinked to sepsis if prominent",
                    "sub_points": [
                      "Toxic granulation",
                      "Döhle bodies",
                      "Cytoplasmic vacuolesLinked to sepsis if prominent",
                      "Linked to sepsis if prominent"
                    ]
                  },
                  {
                    "text": "Secondary neutrophilias generally exhibit single-lineage abnormalities in blood"
                  },
                  {
                    "text": "Degree of left shift generally limited in secondary neutrophiliasPromyelocytes may be present in low percentageMyeloblasts generally absent or very rareMyeloblasts present early on with G-CSF therapy for profound neutropeniaMature neutrophils predominate",
                    "sub_points": [
                      "Promyelocytes may be present in low percentage",
                      "Myeloblasts generally absent or very rare",
                      "Myeloblasts present early on with G-CSF therapy for profound neutropenia",
                      "Mature neutrophils predominate"
                    ]
                  }
                ],
                "BM Examination": [
                  {
                    "text": "Rarely warranted in straightforward secondary neutrophiliaMay be necessary to document specific infection in BM",
                    "sub_points": [
                      "May be necessary to document specific infection in BM"
                    ]
                  },
                  {
                    "text": "If performed for infection work-up, sterilenonanticoagulated specimen is essential for culture"
                  },
                  {
                    "text": "Warranted in patients with unexplained neutrophilia, especially if dysplasia, circulating blasts, nucleated RBCs, or cytopenias presentGenetic assessment essential for potential myeloid neoplasmsBoth cytogenetic and molecular studies usually required",
                    "sub_points": [
                      "Genetic assessment essential for potential myeloid neoplasms",
                      "Both cytogenetic and molecular studies usually required"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Pyruvate Kinase Deficiency": {
            "name": "Pyruvate Kinase Deficiency",
            "url": "https://app.pathprimer.com/document/2f6a106c-0a97-4896-a2d6-a92e0b637424/lesson/92495282-ce4a-41b9-a2f4-c2339cb2cc79",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Pyruvate kinase deficiency (PKD) results in defects in glycolytic pathway, ultimately leading to hereditary hemolytic anemia"
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "> 200 hereditary mutations involvePKLRgene on chromosome 1q21"
                  },
                  {
                    "text": "Majority are missense mutations"
                  },
                  {
                    "text": "Transmission is autosomal recessive"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Along with G6PD deficiency, PKD is most common cause of hereditary nonspherocytic hemolytic anemia"
                  },
                  {
                    "text": "TestingPyruvate kinase enzyme activity testing has been gold standardFalse-negatives with recent transfusion or incomplete removal of WBCsGenetic testing/mutational analysis is becoming more common",
                    "sub_points": [
                      "Pyruvate kinase enzyme activity testing has been gold standardFalse-negatives with recent transfusion or incomplete removal of WBCs",
                      "False-negatives with recent transfusion or incomplete removal of WBCs",
                      "Genetic testing/mutational analysis is becoming more common"
                    ]
                  },
                  {
                    "text": "Clinical history and prognosisSplenectomy results in conspicuous rise in reticulocytes, unique to PKDAnemia often well tolerated due to increased 2,3-DPG in red cells, resulting in right shift (promoting release in tissues) of oxygen dissociation curveDegree of hemolysis varies from very mild to severeIron overload can occur as result of frequent transfusion therapy and in those with no or few transfusions",
                    "sub_points": [
                      "Splenectomy results in conspicuous rise in reticulocytes, unique to PKD",
                      "Anemia often well tolerated due to increased 2,3-DPG in red cells, resulting in right shift (promoting release in tissues) of oxygen dissociation curve",
                      "Degree of hemolysis varies from very mild to severe",
                      "Iron overload can occur as result of frequent transfusion therapy and in those with no or few transfusions"
                    ]
                  },
                  {
                    "text": "TreatmentSupportive care was mainstayNewer drug, mitapivat, elevates hemoglobin in many patients; FDA approved",
                    "sub_points": [
                      "Supportive care was mainstay",
                      "Newer drug, mitapivat, elevates hemoglobin in many patients; FDA approved"
                    ]
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Although not specific, increased shrunken echinocytes in postsplenectomy specimen suggest PKD"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Pyruvate kinase deficiency (PKD)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Red cell PKD"
                  }
                ],
                "Definitions": [
                  {
                    "text": "PKD results in defects in glycolytic pathway, ultimately leading to hereditary hemolytic anemia"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Hereditary Genetic Mutations": [
                  {
                    "text": "> 200 hereditary mutations involvePKLRgene on chromosome 1q21Majority are missense mutations",
                    "sub_points": [
                      "Majority are missense mutations"
                    ]
                  },
                  {
                    "text": "1529A is most common mutation in USA, northern and Central Europe (42%)"
                  },
                  {
                    "text": "1456T is most common mutation in Spain, Portugal, and Italy (~ 30%)"
                  },
                  {
                    "text": "1468T is most common mutation in Asia (56%)"
                  },
                  {
                    "text": "Transmission is autosomal recessive"
                  }
                ],
                "Pathophysiology": [
                  {
                    "text": "PKLRproduces pyruvate kinase (PK) in liver and RBCs, but, as liver has compensatory mechanisms, only RBCs are clinically affected"
                  },
                  {
                    "text": "RBCs are anucleate and lack mitochondriaThus, dependent on glycolytic pathway to perform basic functionsDefects in glycolytic pathway lead to ATP depletion in RBCs with eventual cell death",
                    "sub_points": [
                      "Thus, dependent on glycolytic pathway to perform basic functionsDefects in glycolytic pathway lead to ATP depletion in RBCs with eventual cell death",
                      "Defects in glycolytic pathway lead to ATP depletion in RBCs with eventual cell death"
                    ]
                  },
                  {
                    "text": "Protective effect against malarial parasites"
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "Along with G6PD deficiency, PKD is most common cause of hereditary nonspherocytic hemolytic anemia"
                  },
                  {
                    "text": "Prevalence of ~ 1 in 20,000 in general White populationHigher frequency in Romani and Pennsylvania Amish communities",
                    "sub_points": [
                      "Higher frequency in Romani and Pennsylvania Amish communities"
                    ]
                  }
                ],
                "Ethnicity": [
                  {
                    "text": "Worldwide geographic distribution"
                  },
                  {
                    "text": "Some evidence suggests protective effect against malaria (Plasmodium falciparum) invasion of PK(-) RBCs"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Usually presents in infancy or childhood"
                  },
                  {
                    "text": "Anemia, jaundice, splenomegaly, and gallstones"
                  },
                  {
                    "text": "Degree of hemolysis varies from very mild to severe forms"
                  }
                ],
                "Laboratory Tests": [
                  {
                    "text": "PK enzyme activity testing has been gold standardShould be used as initial diagnostic testLevels decreased in PKD; PK:hexokinase enzyme activity ratio increases sensitivityFalse-negatives with recent transfusion or incomplete removal of WBCs",
                    "sub_points": [
                      "Should be used as initial diagnostic test",
                      "Levels decreased in PKD; PK:hexokinase enzyme activity ratio increases sensitivity",
                      "False-negatives with recent transfusion or incomplete removal of WBCs"
                    ]
                  },
                  {
                    "text": "Genetic testing/mutational analysis is becoming more commonVery useful in cases where enzyme testing is equivocalImportant role as confirmatory testAll exons, flanking regions, and promoter regions are sequencedCryptic mutations are not uncommonLarge deletions and intron mutations at cryptic splice sites may be difficult to detect",
                    "sub_points": [
                      "Very useful in cases where enzyme testing is equivocalImportant role as confirmatory test",
                      "Important role as confirmatory test",
                      "All exons, flanking regions, and promoter regions are sequenced",
                      "Cryptic mutations are not uncommonLarge deletions and intron mutations at cryptic splice sites may be difficult to detect",
                      "Large deletions and intron mutations at cryptic splice sites may be difficult to detect"
                    ]
                  },
                  {
                    "text": "Decreased hemoglobin"
                  },
                  {
                    "text": "Increased reticulocyte countUnlike other hemolytic anemias, reticulocyte count not proportional to severity of hemolysisSplenectomy results in conspicuous rise in reticulocytes, unique to PKD",
                    "sub_points": [
                      "Unlike other hemolytic anemias, reticulocyte count not proportional to severity of hemolysis",
                      "Splenectomy results in conspicuous rise in reticulocytes, unique to PKD"
                    ]
                  },
                  {
                    "text": "Unconjugated bilirubin increasesIf > 85 μmol/L, suspect concomitant Gilbert syndrome",
                    "sub_points": [
                      "If > 85 μmol/L, suspect concomitant Gilbert syndrome"
                    ]
                  },
                  {
                    "text": "Osmotic fragility test typically normal"
                  },
                  {
                    "text": "Iron studies often elevated (particularly ferritin)"
                  }
                ],
                "Natural History": [
                  {
                    "text": "Many infants and young children are transfusion dependentSplenectomy may help somewhat",
                    "sub_points": [
                      "Splenectomy may help somewhat"
                    ]
                  },
                  {
                    "text": "Anemia stabilizes in adulthoodExacerbations with infection, stress, pregnancy",
                    "sub_points": [
                      "Exacerbations with infection, stress, pregnancy"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "MitapivatActivates and stabilizes mutant PKGood response in most with PKD, elevates hemoglobin levels",
                    "sub_points": [
                      "Activates and stabilizes mutant PK",
                      "Good response in most with PKD, elevates hemoglobin levels"
                    ]
                  },
                  {
                    "text": "Transfusion, if neededBecause of increased 2,3-DPG (well-tolerated anemia), use clinical symptoms, not hemoglobin, as guideline",
                    "sub_points": [
                      "Because of increased 2,3-DPG (well-tolerated anemia), use clinical symptoms, not hemoglobin, as guideline"
                    ]
                  },
                  {
                    "text": "Splenectomy considered in transfusion-dependent patients"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Anemia often improves with age"
                  },
                  {
                    "text": "Anemia often well tolerated due to increased 2,3-DPG in red cells with right shift (promoting release in tissues) of oxygen dissociation curve"
                  },
                  {
                    "text": "Iron overload can occur as result of frequent transfusion therapy and in those with no or few transfusions"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Unremarkable RBC morphology on peripheral blood smearMild anisocytosis, poikilocytosis, and polychromatophilia",
                    "sub_points": [
                      "Mild anisocytosis, poikilocytosis, and polychromatophilia"
                    ]
                  },
                  {
                    "text": "Although not specific, increased shrunken echinocytes in postsplenectomy specimen suggest PKD"
                  }
                ],
                "Predominant Pattern/Injury Type": [
                  {
                    "text": "Hypercellular"
                  }
                ],
                "Predominant Cell/Compartment Type": [
                  {
                    "text": "Erythrocyte/RBC"
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Anemia": [
                  {
                    "text": "Other hemolytic anemias"
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Clinically Relevant Pathologic Features": [
                  {
                    "text": "Symptom complex"
                  },
                  {
                    "text": "Symptom time frame"
                  }
                ],
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "Morphologic findings are nonspecific; this diagnosis must be clinically suspected"
                  },
                  {
                    "text": "Should be considered in any patient with active hemolysis where all other causes of hemolytic anemia have been excluded, includingAutoimmune hemolytic anemiaRed cell membrane defectsHemoglobinopathies",
                    "sub_points": [
                      "Autoimmune hemolytic anemia",
                      "Red cell membrane defects",
                      "Hemoglobinopathies"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Red Blood Cell Inclusions": {
            "name": "Red Blood Cell Inclusions",
            "url": "https://app.pathprimer.com/document/a6be209d-aee3-4737-858a-7343bfca47cd/lesson/92495282-ce4a-41b9-a2f4-c2339cb2cc79",
            "content": {}
          },
          "Autoimmune Hemolytic Anemias": {
            "name": "Autoimmune Hemolytic Anemias",
            "url": "https://app.pathprimer.com/document/c6b59797-1c84-4f11-a48a-a1c56c0648c2/lesson/92495282-ce4a-41b9-a2f4-c2339cb2cc79",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "AIHA: RBC destruction caused by antibodies directed against antigens on RBC membrane surface"
                  },
                  {
                    "text": "WAIHA: Autoantibodies react with Rh antigens on RBC surface and cause hemolysis at 37 °C"
                  },
                  {
                    "text": "CAD: Cold agglutination with associated indolent lymphoproliferative disorder"
                  },
                  {
                    "text": "Secondary CAS: Cold agglutinin-mediated syndrome secondary to specific infections or aggressive lymphomas"
                  },
                  {
                    "text": "PCH: Complement-mediated intravascular hemolysis associated with biphasic polyclonal IgG against P antigen on RBC surface"
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "WAIHA: Extravascular hemolysis in spleen through FcR-mediated macrophage erythrohemophagocytosisSignal substance CTLA4 activates immune tolerance regulatory T cellsPD-1 signal pathway is another checkpoint for immune tolerance",
                    "sub_points": [
                      "Signal substance CTLA4 activates immune tolerance regulatory T cells",
                      "PD-1 signal pathway is another checkpoint for immune tolerance"
                    ]
                  },
                  {
                    "text": "Cold agglutinin disorders: Extravascular hemolysis occurs in liver through C3d-mediated phagocytosis by Kupffer cells"
                  },
                  {
                    "text": "PCH: P-anti-P antigen-antibody complex as potent activator of complements leads to massive intravascular hemolysis"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Patients with insidious onset gradually develop anemia-related signs and symptoms, e.g., fatigue, pallor, dizziness, and dyspnea on exertion"
                  },
                  {
                    "text": "Patients with sudden onset may have jaundice, dark urine, organomegaly, and anemia"
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "WAIHA: DAT is positive for IgG; ~ 1/2 of cases positive for both IgG and C3"
                  },
                  {
                    "text": "Cold agglutinin disorders: DAT is positive for C3"
                  },
                  {
                    "text": "In PCH, DAT is positive for C3; negative for IgG; positive Donath-Landsteiner test is confirmatory"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Autoimmune hemolytic anemia (AIHA)"
                  },
                  {
                    "text": "Warm AIHA (WAIHA)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Idiopathic hemolytic anemia (older literature)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "AIHA: Destruction of RBCs in setting of anti-RBC autoantibodyWAIHAAutoantibodies react with Rhesus (Rh) antigens on RBC surface and cause hemolysis at 37 °CCold AIHACold agglutinin-mediated AIHA: Cold agglutinin binds to erythrocytes surface antigens at 1-5 °CPrimary cold agglutinin disease (CAD): Well-defined entity with associated lymphoproliferative disorderSecondary cold agglutinin syndrome (CAS): Cold agglutinin-mediated syndrome secondary to specific infections or aggressive lymphomasParoxysmal cold hemoglobinuria (PCH)Complement-mediated intravascular hemolysis associated with biphasic polyclonal IgG against P antigen on RBCsMixed-type AIHAInvolves both warm- and cold-reacting antibodiesDrug-induced hemolytic anemiaHeterogeneous group of hemolytic reactions, which may or may not be immune mediatedSubset of drug-induced hemolytic anemia is indistinguishable from AIHAIncreasing incidence in post immune checkpoint inhibitor treatment in solid cancer patientsPD-1, PD-L1 inhibitors most commonCTLA4 inhibitorsPostautologous and allogeneic hematopoietic stem cell transplantation",
                    "sub_points": [
                      "WAIHAAutoantibodies react with Rhesus (Rh) antigens on RBC surface and cause hemolysis at 37 °C",
                      "Autoantibodies react with Rhesus (Rh) antigens on RBC surface and cause hemolysis at 37 °C",
                      "Cold AIHACold agglutinin-mediated AIHA: Cold agglutinin binds to erythrocytes surface antigens at 1-5 °CPrimary cold agglutinin disease (CAD): Well-defined entity with associated lymphoproliferative disorderSecondary cold agglutinin syndrome (CAS): Cold agglutinin-mediated syndrome secondary to specific infections or aggressive lymphomasParoxysmal cold hemoglobinuria (PCH)Complement-mediated intravascular hemolysis associated with biphasic polyclonal IgG against P antigen on RBCs",
                      "Cold agglutinin-mediated AIHA: Cold agglutinin binds to erythrocytes surface antigens at 1-5 °CPrimary cold agglutinin disease (CAD): Well-defined entity with associated lymphoproliferative disorderSecondary cold agglutinin syndrome (CAS): Cold agglutinin-mediated syndrome secondary to specific infections or aggressive lymphomas",
                      "Primary cold agglutinin disease (CAD): Well-defined entity with associated lymphoproliferative disorder",
                      "Secondary cold agglutinin syndrome (CAS): Cold agglutinin-mediated syndrome secondary to specific infections or aggressive lymphomas",
                      "Paroxysmal cold hemoglobinuria (PCH)Complement-mediated intravascular hemolysis associated with biphasic polyclonal IgG against P antigen on RBCs",
                      "Complement-mediated intravascular hemolysis associated with biphasic polyclonal IgG against P antigen on RBCs",
                      "Mixed-type AIHAInvolves both warm- and cold-reacting antibodies",
                      "Involves both warm- and cold-reacting antibodies",
                      "Drug-induced hemolytic anemiaHeterogeneous group of hemolytic reactions, which may or may not be immune mediatedSubset of drug-induced hemolytic anemia is indistinguishable from AIHAIncreasing incidence in post immune checkpoint inhibitor treatment in solid cancer patientsPD-1, PD-L1 inhibitors most commonCTLA4 inhibitors",
                      "Heterogeneous group of hemolytic reactions, which may or may not be immune mediated",
                      "Subset of drug-induced hemolytic anemia is indistinguishable from AIHA",
                      "Increasing incidence in post immune checkpoint inhibitor treatment in solid cancer patientsPD-1, PD-L1 inhibitors most commonCTLA4 inhibitors",
                      "PD-1, PD-L1 inhibitors most common",
                      "CTLA4 inhibitors",
                      "Postautologous and allogeneic hematopoietic stem cell transplantation"
                    ]
                  },
                  {
                    "text": "Intravascular hemolysisDestruction of RBCs within circulation through activation of complement system and formation of membrane attack complex (MAC)Antibody is usually IgMPCH is exception with IgG causing severe intravascular hemolysis through activation of complement (C)",
                    "sub_points": [
                      "Destruction of RBCs within circulation through activation of complement system and formation of membrane attack complex (MAC)",
                      "Antibody is usually IgM",
                      "PCH is exception with IgG causing severe intravascular hemolysis through activation of complement (C)"
                    ]
                  },
                  {
                    "text": "Extravascular hemolysisRemoval of RBCs or portion of membrane through Fc receptor (FcR) on macrophages in spleen or C3d opsonized RBCs by Kupffer cells in liverAntibody is usually IgG",
                    "sub_points": [
                      "Removal of RBCs or portion of membrane through Fc receptor (FcR) on macrophages in spleen or C3d opsonized RBCs by Kupffer cells in liver",
                      "Antibody is usually IgG"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Warm Autoimmune Hemolytic Anemia": [
                  {
                    "text": "Etiology/subtypes of WAIHAIdiopathic or primary WAIHA, no underlying disorder identified; seen in ~ 50% of WAIHASecondary WAIHALymphoproliferative disorder, such as chronic lymphocytic leukemia, is most common cause of secondary WAIHAAutoimmune disease [e.g., systemic lupus erythematosus (SLE)]; WAIHA is seen in ~ 1/3 of SLE patientsMedication can trigger WAIHAUnderlying immune deficiency, e.g., common variable immunodeficiencyStem cell and solid organ transplantationsOther predisposition conditionsImmunodeficiencyIgA deficiencyAutoimmune lymphoproliferative disordersHLA-B locus, e.g., B8 and BW6Infections, e.g., parvovirus B19, HCVSpecific infections can be associated with WAIHAHIV, EBV, hepatitis C, CMV, and, rarely, babesiosis infectionsRecently, AIHA has been reported in rare severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and post-SARS-CoV-2 vaccination",
                    "sub_points": [
                      "Idiopathic or primary WAIHA, no underlying disorder identified; seen in ~ 50% of WAIHA",
                      "Secondary WAIHALymphoproliferative disorder, such as chronic lymphocytic leukemia, is most common cause of secondary WAIHAAutoimmune disease [e.g., systemic lupus erythematosus (SLE)]; WAIHA is seen in ~ 1/3 of SLE patientsMedication can trigger WAIHAUnderlying immune deficiency, e.g., common variable immunodeficiencyStem cell and solid organ transplantationsOther predisposition conditionsImmunodeficiencyIgA deficiencyAutoimmune lymphoproliferative disordersHLA-B locus, e.g., B8 and BW6Infections, e.g., parvovirus B19, HCVSpecific infections can be associated with WAIHAHIV, EBV, hepatitis C, CMV, and, rarely, babesiosis infectionsRecently, AIHA has been reported in rare severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and post-SARS-CoV-2 vaccination",
                      "Lymphoproliferative disorder, such as chronic lymphocytic leukemia, is most common cause of secondary WAIHA",
                      "Autoimmune disease [e.g., systemic lupus erythematosus (SLE)]; WAIHA is seen in ~ 1/3 of SLE patients",
                      "Medication can trigger WAIHA",
                      "Underlying immune deficiency, e.g., common variable immunodeficiency",
                      "Stem cell and solid organ transplantations",
                      "Other predisposition conditionsImmunodeficiencyIgA deficiencyAutoimmune lymphoproliferative disordersHLA-B locus, e.g., B8 and BW6Infections, e.g., parvovirus B19, HCV",
                      "Immunodeficiency",
                      "IgA deficiency",
                      "Autoimmune lymphoproliferative disorders",
                      "HLA-B locus, e.g., B8 and BW6",
                      "Infections, e.g., parvovirus B19, HCV",
                      "Specific infections can be associated with WAIHAHIV, EBV, hepatitis C, CMV, and, rarely, babesiosis infectionsRecently, AIHA has been reported in rare severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and post-SARS-CoV-2 vaccination",
                      "HIV, EBV, hepatitis C, CMV, and, rarely, babesiosis infections",
                      "Recently, AIHA has been reported in rare severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and post-SARS-CoV-2 vaccination"
                    ]
                  },
                  {
                    "text": "Pathogenesis/pathophysiologySignal substance cytotoxic T-lymphocyte antigen 4 (CTLA4) activates regulatory T cells, which is critical for immune toleranceIncreased number/activity of CD8(+) cytotoxic T cellsProgrammed cell death 1 (PD-1) signal pathway is another checkpoint for immune toleranceActivated macrophage functionImmune system dysfunction and abnormal autoantigen response likely play roles in pathogenesis of AIHAAutoantibodies developed against individual's own antigens on surface of RBCsRh polypeptides are most common targetPredominantly polyclonal IgG mediated; rarely IgA or IgMAutoantibodies have highest affinity at body temperature (37 °C), where they bind to RBCsExtravascular hemolysis occurs in spleen through FcR-mediated opsonization and phagocytosis of C3-coated RBCs by macrophages, thus destruction of RBCLess commonly in liver through C3d-mediated phagocytosis by Kupffer cellsTo much lesser degree, activation of complement MAC may occur and cause intravascular hemolysis",
                    "sub_points": [
                      "Signal substance cytotoxic T-lymphocyte antigen 4 (CTLA4) activates regulatory T cells, which is critical for immune toleranceIncreased number/activity of CD8(+) cytotoxic T cells",
                      "Increased number/activity of CD8(+) cytotoxic T cells",
                      "Programmed cell death 1 (PD-1) signal pathway is another checkpoint for immune tolerance",
                      "Activated macrophage function",
                      "Immune system dysfunction and abnormal autoantigen response likely play roles in pathogenesis of AIHA",
                      "Autoantibodies developed against individual's own antigens on surface of RBCs",
                      "Rh polypeptides are most common target",
                      "Predominantly polyclonal IgG mediated; rarely IgA or IgM",
                      "Autoantibodies have highest affinity at body temperature (37 °C), where they bind to RBCs",
                      "Extravascular hemolysis occurs in spleen through FcR-mediated opsonization and phagocytosis of C3-coated RBCs by macrophages, thus destruction of RBC",
                      "Less commonly in liver through C3d-mediated phagocytosis by Kupffer cells",
                      "To much lesser degree, activation of complement MAC may occur and cause intravascular hemolysis"
                    ]
                  }
                ],
                "Cold Agglutinin-Mediated Autoimmune Hemolytic Anemia": [
                  {
                    "text": "Etiology/subtypesPrimary CAD associated with underlying indolent lymphoproliferative disorderAutoantibody is usually monoclonal IgM, anti-I specificLight chain is predominantly κSecondary CASMycoplasma pneumoniaeis most common causeAutoantibody is usually polyclonal IgM, anti-I specificHemolysis occurs in small subset of patientsEBV, CMV, SARS-CoV-2, babesiosis infections can also cause CADAggressive lymphomas and other malignanciesAutoantibody is usually monoclonal IgM, anti-I specificLight chain can be κ or λ",
                    "sub_points": [
                      "Primary CAD associated with underlying indolent lymphoproliferative disorderAutoantibody is usually monoclonal IgM, anti-I specificLight chain is predominantly κ",
                      "Autoantibody is usually monoclonal IgM, anti-I specific",
                      "Light chain is predominantly κ",
                      "Secondary CASMycoplasma pneumoniaeis most common causeAutoantibody is usually polyclonal IgM, anti-I specificHemolysis occurs in small subset of patientsEBV, CMV, SARS-CoV-2, babesiosis infections can also cause CADAggressive lymphomas and other malignanciesAutoantibody is usually monoclonal IgM, anti-I specificLight chain can be κ or λ",
                      "Mycoplasma pneumoniaeis most common causeAutoantibody is usually polyclonal IgM, anti-I specificHemolysis occurs in small subset of patients",
                      "Autoantibody is usually polyclonal IgM, anti-I specific",
                      "Hemolysis occurs in small subset of patients",
                      "EBV, CMV, SARS-CoV-2, babesiosis infections can also cause CAD",
                      "Aggressive lymphomas and other malignanciesAutoantibody is usually monoclonal IgM, anti-I specificLight chain can be κ or λ",
                      "Autoantibody is usually monoclonal IgM, anti-I specific",
                      "Light chain can be κ or λ"
                    ]
                  },
                  {
                    "text": "Pathogenesis/pathophysiologyAutoantibody IgM developed against I or i antigen on surface of RBCsIgM binds to antigens on RBCs at low temperature (1-5 °C), followed by complement attachmentDetachment of IgM-antigen complex when return to warm temperature; complement C3b remains on RBCs and is cleaved to produce C3dC3d mediates erythrophagocytosis by Kupffer cells in liver; thus extravascular hemolysis (main site)Rarely, complement MAC formation results in intravascular hemolysis",
                    "sub_points": [
                      "Autoantibody IgM developed against I or i antigen on surface of RBCs",
                      "IgM binds to antigens on RBCs at low temperature (1-5 °C), followed by complement attachment",
                      "Detachment of IgM-antigen complex when return to warm temperature; complement C3b remains on RBCs and is cleaved to produce C3d",
                      "C3d mediates erythrophagocytosis by Kupffer cells in liver; thus extravascular hemolysis (main site)",
                      "Rarely, complement MAC formation results in intravascular hemolysis"
                    ]
                  }
                ],
                "Paroxysmal Cold Hemoglobinuria": [
                  {
                    "text": "EtiologyMost frequently seen in children with antecedent upper respiratory infection of viruses,Mycoplasma, bacteria, or immunizationSecondary to untreated tertiary syphilis patients; has become exceedingly rareRarely secondary to lymphomas",
                    "sub_points": [
                      "Most frequently seen in children with antecedent upper respiratory infection of viruses,Mycoplasma, bacteria, or immunization",
                      "Secondary to untreated tertiary syphilis patients; has become exceedingly rare",
                      "Rarely secondary to lymphomas"
                    ]
                  },
                  {
                    "text": "Pathogenesis/pathophysiologyInfection triggers formation of polyclonal biphasic hemolysin IgG (Donath-Landsteiner antibody) that cross-reacts with P antigen on RBC membraneIgG attaches to RBCs in cold temperatures (in extremities), forming P-anti-P antigen-antibody complexes, potent activators of complement systemWhen RBCs return to warmer central circulation, attached complement is activated to form MAC, hence intravascular hemolysisUsually sudden onset with massive hemolysis",
                    "sub_points": [
                      "Infection triggers formation of polyclonal biphasic hemolysin IgG (Donath-Landsteiner antibody) that cross-reacts with P antigen on RBC membrane",
                      "IgG attaches to RBCs in cold temperatures (in extremities), forming P-anti-P antigen-antibody complexes, potent activators of complement system",
                      "When RBCs return to warmer central circulation, attached complement is activated to form MAC, hence intravascular hemolysis",
                      "Usually sudden onset with massive hemolysis"
                    ]
                  }
                ],
                "Mixed-Type Autoimmune Hemolytic Anemia": [
                  {
                    "text": "Some patients with WAIHA also have cold agglutinin"
                  },
                  {
                    "text": "Can be idiopathic or secondary to SLE or lymphoproliferative disorders"
                  }
                ],
                "Drug-Induced Hemolysis": [
                  {
                    "text": "Incidence ~ 1 per million per year"
                  },
                  {
                    "text": "> 130 individual drugs have been implicated"
                  },
                  {
                    "text": "Majority of drug-induced hemolytic anemias due to 2nd and 3rd generation of cephalosporins, especially cefotetan and ceftriaxoneCefotetan is extremely immunogenic; can cause intravascular hemolysis after initial single dose",
                    "sub_points": [
                      "Cefotetan is extremely immunogenic; can cause intravascular hemolysis after initial single dose"
                    ]
                  },
                  {
                    "text": "Other drugs implicated include antineoplastic, cardiovascular, CNS/musculoskeletal medications"
                  },
                  {
                    "text": "Subtype of drug-induced hemolysis is indistinguishable from idiopathic WAIHAα-methyldopa, procainamide-type drug, can induce production of antierythrocyte IgG autoantibodyPostulated that drug alters Rh complex, rendering it antigenic, and resultant antibody is able to cross-react with normal epitopeAutoantibody causes extravascular hemolysis through mechanism indistinguishable from WAIHA~ 10% of cases are attributed to medications",
                    "sub_points": [
                      "α-methyldopa, procainamide-type drug, can induce production of antierythrocyte IgG autoantibody",
                      "Postulated that drug alters Rh complex, rendering it antigenic, and resultant antibody is able to cross-react with normal epitope",
                      "Autoantibody causes extravascular hemolysis through mechanism indistinguishable from WAIHA",
                      "~ 10% of cases are attributed to medications"
                    ]
                  },
                  {
                    "text": "Subset of drug-induced hemolysis is nonimmune mediatedDrug absorption mechanism (hapten)Drug (e.g., penicillin) attaches to RBC membrane, which stimulates IgG productionExtravascular hemolysis occurs when antibodies bind to large amounts of drug, coating RBC surfaceImmune complex mechanismDrug (e.g., ceftriaxone) induces IgM production, which binds to drug to form drug-antibody complexIntravascular hemolysis occurs when drug-antibody complex binds to RBC membrane and activates complement cascade",
                    "sub_points": [
                      "Drug absorption mechanism (hapten)Drug (e.g., penicillin) attaches to RBC membrane, which stimulates IgG productionExtravascular hemolysis occurs when antibodies bind to large amounts of drug, coating RBC surface",
                      "Drug (e.g., penicillin) attaches to RBC membrane, which stimulates IgG production",
                      "Extravascular hemolysis occurs when antibodies bind to large amounts of drug, coating RBC surface",
                      "Immune complex mechanismDrug (e.g., ceftriaxone) induces IgM production, which binds to drug to form drug-antibody complexIntravascular hemolysis occurs when drug-antibody complex binds to RBC membrane and activates complement cascade",
                      "Drug (e.g., ceftriaxone) induces IgM production, which binds to drug to form drug-antibody complex",
                      "Intravascular hemolysis occurs when drug-antibody complex binds to RBC membrane and activates complement cascade"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Presentation": [
                  {
                    "text": "WAIHAPresentation varies from mild and asymptomatic to life-threatening hemolysisCan be acute, transient, or chronicSymptoms may be related to anemia, such as fatigue, pallor, and dyspnea on exertion, or related to hemolysis, such as jaundice and hemoglobinuriaPatients have increased incidence of thrombosis and may have splenomegaly",
                    "sub_points": [
                      "Presentation varies from mild and asymptomatic to life-threatening hemolysis",
                      "Can be acute, transient, or chronic",
                      "Symptoms may be related to anemia, such as fatigue, pallor, and dyspnea on exertion, or related to hemolysis, such as jaundice and hemoglobinuria",
                      "Patients have increased incidence of thrombosis and may have splenomegaly"
                    ]
                  },
                  {
                    "text": "Cold agglutinin-mediated AIHAAccount for ~ 25-30% of AIHAsCAD with lymphoproliferative disordersUsually older patients with female predominance presenting with Raynaud phenomenonTypically chronic and mildCold environment may exacerbate hemolysisCAS secondary to infectionTypically seen in adolescents or young adultsTransient with hemolysis 2-3 weeks after infection; spontaneously resolves in 2-3 weeks",
                    "sub_points": [
                      "Account for ~ 25-30% of AIHAs",
                      "CAD with lymphoproliferative disordersUsually older patients with female predominance presenting with Raynaud phenomenonTypically chronic and mildCold environment may exacerbate hemolysis",
                      "Usually older patients with female predominance presenting with Raynaud phenomenon",
                      "Typically chronic and mild",
                      "Cold environment may exacerbate hemolysis",
                      "CAS secondary to infectionTypically seen in adolescents or young adultsTransient with hemolysis 2-3 weeks after infection; spontaneously resolves in 2-3 weeks",
                      "Typically seen in adolescents or young adults",
                      "Transient with hemolysis 2-3 weeks after infection; spontaneously resolves in 2-3 weeks"
                    ]
                  },
                  {
                    "text": "PCHPredominates in childrenConcurrent or prior viral infectionSudden onset of hemoglobinuria (dark \"Coca-Cola\" urine)Acute attack with high fever, chills, back &/or leg pain, and abdominal crampingHemolysis and hemophagocytosis can be severe and life threatening",
                    "sub_points": [
                      "Predominates in children",
                      "Concurrent or prior viral infection",
                      "Sudden onset of hemoglobinuria (dark \"Coca-Cola\" urine)",
                      "Acute attack with high fever, chills, back &/or leg pain, and abdominal cramping",
                      "Hemolysis and hemophagocytosis can be severe and life threatening"
                    ]
                  },
                  {
                    "text": "Cefotetan-induced hemolytic anemiaPatient receiving prophylactic cefotetan for surgery may return in 2 weeks with severe hemolytic anemiaHemolysis can mimic hemolytic transfusion reaction or AIHA; causes delay in diagnosisPatient may be febrile, mimicking infectionIf not recognized as drug-induced hemolysis and another dose given, can be fatal or cause acute renal failure",
                    "sub_points": [
                      "Patient receiving prophylactic cefotetan for surgery may return in 2 weeks with severe hemolytic anemia",
                      "Hemolysis can mimic hemolytic transfusion reaction or AIHA; causes delay in diagnosis",
                      "Patient may be febrile, mimicking infection",
                      "If not recognized as drug-induced hemolysis and another dose given, can be fatal or cause acute renal failure"
                    ]
                  }
                ],
                "Laboratory Tests": [
                  {
                    "text": "Common laboratory findings in all types of AIHADirect antiglobulin test (DAT) (a.k.a. direct Coombs test)Detects antibody &/or complement adsorbed to patient's RBCsPositive DAT is indicative of immune-mediated hemolysisNegative DAT does not exclude hemolysis if RBC destruction is massive and completeCauses of false-positive DAT include plasma cell myeloma, SLE, HIV infection, cephalosporin, immune checkpoint inhibitors, such as daratumumabIndirect antiglobulin test (IAT)Detects antibodies in patient plasma or serumOther laboratory findings in hemolysisNormochromic, normocytic anemia with polychromasia, microspherocytes, and nucleated RBCs (nRBCs)Increased indirect bilirubinIncreased lactate dehydrogenase (LDH)Decreased serum haptoglobin in intravascular hemolysisHemoglobinemia in severe cases when serum haptoglobin is saturatedHemoglobinuria in severe cases",
                    "sub_points": [
                      "Direct antiglobulin test (DAT) (a.k.a. direct Coombs test)Detects antibody &/or complement adsorbed to patient's RBCsPositive DAT is indicative of immune-mediated hemolysisNegative DAT does not exclude hemolysis if RBC destruction is massive and completeCauses of false-positive DAT include plasma cell myeloma, SLE, HIV infection, cephalosporin, immune checkpoint inhibitors, such as daratumumab",
                      "Detects antibody &/or complement adsorbed to patient's RBCs",
                      "Positive DAT is indicative of immune-mediated hemolysis",
                      "Negative DAT does not exclude hemolysis if RBC destruction is massive and complete",
                      "Causes of false-positive DAT include plasma cell myeloma, SLE, HIV infection, cephalosporin, immune checkpoint inhibitors, such as daratumumab",
                      "Indirect antiglobulin test (IAT)Detects antibodies in patient plasma or serum",
                      "Detects antibodies in patient plasma or serum",
                      "Other laboratory findings in hemolysisNormochromic, normocytic anemia with polychromasia, microspherocytes, and nucleated RBCs (nRBCs)Increased indirect bilirubinIncreased lactate dehydrogenase (LDH)Decreased serum haptoglobin in intravascular hemolysisHemoglobinemia in severe cases when serum haptoglobin is saturatedHemoglobinuria in severe cases",
                      "Normochromic, normocytic anemia with polychromasia, microspherocytes, and nucleated RBCs (nRBCs)",
                      "Increased indirect bilirubin",
                      "Increased lactate dehydrogenase (LDH)",
                      "Decreased serum haptoglobin in intravascular hemolysis",
                      "Hemoglobinemia in severe cases when serum haptoglobin is saturated",
                      "Hemoglobinuria in severe cases"
                    ]
                  },
                  {
                    "text": "Unique laboratory findings in subtypesWAIHASuspected in patient with hemolytic anemia and morphologic finding of microspherocytes on peripheral blood smearDiagnosis of AIHA requires serologic evidence of RBC-bound autoantibody IgG ± C3 and clinical or laboratory evidence of hemolysisDAT is positive for IgG in > 90% of cases; ~ 1/2 of cases positive for both IgG and complement C3IAT: Autoantibody reacts with all cells on diagnostic panel, i.e., panagglutinationMonoclonal gammopathy common in adults with WAIHADetected in ~ 15% of adults ≥ 50 years who did not have underlying lymphoplasmacytic neoplasmCold agglutinin-mediated AIHAArtifactually increased mean corpuscular volume and decreased red cell number due to clumping; reversible with sample warmingDAT is positive for complement C3DAT is negative for IgM (IgM-antigen complex detached from RBCs when return to warm temperature) or IgGCold agglutinin titers elevatedPCHDAT is positive for C3; negative for IgGPositive biphasic hemolysin (Donath-Landsteiner) test1st sample is incubated for 1 hour at 4 °C followed by 1 hour at 37 °C; control sample is incubated at 37 °C for 2 hoursPositive when 1st sample is hemolyzedAntibody usually appears 1 week after onset of respiratory illness and persists for 1-3 monthsMixed-type AIHAPositive DAT for IgG alone or both IgG and IgMDrug-induced hemolytic anemiaPositive DAT in most casesNegative IATDrug-induced hemolysis is challenging to diagnose due to lack of specific tests",
                    "sub_points": [
                      "WAIHASuspected in patient with hemolytic anemia and morphologic finding of microspherocytes on peripheral blood smearDiagnosis of AIHA requires serologic evidence of RBC-bound autoantibody IgG ± C3 and clinical or laboratory evidence of hemolysisDAT is positive for IgG in > 90% of cases; ~ 1/2 of cases positive for both IgG and complement C3IAT: Autoantibody reacts with all cells on diagnostic panel, i.e., panagglutinationMonoclonal gammopathy common in adults with WAIHADetected in ~ 15% of adults ≥ 50 years who did not have underlying lymphoplasmacytic neoplasm",
                      "Suspected in patient with hemolytic anemia and morphologic finding of microspherocytes on peripheral blood smear",
                      "Diagnosis of AIHA requires serologic evidence of RBC-bound autoantibody IgG ± C3 and clinical or laboratory evidence of hemolysis",
                      "DAT is positive for IgG in > 90% of cases; ~ 1/2 of cases positive for both IgG and complement C3",
                      "IAT: Autoantibody reacts with all cells on diagnostic panel, i.e., panagglutination",
                      "Monoclonal gammopathy common in adults with WAIHADetected in ~ 15% of adults ≥ 50 years who did not have underlying lymphoplasmacytic neoplasm",
                      "Detected in ~ 15% of adults ≥ 50 years who did not have underlying lymphoplasmacytic neoplasm",
                      "Cold agglutinin-mediated AIHAArtifactually increased mean corpuscular volume and decreased red cell number due to clumping; reversible with sample warmingDAT is positive for complement C3DAT is negative for IgM (IgM-antigen complex detached from RBCs when return to warm temperature) or IgGCold agglutinin titers elevated",
                      "Artifactually increased mean corpuscular volume and decreased red cell number due to clumping; reversible with sample warming",
                      "DAT is positive for complement C3",
                      "DAT is negative for IgM (IgM-antigen complex detached from RBCs when return to warm temperature) or IgG",
                      "Cold agglutinin titers elevated",
                      "PCHDAT is positive for C3; negative for IgGPositive biphasic hemolysin (Donath-Landsteiner) test1st sample is incubated for 1 hour at 4 °C followed by 1 hour at 37 °C; control sample is incubated at 37 °C for 2 hoursPositive when 1st sample is hemolyzedAntibody usually appears 1 week after onset of respiratory illness and persists for 1-3 months",
                      "DAT is positive for C3; negative for IgG",
                      "Positive biphasic hemolysin (Donath-Landsteiner) test1st sample is incubated for 1 hour at 4 °C followed by 1 hour at 37 °C; control sample is incubated at 37 °C for 2 hoursPositive when 1st sample is hemolyzed",
                      "1st sample is incubated for 1 hour at 4 °C followed by 1 hour at 37 °C; control sample is incubated at 37 °C for 2 hours",
                      "Positive when 1st sample is hemolyzed",
                      "Antibody usually appears 1 week after onset of respiratory illness and persists for 1-3 months",
                      "Mixed-type AIHAPositive DAT for IgG alone or both IgG and IgM",
                      "Positive DAT for IgG alone or both IgG and IgM",
                      "Drug-induced hemolytic anemiaPositive DAT in most casesNegative IATDrug-induced hemolysis is challenging to diagnose due to lack of specific tests",
                      "Positive DAT in most cases",
                      "Negative IAT",
                      "Drug-induced hemolysis is challenging to diagnose due to lack of specific tests"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "WAIHAGlucocorticoids remain 1st-line therapyGlucocorticoids + rituximab in severe cases or in cases with inadequate response to steroidsImmunosuppressive/chemotherapeutic agents, intravenous immunoglobulin (IVIg), and other agents used for 2nd-, 3rd-, and 4th-line therapiesHigh-dose cyclophosphamide or autologous stem cell transplant may be used as 4th-line therapyTransfusion with least incompatible red cells is limited to cases of life-threatening anemia or high risk of cardiac or cerebrovascular ischemic eventsTreat underlying disease (e.g., SLE, lymphoproliferative disorder)",
                    "sub_points": [
                      "Glucocorticoids remain 1st-line therapyGlucocorticoids + rituximab in severe cases or in cases with inadequate response to steroids",
                      "Glucocorticoids + rituximab in severe cases or in cases with inadequate response to steroids",
                      "Immunosuppressive/chemotherapeutic agents, intravenous immunoglobulin (IVIg), and other agents used for 2nd-, 3rd-, and 4th-line therapiesHigh-dose cyclophosphamide or autologous stem cell transplant may be used as 4th-line therapy",
                      "High-dose cyclophosphamide or autologous stem cell transplant may be used as 4th-line therapy",
                      "Transfusion with least incompatible red cells is limited to cases of life-threatening anemia or high risk of cardiac or cerebrovascular ischemic events",
                      "Treat underlying disease (e.g., SLE, lymphoproliferative disorder)"
                    ]
                  },
                  {
                    "text": "Cold agglutinin-mediated AIHARituximab has become 1st-line therapyCombined rituximab and bendamustine or fludarabine therapy may result in higher response rate than rituximab alone in certain patientsAvoid cold exposureTransfusion as needed as supportive careSplenectomy has no role in treatment as extravascular hemolysis predominantly takes place in liverCorticosteroid therapy has limited responseComplement-directed therapy has potential, but more study is needed",
                    "sub_points": [
                      "Rituximab has become 1st-line therapy",
                      "Combined rituximab and bendamustine or fludarabine therapy may result in higher response rate than rituximab alone in certain patients",
                      "Avoid cold exposure",
                      "Transfusion as needed as supportive care",
                      "Splenectomy has no role in treatment as extravascular hemolysis predominantly takes place in liver",
                      "Corticosteroid therapy has limited response",
                      "Complement-directed therapy has potential, but more study is needed"
                    ]
                  },
                  {
                    "text": "PCHSupportive care is mainstay of treatmentKeep warm, and transfuse as neededCorticosteroids and plasmapheresis can be considered in severe casesImmunosuppressive therapy and rituximab are rarely needed, can be beneficial in selected casesComplement inhibitor eculizumab had mixed results",
                    "sub_points": [
                      "Supportive care is mainstay of treatment",
                      "Keep warm, and transfuse as needed",
                      "Corticosteroids and plasmapheresis can be considered in severe cases",
                      "Immunosuppressive therapy and rituximab are rarely needed, can be beneficial in selected cases",
                      "Complement inhibitor eculizumab had mixed results"
                    ]
                  },
                  {
                    "text": "Drug-induced immune hemolytic anemiaDiscontinue offending drugImmune hemolytic anemia due to drugs is usually mild to moderateSteroids and transfusion can be used in severe or prolonged anemia",
                    "sub_points": [
                      "Discontinue offending drug",
                      "Immune hemolytic anemia due to drugs is usually mild to moderate",
                      "Steroids and transfusion can be used in severe or prolonged anemia"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Favorable in most AIHAsHigh relapse rate (30%)Many become chronic",
                    "sub_points": [
                      "High relapse rate (30%)",
                      "Many become chronic"
                    ]
                  },
                  {
                    "text": "Cold agglutinin-mediated AIHAPrimary CADPrognosis is usually good, overall survival comparable with age- and sex-matched populationSecondary CASDepends on underlying diseaseGreat prognosis with infectionsMalignancies predict adverse outcome",
                    "sub_points": [
                      "Primary CADPrognosis is usually good, overall survival comparable with age- and sex-matched population",
                      "Prognosis is usually good, overall survival comparable with age- and sex-matched population",
                      "Secondary CASDepends on underlying diseaseGreat prognosis with infectionsMalignancies predict adverse outcome",
                      "Depends on underlying disease",
                      "Great prognosis with infections",
                      "Malignancies predict adverse outcome"
                    ]
                  },
                  {
                    "text": "PCHUsually transient and self-limited",
                    "sub_points": [
                      "Usually transient and self-limited"
                    ]
                  },
                  {
                    "text": "Drug-induced hemolytic anemiaExcellent with cessation of offending medication",
                    "sub_points": [
                      "Excellent with cessation of offending medication"
                    ]
                  },
                  {
                    "text": "Postautologous and allogeneic hematopoietic stem cell transplantationOften severe and refractory to treatmentHigh mortality rate",
                    "sub_points": [
                      "Often severe and refractory to treatment",
                      "High mortality rate"
                    ]
                  },
                  {
                    "text": "Severity of anemia at onset is associated with risk of relapse"
                  },
                  {
                    "text": "Concomitant presence of immune thrombocytopenia (Evans syndrome) is associated with higher risk of relapse and refractoriness to treatment"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Blood Findings": [
                  {
                    "text": "Common findings in AIHANormochromic, normocytic anemia; may have nRBCsIncreased reticulocytes (polychromasia)Microspherocytes",
                    "sub_points": [
                      "Normochromic, normocytic anemia; may have nRBCs",
                      "Increased reticulocytes (polychromasia)",
                      "Microspherocytes"
                    ]
                  },
                  {
                    "text": "Findings unique to subtypeCold agglutinin-mediated AIHARed cell clumps on smear reviewDissolution of clumping upon warming upPCHMicrospherocytes and cold agglutination of RBCs are not as prominent as AIHA or cold agglutininBrisk reticulocytosis and nRBC appears few days after hemolysisCharacteristic finding of erythrophagocytosis by neutrophils and monocytes may be seen",
                    "sub_points": [
                      "Cold agglutinin-mediated AIHARed cell clumps on smear reviewDissolution of clumping upon warming up",
                      "Red cell clumps on smear review",
                      "Dissolution of clumping upon warming up",
                      "PCHMicrospherocytes and cold agglutination of RBCs are not as prominent as AIHA or cold agglutininBrisk reticulocytosis and nRBC appears few days after hemolysisCharacteristic finding of erythrophagocytosis by neutrophils and monocytes may be seen",
                      "Microspherocytes and cold agglutination of RBCs are not as prominent as AIHA or cold agglutinin",
                      "Brisk reticulocytosis and nRBC appears few days after hemolysis",
                      "Characteristic finding of erythrophagocytosis by neutrophils and monocytes may be seen"
                    ]
                  }
                ],
                "Bone Marrow Findings": [
                  {
                    "text": "Hypercellular marrow with erythroid hyperplasiaLymphocytes and plasma cells may be increasedRed cell aplasia in rare cases with autoantibodies to erythropoietin receptorErythrophagocytosis with reticulocytopenia noted in rare cases",
                    "sub_points": [
                      "Lymphocytes and plasma cells may be increased",
                      "Red cell aplasia in rare cases with autoantibodies to erythropoietin receptor",
                      "Erythrophagocytosis with reticulocytopenia noted in rare cases"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Other Causes of Anemia": [
                  {
                    "text": "Clinical history and work-up can effectively exclude bleeding, anemia of chronic disease"
                  }
                ],
                "Hereditary Hemolytic Disorders": [
                  {
                    "text": "Hereditary spherocytosis (HS)Presence of spherocytes can mimic immune hemolytic anemiaDAT is negative in HSOsmotic fragility test is positivePositive family history",
                    "sub_points": [
                      "Presence of spherocytes can mimic immune hemolytic anemia",
                      "DAT is negative in HS",
                      "Osmotic fragility test is positive",
                      "Positive family history"
                    ]
                  }
                ],
                "Acquired Nonimmune Hemolytic Disorders": [
                  {
                    "text": "Microangiopathic hemolytic anemia or mechanical destructionSchistocytes on smear reviewNegative DAT",
                    "sub_points": [
                      "Schistocytes on smear review",
                      "Negative DAT"
                    ]
                  },
                  {
                    "text": "Paroxysmal nocturnal hemoglobinuria (PNH)Not immune mediated, acquired myeloid stem cell mutationMutation inPIGAleads to loss of glycosylphosphatidylinositol (GPI); latter links decay accelerated factors (DAF), such as CD55 and CD59CD55 and CD59 are inhibitors of complement systemLoss of CD55 and CD59 leads to hypersensitivity to complement activation, thus hemolysisFlow cytometric analysis detects missing DAF and confirms diagnosis",
                    "sub_points": [
                      "Not immune mediated, acquired myeloid stem cell mutation",
                      "Mutation inPIGAleads to loss of glycosylphosphatidylinositol (GPI); latter links decay accelerated factors (DAF), such as CD55 and CD59",
                      "CD55 and CD59 are inhibitors of complement system",
                      "Loss of CD55 and CD59 leads to hypersensitivity to complement activation, thus hemolysis",
                      "Flow cytometric analysis detects missing DAF and confirms diagnosis"
                    ]
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Clinically Relevant Pathologic Features": [
                  {
                    "text": "Sudden or gradual onset of anemia and associated signs and symptoms"
                  }
                ],
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "Anemia, microspherocytes, and polychromasia on peripheral blood smear"
                  },
                  {
                    "text": "Other laboratory tests to support diagnosis of hemolysis"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Alloimmune Hemolytic Anemia and Hemolytic Disease of Newborn": {
            "name": "Alloimmune Hemolytic Anemia and Hemolytic Disease of Newborn",
            "url": "https://app.pathprimer.com/document/d96efe86-337b-466c-b11f-6e804fee0d69/lesson/92495282-ce4a-41b9-a2f4-c2339cb2cc79",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "RBC destruction caused by alloantibodies directed against antigens on RBC membrane surface resulting from blood transfusion or pregnancy"
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "Hemolytic disease of fetus and newborn (HDFN)RhD hemolytic disease is historically most common HDFN (RhD HDFN), which is now less commonABO incompatibility occurs in 15-25% of all pregnancies, whereas ABO HDFN occurs only in ~ 1% of newborns",
                    "sub_points": [
                      "RhD hemolytic disease is historically most common HDFN (RhD HDFN), which is now less common",
                      "ABO incompatibility occurs in 15-25% of all pregnancies, whereas ABO HDFN occurs only in ~ 1% of newborns"
                    ]
                  },
                  {
                    "text": "Hemolytic transfusion reactions (HTR)ABO incompatible transfusion of RBCs is associated with severe alloimmune hemolysisHemolysis occurs in vasculature, liver, and spleen within minutes",
                    "sub_points": [
                      "ABO incompatible transfusion of RBCs is associated with severe alloimmune hemolysis",
                      "Hemolysis occurs in vasculature, liver, and spleen within minutes"
                    ]
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "HDFNCan range from mild jaundice and anemia to fetal hydropsExtreme hyperbilirubinemia may result in kernicterusABO HDFN is generally mild or undiagnosed",
                    "sub_points": [
                      "Can range from mild jaundice and anemia to fetal hydropsExtreme hyperbilirubinemia may result in kernicterus",
                      "Extreme hyperbilirubinemia may result in kernicterus",
                      "ABO HDFN is generally mild or undiagnosed"
                    ]
                  },
                  {
                    "text": "HTRFever and chills, back pain, sense of \"impending doom\" within minutes of starting transfusion",
                    "sub_points": [
                      "Fever and chills, back pain, sense of \"impending doom\" within minutes of starting transfusion"
                    ]
                  },
                  {
                    "text": "Laboratory testingPositive maternal antenatal antibody screening in RhD HDFNHyperbilirubinemia in newbornKleihauer-Betke test to determine volume of fetal-maternal hemorrhagePositive DAT test in HTR",
                    "sub_points": [
                      "Positive maternal antenatal antibody screening in RhD HDFN",
                      "Hyperbilirubinemia in newborn",
                      "Kleihauer-Betke test to determine volume of fetal-maternal hemorrhage",
                      "Positive DAT test in HTR"
                    ]
                  },
                  {
                    "text": "TreatmentRhIg during pregnancy and post partum to prevent sensitization for RhD HDFNSevere neonatal hyperbilirubinemia may require phototherapy and even exchange transfusionSupportive care for HTR",
                    "sub_points": [
                      "RhIg during pregnancy and post partum to prevent sensitization for RhD HDFN",
                      "Severe neonatal hyperbilirubinemia may require phototherapy and even exchange transfusion",
                      "Supportive care for HTR"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Hemolytic disease of fetus and newborn (HDFN)"
                  },
                  {
                    "text": "Hemolytic transfusion reactions (HTR)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Hemolytic disease of newborn (HDN)"
                  },
                  {
                    "text": "Alloimmune HDFN"
                  }
                ],
                "Definitions": [
                  {
                    "text": "RBC destruction caused by alloantibodies directed against antigens on RBC membrane surface resulting from blood transfusion or pregnancy"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "HDFN: 3 Major Types": [
                  {
                    "text": "RhD HDFNRhD is most antigenic of RBC antigensAnti-RhD antibodies have potential to cause severe hemolysisMother is RhD(-) and fetus/baby is RhD(+)RBCs of baby typically enter mother's circulation late in pregnancy or during deliveryMother develops alloantibodies (IgG) to RhD antigen on fetal RBCsIn subsequent pregnancy, IgG antibodies travel across placenta and target antigens on fetal red cells, causing hemolysis of fetus or newbornPredominantly extravascular hemolysis",
                    "sub_points": [
                      "RhD is most antigenic of RBC antigens",
                      "Anti-RhD antibodies have potential to cause severe hemolysis",
                      "Mother is RhD(-) and fetus/baby is RhD(+)",
                      "RBCs of baby typically enter mother's circulation late in pregnancy or during delivery",
                      "Mother develops alloantibodies (IgG) to RhD antigen on fetal RBCs",
                      "In subsequent pregnancy, IgG antibodies travel across placenta and target antigens on fetal red cells, causing hemolysis of fetus or newborn",
                      "Predominantly extravascular hemolysis"
                    ]
                  },
                  {
                    "text": "ABO HDFNNow most common form of HDFN in resource-rich countries, as prophylaxis is common for RhD-incompatible pregnancyBlood group O mother carries naturally occurring anti-A or anti-B antibodies (predominantly IgM with some IgG)Fetus/baby most often is either blood group A or BABO incompatibility occurs in 15-25% of all pregnancies, while ABO HDFN occurs in only ~ 1%, as IgM does not cross placentaMother's IgG antibodies cross placenta to fetus, causing extravascular hemolysisHemolysis can occur with 1st pregnancyMinor degree of RBC destruction is common; severe hemolysis is rare",
                    "sub_points": [
                      "Now most common form of HDFN in resource-rich countries, as prophylaxis is common for RhD-incompatible pregnancy",
                      "Blood group O mother carries naturally occurring anti-A or anti-B antibodies (predominantly IgM with some IgG)",
                      "Fetus/baby most often is either blood group A or B",
                      "ABO incompatibility occurs in 15-25% of all pregnancies, while ABO HDFN occurs in only ~ 1%, as IgM does not cross placenta",
                      "Mother's IgG antibodies cross placenta to fetus, causing extravascular hemolysis",
                      "Hemolysis can occur with 1st pregnancy",
                      "Minor degree of RBC destruction is common; severe hemolysis is rare"
                    ]
                  },
                  {
                    "text": "HDFN due to non-RhD, non-ABO blood group antigensRBC antibodies with well-recognized association with HDFN include anti-K, anti-C, anti-E, anti-Fya, anti-Jka",
                    "sub_points": [
                      "RBC antibodies with well-recognized association with HDFN include anti-K, anti-C, anti-E, anti-Fya, anti-Jka"
                    ]
                  }
                ],
                "HTR: 2 Major Types": [
                  {
                    "text": "Acute HTR (AHTR)Primary cause is human error; occurs in as frequently as 1 in ~ 30,000 transfusionsABO-incompatible transfusion of RBCs causes severe alloimmune hemolysisMost abundant ABO antibodies are IgM; lower amounts of IgG antibodies are also producedNaturally occurring antibodies against A or B antigens are present in sera of all those who do not express these antigens (e.g., type O individuals)Anti-A and anti-B antibodies (IgM/IgG) bind to transfused RBCs, activate complement, and cause brisk intravascular hemolysis within minutesErythrophagocytosis of RBCs coated with IgG, C3b, and C3d in spleen or liver signifies extravascular hemolysisDestruction of incompatible RBCs causes production of cytokines and activation of WBCs, resulting in fever, chills, and hypotensionHemoglobin released during hemolysis is bound by haptoglobin; once saturated, hemoglobinemia or even hemoglobinuria occursActivation of coagulation cascade can occur, which may result in DICBronchoconstriction occurs as result of histamine release, resulting in respiratory compromiseFree hemoglobinemia damages kidney; in combination with poor perfusion, this may result in acute renal failure",
                    "sub_points": [
                      "Primary cause is human error; occurs in as frequently as 1 in ~ 30,000 transfusions",
                      "ABO-incompatible transfusion of RBCs causes severe alloimmune hemolysis",
                      "Most abundant ABO antibodies are IgM; lower amounts of IgG antibodies are also produced",
                      "Naturally occurring antibodies against A or B antigens are present in sera of all those who do not express these antigens (e.g., type O individuals)",
                      "Anti-A and anti-B antibodies (IgM/IgG) bind to transfused RBCs, activate complement, and cause brisk intravascular hemolysis within minutes",
                      "Erythrophagocytosis of RBCs coated with IgG, C3b, and C3d in spleen or liver signifies extravascular hemolysis",
                      "Destruction of incompatible RBCs causes production of cytokines and activation of WBCs, resulting in fever, chills, and hypotension",
                      "Hemoglobin released during hemolysis is bound by haptoglobin; once saturated, hemoglobinemia or even hemoglobinuria occurs",
                      "Activation of coagulation cascade can occur, which may result in DIC",
                      "Bronchoconstriction occurs as result of histamine release, resulting in respiratory compromise",
                      "Free hemoglobinemia damages kidney; in combination with poor perfusion, this may result in acute renal failure"
                    ]
                  },
                  {
                    "text": "Delayed HTR (DHTR)By definition, occurs days to weeks after transfusion (commonly between 3-7 days)Usually caused by low titer (undetectable) alloantibodies to RBC antigens following prior alloimmunization (may be remote)Antibody can usually be detected prior to transfusion and DHTR can be avoidedAntibody occasionally undetectable leading to anamnestic responseUsually leads to extravascular hemolysis",
                    "sub_points": [
                      "By definition, occurs days to weeks after transfusion (commonly between 3-7 days)",
                      "Usually caused by low titer (undetectable) alloantibodies to RBC antigens following prior alloimmunization (may be remote)",
                      "Antibody can usually be detected prior to transfusion and DHTR can be avoided",
                      "Antibody occasionally undetectable leading to anamnestic response",
                      "Usually leads to extravascular hemolysis"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [
                  {
                    "text": "HDFNPopulation prevalence of Rh(+) antibody screen in pregnant women varies among studies (range: 0.13-0.36%)Historically, RhD HDFN is most common form, now less common due to advent of prophylaxis anti-D immunoglobulin (RhIg)Incidence of RhD HDFN is 1 in 1,000 pregnancies in USA",
                    "sub_points": [
                      "Population prevalence of Rh(+) antibody screen in pregnant women varies among studies (range: 0.13-0.36%)",
                      "Historically, RhD HDFN is most common form, now less common due to advent of prophylaxis anti-D immunoglobulin (RhIg)",
                      "Incidence of RhD HDFN is 1 in 1,000 pregnancies in USA"
                    ]
                  }
                ],
                "Presentation": [
                  {
                    "text": "HDFNRhD HDFNUsually occurs in subsequent pregnancyFetal anemia is almost always present and may be severeAnemia often results in compensatory hyperdynamic circulation, which may lead to cardiomegaly and edema in skin and serous cavities, i.e., fetal hydropsHemolytic process often continuous at birth and may result in severe hyperbilirubinemiaUntreated extreme hyperbilirubinemia may result in permanent CNS damage, i.e., bilirubin encephalopathy (a.k.a. kernicterus)Kernicterus is due to bilirubin deposition in basal ganglia and brainstem nucleiKernicterus is associated with cerebral palsy, hearing loss, and psychomotor sequelaFetal death may occur without appropriate follow-up and interventionABO HDFN is generally mild or undiagnosed due to weak in utero expression of ABO antigens",
                    "sub_points": [
                      "RhD HDFNUsually occurs in subsequent pregnancyFetal anemia is almost always present and may be severeAnemia often results in compensatory hyperdynamic circulation, which may lead to cardiomegaly and edema in skin and serous cavities, i.e., fetal hydropsHemolytic process often continuous at birth and may result in severe hyperbilirubinemiaUntreated extreme hyperbilirubinemia may result in permanent CNS damage, i.e., bilirubin encephalopathy (a.k.a. kernicterus)Kernicterus is due to bilirubin deposition in basal ganglia and brainstem nucleiKernicterus is associated with cerebral palsy, hearing loss, and psychomotor sequelaFetal death may occur without appropriate follow-up and intervention",
                      "Usually occurs in subsequent pregnancy",
                      "Fetal anemia is almost always present and may be severe",
                      "Anemia often results in compensatory hyperdynamic circulation, which may lead to cardiomegaly and edema in skin and serous cavities, i.e., fetal hydrops",
                      "Hemolytic process often continuous at birth and may result in severe hyperbilirubinemia",
                      "Untreated extreme hyperbilirubinemia may result in permanent CNS damage, i.e., bilirubin encephalopathy (a.k.a. kernicterus)",
                      "Kernicterus is due to bilirubin deposition in basal ganglia and brainstem nuclei",
                      "Kernicterus is associated with cerebral palsy, hearing loss, and psychomotor sequela",
                      "Fetal death may occur without appropriate follow-up and intervention",
                      "ABO HDFN is generally mild or undiagnosed due to weak in utero expression of ABO antigens"
                    ]
                  },
                  {
                    "text": "HTRAHTRClassic presenting symptoms include fever, chills, pain, or sense of \"impending doom\" within minutes of starting transfusionAdditional signs of hemolysis include flushing, dyspnea, hypotension, shock, and hemoglobinuriaCoagulopathic bleeding secondary to DICAcute renal failure may occurDHTRMay be asymptomaticFindings include fever, leukocytosis, jaundice, and anemia",
                    "sub_points": [
                      "AHTRClassic presenting symptoms include fever, chills, pain, or sense of \"impending doom\" within minutes of starting transfusionAdditional signs of hemolysis include flushing, dyspnea, hypotension, shock, and hemoglobinuriaCoagulopathic bleeding secondary to DICAcute renal failure may occur",
                      "Classic presenting symptoms include fever, chills, pain, or sense of \"impending doom\" within minutes of starting transfusion",
                      "Additional signs of hemolysis include flushing, dyspnea, hypotension, shock, and hemoglobinuria",
                      "Coagulopathic bleeding secondary to DIC",
                      "Acute renal failure may occur",
                      "DHTRMay be asymptomaticFindings include fever, leukocytosis, jaundice, and anemia",
                      "May be asymptomatic",
                      "Findings include fever, leukocytosis, jaundice, and anemia"
                    ]
                  }
                ],
                "Laboratory Tests": [
                  {
                    "text": "All pregnant women should be tested for blood type (ABO), RhD, and any unexpected antibodies at their 1st prenatal visit"
                  },
                  {
                    "text": "Additional antibody testing recommended for RhD(-) mothers between 28-29 weeks gestation"
                  },
                  {
                    "text": "RhD HDFNSevere, progressive, unconjugated neonatal hyperbilirubinemiaPositive maternal antenatal antibody screening (IgG antibody)Positive direct antiglobulin test (DAT), a.k.a. direct Coombs testKleihauer-Betke test to estimate volume of fetal-maternal hemorrhage and determine dosage of RhIG for postpartum immunizationFetal hemoglobin in fetal or newborn RBCs is resistant to acid elution, whereas hemoglobin A in adults is sensitive",
                    "sub_points": [
                      "Severe, progressive, unconjugated neonatal hyperbilirubinemia",
                      "Positive maternal antenatal antibody screening (IgG antibody)",
                      "Positive direct antiglobulin test (DAT), a.k.a. direct Coombs test",
                      "Kleihauer-Betke test to estimate volume of fetal-maternal hemorrhage and determine dosage of RhIG for postpartum immunizationFetal hemoglobin in fetal or newborn RBCs is resistant to acid elution, whereas hemoglobin A in adults is sensitive",
                      "Fetal hemoglobin in fetal or newborn RBCs is resistant to acid elution, whereas hemoglobin A in adults is sensitive"
                    ]
                  },
                  {
                    "text": "ABO HDFNABO blood group testing of mother and newborn to determine possible fetal-maternal incompatibilityDAT(+/-) due to weakly coated cells or destruction of coated cells",
                    "sub_points": [
                      "ABO blood group testing of mother and newborn to determine possible fetal-maternal incompatibility",
                      "DAT(+/-) due to weakly coated cells or destruction of coated cells"
                    ]
                  },
                  {
                    "text": "AHTRHemoglobinemia: Free hemoglobin will turn plasma from light yellow to pink or redHemoglobinuria (+)Elevated LDH, indirect and direct bilirubin, decreased or absent haptoglobinDAT test in pre- and posttransfusion samples to look for presence of antibody or complement on red cell surfaceIncreased fibrin degradation products in DICPeripheral blood smear may show schistocytes in intravascular hemolysis or spherocytes in extravascular hemolysis",
                    "sub_points": [
                      "Hemoglobinemia: Free hemoglobin will turn plasma from light yellow to pink or red",
                      "Hemoglobinuria (+)",
                      "Elevated LDH, indirect and direct bilirubin, decreased or absent haptoglobin",
                      "DAT test in pre- and posttransfusion samples to look for presence of antibody or complement on red cell surface",
                      "Increased fibrin degradation products in DIC",
                      "Peripheral blood smear may show schistocytes in intravascular hemolysis or spherocytes in extravascular hemolysis"
                    ]
                  },
                  {
                    "text": "DHTRAnemia, elevated LDH, bilirubin, DAT(+)Peripheral blood smear may show spherocytesIndirect antiglobulin test (IAT) to detect unexpected alloantibodies in patient plasma or serumAntibody identification test to determine specificity of alloantibody found by IAT",
                    "sub_points": [
                      "Anemia, elevated LDH, bilirubin, DAT(+)",
                      "Peripheral blood smear may show spherocytes",
                      "Indirect antiglobulin test (IAT) to detect unexpected alloantibodies in patient plasma or serum",
                      "Antibody identification test to determine specificity of alloantibody found by IAT"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "RhD HDFNPrevention by maternal RhIg antepartum and post partum in Rh(-) mothersSubsequent pregnancies can use prophylactic RhIg therapy or recombinant anti-RhD antibodyPrenatal anemia can be treated with intrauterine blood transfusions to prevent hydropsMaintain bilirubin levels; low to prevent kernicterusPhototherapyExchange transfusion with D(-) blood in severe cases",
                    "sub_points": [
                      "Prevention by maternal RhIg antepartum and post partum in Rh(-) mothers",
                      "Subsequent pregnancies can use prophylactic RhIg therapy or recombinant anti-RhD antibody",
                      "Prenatal anemia can be treated with intrauterine blood transfusions to prevent hydrops",
                      "Maintain bilirubin levels; low to prevent kernicterusPhototherapyExchange transfusion with D(-) blood in severe cases",
                      "Phototherapy",
                      "Exchange transfusion with D(-) blood in severe cases"
                    ]
                  },
                  {
                    "text": "ABO HDFNNo intervention to baby is usually necessary; if needed, phototherapy is usually sufficientIf severe, treat like Rh HDFN",
                    "sub_points": [
                      "No intervention to baby is usually necessary; if needed, phototherapy is usually sufficient",
                      "If severe, treat like Rh HDFN"
                    ]
                  },
                  {
                    "text": "Future directions of HDFN managementPharmacotherapeutic agents as alternative treatment optionsImmunoglobulins, albumin, phenobarbital, metalloporphyrins, zinc, clofibrate, and prebioticsFurther studies are warranted to evaluate EPO, folate, and vitamin E in neonatesLong-term follow-up on thrombocytopenia, iron overload, and cholestasis",
                    "sub_points": [
                      "Pharmacotherapeutic agents as alternative treatment optionsImmunoglobulins, albumin, phenobarbital, metalloporphyrins, zinc, clofibrate, and prebiotics",
                      "Immunoglobulins, albumin, phenobarbital, metalloporphyrins, zinc, clofibrate, and prebiotics",
                      "Further studies are warranted to evaluate EPO, folate, and vitamin E in neonates",
                      "Long-term follow-up on thrombocytopenia, iron overload, and cholestasis"
                    ]
                  },
                  {
                    "text": "HTRPrevention by diligent clerical checkStop transfusion immediately when signs of transfusion reaction developPatient should be maintained on 0.9% salineSupportive care (hydration, diuresis) to treat hypotension and prevent renal failureManagement of DICEarly exchange transfusions may be considered in some casesAnticomplement or anticytokine agents may be helpfulIn general, no treatment is needed for mild DHTR",
                    "sub_points": [
                      "Prevention by diligent clerical check",
                      "Stop transfusion immediately when signs of transfusion reaction develop",
                      "Patient should be maintained on 0.9% saline",
                      "Supportive care (hydration, diuresis) to treat hypotension and prevent renal failure",
                      "Management of DIC",
                      "Early exchange transfusions may be considered in some cases",
                      "Anticomplement or anticytokine agents may be helpful",
                      "In general, no treatment is needed for mild DHTR"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "HDFNCan result in fetal anemia, hydrops, or intrauterine deathCan also cause severe neonatal anemia and hyperbilirubinemia, requiring phototherapy, exchange transfusion, &/or other therapiesOverall survival is 80-90% but is reduced (70-80%) for hydropic fetusesNeurologic impairment has been reported to be closely associated with severity of anemia and perinatal hypoxia",
                    "sub_points": [
                      "Can result in fetal anemia, hydrops, or intrauterine death",
                      "Can also cause severe neonatal anemia and hyperbilirubinemia, requiring phototherapy, exchange transfusion, &/or other therapies",
                      "Overall survival is 80-90% but is reduced (70-80%) for hydropic fetuses",
                      "Neurologic impairment has been reported to be closely associated with severity of anemia and perinatal hypoxia"
                    ]
                  },
                  {
                    "text": "HTRDeath may occur in cases with overwhelming hemolysis as result of hypotension, coagulopathy, respiratory compromise, and underlying disease",
                    "sub_points": [
                      "Death may occur in cases with overwhelming hemolysis as result of hypotension, coagulopathy, respiratory compromise, and underlying disease"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Peripheral Blood Findings": [
                  {
                    "text": "RhD HDFNAlloimmune hemolytic anemia typically exhibits frequent spherocytes; however, absence of spherocytes does not exclude diagnosisOften markedly increased polychromasia ± nucleated RBCs (nRBCs)In fetal hydrops, smear often reveals many circulating nRBCs in response to accelerated destruction",
                    "sub_points": [
                      "Alloimmune hemolytic anemia typically exhibits frequent spherocytes; however, absence of spherocytes does not exclude diagnosis",
                      "Often markedly increased polychromasia ± nucleated RBCs (nRBCs)",
                      "In fetal hydrops, smear often reveals many circulating nRBCs in response to accelerated destruction"
                    ]
                  },
                  {
                    "text": "ABO HDFNCharacteristically show many spherocytes and few nRBCs",
                    "sub_points": [
                      "Characteristically show many spherocytes and few nRBCs"
                    ]
                  },
                  {
                    "text": "HTRAnemiaReactive neutrophilia with left shift is commonRBC fragments (schistocytes) in intravascular hemolysis or if when DIC is presentSpherocytes are present with extravascular hemolysis",
                    "sub_points": [
                      "Anemia",
                      "Reactive neutrophilia with left shift is common",
                      "RBC fragments (schistocytes) in intravascular hemolysis or if when DIC is present",
                      "Spherocytes are present with extravascular hemolysis"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Other Causes of Hemolytic Disease With Early-Onset or Severe Neonatal Hyperbilirubinemia That May Mimic HDFN": [
                  {
                    "text": "RBC membrane defectsHereditary spherocytosis (HS)Osmotic fragility test is diagnostic of HSHereditary elliptocytosis (HE)Usually asymptomatic and does not cause severe anemia or sudden hemolysisHereditary pyropoikilocytosis (HPP)Severe hemolytic anemia since birth may raise differential diagnosis of HDFNMarked anisopoikilocytosis with frequent schistocytes is helpful to distinguish HPP from HDFNHemolysis is persistent beyond neonate stage in HPPMutational study of RBC skeleton genes, such as spectrins, may be performed to confirm diagnosis of HPP",
                    "sub_points": [
                      "Hereditary spherocytosis (HS)Osmotic fragility test is diagnostic of HS",
                      "Osmotic fragility test is diagnostic of HS",
                      "Hereditary elliptocytosis (HE)Usually asymptomatic and does not cause severe anemia or sudden hemolysis",
                      "Usually asymptomatic and does not cause severe anemia or sudden hemolysis",
                      "Hereditary pyropoikilocytosis (HPP)Severe hemolytic anemia since birth may raise differential diagnosis of HDFNMarked anisopoikilocytosis with frequent schistocytes is helpful to distinguish HPP from HDFNHemolysis is persistent beyond neonate stage in HPPMutational study of RBC skeleton genes, such as spectrins, may be performed to confirm diagnosis of HPP",
                      "Severe hemolytic anemia since birth may raise differential diagnosis of HDFN",
                      "Marked anisopoikilocytosis with frequent schistocytes is helpful to distinguish HPP from HDFN",
                      "Hemolysis is persistent beyond neonate stage in HPP",
                      "Mutational study of RBC skeleton genes, such as spectrins, may be performed to confirm diagnosis of HPP"
                    ]
                  },
                  {
                    "text": "RBC enzyme defectsG6PD deficiencyPatient can develop severe jaundice during neonatal periodPatient develops acute hemolytic anemia following ingestion of fava beans or when exposed to certain infections or drugsPeripheral blood smear reveals bite cells, characteristic finding in G6PD deficiencyDAT test is always negative in G6PD deficiencyMolecular testing for mutations is available for G6PD deficiencyPyruvate kinase deficiency (PKD)No significant spherocytes are seen in PKDDAT test is always negative in PKDDecreased pyruvate kinase activity on enzymatic testing is gold standard in diagnosis of PKDMutations in pyruvate kinase genes can be performed to confirm diagnosis in difficult cases",
                    "sub_points": [
                      "G6PD deficiencyPatient can develop severe jaundice during neonatal periodPatient develops acute hemolytic anemia following ingestion of fava beans or when exposed to certain infections or drugsPeripheral blood smear reveals bite cells, characteristic finding in G6PD deficiencyDAT test is always negative in G6PD deficiencyMolecular testing for mutations is available for G6PD deficiency",
                      "Patient can develop severe jaundice during neonatal period",
                      "Patient develops acute hemolytic anemia following ingestion of fava beans or when exposed to certain infections or drugs",
                      "Peripheral blood smear reveals bite cells, characteristic finding in G6PD deficiency",
                      "DAT test is always negative in G6PD deficiency",
                      "Molecular testing for mutations is available for G6PD deficiency",
                      "Pyruvate kinase deficiency (PKD)No significant spherocytes are seen in PKDDAT test is always negative in PKDDecreased pyruvate kinase activity on enzymatic testing is gold standard in diagnosis of PKDMutations in pyruvate kinase genes can be performed to confirm diagnosis in difficult cases",
                      "No significant spherocytes are seen in PKD",
                      "DAT test is always negative in PKD",
                      "Decreased pyruvate kinase activity on enzymatic testing is gold standard in diagnosis of PKD",
                      "Mutations in pyruvate kinase genes can be performed to confirm diagnosis in difficult cases"
                    ]
                  },
                  {
                    "text": "Thalassemia majorFamily history is very helpfulLifelong anemia and often chronic hemolytic anemiaTransfusion dependentHemoglobin electrophoresis may be helpful",
                    "sub_points": [
                      "Family history is very helpful",
                      "Lifelong anemia and often chronic hemolytic anemia",
                      "Transfusion dependent",
                      "Hemoglobin electrophoresis may be helpful"
                    ]
                  }
                ],
                "Transfusion Reaction and Clinical Scenarios That May Mimic HTR": [
                  {
                    "text": "Febrile non-HTR (FNHTR), transfusion-related acute lung injury (TRALI)"
                  },
                  {
                    "text": "Septic or hemorrhagic shock, severe allergic transfusion reactions (anaphylaxis), transfusion-associated circulatory overload (TACO)"
                  },
                  {
                    "text": "DAT test (-) in above conditions, in contrast to DAT(+) in HTR"
                  }
                ],
                "Parvovirus B19 Infection": [
                  {
                    "text": "One of common causes of fetal anemia"
                  },
                  {
                    "text": "Mostly asymptomatic but may result in miscarriage, severe anemia with nonimmune hydrops, and stillbirth"
                  },
                  {
                    "text": "Absence of alloantibodies"
                  },
                  {
                    "text": "Parvovirus B19 tests (+)"
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Clinically Relevant Pathologic Features": [
                  {
                    "text": "Positive maternal antenatal antibody screening (IgG antibody) in RhD HDFN"
                  },
                  {
                    "text": "Blood group O mother and group A or B fetus in ABO HDFN"
                  },
                  {
                    "text": "Sudden or gradual onset of anemia and associated signs and symptoms of hemolysis in HTR"
                  }
                ],
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "Hemolytic anemia and hyperbilirubinemia in RhD HDFN"
                  },
                  {
                    "text": "Spherocytosis and few nucleated RBCs in ABO HDFN"
                  },
                  {
                    "text": "Schistocytes or spherocytes in cases of immediate (intravascular) and delayed (extravascular) hemolysis, respectively, in HTR"
                  },
                  {
                    "text": "Other laboratory tests to support diagnosis of hemolysis"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Microangiopathic Hemolytic Anemia": {
            "name": "Microangiopathic Hemolytic Anemia",
            "url": "https://app.pathprimer.com/document/2aead27f-2d8e-4c5c-8565-b9b887c8ddda/lesson/92495282-ce4a-41b9-a2f4-c2339cb2cc79",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Fragmentation of RBCs due to intravascular damage"
                  },
                  {
                    "text": "Thrombotic thrombocytopenic purpura (TTP) is characterized by thrombocytopenia, microangiopathic hemolytic anemia (MAHA), and microthrombi"
                  },
                  {
                    "text": "Hemolytic uremic syndrome (HUS) is characterized by progressive renal failure with associated MAHA and thrombocytopenia"
                  },
                  {
                    "text": "DIC is uncontrolled thrombi formation in microvasculature due to disturbed hemostasis, followed by bleeding"
                  },
                  {
                    "text": "Transplant-associated thrombotic microangiopathy (TMA) most commonly follows allogeneic hematopoietic stem cell transplantation"
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "ADAMTS13 is severely deficient in TTP; ADAMTS13 autoantibodies are detected in immune TTP"
                  },
                  {
                    "text": "Primary events in HUS are microthrombi formation, complement alternative pathway activation, and endothelial injury"
                  },
                  {
                    "text": "Tissue factor or bacterial toxin activation of coagulation cascade is primary event in DIC"
                  },
                  {
                    "text": "Pathogenesis of transplant-associated TMA is most likely due to injury to endothelial cells"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Daily therapeutic plasma exchange is standard treatment for immune TTP"
                  },
                  {
                    "text": "Supportive care is mainstay treatment in HUS and transplant-associated TMA"
                  },
                  {
                    "text": "Eculizumab has shown benefit in aHUS and transplant-associated TMA with possible applications to other TMAs"
                  },
                  {
                    "text": "Treating primary underlying cause of illness is paramount in DIC"
                  }
                ],
                "Diagnostic Checklist": [
                  {
                    "text": "Combination of schistocytosis and thrombocytopenia raises possibility of MAHA"
                  },
                  {
                    "text": "MAHA is diagnosis of clinicopathologic correlation"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Microangiopathic hemolytic anemia (MAHA)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Fragmentation of RBCs due to intravascular damage"
                  },
                  {
                    "text": "Major types and subtypesThrombotic thrombocytopenic purpura (TTP)Congenital TTP (Upshaw-Schulman syndrome)Immune TTPHemolytic uremic syndrome (HUS)Typical HUS: Shiga-like (vero) toxin-associatedAtypical HUS (aHUS): Sporadic or complement mediatedDICAcute DICChronic DICOther thrombotic microangiopathy (TMA) entitiesTransplantation associated [e.g., hematopoietic stem cell transplant (HSCT), solid organ transplant]Pregnancy associated (e.g., HELLP syndrome)Coagulation associatedDrug associated",
                    "sub_points": [
                      "Thrombotic thrombocytopenic purpura (TTP)Congenital TTP (Upshaw-Schulman syndrome)Immune TTP",
                      "Congenital TTP (Upshaw-Schulman syndrome)",
                      "Immune TTP",
                      "Hemolytic uremic syndrome (HUS)Typical HUS: Shiga-like (vero) toxin-associatedAtypical HUS (aHUS): Sporadic or complement mediated",
                      "Typical HUS: Shiga-like (vero) toxin-associated",
                      "Atypical HUS (aHUS): Sporadic or complement mediated",
                      "DICAcute DICChronic DIC",
                      "Acute DIC",
                      "Chronic DIC",
                      "Other thrombotic microangiopathy (TMA) entitiesTransplantation associated [e.g., hematopoietic stem cell transplant (HSCT), solid organ transplant]Pregnancy associated (e.g., HELLP syndrome)Coagulation associatedDrug associated",
                      "Transplantation associated [e.g., hematopoietic stem cell transplant (HSCT), solid organ transplant]",
                      "Pregnancy associated (e.g., HELLP syndrome)",
                      "Coagulation associated",
                      "Drug associated"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Normal Homeostasis of von Willebrand Factor": [
                  {
                    "text": "von Willebrand factor (VWF) is synthesized by endothelial cells and megakaryocytes as ultralarge multimers"
                  },
                  {
                    "text": "Protease ADAMTS13 cleaves ultralarge VWF multimers into smaller VWF forms"
                  },
                  {
                    "text": "VWF is present in platelets, endothelial cells, and subendothelium"
                  },
                  {
                    "text": "VWF mediates platelet aggregation, activation, and thrombus formation at site of vascular injury"
                  }
                ],
                "Complement Activation": [
                  {
                    "text": "Appears to be common pathway for various TMAs"
                  }
                ],
                "Thrombotic Thrombocytopenic Purpura": [
                  {
                    "text": "EtiologyCongenital TTPHomozygous or compound heterozygousADAMTS13mutationsLack of production of ADAMTS13 enzymeImmune TTPAutoimmune disorder that leads to inhibition or clearance of ADAMTS13 enzymeCan be triggered by events, such as malignancy, trauma, transplantation, pregnancy, medications, or infection of any kind (including SARS-CoV-2)",
                    "sub_points": [
                      "Congenital TTPHomozygous or compound heterozygousADAMTS13mutationsLack of production of ADAMTS13 enzyme",
                      "Homozygous or compound heterozygousADAMTS13mutations",
                      "Lack of production of ADAMTS13 enzyme",
                      "Immune TTPAutoimmune disorder that leads to inhibition or clearance of ADAMTS13 enzymeCan be triggered by events, such as malignancy, trauma, transplantation, pregnancy, medications, or infection of any kind (including SARS-CoV-2)",
                      "Autoimmune disorder that leads to inhibition or clearance of ADAMTS13 enzyme",
                      "Can be triggered by events, such as malignancy, trauma, transplantation, pregnancy, medications, or infection of any kind (including SARS-CoV-2)"
                    ]
                  },
                  {
                    "text": "PathogenesisTTPCongenital TTP: Biallelic mutations lead to ADAMTS13 deficiency; episodes are triggered by events, such as infection, acute inflammation, and pregnancyImmune TTP: Autoantibodies cause inhibition or clearance of ADAMTS13 and associated decreased activityADAMTS13 deficiency leads to accumulation of ultralarge VWF multimers, which have greater ability to react with platelets and form microthrombiMultiorgan ischemia results from hemolysis and impaired blood flow",
                    "sub_points": [
                      "TTPCongenital TTP: Biallelic mutations lead to ADAMTS13 deficiency; episodes are triggered by events, such as infection, acute inflammation, and pregnancyImmune TTP: Autoantibodies cause inhibition or clearance of ADAMTS13 and associated decreased activityADAMTS13 deficiency leads to accumulation of ultralarge VWF multimers, which have greater ability to react with platelets and form microthrombiMultiorgan ischemia results from hemolysis and impaired blood flow",
                      "Congenital TTP: Biallelic mutations lead to ADAMTS13 deficiency; episodes are triggered by events, such as infection, acute inflammation, and pregnancy",
                      "Immune TTP: Autoantibodies cause inhibition or clearance of ADAMTS13 and associated decreased activity",
                      "ADAMTS13 deficiency leads to accumulation of ultralarge VWF multimers, which have greater ability to react with platelets and form microthrombi",
                      "Multiorgan ischemia results from hemolysis and impaired blood flow"
                    ]
                  }
                ],
                "Hemolytic Uremic Syndrome": [
                  {
                    "text": "EtiologyShiga-like toxin HUSInfections with Shiga toxin-producingEscherichia coliEnterococcusorShigellais pathogenic organism in some casesaHUS: SporadicStreptococcus pneumoniais most common cause of sporadic aHUSOther infections, drugs, malignancies, organ transplantation, or pregnancyaHUS: Complement mediated (congenital or immune)Majority of patients have mutations in complement factorsInactivating mutations in complement regulatory proteins (factor H or I, membrane cofactor protein)Activating mutations in C3 convertase (factor B, C3)Minority of cases have autoantibody formation against complement regulatory proteins",
                    "sub_points": [
                      "Shiga-like toxin HUSInfections with Shiga toxin-producingEscherichia coliEnterococcusorShigellais pathogenic organism in some cases",
                      "Infections with Shiga toxin-producingEscherichia coli",
                      "EnterococcusorShigellais pathogenic organism in some cases",
                      "aHUS: SporadicStreptococcus pneumoniais most common cause of sporadic aHUSOther infections, drugs, malignancies, organ transplantation, or pregnancy",
                      "Streptococcus pneumoniais most common cause of sporadic aHUS",
                      "Other infections, drugs, malignancies, organ transplantation, or pregnancy",
                      "aHUS: Complement mediated (congenital or immune)Majority of patients have mutations in complement factorsInactivating mutations in complement regulatory proteins (factor H or I, membrane cofactor protein)Activating mutations in C3 convertase (factor B, C3)Minority of cases have autoantibody formation against complement regulatory proteins",
                      "Majority of patients have mutations in complement factorsInactivating mutations in complement regulatory proteins (factor H or I, membrane cofactor protein)Activating mutations in C3 convertase (factor B, C3)",
                      "Inactivating mutations in complement regulatory proteins (factor H or I, membrane cofactor protein)",
                      "Activating mutations in C3 convertase (factor B, C3)",
                      "Minority of cases have autoantibody formation against complement regulatory proteins"
                    ]
                  },
                  {
                    "text": "PathogenesisPrimary events in HUS are complement activation, microthrombi formation, and damage to endothelial cells; injury to RBCs followsShiga-like toxin HUSToxins are proinflammatory, bind to neutrophils, and are delivered to endothelial cells of glomerular microcirculationShiga-like toxin blocks ADAMTS13 binding site on ultralarge VWF, resulting in its persistenceToxins are also prothrombotic; released ultralarge VWF has enhanced activity on platelet aggregation, which leads to binding and further activation of complement pathwayaHUS: SporadicInjury to endothelial cells directly caused by offending agentaHUS due toS. pneumoniainfection is linked to neuraminidase production and T-antigen presentationaHUS: Complement mediated (congenital or immune)Often show incomplete penetrance in congenital settingEven mild viral infection can trigger TMA because of defective regulation of complement systemBoth inactivating (factor H and I) and activating mutations (factor B and C3) lead to enhanced complement activityComplement activation leads to TMA, endothelial and RBC damage (i.e., intravascular hemolysis)",
                    "sub_points": [
                      "Primary events in HUS are complement activation, microthrombi formation, and damage to endothelial cells; injury to RBCs follows",
                      "Shiga-like toxin HUSToxins are proinflammatory, bind to neutrophils, and are delivered to endothelial cells of glomerular microcirculationShiga-like toxin blocks ADAMTS13 binding site on ultralarge VWF, resulting in its persistenceToxins are also prothrombotic; released ultralarge VWF has enhanced activity on platelet aggregation, which leads to binding and further activation of complement pathway",
                      "Toxins are proinflammatory, bind to neutrophils, and are delivered to endothelial cells of glomerular microcirculation",
                      "Shiga-like toxin blocks ADAMTS13 binding site on ultralarge VWF, resulting in its persistence",
                      "Toxins are also prothrombotic; released ultralarge VWF has enhanced activity on platelet aggregation, which leads to binding and further activation of complement pathway",
                      "aHUS: SporadicInjury to endothelial cells directly caused by offending agentaHUS due toS. pneumoniainfection is linked to neuraminidase production and T-antigen presentation",
                      "Injury to endothelial cells directly caused by offending agent",
                      "aHUS due toS. pneumoniainfection is linked to neuraminidase production and T-antigen presentation",
                      "aHUS: Complement mediated (congenital or immune)Often show incomplete penetrance in congenital settingEven mild viral infection can trigger TMA because of defective regulation of complement systemBoth inactivating (factor H and I) and activating mutations (factor B and C3) lead to enhanced complement activityComplement activation leads to TMA, endothelial and RBC damage (i.e., intravascular hemolysis)",
                      "Often show incomplete penetrance in congenital setting",
                      "Even mild viral infection can trigger TMA because of defective regulation of complement system",
                      "Both inactivating (factor H and I) and activating mutations (factor B and C3) lead to enhanced complement activity",
                      "Complement activation leads to TMA, endothelial and RBC damage (i.e., intravascular hemolysis)"
                    ]
                  }
                ],
                "Disseminated Intravascular Coagulation": [
                  {
                    "text": "EtiologyInfections: Gram (+) or (-) bacterial infections; rickettsial infection; viral infectionsTissue factor activation: Malignancies, tissue injury, extensive burn, brain injuryOther: Obstetric disorders, snakebite, vascular disorders",
                    "sub_points": [
                      "Infections: Gram (+) or (-) bacterial infections; rickettsial infection; viral infections",
                      "Tissue factor activation: Malignancies, tissue injury, extensive burn, brain injury",
                      "Other: Obstetric disorders, snakebite, vascular disorders"
                    ]
                  },
                  {
                    "text": "PathogenesisTissue factor or bacterial toxin activates coagulation cascade resulting in disturbed hemostasisOverproduction of thrombin leads to generation of fibrin monomers, which are crosslinked into insoluble fibrin polymers by FXIIIAFibrin polymers deposit in microvasculature (microthrombi) leading to tissue ischemiaEndothelial cell response to thrombi causes excessive fibrinolysisFibrin degradation products (FDP) interfere with platelet aggregation, potentiate bleeding riskDepletion of platelets, fibrinogen, and other hemostatic proteins increase bleeding riskCytokines released by macrophages, monocytes, and endothelial cells may lead to shock",
                    "sub_points": [
                      "Tissue factor or bacterial toxin activates coagulation cascade resulting in disturbed hemostasis",
                      "Overproduction of thrombin leads to generation of fibrin monomers, which are crosslinked into insoluble fibrin polymers by FXIIIA",
                      "Fibrin polymers deposit in microvasculature (microthrombi) leading to tissue ischemia",
                      "Endothelial cell response to thrombi causes excessive fibrinolysis",
                      "Fibrin degradation products (FDP) interfere with platelet aggregation, potentiate bleeding risk",
                      "Depletion of platelets, fibrinogen, and other hemostatic proteins increase bleeding risk",
                      "Cytokines released by macrophages, monocytes, and endothelial cells may lead to shock"
                    ]
                  }
                ],
                "Other Types of Thrombotic Microangiopathy": [
                  {
                    "text": "Transplant-associated TMA associated with HSCT and solid organ transplant, likely due to endothelial injury, immune cell activation, and complement pathway dysregulation"
                  },
                  {
                    "text": "Drug-mediated TMA, either immune reaction (e.g., ticlopidine, quinine) or toxic effect (e.g., VEGF inhibitor)"
                  },
                  {
                    "text": "Coagulation-mediated TMA [e.g., homozygous mutations of diacylglycerol kinase ε (DGKE) gene]"
                  },
                  {
                    "text": "Metabolism-mediated TMA (e.g., mutations ofMMACHCgene)"
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Presentation": [
                  {
                    "text": "TTPTTP triadThrombocytopeniaMAHAMicrothrombi of small vessels in multiple organ systemsSubtypesCongenital TTP is rare, typically presents initially at birth/infancy with recurrent episodes of TMAImmune TTP is predominant type; presentation is diverseOccurs in wide age range and in pregnant patientsClinical signs and symptomsNeurologic symptoms, such as mental status change, are hallmark of TTPInsidious onset with fever, weakness, cardiac injury, GI symptoms, petechiae/purpuraMild renal impairment in minor subset of patientsDIC may arise from prolonged tissue ischemia",
                    "sub_points": [
                      "TTP triadThrombocytopeniaMAHAMicrothrombi of small vessels in multiple organ systems",
                      "Thrombocytopenia",
                      "MAHA",
                      "Microthrombi of small vessels in multiple organ systems",
                      "SubtypesCongenital TTP is rare, typically presents initially at birth/infancy with recurrent episodes of TMAImmune TTP is predominant type; presentation is diverseOccurs in wide age range and in pregnant patients",
                      "Congenital TTP is rare, typically presents initially at birth/infancy with recurrent episodes of TMA",
                      "Immune TTP is predominant type; presentation is diverseOccurs in wide age range and in pregnant patients",
                      "Occurs in wide age range and in pregnant patients",
                      "Clinical signs and symptomsNeurologic symptoms, such as mental status change, are hallmark of TTPInsidious onset with fever, weakness, cardiac injury, GI symptoms, petechiae/purpuraMild renal impairment in minor subset of patients",
                      "Neurologic symptoms, such as mental status change, are hallmark of TTP",
                      "Insidious onset with fever, weakness, cardiac injury, GI symptoms, petechiae/purpura",
                      "Mild renal impairment in minor subset of patients",
                      "DIC may arise from prolonged tissue ischemia"
                    ]
                  },
                  {
                    "text": "HUSHUS in generalProgressive renal failure is hallmark of HUSThrombocytopeniaMAHAHypertension, electrolyte abnormalities, such as hyponatremia and hypocalcemiaShiga-like toxin HUSIncidence: 6 per 100,000 per year in childrenDisease of children younger than 2-3 yearsAbrupt onset occurs 6-14 days after ingestion of contaminated food, often with bloody diarrhea prodromeMost common cause of acute renal failure in childrenaHUSRare; accounts for 5-10% of HUS casesNo prodromal bloody diarrheaSome patients show CNS involvement at onsetChildren with pneumococcal aHUS tend to be younger and have more severe disease compared to Shiga-like toxin HUSComplement-mediated aHUS can occur in children or adults",
                    "sub_points": [
                      "HUS in generalProgressive renal failure is hallmark of HUSThrombocytopeniaMAHAHypertension, electrolyte abnormalities, such as hyponatremia and hypocalcemia",
                      "Progressive renal failure is hallmark of HUS",
                      "Thrombocytopenia",
                      "MAHA",
                      "Hypertension, electrolyte abnormalities, such as hyponatremia and hypocalcemia",
                      "Shiga-like toxin HUSIncidence: 6 per 100,000 per year in childrenDisease of children younger than 2-3 yearsAbrupt onset occurs 6-14 days after ingestion of contaminated food, often with bloody diarrhea prodromeMost common cause of acute renal failure in children",
                      "Incidence: 6 per 100,000 per year in children",
                      "Disease of children younger than 2-3 years",
                      "Abrupt onset occurs 6-14 days after ingestion of contaminated food, often with bloody diarrhea prodrome",
                      "Most common cause of acute renal failure in children",
                      "aHUSRare; accounts for 5-10% of HUS casesNo prodromal bloody diarrheaSome patients show CNS involvement at onsetChildren with pneumococcal aHUS tend to be younger and have more severe disease compared to Shiga-like toxin HUSComplement-mediated aHUS can occur in children or adults",
                      "Rare; accounts for 5-10% of HUS cases",
                      "No prodromal bloody diarrhea",
                      "Some patients show CNS involvement at onset",
                      "Children with pneumococcal aHUS tend to be younger and have more severe disease compared to Shiga-like toxin HUS",
                      "Complement-mediated aHUS can occur in children or adults"
                    ]
                  },
                  {
                    "text": "DICCharacterized byDisturbed hemostasisUncontrolled thrombi formation and fibrinolysis in microvasculatureAcute DICAbrupt onsetUsually secondary to infections, traumas, and obstetric disordersAcute onset of bleeding in GI, GU systems; melena; hematemesis; epistaxis; submucosal, urethral, and vaginal bleedingChronic DICUsually in cancer patientsGradual subclinical systemic activation of coagulationLeads to exhaustion of platelets and coagulation factorsBleeding (e.g., at site of tumor) may be 1st clinical symptom indicating presence of DICIn some cases, clinical presentation of DIC may be reminiscent of TMA",
                    "sub_points": [
                      "Characterized byDisturbed hemostasisUncontrolled thrombi formation and fibrinolysis in microvasculature",
                      "Disturbed hemostasis",
                      "Uncontrolled thrombi formation and fibrinolysis in microvasculature",
                      "Acute DICAbrupt onsetUsually secondary to infections, traumas, and obstetric disordersAcute onset of bleeding in GI, GU systems; melena; hematemesis; epistaxis; submucosal, urethral, and vaginal bleeding",
                      "Abrupt onset",
                      "Usually secondary to infections, traumas, and obstetric disorders",
                      "Acute onset of bleeding in GI, GU systems; melena; hematemesis; epistaxis; submucosal, urethral, and vaginal bleeding",
                      "Chronic DICUsually in cancer patientsGradual subclinical systemic activation of coagulationLeads to exhaustion of platelets and coagulation factorsBleeding (e.g., at site of tumor) may be 1st clinical symptom indicating presence of DICIn some cases, clinical presentation of DIC may be reminiscent of TMA",
                      "Usually in cancer patients",
                      "Gradual subclinical systemic activation of coagulation",
                      "Leads to exhaustion of platelets and coagulation factors",
                      "Bleeding (e.g., at site of tumor) may be 1st clinical symptom indicating presence of DIC",
                      "In some cases, clinical presentation of DIC may be reminiscent of TMA"
                    ]
                  },
                  {
                    "text": "Transplant-associated TMAIncidence: May affect 20-30% of patients with allogeneic HSCT; much lower in autologous setting and in solid organ transplantPresents with many diagnostic and management challengesPatients often present with high blood pressure, severe kidney damage followed by neurologic impairment, and multiorgan failureTypically presents within 120 days post transplantation",
                    "sub_points": [
                      "Incidence: May affect 20-30% of patients with allogeneic HSCT; much lower in autologous setting and in solid organ transplant",
                      "Presents with many diagnostic and management challenges",
                      "Patients often present with high blood pressure, severe kidney damage followed by neurologic impairment, and multiorgan failure",
                      "Typically presents within 120 days post transplantation"
                    ]
                  }
                ],
                "Laboratory Tests": [
                  {
                    "text": "Common findings in all types of MAHAMarked thrombocytopeniaRBC fragmentation (schistocytes), defined as > 1% in adults and full-term infants, > 5% in premature infants by manual countsAutomated RBC fragment count is usually higher than manual counts due to higher false-positive rateSignificantly elevated serum lactate dehydrogenase (LDH) level and other positive biochemical markers of hemolysis (e.g., decreased haptoglobin)Increased indirect bilirubin levelElevated reticulocyte count",
                    "sub_points": [
                      "Marked thrombocytopenia",
                      "RBC fragmentation (schistocytes), defined as > 1% in adults and full-term infants, > 5% in premature infants by manual counts",
                      "Automated RBC fragment count is usually higher than manual counts due to higher false-positive rate",
                      "Significantly elevated serum lactate dehydrogenase (LDH) level and other positive biochemical markers of hemolysis (e.g., decreased haptoglobin)",
                      "Increased indirect bilirubin level",
                      "Elevated reticulocyte count"
                    ]
                  },
                  {
                    "text": "TTPSeverely decreased ADAMTS13 activity, typically < 10% of normal levels, supports diagnosisGenetic analysis demonstrates 2 abnormal copies ofADAMTS13gene in congenital TTPAutoantibodies to ADAMTS13 in immune TTPNormal prothrombin time (PT) and activated partial thromboplastin time partial thromboplastin time (aPTT)Usually normal DIC panel (fibrinogen, D-dimer)Creatinine level may be slightly elevated in subset of patientsAge, hemoglobin level, and creatinine level comprise prediction model for early identification of refractory immune TTP",
                    "sub_points": [
                      "Severely decreased ADAMTS13 activity, typically < 10% of normal levels, supports diagnosis",
                      "Genetic analysis demonstrates 2 abnormal copies ofADAMTS13gene in congenital TTP",
                      "Autoantibodies to ADAMTS13 in immune TTP",
                      "Normal prothrombin time (PT) and activated partial thromboplastin time partial thromboplastin time (aPTT)",
                      "Usually normal DIC panel (fibrinogen, D-dimer)",
                      "Creatinine level may be slightly elevated in subset of patientsAge, hemoglobin level, and creatinine level comprise prediction model for early identification of refractory immune TTP",
                      "Age, hemoglobin level, and creatinine level comprise prediction model for early identification of refractory immune TTP"
                    ]
                  },
                  {
                    "text": "HUSPositive stool culture in Shiga-like toxin HUS patientsMutational study for complement-mediated aHUSProteinuria and microscopic hematuriaElevated serum creatinine levelElevated blood urea nitrogen (BUN) levelNormal PT and PTTMildly increased D-dimer levelDecreased serum complement levels, particularly C3",
                    "sub_points": [
                      "Positive stool culture in Shiga-like toxin HUS patients",
                      "Mutational study for complement-mediated aHUS",
                      "Proteinuria and microscopic hematuria",
                      "Elevated serum creatinine level",
                      "Elevated blood urea nitrogen (BUN) level",
                      "Normal PT and PTT",
                      "Mildly increased D-dimer level",
                      "Decreased serum complement levels, particularly C3"
                    ]
                  },
                  {
                    "text": "DICElevated D-dimer (fibrin degradation product)Progressively falling platelet countProgressively decreasing fibrinogen levelProlonged PT and PTT",
                    "sub_points": [
                      "Elevated D-dimer (fibrin degradation product)",
                      "Progressively falling platelet count",
                      "Progressively decreasing fibrinogen level",
                      "Prolonged PT and PTT"
                    ]
                  },
                  {
                    "text": "Transplant Associated TMANo specific lab test",
                    "sub_points": [
                      "No specific lab test"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "Humanized anticomplement C5 antibody eculizumab has been used in Shiga-like toxin HUS, aHUS, transplant associated TMA, and immune TTP"
                  },
                  {
                    "text": "TTP (primarily immune-mediated TTP)Rapid initiation of therapeutic plasma exchangeDaily therapeutic plasma exchange is mainstay of therapyGlucocorticoids are often used with therapeutic plasma exchangeRituximab has been increasingly utilized in early stages of disease can decrease relapse ratesCaplacizumab, anti-VWF therapeutic, is increasingly used in conjunction with therapeutic plasma exchangeSplenectomy, alternative immunosuppressive agents, and other therapies (e.g. N-acetylcysteine) may be considered in refractory cases",
                    "sub_points": [
                      "Rapid initiation of therapeutic plasma exchange",
                      "Daily therapeutic plasma exchange is mainstay of therapy",
                      "Glucocorticoids are often used with therapeutic plasma exchange",
                      "Rituximab has been increasingly utilized in early stages of disease can decrease relapse rates",
                      "Caplacizumab, anti-VWF therapeutic, is increasingly used in conjunction with therapeutic plasma exchange",
                      "Splenectomy, alternative immunosuppressive agents, and other therapies (e.g. N-acetylcysteine) may be considered in refractory cases"
                    ]
                  },
                  {
                    "text": "HUSShiga-like toxin HUSSupportive care for acute kidney injury, anemia, hypertension, and fluid-electrolyte balance is mainstay of therapyDialysis if neededEculizumab has demonstrated rapid recovery of platelet count, renal function, and neurologic functions in Shiga-like toxin HUSTargeting inflammatory mediators is emerging as another alternativeaHUSEculizumab is mainstay of therapyUtilization of therapeutic plasma exchange is decreasingSupportive care",
                    "sub_points": [
                      "Shiga-like toxin HUSSupportive care for acute kidney injury, anemia, hypertension, and fluid-electrolyte balance is mainstay of therapyDialysis if neededEculizumab has demonstrated rapid recovery of platelet count, renal function, and neurologic functions in Shiga-like toxin HUSTargeting inflammatory mediators is emerging as another alternative",
                      "Supportive care for acute kidney injury, anemia, hypertension, and fluid-electrolyte balance is mainstay of therapy",
                      "Dialysis if needed",
                      "Eculizumab has demonstrated rapid recovery of platelet count, renal function, and neurologic functions in Shiga-like toxin HUS",
                      "Targeting inflammatory mediators is emerging as another alternative",
                      "aHUSEculizumab is mainstay of therapyUtilization of therapeutic plasma exchange is decreasingSupportive care",
                      "Eculizumab is mainstay of therapy",
                      "Utilization of therapeutic plasma exchange is decreasing",
                      "Supportive care"
                    ]
                  },
                  {
                    "text": "DICTreating primary cause is paramountCorrect and restore coagulation systemEspecially important in acute DIC patients with active bleeding or high bleeding riskPlatelet transfusion to correct thrombocytopeniaCryoprecipitate transfusion to replete fibrinogenPlasma transfusion to provide other coagulation factors, if neededAnticoagulantsHeparin or low molecular weight heparin might be beneficial in chronic DIC and thromboembolism, especially in malignant conditionsTherapeutic heparin in acute DIC may increase underlying bleeding riskAntifibrinolytic agentsReserved for patients with prominent fibrinolytic component, e.g., acute promyelocytic leukemiaTissue factor pathway inhibitor agentsMay be beneficial",
                    "sub_points": [
                      "Treating primary cause is paramount",
                      "Correct and restore coagulation systemEspecially important in acute DIC patients with active bleeding or high bleeding riskPlatelet transfusion to correct thrombocytopeniaCryoprecipitate transfusion to replete fibrinogenPlasma transfusion to provide other coagulation factors, if needed",
                      "Especially important in acute DIC patients with active bleeding or high bleeding risk",
                      "Platelet transfusion to correct thrombocytopenia",
                      "Cryoprecipitate transfusion to replete fibrinogen",
                      "Plasma transfusion to provide other coagulation factors, if needed",
                      "AnticoagulantsHeparin or low molecular weight heparin might be beneficial in chronic DIC and thromboembolism, especially in malignant conditionsTherapeutic heparin in acute DIC may increase underlying bleeding risk",
                      "Heparin or low molecular weight heparin might be beneficial in chronic DIC and thromboembolism, especially in malignant conditions",
                      "Therapeutic heparin in acute DIC may increase underlying bleeding risk",
                      "Antifibrinolytic agentsReserved for patients with prominent fibrinolytic component, e.g., acute promyelocytic leukemia",
                      "Reserved for patients with prominent fibrinolytic component, e.g., acute promyelocytic leukemia",
                      "Tissue factor pathway inhibitor agentsMay be beneficial",
                      "May be beneficial"
                    ]
                  },
                  {
                    "text": "Transplant-associated TMASupportive care is mainstay treatmentEculizumab has shown improved response rate and overall survival in small series of studies",
                    "sub_points": [
                      "Supportive care is mainstay treatment",
                      "Eculizumab has shown improved response rate and overall survival in small series of studies"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "TTPLife threatening; > 90% mortality rate if left untreatedMortality rate decreases to ~ 10% with early diagnosis and prompt treatmentAdverse outcome linked toOlder ageSevere neurologic symptomsSevere thrombocytopeniaDIC carries ominous prognosis1/3 of patients experience relapse within 10 yearsSignificantly reduced recurrence rate associated with caplacizumab therapy in conjunction with therapeutic plasma exchange",
                    "sub_points": [
                      "Life threatening; > 90% mortality rate if left untreated",
                      "Mortality rate decreases to ~ 10% with early diagnosis and prompt treatment",
                      "Adverse outcome linked toOlder ageSevere neurologic symptomsSevere thrombocytopeniaDIC carries ominous prognosis",
                      "Older age",
                      "Severe neurologic symptoms",
                      "Severe thrombocytopenia",
                      "DIC carries ominous prognosis",
                      "1/3 of patients experience relapse within 10 yearsSignificantly reduced recurrence rate associated with caplacizumab therapy in conjunction with therapeutic plasma exchange",
                      "Significantly reduced recurrence rate associated with caplacizumab therapy in conjunction with therapeutic plasma exchange"
                    ]
                  },
                  {
                    "text": "HUSShiga-like toxin HUSAcute renal failure in 2/3 of patientsUp to 85% of patients recover renal functionFavorable overall prognosisHigh peripheral blood neutrophil count is associated with poor prognosisUp to 25% of children may have evidence of long-term kidney damageaHUSVaries; depends on etiology, type of mutation, and therapyImproved outcome with eculizumab therapy, usually following plasma exchangeUp to 25% die during acute phase, varies based on etiology1/2 of patients progress to chronic kidney disease, end-stage renal disease, or irreversible brain damageVariable relapse rate; reduced with eculizumab therapyVariable overall outcome based on initial creatinine level and treatment",
                    "sub_points": [
                      "Shiga-like toxin HUSAcute renal failure in 2/3 of patientsUp to 85% of patients recover renal functionFavorable overall prognosisHigh peripheral blood neutrophil count is associated with poor prognosisUp to 25% of children may have evidence of long-term kidney damage",
                      "Acute renal failure in 2/3 of patients",
                      "Up to 85% of patients recover renal function",
                      "Favorable overall prognosis",
                      "High peripheral blood neutrophil count is associated with poor prognosis",
                      "Up to 25% of children may have evidence of long-term kidney damage",
                      "aHUSVaries; depends on etiology, type of mutation, and therapyImproved outcome with eculizumab therapy, usually following plasma exchangeUp to 25% die during acute phase, varies based on etiology1/2 of patients progress to chronic kidney disease, end-stage renal disease, or irreversible brain damageVariable relapse rate; reduced with eculizumab therapyVariable overall outcome based on initial creatinine level and treatment",
                      "Varies; depends on etiology, type of mutation, and therapyImproved outcome with eculizumab therapy, usually following plasma exchange",
                      "Improved outcome with eculizumab therapy, usually following plasma exchange",
                      "Up to 25% die during acute phase, varies based on etiology",
                      "1/2 of patients progress to chronic kidney disease, end-stage renal disease, or irreversible brain damage",
                      "Variable relapse rate; reduced with eculizumab therapy",
                      "Variable overall outcome based on initial creatinine level and treatment"
                    ]
                  },
                  {
                    "text": "DICHighly variable; dependent on cause and severity",
                    "sub_points": [
                      "Highly variable; dependent on cause and severity"
                    ]
                  },
                  {
                    "text": "Transplant-associated TMAHigh mortality rate amongst those with severe disease",
                    "sub_points": [
                      "High mortality rate amongst those with severe disease"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Peripheral Blood Features": [
                  {
                    "text": "Schistocytosis prototypic finding in all types of MAHA"
                  },
                  {
                    "text": "Morphology criteria of schistocytesSmaller than intact RBCs with sharp angles, straight borders, small crescents, helmet cells, keratocytesUsually homogeneously stained, but central area can be slightly paler than peripheryMicrospherocytes are included when other schistocytes are dominantBlood sample for morphology is stable for 3 hours at room temperature and 8 hours at 4 °C",
                    "sub_points": [
                      "Smaller than intact RBCs with sharp angles, straight borders, small crescents, helmet cells, keratocytes",
                      "Usually homogeneously stained, but central area can be slightly paler than periphery",
                      "Microspherocytes are included when other schistocytes are dominant",
                      "Blood sample for morphology is stable for 3 hours at room temperature and 8 hours at 4 °C"
                    ]
                  },
                  {
                    "text": "Polychromasia; may have nucleated RBCs (nRBCs)"
                  },
                  {
                    "text": "Thrombocytopenia"
                  },
                  {
                    "text": "Leukocytosis, reactive neutrophilia common in HUS"
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Between Different Tissue Microangiopathies": [
                  {
                    "text": "Significant overlap in clinical and pathologic features"
                  },
                  {
                    "text": "Distinction may not be possible in some cases"
                  },
                  {
                    "text": "TTPMental status changeMultiorgan system disease with mild renal involvementSevere deficiency ofADAMTS13activity; ADAMTS13 autoantibodies present in immune TTPResponds to therapeutic plasma exchange, immunosuppression, including rituximab and caplacizumab",
                    "sub_points": [
                      "Mental status change",
                      "Multiorgan system disease with mild renal involvement",
                      "Severe deficiency ofADAMTS13activity; ADAMTS13 autoantibodies present in immune TTP",
                      "Responds to therapeutic plasma exchange, immunosuppression, including rituximab and caplacizumab"
                    ]
                  },
                  {
                    "text": "Shiga-like toxin HUSPrimarily renal disease with occasional extrarenal manifestationMost common in childrenProdrome of painful, bloody diarrheaNormalADAMTS13activity levelsTherapeutic plasma exchange of limited benefit",
                    "sub_points": [
                      "Primarily renal disease with occasional extrarenal manifestation",
                      "Most common in children",
                      "Prodrome of painful, bloody diarrhea",
                      "NormalADAMTS13activity levels",
                      "Therapeutic plasma exchange of limited benefit"
                    ]
                  },
                  {
                    "text": "aHUSComplement mutationDistinction of aHUS and TTP can be extremely challenging in some cases",
                    "sub_points": [
                      "Complement mutation",
                      "Distinction of aHUS and TTP can be extremely challenging in some cases"
                    ]
                  },
                  {
                    "text": "Transplant-associated TMAMost common in those with allogeneic HSCT",
                    "sub_points": [
                      "Most common in those with allogeneic HSCT"
                    ]
                  }
                ],
                "Microvascular Thrombotic/Microangiopathic Antiphospholipid Syndrome": [
                  {
                    "text": "a.k.a. antiphospholipid syndrome (APS)Classic APS is defined by 1 or more clinical episodes of small vessel thrombosis in any tissue or organCatastrophic APS shows evidence of involvement of 3 or more organs &/or tissues",
                    "sub_points": [
                      "Classic APS is defined by 1 or more clinical episodes of small vessel thrombosis in any tissue or organ",
                      "Catastrophic APS shows evidence of involvement of 3 or more organs &/or tissues"
                    ]
                  },
                  {
                    "text": "Commonly seen in collagen vascular disease, e.g., systemic lupus erythematosus (SLE)"
                  },
                  {
                    "text": "Microangiopathic antiphospholipid syndrome (MAPS) may show manifestation in skin, kidney, eye, heart, liver, intestines, &/or lungs"
                  },
                  {
                    "text": "Pathologic basis of MAPS is thrombosis in small and large vessels"
                  },
                  {
                    "text": "No significant peripheral blood manifestations"
                  }
                ],
                "Other Conditions May Have Schistocytes": [
                  {
                    "text": "Infections"
                  },
                  {
                    "text": "Autoimmune disorders, including pernicious anemia"
                  },
                  {
                    "text": "Mechanical or thermal RBC injuries"
                  },
                  {
                    "text": "Snake bite"
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "Combination of schistocytosis and thrombocytopenia raises differential diagnosis of MAHA"
                  },
                  {
                    "text": "Communication with clinician is paramount"
                  },
                  {
                    "text": "MAHA is diagnosis of clinicopathologic correlation"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Gelatinous Transformation and Other Bone Marrow Stromal Disorders": {
            "name": "Gelatinous Transformation and Other Bone Marrow Stromal Disorders",
            "url": "https://app.pathprimer.com/document/e8e9bfab-88d6-443a-bbe0-1cb52e85c6a0/lesson/92495282-ce4a-41b9-a2f4-c2339cb2cc79",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Distinctive patterns of stromal alterations associated with specific bone marrow insults or conditions"
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "Gelatinous transformationFat cell atrophy, hyaluronic acid-rich mucopolysaccharide deposition, associated hypocellularity",
                    "sub_points": [
                      "Fat cell atrophy, hyaluronic acid-rich mucopolysaccharide deposition, associated hypocellularity"
                    ]
                  },
                  {
                    "text": "AmyloidAbnormally folded fibrillar proteins with β-pleated sheet structure",
                    "sub_points": [
                      "Abnormally folded fibrillar proteins with β-pleated sheet structure"
                    ]
                  },
                  {
                    "text": "FibrosisCollagen or increased reticulin fibers are pathologic",
                    "sub_points": [
                      "Collagen or increased reticulin fibers are pathologic"
                    ]
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Gelatinous transformationHomogeneous, eosinophilic material, atrophic adipocytes with decreased hematopoiesis",
                    "sub_points": [
                      "Homogeneous, eosinophilic material, atrophic adipocytes with decreased hematopoiesis"
                    ]
                  },
                  {
                    "text": "Amyloid depositionHomogeneous, eosinophilic deposits in vessel walls, interstitium, or periosteal soft tissueAspirate smears show homogeneous eosinophilic to dark purple, waxy globules",
                    "sub_points": [
                      "Homogeneous, eosinophilic deposits in vessel walls, interstitium, or periosteal soft tissue",
                      "Aspirate smears show homogeneous eosinophilic to dark purple, waxy globules"
                    ]
                  },
                  {
                    "text": "FibrosisDacrocytes or teardrop cells in peripheral bloodEosinophilic fibers with streaming of cellular elements and neovascularization in bone marrow biopsies",
                    "sub_points": [
                      "Dacrocytes or teardrop cells in peripheral blood",
                      "Eosinophilic fibers with streaming of cellular elements and neovascularization in bone marrow biopsies"
                    ]
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "Positive stains on bone marrow sectionsGelatinous transformation: Alcian blue at pH 2.5; amyloid: Congo red, PAS, crystal violet, thioflavin TReticulin fibrosis: Silver stains; collagen fibrosis: Trichrome",
                    "sub_points": [
                      "Gelatinous transformation: Alcian blue at pH 2.5; amyloid: Congo red, PAS, crystal violet, thioflavin T",
                      "Reticulin fibrosis: Silver stains; collagen fibrosis: Trichrome"
                    ]
                  }
                ],
                "Diagnostic Checklist": [
                  {
                    "text": "Stromal changes are associated with underlying benign or neoplastic conditionsEvaluate associated cellular, vascular, and bony changes",
                    "sub_points": [
                      "Evaluate associated cellular, vascular, and bony changes"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Synonyms": [
                  {
                    "text": "Gelatinous transformationSerous fat atrophy; starvation marrowGelatinous atrophy or degeneration",
                    "sub_points": [
                      "Serous fat atrophy; starvation marrow",
                      "Gelatinous atrophy or degeneration"
                    ]
                  }
                ],
                "Definitions": [
                  {
                    "text": "Amyloidosis is disease associated with pathologic amyloid deposits"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Gelatinous Transformation": [
                  {
                    "text": "Fat cell atrophy, gelatinous material depositionGelatinous material is hyaluronic acid-rich mucopolysaccharide with increased glycosaminoglycansDeposits interfere with bone marrow microenvironmentHematopoiesis is decreased",
                    "sub_points": [
                      "Gelatinous material is hyaluronic acid-rich mucopolysaccharide with increased glycosaminoglycans",
                      "Deposits interfere with bone marrow microenvironmentHematopoiesis is decreased",
                      "Hematopoiesis is decreased"
                    ]
                  },
                  {
                    "text": "Hypothesized mechanisms leading to depositionFat mobilization due to severe catabolism in starvationCytokine secretion in infection, malignancyTumor cell stimulation of hyaluronic acid formationChemotherapeutic inhibition of tyrosine kinase activityCauses extracellular matrix depositionAlters adipocyte differentiation",
                    "sub_points": [
                      "Fat mobilization due to severe catabolism in starvation",
                      "Cytokine secretion in infection, malignancy",
                      "Tumor cell stimulation of hyaluronic acid formation",
                      "Chemotherapeutic inhibition of tyrosine kinase activityCauses extracellular matrix depositionAlters adipocyte differentiation",
                      "Causes extracellular matrix deposition",
                      "Alters adipocyte differentiation"
                    ]
                  }
                ],
                "Amyloid": [
                  {
                    "text": "Deposition of abnormally folded, fibrillar proteins with β-pleated sheet structure> 30 types of pathogenic amyloid precursor proteinsProteins lose normal structure, misfold, nucleate, polymerize to form elongated fibers",
                    "sub_points": [
                      "> 30 types of pathogenic amyloid precursor proteins",
                      "Proteins lose normal structure, misfold, nucleate, polymerize to form elongated fibers"
                    ]
                  },
                  {
                    "text": "Amyloid light chain (AL) is most common in bone marrowFibrils formed from free light chain produced by clonal plasma cells, λ > κGene mutations alter VL sequence on light chain",
                    "sub_points": [
                      "Fibrils formed from free light chain produced by clonal plasma cells, λ > κ",
                      "Gene mutations alter VL sequence on light chain"
                    ]
                  },
                  {
                    "text": "Amyloid transthyretin (ATTR): Carrier protein from liverTTRmutations alter proteinSeparates into monomers that aggregate to form fibrils",
                    "sub_points": [
                      "TTRmutations alter protein",
                      "Separates into monomers that aggregate to form fibrils"
                    ]
                  },
                  {
                    "text": "Amyloid deposits injure tissue and disrupt normal function"
                  }
                ],
                "Fibrosis": [
                  {
                    "text": "Reticulin fibers are normal component of stroma associated with sinuses, large vessels, lymphoid aggregates"
                  },
                  {
                    "text": "Proinflammatory cytokines and growth factors alter hematopoietic microenvironment, promoting fibrosisProduced by abnormal megakaryocytes, monocytes, macrophages, or lymphocytesCells populations and mediators involved vary depending on underlying conditionChanges in T-cell subsets and immunosuppressive myeloid cells affect normal hematopoiesisMesenchymal stem cells initiate fibrosisProliferation and activation of fibroblastsProduce increased reticulin (type III collagen) fibers in benign and neoplastic conditionsProduce increased type I collagen fibers especially in myeloproliferative neoplasms, metastatic disease",
                    "sub_points": [
                      "Produced by abnormal megakaryocytes, monocytes, macrophages, or lymphocytesCells populations and mediators involved vary depending on underlying conditionChanges in T-cell subsets and immunosuppressive myeloid cells affect normal hematopoiesis",
                      "Cells populations and mediators involved vary depending on underlying condition",
                      "Changes in T-cell subsets and immunosuppressive myeloid cells affect normal hematopoiesis",
                      "Mesenchymal stem cells initiate fibrosisProliferation and activation of fibroblastsProduce increased reticulin (type III collagen) fibers in benign and neoplastic conditionsProduce increased type I collagen fibers especially in myeloproliferative neoplasms, metastatic disease",
                      "Proliferation and activation of fibroblasts",
                      "Produce increased reticulin (type III collagen) fibers in benign and neoplastic conditions",
                      "Produce increased type I collagen fibers especially in myeloproliferative neoplasms, metastatic disease"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "Gelatinous transformation of bone marrowLikely underreported due to lack of awareness0.2-4.8% of bone marrows evaluated",
                    "sub_points": [
                      "Likely underreported due to lack of awareness",
                      "0.2-4.8% of bone marrows evaluated"
                    ]
                  },
                  {
                    "text": "Systemic AL amyloidosis: ~ 4,000 new cases annually in USA"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Gelatinous transformation is seen in all age groupsIndividuals present with weight loss, cytopenia(s)Associated with variety of conditionsNutritional deprivation: Anorexia nervosa, malnutrition, alcoholism, digestive disordersChronic infections: HIV, tuberculosis, othersMalignancy: Hematolymphoid, metastatic carcinomaHeart failure, metabolic disordersChemotherapy: Tyrosine kinase inhibitors, imatinib, thrombopoietin receptor agonists",
                    "sub_points": [
                      "Individuals present with weight loss, cytopenia(s)",
                      "Associated with variety of conditionsNutritional deprivation: Anorexia nervosa, malnutrition, alcoholism, digestive disordersChronic infections: HIV, tuberculosis, othersMalignancy: Hematolymphoid, metastatic carcinomaHeart failure, metabolic disordersChemotherapy: Tyrosine kinase inhibitors, imatinib, thrombopoietin receptor agonists",
                      "Nutritional deprivation: Anorexia nervosa, malnutrition, alcoholism, digestive disorders",
                      "Chronic infections: HIV, tuberculosis, others",
                      "Malignancy: Hematolymphoid, metastatic carcinoma",
                      "Heart failure, metabolic disorders",
                      "Chemotherapy: Tyrosine kinase inhibitors, imatinib, thrombopoietin receptor agonists"
                    ]
                  },
                  {
                    "text": "Symptoms of systemic amyloidosis depend on type and location of amyloid depositionAL amyloidosis is most commonPlasma cell dyscrasias, B-cell lymphomaMajority of cases are systemic vs. localized to boneAmyloid A protein (AA): chronic inflammation [i.e., rheumatoid arthritis (RA)]ATTR: Hereditary (gene mutation) or age related",
                    "sub_points": [
                      "AL amyloidosis is most commonPlasma cell dyscrasias, B-cell lymphomaMajority of cases are systemic vs. localized to bone",
                      "Plasma cell dyscrasias, B-cell lymphoma",
                      "Majority of cases are systemic vs. localized to bone",
                      "Amyloid A protein (AA): chronic inflammation [i.e., rheumatoid arthritis (RA)]",
                      "ATTR: Hereditary (gene mutation) or age related"
                    ]
                  },
                  {
                    "text": "Fibrosis: Symptoms of associated conditionSplenomegaly if extramedullary hematopoiesis",
                    "sub_points": [
                      "Splenomegaly if extramedullary hematopoiesis"
                    ]
                  }
                ],
                "Laboratory Tests": [
                  {
                    "text": "Positive stains on bone marrow sectionsGelatinous transformation: Alcian blue at pH 2.5Amyloid: Congo red, PAS, crystal violet, thioflavin TCongo red stain shows apple green birefringence under polarized lightReticulin fibrosis: Silver stains; collagen fibrosis: Trichrome",
                    "sub_points": [
                      "Gelatinous transformation: Alcian blue at pH 2.5",
                      "Amyloid: Congo red, PAS, crystal violet, thioflavin TCongo red stain shows apple green birefringence under polarized light",
                      "Congo red stain shows apple green birefringence under polarized light",
                      "Reticulin fibrosis: Silver stains; collagen fibrosis: Trichrome"
                    ]
                  },
                  {
                    "text": "Amyloid: Determine subtype for appropriate treatmentMass spectrometry-based proteomic analysis is bestImmunohistochemistry or immunofluorescence techniques are less sensitive and specific",
                    "sub_points": [
                      "Mass spectrometry-based proteomic analysis is best",
                      "Immunohistochemistry or immunofluorescence techniques are less sensitive and specific"
                    ]
                  }
                ],
                "Natural History": [
                  {
                    "text": "Gelatinous transformation is usually reversible with treatment"
                  },
                  {
                    "text": "Cardiac involvement by amyloidosis worsens survival"
                  },
                  {
                    "text": "Reticulin fibrosis is reversed by therapeutic interventions unlike collagen fibrosis"
                  }
                ],
                "Treatment": [
                  {
                    "text": "Therapy is directed at underlying disease for gelatinous transformation and fibrosis"
                  },
                  {
                    "text": "Depends on type of systemic amyloidosisAL: Cytotoxic therapies, autologous stem cell transplant, Dara-CyBorD (FDA approved 2021)AA : Antiinflammatory therapiesATTR: Transthyretin tetramer stabilizers, gene silencers",
                    "sub_points": [
                      "AL: Cytotoxic therapies, autologous stem cell transplant, Dara-CyBorD (FDA approved 2021)",
                      "AA : Antiinflammatory therapies",
                      "ATTR: Transthyretin tetramer stabilizers, gene silencers"
                    ]
                  }
                ]
              },
              "IMAGING": {
                "MR Findings": [
                  {
                    "text": "Gelatinous transformation: Patchy areas of low intensity in T1-weighted images, hyperintensity in T2-weighted images"
                  }
                ]
              },
              "MACROSCOPIC": {
                "General Features": [
                  {
                    "text": "Fibrotic bone marrows are often inaspirable with white-tan core biopsies that have no discernible marrow spaces"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Gelatinous Transformation": [
                  {
                    "text": "Peripheral blood shows anemia (> 75% cases)Occasionally pancytopenia",
                    "sub_points": [
                      "Occasionally pancytopenia"
                    ]
                  },
                  {
                    "text": "Hypocellular or normocellular bone marrowRarely hypercellular with focal areas of hypocellularityHomogeneous, eosinophilic material, adipocyte atrophy, decreased hematopoietic cellsCore biopsy may show focal, patchy, or diffuse pattern",
                    "sub_points": [
                      "Rarely hypercellular with focal areas of hypocellularity",
                      "Homogeneous, eosinophilic material, adipocyte atrophy, decreased hematopoietic cells",
                      "Core biopsy may show focal, patchy, or diffuse pattern"
                    ]
                  }
                ],
                "Amyloid": [
                  {
                    "text": "Aspirate smears show homogeneous, eosinophilic to dark purple, waxy globules"
                  },
                  {
                    "text": "Biopsy has homogeneous, eosinophilic deposits in vessel wall, stroma, periosteal soft tissueVascular deposits in 2/3rds cases; AL, AA, or ATTR amyloidStromal deposits are usually AL amyloidPlasma cells often not abundant unless associated myeloma or lymphoplasmacytic lymphoma",
                    "sub_points": [
                      "Vascular deposits in 2/3rds cases; AL, AA, or ATTR amyloid",
                      "Stromal deposits are usually AL amyloid",
                      "Plasma cells often not abundant unless associated myeloma or lymphoplasmacytic lymphoma"
                    ]
                  }
                ],
                "Fibrosis": [
                  {
                    "text": "Dacrocytes or teardrop cells in peripheral blood"
                  },
                  {
                    "text": "Eosinophilic fibers with streaming of cellular elements in biopsies accompanied by neovascularization"
                  },
                  {
                    "text": "Need stains to quantitate and determine type of fibrosis"
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Aspiration Artifact": [
                  {
                    "text": "Stroma is disrupted with abundant fibrin and RBCs"
                  }
                ],
                "Ischemic Necrosis": [
                  {
                    "text": "Necrosis of medullary cavity alone or with adjacent boneGhost cells in granular matrix",
                    "sub_points": [
                      "Ghost cells in granular matrix"
                    ]
                  },
                  {
                    "text": "Secondary to vascular insufficiencyAssociated with malignancy, sickle cell disease, infection",
                    "sub_points": [
                      "Associated with malignancy, sickle cell disease, infection"
                    ]
                  }
                ],
                "Fibrinoid Necrosis": [
                  {
                    "text": "Seen following myeloablative chemotherapy"
                  },
                  {
                    "text": "Eosinophilic, finely granular net-like stroma"
                  },
                  {
                    "text": "Stromal material stains for fibrinogen and hyaluronidaseAlcian blue, PAS (-)",
                    "sub_points": [
                      "Alcian blue, PAS (-)"
                    ]
                  },
                  {
                    "text": "No fat atrophy"
                  }
                ],
                "Edema": [
                  {
                    "text": "Excess interstitial fluid due to multiple causes"
                  },
                  {
                    "text": "Normal sized adipocytes surrounded by Alcian blue (-) serous material"
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Clinically Relevant Pathologic Features": [
                  {
                    "text": "Evaluate associated cellular, vascular, and bony changes"
                  },
                  {
                    "text": "If amyloid present, evaluate for plasma cell clonality"
                  }
                ],
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "Stromal changes show significant morphologic overlap"
                  },
                  {
                    "text": "Gelatinous transformation is morphologic marker of underlying illness or condition"
                  },
                  {
                    "text": "Not all amyloid deposits are AL type, even if plasma cell dyscrasia or lymphoma is present"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Overview and Classification of Hemophagocytic Disorders in Bone Marrow": {
            "name": "Overview and Classification of Hemophagocytic Disorders in Bone Marrow",
            "url": "https://app.pathprimer.com/document/6a1d0cc8-7878-43e4-8346-f1a8dff3e74a/lesson/92495282-ce4a-41b9-a2f4-c2339cb2cc79",
            "content": {
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Hemophagocytic lymphohistiocytosis (HLH)"
                  },
                  {
                    "text": "Hemophagocytic syndrome (HPS)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Histiocytic medullary reticulosis (Scott and Robb-Smith, 1939)"
                  },
                  {
                    "text": "Familial hemophagocytic reticulosis (Farquhar and Claireaux, 1952)"
                  },
                  {
                    "text": "Macrophage activation syndrome (MAS) (associated with autoimmune diseases)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Life-threatening syndrome characterized by uncontrolled and extreme immune reactionEncompasses group of conditions with similar end-stage phenotypeAffects newborns and adults alikeTriggered in majority of cases by infectionSevere systemic hyperinflammation results fromProliferation of lymphocytes &/or histiocytes in reticuloendothelial system with uncontrolled hemophagocytosisInappropriate and deregulated activation of NK cells, CD8(+) cytotoxic T cells, and macrophagesMay lead to multiorgan dysfunction",
                    "sub_points": [
                      "Encompasses group of conditions with similar end-stage phenotype",
                      "Affects newborns and adults alike",
                      "Triggered in majority of cases by infection",
                      "Severe systemic hyperinflammation results fromProliferation of lymphocytes &/or histiocytes in reticuloendothelial system with uncontrolled hemophagocytosisInappropriate and deregulated activation of NK cells, CD8(+) cytotoxic T cells, and macrophagesMay lead to multiorgan dysfunction",
                      "Proliferation of lymphocytes &/or histiocytes in reticuloendothelial system with uncontrolled hemophagocytosis",
                      "Inappropriate and deregulated activation of NK cells, CD8(+) cytotoxic T cells, and macrophages",
                      "May lead to multiorgan dysfunction"
                    ]
                  },
                  {
                    "text": "Primary HLHPresent in early childhoodResults from inherited genetic mutationsGenetic mutations leading to impaired function of NK and cytotoxic T cellsMutations in perforin geneMutations in genes important for exocytosis of cytotoxic granules",
                    "sub_points": [
                      "Present in early childhood",
                      "Results from inherited genetic mutations",
                      "Genetic mutations leading to impaired function of NK and cytotoxic T cellsMutations in perforin geneMutations in genes important for exocytosis of cytotoxic granules",
                      "Mutations in perforin gene",
                      "Mutations in genes important for exocytosis of cytotoxic granules"
                    ]
                  },
                  {
                    "text": "Secondary (acquired) HLHPresents in adultsInappropriate host response toInfection (usually viral), autoimmune diseases, malignancies, and acquired immune deficiency",
                    "sub_points": [
                      "Presents in adults",
                      "Inappropriate host response toInfection (usually viral), autoimmune diseases, malignancies, and acquired immune deficiency",
                      "Infection (usually viral), autoimmune diseases, malignancies, and acquired immune deficiency"
                    ]
                  }
                ],
                "Etiology": [
                  {
                    "text": "Primary HLHHeritable genetic alterationsResults in altered interaction between NK cells, CD8(+) cytotoxic T cells, and antigen-presenting cellsDeregulated cells increase production of their proinflammatory cytokinesLead to systemic activation of macrophages and cellular destructionPredominantly presents in early childhood2 subtypes of primary HLHPrimary HLH associated with clinical syndromesX-linked lymphoproliferative disorderChediak-Higashi syndromeGriscelli syndromePrimary HLH without associated genetic syndromesTypically designated as familial HLH",
                    "sub_points": [
                      "Heritable genetic alterations",
                      "Results in altered interaction between NK cells, CD8(+) cytotoxic T cells, and antigen-presenting cells",
                      "Deregulated cells increase production of their proinflammatory cytokinesLead to systemic activation of macrophages and cellular destruction",
                      "Lead to systemic activation of macrophages and cellular destruction",
                      "Predominantly presents in early childhood",
                      "2 subtypes of primary HLHPrimary HLH associated with clinical syndromesX-linked lymphoproliferative disorderChediak-Higashi syndromeGriscelli syndromePrimary HLH without associated genetic syndromesTypically designated as familial HLH",
                      "Primary HLH associated with clinical syndromesX-linked lymphoproliferative disorderChediak-Higashi syndromeGriscelli syndrome",
                      "X-linked lymphoproliferative disorder",
                      "Chediak-Higashi syndrome",
                      "Griscelli syndrome",
                      "Primary HLH without associated genetic syndromesTypically designated as familial HLH",
                      "Typically designated as familial HLH"
                    ]
                  },
                  {
                    "text": "Secondary HLHPresent mainly in adults in response to acute illness triggerMost common triggers includeInfection, malignancy, autoimmune disordersHLH in setting of autoimmune disorders is historically referred to as MASNo clear underlying genetic mutations, but allelic polymorphisms in primary HLH genes reported in ~ 14% of adult patientsAllelic polymorphisms may serve as predisposing factor in setting of specific triggers",
                    "sub_points": [
                      "Present mainly in adults in response to acute illness trigger",
                      "Most common triggers includeInfection, malignancy, autoimmune disordersHLH in setting of autoimmune disorders is historically referred to as MAS",
                      "Infection, malignancy, autoimmune disorders",
                      "HLH in setting of autoimmune disorders is historically referred to as MAS",
                      "No clear underlying genetic mutations, but allelic polymorphisms in primary HLH genes reported in ~ 14% of adult patientsAllelic polymorphisms may serve as predisposing factor in setting of specific triggers",
                      "Allelic polymorphisms may serve as predisposing factor in setting of specific triggers"
                    ]
                  }
                ],
                "Pathophysiology": [
                  {
                    "text": "Function of intact NK cells and CD8(+) T-cell subsetProduction of cytolytic enzymes, perforin and granzymePerforin and granzymes are packed into granulesGranules are discharged on target cellsPerforin induces pores in target cells membrane to facilitate entry of highly proteolytic granzymeThis process results in degradation of target cell",
                    "sub_points": [
                      "Production of cytolytic enzymes, perforin and granzyme",
                      "Perforin and granzymes are packed into granulesGranules are discharged on target cellsPerforin induces pores in target cells membrane to facilitate entry of highly proteolytic granzymeThis process results in degradation of target cell",
                      "Granules are discharged on target cells",
                      "Perforin induces pores in target cells membrane to facilitate entry of highly proteolytic granzymeThis process results in degradation of target cell",
                      "This process results in degradation of target cell"
                    ]
                  },
                  {
                    "text": "Deregulated NK cells and CD8(+) cytotoxic T-cells in HLHResults in failure of normal function of NK and CD8(+) cytotoxic T cellsMediated through specific genetic mutations or acquired through highly immunogenic stimulus (e.g., virus)Failure of normal interaction between NK cells, CD8(+) cells and their target leads to extreme hyperinflammation",
                    "sub_points": [
                      "Results in failure of normal function of NK and CD8(+) cytotoxic T cells",
                      "Mediated through specific genetic mutations or acquired through highly immunogenic stimulus (e.g., virus)",
                      "Failure of normal interaction between NK cells, CD8(+) cells and their target leads to extreme hyperinflammation"
                    ]
                  }
                ]
              },
              "EPIDEMIOLOGY": {
                "Age Range": [
                  {
                    "text": "Most common in infants from birth to 18 months of age"
                  },
                  {
                    "text": "Older children and adults can also be affected"
                  }
                ],
                "Incidence": [
                  {
                    "text": "Determination of true incidence of HLH is difficult due to phenotypic overlap with other inflammatory conditions"
                  },
                  {
                    "text": "Increasing incidence rate from 0.52/100,000 in 2014 to 0.70/100,000 in 2020 in German population study"
                  },
                  {
                    "text": "HLH diagnosis is estimated at 1 in 3,000 inpatient admissions at Texas Children's Hospital"
                  },
                  {
                    "text": "In North America, frequency of specific gene defects varies significantly with ethnicityGenetic heterogeneity, presence of founder mutations, and ethnic backgrounds impact local incidence among children and adultsDiagnostic consideration and screening for HLH may also vary significantly based on level of suspicion in different practice settings",
                    "sub_points": [
                      "Genetic heterogeneity, presence of founder mutations, and ethnic backgrounds impact local incidence among children and adults",
                      "Diagnostic consideration and screening for HLH may also vary significantly based on level of suspicion in different practice settings"
                    ]
                  },
                  {
                    "text": "Incidence of HLH in adults is on rise, especially in older individualsThis could reflect increased HLH recognition",
                    "sub_points": [
                      "This could reflect increased HLH recognition"
                    ]
                  }
                ]
              },
              "CLINICAL IMPLICATIONS": {
                "Clinical Findings": [
                  {
                    "text": "Most published data include pediatric patients"
                  },
                  {
                    "text": "HLH also occurs in adults with clinical and laboratory findings similar to pediatric cases"
                  },
                  {
                    "text": "Cardinal symptoms of HLHProlonged feverAnemiaHepatosplenomegaly, lymphadenopathyHemophagocytosisInitially absent in significant proportion of patients",
                    "sub_points": [
                      "Prolonged fever",
                      "Anemia",
                      "Hepatosplenomegaly, lymphadenopathy",
                      "HemophagocytosisInitially absent in significant proportion of patients",
                      "Initially absent in significant proportion of patients"
                    ]
                  },
                  {
                    "text": "Other associated symptoms that may be presentNeurologic abnormalitiesCranial nerve palsySeizures in subset of patientsDecreased level of consciousnessPulmonary infiltrate and pleural effusionCutaneous manifestationsHemorrhagic maculopapular eruptionsGeneralized erythroderma",
                    "sub_points": [
                      "Neurologic abnormalitiesCranial nerve palsySeizures in subset of patientsDecreased level of consciousness",
                      "Cranial nerve palsy",
                      "Seizures in subset of patients",
                      "Decreased level of consciousness",
                      "Pulmonary infiltrate and pleural effusion",
                      "Cutaneous manifestationsHemorrhagic maculopapular eruptionsGeneralized erythroderma",
                      "Hemorrhagic maculopapular eruptions",
                      "Generalized erythroderma"
                    ]
                  },
                  {
                    "text": "Acute renal failure or multiorgan failure with severe HLH"
                  }
                ],
                "History and Physical Examination": [
                  {
                    "text": "HLH typically manifests with hyperinflammatory conditionNonspecific symptoms, including fever, fatigue, and malaise, are typical presenting symptoms",
                    "sub_points": [
                      "Nonspecific symptoms, including fever, fatigue, and malaise, are typical presenting symptoms"
                    ]
                  },
                  {
                    "text": "Significant overlap with other multiorgan inflammatory diseases, including severe infection, autoimmune disorder, and malignancyOverlapping inflammatory conditions often serve as trigger for HLH development, making HLH diagnosis further challengingAcute multiorgan damage, including renal and liver failures, may be presentOther presenting symptoms could includeAdult respiratory distress syndrome (ARDS)Altered mental status",
                    "sub_points": [
                      "Overlapping inflammatory conditions often serve as trigger for HLH development, making HLH diagnosis further challenging",
                      "Acute multiorgan damage, including renal and liver failures, may be present",
                      "Other presenting symptoms could includeAdult respiratory distress syndrome (ARDS)Altered mental status",
                      "Adult respiratory distress syndrome (ARDS)",
                      "Altered mental status"
                    ]
                  },
                  {
                    "text": "Physical examinations should be particularly focused on reticuloendothelial systemHepatosplenomegalyDiffuse lymphadenopathyCytopenia with associated bleeding",
                    "sub_points": [
                      "Hepatosplenomegaly",
                      "Diffuse lymphadenopathy",
                      "Cytopenia with associated bleeding"
                    ]
                  },
                  {
                    "text": "HLH in children can present spontaneously driven by underlying genetic mutations"
                  },
                  {
                    "text": "HLH in children can also develop following trigger, similar to adults with HLHEBV is most common trigger in children with primary HLH",
                    "sub_points": [
                      "EBV is most common trigger in children with primary HLH"
                    ]
                  }
                ],
                "Laboratory Findings": [
                  {
                    "text": "Bi- or pancytopenia"
                  },
                  {
                    "text": "Hypertriglyceridemia &/or hypofibrinogenemia"
                  },
                  {
                    "text": "Hyperferritinemia and liver abnormalities"
                  },
                  {
                    "text": "Hyponatremia, hypoalbuminemia"
                  },
                  {
                    "text": "Exaggerated immune response in HLHOvertly stimulated but ineffective systemic inflammatory responseActivation of macrophages, CD8(+) T cells, and NK cellsMultiorgan infiltration by activated T cells and macrophagesIncreased cytokine production, including IFN-γ, GM-CSF, and TNF-αTissue infiltration by activated T cells and macrophages results in hepatosplenomegaly and lymphadenopathyHigh levels of cytokines, particularly IFN-γ, may lead to progressive organ failure and death in severe cases",
                    "sub_points": [
                      "Overtly stimulated but ineffective systemic inflammatory responseActivation of macrophages, CD8(+) T cells, and NK cellsMultiorgan infiltration by activated T cells and macrophagesIncreased cytokine production, including IFN-γ, GM-CSF, and TNF-α",
                      "Activation of macrophages, CD8(+) T cells, and NK cells",
                      "Multiorgan infiltration by activated T cells and macrophages",
                      "Increased cytokine production, including IFN-γ, GM-CSF, and TNF-α",
                      "Tissue infiltration by activated T cells and macrophages results in hepatosplenomegaly and lymphadenopathy",
                      "High levels of cytokines, particularly IFN-γ, may lead to progressive organ failure and death in severe cases"
                    ]
                  },
                  {
                    "text": "Screening tests for genetic HLHNK-cell functional assayLow to absent NK lytic activity in HLH patients with biallelicPRF1or degranulation-associated genesHistorically considered gold standard diagnostic test, but diagnostic accuracy appears to be somewhat poorHigh sensitivity but low specificityFlow cytometric measurement of perforin and CD107aLow intracellular perforin expression in NK cells in > 90% of HLH patients with biallelicPRF1mutationNormal intracellular perforin expression in NK cells in ~ 83% of patients without biallelicPRF1mutationLow surface CD107a expression in cytotoxic T cells in > 90% of patients with biallelic mutations in HLH-associated degranulation geneLow specificity with only 60% of patients without biallelic degranulation gene mutations showing normal CD107a expressionFlow cytometric analysis of intracellular SAP and XIAP gene productsLow to absent intracellular SAP (encoded bySH2D1Agene) in X-linked lymphoproliferative disease type 1 (XLP1)SAP is intracytoplasmic protein, which is predominantly, but not exclusively, expressed in T and NK cellsUseful in male patients with familial X-linked disorders associated with HLHLow to absent intracellular XIAP protein in CD4(+) and CD8(+) T cells as well as in NK cells and B cells in familial lymphoproliferative disease type 2",
                    "sub_points": [
                      "NK-cell functional assayLow to absent NK lytic activity in HLH patients with biallelicPRF1or degranulation-associated genesHistorically considered gold standard diagnostic test, but diagnostic accuracy appears to be somewhat poorHigh sensitivity but low specificity",
                      "Low to absent NK lytic activity in HLH patients with biallelicPRF1or degranulation-associated genes",
                      "Historically considered gold standard diagnostic test, but diagnostic accuracy appears to be somewhat poorHigh sensitivity but low specificity",
                      "High sensitivity but low specificity",
                      "Flow cytometric measurement of perforin and CD107aLow intracellular perforin expression in NK cells in > 90% of HLH patients with biallelicPRF1mutationNormal intracellular perforin expression in NK cells in ~ 83% of patients without biallelicPRF1mutationLow surface CD107a expression in cytotoxic T cells in > 90% of patients with biallelic mutations in HLH-associated degranulation geneLow specificity with only 60% of patients without biallelic degranulation gene mutations showing normal CD107a expression",
                      "Low intracellular perforin expression in NK cells in > 90% of HLH patients with biallelicPRF1mutation",
                      "Normal intracellular perforin expression in NK cells in ~ 83% of patients without biallelicPRF1mutation",
                      "Low surface CD107a expression in cytotoxic T cells in > 90% of patients with biallelic mutations in HLH-associated degranulation geneLow specificity with only 60% of patients without biallelic degranulation gene mutations showing normal CD107a expression",
                      "Low specificity with only 60% of patients without biallelic degranulation gene mutations showing normal CD107a expression",
                      "Flow cytometric analysis of intracellular SAP and XIAP gene productsLow to absent intracellular SAP (encoded bySH2D1Agene) in X-linked lymphoproliferative disease type 1 (XLP1)SAP is intracytoplasmic protein, which is predominantly, but not exclusively, expressed in T and NK cellsUseful in male patients with familial X-linked disorders associated with HLHLow to absent intracellular XIAP protein in CD4(+) and CD8(+) T cells as well as in NK cells and B cells in familial lymphoproliferative disease type 2",
                      "Low to absent intracellular SAP (encoded bySH2D1Agene) in X-linked lymphoproliferative disease type 1 (XLP1)SAP is intracytoplasmic protein, which is predominantly, but not exclusively, expressed in T and NK cellsUseful in male patients with familial X-linked disorders associated with HLH",
                      "SAP is intracytoplasmic protein, which is predominantly, but not exclusively, expressed in T and NK cells",
                      "Useful in male patients with familial X-linked disorders associated with HLH",
                      "Low to absent intracellular XIAP protein in CD4(+) and CD8(+) T cells as well as in NK cells and B cells in familial lymphoproliferative disease type 2"
                    ]
                  }
                ],
                "Diagnostic Challenges": [
                  {
                    "text": "HLH is difficult to diagnose at early stageMay mimic ordinary infectionsSome diagnostic symptoms may be initially missingOther diagnostic pitfallsIsolated CNS involvementFulminant liver failure, particularly in neonatal periodAbsence of hemophagocytosis in subsets of HLH casesNot necessary for diagnosisDetection of infectious agent does not rule out familial HLH",
                    "sub_points": [
                      "May mimic ordinary infections",
                      "Some diagnostic symptoms may be initially missing",
                      "Other diagnostic pitfallsIsolated CNS involvementFulminant liver failure, particularly in neonatal periodAbsence of hemophagocytosis in subsets of HLH casesNot necessary for diagnosisDetection of infectious agent does not rule out familial HLH",
                      "Isolated CNS involvement",
                      "Fulminant liver failure, particularly in neonatal period",
                      "Absence of hemophagocytosis in subsets of HLH casesNot necessary for diagnosis",
                      "Not necessary for diagnosis",
                      "Detection of infectious agent does not rule out familial HLH"
                    ]
                  }
                ],
                "Diagnostic Criteria": [
                  {
                    "text": "Diagnosis of HLH is established if 1 of following criteria is metMolecular identification of mutations associated with HLH orDetection of 5 out of 8 criteria established by Histiocyte Society for use in HLH-2004 as listed belowFever ≥ 38.5 °CSplenomegalyCytopenia in ≥ 2 cell linesHemoglobin < 9 g/dL (< 10 g/dL if age < 4 weeks)Platelets < 100 x 10⁹/LNeutrophils < 1 x 10⁹/LHypertriglyceridemia &/or hypofibrinogenemiaFasting triglyceride ≥ 3 mmol/L &/or fibrinogen < 1.5 g/LFerritin > 500 µg/LSoluble CD25 (soluble IL-2 receptor) ≥ 2,400 U/mL or elevated based on laboratory-defined normal rangeDecreased or absent NK-cell activityHemophagocytosis in bone marrow, spleen, lymph nodes, CSF, liver, or other tissuesRelatively nonspecific for HLH, but phagocytosis of nucleated hematopoietic cells substantially increases specificity for HLH",
                    "sub_points": [
                      "Molecular identification of mutations associated with HLH or",
                      "Detection of 5 out of 8 criteria established by Histiocyte Society for use in HLH-2004 as listed belowFever ≥ 38.5 °CSplenomegalyCytopenia in ≥ 2 cell linesHemoglobin < 9 g/dL (< 10 g/dL if age < 4 weeks)Platelets < 100 x 10⁹/LNeutrophils < 1 x 10⁹/LHypertriglyceridemia &/or hypofibrinogenemiaFasting triglyceride ≥ 3 mmol/L &/or fibrinogen < 1.5 g/LFerritin > 500 µg/LSoluble CD25 (soluble IL-2 receptor) ≥ 2,400 U/mL or elevated based on laboratory-defined normal rangeDecreased or absent NK-cell activityHemophagocytosis in bone marrow, spleen, lymph nodes, CSF, liver, or other tissuesRelatively nonspecific for HLH, but phagocytosis of nucleated hematopoietic cells substantially increases specificity for HLH",
                      "Fever ≥ 38.5 °C",
                      "Splenomegaly",
                      "Cytopenia in ≥ 2 cell linesHemoglobin < 9 g/dL (< 10 g/dL if age < 4 weeks)Platelets < 100 x 10⁹/LNeutrophils < 1 x 10⁹/L",
                      "Hemoglobin < 9 g/dL (< 10 g/dL if age < 4 weeks)",
                      "Platelets < 100 x 10⁹/L",
                      "Neutrophils < 1 x 10⁹/L",
                      "Hypertriglyceridemia &/or hypofibrinogenemiaFasting triglyceride ≥ 3 mmol/L &/or fibrinogen < 1.5 g/L",
                      "Fasting triglyceride ≥ 3 mmol/L &/or fibrinogen < 1.5 g/L",
                      "Ferritin > 500 µg/L",
                      "Soluble CD25 (soluble IL-2 receptor) ≥ 2,400 U/mL or elevated based on laboratory-defined normal range",
                      "Decreased or absent NK-cell activity",
                      "Hemophagocytosis in bone marrow, spleen, lymph nodes, CSF, liver, or other tissuesRelatively nonspecific for HLH, but phagocytosis of nucleated hematopoietic cells substantially increases specificity for HLH",
                      "Relatively nonspecific for HLH, but phagocytosis of nucleated hematopoietic cells substantially increases specificity for HLH"
                    ]
                  },
                  {
                    "text": "Shortcomings of diagnostic criteriaMany patients with HLH may not meet 5 out of 8 criteria early in disease courseSome patients may present with incomplete or atypical disease manifestationsReported in 17% of primary HLH in large German cohortSome patients with hematologic malignancies, severe infection, rheumatologic diseases, or primary immune deficiencies may meet criteria and be misdiagnosed as HLH",
                    "sub_points": [
                      "Many patients with HLH may not meet 5 out of 8 criteria early in disease course",
                      "Some patients may present with incomplete or atypical disease manifestationsReported in 17% of primary HLH in large German cohort",
                      "Reported in 17% of primary HLH in large German cohort",
                      "Some patients with hematologic malignancies, severe infection, rheumatologic diseases, or primary immune deficiencies may meet criteria and be misdiagnosed as HLH"
                    ]
                  }
                ],
                "Histopathology": [
                  {
                    "text": "Biopsy of lymph node, bone marrow, spleen, or other tissue is typically performed in suspected HLH cases"
                  },
                  {
                    "text": "Tissue biopsy is carefully evaluated for presence of hemophagocytosis"
                  },
                  {
                    "text": "Identification of hemophagocytosis in suspected HLH caseIs virtually pathognomonic when phagocytosed cells include nucleated hematopoietic cellsErythrophagocytosis alone is nonspecific finding",
                    "sub_points": [
                      "Is virtually pathognomonic when phagocytosed cells include nucleated hematopoietic cells",
                      "Erythrophagocytosis alone is nonspecific finding"
                    ]
                  },
                  {
                    "text": "Morphologic review can identify hemophagocytosis among only 67% of pediatric and 85% of adult patients who otherwise meet diagnostic criteria"
                  },
                  {
                    "text": "Hemophagocytosis is not required for diagnosis of HLH"
                  }
                ],
                "Treatment": [
                  {
                    "text": "HLH is rapidly fatal disease if untreatedTreatment with potent immunosuppressive and chemotherapeutic agents as soon as possible is crucialEarly initial treatment with steroids can be considered while waiting for results of diagnostic studiesSteroid therapy should be delayed in suspected cases of leukemia/lymphoma to avoid interference with diagnosis",
                    "sub_points": [
                      "Treatment with potent immunosuppressive and chemotherapeutic agents as soon as possible is crucial",
                      "Early initial treatment with steroids can be considered while waiting for results of diagnostic studiesSteroid therapy should be delayed in suspected cases of leukemia/lymphoma to avoid interference with diagnosis",
                      "Steroid therapy should be delayed in suspected cases of leukemia/lymphoma to avoid interference with diagnosis"
                    ]
                  },
                  {
                    "text": "1st international treatment protocol for HLH (HLH-94)Dexamethasone and etoposide followed by cyclosporine A as maintenance therapy",
                    "sub_points": [
                      "Dexamethasone and etoposide followed by cyclosporine A as maintenance therapy"
                    ]
                  },
                  {
                    "text": "HLH-2004 therapeutic protocolUpfront cyclosporine A along with dexamethasone and etoposideComplete response at ~ 51%",
                    "sub_points": [
                      "Upfront cyclosporine A along with dexamethasone and etoposide",
                      "Complete response at ~ 51%"
                    ]
                  },
                  {
                    "text": "Therapy with antithymocyte globulin (ATG) along with methylprednisoloneComplete response at 73% reported in case series of 38 patients",
                    "sub_points": [
                      "Complete response at 73% reported in case series of 38 patients"
                    ]
                  },
                  {
                    "text": "Ruxolitinib as 1st-line agent in children with HLHRapid response especially in cases initiated by EBV infectionAdditional therapy necessary after initial therapy",
                    "sub_points": [
                      "Rapid response especially in cases initiated by EBV infection",
                      "Additional therapy necessary after initial therapy"
                    ]
                  },
                  {
                    "text": "Hematopoietic stem cell transplantation in patients with genetic HLHIndicated to replace defective immune system with normally functioning cells",
                    "sub_points": [
                      "Indicated to replace defective immune system with normally functioning cells"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Survival prior to chemotherapy and immunotherapy strategies was < 10%"
                  },
                  {
                    "text": "3-year overall survival of 54% on HLH-94 protocol94% of deaths occurred in first 8 weeks in patients with uncontrolled disease",
                    "sub_points": [
                      "94% of deaths occurred in first 8 weeks in patients with uncontrolled disease"
                    ]
                  },
                  {
                    "text": "3-year probability of survival after bone marrow transplant was 62%"
                  },
                  {
                    "text": "Increasing ferritin during 1st week of admission may predict early death in HLH patients"
                  }
                ]
              },
              "Classification of Hemophagocytic Lymphohistiocytosis": {
                "Familial Hemophagocytic Lymphohistiocytosis": [
                  {
                    "text": "Familial HLH type 1 (FHL1)Originally discovered in 4 consanguineous Pakistani familiesLinked to chromosome 9q21.3-22 by gene mappingGenetic defect remains unknown at this time",
                    "sub_points": [
                      "Originally discovered in 4 consanguineous Pakistani families",
                      "Linked to chromosome 9q21.3-22 by gene mapping",
                      "Genetic defect remains unknown at this time"
                    ]
                  },
                  {
                    "text": "Familial HLH type 2 (FHL2)Linked toPRF1gene mutationsPRF1mutations reduce or block perforin synthesisLack of perforin impairs granule-mediated cytotoxic activity of NK/T cells and inability to kill infected cells by NK cells> 70 different mutations, most being missense> 70% of Turkish patients withFHL2harbor c.1122G > A, p.W374X mutationMost affected African and African American patients harbor c.50delT, p.L17fs founder mutationc.1090-91delCT, p.L364fsX confined to Japanese ethnic group",
                    "sub_points": [
                      "Linked toPRF1gene mutationsPRF1mutations reduce or block perforin synthesisLack of perforin impairs granule-mediated cytotoxic activity of NK/T cells and inability to kill infected cells by NK cells> 70 different mutations, most being missense> 70% of Turkish patients withFHL2harbor c.1122G > A, p.W374X mutationMost affected African and African American patients harbor c.50delT, p.L17fs founder mutationc.1090-91delCT, p.L364fsX confined to Japanese ethnic group",
                      "PRF1mutations reduce or block perforin synthesisLack of perforin impairs granule-mediated cytotoxic activity of NK/T cells and inability to kill infected cells by NK cells",
                      "Lack of perforin impairs granule-mediated cytotoxic activity of NK/T cells and inability to kill infected cells by NK cells",
                      "> 70 different mutations, most being missense",
                      "> 70% of Turkish patients withFHL2harbor c.1122G > A, p.W374X mutation",
                      "Most affected African and African American patients harbor c.50delT, p.L17fs founder mutation",
                      "c.1090-91delCT, p.L364fsX confined to Japanese ethnic group"
                    ]
                  },
                  {
                    "text": "Familial HLH type 3 (FHL3)Linked to mutations inUNC13Dgene at 17q25 locusMutations scattered throughout entire gene~ 50% of mutations affect mRNA splicingUNC13Dgene encodes protein that mediates exocytosis of cytotoxic granulesMutation results in defective delivery of perforin and granzymes into target cells",
                    "sub_points": [
                      "Linked to mutations inUNC13Dgene at 17q25 locus",
                      "Mutations scattered throughout entire gene",
                      "~ 50% of mutations affect mRNA splicing",
                      "UNC13Dgene encodes protein that mediates exocytosis of cytotoxic granulesMutation results in defective delivery of perforin and granzymes into target cells",
                      "Mutation results in defective delivery of perforin and granzymes into target cells"
                    ]
                  },
                  {
                    "text": "Familial HLH type 4 (FHL4)Linked to mutations inSTX11gene at 6q24 locusSTX11gene encodes syntaxin 11 protein involved in regulation of intracellular protein transportNK cells fail to degranulate when they encounter susceptible target cellsIL-2 partially restores NK cell ability to degranulateRelatively milder clinical phenotype compared to FHL2 and FHL3 typesFew reported cases are all of Turkish/Arabian origin",
                    "sub_points": [
                      "Linked to mutations inSTX11gene at 6q24 locus",
                      "STX11gene encodes syntaxin 11 protein involved in regulation of intracellular protein transport",
                      "NK cells fail to degranulate when they encounter susceptible target cells",
                      "IL-2 partially restores NK cell ability to degranulate",
                      "Relatively milder clinical phenotype compared to FHL2 and FHL3 types",
                      "Few reported cases are all of Turkish/Arabian origin"
                    ]
                  },
                  {
                    "text": "Familial HLH type 5 (FHL5)Mutations inSTXBP2gene at 19p13.2 locusSTXBP2gene encodes for syntaxin-binding protein 2Syntaxin-binding protein 2 is involved in regulation of vesicle transport to plasma membraneReported in patients of Saudi Arabian, Turkish, and central European origin",
                    "sub_points": [
                      "Mutations inSTXBP2gene at 19p13.2 locus",
                      "STXBP2gene encodes for syntaxin-binding protein 2Syntaxin-binding protein 2 is involved in regulation of vesicle transport to plasma membrane",
                      "Syntaxin-binding protein 2 is involved in regulation of vesicle transport to plasma membrane",
                      "Reported in patients of Saudi Arabian, Turkish, and central European origin"
                    ]
                  }
                ],
                "Immune Deficiency Syndromes Associated With HLH": [
                  {
                    "text": "Chediak-Higashi syndromeMutations inLYSTgene",
                    "sub_points": [
                      "Mutations inLYSTgene"
                    ]
                  },
                  {
                    "text": "Griscelli syndrome type 2Mutations inRAB27Agene",
                    "sub_points": [
                      "Mutations inRAB27Agene"
                    ]
                  },
                  {
                    "text": "Hermansky-Pudlak syndrome type 2Mutations inAP3B1gene",
                    "sub_points": [
                      "Mutations inAP3B1gene"
                    ]
                  },
                  {
                    "text": "XLP1Mutations inSH2D1Agene",
                    "sub_points": [
                      "Mutations inSH2D1Agene"
                    ]
                  },
                  {
                    "text": "X-linked lymphoproliferative disease type 2 (XLP2)Mutations inXIAPgene",
                    "sub_points": [
                      "Mutations inXIAPgene"
                    ]
                  },
                  {
                    "text": "X-linked immunodeficiency withmagnesium defect,EBV infections, andneoplasia (X-MEN disease)Mutations inMAGT1gene",
                    "sub_points": [
                      "Mutations inMAGT1gene"
                    ]
                  },
                  {
                    "text": "Subset of cases with severe combined immunodeficiency"
                  },
                  {
                    "text": "Subset of cases with X-linked hypogammaglobulinemia"
                  }
                ],
                "Acquired Hemophagocytic Lymphohistiocytosis": [
                  {
                    "text": "MASForm of acquired HLH associated with autoimmune diseasesCharacterized by cytopenias, organ dysfunction, and coagulopathy associated with macrophage activationStrong association with systemic juvenile idiopathic arthritis (SJIA)Markedly decreased expression of perforin on CD8(+) T and NK cells in SJIA might be responsible for MASMAS may contribute to coagulation abnormalities (DIC) in SJIALess commonly associated with other childhood rheumatic diseases, including SLE",
                    "sub_points": [
                      "Form of acquired HLH associated with autoimmune diseases",
                      "Characterized by cytopenias, organ dysfunction, and coagulopathy associated with macrophage activation",
                      "Strong association with systemic juvenile idiopathic arthritis (SJIA)",
                      "Markedly decreased expression of perforin on CD8(+) T and NK cells in SJIA might be responsible for MAS",
                      "MAS may contribute to coagulation abnormalities (DIC) in SJIA",
                      "Less commonly associated with other childhood rheumatic diseases, including SLE"
                    ]
                  },
                  {
                    "text": "Established HLH associated with infectionsViruses, including EBV, HSV, CMV, HIV, Parvovirus, and hepatitis virusesEBV-associated HLHMost common triggering agent among viral-induced HLHMore common in East Asian countriesMost cases in immunocompetent children or adultsCan also occur in setting of familial and nonfamilial immune deficienciesNot associated with perforin or other familial-related HLH gene mutationsIn EBV-related HLH, CD8(+) T cells are infected with EBVAlso occur in EBV-associated T-/NK-cell lymphoproliferative disorders and lymphomas as neoplasia-related HLHEBV-related HLH should not be considered benign conditionWorst prognosis compared with HLH associated with other virusesCMV-associated HLHHealthy individualsPatients with inflammatory bowel disease, rheumatologic disease, post organ transplantationHHV8-associated HLHMost cases in setting of Kaposi sarcoma or multicentric Castleman diseaseRarely reported in renal transplant recipientsHIV-associated HLHHIV alone or along with other infectionsHPS can rarely be initial presentation of HIV infectionInfluenza-associated HLHVery rare but described with different influenza virusesPatients with severe avian influenza (H5N1) present with HPSParvovirus-associated HLHHereditary spherocytosis is most common underlying disease in Parvovirus-associated HLHB19-associated HLH carries better prognosis compared to other virus-associated HLHBacterial-associated HLHMycobacteria, BCG therapy, and BCG vaccinationCampylobacter,Mycoplasma,Chlamydia,Salmonella typhi,Rickettsia,Ehrlichia, andBorrelia(Lyme disease)Fungal-associated HLHCandida,Cryptococcus,Pneumocystis,Histoplasma, andAspergillusCommon in setting of AIDS, transplant recipients, and lymphomaParasite-associated HLHLeishmania, malaria,Toxoplasma,Babesia(babesiosis), andStrongyloides stercoralisCOVID-19-associated HLHPresence of distinct COVID-19-related HLH syndrome is somewhat debatableCytokine storm-like picture has been described in reported cases, including increased plasma levels of IL-2, IL7, TNF-a, and G-CSFHepatosplenomegaly and bicytopenia are uncommon in reported casesSo-called HScore tool has been widely used to diagnose reported cases instead of standard SH2004HScore system was developed and validated by Fardet et al for diagnosis of reactive HPSNumerical score based on temperature, presence or absence of organomegaly, cytopenias, marrow hemophagocytosis, immunosuppression, and plasma levels of triglycerides, fibrinogen, and ferritinNumerical score > 169 is considered to be 93% sensitive and 86% specific for HLH",
                    "sub_points": [
                      "Viruses, including EBV, HSV, CMV, HIV, Parvovirus, and hepatitis viruses",
                      "EBV-associated HLHMost common triggering agent among viral-induced HLHMore common in East Asian countriesMost cases in immunocompetent children or adultsCan also occur in setting of familial and nonfamilial immune deficienciesNot associated with perforin or other familial-related HLH gene mutationsIn EBV-related HLH, CD8(+) T cells are infected with EBVAlso occur in EBV-associated T-/NK-cell lymphoproliferative disorders and lymphomas as neoplasia-related HLHEBV-related HLH should not be considered benign conditionWorst prognosis compared with HLH associated with other viruses",
                      "Most common triggering agent among viral-induced HLH",
                      "More common in East Asian countries",
                      "Most cases in immunocompetent children or adults",
                      "Can also occur in setting of familial and nonfamilial immune deficienciesNot associated with perforin or other familial-related HLH gene mutations",
                      "Not associated with perforin or other familial-related HLH gene mutations",
                      "In EBV-related HLH, CD8(+) T cells are infected with EBV",
                      "Also occur in EBV-associated T-/NK-cell lymphoproliferative disorders and lymphomas as neoplasia-related HLH",
                      "EBV-related HLH should not be considered benign condition",
                      "Worst prognosis compared with HLH associated with other viruses",
                      "CMV-associated HLHHealthy individualsPatients with inflammatory bowel disease, rheumatologic disease, post organ transplantation",
                      "Healthy individuals",
                      "Patients with inflammatory bowel disease, rheumatologic disease, post organ transplantation",
                      "HHV8-associated HLHMost cases in setting of Kaposi sarcoma or multicentric Castleman diseaseRarely reported in renal transplant recipients",
                      "Most cases in setting of Kaposi sarcoma or multicentric Castleman disease",
                      "Rarely reported in renal transplant recipients",
                      "HIV-associated HLHHIV alone or along with other infectionsHPS can rarely be initial presentation of HIV infection",
                      "HIV alone or along with other infections",
                      "HPS can rarely be initial presentation of HIV infection",
                      "Influenza-associated HLHVery rare but described with different influenza virusesPatients with severe avian influenza (H5N1) present with HPS",
                      "Very rare but described with different influenza viruses",
                      "Patients with severe avian influenza (H5N1) present with HPS",
                      "Parvovirus-associated HLHHereditary spherocytosis is most common underlying disease in Parvovirus-associated HLHB19-associated HLH carries better prognosis compared to other virus-associated HLH",
                      "Hereditary spherocytosis is most common underlying disease in Parvovirus-associated HLH",
                      "B19-associated HLH carries better prognosis compared to other virus-associated HLH",
                      "Bacterial-associated HLHMycobacteria, BCG therapy, and BCG vaccinationCampylobacter,Mycoplasma,Chlamydia,Salmonella typhi,Rickettsia,Ehrlichia, andBorrelia(Lyme disease)",
                      "Mycobacteria, BCG therapy, and BCG vaccination",
                      "Campylobacter,Mycoplasma,Chlamydia,Salmonella typhi,Rickettsia,Ehrlichia, andBorrelia(Lyme disease)",
                      "Fungal-associated HLHCandida,Cryptococcus,Pneumocystis,Histoplasma, andAspergillusCommon in setting of AIDS, transplant recipients, and lymphoma",
                      "Candida,Cryptococcus,Pneumocystis,Histoplasma, andAspergillus",
                      "Common in setting of AIDS, transplant recipients, and lymphoma",
                      "Parasite-associated HLHLeishmania, malaria,Toxoplasma,Babesia(babesiosis), andStrongyloides stercoralis",
                      "Leishmania, malaria,Toxoplasma,Babesia(babesiosis), andStrongyloides stercoralis",
                      "COVID-19-associated HLHPresence of distinct COVID-19-related HLH syndrome is somewhat debatableCytokine storm-like picture has been described in reported cases, including increased plasma levels of IL-2, IL7, TNF-a, and G-CSFHepatosplenomegaly and bicytopenia are uncommon in reported casesSo-called HScore tool has been widely used to diagnose reported cases instead of standard SH2004HScore system was developed and validated by Fardet et al for diagnosis of reactive HPSNumerical score based on temperature, presence or absence of organomegaly, cytopenias, marrow hemophagocytosis, immunosuppression, and plasma levels of triglycerides, fibrinogen, and ferritinNumerical score > 169 is considered to be 93% sensitive and 86% specific for HLH",
                      "Presence of distinct COVID-19-related HLH syndrome is somewhat debatable",
                      "Cytokine storm-like picture has been described in reported cases, including increased plasma levels of IL-2, IL7, TNF-a, and G-CSF",
                      "Hepatosplenomegaly and bicytopenia are uncommon in reported cases",
                      "So-called HScore tool has been widely used to diagnose reported cases instead of standard SH2004HScore system was developed and validated by Fardet et al for diagnosis of reactive HPSNumerical score based on temperature, presence or absence of organomegaly, cytopenias, marrow hemophagocytosis, immunosuppression, and plasma levels of triglycerides, fibrinogen, and ferritinNumerical score > 169 is considered to be 93% sensitive and 86% specific for HLH",
                      "HScore system was developed and validated by Fardet et al for diagnosis of reactive HPS",
                      "Numerical score based on temperature, presence or absence of organomegaly, cytopenias, marrow hemophagocytosis, immunosuppression, and plasma levels of triglycerides, fibrinogen, and ferritin",
                      "Numerical score > 169 is considered to be 93% sensitive and 86% specific for HLH"
                    ]
                  },
                  {
                    "text": "Established HLH associated with malignanciesLymphomas and leukemiasT-/NK-cell lymphomas/leukemias, anaplastic large cell lymphoma, plasma cell myelomaMonocytic leukemias, acute lymphoblastic leukemiaSolid tumorsGerm cell tumor, thymoma, carcinoma",
                    "sub_points": [
                      "Lymphomas and leukemiasT-/NK-cell lymphomas/leukemias, anaplastic large cell lymphoma, plasma cell myelomaMonocytic leukemias, acute lymphoblastic leukemia",
                      "T-/NK-cell lymphomas/leukemias, anaplastic large cell lymphoma, plasma cell myeloma",
                      "Monocytic leukemias, acute lymphoblastic leukemia",
                      "Solid tumorsGerm cell tumor, thymoma, carcinoma",
                      "Germ cell tumor, thymoma, carcinoma"
                    ]
                  }
                ]
              },
              "Differential Diagnosis": {
                "Overlapping Findings With Other Inflammatory Conditions": [
                  {
                    "text": "Sepsis associated with hemophagocytosis"
                  },
                  {
                    "text": "Severe inflammatory response syndrome"
                  },
                  {
                    "text": "Multiorgan dysfunction syndrome"
                  }
                ]
              },
              "Diagnostic Checklist": {
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "Diagnosis of HLH is established if 1 of following criteria is metMolecular identification of mutations associated with HLH orDetection of 5 out of 8 following findingsFeverSplenomegalyBi- or pancytopeniaHypertriglyceridemia &/or hypofibrinogenemiaHemophagocytosis in bone marrow, spleen, or lymph node in absence of malignancyLow or absent NK-cell cytotoxicityHyperferritinemiaElevated soluble CD25",
                    "sub_points": [
                      "Molecular identification of mutations associated with HLH or",
                      "Detection of 5 out of 8 following findingsFeverSplenomegalyBi- or pancytopeniaHypertriglyceridemia &/or hypofibrinogenemiaHemophagocytosis in bone marrow, spleen, or lymph node in absence of malignancyLow or absent NK-cell cytotoxicityHyperferritinemiaElevated soluble CD25",
                      "Fever",
                      "Splenomegaly",
                      "Bi- or pancytopenia",
                      "Hypertriglyceridemia &/or hypofibrinogenemia",
                      "Hemophagocytosis in bone marrow, spleen, or lymph node in absence of malignancy",
                      "Low or absent NK-cell cytotoxicity",
                      "Hyperferritinemia",
                      "Elevated soluble CD25"
                    ]
                  }
                ],
                "Molecular Testing in Suspected HLH": [
                  {
                    "text": "Gene panel using next-generation sequencing, includingGenes involved in familial HLHPRF1,UNC13D,STX11, andSTXBP2Genes involved in immune deficiency syndromes associated with HLHLYST,RAB27A,AP3B1,SH2D1A, andXIAP",
                    "sub_points": [
                      "Genes involved in familial HLHPRF1,UNC13D,STX11, andSTXBP2",
                      "PRF1,UNC13D,STX11, andSTXBP2",
                      "Genes involved in immune deficiency syndromes associated with HLHLYST,RAB27A,AP3B1,SH2D1A, andXIAP",
                      "LYST,RAB27A,AP3B1,SH2D1A, andXIAP"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Sickle Cell Anemia": {
            "name": "Sickle Cell Anemia",
            "url": "https://app.pathprimer.com/document/bd1cd665-f350-409f-a821-be13dbd57e67/lesson/92495282-ce4a-41b9-a2f4-c2339cb2cc79",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Autosomal recessive inherited genetic disease resulting from homozygous point mutation (valine to glutamine at codon 6) of β globin gene"
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "Abnormal hemoglobin (e.g., HbS) polymerizes under low oxygen tension, resulting in RBC sickling"
                  },
                  {
                    "text": "RBC sickling and adhesion results in chronic anemia, microinfarcts, and painful vascular crisis"
                  },
                  {
                    "text": "Heterozygous state provides protection againstPlasmodium falciparuminfection"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "EthnicityAfrican ancestry most common",
                    "sub_points": [
                      "African ancestry most common"
                    ]
                  },
                  {
                    "text": "Signs, symptoms, and natural historyChronic anemiaAcute pain crises most commonly precipitated by infection, dehydration, high altitude",
                    "sub_points": [
                      "Chronic anemia",
                      "Acute pain crises most commonly precipitated by infection, dehydration, high altitude"
                    ]
                  },
                  {
                    "text": "Diagnostic laboratory testingHemoglobin electrophoresis shows single band of HbS",
                    "sub_points": [
                      "Hemoglobin electrophoresis shows single band of HbS"
                    ]
                  },
                  {
                    "text": "TreatmentHydroxyurea is standardNewer FDA-approved drugs help prevent vasoocclusive crisesGene therapy trials offer potential cure",
                    "sub_points": [
                      "Hydroxyurea is standard",
                      "Newer FDA-approved drugs help prevent vasoocclusive crises",
                      "Gene therapy trials offer potential cure"
                    ]
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Chronic normocytic normochromic anemia"
                  },
                  {
                    "text": "Peripheral blood smear shows sickle cells during acute crisis"
                  },
                  {
                    "text": "Howell-Jolly bodies indicate functional asplenism"
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "Hemoglobin S/β-thalassemia"
                  },
                  {
                    "text": "Hemoglobin SC disease"
                  },
                  {
                    "text": "Microangiopathic hemolytic anemia"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Sickle cell anemia (SCA)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Sickle cell disease (SCD)"
                  },
                  {
                    "text": "Hemoglobin SS diseaseHomozygous hemoglobin S",
                    "sub_points": [
                      "Homozygous hemoglobin S"
                    ]
                  }
                ],
                "Definitions": [
                  {
                    "text": "Autosomal recessive inherited genetic disease"
                  },
                  {
                    "text": "Results from homozygous point mutation in β globin gene resulting in abnormal hemoglobin (e.g., HbS)Mutation at codon 6 of β globin geneValine substituted for glutamineDespite identical mutation, marked interindividual variability in clinical manifestations",
                    "sub_points": [
                      "Mutation at codon 6 of β globin gene",
                      "Valine substituted for glutamine",
                      "Despite identical mutation, marked interindividual variability in clinical manifestations"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Environmental Exposure": [
                  {
                    "text": "Although genetic disease, acute episodes are precipitated by environmental factorsCold temperatureFever or infectionDehydrationLow oxygen (e.g., high altitude)",
                    "sub_points": [
                      "Cold temperature",
                      "Fever or infection",
                      "Dehydration",
                      "Low oxygen (e.g., high altitude)"
                    ]
                  }
                ],
                "Infectious Agents": [
                  {
                    "text": "Heterozygous state provides protection againstPlasmodium falciparuminfectionProtective mechanisms poorly understoodErythrocyte apoptosis may help eliminate organisms in infected cells through phagocytosis",
                    "sub_points": [
                      "Protective mechanisms poorly understood",
                      "Erythrocyte apoptosis may help eliminate organisms in infected cells through phagocytosis"
                    ]
                  }
                ],
                "Pathophysiology": [
                  {
                    "text": "HbS abnormally polymerizes when deoxygenated"
                  },
                  {
                    "text": "Polymerization of hemoglobin results in distorted, stiffened sickle shapeReduced RBC deformability",
                    "sub_points": [
                      "Reduced RBC deformability"
                    ]
                  },
                  {
                    "text": "Other disease features not directly related to erythrocyte sicklingRed cell adhesion to vascular endotheliumIncreased blood viscosityChronic inflammationIschemia reperfusion injuryDysregulated nitric oxide homeostasis",
                    "sub_points": [
                      "Red cell adhesion to vascular endothelium",
                      "Increased blood viscosity",
                      "Chronic inflammation",
                      "Ischemia reperfusion injury",
                      "Dysregulated nitric oxide homeostasis"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "250,000 born each year with SCD worldwide"
                  },
                  {
                    "text": "60,000 people in USA have SCD"
                  }
                ],
                "Age": [
                  {
                    "text": "Usually presents in 1st year of life after fetal hemoglobin levels from infancy are reduced and HbS becomes predominant type"
                  }
                ],
                "Ethnicity": [
                  {
                    "text": "African ancestry most commonSickle cell trait (heterozygous carriers) conveys protection againstPlasmodium falciparum",
                    "sub_points": [
                      "Sickle cell trait (heterozygous carriers) conveys protection againstPlasmodium falciparum"
                    ]
                  },
                  {
                    "text": "Also found at much lower frequency in Mediterranean and Middle Eastern populations"
                  }
                ],
                "Site": [
                  {
                    "text": "HbS protein present only in RBCsResults in anemia and other widespread vascular problems related to adhesion and viscosityComplications can result in damage to multiple organs",
                    "sub_points": [
                      "Results in anemia and other widespread vascular problems related to adhesion and viscosity",
                      "Complications can result in damage to multiple organs"
                    ]
                  }
                ],
                "Presentation": [
                  {
                    "text": "Usually in early childhoodInfants protected by high HbF levels until ~ 6 months of age",
                    "sub_points": [
                      "Infants protected by high HbF levels until ~ 6 months of age"
                    ]
                  },
                  {
                    "text": "Chronic hemolytic anemia"
                  },
                  {
                    "text": "Pain"
                  },
                  {
                    "text": "Dactylitis"
                  },
                  {
                    "text": "Leukocytosis without infection"
                  }
                ],
                "Laboratory Tests": [
                  {
                    "text": "CBCChronic anemiaUsually normochromic normocyticCan be macrocytic if concurrent folate deficiency is present from rapid cell turnoverLeukocytosis &/or thrombocytosisFrequently seen with acute infection or stress from acute crisis",
                    "sub_points": [
                      "Chronic anemiaUsually normochromic normocyticCan be macrocytic if concurrent folate deficiency is present from rapid cell turnover",
                      "Usually normochromic normocytic",
                      "Can be macrocytic if concurrent folate deficiency is present from rapid cell turnover",
                      "Leukocytosis &/or thrombocytosisFrequently seen with acute infection or stress from acute crisis",
                      "Frequently seen with acute infection or stress from acute crisis"
                    ]
                  },
                  {
                    "text": "Reticulocyte countElevated, producing polychromasiaIndicates intact bone marrow response",
                    "sub_points": [
                      "Elevated, producing polychromasia",
                      "Indicates intact bone marrow response"
                    ]
                  },
                  {
                    "text": "Peripheral blood smear reviewSickled erythrocytesHowell-Jolly bodiesNucleated RBCs, polychromasia",
                    "sub_points": [
                      "Sickled erythrocytes",
                      "Howell-Jolly bodies",
                      "Nucleated RBCs, polychromasia"
                    ]
                  },
                  {
                    "text": "Hemoglobin electrophoresis or high-pressure liquid chromatographyNecessary for definitive diagnosisSingle band of HbS in homozygotesAbsence of HbACombination of HbS and HbA indicates sickle cell trait (asymptomatic)May show other abnormal hemoglobins in compound heterozygotes",
                    "sub_points": [
                      "Necessary for definitive diagnosis",
                      "Single band of HbS in homozygotes",
                      "Absence of HbACombination of HbS and HbA indicates sickle cell trait (asymptomatic)",
                      "Combination of HbS and HbA indicates sickle cell trait (asymptomatic)",
                      "May show other abnormal hemoglobins in compound heterozygotes"
                    ]
                  },
                  {
                    "text": "Individual RBC fetal hemoglobin level calculated from flow cytometric HbF resultMay provide more precise information for treatment monitoring",
                    "sub_points": [
                      "May provide more precise information for treatment monitoring"
                    ]
                  }
                ],
                "Natural History": [
                  {
                    "text": "Acute complicationsAcute painful (vasoocclusive) crisisPrecipitating event may or may not be identifiedSevere pain in long bones &/or abdomenLasts several hours to daysAcute febrile illnessAcute splenic sequestrationParvovirus infectionParvovirus B19 infects early erythroid precursorsLeads to red cell aplasiaRapid drop in hemoglobinResults from combined aplasia and shortened RBC lifespanResolves in ~ 1 week with supportive care and treatmentAcute chest syndromeSystemic embolization of necrotic bone marrowLungs are major target organFrequency of acute complications highly variable between individuals but stays roughly constant in given person",
                    "sub_points": [
                      "Acute painful (vasoocclusive) crisisPrecipitating event may or may not be identifiedSevere pain in long bones &/or abdomenLasts several hours to days",
                      "Precipitating event may or may not be identified",
                      "Severe pain in long bones &/or abdomen",
                      "Lasts several hours to days",
                      "Acute febrile illness",
                      "Acute splenic sequestration",
                      "Parvovirus infectionParvovirus B19 infects early erythroid precursorsLeads to red cell aplasiaRapid drop in hemoglobinResults from combined aplasia and shortened RBC lifespanResolves in ~ 1 week with supportive care and treatment",
                      "Parvovirus B19 infects early erythroid precursors",
                      "Leads to red cell aplasia",
                      "Rapid drop in hemoglobin",
                      "Results from combined aplasia and shortened RBC lifespan",
                      "Resolves in ~ 1 week with supportive care and treatment",
                      "Acute chest syndromeSystemic embolization of necrotic bone marrowLungs are major target organ",
                      "Systemic embolization of necrotic bone marrow",
                      "Lungs are major target organ",
                      "Frequency of acute complications highly variable between individuals but stays roughly constant in given person"
                    ]
                  },
                  {
                    "text": "Chronic complicationsNocturnal enuresisGrowth delayAvascular necrosis of hipGallstonesLearning difficultiesMay be associated with occult cerebral infarctsLeg ulcersPriapismSplenic hypofunctionStroke (cerebrovascular accident)Invasive pneumococcal disease",
                    "sub_points": [
                      "Nocturnal enuresis",
                      "Growth delay",
                      "Avascular necrosis of hip",
                      "Gallstones",
                      "Learning difficultiesMay be associated with occult cerebral infarcts",
                      "May be associated with occult cerebral infarcts",
                      "Leg ulcers",
                      "Priapism",
                      "Splenic hypofunction",
                      "Stroke (cerebrovascular accident)",
                      "Invasive pneumococcal disease"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "Vaccinations and penicillin prophylaxis for infection prevention"
                  },
                  {
                    "text": "Transfusion of blood productsOnly for limited indications related to acute crisesNot indicated for asymptomatic anemia, uncomplicated vasoocclusive episode or acute kidney injury",
                    "sub_points": [
                      "Only for limited indications related to acute crises",
                      "Not indicated for asymptomatic anemia, uncomplicated vasoocclusive episode or acute kidney injury"
                    ]
                  },
                  {
                    "text": "Hematopoietic stem cell transplantationOnly curative therapyNot used in most casesLimited to cases with severe, persistent complicationsRisks include death, graft rejection, and graft-vs.-host diseaseDifficulty finding HLA-matched sibling donor without diseaseOnly available in 20%IndicationsOverstrokeFrequent vasoocclusive events while on hydroxyureaRecurrent acute chest syndromePulmonary hypertensionSickle nephropathyRecurrent priapism",
                    "sub_points": [
                      "Only curative therapy",
                      "Not used in most casesLimited to cases with severe, persistent complicationsRisks include death, graft rejection, and graft-vs.-host disease",
                      "Limited to cases with severe, persistent complications",
                      "Risks include death, graft rejection, and graft-vs.-host disease",
                      "Difficulty finding HLA-matched sibling donor without diseaseOnly available in 20%",
                      "Only available in 20%",
                      "IndicationsOverstrokeFrequent vasoocclusive events while on hydroxyureaRecurrent acute chest syndromePulmonary hypertensionSickle nephropathyRecurrent priapism",
                      "Overstroke",
                      "Frequent vasoocclusive events while on hydroxyurea",
                      "Recurrent acute chest syndrome",
                      "Pulmonary hypertension",
                      "Sickle nephropathy",
                      "Recurrent priapism"
                    ]
                  },
                  {
                    "text": "Gene therapy: Ex vivo and in vivo future treatments1st report to treat adolescent in 2017Ex vivo LentiGlobin 2022 trial reported sustained production of HbA in most RBCs2 of 7 patients in initial trial subsequently developed acute myeloid leukemia",
                    "sub_points": [
                      "1st report to treat adolescent in 2017",
                      "Ex vivo LentiGlobin 2022 trial reported sustained production of HbA in most RBCs2 of 7 patients in initial trial subsequently developed acute myeloid leukemia",
                      "2 of 7 patients in initial trial subsequently developed acute myeloid leukemia"
                    ]
                  }
                ],
                "Drugs": [
                  {
                    "text": "HydroxyureaMainstay of therapy although many patients not on this regimenAntimetabolite chemotherapeutic agentStimulates fetal hemoglobin production, which is resistant to sicklingUnwanted side effects include reduced WBC and platelet numbersDecreases RBC adhesiveness to endotheliumWhen used from early age, has protective effects against long-term complications of SCDImproved survival",
                    "sub_points": [
                      "Mainstay of therapy although many patients not on this regimen",
                      "Antimetabolite chemotherapeutic agent",
                      "Stimulates fetal hemoglobin production, which is resistant to sickling",
                      "Unwanted side effects include reduced WBC and platelet numbers",
                      "Decreases RBC adhesiveness to endothelium",
                      "When used from early age, has protective effects against long-term complications of SCD",
                      "Improved survival"
                    ]
                  },
                  {
                    "text": "L-glutamineOral medication, FDA approved in 2017Mechanism not fully understood but helps prevent oxidative damage",
                    "sub_points": [
                      "Oral medication, FDA approved in 2017",
                      "Mechanism not fully understood but helps prevent oxidative damage"
                    ]
                  },
                  {
                    "text": "CrizanlizumabMonoclonal antibody against P-selectin glycoproteinReduces frequency of vasoocclusive crisesFDA approved in 2019 for patients > 16 years of age",
                    "sub_points": [
                      "Monoclonal antibody against P-selectin glycoprotein",
                      "Reduces frequency of vasoocclusive crises",
                      "FDA approved in 2019 for patients > 16 years of age"
                    ]
                  },
                  {
                    "text": "VoxelotorFDA approval in 2019 for patients > 12 years of ageHemoglobin S polymerization inhibitor",
                    "sub_points": [
                      "FDA approval in 2019 for patients > 12 years of age",
                      "Hemoglobin S polymerization inhibitor"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "> 95% reach adulthood and live into 5th decadeLife expectancy beyond 5th decade has not improved in last 40 yearsCardiopulmonary disease is major cause of death",
                    "sub_points": [
                      "Life expectancy beyond 5th decade has not improved in last 40 years",
                      "Cardiopulmonary disease is major cause of death"
                    ]
                  },
                  {
                    "text": "Favorable indicatorsElevated HbF (> 20%) associated with fewer clinical events",
                    "sub_points": [
                      "Elevated HbF (> 20%) associated with fewer clinical events"
                    ]
                  },
                  {
                    "text": "Poor indicatorsLow HbF concentrationDactylitis in infantsHemoglobin < 7 g/dLLeukocytosis in absence of infection",
                    "sub_points": [
                      "Low HbF concentration",
                      "Dactylitis in infants",
                      "Hemoglobin < 7 g/dL",
                      "Leukocytosis in absence of infection"
                    ]
                  }
                ]
              },
              "IMAGING": {
                "Radiographic Findings": [
                  {
                    "text": "Fish vertebra sign"
                  },
                  {
                    "text": "Infarcts of bone"
                  },
                  {
                    "text": "Avascular necrosis"
                  },
                  {
                    "text": "Marrow expansion due to pervasive erythropoiesis"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Bone marrow biopsy generally not indicated"
                  }
                ],
                "Cytologic Features": [
                  {
                    "text": "Peripheral blood smearSickle cellsHowell-Jolly bodies indicate functional asplenismNucleated RBCsIncreased polychromasiaMay see other types of cells in compound heterozygotes",
                    "sub_points": [
                      "Sickle cells",
                      "Howell-Jolly bodies indicate functional asplenism",
                      "Nucleated RBCs",
                      "Increased polychromasia",
                      "May see other types of cells in compound heterozygotes"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Hemoglobin S/β-Thalassemia": [
                  {
                    "text": "Microcytic hypochromic anemia"
                  },
                  {
                    "text": "Abundanttarget cellson peripheral blood smear"
                  },
                  {
                    "text": "Hemoglobin electrophoresis is definitiveProminent HbS and HbA bandsUnlike sickle cell trait, HbS > HbASmall components of HbA₂ and HbF are also present",
                    "sub_points": [
                      "Prominent HbS and HbA bandsUnlike sickle cell trait, HbS > HbA",
                      "Unlike sickle cell trait, HbS > HbA",
                      "Small components of HbA₂ and HbF are also present"
                    ]
                  }
                ],
                "Hemoglobin SC Disease": [
                  {
                    "text": "Peripheral blood smearAbundanttargetcellsBoat-shaped cellsvary slightly from typical sickle cells",
                    "sub_points": [
                      "Abundanttargetcells",
                      "Boat-shaped cellsvary slightly from typical sickle cells"
                    ]
                  },
                  {
                    "text": "Hemoglobin electrophoresisProminent bands in HbS and HbC positionsNo HbA is observed",
                    "sub_points": [
                      "Prominent bands in HbS and HbC positions",
                      "No HbA is observed"
                    ]
                  },
                  {
                    "text": "Clinical syndrome often milder than in SCD"
                  }
                ],
                "Microangiopathic Hemolytic Anemia": [
                  {
                    "text": "Subtypes include DIC and thrombotic thrombocytopenic purpura"
                  },
                  {
                    "text": "Features include anemia, thrombocytopenia, and schistocytes that could be confused with sickle cells"
                  },
                  {
                    "text": "Different clinical presentation from SCD"
                  },
                  {
                    "text": "Normal results on hemoglobin electrophoresis"
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Clinically Relevant Pathologic Features": [
                  {
                    "text": "Sickle cells on peripheral blood smear"
                  },
                  {
                    "text": "HbS as major component on hemoglobin electrophoresis"
                  }
                ],
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "Sickle cells should be distinguished from schistocytes of microangiopathic hemolytic anemiaCorrelate with clinical history and other laboratory findings",
                    "sub_points": [
                      "Correlate with clinical history and other laboratory findings"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Fanconi Anemia": {
            "name": "Fanconi Anemia",
            "url": "https://app.pathprimer.com/document/c54cbe35-8189-439a-bd42-594c748c0e9d/lesson/92495282-ce4a-41b9-a2f4-c2339cb2cc79",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Fanconi anemia (FA) is inherited disorder characterized byDefective DNA repairBM failurePhysical abnormalitiesCancer susceptibility",
                    "sub_points": [
                      "Defective DNA repair",
                      "BM failure",
                      "Physical abnormalities",
                      "Cancer susceptibility"
                    ]
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "Mutations in any of ~ 23 separate genes that participate in sensing and repairing DNA damage (interstrand crosslinks)"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Physical abnormalities present in ~ 75% of casesHypoplastic or absent thumbs &/or radiiShort staturePigmentation abnormalities, including café au lait spots",
                    "sub_points": [
                      "Hypoplastic or absent thumbs &/or radii",
                      "Short stature",
                      "Pigmentation abnormalities, including café au lait spots"
                    ]
                  },
                  {
                    "text": "BM failureGenerally presents in 1st decade of life, but onset may be later",
                    "sub_points": [
                      "Generally presents in 1st decade of life, but onset may be later"
                    ]
                  },
                  {
                    "text": "Myelodysplastic syndrome/acute myeloid leukemia (MDS/AML)Risk of AML in FA is increased ~ 500x above normalIn some cases, MDS/AML will be presenting manifestation",
                    "sub_points": [
                      "Risk of AML in FA is increased ~ 500x above normal",
                      "In some cases, MDS/AML will be presenting manifestation"
                    ]
                  },
                  {
                    "text": "Solid tumorsHead and neck tumors (squamous cell carcinoma) are especially common",
                    "sub_points": [
                      "Head and neck tumors (squamous cell carcinoma) are especially common"
                    ]
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "Acquired aplastic anemia"
                  },
                  {
                    "text": "Dyskeratosis congenita"
                  },
                  {
                    "text": "Other etiologies of myeloid neoplasms with germline predisposition"
                  }
                ],
                "Diagnostic Checklist": [
                  {
                    "text": "Increased chromosomal breakage with diepoxybutane or mitomycin C is traditional test for diagnosis of FA"
                  },
                  {
                    "text": "FA patients may acquire cytogenetic abnormalities that wax and wane"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Fanconi anemia (FA)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Inherited disorder characterized byDefective DNA repairBM failurePhysical abnormalitiesCancer susceptibility",
                    "sub_points": [
                      "Defective DNA repair",
                      "BM failure",
                      "Physical abnormalities",
                      "Cancer susceptibility"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Molecular Pathogenesis": [
                  {
                    "text": "FA is caused by mutations in any of ~ 23 separate genes that collectively participate in sensing and repairing DNA damage (interstrand crosslinks)Autosomal recessive (biallelic mutations)BRCA1,BRCA2,BRIP1,ERCC4,FAAP100,FANCA,FANCC,FANCD2,FANCE,FANCF,FANCG,FANCI,FANCL,FANCM,PALB2,RAD51C,MAD2L2,RFWD3,SLX4,UBE2T,XRCC2Autosomal dominantRAD51X-linkedFANCB",
                    "sub_points": [
                      "Autosomal recessive (biallelic mutations)BRCA1,BRCA2,BRIP1,ERCC4,FAAP100,FANCA,FANCC,FANCD2,FANCE,FANCF,FANCG,FANCI,FANCL,FANCM,PALB2,RAD51C,MAD2L2,RFWD3,SLX4,UBE2T,XRCC2",
                      "BRCA1,BRCA2,BRIP1,ERCC4,FAAP100,FANCA,FANCC,FANCD2,FANCE,FANCF,FANCG,FANCI,FANCL,FANCM,PALB2,RAD51C,MAD2L2,RFWD3,SLX4,UBE2T,XRCC2",
                      "Autosomal dominantRAD51",
                      "RAD51",
                      "X-linkedFANCB",
                      "FANCB"
                    ]
                  },
                  {
                    "text": "(Separately from autosomal recessive FA, monoallelic mutations in some of implicated genes cause other cancer susceptibility syndromes)e.g.,BRCA1andBRCA2(hereditary breast and ovarian cancer, others)",
                    "sub_points": [
                      "e.g.,BRCA1andBRCA2(hereditary breast and ovarian cancer, others)"
                    ]
                  },
                  {
                    "text": "FA core complexIncludes FANCA, FANCB, FANCC, FANCE, FANCF, FANCL, FANCM, FAAP100 proteinsCore complex detects DNA damage in form of intrastrand crosslinks at stalled replication forksThese crosslinks are abnormal covalent attachments of 2 DNA strands in double helixPrevent unwinding of DNA for replication or transcriptionE3 ubiquitin ligase function is activated",
                    "sub_points": [
                      "Includes FANCA, FANCB, FANCC, FANCE, FANCF, FANCL, FANCM, FAAP100 proteins",
                      "Core complex detects DNA damage in form of intrastrand crosslinks at stalled replication forksThese crosslinks are abnormal covalent attachments of 2 DNA strands in double helixPrevent unwinding of DNA for replication or transcriptionE3 ubiquitin ligase function is activated",
                      "These crosslinks are abnormal covalent attachments of 2 DNA strands in double helixPrevent unwinding of DNA for replication or transcription",
                      "Prevent unwinding of DNA for replication or transcription",
                      "E3 ubiquitin ligase function is activated"
                    ]
                  },
                  {
                    "text": "ID complexHeterodimer composed of FANCI and FANCD2 proteinsMonoubiquitinated by FA core complexPromotes cleavage of DNA and unhooking of DNA crosslink",
                    "sub_points": [
                      "Heterodimer composed of FANCI and FANCD2 proteins",
                      "Monoubiquitinated by FA core complex",
                      "Promotes cleavage of DNA and unhooking of DNA crosslink"
                    ]
                  },
                  {
                    "text": "Homologous recombination repairRepairs DNA strand using sister chromatid as templateFA proteins involved include BRCA1, BRCA2, PALB2, RAD51",
                    "sub_points": [
                      "Repairs DNA strand using sister chromatid as template",
                      "FA proteins involved include BRCA1, BRCA2, PALB2, RAD51"
                    ]
                  },
                  {
                    "text": "FA is caused by absence of any of these cooperating proteins due to germline mutationsLeads to unrepaired and accumulating DNA damage and genomic instability",
                    "sub_points": [
                      "Leads to unrepaired and accumulating DNA damage and genomic instability"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [
                  {
                    "text": "FA is most common cause of inherited BM failure and major cause of inherited susceptibility to myeloid neoplasms"
                  },
                  {
                    "text": "Carrier prevalence is increased in some populations (e.g., Ashkenazi Jewish, northern European) due to founder mutations"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Physical abnormalitiesIdentifiable in ~ 3/4 of FA casesHypoplastic or absent thumbs &/or radiiClassic FA findingChanges range from absent thumb to subtle anomalies of clefting between thumb and forefingerShort staturePigmentation abnormalities, including café au lait spotsGenitourinary malformations, including horseshoe kidneyGastrointestinal malformations, such as atresiaMicrocephaly &/or microphthalmiaCardiac defects",
                    "sub_points": [
                      "Identifiable in ~ 3/4 of FA cases",
                      "Hypoplastic or absent thumbs &/or radiiClassic FA findingChanges range from absent thumb to subtle anomalies of clefting between thumb and forefinger",
                      "Classic FA finding",
                      "Changes range from absent thumb to subtle anomalies of clefting between thumb and forefinger",
                      "Short stature",
                      "Pigmentation abnormalities, including café au lait spots",
                      "Genitourinary malformations, including horseshoe kidney",
                      "Gastrointestinal malformations, such as atresia",
                      "Microcephaly &/or microphthalmia",
                      "Cardiac defects"
                    ]
                  },
                  {
                    "text": "Intellectual disability"
                  },
                  {
                    "text": "BM failureGenerally presents in 1st decade of lifeLater presentations into adulthood also occurPancytopenia with marrow aplasiaThrombocytopenia and neutropenia may precede anemia",
                    "sub_points": [
                      "Generally presents in 1st decade of lifeLater presentations into adulthood also occur",
                      "Later presentations into adulthood also occur",
                      "Pancytopenia with marrow aplasia",
                      "Thrombocytopenia and neutropenia may precede anemia"
                    ]
                  },
                  {
                    "text": "Family historyMost cases are autosomal recessive in inheritance (with autosomal dominant or X-linked cases rare)",
                    "sub_points": [
                      "Most cases are autosomal recessive in inheritance (with autosomal dominant or X-linked cases rare)"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "Transfusion support as necessary"
                  },
                  {
                    "text": "Stem cell transplantationComplicated by inherent susceptibility of FA patients to DNA-damaging irradiation and drug therapyReduced intensity conditioning regimens must be used",
                    "sub_points": [
                      "Complicated by inherent susceptibility of FA patients to DNA-damaging irradiation and drug therapyReduced intensity conditioning regimens must be used",
                      "Reduced intensity conditioning regimens must be used"
                    ]
                  }
                ],
                "Drugs": [
                  {
                    "text": "Androgen therapy (e.g., oxymetholone)Improves peripheral counts in ~ 50% of FA patientsResistance often develops",
                    "sub_points": [
                      "Improves peripheral counts in ~ 50% of FA patients",
                      "Resistance often develops"
                    ]
                  },
                  {
                    "text": "G-CSF"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "BM failureBy 5th decade, cumulative incidence is 90%Aplasia is often progressive",
                    "sub_points": [
                      "By 5th decade, cumulative incidence is 90%",
                      "Aplasia is often progressive"
                    ]
                  },
                  {
                    "text": "Myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML)Risk of AML in FA is increased ~ 500x above normalBy 5th decade, cumulative incidence of hematologic malignancy is 10-33%Although in FA BM failure usually precedes MDS/AML, in some cases, MDS/AML will be presenting manifestationTreatment complicated by inherent susceptibility of FA patients to DNA-damaging alkylating drug therapy",
                    "sub_points": [
                      "Risk of AML in FA is increased ~ 500x above normal",
                      "By 5th decade, cumulative incidence of hematologic malignancy is 10-33%",
                      "Although in FA BM failure usually precedes MDS/AML, in some cases, MDS/AML will be presenting manifestation",
                      "Treatment complicated by inherent susceptibility of FA patients to DNA-damaging alkylating drug therapy"
                    ]
                  },
                  {
                    "text": "Solid tumorsBy 5th decade, cumulative incidence is ~ 30%Head and neck tumors (squamous cell carcinoma) are especially common",
                    "sub_points": [
                      "By 5th decade, cumulative incidence is ~ 30%",
                      "Head and neck tumors (squamous cell carcinoma) are especially common"
                    ]
                  },
                  {
                    "text": "Genotype-phenotype correlationsPatients with biallelicBRCA2mutations are at particular risk for early-onset AML and may benefit from early stem cell transplantationFANCBmutations linked to early-onset BM failure, more severe congenital abnormalities, shorter survivalIncidence of AML and severe cytopenia is higher in patients with someFANCGmutations",
                    "sub_points": [
                      "Patients with biallelicBRCA2mutations are at particular risk for early-onset AML and may benefit from early stem cell transplantation",
                      "FANCBmutations linked to early-onset BM failure, more severe congenital abnormalities, shorter survival",
                      "Incidence of AML and severe cytopenia is higher in patients with someFANCGmutations"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Key Microscopic Findings": [
                  {
                    "text": "BloodCytopenias, progressing to pancytopeniaRBCs often show nonspecific changesMacrocytosis",
                    "sub_points": [
                      "Cytopenias, progressing to pancytopenia",
                      "RBCs often show nonspecific changesMacrocytosis",
                      "Macrocytosis"
                    ]
                  },
                  {
                    "text": "BM is hypocellularDegree of hypocellularity depends upon timing of biopsy",
                    "sub_points": [
                      "Degree of hypocellularity depends upon timing of biopsy"
                    ]
                  },
                  {
                    "text": "FA patients may also initially present only after developing MDS or AML"
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Genetic Testing": [
                  {
                    "text": "Chromosomal breakageTraditional standard test for diagnosis of FAPatient lymphocytes are stimulated and exposed to diepoxybutane &/or mitomycin CNumber of chromosomal breaks and radial formations are countedFA is diagnosed if breaks and radials significantly exceed those seen in normal controlsRarely, clinically or molecularly diagnosed FA patients show borderline or even negative resultsIn such cases, reversion mutation may have occurred in hematopoietic compartmentReversion mutation corrects original mutation (e.g., frameshift mutation is shifted back into reading frame)Baseline DNA instability in FA contributes to this unusual phenomenon by increasing mutation rateIf reversion mutation is suspected, chromosomal breakage should be performed on cultured fibroblasts from skin biopsyFA carriers cannot be detected with chromosomal breakage studies",
                    "sub_points": [
                      "Traditional standard test for diagnosis of FA",
                      "Patient lymphocytes are stimulated and exposed to diepoxybutane &/or mitomycin C",
                      "Number of chromosomal breaks and radial formations are counted",
                      "FA is diagnosed if breaks and radials significantly exceed those seen in normal controls",
                      "Rarely, clinically or molecularly diagnosed FA patients show borderline or even negative resultsIn such cases, reversion mutation may have occurred in hematopoietic compartmentReversion mutation corrects original mutation (e.g., frameshift mutation is shifted back into reading frame)Baseline DNA instability in FA contributes to this unusual phenomenon by increasing mutation rateIf reversion mutation is suspected, chromosomal breakage should be performed on cultured fibroblasts from skin biopsy",
                      "In such cases, reversion mutation may have occurred in hematopoietic compartment",
                      "Reversion mutation corrects original mutation (e.g., frameshift mutation is shifted back into reading frame)",
                      "Baseline DNA instability in FA contributes to this unusual phenomenon by increasing mutation rate",
                      "If reversion mutation is suspected, chromosomal breakage should be performed on cultured fibroblasts from skin biopsy",
                      "FA carriers cannot be detected with chromosomal breakage studies"
                    ]
                  },
                  {
                    "text": "Molecular testingSequence analysis and targeted mutation analysis are clinically available to detect mutation in some FA genesFANCAis most commonly affected gene (~ 66%)Next-generation sequencing (NGS) panels often include all FA-related genes as well as genes responsible for other inherited BM failure syndromes or cancer susceptibility syndromesCare must be taken to distinguish acquired somatic mutations from true germline FA mutationsCarrier and prenatal testing are facilitated if specific familial mutation is known",
                    "sub_points": [
                      "Sequence analysis and targeted mutation analysis are clinically available to detect mutation in some FA genesFANCAis most commonly affected gene (~ 66%)",
                      "FANCAis most commonly affected gene (~ 66%)",
                      "Next-generation sequencing (NGS) panels often include all FA-related genes as well as genes responsible for other inherited BM failure syndromes or cancer susceptibility syndromesCare must be taken to distinguish acquired somatic mutations from true germline FA mutations",
                      "Care must be taken to distinguish acquired somatic mutations from true germline FA mutations",
                      "Carrier and prenatal testing are facilitated if specific familial mutation is known"
                    ]
                  }
                ],
                "Complementation Group Analysis": [
                  {
                    "text": "Historically, complementation studies were used to identify defective component of DNA repair pathway"
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Acquired Aplastic Anemia": [
                  {
                    "text": "Key differential diagnostic consideration"
                  },
                  {
                    "text": "Increased susceptibility to chromosomal breakage is not feature of acquired aplastic anemia"
                  }
                ],
                "Other Germline BM Failure Disorders": [
                  {
                    "text": "Dyskeratosis congenita (DKC)DKC classically shows triad of oral leukoplakia, lacy, reticular skin pigmentation, and nail dysgenesis, but these findings may be subtle or variableDiagnosis of DKC is often pursued with flow-FISH measurement of telomere length (or NGS) after negative chromosomal breakage study",
                    "sub_points": [
                      "DKC classically shows triad of oral leukoplakia, lacy, reticular skin pigmentation, and nail dysgenesis, but these findings may be subtle or variable",
                      "Diagnosis of DKC is often pursued with flow-FISH measurement of telomere length (or NGS) after negative chromosomal breakage study"
                    ]
                  }
                ],
                "Other Congenital Syndromes With Radial Abnormalities": [
                  {
                    "text": "Especially relevant if diagnosis is attempted before onset of BM failure (e.g., infant with hypoplastic thumbs)"
                  },
                  {
                    "text": "Specific disorders includeHolt-Oram syndrome (TBX5mutations)SALL4-related disordersDuane-radial ray syndrome (Okihiro syndrome)Acro-renal-ocular syndromeVACTERL association (vertebral,anal,cardiac,tracheal,esophageal,renal,limb abnormality)Thrombocytopenia absent radiusDiamond-Blackfan anemia",
                    "sub_points": [
                      "Holt-Oram syndrome (TBX5mutations)",
                      "SALL4-related disordersDuane-radial ray syndrome (Okihiro syndrome)Acro-renal-ocular syndrome",
                      "Duane-radial ray syndrome (Okihiro syndrome)",
                      "Acro-renal-ocular syndrome",
                      "VACTERL association (vertebral,anal,cardiac,tracheal,esophageal,renal,limb abnormality)",
                      "Thrombocytopenia absent radius",
                      "Diamond-Blackfan anemia"
                    ]
                  }
                ],
                "MDS/AML/Solid Tumors": [
                  {
                    "text": "While BM failure usually precedes malignancy, cancer may be presenting manifestation of FA"
                  },
                  {
                    "text": "GermlineGATA2,RUNX1, or other mutations associated with myeloid neoplasms with germline predisposition may be considered"
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "FA patients may acquire cytogenetic abnormalities that wax and waneGain of 1q is common, may be monitored\"Aberration of indeterminate potential in patient with FA\" has been proposed as label for this and certain other low-risk abnormalitiesGain of 3q, including 3q26-q29, often precedes progression to MDS/AMLAppears to upregulate expression ofMECOM(EVI1)Gains of 3q are rare in non-FA-associated MDS/AML; if detected, may prompt consideration of underlying FAChromosome 7 abnormalities (monosomy 7, deletion 7q) are also common and high risk",
                    "sub_points": [
                      "Gain of 1q is common, may be monitored\"Aberration of indeterminate potential in patient with FA\" has been proposed as label for this and certain other low-risk abnormalities",
                      "\"Aberration of indeterminate potential in patient with FA\" has been proposed as label for this and certain other low-risk abnormalities",
                      "Gain of 3q, including 3q26-q29, often precedes progression to MDS/AMLAppears to upregulate expression ofMECOM(EVI1)Gains of 3q are rare in non-FA-associated MDS/AML; if detected, may prompt consideration of underlying FA",
                      "Appears to upregulate expression ofMECOM(EVI1)",
                      "Gains of 3q are rare in non-FA-associated MDS/AML; if detected, may prompt consideration of underlying FA",
                      "Chromosome 7 abnormalities (monosomy 7, deletion 7q) are also common and high risk"
                    ]
                  },
                  {
                    "text": "Most FA patients show at least mild to moderate baseline dyserythropoiesis, further complicating diagnosis of progression to MDS in this setting"
                  }
                ]
              },
              "Selected References": {}
            }
          }
        }
      },
      "Bone Marrow: Neoplasms": {
        "name": "Bone Marrow: Neoplasms",
        "url": "https://app.pathprimer.com/lesson/6f665b6e-874b-46a5-9d19-463bafa93147",
        "topics": {
          "Overview of Acute Myeloid Leukemia": {
            "name": "Overview of Acute Myeloid Leukemia",
            "url": "https://app.pathprimer.com/document/3710f0c6-f7fe-4599-af8e-801597babc62/lesson/6f665b6e-874b-46a5-9d19-463bafa93147",
            "content": {
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Acute myeloid leukemia (AML)"
                  },
                  {
                    "text": "International Consensus Classification (ICC)"
                  },
                  {
                    "text": "WHO 5th edition (WHO-HAEM5)"
                  },
                  {
                    "text": "Myelodysplasia-related gene mutations (MRG) (ICC designation only)"
                  },
                  {
                    "text": "Myelodysplasia-related cytogenetic abnormalities (i.e., karyotype) (MRC) (ICC designation only)"
                  },
                  {
                    "text": "Myelodysplastic syndrome (MDS) (ICC); myelodysplastic neoplasm (MDN) (WHO-HAEM5)"
                  },
                  {
                    "text": "Myeloproliferative neoplasm (MPN)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Acute myelogenous leukemia"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Clonal hematopoietic stem/progenitor cell neoplasm"
                  },
                  {
                    "text": "Heterogeneous group of genetically distinct neoplasms"
                  }
                ]
              },
              "Classification": {
                "Classification Systems Overview: ICC and WHO-HAEM5 Comparisons": [
                  {
                    "text": "2 major AML categories in both classificationsAML with recurrent (defining) genetic abnormalities (ICC and WHO-HAEM5)ICCrequires≥ 10% blastsfor 20 of 21 subtypes of AML with recurrent genetic abnormalitiesException is that AML withBCR::ABL1has ≥ 20% blast percentage requirementAML with mutated bZIPCEBPA: Specific requirement for this type of mutation in ICCAML with defining genetic abnormalities (WHO-HAEM5)WHO-HAEM5 hasnoblast percentage requirement for 12 of 15 subtypes of AML with defining genetic abnormality subtypes≥ 20% blast requirementfor all other AML subtypes (ICC and WHO-HAEM5)ICCsubtypes includeAML with t(9;22)(q34.1;q11.2)/BCR::ABL1AML with mutatedTP53(ICC entity only)AML, myelodysplasia-related gene mutations (MRG) (ICC designation only)AML, myelodysplasia-related cytogenetic abnormalities (MRC) (ICC designation only)AML, not otherwise specified (NOS)ICC doesnotinclude either therapy-related or germline disorder-associated AML cases as entities\"Therapy-related\" and \"germline disorder-associated\" are listed as qualifiers to primary ICC diagnosisWHO-HAEM5subtypes include3 genetically defined subtypes: AML withCEBPA, AML withBCR::ABL1mutation, and AML, myelodysplasia-related (AML-MR) subtypesAML with biallelicCEBPAmutation, per WHO, has ≥ 20% blast requirement8 other subtypes defined by differentiation (no genetic requirements)Includes AML with minimal differentiation, ± maturation, and AML with monocytic, erythroid, basophilic, or megakaryoblastic differentiationIncludes postcytotoxic therapy and germline predisposition-related secondary AML entitiesKey ICC vs. WHO-HAEM5 differences≥ 10% blast threshold for AML with recurrent genetic abnormalities (ICC); no blast percentage requirement (WHO-HAEM5)ICC requiresin-frame bZIPCEBPAmutation (onlyCEBPAmutation linked to favorable outcome as per recent studies) and ≥ 10% blasts: WHO-HAEM5 requires biallelicCEBPAmutation and ≥ 20% blastsAML with mutatedTP53is entity in ICC; included with complex karyotype in AML-MR in WHO-HAEM5Therapy-related AML is not regarded as diagnostic entity in ICC but is retained in WHO-HAEM5AML entities in ICC are defined largely by genetic profile with therapy-relatedness reported as qualifierWHO-HAEM5 includes therapy-related (postcytotoxic) and germline predisposition-related in secondary AMLAML defined by differentiation (WHO-HAEM5) designated as AML, NOS in ICCMost cases in this category in WHO-HAEM4 have genetic abnormalities that allow them to be moved to 1 of new ICC genetic entitiesRetained in WHO-HAEM5 with largely French American British (FAB) designations and definitionsAML-MR in WHO-HAEM5 corresponds to WHO-HAEM4 AML-MRC definitions",
                    "sub_points": [
                      "AML with recurrent (defining) genetic abnormalities (ICC and WHO-HAEM5)ICCrequires≥ 10% blastsfor 20 of 21 subtypes of AML with recurrent genetic abnormalitiesException is that AML withBCR::ABL1has ≥ 20% blast percentage requirementAML with mutated bZIPCEBPA: Specific requirement for this type of mutation in ICCAML with defining genetic abnormalities (WHO-HAEM5)WHO-HAEM5 hasnoblast percentage requirement for 12 of 15 subtypes of AML with defining genetic abnormality subtypes",
                      "ICCrequires≥ 10% blastsfor 20 of 21 subtypes of AML with recurrent genetic abnormalitiesException is that AML withBCR::ABL1has ≥ 20% blast percentage requirementAML with mutated bZIPCEBPA: Specific requirement for this type of mutation in ICC",
                      "Exception is that AML withBCR::ABL1has ≥ 20% blast percentage requirement",
                      "AML with mutated bZIPCEBPA: Specific requirement for this type of mutation in ICC",
                      "AML with defining genetic abnormalities (WHO-HAEM5)WHO-HAEM5 hasnoblast percentage requirement for 12 of 15 subtypes of AML with defining genetic abnormality subtypes",
                      "WHO-HAEM5 hasnoblast percentage requirement for 12 of 15 subtypes of AML with defining genetic abnormality subtypes",
                      "≥ 20% blast requirementfor all other AML subtypes (ICC and WHO-HAEM5)ICCsubtypes includeAML with t(9;22)(q34.1;q11.2)/BCR::ABL1AML with mutatedTP53(ICC entity only)AML, myelodysplasia-related gene mutations (MRG) (ICC designation only)AML, myelodysplasia-related cytogenetic abnormalities (MRC) (ICC designation only)AML, not otherwise specified (NOS)ICC doesnotinclude either therapy-related or germline disorder-associated AML cases as entities\"Therapy-related\" and \"germline disorder-associated\" are listed as qualifiers to primary ICC diagnosisWHO-HAEM5subtypes include3 genetically defined subtypes: AML withCEBPA, AML withBCR::ABL1mutation, and AML, myelodysplasia-related (AML-MR) subtypesAML with biallelicCEBPAmutation, per WHO, has ≥ 20% blast requirement8 other subtypes defined by differentiation (no genetic requirements)Includes AML with minimal differentiation, ± maturation, and AML with monocytic, erythroid, basophilic, or megakaryoblastic differentiationIncludes postcytotoxic therapy and germline predisposition-related secondary AML entities",
                      "ICCsubtypes includeAML with t(9;22)(q34.1;q11.2)/BCR::ABL1AML with mutatedTP53(ICC entity only)AML, myelodysplasia-related gene mutations (MRG) (ICC designation only)AML, myelodysplasia-related cytogenetic abnormalities (MRC) (ICC designation only)AML, not otherwise specified (NOS)",
                      "AML with t(9;22)(q34.1;q11.2)/BCR::ABL1",
                      "AML with mutatedTP53(ICC entity only)",
                      "AML, myelodysplasia-related gene mutations (MRG) (ICC designation only)",
                      "AML, myelodysplasia-related cytogenetic abnormalities (MRC) (ICC designation only)",
                      "AML, not otherwise specified (NOS)",
                      "ICC doesnotinclude either therapy-related or germline disorder-associated AML cases as entities\"Therapy-related\" and \"germline disorder-associated\" are listed as qualifiers to primary ICC diagnosis",
                      "\"Therapy-related\" and \"germline disorder-associated\" are listed as qualifiers to primary ICC diagnosis",
                      "WHO-HAEM5subtypes include3 genetically defined subtypes: AML withCEBPA, AML withBCR::ABL1mutation, and AML, myelodysplasia-related (AML-MR) subtypesAML with biallelicCEBPAmutation, per WHO, has ≥ 20% blast requirement8 other subtypes defined by differentiation (no genetic requirements)Includes AML with minimal differentiation, ± maturation, and AML with monocytic, erythroid, basophilic, or megakaryoblastic differentiationIncludes postcytotoxic therapy and germline predisposition-related secondary AML entities",
                      "3 genetically defined subtypes: AML withCEBPA, AML withBCR::ABL1mutation, and AML, myelodysplasia-related (AML-MR) subtypes",
                      "AML with biallelicCEBPAmutation, per WHO, has ≥ 20% blast requirement",
                      "8 other subtypes defined by differentiation (no genetic requirements)",
                      "Includes AML with minimal differentiation, ± maturation, and AML with monocytic, erythroid, basophilic, or megakaryoblastic differentiation",
                      "Includes postcytotoxic therapy and germline predisposition-related secondary AML entities",
                      "Key ICC vs. WHO-HAEM5 differences≥ 10% blast threshold for AML with recurrent genetic abnormalities (ICC); no blast percentage requirement (WHO-HAEM5)ICC requiresin-frame bZIPCEBPAmutation (onlyCEBPAmutation linked to favorable outcome as per recent studies) and ≥ 10% blasts: WHO-HAEM5 requires biallelicCEBPAmutation and ≥ 20% blastsAML with mutatedTP53is entity in ICC; included with complex karyotype in AML-MR in WHO-HAEM5Therapy-related AML is not regarded as diagnostic entity in ICC but is retained in WHO-HAEM5AML entities in ICC are defined largely by genetic profile with therapy-relatedness reported as qualifierWHO-HAEM5 includes therapy-related (postcytotoxic) and germline predisposition-related in secondary AMLAML defined by differentiation (WHO-HAEM5) designated as AML, NOS in ICCMost cases in this category in WHO-HAEM4 have genetic abnormalities that allow them to be moved to 1 of new ICC genetic entitiesRetained in WHO-HAEM5 with largely French American British (FAB) designations and definitionsAML-MR in WHO-HAEM5 corresponds to WHO-HAEM4 AML-MRC definitions",
                      "≥ 10% blast threshold for AML with recurrent genetic abnormalities (ICC); no blast percentage requirement (WHO-HAEM5)ICC requiresin-frame bZIPCEBPAmutation (onlyCEBPAmutation linked to favorable outcome as per recent studies) and ≥ 10% blasts: WHO-HAEM5 requires biallelicCEBPAmutation and ≥ 20% blasts",
                      "ICC requiresin-frame bZIPCEBPAmutation (onlyCEBPAmutation linked to favorable outcome as per recent studies) and ≥ 10% blasts: WHO-HAEM5 requires biallelicCEBPAmutation and ≥ 20% blasts",
                      "AML with mutatedTP53is entity in ICC; included with complex karyotype in AML-MR in WHO-HAEM5",
                      "Therapy-related AML is not regarded as diagnostic entity in ICC but is retained in WHO-HAEM5AML entities in ICC are defined largely by genetic profile with therapy-relatedness reported as qualifierWHO-HAEM5 includes therapy-related (postcytotoxic) and germline predisposition-related in secondary AML",
                      "AML entities in ICC are defined largely by genetic profile with therapy-relatedness reported as qualifier",
                      "WHO-HAEM5 includes therapy-related (postcytotoxic) and germline predisposition-related in secondary AML",
                      "AML defined by differentiation (WHO-HAEM5) designated as AML, NOS in ICCMost cases in this category in WHO-HAEM4 have genetic abnormalities that allow them to be moved to 1 of new ICC genetic entitiesRetained in WHO-HAEM5 with largely French American British (FAB) designations and definitions",
                      "Most cases in this category in WHO-HAEM4 have genetic abnormalities that allow them to be moved to 1 of new ICC genetic entities",
                      "Retained in WHO-HAEM5 with largely French American British (FAB) designations and definitions",
                      "AML-MR in WHO-HAEM5 corresponds to WHO-HAEM4 AML-MRC definitions"
                    ]
                  }
                ],
                "ICC": [
                  {
                    "text": "AML with recurrent genetic abnormalities (21 subtypes)"
                  },
                  {
                    "text": "AML, MRG or MRCGene mutations [variant allele frequency (VAF ≥ 2%]:ASXL1,BCOR,EZH2,RUNX1,SF3B1,SRSF2,STAG2,U2AF1,ZRSR2Complexcytogenetic abnormalities (≥ 3 unrelated abnormalities, excluding -Y): del(5q/t(5q)/add(5q), -7/del(7q), +8, del(12p)/t(12p)/add(12p), i(17q), -17/add(17p) or del(17p), del(20q), &/or idic(X)(q13)",
                    "sub_points": [
                      "Gene mutations [variant allele frequency (VAF ≥ 2%]:ASXL1,BCOR,EZH2,RUNX1,SF3B1,SRSF2,STAG2,U2AF1,ZRSR2",
                      "Complexcytogenetic abnormalities (≥ 3 unrelated abnormalities, excluding -Y): del(5q/t(5q)/add(5q), -7/del(7q), +8, del(12p)/t(12p)/add(12p), i(17q), -17/add(17p) or del(17p), del(20q), &/or idic(X)(q13)"
                    ]
                  },
                  {
                    "text": "AML with mutatedTP53(VAF ≥ 10%)"
                  },
                  {
                    "text": "AML, NOS"
                  }
                ],
                "WHO-HAEM5": [
                  {
                    "text": "AML with defining genetic abnormalities"
                  },
                  {
                    "text": "AML-MR"
                  },
                  {
                    "text": "AML defined by differentiation"
                  },
                  {
                    "text": "Secondary AMLCytotoxic therapy relatedGermline predisposition related",
                    "sub_points": [
                      "Cytotoxic therapy related",
                      "Germline predisposition related"
                    ]
                  }
                ]
              },
              "EPIDEMIOLOGY": {
                "Age Range": [
                  {
                    "text": "All ages affected but predominates in older patients; median: ~ 70 years> 50% of patients ≥ 65 at diagnosis",
                    "sub_points": [
                      "> 50% of patients ≥ 65 at diagnosis"
                    ]
                  },
                  {
                    "text": "Overall, proportion of acute leukemias that are AML increases with age~ 80% of acute leukemias in adults are myeloid",
                    "sub_points": [
                      "~ 80% of acute leukemias in adults are myeloid"
                    ]
                  },
                  {
                    "text": "Some disease types are more prevalent in older adultse.g., AML, MRG or AML, MRC",
                    "sub_points": [
                      "e.g., AML, MRG or AML, MRC"
                    ]
                  },
                  {
                    "text": "Some AML types are more prevalent in younger patientsAML with recurring genetic abnormality [e.g., t(15;17), t(8;21), inv(16)/t(16;16), t(9;11)]AML with t(1;22) occurs in infants and children < 3 yearsCongenital AML enriched for cases with 11q23 mutations",
                    "sub_points": [
                      "AML with recurring genetic abnormality [e.g., t(15;17), t(8;21), inv(16)/t(16;16), t(9;11)]",
                      "AML with t(1;22) occurs in infants and children < 3 years",
                      "Congenital AML enriched for cases with 11q23 mutations"
                    ]
                  }
                ],
                "Incidence": [
                  {
                    "text": "4.3 cases per 100,000 population; SEER dataIncidence increases dramatically with ageMale predominance in adults",
                    "sub_points": [
                      "Incidence increases dramatically with age",
                      "Male predominance in adults"
                    ]
                  },
                  {
                    "text": "~ 20,000 new cases in USA each year~ 11,000 AML patients die each year",
                    "sub_points": [
                      "~ 11,000 AML patients die each year"
                    ]
                  }
                ],
                "Natural History": [
                  {
                    "text": "Variable clinical courseClinically aggressive in most casesAcute promyelocytic leukemia (APL) can be cured without conventional chemotherapyAll-trans retinoic acid (ATRA) and arsenic trioxide highly effective in low-stage APL (lower WBC)Very rare cases spontaneously regressNeonatal AML with t(8;16) (p11.2;p13.3)/KAT6A::CREBBPreported rarely to spontaneously regress",
                    "sub_points": [
                      "Clinically aggressive in most cases",
                      "Acute promyelocytic leukemia (APL) can be cured without conventional chemotherapyAll-trans retinoic acid (ATRA) and arsenic trioxide highly effective in low-stage APL (lower WBC)",
                      "All-trans retinoic acid (ATRA) and arsenic trioxide highly effective in low-stage APL (lower WBC)",
                      "Very rare cases spontaneously regressNeonatal AML with t(8;16) (p11.2;p13.3)/KAT6A::CREBBPreported rarely to spontaneously regress",
                      "Neonatal AML with t(8;16) (p11.2;p13.3)/KAT6A::CREBBPreported rarely to spontaneously regress"
                    ]
                  },
                  {
                    "text": "Despite advances in classification and treatment, prognosis remains unfavorable for older patients with adverse AML subtypes and patients who are not eligible for allogeneic stem cell transplantation"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Development of AML": [
                  {
                    "text": "Somatic mutations drive development of AMLSerial acquisition of somatic mutations in hematopoietic stem cells and progenitor cellsComplex series of genetic events that varies by AML subtype",
                    "sub_points": [
                      "Serial acquisition of somatic mutations in hematopoietic stem cells and progenitor cells",
                      "Complex series of genetic events that varies by AML subtype"
                    ]
                  },
                  {
                    "text": "Germline mutations play role in some casesGermline predisposition disorders (familial)Family history and biallelic mutation are clues to familial inheritanceDistinct germline mutations described that are unique to each syndrome/conditionRisk of developing myeloid neoplasm, including AML, variesGermline mutations inCEBPA,GATA2,TP53,RUNX1, and othersRelatively more common germline predisposition syndromes include Fanconi anemia, severe congenital neutropenia, and Shwachman-Diamond syndromeIncreased recognition of germline disorder-associated AML due to increased genetic testingMore often recognized in adults than previouslyDown syndrome (not familial; sporadic)10-20x increased risk for AML> 500x increased risk for acute megakaryoblastic leukemia",
                    "sub_points": [
                      "Germline predisposition disorders (familial)Family history and biallelic mutation are clues to familial inheritanceDistinct germline mutations described that are unique to each syndrome/conditionRisk of developing myeloid neoplasm, including AML, variesGermline mutations inCEBPA,GATA2,TP53,RUNX1, and othersRelatively more common germline predisposition syndromes include Fanconi anemia, severe congenital neutropenia, and Shwachman-Diamond syndrome",
                      "Family history and biallelic mutation are clues to familial inheritanceDistinct germline mutations described that are unique to each syndrome/conditionRisk of developing myeloid neoplasm, including AML, varies",
                      "Distinct germline mutations described that are unique to each syndrome/condition",
                      "Risk of developing myeloid neoplasm, including AML, varies",
                      "Germline mutations inCEBPA,GATA2,TP53,RUNX1, and others",
                      "Relatively more common germline predisposition syndromes include Fanconi anemia, severe congenital neutropenia, and Shwachman-Diamond syndrome",
                      "Increased recognition of germline disorder-associated AML due to increased genetic testingMore often recognized in adults than previously",
                      "More often recognized in adults than previously",
                      "Down syndrome (not familial; sporadic)10-20x increased risk for AML> 500x increased risk for acute megakaryoblastic leukemia",
                      "10-20x increased risk for AML",
                      "> 500x increased risk for acute megakaryoblastic leukemia"
                    ]
                  },
                  {
                    "text": "Environmental exposures and antecedent cytotoxic therapyCases of AML following cytotoxic therapy are increasing likely due to improved survival for primary neoplasmTherapy-related is qualifier in ICC classification but is retained as secondary AML entity in WHO-HAEM5",
                    "sub_points": [
                      "Cases of AML following cytotoxic therapy are increasing likely due to improved survival for primary neoplasm",
                      "Therapy-related is qualifier in ICC classification but is retained as secondary AML entity in WHO-HAEM5"
                    ]
                  }
                ],
                "Progression of Underlying Myeloid Neoplasm": [
                  {
                    "text": "Variable risk of progression of myelodysplastic syndrome (MDS), MDS/myeloproliferative neoplasm (MPN), or MPN to AMLLinked to acquisition of additional mutations associated with increased cell proliferation and reduced cell maturation",
                    "sub_points": [
                      "Linked to acquisition of additional mutations associated with increased cell proliferation and reduced cell maturation"
                    ]
                  },
                  {
                    "text": "Qualifier in ICC; e.g., AML progressed from MDS"
                  },
                  {
                    "text": "Secondary AML in WHO-HAEM5"
                  }
                ]
              },
              "CLINICAL IMPLICATIONS": {
                "Clinical Presentation": [
                  {
                    "text": "Symptoms related to bone marrow failureFatigue (anemia)Bleeding (thrombocytopenia)Infection (neutropenia)",
                    "sub_points": [
                      "Fatigue (anemia)",
                      "Bleeding (thrombocytopenia)",
                      "Infection (neutropenia)"
                    ]
                  },
                  {
                    "text": "Extramedullary involvementSkin lesionsGingival hyperplasiaMyeloid sarcomas in other sites",
                    "sub_points": [
                      "Skin lesions",
                      "Gingival hyperplasia",
                      "Myeloid sarcomas in other sites"
                    ]
                  }
                ],
                "Clinical Risk Factors": [],
                "Risk stratification and other prognostic factors": [
                  {
                    "text": "Risk stratification; European Leukemia Network (ELN) and National Comprehensive Cancer Network (NCCN)Favorable riskCytogenetics: t(8;21), inv(16)Mutations:NPM1withoutFLT3,CEBPA(bZIP)Intermediate riskCytogenetic/molecular abnormalities not classified as favorable or adverset(9:11) and several distinct combinations ofNPM1andFLT3mutations [e.g., (-/+)]Adverse riskCytogenetics: t(6;9), t(v;11q23), t(9;22), t(8;16), inv(3), -5/del(5q), -7, -17/abnl(17p), complex karyotypeMutations:ASXL1,BCOR,EZH2,RUNX1,SF3B1,SRSF2,STAG2,U2AF1, &/orZRSR2MutatedTP53",
                    "sub_points": [
                      "Favorable riskCytogenetics: t(8;21), inv(16)Mutations:NPM1withoutFLT3,CEBPA(bZIP)",
                      "Cytogenetics: t(8;21), inv(16)",
                      "Mutations:NPM1withoutFLT3,CEBPA(bZIP)",
                      "Intermediate riskCytogenetic/molecular abnormalities not classified as favorable or adverset(9:11) and several distinct combinations ofNPM1andFLT3mutations [e.g., (-/+)]",
                      "Cytogenetic/molecular abnormalities not classified as favorable or adverse",
                      "t(9:11) and several distinct combinations ofNPM1andFLT3mutations [e.g., (-/+)]",
                      "Adverse riskCytogenetics: t(6;9), t(v;11q23), t(9;22), t(8;16), inv(3), -5/del(5q), -7, -17/abnl(17p), complex karyotypeMutations:ASXL1,BCOR,EZH2,RUNX1,SF3B1,SRSF2,STAG2,U2AF1, &/orZRSR2MutatedTP53",
                      "Cytogenetics: t(6;9), t(v;11q23), t(9;22), t(8;16), inv(3), -5/del(5q), -7, -17/abnl(17p), complex karyotype",
                      "Mutations:ASXL1,BCOR,EZH2,RUNX1,SF3B1,SRSF2,STAG2,U2AF1, &/orZRSR2",
                      "MutatedTP53"
                    ]
                  },
                  {
                    "text": "Prior chemotherapy &/or radiation adverse"
                  },
                  {
                    "text": "Progression from underlying myeloid neoplasm, e.g., MDS, adverse"
                  },
                  {
                    "text": "Reduced performance status at diagnosis, adverse"
                  }
                ],
                "Therapy": [
                  {
                    "text": "Generally consists of induction, consolidation, and maintenance chemotherapy therapy for non-APL subtypesGoal: No measurable residual disease< 5% residual blastsMeasurable residual disease assessment essentialMeasurable (minimal) residual disease detected by either flow cytometric immunophenotyping or molecular genetic assessment is more predictive of outcome than morphologic assessment",
                    "sub_points": [
                      "Goal: No measurable residual disease< 5% residual blastsMeasurable residual disease assessment essentialMeasurable (minimal) residual disease detected by either flow cytometric immunophenotyping or molecular genetic assessment is more predictive of outcome than morphologic assessment",
                      "< 5% residual blasts",
                      "Measurable residual disease assessment essentialMeasurable (minimal) residual disease detected by either flow cytometric immunophenotyping or molecular genetic assessment is more predictive of outcome than morphologic assessment",
                      "Measurable (minimal) residual disease detected by either flow cytometric immunophenotyping or molecular genetic assessment is more predictive of outcome than morphologic assessment"
                    ]
                  },
                  {
                    "text": "Induction therapy for APLUtilization of ATRA ± arsenic trioxideEarly use of ATRA decreases risk of APL-induced DIC and fibrinolysis and greatly reduces early mortality from hemorrhage or, much less often, thrombosis",
                    "sub_points": [
                      "Utilization of ATRA ± arsenic trioxide",
                      "Early use of ATRA decreases risk of APL-induced DIC and fibrinolysis and greatly reduces early mortality from hemorrhage or, much less often, thrombosis"
                    ]
                  }
                ]
              },
              "MACROSCOPIC": {
                "General Features": [
                  {
                    "text": "Myeloid sarcomasSoft, variable color on fresh sectioningMay be greenish or white/yellowVariable foci of necrosis",
                    "sub_points": [
                      "Soft, variable color on fresh sectioningMay be greenish or white/yellow",
                      "May be greenish or white/yellow",
                      "Variable foci of necrosis"
                    ]
                  }
                ],
                "Specimen Handling": [
                  {
                    "text": "Required for work-up of all cases of AMLCBC and blood &/or bone marrow microscopic examinationFlow cytometric immunophenotyping to determine blast lineageChromosomal study: Conventional karyotypingFISH testing can be included to rapidly assess for specific mutations, such asPML::RARAin APLKey assessment if karyotyping is unsuccessful or cryptic mutation is suspectedMolecular genetic assessmentMyeloid gene panel assessment by next-generation sequencing on all casesOther genetic tests usefulIndividual gene mutation assessment is rapid and useful forNPM1,FLT3, other mutationsComplete clinical historyPrior therapy informationPrior hematologic disorder/neoplasmPrior CBC results",
                    "sub_points": [
                      "CBC and blood &/or bone marrow microscopic examination",
                      "Flow cytometric immunophenotyping to determine blast lineage",
                      "Chromosomal study: Conventional karyotypingFISH testing can be included to rapidly assess for specific mutations, such asPML::RARAin APLKey assessment if karyotyping is unsuccessful or cryptic mutation is suspected",
                      "FISH testing can be included to rapidly assess for specific mutations, such asPML::RARAin APLKey assessment if karyotyping is unsuccessful or cryptic mutation is suspected",
                      "Key assessment if karyotyping is unsuccessful or cryptic mutation is suspected",
                      "Molecular genetic assessmentMyeloid gene panel assessment by next-generation sequencing on all casesOther genetic tests usefulIndividual gene mutation assessment is rapid and useful forNPM1,FLT3, other mutations",
                      "Myeloid gene panel assessment by next-generation sequencing on all cases",
                      "Other genetic tests usefulIndividual gene mutation assessment is rapid and useful forNPM1,FLT3, other mutations",
                      "Individual gene mutation assessment is rapid and useful forNPM1,FLT3, other mutations",
                      "Complete clinical historyPrior therapy informationPrior hematologic disorder/neoplasmPrior CBC results",
                      "Prior therapy information",
                      "Prior hematologic disorder/neoplasm",
                      "Prior CBC results"
                    ]
                  },
                  {
                    "text": "Additional studies to be consideredMPO cytochemical stainUseful for rapid diagnosis of APLUseful in distinction of AML from acute leukemia of ambiguous lineage",
                    "sub_points": [
                      "MPO cytochemical stainUseful for rapid diagnosis of APLUseful in distinction of AML from acute leukemia of ambiguous lineage",
                      "Useful for rapid diagnosis of APL",
                      "Useful in distinction of AML from acute leukemia of ambiguous lineage"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Blasts and Blast Equivalents: General Features": [
                  {
                    "text": "Blasts/blast equivalentsMyeloblastsDispersed, fine, blastic chromatinUsually sparse cytoplasmic azurophilic granules, Auer rods in some casesMonoblastsDispersed, fine, blastic chromatinAbundant blue-gray cytoplasm with variable fine granulesPromonocytesDispersed fine chromatin, minimal nuclear indentationsAbundant blue-gray cytoplasmMegakaryoblastsHighly variable nuclear chromatin, may be fine, blastic, or more condensedMay see cytoplasmic blebbing/shedding but not specificPromyelocytes (abnormal)Counted as blasts/blast equivalents in APL onlySingle or bilobed nuclei, hypo- or hypergranular cytoplasm, may see cytoplasm packed with Auer rodsPronormoblasts enumerated in WHO-HAEM5 category of acute erythroid leukemiaIn ICC, pure erythroid leukemia is included in AML with mutatedTP53categoryRound nuclei with variable nuclear chromatinDeeply basophilic cytoplasm",
                    "sub_points": [
                      "MyeloblastsDispersed, fine, blastic chromatinUsually sparse cytoplasmic azurophilic granules, Auer rods in some cases",
                      "Dispersed, fine, blastic chromatin",
                      "Usually sparse cytoplasmic azurophilic granules, Auer rods in some cases",
                      "MonoblastsDispersed, fine, blastic chromatinAbundant blue-gray cytoplasm with variable fine granules",
                      "Dispersed, fine, blastic chromatin",
                      "Abundant blue-gray cytoplasm with variable fine granules",
                      "PromonocytesDispersed fine chromatin, minimal nuclear indentationsAbundant blue-gray cytoplasm",
                      "Dispersed fine chromatin, minimal nuclear indentations",
                      "Abundant blue-gray cytoplasm",
                      "MegakaryoblastsHighly variable nuclear chromatin, may be fine, blastic, or more condensedMay see cytoplasmic blebbing/shedding but not specific",
                      "Highly variable nuclear chromatin, may be fine, blastic, or more condensed",
                      "May see cytoplasmic blebbing/shedding but not specific",
                      "Promyelocytes (abnormal)Counted as blasts/blast equivalents in APL onlySingle or bilobed nuclei, hypo- or hypergranular cytoplasm, may see cytoplasm packed with Auer rods",
                      "Counted as blasts/blast equivalents in APL only",
                      "Single or bilobed nuclei, hypo- or hypergranular cytoplasm, may see cytoplasm packed with Auer rods",
                      "Pronormoblasts enumerated in WHO-HAEM5 category of acute erythroid leukemiaIn ICC, pure erythroid leukemia is included in AML with mutatedTP53categoryRound nuclei with variable nuclear chromatinDeeply basophilic cytoplasm",
                      "In ICC, pure erythroid leukemia is included in AML with mutatedTP53category",
                      "Round nuclei with variable nuclear chromatin",
                      "Deeply basophilic cytoplasm"
                    ]
                  },
                  {
                    "text": "Enumeration of blast percentageIn bloodPercentage of circulating WBCsIn uncomplicated bone marrowPercentage of all nucleated cells, excluding histiocytes, megakaryocytes, mast cellsIn bone marrow, complicated by 2nd hematologic neoplasmPercentage of all nucleated cells, excluding coexisting tumor cells (e.g., plasma cells in myeloma, lymphoid cells in chronic lymphocytic leukemia)",
                    "sub_points": [
                      "In bloodPercentage of circulating WBCs",
                      "Percentage of circulating WBCs",
                      "In uncomplicated bone marrowPercentage of all nucleated cells, excluding histiocytes, megakaryocytes, mast cells",
                      "Percentage of all nucleated cells, excluding histiocytes, megakaryocytes, mast cells",
                      "In bone marrow, complicated by 2nd hematologic neoplasmPercentage of all nucleated cells, excluding coexisting tumor cells (e.g., plasma cells in myeloma, lymphoid cells in chronic lymphocytic leukemia)",
                      "Percentage of all nucleated cells, excluding coexisting tumor cells (e.g., plasma cells in myeloma, lymphoid cells in chronic lymphocytic leukemia)"
                    ]
                  },
                  {
                    "text": "Key blast count thresholds≥ 10% in blood or bone marrow for ICC category of AML with recurrent genetic abnormalityRequisite ≥ 20% blasts in blood &/or bone marrow for AML withBCR::ABL1, AML with mutatedTP53, AML, MRG, AML, MRC, and AML, NOS per ICC criteria",
                    "sub_points": [
                      "≥ 10% in blood or bone marrow for ICC category of AML with recurrent genetic abnormality",
                      "Requisite ≥ 20% blasts in blood &/or bone marrow for AML withBCR::ABL1, AML with mutatedTP53, AML, MRG, AML, MRC, and AML, NOS per ICC criteria"
                    ]
                  }
                ],
                "Blood": [
                  {
                    "text": "Abnormal CBC"
                  },
                  {
                    "text": "Cytopenias (usually profound hematopoietic failure due to extensive bone marrow effacement by AML)AnemiaThrombocytopeniaNeutropenia",
                    "sub_points": [
                      "Anemia",
                      "Thrombocytopenia",
                      "Neutropenia"
                    ]
                  },
                  {
                    "text": "Circulating blasts/blast equivalents"
                  },
                  {
                    "text": "Assess for dysplasia, which may be present, but is not required for genetically-defined AML subtypes by ICC"
                  },
                  {
                    "text": "Assess erythrocytes for evidence of DIC; most relevant in APL"
                  }
                ],
                "Bone Marrow Aspirate": [
                  {
                    "text": "RequirementsAdequate specimen, well stainedCellularRepresentativeIf fibrotic or dry tap, assess touch preparation",
                    "sub_points": [
                      "Adequate specimen, well stainedCellularRepresentativeIf fibrotic or dry tap, assess touch preparation",
                      "Cellular",
                      "Representative",
                      "If fibrotic or dry tap, assess touch preparation"
                    ]
                  },
                  {
                    "text": "Enumerate blasts"
                  },
                  {
                    "text": "Assess for increased/abnormal-appearing mast cellsMastocytosis may be concurrent",
                    "sub_points": [
                      "Mastocytosis may be concurrent"
                    ]
                  }
                ],
                "Bone Marrow Core Biopsy": [
                  {
                    "text": "RequirementsAdequate, technically optimal specimen",
                    "sub_points": [
                      "Adequate, technically optimal specimen"
                    ]
                  },
                  {
                    "text": "Identify blastsUtilize IHC if neededCaveatsNot all blasts are CD34(+), particularly APL, megakaryocytic, monocytic, and erythroid lineage blastsIHC not as sensitive as flow cytometry",
                    "sub_points": [
                      "Utilize IHC if needed",
                      "CaveatsNot all blasts are CD34(+), particularly APL, megakaryocytic, monocytic, and erythroid lineage blastsIHC not as sensitive as flow cytometry",
                      "Not all blasts are CD34(+), particularly APL, megakaryocytic, monocytic, and erythroid lineage blasts",
                      "IHC not as sensitive as flow cytometry"
                    ]
                  },
                  {
                    "text": "Evaluate for associated concurrent neoplasmMastocytosis, other",
                    "sub_points": [
                      "Mastocytosis, other"
                    ]
                  }
                ],
                "Specialized Testing": [
                  {
                    "text": "Cytochemical stainsMPOUseful for rapid diagnosis of APLStrong uniform positivity in virtually all APL cellsIf positive, confirms myeloid lineageIf negative, does not exclude myeloid lineage~ 5% of acute monoblastic leukemias may show scattered MPO(+) granulesNSEIf positive, confirms monocytic lineageIf negative, does not exclude monocytic lineage",
                    "sub_points": [
                      "MPOUseful for rapid diagnosis of APLStrong uniform positivity in virtually all APL cellsIf positive, confirms myeloid lineageIf negative, does not exclude myeloid lineage~ 5% of acute monoblastic leukemias may show scattered MPO(+) granules",
                      "Useful for rapid diagnosis of APLStrong uniform positivity in virtually all APL cells",
                      "Strong uniform positivity in virtually all APL cells",
                      "If positive, confirms myeloid lineage",
                      "If negative, does not exclude myeloid lineage",
                      "~ 5% of acute monoblastic leukemias may show scattered MPO(+) granules",
                      "NSEIf positive, confirms monocytic lineageIf negative, does not exclude monocytic lineage",
                      "If positive, confirms monocytic lineage",
                      "If negative, does not exclude monocytic lineage"
                    ]
                  },
                  {
                    "text": "Flow cytometric immunophenotyping (FCI)Required for all new cases of AMLEstablishes lineage of blastsEstablishes phenotype \"fingerprint\" for future monitoringBlast markersCD34: Not all blasts are CD34(+)CD117: Also stains pronormoblasts, mast cellsTdT: Stains subset of AMLsMyeloid markersMPO, CD13, CD33Monocytic lineage markersCD14, CD36/CD64 coexpression, CD163, CD4 (weak), CD33 (bright)Megakaryocytic lineage markersCD41b, CD42b, CD61; CD31 also positive but not lineage specificErythroid lineage markersCD235a, hemoglobin A, CD71, E-cadherinE-cadherin most specific and stains most immature erythroid lineage cells",
                    "sub_points": [
                      "Required for all new cases of AML",
                      "Establishes lineage of blasts",
                      "Establishes phenotype \"fingerprint\" for future monitoring",
                      "Blast markersCD34: Not all blasts are CD34(+)CD117: Also stains pronormoblasts, mast cellsTdT: Stains subset of AMLs",
                      "CD34: Not all blasts are CD34(+)",
                      "CD117: Also stains pronormoblasts, mast cells",
                      "TdT: Stains subset of AMLs",
                      "Myeloid markersMPO, CD13, CD33",
                      "MPO, CD13, CD33",
                      "Monocytic lineage markersCD14, CD36/CD64 coexpression, CD163, CD4 (weak), CD33 (bright)",
                      "CD14, CD36/CD64 coexpression, CD163, CD4 (weak), CD33 (bright)",
                      "Megakaryocytic lineage markersCD41b, CD42b, CD61; CD31 also positive but not lineage specific",
                      "CD41b, CD42b, CD61; CD31 also positive but not lineage specific",
                      "Erythroid lineage markersCD235a, hemoglobin A, CD71, E-cadherinE-cadherin most specific and stains most immature erythroid lineage cells",
                      "CD235a, hemoglobin A, CD71, E-cadherinE-cadherin most specific and stains most immature erythroid lineage cells",
                      "E-cadherin most specific and stains most immature erythroid lineage cells"
                    ]
                  },
                  {
                    "text": "IHC stainsUseful if flow cytometry inadequate or not performedIn general, fewer antibodies are available compared with flow cytometrySome are unique to IHC, howeverCD68: Myeloid and monocyticLysozyme: Monocytic",
                    "sub_points": [
                      "Useful if flow cytometry inadequate or not performed",
                      "In general, fewer antibodies are available compared with flow cytometrySome are unique to IHC, howeverCD68: Myeloid and monocyticLysozyme: Monocytic",
                      "Some are unique to IHC, however",
                      "CD68: Myeloid and monocytic",
                      "Lysozyme: Monocytic"
                    ]
                  },
                  {
                    "text": "CytogeneticsShould be performed on all cases of AMLDiagnostic: e.g., AML with recurring genetic abnormalityPrognostic: Favorable, intermediate, and unfavorable risk groups",
                    "sub_points": [
                      "Should be performed on all cases of AML",
                      "Diagnostic: e.g., AML with recurring genetic abnormality",
                      "Prognostic: Favorable, intermediate, and unfavorable risk groups"
                    ]
                  },
                  {
                    "text": "FISHRapid diagnosis of APLPerform as needed; essential if conventional karyotype failsDepending on morphologic suspicionMonocytic differentiation: InvestigateCBFB::MYH11andKMT2AtranslocationsConfirmation of cytogenetic findings as needed",
                    "sub_points": [
                      "Rapid diagnosis of APL",
                      "Perform as needed; essential if conventional karyotype failsDepending on morphologic suspicionMonocytic differentiation: InvestigateCBFB::MYH11andKMT2AtranslocationsConfirmation of cytogenetic findings as needed",
                      "Depending on morphologic suspicionMonocytic differentiation: InvestigateCBFB::MYH11andKMT2Atranslocations",
                      "Monocytic differentiation: InvestigateCBFB::MYH11andKMT2Atranslocations",
                      "Confirmation of cytogenetic findings as needed"
                    ]
                  },
                  {
                    "text": "Molecular geneticsMyeloid gene panel required for all cases; additional genetic tests often neededMust include all AML, MRG genes as well as othersFLT3should be assessed in all AMLsNPM1andFLT3can be assessed by PCR",
                    "sub_points": [
                      "Myeloid gene panel required for all cases; additional genetic tests often neededMust include all AML, MRG genes as well as others",
                      "Must include all AML, MRG genes as well as others",
                      "FLT3should be assessed in all AMLsNPM1andFLT3can be assessed by PCR",
                      "NPM1andFLT3can be assessed by PCR"
                    ]
                  }
                ]
              },
              "Reporting Criteria": {
                "Minimum Requirements": [
                  {
                    "text": "Use ICC &/or WHO-HAEM5 classification"
                  },
                  {
                    "text": "If feasible, issue integrated report to incorporate all genetic testing resultsPathologist must insure that all specialized testing results are available to treating physician",
                    "sub_points": [
                      "Pathologist must insure that all specialized testing results are available to treating physician"
                    ]
                  }
                ],
                "Communication of Results": [
                  {
                    "text": "New diagnosis, unsuspected relapse, suspected APL, associated DIC"
                  },
                  {
                    "text": "Prompt notification of clinician(s)"
                  }
                ]
              },
              "Differential Diagnosis": {
                "Recombinant G-CSF Therapy": [
                  {
                    "text": "Blast count may transiently exceed 20% in hypocellular specimen"
                  },
                  {
                    "text": "Transient phenomenon, nonclonal, no Auer rods"
                  }
                ],
                "Blast Phase or Transformation of Preexisting Myeloid Neoplasm": [
                  {
                    "text": "Clinical history required"
                  }
                ],
                "Other Subtype of Acute Leukemia": [
                  {
                    "text": "Acute lymphoblastic leukemia (ALL)"
                  },
                  {
                    "text": "Acute leukemia of ambiguous lineage (ALAL)"
                  },
                  {
                    "text": "Blastic plasmacytoid dendritic cell neoplasm (BPDCN)"
                  }
                ]
              },
              "Diagnostic Challenges": {
                "AML With Recurrent Genetic Abnormalities (ICC Criteria)": [
                  {
                    "text": "ICC ≥ 10% blast threshold overlaps with ICC MDS/AML cases, MPN in accelerated-phase cases, and chronic myelomonocytic leukemia-2 (CMML-2) cases"
                  },
                  {
                    "text": "Genetic assessment and clinical history are key in making these distinctions"
                  }
                ],
                "Hypocellular AML": [
                  {
                    "text": "Document ≥ 20% blasts by IHC if specimen inadequate for morphologic count or FCI"
                  }
                ],
                "Marked Increase in Erythroid Precursors (> 50% of Total Cells)": [
                  {
                    "text": "High-grade MDS vs. pure (acute) erythroid leukemiaPure erythroid leukemia (AML with mutatedTP53subtype in ICC), (acute erythroid leukemia in WHO-HAEM5)> 80% erythroid precursors> 30% of erythroid precursors are pronormoblastsMDS with abundant erythroid precursors (blasts < 20%)Myeloid blast count determined as percent of all nucleated elementsMDS often shows admixture of all stages of erythroid differentiation",
                    "sub_points": [
                      "Pure erythroid leukemia (AML with mutatedTP53subtype in ICC), (acute erythroid leukemia in WHO-HAEM5)> 80% erythroid precursors> 30% of erythroid precursors are pronormoblasts",
                      "> 80% erythroid precursors",
                      "> 30% of erythroid precursors are pronormoblasts",
                      "MDS with abundant erythroid precursors (blasts < 20%)Myeloid blast count determined as percent of all nucleated elementsMDS often shows admixture of all stages of erythroid differentiation",
                      "Myeloid blast count determined as percent of all nucleated elements",
                      "MDS often shows admixture of all stages of erythroid differentiation"
                    ]
                  },
                  {
                    "text": "Exclude nonneoplastic disordersNutritional deficiency (especially vitamin B12 or folate deficiency)Erythropoietin therapy",
                    "sub_points": [
                      "Nutritional deficiency (especially vitamin B12 or folate deficiency)",
                      "Erythropoietin therapy"
                    ]
                  }
                ],
                "Fibrosis": [
                  {
                    "text": "Often inaspirable"
                  },
                  {
                    "text": "More accurate blast count may require IHC: CD34, CD117"
                  },
                  {
                    "text": "Underlying hematologic malignancy may be masked"
                  }
                ],
                "CMML vs. AML With Monocytic Component": [
                  {
                    "text": "Bone marrow often shows higher proportion of immature cells than blood"
                  },
                  {
                    "text": "Bone marrow examination required for CMML cases by ICC criteria to avoid misdiagnosing blood as CMML when bone marrow shows AML"
                  }
                ],
                "AML vs. ALAL vs. ALL": [
                  {
                    "text": "AML cases commonly show aberrant antigen expression, such as CD19 or TdT, but these cases of otherwise straightforward AML donotquality as ALAL"
                  },
                  {
                    "text": "Aberrant expression of CD13, CD33 may occur in otherwise straightforward B-ALL"
                  },
                  {
                    "text": "Note that cases of B-ALL may show MPO positivity by either FCI or IHC staining"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Overview and Classification of Myelodysplastic Syndromes": {
            "name": "Overview and Classification of Myelodysplastic Syndromes",
            "url": "https://app.pathprimer.com/document/61d1e9a2-5291-402b-a0a5-e05d777965d5/lesson/6f665b6e-874b-46a5-9d19-463bafa93147",
            "content": {
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "International Consensus Classification (ICC)"
                  },
                  {
                    "text": "Myelodysplastic syndrome (MDS) (ICC)"
                  },
                  {
                    "text": "MDS/acute myeloid leukemia (MDS/AML) (ICC only)"
                  },
                  {
                    "text": "WHO 5th edition (WHO-HAEM5)"
                  },
                  {
                    "text": "Myelodysplastic neoplasm (MDN) (WHO-HAEM5)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "MDSs are heterogeneous group of genetically distinct entities that arise for antecedent clonal cytopenia of uncertain significance (CCUS) and haveVariable degrees of ineffective hematopoiesisOften hypercellular BMSimultaneous proliferation and apoptosis of hematopoietic cells< 20% blasts in blood or BMPeripheral blood (PB) with unexplained and persistent cytopenia(s)Can use local laboratory normal ranges to define cytopeniaOptimal to use IPSS values to define cytopenia(s)Hgb < 13 g, males; < 12 g, femalesAbsolute neutrophil count (ANC) < 1.8 x 10⁹/LPlatelet count < 150 x 10⁹/L< 0.5 x 10⁹/L monocytesDysplasia (≥ 10% of cells) in 1 or more hematopoietic lineagesGranulocytic, erythroid, megakaryocyticNeutrophil dysplasia most useful feature to assess in bloodRBC abnormalities common in many nonneoplastic disorders that may mimic MDSKey to assess all lineages for dysplasia in BM, including evaluation for micromegakaryocytes, about size of promyelocytesDysplasia usually present in genetically defined ICC subtypes but not required for diagnosisIncreased risk for development of AML",
                    "sub_points": [
                      "Variable degrees of ineffective hematopoiesisOften hypercellular BMSimultaneous proliferation and apoptosis of hematopoietic cells",
                      "Often hypercellular BM",
                      "Simultaneous proliferation and apoptosis of hematopoietic cells",
                      "< 20% blasts in blood or BM",
                      "Peripheral blood (PB) with unexplained and persistent cytopenia(s)Can use local laboratory normal ranges to define cytopeniaOptimal to use IPSS values to define cytopenia(s)Hgb < 13 g, males; < 12 g, femalesAbsolute neutrophil count (ANC) < 1.8 x 10⁹/LPlatelet count < 150 x 10⁹/L< 0.5 x 10⁹/L monocytes",
                      "Can use local laboratory normal ranges to define cytopenia",
                      "Optimal to use IPSS values to define cytopenia(s)Hgb < 13 g, males; < 12 g, femalesAbsolute neutrophil count (ANC) < 1.8 x 10⁹/LPlatelet count < 150 x 10⁹/L",
                      "Hgb < 13 g, males; < 12 g, females",
                      "Absolute neutrophil count (ANC) < 1.8 x 10⁹/L",
                      "Platelet count < 150 x 10⁹/L",
                      "< 0.5 x 10⁹/L monocytes",
                      "Dysplasia (≥ 10% of cells) in 1 or more hematopoietic lineagesGranulocytic, erythroid, megakaryocyticNeutrophil dysplasia most useful feature to assess in bloodRBC abnormalities common in many nonneoplastic disorders that may mimic MDSKey to assess all lineages for dysplasia in BM, including evaluation for micromegakaryocytes, about size of promyelocytesDysplasia usually present in genetically defined ICC subtypes but not required for diagnosis",
                      "Granulocytic, erythroid, megakaryocyticNeutrophil dysplasia most useful feature to assess in bloodRBC abnormalities common in many nonneoplastic disorders that may mimic MDSKey to assess all lineages for dysplasia in BM, including evaluation for micromegakaryocytes, about size of promyelocytes",
                      "Neutrophil dysplasia most useful feature to assess in blood",
                      "RBC abnormalities common in many nonneoplastic disorders that may mimic MDS",
                      "Key to assess all lineages for dysplasia in BM, including evaluation for micromegakaryocytes, about size of promyelocytes",
                      "Dysplasia usually present in genetically defined ICC subtypes but not required for diagnosis",
                      "Increased risk for development of AML"
                    ]
                  }
                ]
              },
              "Classifications and Comparisons": {
                "ICC System for Myelodysplastic Syndrome in Adults": [
                  {
                    "text": "For most MDS cases, diagnosis is based ondefiningcytogenetic or molecular criteria integrated with blast percentage in blood and BM in patient with sustained, unexplained cytopeniaMolecular genetic features thatdefinevarious ICC MDS entitiesMDS with mutatedSF3B1(normal blast percentages)withoutRUNX1or multihitTP53mutation, del(5q), -7/del(7q), or complex karyotypeVarious types ofTP53mutations with specific blast percentage criteriaBiallelicTP53mutations (multihit) and 0-9% blood/BM blasts inMDS with mutatedTP53[variant allele frequency (VAF) ≥ 10%]Monoallelic or biallelicTP53mutation (VAF ≥ 10%) inMDS/AML with mutatedTP53and 10-19% blasts in blood or BMMDS/AML with myelodysplasia-related gene mutationfor cases with 10-19% blastsASXL1,BCOR,EZH2,RUNX1,SF3B1,SRSF2,STAG2,U2AF1,ZRSR2(VAF ≥ 2%)Cytogenetic abnormalities thatdefineICC MDS entitiesMDS with del(5q)in case with normal blast percentages1 additional cytogenetic abnormality allowed, except any abnormality of chromosome 7MDS, NOS without dysplasia: MDS case with normal blast percentages and < 10% dysplasiaChromosome 7 abnormality or complex karyotype (≥ 3 separate abnormalities, excluding -Y)MDS/AML with myelodysplasia-related cytogenetic abnormalitiesin cases with 10-19% blastsdel(5q), -7, del(7q), or complex karyotype with ≥ 3 independent abnormalities, excluding -Y",
                    "sub_points": [
                      "Molecular genetic features thatdefinevarious ICC MDS entitiesMDS with mutatedSF3B1(normal blast percentages)withoutRUNX1or multihitTP53mutation, del(5q), -7/del(7q), or complex karyotypeVarious types ofTP53mutations with specific blast percentage criteriaBiallelicTP53mutations (multihit) and 0-9% blood/BM blasts inMDS with mutatedTP53[variant allele frequency (VAF) ≥ 10%]Monoallelic or biallelicTP53mutation (VAF ≥ 10%) inMDS/AML with mutatedTP53and 10-19% blasts in blood or BMMDS/AML with myelodysplasia-related gene mutationfor cases with 10-19% blastsASXL1,BCOR,EZH2,RUNX1,SF3B1,SRSF2,STAG2,U2AF1,ZRSR2(VAF ≥ 2%)",
                      "MDS with mutatedSF3B1(normal blast percentages)withoutRUNX1or multihitTP53mutation, del(5q), -7/del(7q), or complex karyotype",
                      "Various types ofTP53mutations with specific blast percentage criteriaBiallelicTP53mutations (multihit) and 0-9% blood/BM blasts inMDS with mutatedTP53[variant allele frequency (VAF) ≥ 10%]Monoallelic or biallelicTP53mutation (VAF ≥ 10%) inMDS/AML with mutatedTP53and 10-19% blasts in blood or BM",
                      "BiallelicTP53mutations (multihit) and 0-9% blood/BM blasts inMDS with mutatedTP53[variant allele frequency (VAF) ≥ 10%]",
                      "Monoallelic or biallelicTP53mutation (VAF ≥ 10%) inMDS/AML with mutatedTP53and 10-19% blasts in blood or BM",
                      "MDS/AML with myelodysplasia-related gene mutationfor cases with 10-19% blastsASXL1,BCOR,EZH2,RUNX1,SF3B1,SRSF2,STAG2,U2AF1,ZRSR2(VAF ≥ 2%)",
                      "ASXL1,BCOR,EZH2,RUNX1,SF3B1,SRSF2,STAG2,U2AF1,ZRSR2(VAF ≥ 2%)",
                      "Cytogenetic abnormalities thatdefineICC MDS entitiesMDS with del(5q)in case with normal blast percentages1 additional cytogenetic abnormality allowed, except any abnormality of chromosome 7MDS, NOS without dysplasia: MDS case with normal blast percentages and < 10% dysplasiaChromosome 7 abnormality or complex karyotype (≥ 3 separate abnormalities, excluding -Y)MDS/AML with myelodysplasia-related cytogenetic abnormalitiesin cases with 10-19% blastsdel(5q), -7, del(7q), or complex karyotype with ≥ 3 independent abnormalities, excluding -Y",
                      "MDS with del(5q)in case with normal blast percentages1 additional cytogenetic abnormality allowed, except any abnormality of chromosome 7",
                      "1 additional cytogenetic abnormality allowed, except any abnormality of chromosome 7",
                      "MDS, NOS without dysplasia: MDS case with normal blast percentages and < 10% dysplasiaChromosome 7 abnormality or complex karyotype (≥ 3 separate abnormalities, excluding -Y)",
                      "Chromosome 7 abnormality or complex karyotype (≥ 3 separate abnormalities, excluding -Y)",
                      "MDS/AML with myelodysplasia-related cytogenetic abnormalitiesin cases with 10-19% blastsdel(5q), -7, del(7q), or complex karyotype with ≥ 3 independent abnormalities, excluding -Y",
                      "del(5q), -7, del(7q), or complex karyotype with ≥ 3 independent abnormalities, excluding -Y"
                    ]
                  },
                  {
                    "text": "Remaining ICC MDS cases lackdefininggenetic abnormality, but karyotype and molecular can still be abnormalFor cases with low blasts: MDS, NOS with single or multilineage dysplasiaIf 2-9% PB blasts or 5-9% BM blasts or Auer rods: MDS-EB in patients ≥ 18 years of ageIf blasts 10-19% in blood or BM: MDS/AML, NOS",
                    "sub_points": [
                      "For cases with low blasts: MDS, NOS with single or multilineage dysplasia",
                      "If 2-9% PB blasts or 5-9% BM blasts or Auer rods: MDS-EB in patients ≥ 18 years of age",
                      "If blasts 10-19% in blood or BM: MDS/AML, NOS"
                    ]
                  },
                  {
                    "text": "Dysplasia in ≥ 10% of HP lineage isnolonger requiredfor MDS cases meeting cytogenetic or molecular criteria for specific ICC MDS subtypes but is required for caseslackingdefiningcytogenetics or molecular mutationsMDS, NOS with single or multilineage dysplasia, and MDS-EB",
                    "sub_points": [
                      "MDS, NOS with single or multilineage dysplasia, and MDS-EB"
                    ]
                  },
                  {
                    "text": "Criteria apply to diagnostic PB and BM specimens prior to any definitive therapy"
                  },
                  {
                    "text": "ICC does not recognize therapy-related or germline mutation-associated neoplasms as separate entities but as qualifiersApply ICC diagnosis and specify \"in the setting of germline mutation\" or \"therapy-related\" as qualifier",
                    "sub_points": [
                      "Apply ICC diagnosis and specify \"in the setting of germline mutation\" or \"therapy-related\" as qualifier"
                    ]
                  }
                ],
                "WHO-HAEM5": [
                  {
                    "text": "Fewer WHO genetic categories than ICC, especially for MDN cases with increased (excess) blastsMDN-IB1 (increased blasts) and MDN-IB2",
                    "sub_points": [
                      "MDN-IB1 (increased blasts) and MDN-IB2"
                    ]
                  },
                  {
                    "text": "Retention of WHO MDN-IB2 categorydiffersfrom 4 ICC MDS/AML entities with similar blast percentage thresholds"
                  },
                  {
                    "text": "Criteria apply to diagnostic PB and BM specimens prior to any definitive therapy"
                  }
                ],
                "Myelodysplastic Syndrome in Children": [
                  {
                    "text": "ICC retains refractory cytopenia of childhood (RCC) and adds MDS, NOS and MDS-EB"
                  },
                  {
                    "text": "WHO-HAEM5 lists childhood (c) MDN-low blasts, hypocellular, cMDN-low blasts, NOS, and cMDN-IB"
                  }
                ]
              },
              "EPIDEMIOLOGY": {
                "Age Range": [
                  {
                    "text": "Primarily disease of older adultsMedian age: 70 years in western countriesAnnual incidence of ~ 30-40/100,000 among those aged > 70 years~ 10% of MDS cases linked to germline predisposition, even in older patientsPrecedes or related to majority of AML cases in older adultsMedian age: ~ 10 years younger in Asian countries",
                    "sub_points": [
                      "Median age: 70 years in western countriesAnnual incidence of ~ 30-40/100,000 among those aged > 70 years~ 10% of MDS cases linked to germline predisposition, even in older patientsPrecedes or related to majority of AML cases in older adults",
                      "Annual incidence of ~ 30-40/100,000 among those aged > 70 years~ 10% of MDS cases linked to germline predisposition, even in older patients",
                      "~ 10% of MDS cases linked to germline predisposition, even in older patients",
                      "Precedes or related to majority of AML cases in older adults",
                      "Median age: ~ 10 years younger in Asian countries"
                    ]
                  },
                  {
                    "text": "Only ~ 10% of MDS patients are < 50 years of ageRare among childrenOften associated with genetic propensity disorder or linked to prior cytotoxic therapy (diagnosis qualifiers in ICC)",
                    "sub_points": [
                      "Rare among childrenOften associated with genetic propensity disorder or linked to prior cytotoxic therapy (diagnosis qualifiers in ICC)",
                      "Often associated with genetic propensity disorder or linked to prior cytotoxic therapy (diagnosis qualifiers in ICC)"
                    ]
                  }
                ],
                "Sex": [
                  {
                    "text": "M:F = 1.8:1Exception is MDS with del(5q), which has female predominance",
                    "sub_points": [
                      "Exception is MDS with del(5q), which has female predominance"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Histogenesis": [
                  {
                    "text": "Precursor lesion is clonal hematopoiesis (CH) resulting from aging-related accumulation of genetic damageHematopoietic stem cell mutationIf linked to sustained cytopenia, it is called CCUSSubset of CCUS cases acquire additional genetic abnormalities that confer cell survival/proliferation advantages and evolve to MDS",
                    "sub_points": [
                      "Hematopoietic stem cell mutation",
                      "If linked to sustained cytopenia, it is called CCUS",
                      "Subset of CCUS cases acquire additional genetic abnormalities that confer cell survival/proliferation advantages and evolve to MDS"
                    ]
                  },
                  {
                    "text": "Clonal evolution of MDS develops with additional mutations (clonal selection)Transformation to high-grade MDS and AML (secondary AML)",
                    "sub_points": [
                      "Transformation to high-grade MDS and AML (secondary AML)"
                    ]
                  },
                  {
                    "text": "MDS-associated mutations affect genes related to specific functional pathwaysSpliceosome machinery (seen in > 50% MDS)SF3B1,SRSF2,U2AF2,ZRSR2,U2AF1, etc.SF3B1mutation is associated with ring sideroblastsDNA methylation:TET2,DNMT3ATranscription regulation:RUNX1,ETV6,BCORChromatin modification:ASXL1,EZH2, etc.Cell signaling/kinases:NRAS,CBL,KRAS, etc.DNA repair control:TP53Cohesin complex:STAG2, etc.Mutations listed adversely impact survival in many studiesException isSF3B1, which is linked to favorable outcome in cases with low blast percentage",
                    "sub_points": [
                      "Spliceosome machinery (seen in > 50% MDS)SF3B1,SRSF2,U2AF2,ZRSR2,U2AF1, etc.SF3B1mutation is associated with ring sideroblasts",
                      "SF3B1,SRSF2,U2AF2,ZRSR2,U2AF1, etc.",
                      "SF3B1mutation is associated with ring sideroblasts",
                      "DNA methylation:TET2,DNMT3A",
                      "Transcription regulation:RUNX1,ETV6,BCOR",
                      "Chromatin modification:ASXL1,EZH2, etc.",
                      "Cell signaling/kinases:NRAS,CBL,KRAS, etc.",
                      "DNA repair control:TP53",
                      "Cohesin complex:STAG2, etc.",
                      "Mutations listed adversely impact survival in many studiesException isSF3B1, which is linked to favorable outcome in cases with low blast percentage",
                      "Exception isSF3B1, which is linked to favorable outcome in cases with low blast percentage"
                    ]
                  }
                ]
              },
              "CLINICAL IMPLICATIONS": {
                "Clinical Presentation": [
                  {
                    "text": "Individuals present with symptoms relating to cytopenia(s)Anemia, most common finding in adults, leads to pallor, weakness, fatigueNeutropenia leads to recurrent infectionsThrombocytopenia leads to bleeding, petechiae",
                    "sub_points": [
                      "Anemia, most common finding in adults, leads to pallor, weakness, fatigue",
                      "Neutropenia leads to recurrent infections",
                      "Thrombocytopenia leads to bleeding, petechiae"
                    ]
                  },
                  {
                    "text": "Childhood MDSMore likely to present with neutropenia or thrombocytopenia than isolated anemia",
                    "sub_points": [
                      "More likely to present with neutropenia or thrombocytopenia than isolated anemia"
                    ]
                  }
                ],
                "Clinical Risk Factors": [
                  {
                    "text": "Highly variable clinical courseRanges from indolent subtypes to forms that are biologically indistinguishable from overt AMLThese cases are termed MDS/AML by ICC criteriaRequires risk-adapted treatment strategy",
                    "sub_points": [
                      "Ranges from indolent subtypes to forms that are biologically indistinguishable from overt AMLThese cases are termed MDS/AML by ICC criteria",
                      "These cases are termed MDS/AML by ICC criteria",
                      "Requires risk-adapted treatment strategy"
                    ]
                  },
                  {
                    "text": "Major risk factor for low-risk MDS is age at diagnosisComorbidities increase with ageDecreased effectiveness of treatment in older adults or patients with significant comorbidities",
                    "sub_points": [
                      "Comorbidities increase with age",
                      "Decreased effectiveness of treatment in older adults or patients with significant comorbidities"
                    ]
                  },
                  {
                    "text": "International Prognostic Scoring System-Molecular (IPSS-M) has greater utility than IPSS-R in predicting outcomeContinuous index defined as weighted sum of prognostic variables(https://mds-risk-model.com)Based on hemoglobin, platelet count, BM blast percentage, IPSS-R cytogenetic category, and specific somatic gene mutations (type and number)Score of 0 represents \"average\" patientNegative score is favorable; positive score is adverse",
                    "sub_points": [
                      "Continuous index defined as weighted sum of prognostic variables(https://mds-risk-model.com)",
                      "Based on hemoglobin, platelet count, BM blast percentage, IPSS-R cytogenetic category, and specific somatic gene mutations (type and number)",
                      "Score of 0 represents \"average\" patient",
                      "Negative score is favorable; positive score is adverse"
                    ]
                  },
                  {
                    "text": "Additional factors that also impact prognosisLactate dehydrogenase, ferritin, and β-2-microglobulin levelsPatient performance status, age",
                    "sub_points": [
                      "Lactate dehydrogenase, ferritin, and β-2-microglobulin levels",
                      "Patient performance status, age"
                    ]
                  }
                ],
                "International Prognostic Scoring System-Revised (IPSS-R) used to stratify patients into risk groups": [
                  {
                    "text": "Based on depth of cytopenia(s), percentage of BM blasts, and cytogenetic abnormalitiesUseful for predicting survival and risk of leukemic transformation for adults",
                    "sub_points": [
                      "Useful for predicting survival and risk of leukemic transformation for adults"
                    ]
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "Conventional cytogenetic analysisRequires adequate BM aspirate specimenMay need to disaggregate trephine biopsy if fibrotic or packed marrowEssential during initial evaluation to establish baseline karyotype45-50% of patients have clonal abnormalityMost common are gains or losses of large chromosome segment [i.e., -5, del(5q), -7, +8]Clonal evolution linked to transformation to MDS/AML or overt AML (≥ 20% blasts)Adverse karyotypes more frequent in MDS/AMLComplex (≥ 3 abnormalities) and monosomal karyotypes",
                    "sub_points": [
                      "Requires adequate BM aspirate specimenMay need to disaggregate trephine biopsy if fibrotic or packed marrow",
                      "May need to disaggregate trephine biopsy if fibrotic or packed marrow",
                      "Essential during initial evaluation to establish baseline karyotype45-50% of patients have clonal abnormalityMost common are gains or losses of large chromosome segment [i.e., -5, del(5q), -7, +8]Clonal evolution linked to transformation to MDS/AML or overt AML (≥ 20% blasts)",
                      "45-50% of patients have clonal abnormality",
                      "Most common are gains or losses of large chromosome segment [i.e., -5, del(5q), -7, +8]",
                      "Clonal evolution linked to transformation to MDS/AML or overt AML (≥ 20% blasts)",
                      "Adverse karyotypes more frequent in MDS/AMLComplex (≥ 3 abnormalities) and monosomal karyotypes",
                      "Complex (≥ 3 abnormalities) and monosomal karyotypes"
                    ]
                  },
                  {
                    "text": "FISHHelpful if insufficient conventional cytogenetic study (i.e., < 20 metaphases)Can perform on BM touch preparations, aspirate smears, or remaining cytogenetic cell pellet",
                    "sub_points": [
                      "Helpful if insufficient conventional cytogenetic study (i.e., < 20 metaphases)Can perform on BM touch preparations, aspirate smears, or remaining cytogenetic cell pellet",
                      "Can perform on BM touch preparations, aspirate smears, or remaining cytogenetic cell pellet"
                    ]
                  },
                  {
                    "text": "Molecular genetic testingNext-generation sequencing (NGS) used to assess multiple genes simultaneouslyMutation detected in > 90% of cases when NGS and cytogenetic abnormalities are combinedMultiple ICC MDS subtypes defined by specific gene mutation(s)SF3B1,TP53, many other mutations impact prognosis in MDSKey component of IPSS-M risk stratification",
                    "sub_points": [
                      "Next-generation sequencing (NGS) used to assess multiple genes simultaneouslyMutation detected in > 90% of cases when NGS and cytogenetic abnormalities are combinedMultiple ICC MDS subtypes defined by specific gene mutation(s)SF3B1,TP53, many other mutations impact prognosis in MDS",
                      "Mutation detected in > 90% of cases when NGS and cytogenetic abnormalities are combined",
                      "Multiple ICC MDS subtypes defined by specific gene mutation(s)",
                      "SF3B1,TP53, many other mutations impact prognosis in MDS",
                      "Key component of IPSS-M risk stratification"
                    ]
                  },
                  {
                    "text": "Flow cytometric analysis (recommended but not required)Screen for increased CD34 or CD117(+) blasts and abnormal featuresCoexpression of CD7, CD56, CD10, CD11b, or CD15 on blastsAbnormal intensity of antigen expression, i.e., increased CD117 and CD13 on CD34(+) blastsAbsence of CD33, CD13, or HLA-DR on blast populationAbsence of significant hematogone populationPossible discordance with BM blast percentagesHemodilution (especially for fibrotic marrow)Lysis of RBCs, including many erythroid lineage precursorsEvaluate for aberrant maturation patterns or antigen expressionHighly suggestive for MDS only if ≥ 3 aberrant features in erythroid, neutrophilic myeloid, or monocytic populationsAberrant maturation patterns are often associated with morphologic findingsAbnormal granulocyte pattern with CD13 and CD16Abnormally low side scatter by granulocytes due to cytoplasmic hypogranularityLack of CD10 expression on neutrophilsGain of abnormal antigens, i.e., abnormal CD56, CD19, CD7, CD5 on myeloid or monocytic cellsReevaluate case over several months if highly suggestive for MDS but other findings are inconclusive",
                    "sub_points": [
                      "Screen for increased CD34 or CD117(+) blasts and abnormal featuresCoexpression of CD7, CD56, CD10, CD11b, or CD15 on blastsAbnormal intensity of antigen expression, i.e., increased CD117 and CD13 on CD34(+) blastsAbsence of CD33, CD13, or HLA-DR on blast populationAbsence of significant hematogone population",
                      "Coexpression of CD7, CD56, CD10, CD11b, or CD15 on blasts",
                      "Abnormal intensity of antigen expression, i.e., increased CD117 and CD13 on CD34(+) blasts",
                      "Absence of CD33, CD13, or HLA-DR on blast population",
                      "Absence of significant hematogone population",
                      "Possible discordance with BM blast percentagesHemodilution (especially for fibrotic marrow)Lysis of RBCs, including many erythroid lineage precursors",
                      "Hemodilution (especially for fibrotic marrow)",
                      "Lysis of RBCs, including many erythroid lineage precursors",
                      "Evaluate for aberrant maturation patterns or antigen expressionHighly suggestive for MDS only if ≥ 3 aberrant features in erythroid, neutrophilic myeloid, or monocytic populationsAberrant maturation patterns are often associated with morphologic findingsAbnormal granulocyte pattern with CD13 and CD16Abnormally low side scatter by granulocytes due to cytoplasmic hypogranularityLack of CD10 expression on neutrophilsGain of abnormal antigens, i.e., abnormal CD56, CD19, CD7, CD5 on myeloid or monocytic cellsReevaluate case over several months if highly suggestive for MDS but other findings are inconclusive",
                      "Highly suggestive for MDS only if ≥ 3 aberrant features in erythroid, neutrophilic myeloid, or monocytic populations",
                      "Aberrant maturation patterns are often associated with morphologic findingsAbnormal granulocyte pattern with CD13 and CD16Abnormally low side scatter by granulocytes due to cytoplasmic hypogranularityLack of CD10 expression on neutrophils",
                      "Abnormal granulocyte pattern with CD13 and CD16",
                      "Abnormally low side scatter by granulocytes due to cytoplasmic hypogranularity",
                      "Lack of CD10 expression on neutrophils",
                      "Gain of abnormal antigens, i.e., abnormal CD56, CD19, CD7, CD5 on myeloid or monocytic cells",
                      "Reevaluate case over several months if highly suggestive for MDS but other findings are inconclusive"
                    ]
                  },
                  {
                    "text": "Immunohistochemistryon BM core biopsy (or clot) sectionsCD34 for blasts; CD117 if blasts are CD34(-)Quantify blasts; evaluate for aggregation or clusteringParticularly helpful for hypoplastic or fibrotic marrowsMyeloperoxidase or CD33Quantify myeloid lineageAbnormal localization of immature precursorsHemoglobin A, glycophorin, or CD71Quantify erythroid lineageDisruption of normal erythroid colony formationCD61 or CD42bQuantify megakaryocytesAbnormal megakaryocytic clustering, size, or paratrabecular localizationMicromegakaryocytes in range of promyelocyte size are particularly useful in establishing megakaryocyte lineage dysplasia",
                    "sub_points": [
                      "CD34 for blasts; CD117 if blasts are CD34(-)Quantify blasts; evaluate for aggregation or clusteringParticularly helpful for hypoplastic or fibrotic marrows",
                      "Quantify blasts; evaluate for aggregation or clustering",
                      "Particularly helpful for hypoplastic or fibrotic marrows",
                      "Myeloperoxidase or CD33Quantify myeloid lineageAbnormal localization of immature precursors",
                      "Quantify myeloid lineage",
                      "Abnormal localization of immature precursors",
                      "Hemoglobin A, glycophorin, or CD71Quantify erythroid lineageDisruption of normal erythroid colony formation",
                      "Quantify erythroid lineage",
                      "Disruption of normal erythroid colony formation",
                      "CD61 or CD42bQuantify megakaryocytesAbnormal megakaryocytic clustering, size, or paratrabecular localizationMicromegakaryocytes in range of promyelocyte size are particularly useful in establishing megakaryocyte lineage dysplasia",
                      "Quantify megakaryocytes",
                      "Abnormal megakaryocytic clustering, size, or paratrabecular localizationMicromegakaryocytes in range of promyelocyte size are particularly useful in establishing megakaryocyte lineage dysplasia",
                      "Micromegakaryocytes in range of promyelocyte size are particularly useful in establishing megakaryocyte lineage dysplasia"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "Low- and intermediate-risk MDSObservation alone if asymptomatic with relatively preserved blood countsIf symptomatic due to cytopenia(s)Anemia: RBC transfusions, erythropoiesis-stimulating agentsNeutropenia: Antimicrobial prophylaxis, G-CSFThrombocytopenia: Platelet transfusions, anabolic steroids, thrombopoietin receptor agonistsVariety of treatment options for MDSHypomethylating agent (HMA): Standard of careAzacytidine, decitiabineVenetoclax (BCL2 inhibitor) therapyClinical trial using novel agents",
                    "sub_points": [
                      "Observation alone if asymptomatic with relatively preserved blood counts",
                      "If symptomatic due to cytopenia(s)Anemia: RBC transfusions, erythropoiesis-stimulating agentsNeutropenia: Antimicrobial prophylaxis, G-CSFThrombocytopenia: Platelet transfusions, anabolic steroids, thrombopoietin receptor agonists",
                      "Anemia: RBC transfusions, erythropoiesis-stimulating agents",
                      "Neutropenia: Antimicrobial prophylaxis, G-CSF",
                      "Thrombocytopenia: Platelet transfusions, anabolic steroids, thrombopoietin receptor agonists",
                      "Variety of treatment options for MDSHypomethylating agent (HMA): Standard of careAzacytidine, decitiabineVenetoclax (BCL2 inhibitor) therapyClinical trial using novel agents",
                      "Hypomethylating agent (HMA): Standard of careAzacytidine, decitiabine",
                      "Azacytidine, decitiabine",
                      "Venetoclax (BCL2 inhibitor) therapy",
                      "Clinical trial using novel agents"
                    ]
                  },
                  {
                    "text": "High-risk MDSASCT only curative optionConsider age (< 70 years), comorbidity indexEnroll in clinical trials using novel agentsPatients with mutatedTP53currently have poor outcome even with transplantation",
                    "sub_points": [
                      "ASCT only curative optionConsider age (< 70 years), comorbidity index",
                      "Consider age (< 70 years), comorbidity index",
                      "Enroll in clinical trials using novel agentsPatients with mutatedTP53currently have poor outcome even with transplantation",
                      "Patients with mutatedTP53currently have poor outcome even with transplantation"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Median survival time and risk for AML is based on IPSS-R/IPSS-M risk stratificationsPrimary cause of deathAML in high-risk MDSComplications from BM failure and comorbidities in lower risk MDS",
                    "sub_points": [
                      "Primary cause of deathAML in high-risk MDSComplications from BM failure and comorbidities in lower risk MDS",
                      "AML in high-risk MDS",
                      "Complications from BM failure and comorbidities in lower risk MDS"
                    ]
                  },
                  {
                    "text": "Secondary AML develops in ~ 30% of MDS cases"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Peripheral Blood": [
                  {
                    "text": "Cytopenias (percentage of cases)Anemia (85%); hemoglobin < 10 g/dLNeutropenia (40%); consider ethnic variation in reference rangesThrombocytopenia (30%)Pancytopenia (15%)",
                    "sub_points": [
                      "Anemia (85%); hemoglobin < 10 g/dL",
                      "Neutropenia (40%); consider ethnic variation in reference ranges",
                      "Thrombocytopenia (30%)",
                      "Pancytopenia (15%)"
                    ]
                  },
                  {
                    "text": "Evaluate blast percentageBased on 200-cell leukocyte differential countBlast morphology defined by International Working Group on Morphology of MDS DeterminationBlasts in blood common in higher grade MDS",
                    "sub_points": [
                      "Based on 200-cell leukocyte differential countBlast morphology defined by International Working Group on Morphology of MDS Determination",
                      "Blast morphology defined by International Working Group on Morphology of MDS Determination",
                      "Blasts in blood common in higher grade MDS"
                    ]
                  },
                  {
                    "text": "Evaluate for dysplasia (must exceed 10% threshold only in cases thatlackdefining genetic abnormality in ICC)RBCs, granulocytes, plateletsProvide percentage dysplasia and describe unique featuresTP53,ASXL1,RUNX1,SRSF2mutations associated with severe granulocytic dysplasiaTP53mutation: Pseudo-Pelger-Huët nuclei, neutrophils with small cytoplasmic vacuoles",
                    "sub_points": [
                      "RBCs, granulocytes, plateletsProvide percentage dysplasia and describe unique features",
                      "Provide percentage dysplasia and describe unique features",
                      "TP53,ASXL1,RUNX1,SRSF2mutations associated with severe granulocytic dysplasiaTP53mutation: Pseudo-Pelger-Huët nuclei, neutrophils with small cytoplasmic vacuoles",
                      "TP53mutation: Pseudo-Pelger-Huët nuclei, neutrophils with small cytoplasmic vacuoles"
                    ]
                  }
                ],
                "Bone Marrow": [
                  {
                    "text": "Aspirate or touch preparationsPerform 500-cell leukocyte differential countBlast percentage based on manual differential count; not flow cytometric analysisInclude all cells in count except neoplastic lymphocytes, plasma cellsDysplasia in ≥ 10% of cell lineage thresholdRequires high-quality smears/preparationsDo not perform on specimens exposed to anticoagulants for > 2 hours before smear preparation",
                    "sub_points": [
                      "Perform 500-cell leukocyte differential countBlast percentage based on manual differential count; not flow cytometric analysisInclude all cells in count except neoplastic lymphocytes, plasma cells",
                      "Blast percentage based on manual differential count; not flow cytometric analysis",
                      "Include all cells in count except neoplastic lymphocytes, plasma cells",
                      "Dysplasia in ≥ 10% of cell lineage thresholdRequires high-quality smears/preparationsDo not perform on specimens exposed to anticoagulants for > 2 hours before smear preparation",
                      "Requires high-quality smears/preparations",
                      "Do not perform on specimens exposed to anticoagulants for > 2 hours before smear preparation"
                    ]
                  },
                  {
                    "text": "BM trephine biopsy and clot sectionsBiopsy adequate if 1.5 cm in lengthCellularityUsually hypercellular or normocellular with ineffective hematopoiesisErythroid hyperplasia is commonHypocellular in ~ 10% of adults, ~ 70% of childrenHypocellular if < 30% or < 20% cellular at diagnosis and < 60 or ≥ 60 years old, respectivelyBlasts in aggregates (3-5 cells) or clusters (> 5 cells) by CD34 stainAssociated with MDS if localized away from vascular structures or bony trabeculaeBlasts primarily myeloblasts; other blast types infrequentMegakaryocyte dysplasia may be better appreciated in biopsy sections than aspirate smearsEvaluation of ≥ 30 megakaryocytes is required (includes aspirate smears and touch preparations)Micromegakaryocytes are relatively specific for MDSHigher specificity for MDS than other types of megakaryocyte dysplasia",
                    "sub_points": [
                      "Biopsy adequate if 1.5 cm in length",
                      "CellularityUsually hypercellular or normocellular with ineffective hematopoiesisErythroid hyperplasia is commonHypocellular in ~ 10% of adults, ~ 70% of childrenHypocellular if < 30% or < 20% cellular at diagnosis and < 60 or ≥ 60 years old, respectively",
                      "Usually hypercellular or normocellular with ineffective hematopoiesis",
                      "Erythroid hyperplasia is common",
                      "Hypocellular in ~ 10% of adults, ~ 70% of children",
                      "Hypocellular if < 30% or < 20% cellular at diagnosis and < 60 or ≥ 60 years old, respectively",
                      "Blasts in aggregates (3-5 cells) or clusters (> 5 cells) by CD34 stainAssociated with MDS if localized away from vascular structures or bony trabeculaeBlasts primarily myeloblasts; other blast types infrequent",
                      "Associated with MDS if localized away from vascular structures or bony trabeculae",
                      "Blasts primarily myeloblasts; other blast types infrequent",
                      "Megakaryocyte dysplasia may be better appreciated in biopsy sections than aspirate smearsEvaluation of ≥ 30 megakaryocytes is required (includes aspirate smears and touch preparations)Micromegakaryocytes are relatively specific for MDSHigher specificity for MDS than other types of megakaryocyte dysplasia",
                      "Evaluation of ≥ 30 megakaryocytes is required (includes aspirate smears and touch preparations)",
                      "Micromegakaryocytes are relatively specific for MDSHigher specificity for MDS than other types of megakaryocyte dysplasia",
                      "Higher specificity for MDS than other types of megakaryocyte dysplasia"
                    ]
                  }
                ],
                "General Features": [
                  {
                    "text": "Most morphologic features are not unique or pathognomonic of MDS"
                  }
                ]
              },
              "Differential Diagnosis": {
                "Idiopathic Cytopenia of Uncertain Significance": [
                  {
                    "text": "Patient with sustained cytopenia(s)Cytopenia ≥ 1 lineage without significant dysplasia or increased blastsNo genetic abnormality detected",
                    "sub_points": [
                      "Cytopenia ≥ 1 lineage without significant dysplasia or increased blasts",
                      "No genetic abnormality detected"
                    ]
                  }
                ],
                "Clonal Cytopenia of Uncertain Significance": [
                  {
                    "text": "Unexplained, sustained cytopenia without significant dysplasia or increased blasts"
                  },
                  {
                    "text": "Clonal gene mutation or, much less often, clonal cytogenetic abnormality (not MDS associated)"
                  },
                  {
                    "text": "Criteria for MDSnotmet"
                  }
                ],
                "Reactive Disorders With Dysplasia": [
                  {
                    "text": "Nutrient deficiency: Vitamin B12, folate, copper"
                  },
                  {
                    "text": "Infection: HIV, EBV, parvovirus, CMV"
                  },
                  {
                    "text": "Chemotherapy or multiple medications"
                  },
                  {
                    "text": "Toxins: Alcohol, heavy metal poisoning (particularly arsenic)"
                  },
                  {
                    "text": "Autoimmune disorders: SLE, collagen vascular disordersMay induce myelofibrosis",
                    "sub_points": [
                      "May induce myelofibrosis"
                    ]
                  }
                ],
                "Other Myeloid Neoplasm": [
                  {
                    "text": "AML with ≥ 10% blasts and ICC-defined recurrent genetic abnormality"
                  },
                  {
                    "text": "MDS/MPN"
                  }
                ],
                "Congenital (Germline) Disorders": [
                  {
                    "text": "Congenital dyserythropoietic anemia, congenital sideroblastic anemias"
                  },
                  {
                    "text": "Familial MDN (germline predisposition)These patients may get bona fide MDS during lifetime",
                    "sub_points": [
                      "These patients may get bona fide MDS during lifetime"
                    ]
                  }
                ],
                "VEXAS Syndrome": [
                  {
                    "text": "Acquired somatic mutation inUBA1in older men"
                  },
                  {
                    "text": "Associated with cytopenias, severe autoimmune symptoms, and vacuoles in erythroid and myeloid precursors"
                  },
                  {
                    "text": "May develop overt MDS usually associated with additional genetic abnormalities"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Overview of Myeloproliferative Neoplasms": {
            "name": "Overview of Myeloproliferative Neoplasms",
            "url": "https://app.pathprimer.com/document/48e2882a-1979-4645-880b-11a9aca79678/lesson/6f665b6e-874b-46a5-9d19-463bafa93147",
            "content": {
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Myeloproliferative neoplasms (MPNs)"
                  },
                  {
                    "text": "International Consensus Classification (ICC)"
                  },
                  {
                    "text": "WHO 5th edition (WHO-HAEM5)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Chronic myeloproliferative disorders (CMPD)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Clonal hematopoietic (HP) neoplasm characterized by bone marrow hypercellularity and intact maturation with effective hematopoieses, resulting in elevations of ≥ 1 HP lineages in bloodMyeloblasts not substantially increased, and dysplasia is not significant in chronic phase of MPNMolecular genetic abnormalities are present in MPN and define several subtypesMutation status also predictive of outcomeMutations in tyrosine kinase genes in most MPNs~ 5-8% of classic (JAK2-predominant) MPN cases are unclassifiable",
                    "sub_points": [
                      "Myeloblasts not substantially increased, and dysplasia is not significant in chronic phase of MPN",
                      "Molecular genetic abnormalities are present in MPN and define several subtypesMutation status also predictive of outcome",
                      "Mutation status also predictive of outcome",
                      "Mutations in tyrosine kinase genes in most MPNs",
                      "~ 5-8% of classic (JAK2-predominant) MPN cases are unclassifiable"
                    ]
                  }
                ]
              },
              "Classification": {
                "ICC/WHO-HAEM5 Classification of MPN Into 4 Broad Categories": [
                  {
                    "text": "1 MPN defined byBCR::ABL1fusion:Chronic myeloid leukemia (CML)"
                  },
                  {
                    "text": "4JAK2mutation-predominant (classic) MPNs:Polycythemia vera(PV), essential thrombocythemia (ET), primary myelofibrosis (PMF), andMPN, unclassifiable(MPN-U)"
                  },
                  {
                    "text": "1CSF3Rmutation-associated MPN:Chronic neutrophilic leukemia (CNL)"
                  },
                  {
                    "text": "1 eosinophilia-related MPN:Chronic eosinophilic leukemia, not otherwise specified (CEL, NOS)"
                  },
                  {
                    "text": "MPN-UCases do not fulfill criteria for other MPN but have many features or overlapping features of MPNsUsually has features ofJAK2mutation-predominant (classic) MPN",
                    "sub_points": [
                      "Cases do not fulfill criteria for other MPN but have many features or overlapping features of MPNsUsually has features ofJAK2mutation-predominant (classic) MPN",
                      "Usually has features ofJAK2mutation-predominant (classic) MPN"
                    ]
                  }
                ],
                "ICC and WHO-HAEM5 Classification Comparisons": [
                  {
                    "text": "Many similarities between ICC and WHO-HAEM5 MPN entities and diagnostic criteria"
                  },
                  {
                    "text": "ICC includes accelerated phase (AP) for CML, while WHO-HAEM5 does not include APWHO-HAEM5 considers CML biphasic disease (chronic and blast phase) in era of tyrosine kinase inhibitor (TKI) therapy",
                    "sub_points": [
                      "WHO-HAEM5 considers CML biphasic disease (chronic and blast phase) in era of tyrosine kinase inhibitor (TKI) therapy"
                    ]
                  },
                  {
                    "text": "WHO-HAEM5 includes juvenile myelomonocytic leukemia (JMML) in MPN category, while ICC includes JMML in new pediatric &/or germline mutation-associated disorders category"
                  }
                ]
              },
              "EPIDEMIOLOGY": {
                "Age Range": [
                  {
                    "text": "MPNs predominate in middle-aged to older adults"
                  },
                  {
                    "text": "Rare presentations in children (CML most common)"
                  }
                ],
                "Sex": [
                  {
                    "text": "No striking predilection"
                  }
                ],
                "Ethnicity Relationship": [
                  {
                    "text": "No striking ethnic predilection"
                  }
                ],
                "Incidence": [
                  {
                    "text": "Rates for MPN subtypes range from rare case reports of CNL to 1-2 cases per 100,000 for CML and ET"
                  }
                ],
                "Natural History/Disease Course": [
                  {
                    "text": "Disease course best delineated for CML, PV, PMF, and ET"
                  },
                  {
                    "text": "ET often very indolent, requiring minimal antithrombotic therapy; prolonged survival times (> 25 years)Low rate of either fibrotic progression (< 10%) or progression to myelodysplasia or acute myeloid leukemia (< 5%)",
                    "sub_points": [
                      "Low rate of either fibrotic progression (< 10%) or progression to myelodysplasia or acute myeloid leukemia (< 5%)"
                    ]
                  },
                  {
                    "text": "PV characterized by long stable phase usually with eventual progression to myelofibrosis (> 10-year survival); substantial risk of thrombosis; antithrombotic therapy needed"
                  },
                  {
                    "text": "PMF shows variable survival times: Range of ~ 6-15 yearsJAK2vs.CALRvs.MPLvs. triple-negative mutation status linked to outcome and thrombosis riskMutation-enhanced International Prognostic Scoring System/others integrate cytogenetics and molecular findings",
                    "sub_points": [
                      "JAK2vs.CALRvs.MPLvs. triple-negative mutation status linked to outcome and thrombosis risk",
                      "Mutation-enhanced International Prognostic Scoring System/others integrate cytogenetics and molecular findings"
                    ]
                  },
                  {
                    "text": "CML patients experience overall 10-year survival rate of 80-90% due to effective TKI therapy"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Mutations in Tyrosine Kinase Genes Resulting in Constitutive Activation": [
                  {
                    "text": "Present in almost all types of common MPN"
                  },
                  {
                    "text": "BCR::ABL1fusion geneDefines CML; required for diagnosisResponsible for dysregulated overproduction of neutrophils, basophils, and variable other HP cells",
                    "sub_points": [
                      "Defines CML; required for diagnosis",
                      "Responsible for dysregulated overproduction of neutrophils, basophils, and variable other HP cells"
                    ]
                  },
                  {
                    "text": "JAK2V617F mutationDetected in virtually all cases of PV (alternateJAK2mutation in remainder)Detected in ~ 60% of ET and PMF casesOccasionally detected in other myeloid neoplasms",
                    "sub_points": [
                      "Detected in virtually all cases of PV (alternateJAK2mutation in remainder)",
                      "Detected in ~ 60% of ET and PMF cases",
                      "Occasionally detected in other myeloid neoplasms"
                    ]
                  },
                  {
                    "text": "CALRmutations in PMF and ET that lackJAK2mutationLinked to outcomeMany differentCALRmutations described with common feature of constitutive tyrosine kinase activity",
                    "sub_points": [
                      "Linked to outcome",
                      "Many differentCALRmutations described with common feature of constitutive tyrosine kinase activity"
                    ]
                  },
                  {
                    "text": "MPLW515 L/K mutationDetected in some PMF and ET cases",
                    "sub_points": [
                      "Detected in some PMF and ET cases"
                    ]
                  },
                  {
                    "text": "CSF3Rmutation characteristic in CNLPredominates in CNL but seen in other myeloid neoplasms, including atypical CML (aCML)",
                    "sub_points": [
                      "Predominates in CNL but seen in other myeloid neoplasms, including atypical CML (aCML)"
                    ]
                  }
                ]
              },
              "CLINICAL IMPLICATIONS": {
                "Presentation": [
                  {
                    "text": "Most MPNs exhibit indolent type of presentation with gradual onset of symptomatology"
                  },
                  {
                    "text": "Splenomegaly is hallmark of many MPNsCML, PV, PMF",
                    "sub_points": [
                      "CML, PV, PMF"
                    ]
                  }
                ],
                "Laboratory Tests": [
                  {
                    "text": "CBC with differential provides many clues to MPN and specific MPN subtypesMarked nontoxic neutrophilia, left shift to blasts, and basophilia in CMLErythrocytosis in PVPV is only MPN in which erythrocytosis is featureLeukocytosis, leukoerythroblastic picture, and teardrop-shaped RBCs in PMF, fibrotic phaseThrombocytosis in ET; also common in CML, early, prefibrotic PMF, and prepolycythemic PVMarked mature neutrophilia with toxic changes and minimal left shift in CNLMarked eosinophilia in CEL, NOS",
                    "sub_points": [
                      "Marked nontoxic neutrophilia, left shift to blasts, and basophilia in CML",
                      "Erythrocytosis in PVPV is only MPN in which erythrocytosis is feature",
                      "PV is only MPN in which erythrocytosis is feature",
                      "Leukocytosis, leukoerythroblastic picture, and teardrop-shaped RBCs in PMF, fibrotic phase",
                      "Thrombocytosis in ET; also common in CML, early, prefibrotic PMF, and prepolycythemic PV",
                      "Marked mature neutrophilia with toxic changes and minimal left shift in CNL",
                      "Marked eosinophilia in CEL, NOS"
                    ]
                  },
                  {
                    "text": "Many other laboratory tests utilized to exclude differential diagnostic considerations and assess cell turnover, iron stores, and erythropoietin levels"
                  }
                ],
                "Treatment": [
                  {
                    "text": "TKI therapy has resulted in markedly prolonged survival in CMLDramatic reduction in incidence of blast phase",
                    "sub_points": [
                      "Dramatic reduction in incidence of blast phase"
                    ]
                  },
                  {
                    "text": "Prevention of thrombotic complications is key goal in classic MPN therapy"
                  },
                  {
                    "text": "TKIs inJAK2mutation-mediated neoplasms in clinical useMany novel inhibitors of other pathways under development, especially for PMF",
                    "sub_points": [
                      "Many novel inhibitors of other pathways under development, especially for PMF"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Blood": [
                  {
                    "text": "Key general features during stable phase of disease include cytosis(es), lack of dysplasia, blasts < 2%"
                  },
                  {
                    "text": "Other specific features of individual MPNsErythrocytosis in PVNeutrophilia in CML and CNLLeft shift with low blast percentage and basophilia in CMLMinimal, more limited, left shift with toxic changes in CNLTeardrop-shaped erythrocytes in PMF, fibrotic phaseMarked eosinophilia in CEL",
                    "sub_points": [
                      "Erythrocytosis in PV",
                      "Neutrophilia in CML and CNLLeft shift with low blast percentage and basophilia in CMLMinimal, more limited, left shift with toxic changes in CNL",
                      "Left shift with low blast percentage and basophilia in CML",
                      "Minimal, more limited, left shift with toxic changes in CNL",
                      "Teardrop-shaped erythrocytes in PMF, fibrotic phase",
                      "Marked eosinophilia in CEL"
                    ]
                  }
                ],
                "Bone Marrow": [
                  {
                    "text": "General featuresHypercellularityPanmyelosis in PVPredominance of granulocytic lineage in CML, PMF, and CNLIncreased megakaryocytes, often with distinctive features that support subclassificationDistinctive abnormal megakaryocytes in CML and classic MPNsIntact maturation, blasts not increased in chronic (stable) phaseLack of dysplasia in stable phase",
                    "sub_points": [
                      "HypercellularityPanmyelosis in PVPredominance of granulocytic lineage in CML, PMF, and CNL",
                      "Panmyelosis in PV",
                      "Predominance of granulocytic lineage in CML, PMF, and CNL",
                      "Increased megakaryocytes, often with distinctive features that support subclassificationDistinctive abnormal megakaryocytes in CML and classic MPNs",
                      "Distinctive abnormal megakaryocytes in CML and classic MPNs",
                      "Intact maturation, blasts not increased in chronic (stable) phase",
                      "Lack of dysplasia in stable phase"
                    ]
                  },
                  {
                    "text": "Distinctive MPN subtype-specific featuresSmall, hypolobated (dwarf) megakaryocytes in CMLMarkedly hyperlobated (staghorn) megakaryocytes in ETProminent intrasinusoidal megakaryocytes in PMFPleomorphic megakaryocytes in PMF with prominent clusteringOsteosclerosis in PMFFibrosis in PMFProgresses over timeNormocellularity in some ETMarked eosinophilia in CEL",
                    "sub_points": [
                      "Small, hypolobated (dwarf) megakaryocytes in CML",
                      "Markedly hyperlobated (staghorn) megakaryocytes in ET",
                      "Prominent intrasinusoidal megakaryocytes in PMFPleomorphic megakaryocytes in PMF with prominent clustering",
                      "Pleomorphic megakaryocytes in PMF with prominent clustering",
                      "Osteosclerosis in PMF",
                      "Fibrosis in PMFProgresses over time",
                      "Progresses over time",
                      "Normocellularity in some ET",
                      "Marked eosinophilia in CEL"
                    ]
                  }
                ]
              },
              "Ancillary Tests": {
                "Flow Cytometric Immunophenotyping": [
                  {
                    "text": "Relatively limited utility in chronic-phase MPNValuable for blast lineage assessment and enumeration in progressive MPNs",
                    "sub_points": [
                      "Valuable for blast lineage assessment and enumeration in progressive MPNs"
                    ]
                  }
                ],
                "Cytogenetics/FISH/Molecular Genetic Testing": [
                  {
                    "text": "Essential in diagnosis of all MPN subtypesInitial diagnostic step is to identify asBCR::ABL1(+) or (-)JAK2,CALR, orMPLmutation status essential in classic MPNsMany additional gene mutations may be identified that impact prognosisConfirmation of clonality in CNL, CEL, NOS",
                    "sub_points": [
                      "Initial diagnostic step is to identify asBCR::ABL1(+) or (-)",
                      "JAK2,CALR, orMPLmutation status essential in classic MPNs",
                      "Many additional gene mutations may be identified that impact prognosis",
                      "Confirmation of clonality in CNL, CEL, NOS"
                    ]
                  },
                  {
                    "text": "Essential forexclusionaryreasons in many MPNs"
                  }
                ]
              },
              "Differential Diagnosis": {
                "MPN vs. Disorders That Mimic MPN": [
                  {
                    "text": "Collagen vascular diseases"
                  },
                  {
                    "text": "Chronic infections"
                  },
                  {
                    "text": "Myeloma-associated with paraneoplastic neutrophilia that mimics CNL"
                  }
                ],
                "MPN vs. Other Myeloid Neoplasms": [
                  {
                    "text": "Apply ICC/WHO-HAEM5 criteria"
                  }
                ],
                "MPN in Stable (Chronic) Phase vs. MPN in Progression to More Aggressive Process": [
                  {
                    "text": "Blast percentage, additional genetic findings, fibrosis, and clinical changes define disease progression"
                  }
                ]
              },
              "Diagnostic Checklist": {
                "Clinical and Pathologic Tips": [
                  {
                    "text": "Review of CBC data and blood smear for clues to MPN and likely specific MPN subtype"
                  },
                  {
                    "text": "Generous use of molecular/genetic testing and conventional karyotyping/FISH as appropriateMolecular genetic tests can be performed on bloodBone marrow specimens optimal for conventional cytogenetics",
                    "sub_points": [
                      "Molecular genetic tests can be performed on blood",
                      "Bone marrow specimens optimal for conventional cytogenetics"
                    ]
                  },
                  {
                    "text": "Appropriate testing to exclude neoplastic and nonneoplastic differential diagnostic considerations"
                  },
                  {
                    "text": "Integrate clinical, hematologic, morphologic, and genetic findings into final diagnosis"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Overview of Myelodysplastic/Myeloproliferative Neoplasms": {
            "name": "Overview of Myelodysplastic/Myeloproliferative Neoplasms",
            "url": "https://app.pathprimer.com/document/7b0d0433-54fd-459a-a769-586eca10692f/lesson/6f665b6e-874b-46a5-9d19-463bafa93147",
            "content": {
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Myelodysplastic/myeloproliferative neoplasms (MDS/MPN)"
                  },
                  {
                    "text": "International Consensus Classification (ICC)"
                  },
                  {
                    "text": "WHO 5th edition (WHO-HAEM5)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "De novo clonal myeloid neoplasm characterized at presentation by sustained, unexplained hybrid myelodysplastic and myeloproliferative features manifested by at least 1 cytopenia and at least 1 cytosis in blood"
                  },
                  {
                    "text": "Maturation is intact; mature cells predominate"
                  },
                  {
                    "text": "Blasts and blast equivalents (promonocytes) are ≤ 20% in blood and bone marrow"
                  },
                  {
                    "text": "Multiple subtypes defined with specific criteria"
                  },
                  {
                    "text": "Multiple exclusionary criteria"
                  }
                ]
              },
              "Classification": {
                "ICC of MDS/MPN": [
                  {
                    "text": "Chronic myelomonocytic leukemia (CMML)Myelodysplastic and myeloproliferative subtypes based on WBC count < or > 13.0 x 10⁹/LCMML types 1 and 2 based on blast percentages in blood and bone marrowMonocyte count ≥ 0.5 x 10⁹/L and ≥ 10% of WBC needed for clonality-confirmed cases",
                    "sub_points": [
                      "Myelodysplastic and myeloproliferative subtypes based on WBC count < or > 13.0 x 10⁹/L",
                      "CMML types 1 and 2 based on blast percentages in blood and bone marrow",
                      "Monocyte count ≥ 0.5 x 10⁹/L and ≥ 10% of WBC needed for clonality-confirmed cases"
                    ]
                  },
                  {
                    "text": "Atypical chronic myeloid leukemia (aCML)"
                  },
                  {
                    "text": "MDS/MPN withSF3B1mutation and thrombocytosis (MDS/MPN-SF3B1-T)"
                  },
                  {
                    "text": "MDS/MPN with ring sideroblasts and thrombocytosis, not otherwise specified (MDS/MPN-RS-T, NOS)"
                  },
                  {
                    "text": "MDS/MPN, NOS"
                  },
                  {
                    "text": "MDS/MPN with iso(17q) (provisional entity)"
                  }
                ],
                "WHO-HAEM5 Classification of MDS/MPN": [
                  {
                    "text": "CMMLMyelodysplastic and myeloproliferative subtypes based on WBC < or > 13.0 x 10⁹/LCMML types 1 and 2 based of blast percentages in blood and bone marrowMonocyte count ≥ 0.5 x 10⁹/L and ≥ 10% WBC for clonality-confirmed cases",
                    "sub_points": [
                      "Myelodysplastic and myeloproliferative subtypes based on WBC < or > 13.0 x 10⁹/L",
                      "CMML types 1 and 2 based of blast percentages in blood and bone marrow",
                      "Monocyte count ≥ 0.5 x 10⁹/L and ≥ 10% WBC for clonality-confirmed cases"
                    ]
                  },
                  {
                    "text": "MDS/MPN with neutrophilia (N)"
                  },
                  {
                    "text": "MDS/MPN-SF3B1-T≥ 15% ring sideroblasts is substitute forSF3B1mutation",
                    "sub_points": [
                      "≥ 15% ring sideroblasts is substitute forSF3B1mutation"
                    ]
                  },
                  {
                    "text": "MDS/MPN-NOS"
                  }
                ],
                "Comparison of ICC and WHO-HAEM5": [
                  {
                    "text": "Many similarities in classification criteria"
                  },
                  {
                    "text": "Different name: aCML (ICC) vs. MDS/MPN-N (neutrophilia) (WHO-HAEM5)"
                  },
                  {
                    "text": "Ring sideroblast substitution forSF3B1mutation only in WHO-HAEM5"
                  },
                  {
                    "text": "Both ICC and WHO-HAEM5 remove juvenile myelomonocytic leukemia (JMML) from MDS/MPNICC assigns JMML to pediatric/childhood MDS and germline predisposition disorders groupingWHO-HAEM5 assigns JMML to MPNs category",
                    "sub_points": [
                      "ICC assigns JMML to pediatric/childhood MDS and germline predisposition disorders grouping",
                      "WHO-HAEM5 assigns JMML to MPNs category"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Molecular Genetic Findings": [
                  {
                    "text": "Confirmation of clonality key in MDS/MPNCytogenetic clone (≥ 2 metaphases) or specific gene mutation (variant allele frequency ≥ 10%)SRSF2,TET2, &/orASXL1mutations frequent in CMMLSF3B1and other myeloid neoplasm driver mutations in other MDS/MPN",
                    "sub_points": [
                      "Cytogenetic clone (≥ 2 metaphases) or specific gene mutation (variant allele frequency ≥ 10%)SRSF2,TET2, &/orASXL1mutations frequent in CMMLSF3B1and other myeloid neoplasm driver mutations in other MDS/MPN",
                      "SRSF2,TET2, &/orASXL1mutations frequent in CMML",
                      "SF3B1and other myeloid neoplasm driver mutations in other MDS/MPN"
                    ]
                  },
                  {
                    "text": "Manyexclusionarygenetic findings, includingabsenceofBCR::ABL1,PDGFRA/PDGFRB,FGFR1rearrangements, isolated del(5q), inv3(q21.3q26.2), and acute myeloid leukemia (AML)-defining translocations, including AML with t(8;21) or inv(16)All of these cytogenetic and gene mutations are pathogenetically linked to other types of myeloid neoplasms",
                    "sub_points": [
                      "All of these cytogenetic and gene mutations are pathogenetically linked to other types of myeloid neoplasms"
                    ]
                  }
                ]
              },
              "EPIDEMIOLOGY": {
                "Age Range": [
                  {
                    "text": "MDS/MPN usually affect older adults; median age > 70 years"
                  }
                ],
                "Sex": [
                  {
                    "text": "Male predominance in CMML"
                  }
                ],
                "Incidence": [
                  {
                    "text": "All MDS/MPN are rare; CMML is most common"
                  }
                ],
                "Presentation": [
                  {
                    "text": "MDS/MPN patients are generally older adults who manifest with gradual symptoms of progressive cytopenias (notably anemia) and splenomegaly"
                  },
                  {
                    "text": "Splenomegaly is common in all types of MDS/MPN"
                  },
                  {
                    "text": "Abnormal myelomonocytic infiltrates can manifest in skin, lymph nodes, or mucosal sites in CMML"
                  }
                ],
                "Laboratory Tests": [
                  {
                    "text": "CBC with differential and morphologic reviewConfirm hybrid cytosis/cytopenia pictureAssess all lineages for dysplasia ≥ 10% (notrequired in clonality-confirmed cases by ICC)Determine percent of blasts/blast equivalents (promonocytes)Must be < 20% for all MDS/MPNDetermine absolute neutrophil, monocyte, eosinophil, and basophil countsDetermine extent of left shift in neutrophil lineageSignificant left shift (≥ 10%) required for aCML",
                    "sub_points": [
                      "Confirm hybrid cytosis/cytopenia picture",
                      "Assess all lineages for dysplasia ≥ 10% (notrequired in clonality-confirmed cases by ICC)",
                      "Determine percent of blasts/blast equivalents (promonocytes)Must be < 20% for all MDS/MPN",
                      "Must be < 20% for all MDS/MPN",
                      "Determine absolute neutrophil, monocyte, eosinophil, and basophil counts",
                      "Determine extent of left shift in neutrophil lineageSignificant left shift (≥ 10%) required for aCML",
                      "Significant left shift (≥ 10%) required for aCML"
                    ]
                  },
                  {
                    "text": "Many other tests to exclude other myeloid neoplasms and nonneoplastic causes for blood abnormalities"
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "Cytogenetic/molecular genetic testingAssess for clonalityCytogenetics and molecular mutation assessment in all casesKey role in confirming clonalityIsochromosome 17q defines MDS/MPN with iso(17q); provisional subtype in ICCMutations, such asSF3B1that defines MDS/MPN-SF3B1-T, often with concurrentJAK2mutationMajor exclusionary role in MDS/MPNFor exclusion of multiple other genetically defined myeloid neoplasms",
                    "sub_points": [
                      "Assess for clonalityCytogenetics and molecular mutation assessment in all casesKey role in confirming clonalityIsochromosome 17q defines MDS/MPN with iso(17q); provisional subtype in ICCMutations, such asSF3B1that defines MDS/MPN-SF3B1-T, often with concurrentJAK2mutation",
                      "Cytogenetics and molecular mutation assessment in all cases",
                      "Key role in confirming clonalityIsochromosome 17q defines MDS/MPN with iso(17q); provisional subtype in ICC",
                      "Isochromosome 17q defines MDS/MPN with iso(17q); provisional subtype in ICC",
                      "Mutations, such asSF3B1that defines MDS/MPN-SF3B1-T, often with concurrentJAK2mutation",
                      "Major exclusionary role in MDS/MPNFor exclusion of multiple other genetically defined myeloid neoplasms",
                      "For exclusion of multiple other genetically defined myeloid neoplasms"
                    ]
                  },
                  {
                    "text": "Flow cytometric immunophenotyping (FCI)Determine lineage of immature cellsAberrant antigen expression profileDelineate monocytic lineage cells often with aberrant antigen expressionMonocyte partitioning by FCI based on pattern and intensity of CD14 and CD16 coexpressionCan distinguish CMML from both reactive monocytoses and other monocytic leukemiasNot commonly used modality in current practice",
                    "sub_points": [
                      "Determine lineage of immature cells",
                      "Aberrant antigen expression profile",
                      "Delineate monocytic lineage cells often with aberrant antigen expression",
                      "Monocyte partitioning by FCI based on pattern and intensity of CD14 and CD16 coexpressionCan distinguish CMML from both reactive monocytoses and other monocytic leukemiasNot commonly used modality in current practice",
                      "Can distinguish CMML from both reactive monocytoses and other monocytic leukemias",
                      "Not commonly used modality in current practice"
                    ]
                  },
                  {
                    "text": "Cytochemical stainingNSE stain valuable in delineating monocytic lineage on bone marrow aspirate smearsMonocytic lineage cells often inconspicuous by Wright stain",
                    "sub_points": [
                      "NSE stain valuable in delineating monocytic lineage on bone marrow aspirate smearsMonocytic lineage cells often inconspicuous by Wright stain",
                      "Monocytic lineage cells often inconspicuous by Wright stain"
                    ]
                  },
                  {
                    "text": "Prussian blue stain for ironDelineates ring sideroblasts, but ring sideroblasts ≥ 15% required only in MDS/MPN-RS-T, NOS cases, which lackSF3B1mutation in ICC≥ 15% ring sideroblasts is surrogate forSF3B1mutation in WHO-HAEM5",
                    "sub_points": [
                      "Delineates ring sideroblasts, but ring sideroblasts ≥ 15% required only in MDS/MPN-RS-T, NOS cases, which lackSF3B1mutation in ICC",
                      "≥ 15% ring sideroblasts is surrogate forSF3B1mutation in WHO-HAEM5"
                    ]
                  }
                ]
              },
              "Natural History": {
                "Prognosis": [
                  {
                    "text": "CMML is linked to intermediate prognosis"
                  },
                  {
                    "text": "aCML has adverse prognosis"
                  },
                  {
                    "text": "MDS/MPN-SF3B1-T often relatively indolent"
                  }
                ],
                "Therapy": [
                  {
                    "text": "Supportive care and nonaggressive chemotherapy typical for CMML and aCML patients"
                  },
                  {
                    "text": "Stem cell transplant only curative therapy but not widely used due to advanced age of most patients"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Blood": [
                  {
                    "text": "Dysplasia in at least 1 lineage for caseswithoutconfirmed clonality by cytogenetic or molecular testing in ICC"
                  },
                  {
                    "text": "Dysplasia ≥ 10% required in WHO-HAEM5"
                  },
                  {
                    "text": "Atypical, absolute monocytosis (≥ 10% of WBC) in CMML"
                  },
                  {
                    "text": "Neutrophilia with left shift and prominent dysplastic changes in aCML"
                  },
                  {
                    "text": "Blasts, including promonocytes, ≤ 20%"
                  },
                  {
                    "text": "Other criteria for specific MDS/MPN subtypes"
                  }
                ],
                "Bone Marrow": [
                  {
                    "text": "Hypercellular in all MDS/MPN subtypesBone marrow required in all cases to delineate specific bone marrow features of each MDS/MPN subtypeBone marrow examination also key toexcludeAML",
                    "sub_points": [
                      "Bone marrow required in all cases to delineate specific bone marrow features of each MDS/MPN subtype",
                      "Bone marrow examination also key toexcludeAML"
                    ]
                  },
                  {
                    "text": "Increased megakaryocytes with variable dysplasia"
                  },
                  {
                    "text": "Hyperlobated MPN-like megakaryocytes in MPS/MPN-SF3B1-T"
                  },
                  {
                    "text": "Dysplasia in at least 1 lineage for cases without confirmation of clonality in ICC, for all cases in WHO-HAEM5"
                  },
                  {
                    "text": "≥ 15% ring sideroblasts in MDS/MPN-RS-T, NOS"
                  },
                  {
                    "text": "Prominent myelomonocytic cells in CMML"
                  },
                  {
                    "text": "Blasts, including promonocytes ≤ 20%"
                  }
                ]
              },
              "Diagnostic Checklist": {
                "Clinicopathologic Interpretation Pearls": [
                  {
                    "text": "Clinical information is essential in confirmingde novopresentation of MDS/MPN"
                  },
                  {
                    "text": "Transformations of either MDS or MPN shouldnotbe included within MDS/MPN"
                  },
                  {
                    "text": "Many nonneoplastic disorders can exhibit hybrid cytopenias and cytoses"
                  },
                  {
                    "text": "Appropriate testing essential to exclude nonneoplastic disorders, such as chronic infections, collagen vascular disorders"
                  },
                  {
                    "text": "Knowledge of recent chemotherapy or cytokine therapy, notably G-CSF therapy, is essentialRecombinant G-CSF can increase blasts and neutrophils",
                    "sub_points": [
                      "Recombinant G-CSF can increase blasts and neutrophils"
                    ]
                  },
                  {
                    "text": "Genetic testing is essential for both diagnostic and exclusionary purposes in MDS/MPN"
                  },
                  {
                    "text": "Bone marrow examination essential in all cases; key modality to exclude AML"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "B-Acute Lymphoblastic Leukemias: Cytogenetic Subtypes and Not Otherwise Specified (ICC)": {
            "name": "B-Acute Lymphoblastic Leukemias: Cytogenetic Subtypes and Not Otherwise Specified (ICC)",
            "url": "https://app.pathprimer.com/document/dc2b014a-6364-4087-85ce-41448c93f82d/lesson/6f665b6e-874b-46a5-9d19-463bafa93147",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "B-acute lymphoblastic leukemia (B-ALL) is neoplasm of precursors (lymphoblasts) committed to B-cell lineage"
                  },
                  {
                    "text": "When blood and BM are extensively involved, ALL is appropriate term"
                  },
                  {
                    "text": "When disease is confined to tissue mass with absent or minimal blood and marrow involvement, term lymphoblastic lymphoma (B-LBL) is used"
                  },
                  {
                    "text": "If patient presents with tissue mass and blood and BM involvement, 25% blasts in marrow defines leukemia (B-ALL)"
                  },
                  {
                    "text": "Blasts express immature markers (CD34 and TdT) and B-cell markers (CD19, CD22, CD79a, subset CD20)"
                  }
                ],
                "Classification": [
                  {
                    "text": "B-ALL with recurrent genetic abnormalities"
                  },
                  {
                    "text": "B-ALL, not otherwise specified"
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "Causes of ALL remain largely unknown"
                  },
                  {
                    "text": "Many ALLs are thought to be congenital"
                  },
                  {
                    "text": "Genetic abnormalities result in constitutively activated oncogenes, activated kinase activity, or altered transcriptional regulation"
                  },
                  {
                    "text": "Certain genomic syndromes have increased incidence of B-ALL"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "B-ALL is most common childhood neoplasm"
                  },
                  {
                    "text": "Complex prognostic systems include clinical, hematologic, cytogenetic/other genetic findings, and initial treatment response"
                  },
                  {
                    "text": "Overall excellent prognosis"
                  },
                  {
                    "text": "Intensive multiagent chemotherapy is mainstay treatment"
                  },
                  {
                    "text": "Patients at very high risk may benefit from allogeneic stem cell transplant"
                  },
                  {
                    "text": "Intrathecal prophylactic therapy routinely done to prevent CNS relapse"
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "Routine karyotype is required on all new B-ALL cases"
                  },
                  {
                    "text": "Specific FISH panel is required by COG protocol"
                  },
                  {
                    "text": "Molecular testing is required for diagnosis of certain subtypes, e.g., B-ALL,BCL::ABL1-like, and entities with point mutations"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "B-acute lymphoblastic leukemia (B-ALL) [International Consensus Classification (ICC)]"
                  },
                  {
                    "text": "B-ALL with t(9;22)(q34.1;q11.2)/BCR::ABL1[BCR::ABL1(+) B-ALL]"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "B-lymphoblastic leukemia/lymphoma (B-LL/LL) [WHO 5th edition (WHO-HAEM5)]"
                  }
                ],
                "Definitions": [
                  {
                    "text": "B-ALL: Neoplasm of precursors (lymphoblasts) committed to B-cell lineage"
                  },
                  {
                    "text": "Blasts express immature markers (CD34 and TdT) and B-cell markers (CD19, CD22, CD79a, subset CD20)"
                  },
                  {
                    "text": "When blood and BM are extensively involved, ALL is appropriate"
                  },
                  {
                    "text": "When disease is confined to mass with absent or minimal blood and BM involvement, term B-lymphoblastic lymphoma (B-LBL) is used"
                  },
                  {
                    "text": "If patient presents with mass lesion and blood and BM involvement, 25% blasts in marrow defines leukemia (B-ALL)"
                  }
                ]
              },
              "CLASSIFICATION": {
                "ICC": [
                  {
                    "text": "B-ALL with recurrent genetic abnormalities"
                  },
                  {
                    "text": "B-ALL with t(9;22)(q34.1;q11.2)/BCR::ABL1With lymphoid only involvementWith multilineage involvement",
                    "sub_points": [
                      "With lymphoid only involvement",
                      "With multilineage involvement"
                    ]
                  },
                  {
                    "text": "B-ALL with t(v;11q23.3)/KMT2Arearranged"
                  },
                  {
                    "text": "B-ALL with t(12;21)(p13.2;q22.1)/ETV6::RUNX1"
                  },
                  {
                    "text": "B-ALL hyperdiploid"
                  },
                  {
                    "text": "B-ALL low hypodiploid"
                  },
                  {
                    "text": "B-ALL near haploid"
                  },
                  {
                    "text": "B-ALL with t(5;14)(q31.1;q32.1)/IL3::IGH"
                  },
                  {
                    "text": "B-ALL with t(1;19)(q23;p13.3)/TCF3::PBX1"
                  },
                  {
                    "text": "B-ALLBCR::ABL1-like, ABL-1 class rearranged"
                  },
                  {
                    "text": "B-ALLBCR::ABL1-like, JAK-STAT activated"
                  },
                  {
                    "text": "B-ALLBCR::ABL1-like, not otherwise specified (NOS)"
                  },
                  {
                    "text": "B-ALL with iAMP21"
                  },
                  {
                    "text": "B-ALL withMYCrearrangement"
                  },
                  {
                    "text": "B-ALL withDUX4rearrangement"
                  },
                  {
                    "text": "B-ALL withMEF2Drearrangement"
                  },
                  {
                    "text": "B-ALL withZNF384/ZNF362rearrangement"
                  },
                  {
                    "text": "B-ALL withNUTM1rearrangement"
                  },
                  {
                    "text": "B-ALL withHLFrearrangement"
                  },
                  {
                    "text": "B-ALL withUBTF::ATXN7L3/PAN3,CDX2(\"CDX2/UBTF\")"
                  },
                  {
                    "text": "B-ALL with mutatedIKZF1N159Y"
                  },
                  {
                    "text": "B-ALL with mutatedPAX5P80R"
                  },
                  {
                    "text": "Provisional entity: B-ALLETV6::RUNX1-like"
                  },
                  {
                    "text": "Provisional entity: B-ALL withPAX5alteration"
                  },
                  {
                    "text": "Provisional entity: B-ALL with mutatedZEB2(p.H1038R)/IGH::CEBPE"
                  },
                  {
                    "text": "Provisional entity: B-ALL,ZNF384rearranged-like"
                  },
                  {
                    "text": "Provisional entity: B-ALL,KMT2Arearranged-like"
                  },
                  {
                    "text": "B-ALL, NOS"
                  }
                ],
                "WHO-HAEM5": [
                  {
                    "text": "B-LL/LL with high hyperdiploidy"
                  },
                  {
                    "text": "B-LL/LL with hypodiploidy"
                  },
                  {
                    "text": "B-LL/LL with iAMP21"
                  },
                  {
                    "text": "B-LL/LL withBCR::ABL1fusion"
                  },
                  {
                    "text": "B-LL/LL withBCR::ABL1-like features"
                  },
                  {
                    "text": "B-LL/LL withKMT2Arearrangement"
                  },
                  {
                    "text": "B-LL/LL withETV6::RUNX1fusion"
                  },
                  {
                    "text": "B-LL/LL withETV6::RUNX1-like features"
                  },
                  {
                    "text": "B-LL/LL withTCF3::PBX1fusion"
                  },
                  {
                    "text": "B-LL/LL withIGH::IL3fusion"
                  },
                  {
                    "text": "B-LL/LL withTCF3::HLFfusion"
                  },
                  {
                    "text": "B-LL/LL with other defined genetic abnormalities"
                  },
                  {
                    "text": "B-LL/LL, NOS"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Etiology": [
                  {
                    "text": "Causes of ALL remain largely unknown"
                  },
                  {
                    "text": "B-ALL arises in either hematopoietic stem cell or B-cell progenitor"
                  }
                ],
                "Pathogenesis": [
                  {
                    "text": "Genetic factorsSubstantial evidence supports that many ALL cases are congenitalGenetic alterations in preleukemic cells in utero are proposed as initiating eventsMonozygotic twins with concordant leukemia share same genetic abnormalitiesPresence ofETV6::RUNX1gene fusion or hyperdiploidy detected in neonatal blood spots on Guthrie cards2nd hit may be required for developing overt leukemiaMost cases of ALL withETV6::RUNX1fusion have deletion of nonarrangedETV6allele, latter is subclonal and probably occurs postnatallyLeukemia can develop many years after identification ofETV6::RUNX1fusionGenetic abnormalities result in constitutively activated oncogenes, activated kinase activity, or altered transcriptional regulationPAX5germline mutation is responsible for familial B-ALL in at least 3 kindreds with incomplete penetranceEVT6germline mutations carry increased risk of developing B-ALL and thrombocytopeniaB-ALL,BCR::ABL1-like has gene expression profile similar to B-ALL with t(9;22)(q34.1;q11.2)/BCR::ABL1but does not haveBCR::ABL1fusionExhibits diverse genetic aberrations that activate tyrosine kinase, may involveABL1,ABL2,PDGFRB,NTRK3,TYK2,CSF1R, andJAK2Alternative translocations involving cytokine receptor-like factor 2 (CRLF2) that are often associated with JAK gene mutationsLess commonly, rearrangements leading to activation of erythropoietin receptor (EPOR)B-ALL with iAMP21 has ≥ 5 copies ofRUNX1geneSyndromes with increased incidence of B-ALLDown syndromeCases withCRLF2translocations are particularly common in Down syndrome-associated B-ALLRobertsonian translocation, rob(15;21)(q10;q10)c, have 2,700x increased risk of developing B-ALL iAMP21All rob(15;21)(q10;q10) patients who developed B-ALL are iAMP21 subtype in one study3.2% of all B-ALL with iAMP21 have rob(15;21)(q10;q10)cSyndromes with increased incidence of malignancies, including B-ALLLi-Fraumeni syndromeNeurofibromatosis type 1 (NF1)Bloom syndromeAtaxia telangiectasia",
                    "sub_points": [
                      "Substantial evidence supports that many ALL cases are congenitalGenetic alterations in preleukemic cells in utero are proposed as initiating eventsMonozygotic twins with concordant leukemia share same genetic abnormalitiesPresence ofETV6::RUNX1gene fusion or hyperdiploidy detected in neonatal blood spots on Guthrie cards2nd hit may be required for developing overt leukemiaMost cases of ALL withETV6::RUNX1fusion have deletion of nonarrangedETV6allele, latter is subclonal and probably occurs postnatallyLeukemia can develop many years after identification ofETV6::RUNX1fusion",
                      "Genetic alterations in preleukemic cells in utero are proposed as initiating events",
                      "Monozygotic twins with concordant leukemia share same genetic abnormalities",
                      "Presence ofETV6::RUNX1gene fusion or hyperdiploidy detected in neonatal blood spots on Guthrie cards",
                      "2nd hit may be required for developing overt leukemiaMost cases of ALL withETV6::RUNX1fusion have deletion of nonarrangedETV6allele, latter is subclonal and probably occurs postnatallyLeukemia can develop many years after identification ofETV6::RUNX1fusion",
                      "Most cases of ALL withETV6::RUNX1fusion have deletion of nonarrangedETV6allele, latter is subclonal and probably occurs postnatally",
                      "Leukemia can develop many years after identification ofETV6::RUNX1fusion",
                      "Genetic abnormalities result in constitutively activated oncogenes, activated kinase activity, or altered transcriptional regulationPAX5germline mutation is responsible for familial B-ALL in at least 3 kindreds with incomplete penetranceEVT6germline mutations carry increased risk of developing B-ALL and thrombocytopeniaB-ALL,BCR::ABL1-like has gene expression profile similar to B-ALL with t(9;22)(q34.1;q11.2)/BCR::ABL1but does not haveBCR::ABL1fusionExhibits diverse genetic aberrations that activate tyrosine kinase, may involveABL1,ABL2,PDGFRB,NTRK3,TYK2,CSF1R, andJAK2Alternative translocations involving cytokine receptor-like factor 2 (CRLF2) that are often associated with JAK gene mutationsLess commonly, rearrangements leading to activation of erythropoietin receptor (EPOR)B-ALL with iAMP21 has ≥ 5 copies ofRUNX1gene",
                      "PAX5germline mutation is responsible for familial B-ALL in at least 3 kindreds with incomplete penetrance",
                      "EVT6germline mutations carry increased risk of developing B-ALL and thrombocytopenia",
                      "B-ALL,BCR::ABL1-like has gene expression profile similar to B-ALL with t(9;22)(q34.1;q11.2)/BCR::ABL1but does not haveBCR::ABL1fusionExhibits diverse genetic aberrations that activate tyrosine kinase, may involveABL1,ABL2,PDGFRB,NTRK3,TYK2,CSF1R, andJAK2Alternative translocations involving cytokine receptor-like factor 2 (CRLF2) that are often associated with JAK gene mutationsLess commonly, rearrangements leading to activation of erythropoietin receptor (EPOR)",
                      "Exhibits diverse genetic aberrations that activate tyrosine kinase, may involveABL1,ABL2,PDGFRB,NTRK3,TYK2,CSF1R, andJAK2",
                      "Alternative translocations involving cytokine receptor-like factor 2 (CRLF2) that are often associated with JAK gene mutations",
                      "Less commonly, rearrangements leading to activation of erythropoietin receptor (EPOR)",
                      "B-ALL with iAMP21 has ≥ 5 copies ofRUNX1gene",
                      "Syndromes with increased incidence of B-ALLDown syndromeCases withCRLF2translocations are particularly common in Down syndrome-associated B-ALLRobertsonian translocation, rob(15;21)(q10;q10)c, have 2,700x increased risk of developing B-ALL iAMP21All rob(15;21)(q10;q10) patients who developed B-ALL are iAMP21 subtype in one study3.2% of all B-ALL with iAMP21 have rob(15;21)(q10;q10)c",
                      "Down syndromeCases withCRLF2translocations are particularly common in Down syndrome-associated B-ALL",
                      "Cases withCRLF2translocations are particularly common in Down syndrome-associated B-ALL",
                      "Robertsonian translocation, rob(15;21)(q10;q10)c, have 2,700x increased risk of developing B-ALL iAMP21All rob(15;21)(q10;q10) patients who developed B-ALL are iAMP21 subtype in one study3.2% of all B-ALL with iAMP21 have rob(15;21)(q10;q10)c",
                      "All rob(15;21)(q10;q10) patients who developed B-ALL are iAMP21 subtype in one study",
                      "3.2% of all B-ALL with iAMP21 have rob(15;21)(q10;q10)c",
                      "Syndromes with increased incidence of malignancies, including B-ALLLi-Fraumeni syndromeNeurofibromatosis type 1 (NF1)Bloom syndromeAtaxia telangiectasia",
                      "Li-Fraumeni syndrome",
                      "Neurofibromatosis type 1 (NF1)",
                      "Bloom syndrome",
                      "Ataxia telangiectasia"
                    ]
                  },
                  {
                    "text": "Environmental factors linked to increased incidenceExposure to intrauterine ionizing radiationExposure to ionizing radiationExposure to pesticidesPost chemotherapy",
                    "sub_points": [
                      "Exposure to intrauterine ionizing radiation",
                      "Exposure to ionizing radiation",
                      "Exposure to pesticides",
                      "Post chemotherapy"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [
                  {
                    "text": "B-ALL is most common childhood neoplasm"
                  },
                  {
                    "text": "Incidence is estimated at 1-4.75/100,000 persons per year"
                  },
                  {
                    "text": "80-85% of ALL is of B-cell origin"
                  },
                  {
                    "text": "75% of cases present before age 6"
                  },
                  {
                    "text": "Slight male predominance"
                  }
                ],
                "Site": [
                  {
                    "text": "BM is primary site"
                  },
                  {
                    "text": "Blood is typically involved"
                  },
                  {
                    "text": "CNS, lymph nodes, liver, spleen, and testis in males are often involved"
                  },
                  {
                    "text": "Skin, soft tissue, bone, and lymph nodes are primary sites of involvement in B-LBL"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Constitutional symptomsFever, night sweats, weight loss",
                    "sub_points": [
                      "Fever, night sweats, weight loss"
                    ]
                  },
                  {
                    "text": "Symptoms related to anemia, thrombocytopenia, or neutropeniaFatigue, bleeding tendency, neutropenic fever",
                    "sub_points": [
                      "Fatigue, bleeding tendency, neutropenic fever"
                    ]
                  },
                  {
                    "text": "Signs and symptoms related to leukemic infiltrateBone pain, arthralgias, CNS symptomsFrequent hepatosplenomegalyLymphadenopathy may be present",
                    "sub_points": [
                      "Bone pain, arthralgias, CNS symptoms",
                      "Frequent hepatosplenomegaly",
                      "Lymphadenopathy may be present"
                    ]
                  },
                  {
                    "text": "Unique featuresB-ALL with t(12;21)(p13.2;q22.1)/ETV6::RUNX1is common in children, accounting for ~ 25% of B-ALL but rare in infants or adultsB-ALL with t(9;22)(q34.1;q11.2)/BCR::ABL1is seen in ~ 25% of adult patients but only 2-5% in childhood B-ALLB-ALLBCR::ABL1-like share gene expression and phenotypic similarities with B-ALL withBCR::ABL1fusion and shows significant benefit from targeted therapiesB-ALL withKMT2Arearrangement is most common in infants, who often present with very high WBC count and higher rate of CNS involvementB-ALL with iAMP21 B-ALL occurs in ~ 2% of children with ALL, especially older children with median age of 9 years and low WBC countsB-ALL with t(5;14)(q31.1;q32.3)/IL3::IGHis often accompanied by eosinophiliaB-ALL withHLFrearrangement:TCF3::HLFfusion is characterized by particularly aggressive behavior",
                    "sub_points": [
                      "B-ALL with t(12;21)(p13.2;q22.1)/ETV6::RUNX1is common in children, accounting for ~ 25% of B-ALL but rare in infants or adults",
                      "B-ALL with t(9;22)(q34.1;q11.2)/BCR::ABL1is seen in ~ 25% of adult patients but only 2-5% in childhood B-ALL",
                      "B-ALLBCR::ABL1-like share gene expression and phenotypic similarities with B-ALL withBCR::ABL1fusion and shows significant benefit from targeted therapies",
                      "B-ALL withKMT2Arearrangement is most common in infants, who often present with very high WBC count and higher rate of CNS involvement",
                      "B-ALL with iAMP21 B-ALL occurs in ~ 2% of children with ALL, especially older children with median age of 9 years and low WBC counts",
                      "B-ALL with t(5;14)(q31.1;q32.3)/IL3::IGHis often accompanied by eosinophilia",
                      "B-ALL withHLFrearrangement:TCF3::HLFfusion is characterized by particularly aggressive behavior"
                    ]
                  }
                ],
                "Laboratory Tests": [
                  {
                    "text": "Variable WBC count50% of patients have WBC < 10 x 10⁹/L (low)30% of patients have WBC between 10-50 x 10⁹/L20% of patients have WBC > 50 x 10⁹/L20% of patients may have preleukemic state with cytopenia 2-9 months before overt leukemia",
                    "sub_points": [
                      "50% of patients have WBC < 10 x 10⁹/L (low)",
                      "30% of patients have WBC between 10-50 x 10⁹/L",
                      "20% of patients have WBC > 50 x 10⁹/L",
                      "20% of patients may have preleukemic state with cytopenia 2-9 months before overt leukemia"
                    ]
                  },
                  {
                    "text": "Anemia and thrombocytopenia almost always present"
                  },
                  {
                    "text": "Rarely patients present with asymptomatic eosinophilia"
                  }
                ],
                "Treatment": [
                  {
                    "text": "Multiagent chemotherapy is mainstay of treatmentPatients are stratified as standard risk or high risk based on clinical, biologic prognostic factors and cytogenetic findingsPatients are further stratified at end of induction based on response to therapy and measurable residual disease (MRD) assessment",
                    "sub_points": [
                      "Patients are stratified as standard risk or high risk based on clinical, biologic prognostic factors and cytogenetic findings",
                      "Patients are further stratified at end of induction based on response to therapy and measurable residual disease (MRD) assessment"
                    ]
                  },
                  {
                    "text": "Intrathecal prophylactic therapy routinely done to prevent CNS relapse"
                  },
                  {
                    "text": "Cranial radiation can be limited to small subset of patients or abandoned to reduce neuropsychologic sequelae"
                  },
                  {
                    "text": "Stem cell/BM transplantationAutologous stem cell transplant (SCT) not effectivePatients with very high-risk findings may benefit from allogeneic SCTFailure to achieve complete remission after 5 weeks of therapyB-ALL with t(9;22) or t(4;11) translocationWBC count > 100 x 10⁹/L",
                    "sub_points": [
                      "Autologous stem cell transplant (SCT) not effective",
                      "Patients with very high-risk findings may benefit from allogeneic SCTFailure to achieve complete remission after 5 weeks of therapyB-ALL with t(9;22) or t(4;11) translocationWBC count > 100 x 10⁹/L",
                      "Failure to achieve complete remission after 5 weeks of therapy",
                      "B-ALL with t(9;22) or t(4;11) translocation",
                      "WBC count > 100 x 10⁹/L"
                    ]
                  },
                  {
                    "text": "Supportive therapy for cytopenia(s)"
                  },
                  {
                    "text": "Novel therapiesTargeted therapy: B-ALL,BCR::ABL1-like may be targeted with tyrosine kinase inhibitors &/or JAK inhibitorsImmunotherapy: Bispecific T-cell engager antibodies and CAR T cells may offer greater promise in relapsed patients",
                    "sub_points": [
                      "Targeted therapy: B-ALL,BCR::ABL1-like may be targeted with tyrosine kinase inhibitors &/or JAK inhibitors",
                      "Immunotherapy: Bispecific T-cell engager antibodies and CAR T cells may offer greater promise in relapsed patients"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Overall prognosisExcellent; complete remission rate > 95% in children and 60-85% in adultsCure rate is ~ 80% in children and < 50% in adultsAdolescents and young adults have better outcome when treated with pediatric protocols than with adult protocolsCNS and testis are sanctuary for leukemic cells and are common relapse sites",
                    "sub_points": [
                      "Excellent; complete remission rate > 95% in children and 60-85% in adults",
                      "Cure rate is ~ 80% in children and < 50% in adults",
                      "Adolescents and young adults have better outcome when treated with pediatric protocols than with adult protocols",
                      "CNS and testis are sanctuary for leukemic cells and are common relapse sites"
                    ]
                  },
                  {
                    "text": "Clinical and biologic prognostic factorsFavorable factorsAge 1-10 yearsFemale sexWBC < 50 x 10⁹/LCommon type of B-ALL by immunophenotypeNo CNS diseaseUnfavorable factors< 1 or > 10 yearsMale sexWBC > 50 x 10⁹/LLack of CD10 expression by immunophenotypingPresence of CNS disease",
                    "sub_points": [
                      "Favorable factorsAge 1-10 yearsFemale sexWBC < 50 x 10⁹/LCommon type of B-ALL by immunophenotypeNo CNS disease",
                      "Age 1-10 years",
                      "Female sex",
                      "WBC < 50 x 10⁹/L",
                      "Common type of B-ALL by immunophenotype",
                      "No CNS disease",
                      "Unfavorable factors< 1 or > 10 yearsMale sexWBC > 50 x 10⁹/LLack of CD10 expression by immunophenotypingPresence of CNS disease",
                      "< 1 or > 10 years",
                      "Male sex",
                      "WBC > 50 x 10⁹/L",
                      "Lack of CD10 expression by immunophenotyping",
                      "Presence of CNS disease"
                    ]
                  },
                  {
                    "text": "Cytogenetic abnormalities as prognostic predicatorsFavorableB-ALL hyperdiploidB-ALL with t(12;21)(p13.2;q22.1)/ETV6::RUNX1UnfavorableB-ALL low hypodiploidB-ALL near haploidB-ALL with t(9;22)(q34.1;q11.2)/BCR::ABL1B-ALL,BCR::ABL1-likeB-ALL with t(v;11q23.3)/KMT2Arearranged, t(4;11)/KMT2A::AFF1fusionB-ALL with iAMP21B-ALL withTCF3::HLFfusionComplex abnormalitiesIntermediateB-ALL with t(5;14)(q31.1;q32.3)/IL3::IGHB-ALL with t(1;19)(q23.3;p13.3)/TCF3::PBX1Normal karyotypeAny other abnormalities not in favorable or unfavorable categories",
                    "sub_points": [
                      "FavorableB-ALL hyperdiploidB-ALL with t(12;21)(p13.2;q22.1)/ETV6::RUNX1",
                      "B-ALL hyperdiploid",
                      "B-ALL with t(12;21)(p13.2;q22.1)/ETV6::RUNX1",
                      "UnfavorableB-ALL low hypodiploidB-ALL near haploidB-ALL with t(9;22)(q34.1;q11.2)/BCR::ABL1B-ALL,BCR::ABL1-likeB-ALL with t(v;11q23.3)/KMT2Arearranged, t(4;11)/KMT2A::AFF1fusionB-ALL with iAMP21B-ALL withTCF3::HLFfusionComplex abnormalities",
                      "B-ALL low hypodiploid",
                      "B-ALL near haploid",
                      "B-ALL with t(9;22)(q34.1;q11.2)/BCR::ABL1",
                      "B-ALL,BCR::ABL1-like",
                      "B-ALL with t(v;11q23.3)/KMT2Arearranged, t(4;11)/KMT2A::AFF1fusion",
                      "B-ALL with iAMP21",
                      "B-ALL withTCF3::HLFfusion",
                      "Complex abnormalities",
                      "IntermediateB-ALL with t(5;14)(q31.1;q32.3)/IL3::IGHB-ALL with t(1;19)(q23.3;p13.3)/TCF3::PBX1Normal karyotypeAny other abnormalities not in favorable or unfavorable categories",
                      "B-ALL with t(5;14)(q31.1;q32.3)/IL3::IGH",
                      "B-ALL with t(1;19)(q23.3;p13.3)/TCF3::PBX1",
                      "Normal karyotype",
                      "Any other abnormalities not in favorable or unfavorable categories"
                    ]
                  },
                  {
                    "text": "Response to therapy as prognostic predicatorFavorableNo blasts in marrow at day 7 or 14Morphologic remission at end of inductionGood peripheral blood response to systemic steroid therapy prior to multiagent chemotherapyUnfavorableMorphologic blasts in marrow at day 7 or 14Requirement for ≥ 2 cycles of induction chemotherapy to achieve complete morphologic remissionPoor peripheral blood response to week of systemic steroid therapy",
                    "sub_points": [
                      "FavorableNo blasts in marrow at day 7 or 14Morphologic remission at end of inductionGood peripheral blood response to systemic steroid therapy prior to multiagent chemotherapy",
                      "No blasts in marrow at day 7 or 14",
                      "Morphologic remission at end of induction",
                      "Good peripheral blood response to systemic steroid therapy prior to multiagent chemotherapy",
                      "UnfavorableMorphologic blasts in marrow at day 7 or 14Requirement for ≥ 2 cycles of induction chemotherapy to achieve complete morphologic remissionPoor peripheral blood response to week of systemic steroid therapy",
                      "Morphologic blasts in marrow at day 7 or 14",
                      "Requirement for ≥ 2 cycles of induction chemotherapy to achieve complete morphologic remission",
                      "Poor peripheral blood response to week of systemic steroid therapy"
                    ]
                  },
                  {
                    "text": "MRD assessmentLow risk for relapseLow MRD (< 10⁻³) at day 8 or 15Low MRD (< 10⁻³) at end of inductionHigh risk for relapseHigh MRD (> 10⁻³) at day 8 or 15High MRD (> 10⁻³) at end of induction",
                    "sub_points": [
                      "Low risk for relapseLow MRD (< 10⁻³) at day 8 or 15Low MRD (< 10⁻³) at end of induction",
                      "Low MRD (< 10⁻³) at day 8 or 15",
                      "Low MRD (< 10⁻³) at end of induction",
                      "High risk for relapseHigh MRD (> 10⁻³) at day 8 or 15High MRD (> 10⁻³) at end of induction",
                      "High MRD (> 10⁻³) at day 8 or 15",
                      "High MRD (> 10⁻³) at end of induction"
                    ]
                  },
                  {
                    "text": "PharmacogenomicsCan predict how rapidly and effectively individual patients metabolize certain chemotherapeutic agents",
                    "sub_points": [
                      "Can predict how rapidly and effectively individual patients metabolize certain chemotherapeutic agents"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "BloodBlasts are usually present in peripheral bloodBlasts vary in size from small to largeL1 blasts: Small blasts with scant cytoplasm, condensed chromatin, and indistinctive nucleoliL2 blasts: Large blasts with moderate cytoplasm, dispersed chromatin, and variable nucleoliMay have coarse azurophilic cytoplasmic granulesEosinophilia often seen in B-ALL with t(5;14)(q31.1;q32.3)/IL3::IGH",
                    "sub_points": [
                      "Blasts are usually present in peripheral blood",
                      "Blasts vary in size from small to large",
                      "L1 blasts: Small blasts with scant cytoplasm, condensed chromatin, and indistinctive nucleoli",
                      "L2 blasts: Large blasts with moderate cytoplasm, dispersed chromatin, and variable nucleoli",
                      "May have coarse azurophilic cytoplasmic granules",
                      "Eosinophilia often seen in B-ALL with t(5;14)(q31.1;q32.3)/IL3::IGH"
                    ]
                  },
                  {
                    "text": "BMHypercellular marrow, usually extensively replaced by lymphoblastsBlasts are fairly uniform in BMCore biopsy shows extensive replacement by lymphoblastsCore biopsy may show starry-sky pattern due to high number of mitotic figuresPatchy or diffuse preserved hematopoietic cellsRarely marrow necrosis; ALL is most common neoplasm to present as diffuse necrosis in BM",
                    "sub_points": [
                      "Hypercellular marrow, usually extensively replaced by lymphoblasts",
                      "Blasts are fairly uniform in BM",
                      "Core biopsy shows extensive replacement by lymphoblasts",
                      "Core biopsy may show starry-sky pattern due to high number of mitotic figures",
                      "Patchy or diffuse preserved hematopoietic cells",
                      "Rarely marrow necrosis; ALL is most common neoplasm to present as diffuse necrosis in BM"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "Often used when flow cytometric analysis is not availableCD34, TdT to confirm immaturity of blastsCD19, CD79a, and CD20 to identify B-cell lineage",
                    "sub_points": [
                      "CD34, TdT to confirm immaturity of blasts",
                      "CD19, CD79a, and CD20 to identify B-cell lineage"
                    ]
                  }
                ],
                "Flow Cytometry": [
                  {
                    "text": "Degree of differentiation determines immunophenotypeEarliest stage blasts express CD19, cytoplasmic CD79a, cytoplasmic CD22, and TdT; such B-ALLs occur in infancyIntermediate-stage blasts express CD10, CD19, surface CD79a, surface CD22, and TdTMost mature-stage blasts express cytoplasmic μ chains (c-μ), CD34 often (-)",
                    "sub_points": [
                      "Earliest stage blasts express CD19, cytoplasmic CD79a, cytoplasmic CD22, and TdT; such B-ALLs occur in infancy",
                      "Intermediate-stage blasts express CD10, CD19, surface CD79a, surface CD22, and TdT",
                      "Most mature-stage blasts express cytoplasmic μ chains (c-μ), CD34 often (-)"
                    ]
                  },
                  {
                    "text": "CD34 and CD20 expression variable"
                  },
                  {
                    "text": "CD45 can be negative but is typically weak"
                  },
                  {
                    "text": "~ 20-30% of cases also express myeloid-associated antigen markers CD15, CD13, and CD33"
                  },
                  {
                    "text": "CD13 expression is often seen in B-ALL with t(12;21)(p13.2;q22.1)/ETV6::RUNX1"
                  },
                  {
                    "text": "CD13 and CD33 often expressed in B-ALL with t(9;22)(q34.1;q11.2)/BCR::ABL1"
                  },
                  {
                    "text": "Shift in immunophenotype during therapy is very common, usually gain or loss of myeloid markers"
                  }
                ],
                "PCR": [
                  {
                    "text": "Almost all cases have clonal rearrangement ofIGHgene"
                  },
                  {
                    "text": "Majority of cases also have clonal rearrangement of TCR gene"
                  },
                  {
                    "text": "RT-PCR is performed if fusion is detected, such asBCR::ABL1, to establish baseline and to follow-up MRD"
                  },
                  {
                    "text": "Cancer gene panels are performed in selected institutions &/or selected patients"
                  }
                ],
                "Genetic Testing": [
                  {
                    "text": "Cytogenetic studyRoutine karyotype is required on all new B-ALL casesAbnormalities are found in majority of B-ALL casesB-ALL with t(12;21)(p13;q22)/ETV6::RUNX1; most common fusion in pediatric B-ALLCryptic, cannot be detected by karyotype, requires FISHB-ALL with t(1;19)(q23;p13.3)/TCF3::PBX1B-ALL with t(9;22)(q34.1;q11.2)/BCR::ABL1B-ALL with t(v;11q23.3)/KMT2Arearranged; especially B-ALL in neonates/infantsB-ALL with t(5;14)(q31;q32)/IL3::IGH, associated with eosinophiliaB-ALL, hyperdiploidyB-ALL, hypodiploidy",
                    "sub_points": [
                      "Routine karyotype is required on all new B-ALL cases",
                      "Abnormalities are found in majority of B-ALL cases",
                      "B-ALL with t(12;21)(p13;q22)/ETV6::RUNX1; most common fusion in pediatric B-ALLCryptic, cannot be detected by karyotype, requires FISH",
                      "Cryptic, cannot be detected by karyotype, requires FISH",
                      "B-ALL with t(1;19)(q23;p13.3)/TCF3::PBX1",
                      "B-ALL with t(9;22)(q34.1;q11.2)/BCR::ABL1",
                      "B-ALL with t(v;11q23.3)/KMT2Arearranged; especially B-ALL in neonates/infants",
                      "B-ALL with t(5;14)(q31;q32)/IL3::IGH, associated with eosinophilia",
                      "B-ALL, hyperdiploidy",
                      "B-ALL, hypodiploidy"
                    ]
                  },
                  {
                    "text": "FISH studiesRequired by Children's Oncology Group (COG) protocolt(9;22)(q34.1;q11.2)/BCR::ABL1Aneuploidy for chromosomes 4, 10, 17KMT2Agene rearrangementt(12;21)(p13.2;q22.1)/ETV6::RUNX1to detect fusion gene as well as to assess copy number ofRUNX1gene to evaluate for iAMP21FISH is required to subclassify B-ALL with t(9;22)(q34.1;q11.2)/BCR::ABL1B-ALL with t(9;22)(q34.1;q11.2)/BCR::ABL1with lymphoid-only involvementBCR::ABL1fusion present in lymphoblasts onlyB-ALL with t(9;22)(q34.1;q11.2)/BCR::ABL1with multilineage involvementBCR::ABL1fusion present in granulocytes as well",
                    "sub_points": [
                      "Required by Children's Oncology Group (COG) protocolt(9;22)(q34.1;q11.2)/BCR::ABL1Aneuploidy for chromosomes 4, 10, 17KMT2Agene rearrangementt(12;21)(p13.2;q22.1)/ETV6::RUNX1to detect fusion gene as well as to assess copy number ofRUNX1gene to evaluate for iAMP21",
                      "t(9;22)(q34.1;q11.2)/BCR::ABL1",
                      "Aneuploidy for chromosomes 4, 10, 17",
                      "KMT2Agene rearrangement",
                      "t(12;21)(p13.2;q22.1)/ETV6::RUNX1to detect fusion gene as well as to assess copy number ofRUNX1gene to evaluate for iAMP21",
                      "FISH is required to subclassify B-ALL with t(9;22)(q34.1;q11.2)/BCR::ABL1B-ALL with t(9;22)(q34.1;q11.2)/BCR::ABL1with lymphoid-only involvementBCR::ABL1fusion present in lymphoblasts onlyB-ALL with t(9;22)(q34.1;q11.2)/BCR::ABL1with multilineage involvementBCR::ABL1fusion present in granulocytes as well",
                      "B-ALL with t(9;22)(q34.1;q11.2)/BCR::ABL1with lymphoid-only involvementBCR::ABL1fusion present in lymphoblasts only",
                      "BCR::ABL1fusion present in lymphoblasts only",
                      "B-ALL with t(9;22)(q34.1;q11.2)/BCR::ABL1with multilineage involvementBCR::ABL1fusion present in granulocytes as well",
                      "BCR::ABL1fusion present in granulocytes as well"
                    ]
                  },
                  {
                    "text": "Molecular testingRequired for diagnosis of certain subtypes, e.g., B-ALL,BCL::ABL1-like and entities with point mutations, among others",
                    "sub_points": [
                      "Required for diagnosis of certain subtypes, e.g., B-ALL,BCL::ABL1-like and entities with point mutations, among others"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Hematogones": [
                  {
                    "text": "Can be numerous in children, especially during recovery after BM insults"
                  },
                  {
                    "text": "Immunophenotypic spectrum of hematogonesDemonstrates gradual gain of CD20 expressionGradual loss of CD10, TdT, and CD34Lack of aberrant antigen expression",
                    "sub_points": [
                      "Demonstrates gradual gain of CD20 expression",
                      "Gradual loss of CD10, TdT, and CD34",
                      "Lack of aberrant antigen expression"
                    ]
                  }
                ],
                "High-Grade B-Cell Lymphoma WithMYCandBCL2Rearrangements orBCL6Rearrangements": [
                  {
                    "text": "Should be differentiated from B-ALL withMYCrearrangement"
                  },
                  {
                    "text": "High-grade B-cell lymphoma-double hit (HGBCL-DH) are mature B-cell lymphomas, while B-ALL withMYCrearrangement has immature features"
                  },
                  {
                    "text": "HGBCL-DH may express TdT but shows evidence of somatic hypermutation"
                  },
                  {
                    "text": "HGBCL-DH are CD34(-), while B-ALL is CD34(+) in most cases"
                  },
                  {
                    "text": "B-ALL withMYCrearrangement has unmutated immunoglobulin V(H) genes"
                  }
                ],
                "Burkitt Lymphoma": [
                  {
                    "text": "Mature HGBCL; should be differentiated from B-ALL withMYCrearrangement"
                  },
                  {
                    "text": "Lymphoma cells are large with unique punctate cytoplasmic vacuoles"
                  },
                  {
                    "text": "Expresses surface immunoglobulin and lacks immature markers CD34 or TdT"
                  }
                ],
                "Other Leukemias": [
                  {
                    "text": "Immunophenotyping is helpful to distinguish B-ALL from other leukemias"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "T- and NK-Cell Acute Lymphoblastic Leukemia (ICC)": {
            "name": "T- and NK-Cell Acute Lymphoblastic Leukemia (ICC)",
            "url": "https://app.pathprimer.com/document/c4de1c6e-2d68-49b0-9c3f-cb4ee0ef92a6/lesson/6f665b6e-874b-46a5-9d19-463bafa93147",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "AbbreviationsT-acute lymphoblastic leukemia (T-ALL)/T-lymphoblastic lymphoma (T-LBL)",
                    "sub_points": [
                      "T-acute lymphoblastic leukemia (T-ALL)/T-lymphoblastic lymphoma (T-LBL)"
                    ]
                  },
                  {
                    "text": "Definitions"
                  },
                  {
                    "text": "Neoplasm of lymphoblasts committed to T-cell lineage"
                  },
                  {
                    "text": "T-ALL and T-LBL are separated based on numbers of lymphoblasts in bone marrowT-ALL when > 25% blasts in bone marrowDistinction between leukemia and lymphoma becomes arbitrary when there is mass lesion and increased marrow blasts",
                    "sub_points": [
                      "T-ALL when > 25% blasts in bone marrow",
                      "Distinction between leukemia and lymphoma becomes arbitrary when there is mass lesion and increased marrow blasts"
                    ]
                  },
                  {
                    "text": "Blast percentage requirement to establish diagnosis of T-ALLIn contrast to AML, there is no agreement on lower limit of blast percentage required to diagnose T-ALL",
                    "sub_points": [
                      "In contrast to AML, there is no agreement on lower limit of blast percentage required to diagnose T-ALL"
                    ]
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "IncidenceT-ALL~ 15% of all childhood ALL~ 25% of adult ALLT-LBL~ 85% of all LBLMore common in adults",
                    "sub_points": [
                      "T-ALL~ 15% of all childhood ALL~ 25% of adult ALL",
                      "~ 15% of all childhood ALL",
                      "~ 25% of adult ALL",
                      "T-LBL~ 85% of all LBLMore common in adults",
                      "~ 85% of all LBL",
                      "More common in adults"
                    ]
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "Flow cytometry/immunohistochemistryT lymphoblasts usually express TdTT lymphoblasts variably express CD1a, CD2, CD4, CD5, CD7, CD8, and CD3 (surface or cytoplasmic)T lymphoblasts may also coexpress CD10 &/or CD34",
                    "sub_points": [
                      "T lymphoblasts usually express TdT",
                      "T lymphoblasts variably express CD1a, CD2, CD4, CD5, CD7, CD8, and CD3 (surface or cytoplasmic)",
                      "T lymphoblasts may also coexpress CD10 &/or CD34"
                    ]
                  },
                  {
                    "text": "CytogeneticsStructural chromosomal abnormalities detected in ~ 50% of T-ALL/T-LBLTranslocations involving loci of T-cell receptor genes are commonTranscription factor genes commonly juxtaposed to promoters and enhancers loci of T-cell receptor genes",
                    "sub_points": [
                      "Structural chromosomal abnormalities detected in ~ 50% of T-ALL/T-LBL",
                      "Translocations involving loci of T-cell receptor genes are common",
                      "Transcription factor genes commonly juxtaposed to promoters and enhancers loci of T-cell receptor genes"
                    ]
                  },
                  {
                    "text": "NOTCH1andCDKN2Amutations are common across all T-ALL, except early T-cell precursor ALL"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "T-acute lymphoblastic leukemia (T-ALL)/T-lymphoblastic lymphoma (T-LBL)"
                  },
                  {
                    "text": "International Consensus Classification (ICC)"
                  },
                  {
                    "text": "WHO 5th edition (WHO-HAEM5)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Precursor T-cell neoplasms"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Neoplasm of lymphoblasts committed to T-cell lineage"
                  },
                  {
                    "text": "T-ALL and T-LBL are separated based on numbers of lymphoblasts in bone marrowT-ALL when > 25% blasts in bone marrowDistinction between leukemia and lymphoma becomes arbitrary when there is mass lesion and increased marrow blasts",
                    "sub_points": [
                      "T-ALL when > 25% blasts in bone marrow",
                      "Distinction between leukemia and lymphoma becomes arbitrary when there is mass lesion and increased marrow blasts"
                    ]
                  },
                  {
                    "text": "Blast percentage requirement to establish diagnosis of T-ALLThere is no agreement on lower limit of blast percentage required to diagnose T-ALL",
                    "sub_points": [
                      "There is no agreement on lower limit of blast percentage required to diagnose T-ALL"
                    ]
                  }
                ]
              },
              "CLASSIFICATION": {
                "ICC": [
                  {
                    "text": "T-ALL"
                  },
                  {
                    "text": "Early T-cell precursor ALL (ETP-ALL),BCL11B-activated (new entity)"
                  },
                  {
                    "text": "ETP-ALL, not otherwise specified (NOS)"
                  },
                  {
                    "text": "Near-early T-cell precursorAccounts for subset of ETP-ALLPhenotypically similar to ETP-ALL except for ≥ 75% expression of CD5 on blastsDifferent gene lesions than ETP-ALL with enrichment forTLX3rearrangementsMinor differences in clinical presentation and response to therapy",
                    "sub_points": [
                      "Accounts for subset of ETP-ALL",
                      "Phenotypically similar to ETP-ALL except for ≥ 75% expression of CD5 on blasts",
                      "Different gene lesions than ETP-ALL with enrichment forTLX3rearrangements",
                      "Minor differences in clinical presentation and response to therapy"
                    ]
                  },
                  {
                    "text": "T-ALL provisional entities classified based on aberrant activation of families of transcription factor genes, includingTAL1/TAL2TLX1TLX3HOXA gene clusterLMO1/LMO2NKX2-1,NKX2-2, andNKX2-5SPI1OLIG1/OLIG2",
                    "sub_points": [
                      "TAL1/TAL2",
                      "TLX1",
                      "TLX3",
                      "HOXA gene cluster",
                      "LMO1/LMO2",
                      "NKX2-1,NKX2-2, andNKX2-5",
                      "SPI1",
                      "OLIG1/OLIG2"
                    ]
                  },
                  {
                    "text": "NK-cell ALL (provisional entity)"
                  }
                ],
                "WHO-HAEM5": [
                  {
                    "text": "T-lymphoblastic leukemia/lymphoma, NOS"
                  },
                  {
                    "text": "Early T-precursor lymphoblastic leukemia/lymphoma"
                  },
                  {
                    "text": "Genetically defined provisional T-ALL entities as listed in ICC are not currently recognized by WHO-HAEM5Not sufficient evidence to establish genetically defined T-ALL with clinical relevance per WHO-HAEM5",
                    "sub_points": [
                      "Not sufficient evidence to establish genetically defined T-ALL with clinical relevance per WHO-HAEM5"
                    ]
                  },
                  {
                    "text": "NK lymphoblastic leukemia (NK-LL)/lymphoma is not separately listed in WHO-HAEM5Lack of clear-cut and reliable diagnostic criteria per WHO-HAEM5",
                    "sub_points": [
                      "Lack of clear-cut and reliable diagnostic criteria per WHO-HAEM5"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "T-ALL~ 15% of all childhood ALL~ 25% of adult ALLAge at diagnosis: < 10 years in ~ 1/2 of childhood T-ALLMore common in adolescent males",
                    "sub_points": [
                      "~ 15% of all childhood ALL",
                      "~ 25% of adult ALL",
                      "Age at diagnosis: < 10 years in ~ 1/2 of childhood T-ALL",
                      "More common in adolescent males"
                    ]
                  },
                  {
                    "text": "T-LBL85-90% of all LBLAge at diagnosis: < 10 years in ~ 1/2 of childhood T-LBLMore common in adolescent males",
                    "sub_points": [
                      "85-90% of all LBL",
                      "Age at diagnosis: < 10 years in ~ 1/2 of childhood T-LBL",
                      "More common in adolescent males"
                    ]
                  }
                ],
                "Presentation": [
                  {
                    "text": "T-ALLCommonly manifests with high leukocyte count with circulating blastsAleukemic presentation is uncommonBone marrow is always involvedRelative sparing of trilineage hematopoiesis in bone marrow compared to B-ALLConcurrent mediastinal/thymic or other mass lesion often presentLymphadenopathy and hepatosplenomegaly are commonCNS involvement is more common than in T-LBL",
                    "sub_points": [
                      "Commonly manifests with high leukocyte count with circulating blastsAleukemic presentation is uncommon",
                      "Aleukemic presentation is uncommon",
                      "Bone marrow is always involvedRelative sparing of trilineage hematopoiesis in bone marrow compared to B-ALL",
                      "Relative sparing of trilineage hematopoiesis in bone marrow compared to B-ALL",
                      "Concurrent mediastinal/thymic or other mass lesion often present",
                      "Lymphadenopathy and hepatosplenomegaly are common",
                      "CNS involvement is more common than in T-LBL"
                    ]
                  },
                  {
                    "text": "T-LBLFrequently manifests with rapidly growing anterior mediastinal/thymic massPleural &/or pericardial effusions often presentRespiratory symptoms and superior vena cava syndrome may be seenLymph node involvement may be presentInvolvement of extranodal sitesSkin, tonsil, spleen, liver, CNS, and testis may be involvedBone marrow involvement at diagnosis in ~ 20% of cases",
                    "sub_points": [
                      "Frequently manifests with rapidly growing anterior mediastinal/thymic massPleural &/or pericardial effusions often presentRespiratory symptoms and superior vena cava syndrome may be seen",
                      "Pleural &/or pericardial effusions often present",
                      "Respiratory symptoms and superior vena cava syndrome may be seen",
                      "Lymph node involvement may be present",
                      "Involvement of extranodal sitesSkin, tonsil, spleen, liver, CNS, and testis may be involved",
                      "Skin, tonsil, spleen, liver, CNS, and testis may be involved",
                      "Bone marrow involvement at diagnosis in ~ 20% of cases"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Childhood T-ALLHigher risk compared to B-ALLIncreased risk of induction failure and early relapseIncreased risk of isolated CNS relapseWhite count is not prognostic factorDetectable measurable residual disease (MRD) after therapy is strong adverse prognostic factorPatients with detectable MRD at end of induction may still do well if no MRD is detected by day 78",
                    "sub_points": [
                      "Higher risk compared to B-ALL",
                      "Increased risk of induction failure and early relapse",
                      "Increased risk of isolated CNS relapse",
                      "White count is not prognostic factor",
                      "Detectable measurable residual disease (MRD) after therapy is strong adverse prognostic factorPatients with detectable MRD at end of induction may still do well if no MRD is detected by day 78",
                      "Patients with detectable MRD at end of induction may still do well if no MRD is detected by day 78"
                    ]
                  },
                  {
                    "text": "Adult T-ALLBetter prognosis than B-ALL likely due to low rate of adverse cytogenetic abnormalities in adult T-ALL",
                    "sub_points": [
                      "Better prognosis than B-ALL likely due to low rate of adverse cytogenetic abnormalities in adult T-ALL"
                    ]
                  },
                  {
                    "text": "Pediatric T-LBLInferior event-free survival with marrow &/or CNS involvement compared to patients with stage I-III diseasePrognostic relevance of submicroscopic minimally disseminated disease &/or microscopic stage IV disease might be influenced by type of treatment",
                    "sub_points": [
                      "Inferior event-free survival with marrow &/or CNS involvement compared to patients with stage I-III disease",
                      "Prognostic relevance of submicroscopic minimally disseminated disease &/or microscopic stage IV disease might be influenced by type of treatment"
                    ]
                  },
                  {
                    "text": "Adult T-LBLLonger survival, complete remission (CR) rate, and CR duration in patients withAge < 40 yearsLactate dehydrogenase (LDH) level < 2x upper limits of normalAbsent or single extranodal site of diseaseShort survival with failure to achieve CR in patients withAge > 40 yearsLDH level > 2x upper limits of normalHemoglobin level < 10 g/dL",
                    "sub_points": [
                      "Longer survival, complete remission (CR) rate, and CR duration in patients withAge < 40 yearsLactate dehydrogenase (LDH) level < 2x upper limits of normalAbsent or single extranodal site of disease",
                      "Age < 40 years",
                      "Lactate dehydrogenase (LDH) level < 2x upper limits of normal",
                      "Absent or single extranodal site of disease",
                      "Short survival with failure to achieve CR in patients withAge > 40 yearsLDH level > 2x upper limits of normalHemoglobin level < 10 g/dL",
                      "Age > 40 years",
                      "LDH level > 2x upper limits of normal",
                      "Hemoglobin level < 10 g/dL"
                    ]
                  },
                  {
                    "text": "Indolent T-lymphoblastic proliferationInvolve upper aerodigestive tract in most casesMultiple recurrences without systemic dissemination",
                    "sub_points": [
                      "Involve upper aerodigestive tract in most cases",
                      "Multiple recurrences without systemic dissemination"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Blood and Bone Marrow Findings": [
                  {
                    "text": "Peripheral blood findings in T-ALLLeukocytosis with circulating lymphoblastsSmall to medium-sized blasts with high N:C ratio in most casesSignificant size variation ranging from small to largeSmall lymphoblasts often contain condensed chromatin with inconspicuous nucleoli﻿Small lymphoblasts may be confused with circulating mature T-cell lymphomaLarge lymphoblasts typically contain finely dispersed nuclear chromatin and distinct nucleoli﻿Nuclei of lymphoblasts may be round, slightly irregular, or convoluted﻿Cytoplasmic vacuoles may be seen in some cases﻿T lymphoblasts are morphologically indistinguishable from B lymphoblasts﻿Cytopenias may be present",
                    "sub_points": [
                      "Leukocytosis with circulating lymphoblastsSmall to medium-sized blasts with high N:C ratio in most casesSignificant size variation ranging from small to largeSmall lymphoblasts often contain condensed chromatin with inconspicuous nucleoli﻿Small lymphoblasts may be confused with circulating mature T-cell lymphomaLarge lymphoblasts typically contain finely dispersed nuclear chromatin and distinct nucleoli﻿Nuclei of lymphoblasts may be round, slightly irregular, or convoluted﻿Cytoplasmic vacuoles may be seen in some cases﻿T lymphoblasts are morphologically indistinguishable from B lymphoblasts﻿",
                      "Small to medium-sized blasts with high N:C ratio in most cases",
                      "Significant size variation ranging from small to large",
                      "Small lymphoblasts often contain condensed chromatin with inconspicuous nucleoli﻿Small lymphoblasts may be confused with circulating mature T-cell lymphoma",
                      "Small lymphoblasts may be confused with circulating mature T-cell lymphoma",
                      "Large lymphoblasts typically contain finely dispersed nuclear chromatin and distinct nucleoli﻿",
                      "Nuclei of lymphoblasts may be round, slightly irregular, or convoluted﻿",
                      "Cytoplasmic vacuoles may be seen in some cases﻿",
                      "T lymphoblasts are morphologically indistinguishable from B lymphoblasts﻿",
                      "Cytopenias may be present"
                    ]
                  },
                  {
                    "text": "Bone marrow findings in T-ALLLymphoblasts morphologic features similar to those found in bloodExtensive marrow involvement on core biopsy and clot sectionsSheets of blasts with immature nuclear chromatinHigher mitotic figures compared to B-ALLIn contrast to B-lineage ALL, normal trilineage hematopoiesis relatively preserved",
                    "sub_points": [
                      "Lymphoblasts morphologic features similar to those found in blood",
                      "Extensive marrow involvement on core biopsy and clot sectionsSheets of blasts with immature nuclear chromatinHigher mitotic figures compared to B-ALL",
                      "Sheets of blasts with immature nuclear chromatin",
                      "Higher mitotic figures compared to B-ALL",
                      "In contrast to B-lineage ALL, normal trilineage hematopoiesis relatively preserved"
                    ]
                  },
                  {
                    "text": "Peripheral blood findings in T-LBLAbsent to minimal involvement of peripheral blood",
                    "sub_points": [
                      "Absent to minimal involvement of peripheral blood"
                    ]
                  },
                  {
                    "text": "Bone marrow findings in T-LBLBone marrow involved in < 20% of cases at diagnosisBy definition, blasts account for < 25% of nucleated marrow cells in cases with marrow involvement",
                    "sub_points": [
                      "Bone marrow involved in < 20% of cases at diagnosis",
                      "By definition, blasts account for < 25% of nucleated marrow cells in cases with marrow involvement"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Histochemistry": [
                  {
                    "text": "T lymphoblasts show frequent focal acid phosphatase activityAcid phosphatase activity is not specific",
                    "sub_points": [
                      "Acid phosphatase activity is not specific"
                    ]
                  }
                ],
                "Flow Cytometry": [
                  {
                    "text": "T lymphoblasts usually express TdT and variably express CD1a, CD2, CD3 (surface or cytoplasmic), CD4, CD5, CD7, and CD8CD7 and cytoplasmic CD3 are most often positiveOnly CD3 is considered lineage specificFrequent coexpression of CD4 and CD8 but can express only former/latter or neitherT lymphoblasts may also coexpress CD10CD10 expression can also be seen in peripheral T-cell lymphoma, most commonly in angioimmunoblastic T-cell lymphoma",
                    "sub_points": [
                      "CD7 and cytoplasmic CD3 are most often positive",
                      "Only CD3 is considered lineage specific",
                      "Frequent coexpression of CD4 and CD8 but can express only former/latter or neither",
                      "T lymphoblasts may also coexpress CD10CD10 expression can also be seen in peripheral T-cell lymphoma, most commonly in angioimmunoblastic T-cell lymphoma",
                      "CD10 expression can also be seen in peripheral T-cell lymphoma, most commonly in angioimmunoblastic T-cell lymphoma"
                    ]
                  },
                  {
                    "text": "Subset of T-ALL/T-LBL cases also express CD34In addition to CD34 and TdT, expression of CD1a and CD99 help to determine precursor nature of T lymphoblasts",
                    "sub_points": [
                      "In addition to CD34 and TdT, expression of CD1a and CD99 help to determine precursor nature of T lymphoblasts"
                    ]
                  },
                  {
                    "text": "CD79A is expressed in ~ 10% of cases"
                  },
                  {
                    "text": "CD13 &/or CD33 are expressed in 20-30% of casesMyeloid antigens expression does not exclude T-ALL/T-LBLDoes not indicate mixed phenotype acute leukemia",
                    "sub_points": [
                      "Myeloid antigens expression does not exclude T-ALL/T-LBL",
                      "Does not indicate mixed phenotype acute leukemia"
                    ]
                  },
                  {
                    "text": "CD117 is occasionally expressedCD117 expression is associated with presence ofFLT3-activating mutations",
                    "sub_points": [
                      "CD117 expression is associated with presence ofFLT3-activating mutations"
                    ]
                  },
                  {
                    "text": "Distinction of true NK-LL from T-ALL that only expresses immature markers may be difficult"
                  }
                ],
                "T-ALL Stages of Intrathymic Differentiation": [
                  {
                    "text": "Pro-T/T-I"
                  },
                  {
                    "text": "Pre-T/T-IIMany cases previously classified as pro-T or pre-T would now meet criteria for ETP-ALL entity in revised 2016 WHO classification",
                    "sub_points": [
                      "Many cases previously classified as pro-T or pre-T would now meet criteria for ETP-ALL entity in revised 2016 WHO classification"
                    ]
                  },
                  {
                    "text": "Cortical T/T-IIICD4/CD8 (+) and CD1a expression in most cases corresponding to this stage",
                    "sub_points": [
                      "CD4/CD8 (+) and CD1a expression in most cases corresponding to this stage"
                    ]
                  },
                  {
                    "text": "Medullary T/T-IVExpresses either CD4 or CD8",
                    "sub_points": [
                      "Expresses either CD4 or CD8"
                    ]
                  }
                ],
                "Genetic Testing": [
                  {
                    "text": "Antigen receptor gene rearrangementsClonal rearrangements of T-cell receptor genes detected in virtually all casesConcomitant clonal rearrangements of immunoglobulin heavy chain gene detected in 20% of cases",
                    "sub_points": [
                      "Clonal rearrangements of T-cell receptor genes detected in virtually all cases",
                      "Concomitant clonal rearrangements of immunoglobulin heavy chain gene detected in 20% of cases"
                    ]
                  },
                  {
                    "text": "Recurrent cytogenetic abnormalitiesStructural chromosomal abnormalities detected in ~ 60% of T-ALL/T-LBLTranslocations involving T-cell receptor genes are most common recurrent cytogenetic abnormalityFound in ~ 40% of T-ALL casesTRAandTRDat 14q11.2,TRBat 7q34, andTRGat 7p14 are involvedPartner genes are juxtaposed to regulatory regions of T-cell receptor genesResults in dysregulation of transcription of partner genesTranscription factor genes commonly juxtaposed to T-cell receptor regulatory regions",
                    "sub_points": [
                      "Structural chromosomal abnormalities detected in ~ 60% of T-ALL/T-LBL",
                      "Translocations involving T-cell receptor genes are most common recurrent cytogenetic abnormalityFound in ~ 40% of T-ALL casesTRAandTRDat 14q11.2,TRBat 7q34, andTRGat 7p14 are involvedPartner genes are juxtaposed to regulatory regions of T-cell receptor genesResults in dysregulation of transcription of partner genes",
                      "Found in ~ 40% of T-ALL cases",
                      "TRAandTRDat 14q11.2,TRBat 7q34, andTRGat 7p14 are involved",
                      "Partner genes are juxtaposed to regulatory regions of T-cell receptor genesResults in dysregulation of transcription of partner genes",
                      "Results in dysregulation of transcription of partner genes",
                      "Transcription factor genes commonly juxtaposed to T-cell receptor regulatory regions"
                    ]
                  },
                  {
                    "text": "Provisional T-ALL entities in ICC with aberrant rearrangements/activation of families of transcription factorsTAL1andTAL2rearrangements:TRD::TAL1;TRB::TAL1;STIL::TAL1;TRB::TAL2TLX1rearrangements:TLX1::TRB;TLX1::TRDTLX3rearrangements:TLX3::BCL11B(cryptic);TLX3::CDK6HOXA gene cluster: inv(7)(p15q34)/TRB::HOXA10Other rearrangements:KMT2A-R;PICALM::MLLT10(often cryptic); SET::NUP214KMT2Apartner gene (includingMLLT1,AFDN,MLLT10,FOXO4,AFF1) fusion, 8%LMO1/LMO2genes rearrangements:LMO1::TRA;TRD::LMO2;TRB::LMO2NKX2-1/NKX2-2/NKX2-5rearrangements:NKX2-1::TRA;NKX2-2::TRDSPI1rearrangement:SPI1::BCL11BOLIG1/OLIG2;LYL1rearrangement:OLIG2::TRA/TRD;LYL1::TRBCytogenetic and available FISH probes can identify good subset of casesComprehensive genomic analysis may be required to classify all genetic subtypes",
                    "sub_points": [
                      "TAL1andTAL2rearrangements:TRD::TAL1;TRB::TAL1;STIL::TAL1;TRB::TAL2",
                      "TLX1rearrangements:TLX1::TRB;TLX1::TRD",
                      "TLX3rearrangements:TLX3::BCL11B(cryptic);TLX3::CDK6",
                      "HOXA gene cluster: inv(7)(p15q34)/TRB::HOXA10Other rearrangements:KMT2A-R;PICALM::MLLT10(often cryptic); SET::NUP214KMT2Apartner gene (includingMLLT1,AFDN,MLLT10,FOXO4,AFF1) fusion, 8%",
                      "Other rearrangements:KMT2A-R;PICALM::MLLT10(often cryptic); SET::NUP214",
                      "KMT2Apartner gene (includingMLLT1,AFDN,MLLT10,FOXO4,AFF1) fusion, 8%",
                      "LMO1/LMO2genes rearrangements:LMO1::TRA;TRD::LMO2;TRB::LMO2",
                      "NKX2-1/NKX2-2/NKX2-5rearrangements:NKX2-1::TRA;NKX2-2::TRD",
                      "SPI1rearrangement:SPI1::BCL11B",
                      "OLIG1/OLIG2;LYL1rearrangement:OLIG2::TRA/TRD;LYL1::TRBCytogenetic and available FISH probes can identify good subset of casesComprehensive genomic analysis may be required to classify all genetic subtypes",
                      "Cytogenetic and available FISH probes can identify good subset of cases",
                      "Comprehensive genomic analysis may be required to classify all genetic subtypes"
                    ]
                  },
                  {
                    "text": "Translocations generating fusion genes encoding oncogenic chimeric proteinsMYC::TRA/TRDin t(8;14)(q24;q11)ETV6::JAK2gene fusion in t(9;12)(p24;p13)NUP98::RAP1GDS1gene fusion in t(4;11)(q23;p15.4)",
                    "sub_points": [
                      "MYC::TRA/TRDin t(8;14)(q24;q11)",
                      "ETV6::JAK2gene fusion in t(9;12)(p24;p13)",
                      "NUP98::RAP1GDS1gene fusion in t(4;11)(q23;p15.4)"
                    ]
                  },
                  {
                    "text": "Other translocations/rearrangements in T-ALLABL1rearrangements in T-ALLNUP214::ABL1gene fusion, strictly associated with T-ALLCryptic translocation not detectable by cytogeneticsETV6::ABL1gene fusion in t(9;12)(q34;p13)BCR::ABL1gene fusion in t(9;22)(q34.1;q11.23), very rareLCK::TRBgene involved in t(1;7)(p35;q34)NOTCH1::TRBin t(7;9)(q34.q34)CCND2::TRA/TRDandTRB::CCND2Cryptic deletions leading to loss of tumor suppressor genesCryptic deletions are frequent and may be concomitant with other changesDeletion ofCDKN2Aat 9p21, most frequent cryptic deletionPresent in > 50% of T-ALLVariable size deletion at chromosome (6q)",
                    "sub_points": [
                      "ABL1rearrangements in T-ALLNUP214::ABL1gene fusion, strictly associated with T-ALLCryptic translocation not detectable by cytogeneticsETV6::ABL1gene fusion in t(9;12)(q34;p13)BCR::ABL1gene fusion in t(9;22)(q34.1;q11.23), very rareLCK::TRBgene involved in t(1;7)(p35;q34)NOTCH1::TRBin t(7;9)(q34.q34)CCND2::TRA/TRDandTRB::CCND2",
                      "NUP214::ABL1gene fusion, strictly associated with T-ALLCryptic translocation not detectable by cytogenetics",
                      "Cryptic translocation not detectable by cytogenetics",
                      "ETV6::ABL1gene fusion in t(9;12)(q34;p13)",
                      "BCR::ABL1gene fusion in t(9;22)(q34.1;q11.23), very rare",
                      "LCK::TRBgene involved in t(1;7)(p35;q34)",
                      "NOTCH1::TRBin t(7;9)(q34.q34)",
                      "CCND2::TRA/TRDandTRB::CCND2",
                      "Cryptic deletions leading to loss of tumor suppressor genesCryptic deletions are frequent and may be concomitant with other changesDeletion ofCDKN2Aat 9p21, most frequent cryptic deletionPresent in > 50% of T-ALLVariable size deletion at chromosome (6q)",
                      "Cryptic deletions are frequent and may be concomitant with other changes",
                      "Deletion ofCDKN2Aat 9p21, most frequent cryptic deletionPresent in > 50% of T-ALL",
                      "Present in > 50% of T-ALL",
                      "Variable size deletion at chromosome (6q)"
                    ]
                  },
                  {
                    "text": "Gene mutations in T-ALLNOTCH1(key regulator of T-cell fate) mutationsActivating mutations present in > 50% of T-ALL casesFBXW7-inactivating mutationsPresent in ~ 30% of T-ALLImpairs proteosomal degradation of activated NOTCH1Contributes to NOTCH1 signaling activationGATA3-inactivating mutationsPresent in ~ 5% of T-ALLPTEN-inactivating mutations, ~ 10%FLT3-ITD-activating mutation in ~ 2-4%Common colesion inBCL11B-activated ETP and T/myeloidNRAS-activating mutations in 5-10% of pediatric T-ALLNF1-inactivating mutations/deletions in 3%JAK1-activating mutations in 4-18%JAK3-activating mutations in 5%EZH2-inactivating mutation/deletion in 10-15%SUZ12-inactivating mutation/deletion in 10%PHF6-inactivating mutation/deletion 20-40%EED-inactivating mutation/deletion in 10%",
                    "sub_points": [
                      "NOTCH1(key regulator of T-cell fate) mutationsActivating mutations present in > 50% of T-ALL cases",
                      "Activating mutations present in > 50% of T-ALL cases",
                      "FBXW7-inactivating mutationsPresent in ~ 30% of T-ALLImpairs proteosomal degradation of activated NOTCH1Contributes to NOTCH1 signaling activation",
                      "Present in ~ 30% of T-ALL",
                      "Impairs proteosomal degradation of activated NOTCH1",
                      "Contributes to NOTCH1 signaling activation",
                      "GATA3-inactivating mutationsPresent in ~ 5% of T-ALL",
                      "Present in ~ 5% of T-ALL",
                      "PTEN-inactivating mutations, ~ 10%",
                      "FLT3-ITD-activating mutation in ~ 2-4%Common colesion inBCL11B-activated ETP and T/myeloid",
                      "Common colesion inBCL11B-activated ETP and T/myeloid",
                      "NRAS-activating mutations in 5-10% of pediatric T-ALL",
                      "NF1-inactivating mutations/deletions in 3%",
                      "JAK1-activating mutations in 4-18%",
                      "JAK3-activating mutations in 5%",
                      "EZH2-inactivating mutation/deletion in 10-15%",
                      "SUZ12-inactivating mutation/deletion in 10%",
                      "PHF6-inactivating mutation/deletion 20-40%",
                      "EED-inactivating mutation/deletion in 10%"
                    ]
                  }
                ],
                "Gene Expression Profiling": [
                  {
                    "text": "Several gene expression signatures have been described, includingLYL1signature that corresponds to immature prothymocytesTLX1signature that corresponds to early cortical thymocytesTAL1signature that correspond to late thymocytes",
                    "sub_points": [
                      "LYL1signature that corresponds to immature prothymocytes",
                      "TLX1signature that corresponds to early cortical thymocytes",
                      "TAL1signature that correspond to late thymocytes"
                    ]
                  }
                ],
                "ETP-ALL": [
                  {
                    "text": "ETP-ALL with activatedBCL11BAssociated with chromosomal rearrangements in 80%Remaining cases associated with focal amplification with generation of neoenhacer distal toBCL11B",
                    "sub_points": [
                      "Associated with chromosomal rearrangements in 80%",
                      "Remaining cases associated with focal amplification with generation of neoenhacer distal toBCL11B"
                    ]
                  },
                  {
                    "text": "Diagnosed when case of T-ALL meetsallfollowing criteriaAbsence of expression of CD1a and CD8Absence or weak expression of CD5 in < 75% of blastsExpression of ≥ 1 of following myeloid- or stem cell-associated antigens in ≥ 25% of blastsCD117, CD34, HLA-DR, CD13, CD33, CD11b, &/or CD65",
                    "sub_points": [
                      "Absence of expression of CD1a and CD8",
                      "Absence or weak expression of CD5 in < 75% of blasts",
                      "Expression of ≥ 1 of following myeloid- or stem cell-associated antigens in ≥ 25% of blasts",
                      "CD117, CD34, HLA-DR, CD13, CD33, CD11b, &/or CD65"
                    ]
                  },
                  {
                    "text": "Near-ETP-ALLPhenotypically similar to ETP-ALL except for expression of CD5 on ≥ 75% of blastsDifferent genetic profile than ETP-ALL with enrichment ofTLX3rearrangements",
                    "sub_points": [
                      "Phenotypically similar to ETP-ALL except for expression of CD5 on ≥ 75% of blasts",
                      "Different genetic profile than ETP-ALL with enrichment ofTLX3rearrangements"
                    ]
                  }
                ],
                "NK-LL": [
                  {
                    "text": "Provisional entity in ICC only"
                  },
                  {
                    "text": "Expresses CD56, immature markers, and T-cell markers, such as CD2 and CD7"
                  },
                  {
                    "text": "Mutational profile has not yet been characterized"
                  },
                  {
                    "text": "Overlapping phenotype and clinicopathologic spectrum with other immature CD56(+) hematopoietic neoplasms"
                  },
                  {
                    "text": "Differential diagnosis includesCD56(+) acute undifferentiated leukemiaBlastic plasmacytoid dendritic cell neoplasmT-ALLAMLEBV-associated aggressive NK-cell leukemia with lack of immature markers is excluded",
                    "sub_points": [
                      "CD56(+) acute undifferentiated leukemia",
                      "Blastic plasmacytoid dendritic cell neoplasm",
                      "T-ALL",
                      "AML",
                      "EBV-associated aggressive NK-cell leukemia with lack of immature markers is excluded"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Precursor B-Lymphoblastic Leukemia/Lymphoma": [
                  {
                    "text": "B lymphoblasts are cytomorphologically similar to T lymphoblasts"
                  },
                  {
                    "text": "Flow cytometry or immunohistochemistry can easily separate T lymphoblasts from B lymphoblasts"
                  }
                ],
                "Mature T-Cell Lymphoma": [
                  {
                    "text": "Subset of T lymphoblasts with mature-appearing morphology may mimic mature T-cell lymphoma"
                  },
                  {
                    "text": "Angioimmunoblastic T-cell lymphoma may have overlapping immunophenotype, including expression of CD3 and CD10"
                  },
                  {
                    "text": "Expression of immature markers in T-ALL separate it from mature T-cell lymphoma"
                  }
                ],
                "Myeloid/Lymphoid Neoplasms With Eosinophilia andFGFR1Rearrangements": [
                  {
                    "text": "Cases with acute leukemia presentation may fulfill criteria for T-ALL, B-ALL, or mixed phenotype acute leukemia (MPAL)"
                  },
                  {
                    "text": "Cases with t(8;13)(p11;q12)/ZMYM2::FGFR1frequently present with T-ALL component with scattered myeloblasts, termed bilineal lymphoma"
                  },
                  {
                    "text": "Eosinophilia is seen, especially in patients with myeloproliferative featuresMyeloproliferative neoplasm may be obscured by blasts and become more obvious postmyeloablative treatment",
                    "sub_points": [
                      "Myeloproliferative neoplasm may be obscured by blasts and become more obvious postmyeloablative treatment"
                    ]
                  }
                ],
                "Indolent T-Lymphoblastic Proliferation": [
                  {
                    "text": "Isolated case reports of indolent T-lymphoblastic proliferation in upper airway"
                  },
                  {
                    "text": "Nonclonal by T-cell receptor gene rearrangement studies"
                  },
                  {
                    "text": "Ectopic thymic tissue needs to be excluded"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Overview and Classification of Mature B-Cell Leukemias, Immunosecretory Neoplasms": {
            "name": "Overview and Classification of Mature B-Cell Leukemias, Immunosecretory Neoplasms",
            "url": "https://app.pathprimer.com/document/71cf617c-c3e5-4046-b370-3003106cf7fc/lesson/6f665b6e-874b-46a5-9d19-463bafa93147",
            "content": {
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "International Consensus Classification (ICC)"
                  },
                  {
                    "text": "WHO 5th edition (WHO-HAEM5)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Chronic lymphocytic leukemia (CLL) (ICC and WHO-HAEM5)"
                  },
                  {
                    "text": "Small lymphocytic lymphoma (SLL) (ICC and WHO-HAEM5)"
                  },
                  {
                    "text": "Monoclonal B-cell lymphocytosis (MBL) (ICC and WHO-HAEM5)"
                  },
                  {
                    "text": "B-prolymphocytic leukemia (B-PLL) (ICC,notin WHO-HAEM5)"
                  },
                  {
                    "text": "Splenic marginal zone lymphoma (SMZL) (ICC and WHO-HAEM5)"
                  },
                  {
                    "text": "Hairy cell leukemia (HCL) (ICC and WHO-HAEM5)"
                  },
                  {
                    "text": "Splenic B-cell lymphoma/leukemia, unclassifiable (SBL, U) (ICC)HCL variant (HCLv) (ICC); splenic B-cell leukemia with prominent nucleoli (WHO-HAEM5)Splenic diffuse red pulp small B-cell lymphoma (ICC and WHO-HAEM5)",
                    "sub_points": [
                      "HCL variant (HCLv) (ICC); splenic B-cell leukemia with prominent nucleoli (WHO-HAEM5)",
                      "Splenic diffuse red pulp small B-cell lymphoma (ICC and WHO-HAEM5)"
                    ]
                  },
                  {
                    "text": "Lymphoplasmacytic lymphoma (LPL) (ICC and WHO-HAEM5)"
                  },
                  {
                    "text": "Gamma heavy chain disease (γ-HCD) (ICC and WHO-HAEM5)"
                  },
                  {
                    "text": "Monoclonal gammopathy of uncertain significance (MGUS) (ICC and WHO-HAEM5)"
                  },
                  {
                    "text": "Multiple myeloma/plasma cell myeloma (MM/PCM) (ICC); PCM (WHO-HAEM5)"
                  },
                  {
                    "text": "Mantle cell lymphoma (MCL) (ICC and WHO-HAEM5)"
                  },
                  {
                    "text": "Follicular lymphoma (FL) (ICC and WHO-HAEM5)"
                  },
                  {
                    "text": "Diffuse large B-cell lymphoma (DLBCL) (ICC and WHO-HAEM5)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Clonal mature lymphoid lineage neoplasm derived from B cell or plasma cellCharacteristic peripheral blood and bone marrow involvement in mature B-cell leukemias and plasma cell neoplasmsVariable involvement of peripheral blood/bone marrow with B-cell lymphomasLineage, maturity, and immunophenotypic profile determined by flow cytometric immunophenotyping (FCI)Distinctive immunophenotypic and genetic profile for many B-cell leukemias and lymphomas",
                    "sub_points": [
                      "Characteristic peripheral blood and bone marrow involvement in mature B-cell leukemias and plasma cell neoplasms",
                      "Variable involvement of peripheral blood/bone marrow with B-cell lymphomas",
                      "Lineage, maturity, and immunophenotypic profile determined by flow cytometric immunophenotyping (FCI)",
                      "Distinctive immunophenotypic and genetic profile for many B-cell leukemias and lymphomas"
                    ]
                  }
                ],
                "Classification of Mature B-Cell Leukemias": [
                  {
                    "text": "MBLPrecursor to CLLMonoclonal B-cell count does not exceed 5.0 x 10⁹/L threshold",
                    "sub_points": [
                      "Precursor to CLL",
                      "Monoclonal B-cell count does not exceed 5.0 x 10⁹/L threshold"
                    ]
                  },
                  {
                    "text": "CLL/SLL"
                  },
                  {
                    "text": "B-PLL"
                  },
                  {
                    "text": "HCL"
                  },
                  {
                    "text": "SMZL"
                  },
                  {
                    "text": "SBL, U, HCLv subtype"
                  }
                ],
                "Classification of Plasma Cell/Lymphoplasmacytic Neoplasms": [
                  {
                    "text": "MGUS (IgM and non-IgM subtypes)"
                  },
                  {
                    "text": "LPL"
                  },
                  {
                    "text": "MM/PCM"
                  },
                  {
                    "text": "γ-HCD"
                  }
                ],
                "Classification of Mature B-Cell Lymphomas That May Involve Peripheral Blood/Bone Marrow": [
                  {
                    "text": "MCL, especially leukemic, nonnodal subtype"
                  },
                  {
                    "text": "FL"
                  },
                  {
                    "text": "DLBCL"
                  },
                  {
                    "text": "Intravascular large B-cell lymphoma"
                  },
                  {
                    "text": "Burkitt lymphoma (BL)"
                  },
                  {
                    "text": "Other B-cell non-Hodgkin lymphomas"
                  }
                ]
              },
              "Clinical Issues": {
                "Epidemiology": [
                  {
                    "text": "IncidenceVariable; dependent on B-cell leukemia/plasma cell neoplasm subtypeMBL ~ 100x more common than CLLCLL/SLL common; ~ 5 new cases per 100,000 individualsMGUS common> 3% of individuals ≥ 50 years old",
                    "sub_points": [
                      "Variable; dependent on B-cell leukemia/plasma cell neoplasm subtypeMBL ~ 100x more common than CLLCLL/SLL common; ~ 5 new cases per 100,000 individualsMGUS common> 3% of individuals ≥ 50 years old",
                      "MBL ~ 100x more common than CLL",
                      "CLL/SLL common; ~ 5 new cases per 100,000 individuals",
                      "MGUS common> 3% of individuals ≥ 50 years old",
                      "> 3% of individuals ≥ 50 years old"
                    ]
                  },
                  {
                    "text": "Age rangeHighly variableMature B-cell leukemias, plasma cell neoplasms tend to affect adultsBL seen in children and adults",
                    "sub_points": [
                      "Highly variableMature B-cell leukemias, plasma cell neoplasms tend to affect adultsBL seen in children and adults",
                      "Mature B-cell leukemias, plasma cell neoplasms tend to affect adults",
                      "BL seen in children and adults"
                    ]
                  }
                ],
                "Site": [
                  {
                    "text": "Peripheral blood and bone marrow involvementTypical of leukemiasBone marrow involvement typical of MM/PCM and MGUS",
                    "sub_points": [
                      "Typical of leukemias",
                      "Bone marrow involvement typical of MM/PCM and MGUS"
                    ]
                  },
                  {
                    "text": "Extramedullary sites with possible involvement of peripheral blood/bone marrowMature B-cell lymphomasMM/PCM",
                    "sub_points": [
                      "Mature B-cell lymphomas",
                      "MM/PCM"
                    ]
                  }
                ],
                "Presentation": [
                  {
                    "text": "Highly variable; disease subtype dependent"
                  },
                  {
                    "text": "Asymptomatic/insidious onset with indolent disordersNonprogressive or minimally progressive symptomatologyMBL and MGUSCLL/SLL, SMZL, HCL, HCLv; may have indolent presentation",
                    "sub_points": [
                      "Nonprogressive or minimally progressive symptomatologyMBL and MGUS",
                      "MBL and MGUS",
                      "CLL/SLL, SMZL, HCL, HCLv; may have indolent presentation"
                    ]
                  },
                  {
                    "text": "Acute onset with more aggressive disordersGenerally requires clinical interventionSignificant clinical symptomatology",
                    "sub_points": [
                      "Generally requires clinical intervention",
                      "Significant clinical symptomatology"
                    ]
                  },
                  {
                    "text": "Mature B-cell leukemias/lymphomas that tend to exhibit leukemic manifestationsCLL, HCL, SMZL, B-PLL, HCLv, some LPL",
                    "sub_points": [
                      "CLL, HCL, SMZL, B-PLL, HCLv, some LPL"
                    ]
                  },
                  {
                    "text": "Mature B-cell leukemias that also involve spleenHCL, SMZL, B-PLL, HCLv ,other SBL-U, some LPL, nonnodal MCL",
                    "sub_points": [
                      "HCL, SMZL, B-PLL, HCLv ,other SBL-U, some LPL, nonnodal MCL"
                    ]
                  },
                  {
                    "text": "Plasma cell neoplasmsMGUSBone marrow involvement limitedNon-IgM types progress to myeloma at rate of 1% per yearMM/PCMBony lesions; may see tissue plasmacytomas, bone marrow involvement, peripheral blood involvement in rare plasma cell leukemia",
                    "sub_points": [
                      "MGUSBone marrow involvement limitedNon-IgM types progress to myeloma at rate of 1% per year",
                      "Bone marrow involvement limited",
                      "Non-IgM types progress to myeloma at rate of 1% per year",
                      "MM/PCMBony lesions; may see tissue plasmacytomas, bone marrow involvement, peripheral blood involvement in rare plasma cell leukemia",
                      "Bony lesions; may see tissue plasmacytomas, bone marrow involvement, peripheral blood involvement in rare plasma cell leukemia"
                    ]
                  }
                ],
                "Natural History": [
                  {
                    "text": "May approach normal lifespan in many MBL and MGUS patients and subset of CLL, HCL patients"
                  },
                  {
                    "text": "Progressive/more aggressive disease (e.g., some CLL, B-PLL, some LPL, MM/PCM) requires therapeutic intervention for disease control/overall survival"
                  }
                ],
                "Laboratory Tests": [
                  {
                    "text": "CBC with differential"
                  },
                  {
                    "text": "Peripheral blood smear morphologic reviewCirculating mature leukemia cells often evident",
                    "sub_points": [
                      "Circulating mature leukemia cells often evident"
                    ]
                  },
                  {
                    "text": "Many other laboratory tests depending on disease type and need for assessment of protein levels, underlying infection, cell turnover"
                  },
                  {
                    "text": "Bone marrow biopsy"
                  },
                  {
                    "text": "FCIPreferred method to define immunophenotypic profile of leukemia/lymphoma",
                    "sub_points": [
                      "Preferred method to define immunophenotypic profile of leukemia/lymphoma"
                    ]
                  },
                  {
                    "text": "IHC on case-by-case basis: Cyclin-D1, annexin A1, ALK, EBV, many other possible stains"
                  },
                  {
                    "text": "Genetics (cytogenetics/FISH/molecular) required in essentially all mature B- and plasma cell neoplasms"
                  }
                ],
                "Treatment": [
                  {
                    "text": "Highly variable; disease subtype dependent"
                  },
                  {
                    "text": "Patients with indolent disease may not require initial therapy"
                  },
                  {
                    "text": "Chemotherapy &/or other therapies for aggressive tumors"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Highly Variable": [
                  {
                    "text": "Subtype dependent"
                  }
                ],
                "Translocations": [
                  {
                    "text": "IGHrearrangements in plasma cell neoplasms"
                  },
                  {
                    "text": "MCL with t(11;14)(q13;q32);CCND1::IGH"
                  },
                  {
                    "text": "BL/high grade withMYCtranslocation"
                  }
                ],
                "Viral Oncogenic Role": [
                  {
                    "text": "EBV in BL"
                  }
                ]
              },
              "MICROSCOPIC": {
                "General Features": [
                  {
                    "text": "Diagnostic approachClinical featuresWaldenström macroglobulinemiaLaboratory studiese.g., monoclonal serum proteinRenal insufficiencyRadiologic featuresLymphadenopathySplenomegalyLytic bony lesionsPathologyExtramedullary tissue biopsyImmunophenotypic profile/antigen expressionCytologic features in peripheral bloodPattern of bone marrow involvementGeneticsRecurring genetic abnormalityMYD88L265P mutation in LPL (not entirely specific)BRAFV600E mutation in HCL ( highly specific among B-cell neoplasms)CCND1::IGHfusion in MCL and some myeloma casesIGHrearrangements with multiple gene partners, hyperdiploidy in plasma cell lesions",
                    "sub_points": [
                      "Clinical featuresWaldenström macroglobulinemia",
                      "Waldenström macroglobulinemia",
                      "Laboratory studiese.g., monoclonal serum proteinRenal insufficiency",
                      "e.g., monoclonal serum protein",
                      "Renal insufficiency",
                      "Radiologic featuresLymphadenopathySplenomegalyLytic bony lesions",
                      "Lymphadenopathy",
                      "Splenomegaly",
                      "Lytic bony lesions",
                      "PathologyExtramedullary tissue biopsyImmunophenotypic profile/antigen expressionCytologic features in peripheral bloodPattern of bone marrow involvement",
                      "Extramedullary tissue biopsy",
                      "Immunophenotypic profile/antigen expression",
                      "Cytologic features in peripheral blood",
                      "Pattern of bone marrow involvement",
                      "GeneticsRecurring genetic abnormalityMYD88L265P mutation in LPL (not entirely specific)BRAFV600E mutation in HCL ( highly specific among B-cell neoplasms)CCND1::IGHfusion in MCL and some myeloma casesIGHrearrangements with multiple gene partners, hyperdiploidy in plasma cell lesions",
                      "Recurring genetic abnormality",
                      "MYD88L265P mutation in LPL (not entirely specific)",
                      "BRAFV600E mutation in HCL ( highly specific among B-cell neoplasms)",
                      "CCND1::IGHfusion in MCL and some myeloma cases",
                      "IGHrearrangements with multiple gene partners, hyperdiploidy in plasma cell lesions"
                    ]
                  }
                ],
                "Blood": [
                  {
                    "text": "Circulating tumor cells in CLL/SLL, B-PLL, HCL, leukemic, nonnodal MCL, some SMZL"
                  },
                  {
                    "text": "Occasional cases with circulating tumor cells in LPL, MM/PCM, FL, BL, large cell lymphomas"
                  },
                  {
                    "text": "Distinctive morphologyCLL/SLL: Small, clumped chromatin, scant cytoplasmB-PLL: Prominent central nucleoliHCL: Reniform nucleus, circumferential cytoplasmic projectionsLeukemic, nonnodal MCL: Highly variable morphology, can be very CLL-like or highly atypical-appearingSMZL: Round nucleus, polar villous projectionsLPL: Spectrum of lymphoid, lymphoplasmacytic, and plasma cells in bone marrowMyeloma: Plasma cells (highly variable morphology)FL: Small, deeply clefted nuclei, scant cytoplasm",
                    "sub_points": [
                      "CLL/SLL: Small, clumped chromatin, scant cytoplasm",
                      "B-PLL: Prominent central nucleoli",
                      "HCL: Reniform nucleus, circumferential cytoplasmic projections",
                      "Leukemic, nonnodal MCL: Highly variable morphology, can be very CLL-like or highly atypical-appearing",
                      "SMZL: Round nucleus, polar villous projections",
                      "LPL: Spectrum of lymphoid, lymphoplasmacytic, and plasma cells in bone marrow",
                      "Myeloma: Plasma cells (highly variable morphology)",
                      "FL: Small, deeply clefted nuclei, scant cytoplasm"
                    ]
                  }
                ],
                "Bone Marrow": [
                  {
                    "text": "Distinctive patterns of involvement depending on B-cell leukemia, lymphoma, or plasma cell subtypeFocal nonparatrabecularCLL/SLL, SMZLFocal paratrabecularFL, MCL, LPLDiffuse/interstitialB-PLL, HCL, LPL, DLBCL, BLSinusoidal; may be associated with other patterns of infiltrationSMZL, intravascular LBCL, HCLvExclusive intravascular localization in intravascular LBCL",
                    "sub_points": [
                      "Focal nonparatrabecularCLL/SLL, SMZL",
                      "CLL/SLL, SMZL",
                      "Focal paratrabecularFL, MCL, LPL",
                      "FL, MCL, LPL",
                      "Diffuse/interstitialB-PLL, HCL, LPL, DLBCL, BL",
                      "B-PLL, HCL, LPL, DLBCL, BL",
                      "Sinusoidal; may be associated with other patterns of infiltrationSMZL, intravascular LBCL, HCLvExclusive intravascular localization in intravascular LBCL",
                      "SMZL, intravascular LBCL, HCLvExclusive intravascular localization in intravascular LBCL",
                      "Exclusive intravascular localization in intravascular LBCL"
                    ]
                  }
                ]
              },
              "Ancillary Tests": {
                "Immunohistochemistry": [
                  {
                    "text": "Pan-B-cell antigens: CD19, CD20, CD79a, PAX5, CD200"
                  },
                  {
                    "text": "Plasma cell-associated antigens: CD38 (bright), CD138, cytoplasmic κ or λ, MUM1"
                  },
                  {
                    "text": "Germinal center-associated antigens: CD10, BCL6, MEF2B"
                  },
                  {
                    "text": "CD5 expression: CLL and MCL; 10-20% of LPL and SMZL cases"
                  },
                  {
                    "text": "EBV"
                  },
                  {
                    "text": "Annexin A1, CD123, CD103, BRAF, weak cyclin-D1: HCL profile"
                  },
                  {
                    "text": "Cyclin-D1: MCL, HCL (weak) , MM/PCM (subset)"
                  }
                ],
                "Flow Cytometry": [
                  {
                    "text": "Identify B-lineage &/or plasma cell population"
                  },
                  {
                    "text": "Assess surface/cytoplasmic light chain restriction"
                  },
                  {
                    "text": "Assess aberrant/restricted antigen expression on B cells: CD5, CD10, CD23, CD103, CD200"
                  },
                  {
                    "text": "Assess antigen expression on plasma cells: CD19 and CD45 (-)"
                  },
                  {
                    "text": "Discriminate mature from immature B-cell process: CD34, TdT"
                  }
                ],
                "Molecular": [
                  {
                    "text": "Clonal immunoglobulin gene rearrangement in B-lineage neoplasia"
                  },
                  {
                    "text": "MYD88L265P mutationSeen in > 90% of LPL casesSeen in < 10% of SMZL and other small B-cell neoplasms",
                    "sub_points": [
                      "Seen in > 90% of LPL cases",
                      "Seen in < 10% of SMZL and other small B-cell neoplasms"
                    ]
                  },
                  {
                    "text": "BRAFV600E mutationSeen in > 85% of HCL cases",
                    "sub_points": [
                      "Seen in > 85% of HCL cases"
                    ]
                  }
                ],
                "Cytogenetics/FISH": [
                  {
                    "text": "DiagnosisMCLt(11;14)(q13;q32);CCND1::IGH",
                    "sub_points": [
                      "MCLt(11;14)(q13;q32);CCND1::IGH",
                      "t(11;14)(q13;q32);CCND1::IGH"
                    ]
                  },
                  {
                    "text": "PrognosisCLLDeletionTP53,ATM, 13q14, 13q34,IGHtranslocations, and trisomy 12 by FISHMM/PCMConventional cytogeneticsFISH:TP53(17p13) deletion,IGHrearrangements, othersMany other molecular mutations of prognostic significance, especiallyTP53mutations",
                    "sub_points": [
                      "CLLDeletionTP53,ATM, 13q14, 13q34,IGHtranslocations, and trisomy 12 by FISH",
                      "DeletionTP53,ATM, 13q14, 13q34,IGHtranslocations, and trisomy 12 by FISH",
                      "MM/PCMConventional cytogeneticsFISH:TP53(17p13) deletion,IGHrearrangements, others",
                      "Conventional cytogenetics",
                      "FISH:TP53(17p13) deletion,IGHrearrangements, others",
                      "Many other molecular mutations of prognostic significance, especiallyTP53mutations"
                    ]
                  }
                ]
              },
              "Differential Diagnosis": {
                "Nonneoplastic B-Cell or Plasma Cell Proliferations": [
                  {
                    "text": "Chronic infection/chronic immune response"
                  },
                  {
                    "text": "Collagen vascular diseases"
                  }
                ],
                "Benign Lymphoid Aggregates": [
                  {
                    "text": "Predominance of CD3(+) T cells or equal numbers of CD20(+) B cells/CD3(+) T cells"
                  },
                  {
                    "text": "No aberrant antigen expression on B cells, nonclonal"
                  }
                ],
                "Immature B-Cell Process": [
                  {
                    "text": "B-lymphoblastic leukemia/lymphomaCD34(+), TdT(+), sIg(-), CD45 weak (+) or (-)",
                    "sub_points": [
                      "CD34(+), TdT(+), sIg(-), CD45 weak (+) or (-)"
                    ]
                  }
                ],
                "Benign Hematogones": [
                  {
                    "text": "Characteristic dense nuclear chromatin"
                  },
                  {
                    "text": "May mimic mature leukemias/lymphomas"
                  },
                  {
                    "text": "Characteristic B-cell spectrum of maturation pattern by flow cytometry"
                  }
                ]
              },
              "Diagnostic Checklist": {
                "Integrate Clinical, Laboratory, Morphologic, Immunophenotypic, and Genetic Features": [
                  {
                    "text": "Adequate clinical information"
                  },
                  {
                    "text": "Carefully assess peripheral blood and bone marrow cytologic features and pattern of bone marrow involvement"
                  },
                  {
                    "text": "Immunophenotypically characterize lymphoid &/or plasmacytic infiltrate"
                  },
                  {
                    "text": "Subtle/low-level bone marrow involvement may be morphologically occult and require IHC to visualize"
                  },
                  {
                    "text": "Integrate FISH/cytogenetic/molecular testing"
                  },
                  {
                    "text": "Suggest additional testing (e.g., extramedullary tissue sampling) for cases in which definitive diagnosis is not possible but clinically indicated"
                  }
                ],
                "Utilize": [
                  {
                    "text": "ICC 2022 or WHO-HAEM5 classification and terminology"
                  }
                ],
                "Report": [
                  {
                    "text": "Ancillary studies results as pertinent"
                  }
                ],
                "Provide": [
                  {
                    "text": "Prognostic data (especially important in CLL, PCM)"
                  },
                  {
                    "text": "Key genetic/immunophenotype information for targeted therapy options"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Blastic Plasmacytoid Dendritic Cell Neoplasm": {
            "name": "Blastic Plasmacytoid Dendritic Cell Neoplasm",
            "url": "https://app.pathprimer.com/document/051e3af0-c47e-4dfb-99e0-ef74553604a7/lesson/6f665b6e-874b-46a5-9d19-463bafa93147",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "a.k.a. CD4(+)/CD56(+) hematodermic neoplasm"
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "Cell of origin: Plasmacytoid dendritic cell precursor"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Rare disease; mainly affects adults (M:F = 3-4:1)"
                  },
                  {
                    "text": "Often presents with skin involvement"
                  },
                  {
                    "text": "Leukemia with bone marrow and blood involvement in majority of cases"
                  },
                  {
                    "text": "Multiple targeted therapy options, including anti-CD123 or anti-BCL2"
                  },
                  {
                    "text": "Disease courseAggressive; median survival 9-20 months",
                    "sub_points": [
                      "Aggressive; median survival 9-20 months"
                    ]
                  },
                  {
                    "text": "Diagnosis of exclusionAccurate diagnosis is significant issue",
                    "sub_points": [
                      "Accurate diagnosis is significant issue"
                    ]
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Blastic nuclear features"
                  },
                  {
                    "text": "Agranular, pseudopod-like cytoplasm"
                  },
                  {
                    "text": "Perinuclear circumferential vacuoles"
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "Cytochemistry: MPO and NSE (-)"
                  },
                  {
                    "text": "ImmunophenotypeCD4, CD56, CD123, cTCL1, BDCA2 (CD303), HLA-DR, CD304 (+)MPO, CD14, CD19, CD22, cCD3, lysozyme, Epstein-Barr virus (-)May be TdT, CD33, CD2, CD5, CD7, CD117 (+)Dual SOX4 (nuclear) and CD123 (cytoplasmic) positivity specific for blastic plasmacytoid dendritic cell neoplasmCoexpression of CD123 and TCF4 highly associated with diagnosis but can also be positive in reactive plasmacytoid dendritic cell",
                    "sub_points": [
                      "CD4, CD56, CD123, cTCL1, BDCA2 (CD303), HLA-DR, CD304 (+)",
                      "MPO, CD14, CD19, CD22, cCD3, lysozyme, Epstein-Barr virus (-)",
                      "May be TdT, CD33, CD2, CD5, CD7, CD117 (+)",
                      "Dual SOX4 (nuclear) and CD123 (cytoplasmic) positivity specific for blastic plasmacytoid dendritic cell neoplasm",
                      "Coexpression of CD123 and TCF4 highly associated with diagnosis but can also be positive in reactive plasmacytoid dendritic cell"
                    ]
                  },
                  {
                    "text": "GeneticsComplex karyotypeTCR andIGHgermline configurationNonspecific karyotypic abnormalitiesMyeloid-disease associated gene mutations (e.g.,TET2,ASXL1)",
                    "sub_points": [
                      "Complex karyotype",
                      "TCR andIGHgermline configuration",
                      "Nonspecific karyotypic abnormalities",
                      "Myeloid-disease associated gene mutations (e.g.,TET2,ASXL1)"
                    ]
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "Mature plasmacytoid dendritic cell proliferation associated with myeloid neoplasm"
                  },
                  {
                    "text": "Acute myeloid or acute lymphoblastic leukemia"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Blastic plasmacytoid dendritic cell neoplasm (BPDCN)"
                  },
                  {
                    "text": "Plasmacytoid dendritic cell (PDC)"
                  },
                  {
                    "text": "International Consensus Classification (ICC)"
                  },
                  {
                    "text": "WHO 5th edition (WHO-HAEM5)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "CD4(+)/CD56(+) hematodermic neoplasm"
                  },
                  {
                    "text": "CD4(+)/CD56(+) lineage (-) malignancy"
                  },
                  {
                    "text": "Agranular CD4(+) NK-cell leukemia"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Neoplasm derived from PDC precursors"
                  },
                  {
                    "text": "Associated with cutaneous and bone marrow involvement"
                  }
                ]
              },
              "CLASSIFICATION": {
                "ICC and WHO-HAEM5 Classifications": [
                  {
                    "text": "Diagnostic criteria similar in both"
                  },
                  {
                    "text": "Immunophenotypic diagnostic criteria requires eitherExpression of CD123 and one other PDC marker (TCF4, TCL1, CD303, CD304) in addition to CD4 &/or CD56, orExpression of any 3 PDC markers (CD123, TCF4, TCL1, CD303, CD304) and no expression of expected negative markers (CD3, CD14, CD19, CD34, lysozyme, MPO)",
                    "sub_points": [
                      "Expression of CD123 and one other PDC marker (TCF4, TCL1, CD303, CD304) in addition to CD4 &/or CD56, or",
                      "Expression of any 3 PDC markers (CD123, TCF4, TCL1, CD303, CD304) and no expression of expected negative markers (CD3, CD14, CD19, CD34, lysozyme, MPO)"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Environmental Exposure": [
                  {
                    "text": "Can occur following cytotoxic therapy"
                  }
                ],
                "Infectious Agents": [
                  {
                    "text": "No link with Epstein-Barr virus infection"
                  }
                ],
                "Postulated Normal Cell Counterpart": [
                  {
                    "text": "PDC precursorInvolved in innate immunityNeoplasia associated with aberrant NF-κB pathway activationProduce high amounts of α-interferonNeoplasia linked to 12p13/ETV6deletion",
                    "sub_points": [
                      "Involved in innate immunity",
                      "Neoplasia associated with aberrant NF-κB pathway activationProduce high amounts of α-interferon",
                      "Produce high amounts of α-interferon",
                      "Neoplasia linked to 12p13/ETV6deletion"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "Rare disease but likely underdiagnosed0.04 cases/100,000 in USA500-1,000 patients per year",
                    "sub_points": [
                      "0.04 cases/100,000 in USA500-1,000 patients per year",
                      "500-1,000 patients per year"
                    ]
                  }
                ],
                "Age": [
                  {
                    "text": "Mainly adultsAverage range: 55-65 years",
                    "sub_points": [
                      "Average range: 55-65 years"
                    ]
                  },
                  {
                    "text": "5% of BPDCN affect children < 10 years of age"
                  }
                ],
                "Sex": [
                  {
                    "text": "Male predominance (M:F = 3-5:1) in patients > 60 years of age"
                  },
                  {
                    "text": "More equal M:F ratio in patients < 40 years of age"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Spectrum of clinical presentations"
                  },
                  {
                    "text": "Often dermatopathic> 80-90% of casesMay be subtle infiltrateMultiple skin lesions: Plaques, ecchymotic (bruise-like); later evolution to tumor nodulesMost common on upper trunk, head, and neckMay involve mucosaOther visceral organs may also be involved: Lymph node (40%), spleen (25%), liver (15%)Typically followed by florid leukemia after weeks to months",
                    "sub_points": [
                      "> 80-90% of cases",
                      "May be subtle infiltrate",
                      "Multiple skin lesions: Plaques, ecchymotic (bruise-like); later evolution to tumor nodules",
                      "Most common on upper trunk, head, and neck",
                      "May involve mucosa",
                      "Other visceral organs may also be involved: Lymph node (40%), spleen (25%), liver (15%)",
                      "Typically followed by florid leukemia after weeks to months"
                    ]
                  },
                  {
                    "text": "LeukemiaFrank involvement of peripheral blood and bone marrowBone marrow involved in 63%May precede, coincide with, or follow dermatopathic presentationProgressive pancytopenia with variable degree of circulating tumor cellsCirculating tumor cells in 76% of casesMay have associated monocytosisPresent with fatigue, bleeding, bruising, recurrent infections",
                    "sub_points": [
                      "Frank involvement of peripheral blood and bone marrowBone marrow involved in 63%",
                      "Bone marrow involved in 63%",
                      "May precede, coincide with, or follow dermatopathic presentation",
                      "Progressive pancytopenia with variable degree of circulating tumor cellsCirculating tumor cells in 76% of casesMay have associated monocytosisPresent with fatigue, bleeding, bruising, recurrent infections",
                      "Circulating tumor cells in 76% of cases",
                      "May have associated monocytosis",
                      "Present with fatigue, bleeding, bruising, recurrent infections"
                    ]
                  },
                  {
                    "text": "Lymphadenopathy in 50% of patientsMost commonly cervical or inguinal",
                    "sub_points": [
                      "Most commonly cervical or inguinal"
                    ]
                  },
                  {
                    "text": "CNS involved in > 38% of patients"
                  },
                  {
                    "text": "Presentation associated with another myeloid neoplasm in 10-20%May precede, present concurrently, or occur following another myeloid neoplasmMost commonly acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or MDS/myeloproliferative neoplasm",
                    "sub_points": [
                      "May precede, present concurrently, or occur following another myeloid neoplasm",
                      "Most commonly acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or MDS/myeloproliferative neoplasm"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "Major issue is accurate diagnosis"
                  },
                  {
                    "text": "Treatment not standardizedAnti-CD123 targeted therapyTagraxofusp offers highly specific cytotoxicity with minimal side effectsAssociated with good overall response, although relapse rates remain highOther anti-CD123 agents in developmentBCL2 antagonistsVenetoclax associated with tumor suppressionResults are transientMultiagent chemotherapyAML-like, acute lymphoblastic leukemia (ALL)-like, lymphoma-like, or myeloma-like therapy may be used",
                    "sub_points": [
                      "Anti-CD123 targeted therapyTagraxofusp offers highly specific cytotoxicity with minimal side effectsAssociated with good overall response, although relapse rates remain highOther anti-CD123 agents in development",
                      "Tagraxofusp offers highly specific cytotoxicity with minimal side effectsAssociated with good overall response, although relapse rates remain high",
                      "Associated with good overall response, although relapse rates remain high",
                      "Other anti-CD123 agents in development",
                      "BCL2 antagonistsVenetoclax associated with tumor suppressionResults are transient",
                      "Venetoclax associated with tumor suppression",
                      "Results are transient",
                      "Multiagent chemotherapyAML-like, acute lymphoblastic leukemia (ALL)-like, lymphoma-like, or myeloma-like therapy may be used",
                      "AML-like, acute lymphoblastic leukemia (ALL)-like, lymphoma-like, or myeloma-like therapy may be used"
                    ]
                  },
                  {
                    "text": "Allogeneic transplant in 1st remission offers best chance of long-term survivalAutologous transplant may be used in selected patients who are not candidates for allogeneic transplant",
                    "sub_points": [
                      "Autologous transplant may be used in selected patients who are not candidates for allogeneic transplant"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Aggressive clinical course"
                  },
                  {
                    "text": "Median survival 8-16 monthsHigh rate of early mortality",
                    "sub_points": [
                      "High rate of early mortality"
                    ]
                  },
                  {
                    "text": "Most cases initially respond to multiagent chemotherapy (> 80%)"
                  },
                  {
                    "text": "Subsequent relapse; treatment resistantComplete remission only attained in 40-55%",
                    "sub_points": [
                      "Complete remission only attained in 40-55%"
                    ]
                  },
                  {
                    "text": "Pediatric patients may do better with high-risk ALL-like regimens"
                  },
                  {
                    "text": "Rare reports of long-term survival"
                  },
                  {
                    "text": "Allogeneic transplantation is advocated for eligible patients who achieve clinical remission"
                  }
                ]
              },
              "MACROSCOPIC": {
                "General Features": [
                  {
                    "text": "Skin lesions (> 90%)"
                  },
                  {
                    "text": "Splenomegaly"
                  },
                  {
                    "text": "Hepatomegaly (< 20%)"
                  },
                  {
                    "text": "CNS involvement (> 38%)"
                  },
                  {
                    "text": "Lymphadenopathy"
                  },
                  {
                    "text": "Leukemic presentation (~ 65%)"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Predominant Pattern/Injury Type": [
                  {
                    "text": "Infiltrative"
                  }
                ],
                "Predominant Cell/Compartment Type": [
                  {
                    "text": "Dendritic cell"
                  }
                ],
                "Histologic Features": [
                  {
                    "text": "Peripheral blood and bone marrow aspirateBlastic nuclear features, agranular cytoplasmAuer rods absentMost often lymphoblast-like: Small to intermediate size, condensed chromatin, scant cytoplasm, inconspicuous nucleoliOccasionally myeloid/monocytic-like: Large size, dispersed chromatin, more abundant cytoplasm, ≥ 1 prominent nucleoliUnique, but not specific, featuresCircumferential rim of evenly sized microvacuoles around nucleus or single large round vacuolePseudopods; unipolar cytoplasmic extensions (tadpole appearance)Immunoblastoid cytology described more commonly in cases with MYC rearrangement",
                    "sub_points": [
                      "Blastic nuclear features, agranular cytoplasmAuer rods absent",
                      "Auer rods absent",
                      "Most often lymphoblast-like: Small to intermediate size, condensed chromatin, scant cytoplasm, inconspicuous nucleoli",
                      "Occasionally myeloid/monocytic-like: Large size, dispersed chromatin, more abundant cytoplasm, ≥ 1 prominent nucleoli",
                      "Unique, but not specific, featuresCircumferential rim of evenly sized microvacuoles around nucleus or single large round vacuolePseudopods; unipolar cytoplasmic extensions (tadpole appearance)",
                      "Circumferential rim of evenly sized microvacuoles around nucleus or single large round vacuole",
                      "Pseudopods; unipolar cytoplasmic extensions (tadpole appearance)",
                      "Immunoblastoid cytology described more commonly in cases with MYC rearrangement"
                    ]
                  },
                  {
                    "text": "Bone marrowHighly variable percent of bone marrow involvementDiffuse interstitial infiltrateMarrow replacement with marked trilineage hypoplasiaFew residual megakaryocytes not uncommonMay see patchy marrow involvementMainly in dermatopathic presentation",
                    "sub_points": [
                      "Highly variable percent of bone marrow involvement",
                      "Diffuse interstitial infiltrate",
                      "Marrow replacement with marked trilineage hypoplasiaFew residual megakaryocytes not uncommon",
                      "Few residual megakaryocytes not uncommon",
                      "May see patchy marrow involvementMainly in dermatopathic presentation",
                      "Mainly in dermatopathic presentation"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Cytochemical Stains": [
                  {
                    "text": "MPO and NSE (-)"
                  }
                ],
                "Immunophenotyping": [
                  {
                    "text": "Flow cytometry &/or IHC"
                  },
                  {
                    "text": "PositiveCD4, CD56, CD123, TCL1, TCF4, CD303 (BDCA2), CD304, HLA-DR, IRF8CD123 expression seen in 100% of casesFrequent selected myeloid and T-cell antigen expressionCD33, CD7, TdT (~ 30%; patchy, weak), CD68 (dot-like)OccasionalCD2, CD117, CD5Dual SOX4 (nuclear) and CD123 (cytoplasmic) positivity specific for BPDCNNonneoplastic PDCs and other myeloid and lymphoid neoplasms (-)",
                    "sub_points": [
                      "CD4, CD56, CD123, TCL1, TCF4, CD303 (BDCA2), CD304, HLA-DR, IRF8CD123 expression seen in 100% of cases",
                      "CD123 expression seen in 100% of cases",
                      "Frequent selected myeloid and T-cell antigen expressionCD33, CD7, TdT (~ 30%; patchy, weak), CD68 (dot-like)",
                      "CD33, CD7, TdT (~ 30%; patchy, weak), CD68 (dot-like)",
                      "OccasionalCD2, CD117, CD5",
                      "CD2, CD117, CD5",
                      "Dual SOX4 (nuclear) and CD123 (cytoplasmic) positivity specific for BPDCNNonneoplastic PDCs and other myeloid and lymphoid neoplasms (-)",
                      "Nonneoplastic PDCs and other myeloid and lymphoid neoplasms (-)"
                    ]
                  },
                  {
                    "text": "NegativeCD34 (mostly -)Lineage-specific markers should be negativeCD19, CD3, MPO, lysozyme, CD14Epstein-Barr virus",
                    "sub_points": [
                      "CD34 (mostly -)",
                      "Lineage-specific markers should be negativeCD19, CD3, MPO, lysozyme, CD14",
                      "CD19, CD3, MPO, lysozyme, CD14",
                      "Epstein-Barr virus"
                    ]
                  },
                  {
                    "text": "CaveatsCD123 not specific; seen in AML and occasional lymphoblastic leukemiaTCL1 not specific; seen in mature B-cell lymphomas and T-cell prolymphocytic leukemiaCD4 and CD56 often positive in acute monoblastic leukemia",
                    "sub_points": [
                      "CD123 not specific; seen in AML and occasional lymphoblastic leukemia",
                      "TCL1 not specific; seen in mature B-cell lymphomas and T-cell prolymphocytic leukemia",
                      "CD4 and CD56 often positive in acute monoblastic leukemia"
                    ]
                  }
                ],
                "Genetics": [
                  {
                    "text": "Karyotyping and DNA copy number alterationsNo specific abnormalities; complex karyotype in 60%Recurring chromosomal abnormalities include del(5q), del(12p), del(13q), del(6q), 15q, and 98q24 rearrangement in 1/3 of cases associated with immunoblastoid morphology and MYC expressionRecurrent deletions on chromosomes 4(4q34), 9(9p and 9q), and 13(13q)Multiple losses of tumor suppressor genes;CDKN2A,CDKN2B, etc.MYBrearrangement in 20%, especially children and young adults",
                    "sub_points": [
                      "No specific abnormalities; complex karyotype in 60%",
                      "Recurring chromosomal abnormalities include del(5q), del(12p), del(13q), del(6q), 15q, and 9",
                      "8q24 rearrangement in 1/3 of cases associated with immunoblastoid morphology and MYC expression",
                      "Recurrent deletions on chromosomes 4(4q34), 9(9p and 9q), and 13(13q)",
                      "Multiple losses of tumor suppressor genes;CDKN2A,CDKN2B, etc.",
                      "MYBrearrangement in 20%, especially children and young adults"
                    ]
                  },
                  {
                    "text": "FISH: No known utility"
                  },
                  {
                    "text": "Gene expressionUnique signature distinct from AML and ALL",
                    "sub_points": [
                      "Unique signature distinct from AML and ALL"
                    ]
                  },
                  {
                    "text": "Molecular geneticsMutations similar to other myeloid neoplasms withTET2andASXL1most commonTumor suppressor genesTP53,RB1,CDKN1B,CDKN2AOncogenesNRAS,KRAS,FLT3,RUNX2,HES6Epigenetic modifiersIDH1,IDH2,TET1,TET2,ASXL1OtherZRSR2,IFNGR,TGFB,CLEC4CTCR andIGHgermline configurationMonoallelic deletion ofNR3C1(5q31-q32), encoding glucocorticoid receptor",
                    "sub_points": [
                      "Mutations similar to other myeloid neoplasms withTET2andASXL1most commonTumor suppressor genesTP53,RB1,CDKN1B,CDKN2AOncogenesNRAS,KRAS,FLT3,RUNX2,HES6Epigenetic modifiersIDH1,IDH2,TET1,TET2,ASXL1OtherZRSR2,IFNGR,TGFB,CLEC4C",
                      "Tumor suppressor genesTP53,RB1,CDKN1B,CDKN2A",
                      "TP53,RB1,CDKN1B,CDKN2A",
                      "OncogenesNRAS,KRAS,FLT3,RUNX2,HES6",
                      "NRAS,KRAS,FLT3,RUNX2,HES6",
                      "Epigenetic modifiersIDH1,IDH2,TET1,TET2,ASXL1",
                      "IDH1,IDH2,TET1,TET2,ASXL1",
                      "OtherZRSR2,IFNGR,TGFB,CLEC4C",
                      "ZRSR2,IFNGR,TGFB,CLEC4C",
                      "TCR andIGHgermline configuration",
                      "Monoallelic deletion ofNR3C1(5q31-q32), encoding glucocorticoid receptor"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Acute Myeloid Leukemia": [
                  {
                    "text": "Features similar to BPDCNLeukemic presentationBone marrow effacementSkin nodules20-40% of AMLs depending on subtypeAML with monocytic differentiation may be challenging to distinguish without extensive ancillary studies",
                    "sub_points": [
                      "Leukemic presentation",
                      "Bone marrow effacement",
                      "Skin nodules20-40% of AMLs depending on subtypeAML with monocytic differentiation may be challenging to distinguish without extensive ancillary studies",
                      "20-40% of AMLs depending on subtype",
                      "AML with monocytic differentiation may be challenging to distinguish without extensive ancillary studies"
                    ]
                  },
                  {
                    "text": "Distinguishing characteristics from BPDCNCytologyMay see cytoplasmic granules, Auer rodsCytochemistryMPO(+) (myeloid); NSE(+) (monocytic)Immunophenotypic profileVariable, combined expression of CD13, CD33, CD34, and CD117 (myeloid)Variable, combined expression of CD4, CD36/CD64, CD14 (monocytic)CD123 (IL-3 α receptor) expression not specific for BPDCN; seen in up to 40-50% of AMLRecurring genetic abnormality excludes BPDCN: e.g., t(8;21),KMT2Agene rearrangement, t(15;17), t(9;22)",
                    "sub_points": [
                      "CytologyMay see cytoplasmic granules, Auer rods",
                      "May see cytoplasmic granules, Auer rods",
                      "CytochemistryMPO(+) (myeloid); NSE(+) (monocytic)",
                      "MPO(+) (myeloid); NSE(+) (monocytic)",
                      "Immunophenotypic profileVariable, combined expression of CD13, CD33, CD34, and CD117 (myeloid)Variable, combined expression of CD4, CD36/CD64, CD14 (monocytic)CD123 (IL-3 α receptor) expression not specific for BPDCN; seen in up to 40-50% of AML",
                      "Variable, combined expression of CD13, CD33, CD34, and CD117 (myeloid)",
                      "Variable, combined expression of CD4, CD36/CD64, CD14 (monocytic)",
                      "CD123 (IL-3 α receptor) expression not specific for BPDCN; seen in up to 40-50% of AML",
                      "Recurring genetic abnormality excludes BPDCN: e.g., t(8;21),KMT2Agene rearrangement, t(15;17), t(9;22)"
                    ]
                  }
                ],
                "Acute Lymphoblastic Leukemia": [
                  {
                    "text": "Features similar to BPDCNLeukemic presentationBone marrow effacement",
                    "sub_points": [
                      "Leukemic presentation",
                      "Bone marrow effacement"
                    ]
                  },
                  {
                    "text": "Distinguishing characteristics from BPDCNImmunophenotypic profile of ALLB lineage: Variable, combined expression of CD19 with CD79a, CD22, CD10, CD20 (subset variable), strong and uniform TdT, &/or CD34T lineage: Variable, combined expression of CD1a, CD2, cytoplasmic CD3 (must have), CD5, CD7, strong and uniform CD34, &/or TdTRecurring genetic abnormality excludes BPDCNe.g., t(12;21),KMT2Agene rearrangement, t(9;22)",
                    "sub_points": [
                      "Immunophenotypic profile of ALLB lineage: Variable, combined expression of CD19 with CD79a, CD22, CD10, CD20 (subset variable), strong and uniform TdT, &/or CD34T lineage: Variable, combined expression of CD1a, CD2, cytoplasmic CD3 (must have), CD5, CD7, strong and uniform CD34, &/or TdT",
                      "B lineage: Variable, combined expression of CD19 with CD79a, CD22, CD10, CD20 (subset variable), strong and uniform TdT, &/or CD34",
                      "T lineage: Variable, combined expression of CD1a, CD2, cytoplasmic CD3 (must have), CD5, CD7, strong and uniform CD34, &/or TdT",
                      "Recurring genetic abnormality excludes BPDCNe.g., t(12;21),KMT2Agene rearrangement, t(9;22)",
                      "e.g., t(12;21),KMT2Agene rearrangement, t(9;22)"
                    ]
                  }
                ],
                "Mature Plasmacytoid Dendritic Cells in Association With Myeloid Disorders": [
                  {
                    "text": "Nodular collections of PDC; similar to normal PDCs but often more nuclear irregularity; CD56(-)"
                  },
                  {
                    "text": "Chronic myelomonocytic leukemia most common; rarely MDS and AML"
                  },
                  {
                    "text": "Some cases have shown clonal relatedness between PDCs and myeloid neoplasm"
                  }
                ],
                "Aggressive NK-Cell Leukemia": [
                  {
                    "text": "Epstein-Barr virus (+) (EBER)"
                  }
                ],
                "Blastic Mantle Cell Lymphoma": [
                  {
                    "text": "Monoclonal B-cell neoplasm by flow cytometry"
                  },
                  {
                    "text": "Translocation (11;14)(q13;q32);CCND1::IGHfusion &/or cyclin-D1 (+)"
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Clinically Relevant Pathologic Features": [
                  {
                    "text": "Tissue distribution: Skin and bone marrow"
                  },
                  {
                    "text": "BPDCN mimics other types of acute leukemia with cutaneous presentation"
                  }
                ],
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "Hematodermic presentation"
                  },
                  {
                    "text": "Blastic cytology"
                  },
                  {
                    "text": "Diagnosis of exclusion"
                  },
                  {
                    "text": "Diagnosis relies on demonstrating expression of CD4, CD56, CD123, CD303, cTCL1 and lack of expression of specific B, T, NK, or myeloid markers"
                  }
                ]
              },
              "REPORTING": {
                "Utilize WHO Terminology": [
                  {
                    "text": "Document immunophenotypic profile diagnostic of BPDCN"
                  }
                ],
                "Exclude Differential Diagnostic Considerations": [
                  {
                    "text": "Document ancillary testing performed to exclude differential diagnoses"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Burkitt Lymphoma": {
            "name": "Burkitt Lymphoma",
            "url": "https://app.pathprimer.com/document/7f5c0194-7d57-4a3c-82ac-2980590e4096/lesson/6f665b6e-874b-46a5-9d19-463bafa93147",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Burkitt lymphoma (BL) is highly aggressive B-cell neoplasm"
                  },
                  {
                    "text": "eBL: Occurs in equatorial Africa, correlating with endemic zone ofPlasmodium falciparummalaria and Epstein-Barr virus (EBV) infection"
                  },
                  {
                    "text": "sBL: Occurs throughout world, sporadic"
                  },
                  {
                    "text": "iBL: Occurs in setting of immunodeficiency"
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "BL is derived from germinal center B cells or postgerminal center B cells"
                  },
                  {
                    "text": "Translocation ofMYCis characteristic"
                  },
                  {
                    "text": "Relationship of endemicP.falciparum malaria, EBV infection, and BL has long been recognized"
                  },
                  {
                    "text": "EBV reactivation, expansion of B cells, and reduced T-cell function may play roles in pathogenesis of endemic BL"
                  },
                  {
                    "text": "BL is more common in HIV immunodeficiency than other types of immunodeficiency"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "eBL: Most common childhood malignancy in endemic area, jaws and facial bones are most common sites of involvement"
                  },
                  {
                    "text": "iBL: Predominantly seen in HIV(+) patients; accounting for 30% of all HIV-associated lymphomasCNS and bone marrow involvement common",
                    "sub_points": [
                      "CNS and bone marrow involvement common"
                    ]
                  },
                  {
                    "text": "Incidence peaks from 4-7 years"
                  },
                  {
                    "text": "Ileum and cecum are most frequently involved in sporadic BL"
                  },
                  {
                    "text": "Circulating neoplastic cells can be seen when blood is involved"
                  },
                  {
                    "text": "Typically, patients have symptoms of only few weeks duration"
                  },
                  {
                    "text": "Lymphoma cell doubling time is 24-26 hours, and tumor size could double within 1 day"
                  },
                  {
                    "text": "Intensive combination of chemotherapy is mainstay of treatment"
                  },
                  {
                    "text": "BL is highly chemosensitive and potentially curable"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Medium-sized lymphoma cells with deeply basophilic cytoplasm with distinct cytoplasmic lipid vacuoles"
                  },
                  {
                    "text": "Brisk mitotic and apoptotic bodies form starry-sky pattern on tissue sections"
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "CD20(+), CD10(+), BCL6(+), and CD43(+); BCL2(-)"
                  },
                  {
                    "text": "Ki-67(+) in ~ 100% of neoplastic cells"
                  },
                  {
                    "text": "t(8;14)(q24;q32)MYC::IGHas sole abnormality"
                  },
                  {
                    "text": "Alternative translocations includet(2;8)(p12;q24)IGK::MYCt(8;22)(q24;q11)MYC::IGL",
                    "sub_points": [
                      "t(2;8)(p12;q24)IGK::MYC",
                      "t(8;22)(q24;q11)MYC::IGL"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Burkitt lymphoma (BL)"
                  },
                  {
                    "text": "International Consensus Classification (ICC)"
                  },
                  {
                    "text": "WHO 5th edition (WHO-HAEM5)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Burkitt lymphoma/leukemia (WHO-HAEM5)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Highly aggressive mature B-cell neoplasm"
                  },
                  {
                    "text": "Endemic BL (eBL): Occurs in equatorial Africa, correlating with endemic zone ofPlasmodium falciparummalaria and Epstein-Barr virus (EBV) infections"
                  },
                  {
                    "text": "Sporadic BL (sBL): Occurs throughout world"
                  },
                  {
                    "text": "Immunodeficiency-associated BL (iBL): Occurs primarily in setting of HIV infection"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Cell of Origin": [
                  {
                    "text": "BL is derived from dark zone germinal center B cells (GCB)"
                  }
                ],
                "Pathogenesis": [
                  {
                    "text": "Translocation ofMYCis highly characteristic in BLActivation-induced cytidine deaminase-mediated immunoglobulin class switch recombination is primary mechanism forIGH::MYCtranslocation in sBLSomatic hypermutation is another mechanism forIGH::MYCtranslocation in sBL",
                    "sub_points": [
                      "Activation-induced cytidine deaminase-mediated immunoglobulin class switch recombination is primary mechanism forIGH::MYCtranslocation in sBL",
                      "Somatic hypermutation is another mechanism forIGH::MYCtranslocation in sBL"
                    ]
                  },
                  {
                    "text": "Relationship ofP.falciparummalaria and EBV infection with eBL has long been recognizedP.falciparumis proposed in pathogenesis of eBLInduces B-cell expansion and EBV reactivationDecreased EBV-specific T cells, thus loss of control of EBV(+) B cellsIncreases chance ofMYCtranslocation during expansion of EBV(+) B cellsEBV(+) status is related to unique genomic mutation profilingGenome-wide increase in somatic hypermutationsIncreased activation-induced cytidine deaminase (AICDA) activityFewer driver mutations despite greater mutational load",
                    "sub_points": [
                      "P.falciparumis proposed in pathogenesis of eBLInduces B-cell expansion and EBV reactivationDecreased EBV-specific T cells, thus loss of control of EBV(+) B cellsIncreases chance ofMYCtranslocation during expansion of EBV(+) B cells",
                      "Induces B-cell expansion and EBV reactivation",
                      "Decreased EBV-specific T cells, thus loss of control of EBV(+) B cells",
                      "Increases chance ofMYCtranslocation during expansion of EBV(+) B cells",
                      "EBV(+) status is related to unique genomic mutation profilingGenome-wide increase in somatic hypermutationsIncreased activation-induced cytidine deaminase (AICDA) activityFewer driver mutations despite greater mutational load",
                      "Genome-wide increase in somatic hypermutations",
                      "Increased activation-induced cytidine deaminase (AICDA) activity",
                      "Fewer driver mutations despite greater mutational load"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "eBLMost common childhood malignancy in endemic areas30-50% of all childhood lymphomas",
                    "sub_points": [
                      "Most common childhood malignancy in endemic areas30-50% of all childhood lymphomas",
                      "30-50% of all childhood lymphomas"
                    ]
                  },
                  {
                    "text": "sBL1-2% of all lymphomas in western Europe and USA",
                    "sub_points": [
                      "1-2% of all lymphomas in western Europe and USA"
                    ]
                  },
                  {
                    "text": "iBLPredominantly seen in HIV(+) patients; BL accounts for 30% of all HIV-associated lymphomasOccurs early in infectionOccurs despite antiretroviral therapy",
                    "sub_points": [
                      "Predominantly seen in HIV(+) patients; BL accounts for 30% of all HIV-associated lymphomas",
                      "Occurs early in infection",
                      "Occurs despite antiretroviral therapy"
                    ]
                  }
                ],
                "Age": [
                  {
                    "text": "eBL: Peak incidence between 6-8 years"
                  },
                  {
                    "text": "sBL: Age-dependent incidence peaks at 10, 30, and 70 years"
                  },
                  {
                    "text": "iBL: Primarily adults"
                  }
                ],
                "Sex": [
                  {
                    "text": "M:F = 2-3:1 in all types of BL"
                  }
                ],
                "Site": [
                  {
                    "text": "eBLJaws or periorbital facial bones are most common sites of involvement; seen in 50% of casesDistal ileum, cecum, omentum, gonads, kidneys, long bones, thyroid, salivary glands, and breast can be affectedBone marrow and CNS can be involved",
                    "sub_points": [
                      "Jaws or periorbital facial bones are most common sites of involvement; seen in 50% of cases",
                      "Distal ileum, cecum, omentum, gonads, kidneys, long bones, thyroid, salivary glands, and breast can be affected",
                      "Bone marrow and CNS can be involved"
                    ]
                  },
                  {
                    "text": "sBLIleum or cecum are most frequent sites of involvementHead and neck (particularly Waldeyer ring) followsOvaries, kidneys, and breasts are other common sitesBilateral and massive breast involvement often coincident with onset of pubertyCNS can be involvedJaw is rarely involved",
                    "sub_points": [
                      "Ileum or cecum are most frequent sites of involvementHead and neck (particularly Waldeyer ring) follows",
                      "Head and neck (particularly Waldeyer ring) follows",
                      "Ovaries, kidneys, and breasts are other common sites",
                      "Bilateral and massive breast involvement often coincident with onset of puberty",
                      "CNS can be involved",
                      "Jaw is rarely involved"
                    ]
                  },
                  {
                    "text": "iBLFrequent bone marrow and CNS involvement",
                    "sub_points": [
                      "Frequent bone marrow and CNS involvement"
                    ]
                  }
                ],
                "Presentation": [
                  {
                    "text": "2/3 of patients present with advanced-stage disease with rapidly growing bulky disease of only few weeks duration"
                  },
                  {
                    "text": "eBLJaw/facial bone mass is most frequent presentation in younger childrenAbdomen involvement in older children",
                    "sub_points": [
                      "Jaw/facial bone mass is most frequent presentation in younger children",
                      "Abdomen involvement in older children"
                    ]
                  },
                  {
                    "text": "sBLAbdominal mass is most common presentation due to ileum or cecum involvementRetroperitoneal mass or lymphadenopathy can be seen",
                    "sub_points": [
                      "Abdominal mass is most common presentation due to ileum or cecum involvement",
                      "Retroperitoneal mass or lymphadenopathy can be seen"
                    ]
                  },
                  {
                    "text": "iBLCommonly manifests as leukemia with blood and bone marrow involvementHigh incidence of CNS involvement",
                    "sub_points": [
                      "Commonly manifests as leukemia with blood and bone marrow involvement",
                      "High incidence of CNS involvement"
                    ]
                  }
                ],
                "Laboratory Tests": [
                  {
                    "text": "Cytopenia(s) when bone marrow is involved"
                  },
                  {
                    "text": "Circulating lymphoma cells when blood is involved"
                  },
                  {
                    "text": "Serum lactate dehydrogenase (LDH) level very high"
                  }
                ],
                "Natural History": [
                  {
                    "text": "Lymphoma cell doubling time is 24-26 hours, and tumor size may double within 1 day"
                  },
                  {
                    "text": "Patients die of disease within weeks if left untreated"
                  }
                ],
                "Treatment": [
                  {
                    "text": "Intensive combination of chemotherapy is mainstay of treatment"
                  },
                  {
                    "text": "Tumor lysis syndrome often occurs at initiation of therapyMajor manifestations of tumor lysis syndrome include hyperuricemia, hyperkalemia, and hyperphosphatemiaHyperkalemia is most serious complication; it may cause fatal cardiac arrest within hours of initiation of therapyCan be prevented by maintaining high urine output by diuresis in combination with use of allopurinolHemodialysis is occasionally required to control azotemia, hyperkalemia, hyperuricemia, or hyperphosphatemia",
                    "sub_points": [
                      "Major manifestations of tumor lysis syndrome include hyperuricemia, hyperkalemia, and hyperphosphatemia",
                      "Hyperkalemia is most serious complication; it may cause fatal cardiac arrest within hours of initiation of therapy",
                      "Can be prevented by maintaining high urine output by diuresis in combination with use of allopurinol",
                      "Hemodialysis is occasionally required to control azotemia, hyperkalemia, hyperuricemia, or hyperphosphatemia"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "BL is highly chemosensitive and potentially curable"
                  },
                  {
                    "text": "Cure rate in low-stage disease is > 90% and 60-80% in advanced-stage disease for eBL"
                  },
                  {
                    "text": "Survival is better in children than in adults"
                  },
                  {
                    "text": "Adverse prognostic findingsBone marrow and CNS involvementUnresectable tumor > 10 cm in diameterHigh serum LDH level",
                    "sub_points": [
                      "Bone marrow and CNS involvement",
                      "Unresectable tumor > 10 cm in diameter",
                      "High serum LDH level"
                    ]
                  },
                  {
                    "text": "Relapse may occur in subset of patients, usually within 1st year after diagnosis, and carries dismal prognosis"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Microscopic Features": [
                  {
                    "text": "BloodMedium-sized lymphoma cells with moderate deeply basophilic cytoplasm and cytoplasmic lipid vacuolesRound nuclei with finely clumped chromatin and multiple nucleoli",
                    "sub_points": [
                      "Medium-sized lymphoma cells with moderate deeply basophilic cytoplasm and cytoplasmic lipid vacuoles",
                      "Round nuclei with finely clumped chromatin and multiple nucleoli"
                    ]
                  },
                  {
                    "text": "Bone marrow aspirateBL cells typically admixed with hematopoietic cellsBL cells are variably sized on bone marrow aspirate smears despite typical small to intermediate cell size in tissue sectionsMay mimic large cell lymphoma",
                    "sub_points": [
                      "BL cells typically admixed with hematopoietic cells",
                      "BL cells are variably sized on bone marrow aspirate smears despite typical small to intermediate cell size in tissue sectionsMay mimic large cell lymphoma",
                      "May mimic large cell lymphoma"
                    ]
                  },
                  {
                    "text": "Bone marrow core biopsyInterstitial aggregates or diffuse interstitial patterns in early bone marrow involvementSolid infiltration pattern in late stage of involvementBrisk mitotic and apoptotic rateMay exhibit starry-sky pattern on low power due to increased tingible body macrophages containing apoptotic tumor cellsMay demonstrate areas of necrosisFrequently exhibits plasmacytoid differentiation in iBL",
                    "sub_points": [
                      "Interstitial aggregates or diffuse interstitial patterns in early bone marrow involvement",
                      "Solid infiltration pattern in late stage of involvement",
                      "Brisk mitotic and apoptotic rate",
                      "May exhibit starry-sky pattern on low power due to increased tingible body macrophages containing apoptotic tumor cells",
                      "May demonstrate areas of necrosis",
                      "Frequently exhibits plasmacytoid differentiation in iBL"
                    ]
                  },
                  {
                    "text": "Lymph node/tissue biopsyComplete effacement of normal architectureUniform, medium-sized cells with \"squared-off\" bordersHigh rate of mitosis and apoptosisStarry-sky pattern on low powerFocal or diffuse necrosis may occur",
                    "sub_points": [
                      "Complete effacement of normal architecture",
                      "Uniform, medium-sized cells with \"squared-off\" borders",
                      "High rate of mitosis and apoptosis",
                      "Starry-sky pattern on low power",
                      "Focal or diffuse necrosis may occur"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "Typically used in conjunction with flow cytometric analysis"
                  },
                  {
                    "text": "No single stain is diagnostic"
                  },
                  {
                    "text": "Panel of stains is required, including CD20, CD10, BCL6, BCL2, CD43, Ki-67, EBER"
                  },
                  {
                    "text": "CD20, CD10, BCL6, and CD43 usually (+)"
                  },
                  {
                    "text": "BCL2(-) or very weak"
                  },
                  {
                    "text": "TdT(-)"
                  },
                  {
                    "text": "Ki-67(+) in ~ 100% of neoplastic cells"
                  },
                  {
                    "text": "EBER(+) inAlmost all eBL cases30% of sBL cases2/3 of iBL with plasmacytoid differentiation1/3 of iBL with typical morphologyMajority of posttransplant BL~ 30% of iatrogenic immunosuppression-associated BL",
                    "sub_points": [
                      "Almost all eBL cases",
                      "30% of sBL cases",
                      "2/3 of iBL with plasmacytoid differentiation",
                      "1/3 of iBL with typical morphology",
                      "Majority of posttransplant BL",
                      "~ 30% of iatrogenic immunosuppression-associated BL"
                    ]
                  },
                  {
                    "text": "EBNA1 is only latent protein consistently expressed"
                  }
                ],
                "Flow Cytometry": [
                  {
                    "text": "Flow needs to be done very quickly due to rapid cell death during transportation"
                  },
                  {
                    "text": "Typically reveals CD10 and surface immunoglobulin (+) monoclonal B-cell population"
                  },
                  {
                    "text": "CD5, CD23 typically (-); helpful to exclude other lymphomas/leukemias"
                  },
                  {
                    "text": "CD34, TdT (-); excludes B-acute lymphoblastic leukemia (B-ALL)"
                  },
                  {
                    "text": "Medium to large size on forward scatter"
                  }
                ],
                "PCR": [
                  {
                    "text": "RearrangedIGHgene"
                  },
                  {
                    "text": "Next-generation sequencing (NGS) detects mutations in various pathwaysPi3K signaling pathwayTranscription factorTCF3or its negative regulatorID3present in ~ 70% of sBL and iBL and 40% of eBL casesTumor suppressor genesMutations inTP53,ARF,USP7,DDX3Xgenes have been implicatedCell cycle regulation genesMutations inCCND3,CDKN2A,P2RY8,GNA13,FBXO11,RASgenes are commonEBV status is related to mutation profilingEBV(+) BL exhibits high expression of activation-induced cytidine deaminase and, thus, much higher mutational burdenEBV(-) BL more commonly reveal activate cyclin D3 and inactive p53 either byTP53mutations or by inactivating ARF or USP7",
                    "sub_points": [
                      "Pi3K signaling pathwayTranscription factorTCF3or its negative regulatorID3present in ~ 70% of sBL and iBL and 40% of eBL cases",
                      "Transcription factorTCF3or its negative regulatorID3present in ~ 70% of sBL and iBL and 40% of eBL cases",
                      "Tumor suppressor genesMutations inTP53,ARF,USP7,DDX3Xgenes have been implicated",
                      "Mutations inTP53,ARF,USP7,DDX3Xgenes have been implicated",
                      "Cell cycle regulation genesMutations inCCND3,CDKN2A,P2RY8,GNA13,FBXO11,RASgenes are common",
                      "Mutations inCCND3,CDKN2A,P2RY8,GNA13,FBXO11,RASgenes are common",
                      "EBV status is related to mutation profilingEBV(+) BL exhibits high expression of activation-induced cytidine deaminase and, thus, much higher mutational burdenEBV(-) BL more commonly reveal activate cyclin D3 and inactive p53 either byTP53mutations or by inactivating ARF or USP7",
                      "EBV(+) BL exhibits high expression of activation-induced cytidine deaminase and, thus, much higher mutational burden",
                      "EBV(-) BL more commonly reveal activate cyclin D3 and inactive p53 either byTP53mutations or by inactivating ARF or USP7"
                    ]
                  }
                ],
                "Genetic Testing": [
                  {
                    "text": "t(8;14)(q24;q32)MYC::IGHin 80% of BL cases"
                  },
                  {
                    "text": "Alternative translocations includet(2;8)(p12;q24)IGK::MYC(15%)t(8;22)(q24;q11)MYC::IGL(5%)",
                    "sub_points": [
                      "t(2;8)(p12;q24)IGK::MYC(15%)",
                      "t(8;22)(q24;q11)MYC::IGL(5%)"
                    ]
                  },
                  {
                    "text": "By itselfMYC::IGHis not specific and can be seen in other lymphomas, such as diffuse large B-cell lymphoma (DLBCL), especially with additional abnormalities"
                  },
                  {
                    "text": "Complex karyotype in majority of patients at relapse; most common are 1q gain, 7q gain, del(13q), 11q aberration, del(17p), tri12, del(6q)"
                  }
                ],
                "Gene Expression Profiling": [
                  {
                    "text": "Consistent gene expression signature for BL, which is different from DLBCL"
                  },
                  {
                    "text": "Intermediate cases are also seen"
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "High-Grade B-Cell Lymphoma With 11q Aberration": [
                  {
                    "text": "Formerly called Burkitt-like lymphoma in WHO revised 4th edition, now classified as high-grade B-cell lymphoma (HGBCL)"
                  },
                  {
                    "text": "Subtype of GCB lymphoma"
                  },
                  {
                    "text": "11q aberration characteristic"
                  },
                  {
                    "text": "Some similarities to either BL or DLBCL based on various studiesSome cases resemble BL both morphologically and immunophenotypicallyStarry-sky morphology and GCB phenotypeImportant differences include absence ofMYCexpression and also absence ofMYCrearrangementCytogenetically more complex than BLSome cases resemble DLBCL or HGBCLThese cases are more morphologically and biologically similar to large cell lymphomas based on molecular genetic studies",
                    "sub_points": [
                      "Some cases resemble BL both morphologically and immunophenotypicallyStarry-sky morphology and GCB phenotypeImportant differences include absence ofMYCexpression and also absence ofMYCrearrangementCytogenetically more complex than BL",
                      "Starry-sky morphology and GCB phenotype",
                      "Important differences include absence ofMYCexpression and also absence ofMYCrearrangement",
                      "Cytogenetically more complex than BL",
                      "Some cases resemble DLBCL or HGBCLThese cases are more morphologically and biologically similar to large cell lymphomas based on molecular genetic studies",
                      "These cases are more morphologically and biologically similar to large cell lymphomas based on molecular genetic studies"
                    ]
                  }
                ],
                "High-Grade B-Cell Lymphoma WithMYCandBCL2orMYCandBCL6Rearrangements": [
                  {
                    "text": "HGBCL with MYC andBCL2rearrangements (HGBCL-DH-BCL2)Accounts for 80-90% of double-hit/triple-hit (DH/TH) lymphomas and 2% of overall non-Hodgkin lymphomasMedian age ~ 60 years with slight male predominanceMost patients present with advanced-stage diseaseLimited response to R-CHOP [rituximab, cyclophosphamide, hydroxydaunorubicin (doxorubicin), oncovin (vincristine), prednisone/prednisolone] or show early relapse after complete remission",
                    "sub_points": [
                      "Accounts for 80-90% of double-hit/triple-hit (DH/TH) lymphomas and 2% of overall non-Hodgkin lymphomas",
                      "Median age ~ 60 years with slight male predominance",
                      "Most patients present with advanced-stage disease",
                      "Limited response to R-CHOP [rituximab, cyclophosphamide, hydroxydaunorubicin (doxorubicin), oncovin (vincristine), prednisone/prednisolone] or show early relapse after complete remission"
                    ]
                  },
                  {
                    "text": "HGBCL with MYC andBCL6rearrangements (HGBCL-DH-BCL6)Provisional entity in ICC classificationAccounts for 10-20% of DH-TH lymphomasLess well defined than HGBCL-DH-BCL2Demographic features similar to HGBCL-DH-BCL2May have particular predilection to extranodal diseaseOnly 1/2 of cases exhibit GCB originLess CD10 expression than HGBCL-DH-BCL2IRF4/MUM1 expressed in 40-90% of casesBCL2 expressed in 20-80% of casesPrognosis controversial",
                    "sub_points": [
                      "Provisional entity in ICC classification",
                      "Accounts for 10-20% of DH-TH lymphomas",
                      "Less well defined than HGBCL-DH-BCL2",
                      "Demographic features similar to HGBCL-DH-BCL2",
                      "May have particular predilection to extranodal disease",
                      "Only 1/2 of cases exhibit GCB origin",
                      "Less CD10 expression than HGBCL-DH-BCL2",
                      "IRF4/MUM1 expressed in 40-90% of cases",
                      "BCL2 expressed in 20-80% of cases",
                      "Prognosis controversial"
                    ]
                  },
                  {
                    "text": "Cases with rearrangements ofMYC,BCL2, andBCL6are classified under HGBCL-DH-BCL2since significance ofBCL6rearrangement in this setting is unclear"
                  },
                  {
                    "text": "Pathologic characteristicsImmunohistochemical stains cannot be used to assign DH or TH lymphomas (FISH required)1/2 of cases show morphology of DLBCL and other 1/2 mimic BLStarry-sky pattern may be present, may be focalLymphoma cells often have more abundant, less basophilic cytoplasm than BLCD10 and BCL6 are expressed in majority of HGBCL-DH-BCL2and HGBCL-DH-BCL6casesOften strongBCL2expression, in contrast to negativeBCL2in BLOften have complex karyotype with many other structural and numerical abnormalitiesFISH forMYC,BCL2, andBCL6rearrangements helps to distinguish from BL",
                    "sub_points": [
                      "Immunohistochemical stains cannot be used to assign DH or TH lymphomas (FISH required)",
                      "1/2 of cases show morphology of DLBCL and other 1/2 mimic BL",
                      "Starry-sky pattern may be present, may be focal",
                      "Lymphoma cells often have more abundant, less basophilic cytoplasm than BL",
                      "CD10 and BCL6 are expressed in majority of HGBCL-DH-BCL2and HGBCL-DH-BCL6cases",
                      "Often strongBCL2expression, in contrast to negativeBCL2in BL",
                      "Often have complex karyotype with many other structural and numerical abnormalities",
                      "FISH forMYC,BCL2, andBCL6rearrangements helps to distinguish from BL"
                    ]
                  },
                  {
                    "text": "Lymphomas with history of preexistent or coexistent indolent lymphoma should be diagnosed as suchHGBCL-DH-BCL2, transformed from follicular lymphoma",
                    "sub_points": [
                      "HGBCL-DH-BCL2, transformed from follicular lymphoma"
                    ]
                  },
                  {
                    "text": "Short median survival (4.5-18.5 months)"
                  }
                ],
                "B-Acute Lymphoblastic Leukemia": [
                  {
                    "text": "Primarily occurs in children who present with signs and symptoms related to marrow failure or extramedullary leukemic infiltration"
                  },
                  {
                    "text": "Blasts have scant cytoplasm, fine chromatin pattern, small to prominent nucleoli, no cytoplasmic vacuoles"
                  },
                  {
                    "text": "Immunophenotype demonstrates surface immunoglobulin (-), CD10(+)/CD19(+) B-cell population"
                  },
                  {
                    "text": "Expression of immature cell markers, such as CD34, TdT"
                  },
                  {
                    "text": "Lack ofMYCrearrangement; not EBV associated"
                  },
                  {
                    "text": "Frequent presence of B-ALL-associated cytogenetic changes"
                  }
                ],
                "EBV(+) Diffuse Large B-Cell Lymphoma, Not Otherwise Specified": [
                  {
                    "text": "Usually affects older patients > 70 years old"
                  },
                  {
                    "text": "Predominates in Asia, Latin America"
                  },
                  {
                    "text": "Morphologic and immunophenotypic spectrum"
                  },
                  {
                    "text": "Main overlap with Burkitt lymphoma is EBV positivity"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Metastatic Carcinoma and Sarcoma": {
            "name": "Metastatic Carcinoma and Sarcoma",
            "url": "https://app.pathprimer.com/document/777ca1e8-5644-4985-9e8f-9c269f2a0814/lesson/6f665b6e-874b-46a5-9d19-463bafa93147",
            "content": {
              "KEY FACTS": {
                "Clinical Issues": [
                  {
                    "text": "Clinical findings due to underlying primary tumorAnemia generally most common findingWeight loss commonNo single specific clinical finding predicts bone marrow metastasesNo predictive value for marrow metastases based on CBC, alkaline phosphatase, calcium level, or sedimentation rateBone marrow is seldom single involved site in systemic nonhematologic malignancies",
                    "sub_points": [
                      "Anemia generally most common finding",
                      "Weight loss common",
                      "No single specific clinical finding predicts bone marrow metastases",
                      "No predictive value for marrow metastases based on CBC, alkaline phosphatase, calcium level, or sedimentation rate",
                      "Bone marrow is seldom single involved site in systemic nonhematologic malignancies"
                    ]
                  },
                  {
                    "text": "Findings that may correlate with bone marrow metastasesSkeletal painThrombocytopeniaBone abnormalities detected by CT &/or MR",
                    "sub_points": [
                      "Skeletal pain",
                      "Thrombocytopenia",
                      "Bone abnormalities detected by CT &/or MR"
                    ]
                  },
                  {
                    "text": "Common nonhematologic tumors involving bone marrow in adultsCarcinomas of prostate, breast, lung, and gastrointestinal originsNeuroblastoma, melanoma, and sarcoma",
                    "sub_points": [
                      "Carcinomas of prostate, breast, lung, and gastrointestinal origins",
                      "Neuroblastoma, melanoma, and sarcoma"
                    ]
                  },
                  {
                    "text": "Common nonhematologic tumors involving bone marrow in childrenNeuroblastoma (most common)Ewing sarcoma/peripheral neuroectodermal tumorRetinoblastomaRhabdomyosarcoma",
                    "sub_points": [
                      "Neuroblastoma (most common)",
                      "Ewing sarcoma/peripheral neuroectodermal tumor",
                      "Retinoblastoma",
                      "Rhabdomyosarcoma"
                    ]
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Peripheral blood morphologic findingsLeukemoid reactionCirculating tumor cells in rare cases of carcinoma, sarcoma, or melanoma",
                    "sub_points": [
                      "Leukemoid reaction",
                      "Circulating tumor cells in rare cases of carcinoma, sarcoma, or melanoma"
                    ]
                  },
                  {
                    "text": "Bone marrow trephine biopsyProvides highest yield for detection of metastatic disease",
                    "sub_points": [
                      "Provides highest yield for detection of metastatic disease"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Definitions": [
                  {
                    "text": "Bone marrow involvement by metastatic carcinoma or sarcoma"
                  },
                  {
                    "text": "Carcinocythemia in cases with circulating tumor cells in blood"
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Clinical Findings Due to Underlying Primary Tumor": [
                  {
                    "text": "Anemia generally most common finding"
                  },
                  {
                    "text": "Weight loss common"
                  },
                  {
                    "text": "No single specific clinical finding predicts bone marrow metastases"
                  },
                  {
                    "text": "No predictive value for marrow metastases based on CBC, alkaline phosphatase, calcium level, or sedimentation rate"
                  },
                  {
                    "text": "Bone marrow is seldom single involved site in systemic nonhematologic malignancies"
                  }
                ],
                "Findings That May Correlate With Bone Marrow Metastases": [
                  {
                    "text": "Skeletal pain"
                  },
                  {
                    "text": "Thrombocytopenia"
                  },
                  {
                    "text": "Bone abnormalities detected by CT &/or MR"
                  }
                ],
                "Common Nonhematologic Tumors Involving Bone Marrow in Adults": [
                  {
                    "text": "Carcinomas of prostate, breast, lung, and gastrointestinal origin"
                  },
                  {
                    "text": "Neuroblastoma, melanoma, and sarcoma"
                  }
                ],
                "Common Nonhematologic Tumors Involving Bone Marrow in Children": [
                  {
                    "text": "Neuroblastoma (most common)"
                  },
                  {
                    "text": "Ewing sarcoma/peripheral neuroectodermal tumor (ES/PNET)"
                  },
                  {
                    "text": "Retinoblastoma"
                  },
                  {
                    "text": "Rhabdomyosarcoma (RMS)"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Peripheral Blood": [
                  {
                    "text": "Anemia (most common) &/or thrombocytopenia"
                  },
                  {
                    "text": "Leukoerythroblastic reactionLeft-shifted granulocytic lineage up to occasional blasts along with nucleated RBCsIncreased \"teardrop\" RBCsIncreased RDW",
                    "sub_points": [
                      "Left-shifted granulocytic lineage up to occasional blasts along with nucleated RBCs",
                      "Increased \"teardrop\" RBCs",
                      "Increased RDW"
                    ]
                  },
                  {
                    "text": "Leukemoid reactionLeukocytosis, which may be due to cytokine produced by tumor",
                    "sub_points": [
                      "Leukocytosis, which may be due to cytokine produced by tumor"
                    ]
                  },
                  {
                    "text": "Thrombocytosis (paraneoplastic)Increased hepatic thrombopoietin synthesis in response to tumor-derived thrombopoietic cytokines",
                    "sub_points": [
                      "Increased hepatic thrombopoietin synthesis in response to tumor-derived thrombopoietic cytokines"
                    ]
                  },
                  {
                    "text": "Microangiopathic hemolytic pictureSecondary to mucin in metastatic adenocarcinomaCan also be seen secondary to therapeutic agents (mitomycin C)",
                    "sub_points": [
                      "Secondary to mucin in metastatic adenocarcinoma",
                      "Can also be seen secondary to therapeutic agents (mitomycin C)"
                    ]
                  },
                  {
                    "text": "Circulating tumor cells (carcinoma or sarcoma)Rarely detected in following disseminated neoplasms (enriched at feather edge)Breast carcinomaSmall cell carcinoma of lungRMSMelanoma; may be pigmentedNeutrophils may contain pigment",
                    "sub_points": [
                      "Rarely detected in following disseminated neoplasms (enriched at feather edge)Breast carcinomaSmall cell carcinoma of lungRMSMelanoma; may be pigmentedNeutrophils may contain pigment",
                      "Breast carcinoma",
                      "Small cell carcinoma of lung",
                      "RMS",
                      "Melanoma; may be pigmentedNeutrophils may contain pigment",
                      "Neutrophils may contain pigment"
                    ]
                  }
                ],
                "Bone Marrow": [
                  {
                    "text": "Bone marrow aspirateMay contain metastatic carcinoma/sarcoma cells, often in clustersIndividually dispersed metastatic tumor cells mimic acute leukemiaLow yield due to tumor-associated fibrosis",
                    "sub_points": [
                      "May contain metastatic carcinoma/sarcoma cells, often in clusters",
                      "Individually dispersed metastatic tumor cells mimic acute leukemia",
                      "Low yield due to tumor-associated fibrosis"
                    ]
                  },
                  {
                    "text": "Bone marrow touch imprintsHigher yield in detecting metastatic tumor cells compared to aspirate smears",
                    "sub_points": [
                      "Higher yield in detecting metastatic tumor cells compared to aspirate smears"
                    ]
                  },
                  {
                    "text": "Bone marrow trephine biopsyProvides highest yield for detection of metastatic diseaseAdequate length of core biopsy required due to focal and patchy distribution of some metastasesStep sections may prove useful in cases with high clinical suspicion for metastasis",
                    "sub_points": [
                      "Provides highest yield for detection of metastatic disease",
                      "Adequate length of core biopsy required due to focal and patchy distribution of some metastases",
                      "Step sections may prove useful in cases with high clinical suspicion for metastasis"
                    ]
                  },
                  {
                    "text": "Morphologic findings in metastatic carcinomas; adultsMetastatic carcinoma usually inaspirableBest appreciated on trephine biopsy sections; clumping, gland formation, cords of neoplastic cellsExtensive fibrosis may mask sparse carcinoma cellsOften induces extensive desmoplastic stromal response with severe marrow fibrosisLobular carcinoma of breast may present on aspirate and often shows singly distributed cells admixed with bone marrow on core biopsySmall cell carcinoma may exhibit clusters of tumor cells on aspirate smears",
                    "sub_points": [
                      "Metastatic carcinoma usually inaspirable",
                      "Best appreciated on trephine biopsy sections; clumping, gland formation, cords of neoplastic cells",
                      "Extensive fibrosis may mask sparse carcinoma cells",
                      "Often induces extensive desmoplastic stromal response with severe marrow fibrosis",
                      "Lobular carcinoma of breast may present on aspirate and often shows singly distributed cells admixed with bone marrow on core biopsy",
                      "Small cell carcinoma may exhibit clusters of tumor cells on aspirate smears"
                    ]
                  },
                  {
                    "text": "Morphologic findings in metastatic sarcomasES/PNET often represented in small clusters in marrow aspirate smearsRMS in adults is typically polymorphic with occasional differentiating cells and rhabdomyoblastsRMS is usually aspirable and can present as singly distributed cells on marrow aspirate smears mimicking leukemiaSignificant stromal response typically absent in ES/PNET and RMSSynovial sarcoma rarely involves bone marrow and shows variable cytomorphologyMost synovial sarcomas appear biphasic with epithelial and spindle cell componentsPoorly differentiated synovial sarcoma resembles other round cell tumorsKaposi sarcoma and angiosarcoma rarely encountered in bone marrow; case report levelMorphologic features similar to that seen in other sites",
                    "sub_points": [
                      "ES/PNET often represented in small clusters in marrow aspirate smears",
                      "RMS in adults is typically polymorphic with occasional differentiating cells and rhabdomyoblasts",
                      "RMS is usually aspirable and can present as singly distributed cells on marrow aspirate smears mimicking leukemia",
                      "Significant stromal response typically absent in ES/PNET and RMS",
                      "Synovial sarcoma rarely involves bone marrow and shows variable cytomorphology",
                      "Most synovial sarcomas appear biphasic with epithelial and spindle cell components",
                      "Poorly differentiated synovial sarcoma resembles other round cell tumors",
                      "Kaposi sarcoma and angiosarcoma rarely encountered in bone marrow; case report levelMorphologic features similar to that seen in other sites",
                      "Morphologic features similar to that seen in other sites"
                    ]
                  },
                  {
                    "text": "Morphologic findings in metastatic melanomaPigment may be present in macrophages, neutrophils, and neoplastic cellsMay mimic plasma cells on biopsy",
                    "sub_points": [
                      "Pigment may be present in macrophages, neutrophils, and neoplastic cells",
                      "May mimic plasma cells on biopsy"
                    ]
                  },
                  {
                    "text": "Bone marrow morphologic findings in nonhematologic metastatic deposits in childrenES/PNETUniform small, round cells with hyperchromatic nuclei and scant cytoplasm and, in some cases, blastic morphologyDistributed usually in small clusters on marrow aspirate, if aspirablePseudorosette, or, rarely, true rosette formations may be seenMorphologically mimics other undifferentiated cells on aspirate smears, including leukemia, neuroblastoma, or RMSCan rarely coexist simultaneously with therapy-related acute myeloid leukemia in cases resistant to ES therapyRMSEmbryonal subtype often shows undifferentiated primitive cells in children < 10 years of ageSmall hyperchromatic cells mixed with occasional differentiated cells with eosinophilic cytoplasm (rhabdomyoblasts)Poorly differentiated tumors mimic leukemic cells or other small blue cell tumorsDiagnosis can be suggested in typical alveolar subtype if distinct alveolar pattern is presentSeparation of solid variant of alveolar RMS from embryonal subtype can be extremely difficultMetastatic carcinoma, uncommon in children",
                    "sub_points": [
                      "ES/PNETUniform small, round cells with hyperchromatic nuclei and scant cytoplasm and, in some cases, blastic morphologyDistributed usually in small clusters on marrow aspirate, if aspirablePseudorosette, or, rarely, true rosette formations may be seenMorphologically mimics other undifferentiated cells on aspirate smears, including leukemia, neuroblastoma, or RMSCan rarely coexist simultaneously with therapy-related acute myeloid leukemia in cases resistant to ES therapy",
                      "Uniform small, round cells with hyperchromatic nuclei and scant cytoplasm and, in some cases, blastic morphology",
                      "Distributed usually in small clusters on marrow aspirate, if aspirable",
                      "Pseudorosette, or, rarely, true rosette formations may be seen",
                      "Morphologically mimics other undifferentiated cells on aspirate smears, including leukemia, neuroblastoma, or RMS",
                      "Can rarely coexist simultaneously with therapy-related acute myeloid leukemia in cases resistant to ES therapy",
                      "RMSEmbryonal subtype often shows undifferentiated primitive cells in children < 10 years of ageSmall hyperchromatic cells mixed with occasional differentiated cells with eosinophilic cytoplasm (rhabdomyoblasts)Poorly differentiated tumors mimic leukemic cells or other small blue cell tumorsDiagnosis can be suggested in typical alveolar subtype if distinct alveolar pattern is presentSeparation of solid variant of alveolar RMS from embryonal subtype can be extremely difficult",
                      "Embryonal subtype often shows undifferentiated primitive cells in children < 10 years of age",
                      "Small hyperchromatic cells mixed with occasional differentiated cells with eosinophilic cytoplasm (rhabdomyoblasts)",
                      "Poorly differentiated tumors mimic leukemic cells or other small blue cell tumors",
                      "Diagnosis can be suggested in typical alveolar subtype if distinct alveolar pattern is present",
                      "Separation of solid variant of alveolar RMS from embryonal subtype can be extremely difficult",
                      "Metastatic carcinoma, uncommon in children"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "Metastatic carcinomas in bone marrowCytokeratin expression in metastatic bone marrow deposits supports epithelial originEstrogen receptor (ER) hormone expression supports breast or female genital tract originChromogranin, synaptophysin, neuron-specific enolase (NSE), and CD56 expression would support neuroendocrine originExpression of TTF-1, napsin A, and CK7 in patient with known lung cancer supports adenocarcinoma of pulmonary origin",
                    "sub_points": [
                      "Cytokeratin expression in metastatic bone marrow deposits supports epithelial origin",
                      "Estrogen receptor (ER) hormone expression supports breast or female genital tract origin",
                      "Chromogranin, synaptophysin, neuron-specific enolase (NSE), and CD56 expression would support neuroendocrine origin",
                      "Expression of TTF-1, napsin A, and CK7 in patient with known lung cancer supports adenocarcinoma of pulmonary origin"
                    ]
                  },
                  {
                    "text": "Metastatic sarcoma in bone marrowES/PNET typically expresses FLI1, NKX2.2, CD99, and variably NSE and neurofilamentsExpression of CD99 not specific for ES/PNET and can be seen in other tumorsDesmin, actin, myogenin, and MyoD1 typically expressed in RMSS100 protein and NSE could prove useful in separating neuroblastoma from other mimicsEpithelial component of biphasic synovial sarcoma expresses cytokeratin and epithelial membrane antigen",
                    "sub_points": [
                      "ES/PNET typically expresses FLI1, NKX2.2, CD99, and variably NSE and neurofilamentsExpression of CD99 not specific for ES/PNET and can be seen in other tumors",
                      "Expression of CD99 not specific for ES/PNET and can be seen in other tumors",
                      "Desmin, actin, myogenin, and MyoD1 typically expressed in RMS",
                      "S100 protein and NSE could prove useful in separating neuroblastoma from other mimics",
                      "Epithelial component of biphasic synovial sarcoma expresses cytokeratin and epithelial membrane antigen"
                    ]
                  },
                  {
                    "text": "Metastatic melanoma in bone marrowMelanoma-associated markers, including S100, HMB-45, SOX10, and melan-A expression usefulBRAF V600E IHC (+) in ~ 50% of cases",
                    "sub_points": [
                      "Melanoma-associated markers, including S100, HMB-45, SOX10, and melan-A expression useful",
                      "BRAF V600E IHC (+) in ~ 50% of cases"
                    ]
                  }
                ],
                "PCR": [
                  {
                    "text": "Fusion genes in ES/PNET, RMS, and synovial sarcoma can be assessed by RT-PCR for diagnostic purposesRT-PCR is also highly sensitive tool for monitoring measurable residual disease and early relapseRT-PCR may detect low numbers of circulating carcinoma/sarcoma cells",
                    "sub_points": [
                      "RT-PCR is also highly sensitive tool for monitoring measurable residual disease and early relapse",
                      "RT-PCR may detect low numbers of circulating carcinoma/sarcoma cells"
                    ]
                  }
                ],
                "Genetic Testing": [
                  {
                    "text": "t(11;22)(q24;q12);EWSR1::FLI1fusion in ES/PNET"
                  },
                  {
                    "text": "t(2;13)(q36;q14);PAX3::FOXO1fusion in majority of alveolar RMS"
                  },
                  {
                    "text": "t(1;13)(p36;q14);PAX7::FOXO1fusion in minor subset of alveolar RMS"
                  },
                  {
                    "text": "t(X;18)(p11;q12);SSX1::SYT1orSSX2::SYT1fusion in synovial sarcoma"
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Metastatic Epithelial Neoplasm": [
                  {
                    "text": "Ancillary studies often needed to reliably identify primary site of carcinoma in absence of documented primaryIHC stains for ER can separate breast or female genital tract origin from othersIHC stains for neuroendocrine markers and TTF-1 useful in suspected carcinoma of lung primary",
                    "sub_points": [
                      "IHC stains for ER can separate breast or female genital tract origin from others",
                      "IHC stains for neuroendocrine markers and TTF-1 useful in suspected carcinoma of lung primary"
                    ]
                  },
                  {
                    "text": "Lobular carcinoma of breast may mimic hematolymphoid neoplasm due to frequent singly dispersed tumor cells among normal bone marrow cellsFlow cytometry &/or IHC may be needed in problematic cases",
                    "sub_points": [
                      "Flow cytometry &/or IHC may be needed in problematic cases"
                    ]
                  },
                  {
                    "text": "Small cell carcinoma may mimic lymphoblastic lymphoma/leukemiaFlow cytometry &/or IHC would easily separate these entities in difficult cases",
                    "sub_points": [
                      "Flow cytometry &/or IHC would easily separate these entities in difficult cases"
                    ]
                  }
                ],
                "Metastatic Sarcomas": [
                  {
                    "text": "Undifferentiated RMS may mimic acute myeloid or lymphoid leukemia and other undifferentiated sarcomasFlow cytometry &/or IHC are helpfulAcute leukemias can be diagnosed based on expression of myeloid- or lymphoid-associated antigensRMSs express muscle-associated antigens and lack hematopoietic markersMost alveolar subtypes of RMS demonstrate t(2;13) or t(1;13) chromosomal translocation",
                    "sub_points": [
                      "Flow cytometry &/or IHC are helpful",
                      "Acute leukemias can be diagnosed based on expression of myeloid- or lymphoid-associated antigens",
                      "RMSs express muscle-associated antigens and lack hematopoietic markers",
                      "Most alveolar subtypes of RMS demonstrate t(2;13) or t(1;13) chromosomal translocation"
                    ]
                  },
                  {
                    "text": "ES/PNET can morphologically mimic leukemia and other sarcoma subtypesFlow cytometry and IHC usually needed for appropriate classificationCD99 (MIC2) strongly expressed in ES/PNET but not specific for this neoplasmES/PNET typically demonstrate distinct (11;22) chromosomal translocation by cytogeneticsES/PNET can rarely coexist simultaneously with therapy-related acute myeloid leukemiaCorrect diagnosis requires flow cytometry, IHC, and cytogenetics",
                    "sub_points": [
                      "Flow cytometry and IHC usually needed for appropriate classification",
                      "CD99 (MIC2) strongly expressed in ES/PNET but not specific for this neoplasm",
                      "ES/PNET typically demonstrate distinct (11;22) chromosomal translocation by cytogenetics",
                      "ES/PNET can rarely coexist simultaneously with therapy-related acute myeloid leukemiaCorrect diagnosis requires flow cytometry, IHC, and cytogenetics",
                      "Correct diagnosis requires flow cytometry, IHC, and cytogenetics"
                    ]
                  }
                ],
                "Metastatic Melanoma": [
                  {
                    "text": "Malignant melanoma may mimic carcinoma, sarcoma, or lymphoid neoplasmImmunophenotyping and IHC stains essential for distinction",
                    "sub_points": [
                      "Immunophenotyping and IHC stains essential for distinction"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          }
        }
      },
      "Lymph Node: Nonneoplastic Lesions": {
        "name": "Lymph Node: Nonneoplastic Lesions",
        "url": "https://app.pathprimer.com/lesson/1ca98c4c-c6e6-4862-8c12-8cba7a24c075",
        "topics": {
          "Infectious Mononucleosis": {
            "name": "Infectious Mononucleosis",
            "url": "https://app.pathprimer.com/document/64034cc2-a97f-4644-92bb-110a1cb12357/lesson/1ca98c4c-c6e6-4862-8c12-8cba7a24c075",
            "content": {
              "KEY FACTS": {
                "Etiology/Pathogenesis": [
                  {
                    "text": "Epstein-Barr virus (EBV) infection"
                  },
                  {
                    "text": "EBV is gamma herpesvirus that infects ~ 90% of persons worldwide"
                  },
                  {
                    "text": "Infectious mononucleosis is result of acute infectionUsually follows initial exposure to virus",
                    "sub_points": [
                      "Usually follows initial exposure to virus"
                    ]
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Fatigue, fever, exudative pharyngitis"
                  },
                  {
                    "text": "Anterior and posterior cervical lymphadenopathy"
                  },
                  {
                    "text": "Infection is usually self-limitedEBV infection is rarely fatalUsually associated with immunodeficiency",
                    "sub_points": [
                      "EBV infection is rarely fatalUsually associated with immunodeficiency",
                      "Usually associated with immunodeficiency"
                    ]
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Distorted lymph node architecture"
                  },
                  {
                    "text": "Interfollicular hyperplasia; starry-sky pattern (+/-)"
                  },
                  {
                    "text": "Spectrum of cells: Small and large lymphocytes &/or immunoblasts"
                  },
                  {
                    "text": "Plasma cells and histiocytes common"
                  },
                  {
                    "text": "Immunoblasts are CD30(+) and CD45(+)"
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "EBV-specific antibody tests"
                  },
                  {
                    "text": "Immunophenotyping shows increased CD3(+) and CD8(+) cytotoxic T cellsIn blood (Downey type II cells) and lymphoid organs",
                    "sub_points": [
                      "In blood (Downey type II cells) and lymphoid organs"
                    ]
                  },
                  {
                    "text": "In situ hybridization for EBV-encoded small RNA (EBER) highlights infected cells"
                  },
                  {
                    "text": "Monospot test (a.k.a. heterophile antibody test) is inexpensive and easy to perform"
                  },
                  {
                    "text": "Laboratory tests showing acute infection by EBVElevated IgM antiviral capsid antigenNo antibodies to EBV nuclear antigen (EBNA)",
                    "sub_points": [
                      "Elevated IgM antiviral capsid antigen",
                      "No antibodies to EBV nuclear antigen (EBNA)"
                    ]
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "Chronic active EBV infection"
                  },
                  {
                    "text": "Other types of viral-induced lymphadenitis"
                  },
                  {
                    "text": "Peripheral T-cell lymphoma, not otherwise specified"
                  },
                  {
                    "text": "Classic Hodgkin lymphoma"
                  },
                  {
                    "text": "Anaplastic large cell lymphoma"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Infectious mononucleosis (IM)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Epstein-Barr virus (EBV) lymphadenitis, Pfeiffer disease, glandular fever"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Acute lymphadenitis induced by EBV infectionNeeds to be distinguished from chronic and EBV(+) lymphoid proliferations of B, T, and NK lineage",
                    "sub_points": [
                      "Needs to be distinguished from chronic and EBV(+) lymphoid proliferations of B, T, and NK lineage"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Infectious Agents": [
                  {
                    "text": "EBV is gamma herpesvirus that infects ~ 90% of worldwide populationUsually spread through intimate oral contact",
                    "sub_points": [
                      "Usually spread through intimate oral contact"
                    ]
                  },
                  {
                    "text": "During primary infection, virus infects tonsillar epithelium as well as tonsillar B lymphocytesInitial humoral antibody responseSubsequent cell-mediated immune responseIncreased numbers of CD8(+) T cells to control EBV-infected B cellsCytotoxic T cells specific against early lytic proteins of EBVCD4(+) T cells and natural-killer (NK) cells also play role in EBV controlCD4(+) T cells mainly directed against latent antigens",
                    "sub_points": [
                      "Initial humoral antibody response",
                      "Subsequent cell-mediated immune responseIncreased numbers of CD8(+) T cells to control EBV-infected B cellsCytotoxic T cells specific against early lytic proteins of EBV",
                      "Increased numbers of CD8(+) T cells to control EBV-infected B cells",
                      "Cytotoxic T cells specific against early lytic proteins of EBV",
                      "CD4(+) T cells and natural-killer (NK) cells also play role in EBV controlCD4(+) T cells mainly directed against latent antigens",
                      "CD4(+) T cells mainly directed against latent antigens"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Age": [
                  {
                    "text": "Mostly immunocompetent adolescents and young adults in USAEven younger age in developing countries",
                    "sub_points": [
                      "Even younger age in developing countries"
                    ]
                  }
                ],
                "Sex": [
                  {
                    "text": "No predominance"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Fatigue, fever, exudative pharyngitis, and lymphadenopathyMononucleosis syndrome also associated with cytomegalovirus and toxoplasmosis",
                    "sub_points": [
                      "Mononucleosis syndrome also associated with cytomegalovirus and toxoplasmosis"
                    ]
                  },
                  {
                    "text": "Most young adults develop IM after primary EBV infectionProbably related to larger viral inoculum when transmission occurs through deep kissing",
                    "sub_points": [
                      "Probably related to larger viral inoculum when transmission occurs through deep kissing"
                    ]
                  },
                  {
                    "text": "Primary infection in children is mostly asymptomaticLikely due to lower virus inoculumMechanism of spread is uncertain in most childhood cases",
                    "sub_points": [
                      "Likely due to lower virus inoculum",
                      "Mechanism of spread is uncertain in most childhood cases"
                    ]
                  },
                  {
                    "text": "Anterior and posterior cervical lymphadenopathyNeck often swollen",
                    "sub_points": [
                      "Neck often swollen"
                    ]
                  },
                  {
                    "text": "Convalescence is 3-6 months post infectionNumber of CD8(+) T cells declines to normal levels",
                    "sub_points": [
                      "Number of CD8(+) T cells declines to normal levels"
                    ]
                  }
                ],
                "Laboratory Tests": [
                  {
                    "text": "Peripheral blood lymphocytosis atypical lymphocytesAtypical lymphocytes (Downey type II cells)",
                    "sub_points": [
                      "Atypical lymphocytes (Downey type II cells)"
                    ]
                  },
                  {
                    "text": "Monospot test (a.k.a. heterophile antibody test) is inexpensive and easy to performFalse-positive in acute infections, autoimmune diseases, and certain malignanciesFalse-negative in children",
                    "sub_points": [
                      "False-positive in acute infections, autoimmune diseases, and certain malignancies",
                      "False-negative in children"
                    ]
                  },
                  {
                    "text": "EBV-specific antibody testsElevated IgM antiviral capsid antigen (VCA) without antibodies to EBV nuclear antigen (EBNA) indicates acute infectionEBV early antigen (EA) is positive in 60-80% of acutely ill patientsAlso can be present for years in 20% of healthy personsThus, not useful to assess for acute infection",
                    "sub_points": [
                      "Elevated IgM antiviral capsid antigen (VCA) without antibodies to EBV nuclear antigen (EBNA) indicates acute infection",
                      "EBV early antigen (EA) is positive in 60-80% of acutely ill patientsAlso can be present for years in 20% of healthy personsThus, not useful to assess for acute infection",
                      "Also can be present for years in 20% of healthy personsThus, not useful to assess for acute infection",
                      "Thus, not useful to assess for acute infection"
                    ]
                  },
                  {
                    "text": "IgG against EBV VCA indicates prior infection"
                  },
                  {
                    "text": "EBV DNA blood viral load is best test to diagnose and monitor EBV infectionUseful for monitoring infection in immunocompromised patients",
                    "sub_points": [
                      "Useful for monitoring infection in immunocompromised patients"
                    ]
                  }
                ],
                "Treatment": [],
                "Options, risks, complications": [
                  {
                    "text": "Observation is sufficient in most cases as disease resolves by itself"
                  },
                  {
                    "text": "Antiviral agents (e.g., acyclovir or valacyclovir) do not seem to modify disease course"
                  },
                  {
                    "text": "Corticosteroids can be of benefit for airway obstruction, autoimmune anemia, or thrombocytopenia"
                  },
                  {
                    "text": "Infection may be complicated by rupture of spleen or hepatitis"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Usually self-limited; EBV rarely fatal except in patients with immunodeficiency< 1% of patients develop hemophagocytic syndrome or splenic ruptureChronic active EBV infection is less common",
                    "sub_points": [
                      "< 1% of patients develop hemophagocytic syndrome or splenic rupture",
                      "Chronic active EBV infection is less common"
                    ]
                  },
                  {
                    "text": "Higher risk of subsequent EBV-associated neoplasmsAssociated with early age of infection and symptomatic disease",
                    "sub_points": [
                      "Associated with early age of infection and symptomatic disease"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Distorted lymph node architecturePredominantly interfollicular process; starry-sky pattern (+/-)Small- and intermediate-sized lymphocytes and large cells &/or immunoblastsReed-Sternberg-like and Hodgkin-like (RS+H) cells can be presentLarge immunoblasts or Hodgkin-like cells; sometimes in sheetsMany histiocytes and plasma cells; eosinophils (+/-)Foci of necrosis are commonFollicles can be hyperplasticProminent germinal centers with tingible body macrophages and mitoses",
                    "sub_points": [
                      "Predominantly interfollicular process; starry-sky pattern (+/-)Small- and intermediate-sized lymphocytes and large cells &/or immunoblastsReed-Sternberg-like and Hodgkin-like (RS+H) cells can be presentLarge immunoblasts or Hodgkin-like cells; sometimes in sheetsMany histiocytes and plasma cells; eosinophils (+/-)Foci of necrosis are common",
                      "Small- and intermediate-sized lymphocytes and large cells &/or immunoblasts",
                      "Reed-Sternberg-like and Hodgkin-like (RS+H) cells can be present",
                      "Large immunoblasts or Hodgkin-like cells; sometimes in sheets",
                      "Many histiocytes and plasma cells; eosinophils (+/-)",
                      "Foci of necrosis are common",
                      "Follicles can be hyperplasticProminent germinal centers with tingible body macrophages and mitoses",
                      "Prominent germinal centers with tingible body macrophages and mitoses"
                    ]
                  }
                ],
                "Predominant Pattern/Injury Type": [
                  {
                    "text": "Lymphoid, interfollicular"
                  }
                ],
                "Predominant Cell/Compartment Type": [
                  {
                    "text": "Hematopoietic, lymphoid"
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "Most lymphocytes are CD3(+), CD8(+) reactive T cells"
                  },
                  {
                    "text": "Immunoblasts are CD30(+) and CD45(+)"
                  },
                  {
                    "text": "EBV-latent membrane protein 1 is expressed by subset of infected cells"
                  }
                ],
                "In Situ Hybridization": [
                  {
                    "text": "EBV-encoded RNA present in numerous infected cells"
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Chronic Active EBV Infection": [
                  {
                    "text": "Late complication of acute IMHas been known for > 70 years in Asian countriesCases from South America also reportedCases with skin manifestations included as hydroa vacciniforme-like lymphoproliferative disorderImmunocompetent patientsPersistent fever, lymphadenopathy, hepatosplenomegalyMarked elevation of EBV DNA in bloodMarked elevation of IgG titers to VCANegative for IgM VCA",
                    "sub_points": [
                      "Has been known for > 70 years in Asian countries",
                      "Cases from South America also reportedCases with skin manifestations included as hydroa vacciniforme-like lymphoproliferative disorder",
                      "Cases with skin manifestations included as hydroa vacciniforme-like lymphoproliferative disorder",
                      "Immunocompetent patients",
                      "Persistent fever, lymphadenopathy, hepatosplenomegaly",
                      "Marked elevation of EBV DNA in blood",
                      "Marked elevation of IgG titers to VCANegative for IgM VCA",
                      "Negative for IgM VCA"
                    ]
                  },
                  {
                    "text": "Disease can be progressive and fatalFatalities related toHemophagocytic syndromeTransformation to lymphoma of T- or NK-cell lineageCurrent proposed terminology: Systemic EBV(+) T-cell lymphoma of childhoodMultiorgan failure: Heart, digestive tract, pulmonaryStem cell transplant appears as best option for patients developing lymphomaNo observed benefit shown usingAntiviral agents: Acyclovir or ganciclovirImmunoenhancers: InterferonChemotherapy: Cyclophosphamide, daunorubicin, vincristine, prednisone (CHOP)",
                    "sub_points": [
                      "Fatalities related toHemophagocytic syndromeTransformation to lymphoma of T- or NK-cell lineageCurrent proposed terminology: Systemic EBV(+) T-cell lymphoma of childhoodMultiorgan failure: Heart, digestive tract, pulmonary",
                      "Hemophagocytic syndrome",
                      "Transformation to lymphoma of T- or NK-cell lineageCurrent proposed terminology: Systemic EBV(+) T-cell lymphoma of childhood",
                      "Current proposed terminology: Systemic EBV(+) T-cell lymphoma of childhood",
                      "Multiorgan failure: Heart, digestive tract, pulmonary",
                      "Stem cell transplant appears as best option for patients developing lymphoma",
                      "No observed benefit shown usingAntiviral agents: Acyclovir or ganciclovirImmunoenhancers: InterferonChemotherapy: Cyclophosphamide, daunorubicin, vincristine, prednisone (CHOP)",
                      "Antiviral agents: Acyclovir or ganciclovir",
                      "Immunoenhancers: Interferon",
                      "Chemotherapy: Cyclophosphamide, daunorubicin, vincristine, prednisone (CHOP)"
                    ]
                  }
                ],
                "Other Types of Viral-Induced Lymphadenitis": [
                  {
                    "text": "Cytomegalovirus (CMV) or early HIV infection may show similar features in lymph nodes"
                  },
                  {
                    "text": "Clinical setting and serologic studies needed to confirm diagnosis"
                  },
                  {
                    "text": "Immunohistochemistry is useful for CMV and HIV (p24) infections"
                  }
                ],
                "Peripheral T-Cell Lymphoma, Not Otherwise Specified": [
                  {
                    "text": "Intermixed eosinophils and histiocytes may impart background similar to EBV lymphadenitis"
                  },
                  {
                    "text": "Neoplastic lymphoid cells are usually cytologically atypicalMore commonly positive for CD4 than CD8; usually CD30(-)",
                    "sub_points": [
                      "More commonly positive for CD4 than CD8; usually CD30(-)"
                    ]
                  },
                  {
                    "text": "Immunophenotype shows T cells with aberrant expression patterns"
                  },
                  {
                    "text": "Monoclonal T-cell receptor gene rearrangements in most cases"
                  }
                ],
                "Classic Hodgkin Lymphoma": [
                  {
                    "text": "Mixed cellular background with predominantly small lymphocytes and occasional RS+H cellsNo spectrum of small to large cells as seen in EBV lymphadenitis",
                    "sub_points": [
                      "No spectrum of small to large cells as seen in EBV lymphadenitis"
                    ]
                  },
                  {
                    "text": "Immunoblasts are usually weakly CD30(+) and CD45(+), and CD15(-)"
                  },
                  {
                    "text": "RS+H cells are CD30(+), CD15(+), and CD45(-)"
                  }
                ],
                "Anaplastic Large Cell Lymphoma (ALCL)": [
                  {
                    "text": "Most cells are large with prominent nucleoli; variable numbers of hallmark cells"
                  },
                  {
                    "text": "Large cells can be form sheets or show sinusoidal pattern of infiltration"
                  },
                  {
                    "text": "Large cells are uniformly and strongly CD30(+); T-cell lineage"
                  },
                  {
                    "text": "Small cell variant of ALCL can be deceptive and confused with reactive processHigh index of suspicion, CD30 and ALK immunohistochemistry are needed to identify this variant",
                    "sub_points": [
                      "High index of suspicion, CD30 and ALK immunohistochemistry are needed to identify this variant"
                    ]
                  },
                  {
                    "text": "60-80% of ALCLs are ALK1(+); more common in younger patients"
                  }
                ],
                "IgG4-Related Disease": [
                  {
                    "text": "One pattern in lymph nodes resembles IM"
                  },
                  {
                    "text": "Elevated IgG4:IgG ratio &/or elevated serum IgG4 levels supports IgG4-related disease"
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Clinically Relevant Pathologic Features": [
                  {
                    "text": "Mostly adolescents but may occur in immunocompromised patients of any age"
                  }
                ],
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "Marked interfollicular hyperplasia often with starry-sky pattern"
                  },
                  {
                    "text": "May show completely effaced architecture, but, usually, residual architecture is present"
                  },
                  {
                    "text": "Spectrum of small to large lymphocytes &/or immunoblasts"
                  },
                  {
                    "text": "Immunoblasts are CD45(+), CD30(+)"
                  },
                  {
                    "text": "T lymphocytes are predominantly CD8(+) cytotoxic T cells"
                  },
                  {
                    "text": "Hemophagocytosis may be present"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "ToxoplasmaLymphadenitis": {
            "name": "ToxoplasmaLymphadenitis",
            "url": "https://app.pathprimer.com/document/2d0e283e-a666-4ff3-ac78-f5548f447a1f/lesson/1ca98c4c-c6e6-4862-8c12-8cba7a24c075",
            "content": {
              "KEY FACTS": {
                "Etiology/Pathogenesis": [
                  {
                    "text": "Toxoplasmosis is common parasitic disease worldwide"
                  },
                  {
                    "text": "Toxoplasma gondiiis parasitic protozoan"
                  },
                  {
                    "text": "Cat is definitive host for sexual stage of reproduction"
                  },
                  {
                    "text": "Oocysts containing trophozoites are generated that are eliminated in feces"
                  },
                  {
                    "text": "Humans and animals are intermediate hosts"
                  },
                  {
                    "text": "Humans ingest oocysts from contaminated soil or undercooked meat"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Self-limited clinical course in most patients"
                  },
                  {
                    "text": "Children and young adults (65%) most often affected"
                  },
                  {
                    "text": "Unilateral lymphadenopathy, commonly posterior cervical"
                  },
                  {
                    "text": "Is usually opportunistic infection"
                  },
                  {
                    "text": "Lymph nodes are commonly affected"
                  },
                  {
                    "text": "In immunocompetent patients, infection is self-limiting"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Diagnostic triadFlorid reactive follicular hyperplasiaMonocytoid B-cell hyperplasia in sinusesEpithelioid histiocytes in paracortical areasEncroach into germinal centers",
                    "sub_points": [
                      "Florid reactive follicular hyperplasia",
                      "Monocytoid B-cell hyperplasia in sinuses",
                      "Epithelioid histiocytes in paracortical areasEncroach into germinal centers",
                      "Encroach into germinal centers"
                    ]
                  },
                  {
                    "text": "No multinucleated giant cells; no necrosis"
                  },
                  {
                    "text": "Numerous epithelioid histiocytes in interfollicular and paracortical regions"
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "Sabin-Feldman dye test"
                  },
                  {
                    "text": "IgM screening antibody test positive in first 3 months"
                  },
                  {
                    "text": "PositiveToxoplasma-specific antibodies are detected by enzyme immunoassays"
                  },
                  {
                    "text": "Immunohistochemistry detects presence of parasites"
                  },
                  {
                    "text": "Toxoplasmagenomes can be detected by PCR"
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "HIV lymphadenitis"
                  },
                  {
                    "text": "Dermatopathic lymphadenopathy"
                  },
                  {
                    "text": "Non-Hodgkin lymphoma: Lennert lymphoma"
                  },
                  {
                    "text": "Classic Hodgkin lymphoma"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Synonyms": [
                  {
                    "text": "Toxoplasmic lymphadenitis"
                  },
                  {
                    "text": "Glandular toxoplasmosis"
                  },
                  {
                    "text": "Piringer-Kuchinka lymphadenopathy"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Inflammation of lymph node caused by infection withToxoplasma gondii"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Toxoplasma gondiiInfection": [
                  {
                    "text": "T. gondiiis protozoan that can invade many cell types"
                  },
                  {
                    "text": "Cat is definitive host for sexual stage of reproductionTrophozoites reproduce in intestinal epitheliumOocysts are generated that are eliminated in feces",
                    "sub_points": [
                      "Trophozoites reproduce in intestinal epithelium",
                      "Oocysts are generated that are eliminated in feces"
                    ]
                  },
                  {
                    "text": "Humans and animals are intermediate hostsIngest oocysts from contaminated soilHumans can ingest oocysts from undercooked meat",
                    "sub_points": [
                      "Ingest oocysts from contaminated soil",
                      "Humans can ingest oocysts from undercooked meat"
                    ]
                  },
                  {
                    "text": "In humans and animals, oocysts are degraded by digestive enzymesTrophozoites are released into intestineOrganisms are carried by macrophagesSpread via lymphatics and blood vessels to internal organsWithin macrophages, trophozoites can multiply and become crescent-shaped tachyzoites",
                    "sub_points": [
                      "Trophozoites are released into intestineOrganisms are carried by macrophagesSpread via lymphatics and blood vessels to internal organs",
                      "Organisms are carried by macrophages",
                      "Spread via lymphatics and blood vessels to internal organs",
                      "Within macrophages, trophozoites can multiply and become crescent-shaped tachyzoites"
                    ]
                  },
                  {
                    "text": "In immunocompetent patients, tachyzoites usually become bradyzoites with slow cell divisionWithin cysts, organisms are slow-growing bradyzoitesInfection typically resolvesCD40 activation of autophagy in macrophages contributes to parasite killing",
                    "sub_points": [
                      "Within cysts, organisms are slow-growing bradyzoites",
                      "Infection typically resolves",
                      "CD40 activation of autophagy in macrophages contributes to parasite killing"
                    ]
                  },
                  {
                    "text": "In immunodeficient patients, bradyzoites become tachyzoites and widely disseminate, causing acute infection"
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "Toxoplasmosis is common parasitic disease worldwideMore prevalent in warm and humid climates~ 30% worldwide population has evidence of previous exposure",
                    "sub_points": [
                      "More prevalent in warm and humid climates",
                      "~ 30% worldwide population has evidence of previous exposure"
                    ]
                  },
                  {
                    "text": "Is usually opportunistic infectionPatients with underlying conditions with immunodeficiency",
                    "sub_points": [
                      "Patients with underlying conditions with immunodeficiency"
                    ]
                  },
                  {
                    "text": "In USA, toxoplasmosis is most common parasitic infection50% of USA individuals have serum antibodies toT. gondii: Evidence of chronic infection",
                    "sub_points": [
                      "50% of USA individuals have serum antibodies toT. gondii: Evidence of chronic infection"
                    ]
                  },
                  {
                    "text": "T. gondiican be spread transplacentally from mother to fetus1 in every 1,000 live births in USA~ 3,000 births are affected annuallyPotential malformations to fetus is greatest with infection in 1st trimesterRisk of stillbirth or abortion in pregnant women with primary infection",
                    "sub_points": [
                      "1 in every 1,000 live births in USA",
                      "~ 3,000 births are affected annually",
                      "Potential malformations to fetus is greatest with infection in 1st trimester",
                      "Risk of stillbirth or abortion in pregnant women with primary infection"
                    ]
                  },
                  {
                    "text": "Rarely,T. gondiiinfection can be transmitted via transplanted organ"
                  }
                ],
                "Age": [
                  {
                    "text": "Children and young adults most often affected"
                  }
                ],
                "Sex": [
                  {
                    "text": "No preference"
                  }
                ],
                "Site": [
                  {
                    "text": "Lymph nodes are commonly affectedPosterior cervical lymph nodes are characteristic siteOften unilateralAny group of lymph nodes can be involvedOther cervical, supraclavicular, occipital, parotid, intramammary regionsGeneralized lymphadenopathy or hepatosplenomegaly can occur but is unusual",
                    "sub_points": [
                      "Posterior cervical lymph nodes are characteristic siteOften unilateral",
                      "Often unilateral",
                      "Any group of lymph nodes can be involvedOther cervical, supraclavicular, occipital, parotid, intramammary regions",
                      "Other cervical, supraclavicular, occipital, parotid, intramammary regions",
                      "Generalized lymphadenopathy or hepatosplenomegaly can occur but is unusual"
                    ]
                  }
                ],
                "Presentation": [
                  {
                    "text": "Asymptomatic infection is common in immunocompetent patients"
                  },
                  {
                    "text": "Mild illness also can occur, manifested by malaise, fever, myalgia"
                  },
                  {
                    "text": "Immunocompromised patients may develop encephalitis, pulmonary or disseminated infection"
                  },
                  {
                    "text": "Chorioretinitis and uveitis in both immunocompetent and immunocompromised patients"
                  },
                  {
                    "text": "Active infection may result from reactivation of earlier infectionCommon in patients with cancers and diabetes mellitus",
                    "sub_points": [
                      "Common in patients with cancers and diabetes mellitus"
                    ]
                  },
                  {
                    "text": "Physical examination of lymph nodesTender or nontenderFirm but not rock hard0.5-3.0 cm",
                    "sub_points": [
                      "Tender or nontender",
                      "Firm but not rock hard",
                      "0.5-3.0 cm"
                    ]
                  }
                ],
                "Laboratory Tests": [
                  {
                    "text": "Sabin-Feldman dye testHighly sensitive and specificTest used mainly in reference laboratoriesT. gondiiorganisms do not stain with alkaline methylene blue if they have been exposed to serum anti-T. gondiiantibodiesPositive result: Change from negative to positive or rapidly increasing titers",
                    "sub_points": [
                      "Highly sensitive and specificTest used mainly in reference laboratories",
                      "Test used mainly in reference laboratories",
                      "T. gondiiorganisms do not stain with alkaline methylene blue if they have been exposed to serum anti-T. gondiiantibodies",
                      "Positive result: Change from negative to positive or rapidly increasing titers"
                    ]
                  },
                  {
                    "text": "Antibodies toT. gondiican be detected by enzyme immunoassays or indirect immunofluorescenceIgM or IgG antibodies against cell wall antigensWHO recommends using international standards for calibration of testsAntibody levels to be reported as IU/mLReference ranges provided by manufacturersIgM antibodies detected within few days after infectionTiters of 1:80 or higher indicate recent infectionPositive IgG level occurs at 6-8 weeks after infectionCan persist for yearsInterpretation of serologic testing is difficult",
                    "sub_points": [
                      "IgM or IgG antibodies against cell wall antigens",
                      "WHO recommends using international standards for calibration of testsAntibody levels to be reported as IU/mLReference ranges provided by manufacturers",
                      "Antibody levels to be reported as IU/mL",
                      "Reference ranges provided by manufacturers",
                      "IgM antibodies detected within few days after infectionTiters of 1:80 or higher indicate recent infection",
                      "Titers of 1:80 or higher indicate recent infection",
                      "Positive IgG level occurs at 6-8 weeks after infectionCan persist for years",
                      "Can persist for years",
                      "Interpretation of serologic testing is difficult"
                    ]
                  },
                  {
                    "text": "Latex agglutination test and ELISA assays available"
                  },
                  {
                    "text": "PCR can be used to amplifyT. gondiiDNACommonly used on amniotic fluid",
                    "sub_points": [
                      "Commonly used on amniotic fluid"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "Pyrimethamine/sulfadiazine"
                  },
                  {
                    "text": "Attenuated vaccines and passive vaccination in immunodeficient patients; experimental"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "In immunocompetent patients, infection is self-limiting"
                  },
                  {
                    "text": "In immunodeficient patients, great risk of acute disseminationEncephalitis, chorioretinitis, pneumonia, and cardiac involvementDeath may result from these conditions",
                    "sub_points": [
                      "Encephalitis, chorioretinitis, pneumonia, and cardiac involvementDeath may result from these conditions",
                      "Death may result from these conditions"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Lymph nodeArchitecture: PreservedCapsule/pericapsule: Minimal involvementSinuses: Distended by monocytoid B cellsLarge cells with sharp, visible cell borders, clear cytoplasm, and small, darkly stained nucleiFollicles: Florid reactive follicular hyperplasiaNumerous tingible body macrophagesGerminal centers can have ragged, indistinct marginsNumerous epithelioid histiocytes in interfollicular and paracortical regionsEncroach upon and invade into germinal centersForm collections of < 25 epithelioid cells (microgranulomas)Plasma cells and immunoblasts in medullary cordsToxoplasmacysts and bradyzoites are rare (1% of cases)Can identify by routine histologic examination in ~ 1% of casesNecrosis is absentWell-formed (sarcoid-like) granulomas do not occurNo multinucleated giant cells; no fibrosis",
                    "sub_points": [
                      "Architecture: Preserved",
                      "Capsule/pericapsule: Minimal involvement",
                      "Sinuses: Distended by monocytoid B cellsLarge cells with sharp, visible cell borders, clear cytoplasm, and small, darkly stained nuclei",
                      "Large cells with sharp, visible cell borders, clear cytoplasm, and small, darkly stained nuclei",
                      "Follicles: Florid reactive follicular hyperplasiaNumerous tingible body macrophagesGerminal centers can have ragged, indistinct margins",
                      "Numerous tingible body macrophages",
                      "Germinal centers can have ragged, indistinct margins",
                      "Numerous epithelioid histiocytes in interfollicular and paracortical regionsEncroach upon and invade into germinal centersForm collections of < 25 epithelioid cells (microgranulomas)",
                      "Encroach upon and invade into germinal centers",
                      "Form collections of < 25 epithelioid cells (microgranulomas)",
                      "Plasma cells and immunoblasts in medullary cords",
                      "Toxoplasmacysts and bradyzoites are rare (1% of cases)Can identify by routine histologic examination in ~ 1% of cases",
                      "Can identify by routine histologic examination in ~ 1% of cases",
                      "Necrosis is absent",
                      "Well-formed (sarcoid-like) granulomas do not occur",
                      "No multinucleated giant cells; no fibrosis"
                    ]
                  }
                ],
                "Cytologic Features": [
                  {
                    "text": "Diagnosis can be established by fine-needle aspiration (FNA) of lymph nodeDiff-Quik smears show polymorphous cell populationSmall and large lymphocytesClusters of epithelioid histiocytes (microgranulomas)Plasma cellsRarely, parasitic cysts can be detected",
                    "sub_points": [
                      "Diff-Quik smears show polymorphous cell populationSmall and large lymphocytesClusters of epithelioid histiocytes (microgranulomas)Plasma cells",
                      "Small and large lymphocytes",
                      "Clusters of epithelioid histiocytes (microgranulomas)",
                      "Plasma cells",
                      "Rarely, parasitic cysts can be detected"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "Anti-T.gondiiantibodies can be used to detect presence of parasites in tissues"
                  }
                ],
                "PCR": [
                  {
                    "text": "Toxoplasmagenomes are detected by conventional and nested polymerase chain reactionOften not detected in lymph nodes with changes ofToxoplasmalymphadenitis",
                    "sub_points": [
                      "Often not detected in lymph nodes with changes ofToxoplasmalymphadenitis"
                    ]
                  },
                  {
                    "text": "Does not distinguish active from latent infection"
                  }
                ],
                "Electron Microscopy": [
                  {
                    "text": "T.gondiihas distinctive featuresPaired organelles, dense bodiesConoid nuclei at rounded posterior endDouble-layered pellicles",
                    "sub_points": [
                      "Paired organelles, dense bodies",
                      "Conoid nuclei at rounded posterior end",
                      "Double-layered pellicles"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "HIV Lymphadenitis": [
                  {
                    "text": "Early stage of HIV infection can be associated with changes that mimic toxoplasmosis"
                  },
                  {
                    "text": "Florid follicular hyperplasia"
                  },
                  {
                    "text": "Sinusoidal and paracortical monocytoid B-cell hyperplasia"
                  },
                  {
                    "text": "Epithelioid histiocytes can be present or absent"
                  },
                  {
                    "text": "Positive immunohistochemical staining for HIV p24"
                  }
                ],
                "Dermatopathic Lymphadenopathy": [
                  {
                    "text": "Paracortical distributionNumerous histiocytes, many with twisted nucleiS100 protein (+), CD1a(+, subset)Melanin pigment",
                    "sub_points": [
                      "Numerous histiocytes, many with twisted nucleiS100 protein (+), CD1a(+, subset)",
                      "S100 protein (+), CD1a(+, subset)",
                      "Melanin pigment"
                    ]
                  }
                ],
                "Non-Hodgkin Lymphoma": [
                  {
                    "text": "Clusters of epithelioid histiocytes can be present in various non-Hodgkin lymphoma typesLymphoepithelioid variant of peripheral T-cell lymphomaSo-called Lennert lymphoma",
                    "sub_points": [
                      "Lymphoepithelioid variant of peripheral T-cell lymphomaSo-called Lennert lymphoma",
                      "So-called Lennert lymphoma"
                    ]
                  },
                  {
                    "text": "Lymph node architecture is usually effaced"
                  },
                  {
                    "text": "Monocytoid B-cell hyperplasia absent or minimal"
                  },
                  {
                    "text": "Aberrant expression of T-cell markers"
                  },
                  {
                    "text": "Monoclonal rearrangement of T-cell receptor"
                  }
                ],
                "Classic Hodgkin Lymphoma": [
                  {
                    "text": "Epithelioid histiocytes can be numerous"
                  },
                  {
                    "text": "Most common in mixed cellularity type"
                  },
                  {
                    "text": "Reed-Sternberg and Hodgkin cells presentCD15(+), CD30(+), CD45/LCA(-), pax-5(+)",
                    "sub_points": [
                      "CD15(+), CD30(+), CD45/LCA(-), pax-5(+)"
                    ]
                  }
                ],
                "Leishmaniasis Lymphadenitis": [
                  {
                    "text": "Histologic findings can closely mimic toxoplasmosis"
                  },
                  {
                    "text": "Multinucleated giant cells are usually present"
                  },
                  {
                    "text": "Leishman-Donovan bodies may be seen in cytoplasm of histiocytes"
                  }
                ],
                "Sarcoidosis": [
                  {
                    "text": "Well-formed granulomas, unlike toxoplasmosis"
                  },
                  {
                    "text": "Multinucleated giant cells often present"
                  },
                  {
                    "text": "Monocytoid B-cell hyperplasia is usually absent or minimal"
                  }
                ],
                "Systemic Lupus Erythematosus Lymphadenopathy": [
                  {
                    "text": "Areas of paracortical necrosis; ± hematoxyphilic bodies"
                  },
                  {
                    "text": "Clinical history and serologic findings of systemic lupus erythematosus"
                  }
                ],
                "Infectious Mononucleosis": [
                  {
                    "text": "Paracortical and polymorphous lymphoid proliferation"
                  },
                  {
                    "text": "Numerous immunoblasts and foci of necrosis"
                  },
                  {
                    "text": "No epithelioid histiocytes encroaching on germinal centers"
                  },
                  {
                    "text": "Positive for Epstein-Barr virus (EBV) infectionEBER is sensitive test for EBV infection",
                    "sub_points": [
                      "EBER is sensitive test for EBV infection"
                    ]
                  }
                ],
                "Nodular Lymphocyte-Predominant Hodgkin Lymphoma": [
                  {
                    "text": "Epithelioid histiocytes can be numerous, particularly in pattern F"
                  },
                  {
                    "text": "Large, vague nodules that are closely packed and lack mantle zonesFollicular dendritic cell networks in nodules",
                    "sub_points": [
                      "Follicular dendritic cell networks in nodules"
                    ]
                  },
                  {
                    "text": "Lymphocyte-predominant cells are presentFormerly known as popcorn cells or lymphocytic and histiocytic cellsCD20(+), pax-5 [+, strong], CD45/LCA(+)",
                    "sub_points": [
                      "Formerly known as popcorn cells or lymphocytic and histiocytic cells",
                      "CD20(+), pax-5 [+, strong], CD45/LCA(+)"
                    ]
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Clinically Relevant Pathologic Features": [
                  {
                    "text": "Persistent unilateral lymphadenopathyPosterior cervical lymph nodes commonly affected",
                    "sub_points": [
                      "Posterior cervical lymph nodes commonly affected"
                    ]
                  }
                ],
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "Diagnostic triad is characteristic ofToxoplasmalymphadenitis and correlates with serologic dataMarked reactive follicular hyperplasiaMonocytoid B-cell hyperplasia in sinusesEpithelioid histiocytes in paracortex that encroach on germinal centers",
                    "sub_points": [
                      "Marked reactive follicular hyperplasia",
                      "Monocytoid B-cell hyperplasia in sinuses",
                      "Epithelioid histiocytes in paracortex that encroach on germinal centers"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Unicentric Hyaline-Vascular Variant Castleman Disease": {
            "name": "Unicentric Hyaline-Vascular Variant Castleman Disease",
            "url": "https://app.pathprimer.com/document/d8b33b95-159f-4f16-b394-6cc9f2d1ace4/lesson/1ca98c4c-c6e6-4862-8c12-8cba7a24c075",
            "content": {
              "KEY FACTS": {
                "Clinical Issues": [
                  {
                    "text": "Young adults"
                  },
                  {
                    "text": "Lymphadenopathy, localized"
                  },
                  {
                    "text": "Excision is usually curative"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Changes in follicular and interfollicular (stromal) regions"
                  },
                  {
                    "text": "Follicular componentLarge follicles with regressed (involuted) germinal centersHyaline-vascular lesions (lollipop) features2 or more germinal centers per follicle (\"twinning\")Concentric rings of mantle zone lymphocytes (onion skin)",
                    "sub_points": [
                      "Large follicles with regressed (involuted) germinal centersHyaline-vascular lesions (lollipop) features",
                      "Hyaline-vascular lesions (lollipop) features",
                      "2 or more germinal centers per follicle (\"twinning\")",
                      "Concentric rings of mantle zone lymphocytes (onion skin)"
                    ]
                  },
                  {
                    "text": "Interfollicular or stromal componentIncreased vascular proliferation in interfollicular zonesIncreased spindle cells, including follicular dendritic cellsInterfollicular changes can predominate (stroma rich)Increased plasmacytoid dendritic cells in clusters",
                    "sub_points": [
                      "Increased vascular proliferation in interfollicular zones",
                      "Increased spindle cells, including follicular dendritic cells",
                      "Interfollicular changes can predominate (stroma rich)",
                      "Increased plasmacytoid dendritic cells in clusters"
                    ]
                  },
                  {
                    "text": "Plasma cells are infrequent"
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "Polytypic B cells and T cells"
                  },
                  {
                    "text": "Increased follicular dendritic cells in germinal centersCD21(+), CD23(+), CD35(+)Decreased germinal center B cells",
                    "sub_points": [
                      "CD21(+), CD23(+), CD35(+)",
                      "Decreased germinal center B cells"
                    ]
                  },
                  {
                    "text": "TdT(+) small lymphocytes can be present between follicles"
                  },
                  {
                    "text": "No consistent cytogenetic or molecular abnormalities"
                  },
                  {
                    "text": "Evidence that unicentric hyaline-vascular Castleman disease (HV-CD) is benign tumor of stromal cellsHUMARA shows loss of heterozygosityNoIGH,TRG, orTRBrearrangementsClonal cytogenetic abnormalities and gene mutations in subset of cases",
                    "sub_points": [
                      "HUMARA shows loss of heterozygosity",
                      "NoIGH,TRG, orTRBrearrangements",
                      "Clonal cytogenetic abnormalities and gene mutations in subset of cases"
                    ]
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "Unicentric mixed/plasmacytic Castleman disease"
                  },
                  {
                    "text": "Multicentric Castleman disease, idiopathic"
                  },
                  {
                    "text": "Multicentric Castleman disease, HHV8(+)"
                  },
                  {
                    "text": "Castleman-like changes associated with lymphomas"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Hyaline-vascular Castleman disease (HV-CD)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Angiofollicular lymph node hyperplasia (used rarely)"
                  },
                  {
                    "text": "Angiomatous lymphoid hamartoma (obsolete)"
                  },
                  {
                    "text": "Giant lymph node hyperplasia (obsolete)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Unicentric is defined as involvement of single lymph node or group of lymph nodes in same lymph node station"
                  },
                  {
                    "text": "HV-CDBenign proliferation of lymphocytes, vasculature, and stromal cells of unknown etiology",
                    "sub_points": [
                      "Benign proliferation of lymphocytes, vasculature, and stromal cells of unknown etiology"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Unknown": [
                  {
                    "text": "Possible factors in pathogenesisDysregulation of vascular endothelial growth factorFollicular dendritic cell (FDC) dysplasia may be precursor",
                    "sub_points": [
                      "Dysregulation of vascular endothelial growth factor",
                      "Follicular dendritic cell (FDC) dysplasia may be precursor"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "Unicentric HV-CD is rare"
                  },
                  {
                    "text": "11-13 per million persons in USA3,500-4,200 new cases each year",
                    "sub_points": [
                      "3,500-4,200 new cases each year"
                    ]
                  }
                ],
                "Age": [
                  {
                    "text": "Wide range: 2-80 yearsMedian: 4th decade",
                    "sub_points": [
                      "Median: 4th decade"
                    ]
                  }
                ],
                "Sex": [
                  {
                    "text": "Mild female predominance in some studiesOther studies report no sex preference",
                    "sub_points": [
                      "Other studies report no sex preference"
                    ]
                  }
                ],
                "Presentation": [
                  {
                    "text": "Patients present with localized mass (unicentric)Mass often detected incidentally byRadiologic imaging studiesPhysical examination",
                    "sub_points": [
                      "Mass often detected incidentally byRadiologic imaging studiesPhysical examination",
                      "Radiologic imaging studies",
                      "Physical examination"
                    ]
                  },
                  {
                    "text": "Symptoms may result from compression of adjacent tissues by enlarged lymph nodes"
                  },
                  {
                    "text": "~ 5% of HV-CD patients may have inflammatory-like stateConstitutional symptoms, hepatosplenomegaly, effusions, laboratory abnormalitiesThis inflammatory-like state resembles, in part, that seen in multicentric CD (MCD) patients",
                    "sub_points": [
                      "Constitutional symptoms, hepatosplenomegaly, effusions, laboratory abnormalities",
                      "This inflammatory-like state resembles, in part, that seen in multicentric CD (MCD) patients"
                    ]
                  },
                  {
                    "text": "Lymphadenopathy, localizedMost common anatomic sitesIn order of frequency: Mediastinum, neck, abdomen, retroperitoneumExtranodal sites are rarely involvedOrbital region, Waldeyer ring, spleen, gastrointestinal tract, kidney, adrenal gland",
                    "sub_points": [
                      "Most common anatomic sitesIn order of frequency: Mediastinum, neck, abdomen, retroperitoneumExtranodal sites are rarely involvedOrbital region, Waldeyer ring, spleen, gastrointestinal tract, kidney, adrenal gland",
                      "In order of frequency: Mediastinum, neck, abdomen, retroperitoneum",
                      "Extranodal sites are rarely involvedOrbital region, Waldeyer ring, spleen, gastrointestinal tract, kidney, adrenal gland",
                      "Orbital region, Waldeyer ring, spleen, gastrointestinal tract, kidney, adrenal gland"
                    ]
                  },
                  {
                    "text": "Autoimmune diseases are associated with HV-CD in ~ 5% of patientsParaneoplastic pemphigus, myasthenia gravisAutoimmune hemolytic anemia, bronchiolitis obliteransSjögren syndrome",
                    "sub_points": [
                      "Paraneoplastic pemphigus, myasthenia gravis",
                      "Autoimmune hemolytic anemia, bronchiolitis obliterans",
                      "Sjögren syndrome"
                    ]
                  }
                ],
                "Treatment": [],
                "Surgical approaches": [
                  {
                    "text": "Excise enlarged lymph node or mass"
                  }
                ],
                "Adjuvant therapy": [
                  {
                    "text": "Usually not necessary"
                  },
                  {
                    "text": "For patients with compression symptoms or unresectable diseaseRadiation therapy or immunochemotherapy may be used",
                    "sub_points": [
                      "Radiation therapy or immunochemotherapy may be used"
                    ]
                  },
                  {
                    "text": "For rare patients with inflammatory symptomsSiltuximab (anti-IL-6) or tocilizumab (anti-IL-6 receptor) may be helpfulIn small patient subset, immunochemotherapy may be required",
                    "sub_points": [
                      "Siltuximab (anti-IL-6) or tocilizumab (anti-IL-6 receptor) may be helpful",
                      "In small patient subset, immunochemotherapy may be required"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Excellent"
                  },
                  {
                    "text": "Surgical removal is usually curative; relapse rare"
                  },
                  {
                    "text": "Malignant neoplasms can arise in association with HV-CDFDC sarcomas are most commonVascular neoplasmsSecondary neoplasms are often low grade, but metastases have been reported",
                    "sub_points": [
                      "FDC sarcomas are most common",
                      "Vascular neoplasms",
                      "Secondary neoplasms are often low grade, but metastases have been reported"
                    ]
                  }
                ]
              },
              "IMAGING": {
                "Radiographic Findings": [
                  {
                    "text": "Enlarged lymph node or lymph nodes in same lymph node stationRoutine x-rays or CT: Mass; may show calcification (eggshell)PET scan: SUV usually < 6",
                    "sub_points": [
                      "Routine x-rays or CT: Mass; may show calcification (eggshell)",
                      "PET scan: SUV usually < 6"
                    ]
                  }
                ]
              },
              "MACROSCOPIC": {
                "General Features": [
                  {
                    "text": "Large lymph nodeMedian: 7 cm (range: 2-20 cm)Firm, white, nodular cut surface",
                    "sub_points": [
                      "Median: 7 cm (range: 2-20 cm)",
                      "Firm, white, nodular cut surface"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Obliteration of subcapsular sinuses"
                  },
                  {
                    "text": "There are changes in follicular and interfollicular (stromal) regionsFollicular component2 or more germinal centers within follicle (\"twinning\")Follicles typically large with regressed (or involuted) germinal centersGerminal centers are composed of many FDCsFDCs often hyperplastic; can show dysplasiaSome follicles show HV lesions, so-called lollipop lesions characterized bySclerotic blood vessels radially traversing into germinal centerConcentric rings of mantle zone lymphocytes (onion skin appearance)Interfollicular or stromal componentIncreased number of high endothelial venules with hyalinized wallsStromal component can predominate with only few HV folliclesSo-called stromal-rich variantIncreased smooth muscle actin (+) cells in stroma of small subset of casesSo-called angiomyoid areasNo impact on prognosisIncreased proliferation of FDCs in stroma of small subset of HV-CD casesCD21(+), CD23(+), CD35(+)Can be precursor of FDC sarcoma",
                    "sub_points": [
                      "Follicular component2 or more germinal centers within follicle (\"twinning\")Follicles typically large with regressed (or involuted) germinal centersGerminal centers are composed of many FDCsFDCs often hyperplastic; can show dysplasiaSome follicles show HV lesions, so-called lollipop lesions characterized bySclerotic blood vessels radially traversing into germinal centerConcentric rings of mantle zone lymphocytes (onion skin appearance)",
                      "2 or more germinal centers within follicle (\"twinning\")",
                      "Follicles typically large with regressed (or involuted) germinal centersGerminal centers are composed of many FDCsFDCs often hyperplastic; can show dysplasia",
                      "Germinal centers are composed of many FDCs",
                      "FDCs often hyperplastic; can show dysplasia",
                      "Some follicles show HV lesions, so-called lollipop lesions characterized bySclerotic blood vessels radially traversing into germinal center",
                      "Sclerotic blood vessels radially traversing into germinal center",
                      "Concentric rings of mantle zone lymphocytes (onion skin appearance)",
                      "Interfollicular or stromal componentIncreased number of high endothelial venules with hyalinized wallsStromal component can predominate with only few HV folliclesSo-called stromal-rich variantIncreased smooth muscle actin (+) cells in stroma of small subset of casesSo-called angiomyoid areasNo impact on prognosisIncreased proliferation of FDCs in stroma of small subset of HV-CD casesCD21(+), CD23(+), CD35(+)Can be precursor of FDC sarcoma",
                      "Increased number of high endothelial venules with hyalinized walls",
                      "Stromal component can predominate with only few HV folliclesSo-called stromal-rich variant",
                      "So-called stromal-rich variant",
                      "Increased smooth muscle actin (+) cells in stroma of small subset of casesSo-called angiomyoid areasNo impact on prognosis",
                      "So-called angiomyoid areas",
                      "No impact on prognosis",
                      "Increased proliferation of FDCs in stroma of small subset of HV-CD casesCD21(+), CD23(+), CD35(+)Can be precursor of FDC sarcoma",
                      "CD21(+), CD23(+), CD35(+)",
                      "Can be precursor of FDC sarcoma"
                    ]
                  },
                  {
                    "text": "Clusters of plasmacytoid dendritic cells can be prominentUsually present in tight clustersVery common but not specific",
                    "sub_points": [
                      "Usually present in tight clusters",
                      "Very common but not specific"
                    ]
                  },
                  {
                    "text": "Plasma cells and immunoblasts are infrequent in unicentric HV-CDMuch more common in unicentric mixed/plasmacytic type",
                    "sub_points": [
                      "Much more common in unicentric mixed/plasmacytic type"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Cytology": [
                  {
                    "text": "Challenging diagnosis by fine-needle aspirationMay see increased FDCs and capillaries associated with aggregates of lymphocytesBiopsy is recommended to establish diagnosis",
                    "sub_points": [
                      "May see increased FDCs and capillaries associated with aggregates of lymphocytes",
                      "Biopsy is recommended to establish diagnosis"
                    ]
                  }
                ],
                "Immunohistochemistry": [
                  {
                    "text": "Polytypic B cells and T cells"
                  },
                  {
                    "text": "Involuted germinal centers have increased FDCsCD21(+), CD23(+), CD35(+), EGFR(+)Dysplastic FDCs often stain variably for FDC markersGerminal center B cells are decreased",
                    "sub_points": [
                      "CD21(+), CD23(+), CD35(+), EGFR(+)",
                      "Dysplastic FDCs often stain variably for FDC markers",
                      "Germinal center B cells are decreased"
                    ]
                  },
                  {
                    "text": "Blood vessels: CD31(+), CD34(+), ERG(+)"
                  },
                  {
                    "text": "Mantle zones: CD19(+), CD20(+), IgD(+), BCL-2(+)"
                  },
                  {
                    "text": "Plasmacytoid dendritic cell clusters: CD123(+), TCL1(+), CD68(+)"
                  },
                  {
                    "text": "TdT(+) small lymphocytes can be present between folliclesRarely, these cells are numerous and mimic T-lymphoblastic lymphomaKnown as indolent T-lymphoblastic proliferation",
                    "sub_points": [
                      "Rarely, these cells are numerous and mimic T-lymphoblastic lymphomaKnown as indolent T-lymphoblastic proliferation",
                      "Known as indolent T-lymphoblastic proliferation"
                    ]
                  },
                  {
                    "text": "Infrequent plasma cells are polytypic"
                  },
                  {
                    "text": "Human herpesvirus type 8 (HHV8) is absent"
                  }
                ],
                "Flow Cytometry": [
                  {
                    "text": "Polytypic B cells and T cells with normal immunophenotype"
                  }
                ],
                "PCR": [
                  {
                    "text": "No evidence of monoclonalIGH,TRG, orTRBrearrangements"
                  },
                  {
                    "text": "Results of human androgen receptor assay (HUMARA)Many cases of show loss of heterozygosityImplication is that stromal cells in HV-CD are monoclonal",
                    "sub_points": [
                      "Many cases of show loss of heterozygosityImplication is that stromal cells in HV-CD are monoclonal",
                      "Implication is that stromal cells in HV-CD are monoclonal"
                    ]
                  }
                ],
                "Genetic Testing": [
                  {
                    "text": "Rare cases reported with chromosomal translocations or other clonal abnormalitiesNo consistent cytogenetic findings",
                    "sub_points": [
                      "No consistent cytogenetic findings"
                    ]
                  },
                  {
                    "text": "Del(12q13-15) resulted in intragenicHMGA2rearrangement reported in one case"
                  },
                  {
                    "text": "Mutations reported in 10-15% of unicentric CD casesPDGFRBis most common, 10-15% of casesMutations in MAPK and chromatin-remodeling pathways",
                    "sub_points": [
                      "PDGFRBis most common, 10-15% of cases",
                      "Mutations in MAPK and chromatin-remodeling pathways"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Unicentric Mixed/Plasmacytic Castleman Disease": [
                  {
                    "text": "20-30% of unicentric CD cases"
                  },
                  {
                    "text": "Any lymph node group can be affectedMediastinal involvement less common than HV-CD",
                    "sub_points": [
                      "Mediastinal involvement less common than HV-CD"
                    ]
                  },
                  {
                    "text": "Preserved overall lymph node architecture; sinuses are usually patent"
                  },
                  {
                    "text": "Sheets of plasma cells in interfollicular areasNo cytologic atypia",
                    "sub_points": [
                      "No cytologic atypia"
                    ]
                  },
                  {
                    "text": "Variable follicular hyperplasia with HV changesVariable regressive changes in follicles;HV lesions less well developed than in HV-CD",
                    "sub_points": [
                      "Variable regressive changes in follicles;",
                      "HV lesions less well developed than in HV-CD"
                    ]
                  },
                  {
                    "text": "No evidence of HHV8"
                  }
                ],
                "Multicentric Castleman Disease, Idiopathic": [
                  {
                    "text": "2 or more lymph nodes in 2 or more lymph node stations"
                  },
                  {
                    "text": "No association with HIV infection"
                  },
                  {
                    "text": "Constitutional symptoms and laboratory abnormalities commonCytopenias, hypoalbuminemia, elevated ESRElevated IL-6 levels, polyclonal hypergammaglobulinemia",
                    "sub_points": [
                      "Cytopenias, hypoalbuminemia, elevated ESR",
                      "Elevated IL-6 levels, polyclonal hypergammaglobulinemia"
                    ]
                  },
                  {
                    "text": "Hepatosplenomegaly, pleural effusions, edema"
                  },
                  {
                    "text": "Morphologic findings resemble, in large part, unicentric mixed/plasmacytic CD"
                  },
                  {
                    "text": "No evidence of HHV8 infection"
                  }
                ],
                "Multicentric Castleman Disease, HHV8(+)": [
                  {
                    "text": "2 or more lymph nodes in 2 or more lymph node stations"
                  },
                  {
                    "text": "High association with HIV infection in USAOccurs in patients with low CD4(+) counts",
                    "sub_points": [
                      "Occurs in patients with low CD4(+) counts"
                    ]
                  },
                  {
                    "text": "Constitutional symptoms and laboratory abnormalities common"
                  },
                  {
                    "text": "Hepatosplenomegaly, pleural effusions, edema"
                  },
                  {
                    "text": "Morphologic findings resemble, in large part, unicentric mixed/plasmacytic CDOften more lymphocyte depletion than idiopathic MCD",
                    "sub_points": [
                      "Often more lymphocyte depletion than idiopathic MCD"
                    ]
                  },
                  {
                    "text": "HHV8(+) defines this variant of CDPlasmablasts present mostly in mantle zones",
                    "sub_points": [
                      "Plasmablasts present mostly in mantle zones"
                    ]
                  },
                  {
                    "text": "Associated with increased risk of HHV8(+) large B-cell lymphoma"
                  }
                ],
                "Multicentric Castleman Disease Associated With POEMS Syndrome": [
                  {
                    "text": "MCD occurs in ~ 50% of patients"
                  },
                  {
                    "text": "Morphologic findings resemble, in large part, unicentric mixed/plasmacytic CD"
                  },
                  {
                    "text": "POEMS = polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes"
                  }
                ],
                "Castleman Disease-Like Changes Associated With Lymphomas": [
                  {
                    "text": "Some HV-CD-like features can be observed in association with various lymphomasMost common: Hodgkin lymphoma, follicular lymphoma, angioimmunoblastic T-cell lymphoma (AITL)",
                    "sub_points": [
                      "Most common: Hodgkin lymphoma, follicular lymphoma, angioimmunoblastic T-cell lymphoma (AITL)"
                    ]
                  },
                  {
                    "text": "Usually manifested as focal HV lesions and plasmacytosis"
                  },
                  {
                    "text": "May be associated with IL-6 dysregulation"
                  },
                  {
                    "text": "No apparent clinical significance"
                  }
                ],
                "Thymoma": [
                  {
                    "text": "Epithelial neoplasm"
                  },
                  {
                    "text": "Cytokeratin highlights epithelial cell network"
                  },
                  {
                    "text": "Lymphocytes are of immature T-cell lineage [TdT(+)]"
                  },
                  {
                    "text": "Unlike unicentric HV-CD, thymomas lackHV follicles (lollipop lesions)Stromal proliferationFDC dysplasia",
                    "sub_points": [
                      "HV follicles (lollipop lesions)",
                      "Stromal proliferation",
                      "FDC dysplasia"
                    ]
                  }
                ],
                "Angioimmunoblastic T-Cell Lymphoma": [
                  {
                    "text": "Follicles can show regressive changesSeverely involved follicles referred to as burnt outCan resemble involuted germinal centers of unicentric HV-CD",
                    "sub_points": [
                      "Severely involved follicles referred to as burnt out",
                      "Can resemble involuted germinal centers of unicentric HV-CD"
                    ]
                  },
                  {
                    "text": "Unlike HV-CD, AITL is characterized byParacortical distribution; often many eosinophilsProliferation of high endothelial venulesAtypical cells with clear cytoplasmMarkers of FDC show pattern of proliferation quite different from HV-CDAberrant CD4(+) T-helper cell populationPositive for multiple follicular T-helper markersCD10(+), BCL-6(+), ICOS(+), CXCL13(+), PD-1/CD279(+)Monoclonal T-cell receptor gene rearrangements",
                    "sub_points": [
                      "Paracortical distribution; often many eosinophils",
                      "Proliferation of high endothelial venules",
                      "Atypical cells with clear cytoplasm",
                      "Markers of FDC show pattern of proliferation quite different from HV-CD",
                      "Aberrant CD4(+) T-helper cell populationPositive for multiple follicular T-helper markersCD10(+), BCL-6(+), ICOS(+), CXCL13(+), PD-1/CD279(+)",
                      "Positive for multiple follicular T-helper markersCD10(+), BCL-6(+), ICOS(+), CXCL13(+), PD-1/CD279(+)",
                      "CD10(+), BCL-6(+), ICOS(+), CXCL13(+), PD-1/CD279(+)",
                      "Monoclonal T-cell receptor gene rearrangements"
                    ]
                  }
                ],
                "HIV Lymphadenitis": [
                  {
                    "text": "Prominent reactive follicular hyperplasia in early stages of infection"
                  },
                  {
                    "text": "Involuted follicles and vascular proliferation can occur in later stagesWhen present, HV lesions tend to be focal and not well developed",
                    "sub_points": [
                      "When present, HV lesions tend to be focal and not well developed"
                    ]
                  },
                  {
                    "text": "HIV serologic testing needed to confirm diagnosis"
                  }
                ],
                "Follicular Lymphoma": [
                  {
                    "text": "Numerous follicles that replace lymph node architecture"
                  },
                  {
                    "text": "HV lesions can occur uncommonlyWhen present, focal and not well developed",
                    "sub_points": [
                      "When present, focal and not well developed"
                    ]
                  },
                  {
                    "text": "Monotypic B-cell population; CD10(+), BCL-6(+)"
                  },
                  {
                    "text": "MonoclonalIGHrearrangements"
                  },
                  {
                    "text": "t(14;18)(q32;q21)/IGH::BCL2in 70-80%"
                  }
                ],
                "Mantle Cell Lymphoma, Mantle Zone Pattern": [
                  {
                    "text": "Follicles can be prominent with concentric rings of lymphocytes"
                  },
                  {
                    "text": "No HV lesions or stromal proliferation"
                  },
                  {
                    "text": "Monotypic B-cell population; CD5(+), cyclin-D1 (+)"
                  },
                  {
                    "text": "MonoclonalIGHrearrangements"
                  },
                  {
                    "text": "t(11;14)(q13;q32)/CCND1::IGHin 90-95%"
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Clinically Relevant Pathologic Features": [
                  {
                    "text": "Single lymph node or group of lymph nodes in same lymph node stationLymphadenopathy (2-20 cm)Mediastinum > neck > abdomen > retroperitoneumRarely involves extranodal sites",
                    "sub_points": [
                      "Lymphadenopathy (2-20 cm)Mediastinum > neck > abdomen > retroperitoneum",
                      "Mediastinum > neck > abdomen > retroperitoneum",
                      "Rarely involves extranodal sites"
                    ]
                  }
                ],
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "Both follicular and interfollicular (stromal) changesEither component may predominate",
                    "sub_points": [
                      "Either component may predominate"
                    ]
                  },
                  {
                    "text": "Follicular componentLarge follicles with small, regressed germinal centersHV (lollipop) lesionsExpanded concentric rings of mantle zone lymphocytesOnion skin",
                    "sub_points": [
                      "Large follicles with small, regressed germinal centersHV (lollipop) lesions",
                      "HV (lollipop) lesions",
                      "Expanded concentric rings of mantle zone lymphocytesOnion skin",
                      "Onion skin"
                    ]
                  },
                  {
                    "text": "Interfollicular componentVascular proliferation, increased FDCsIncreased plasmacytoid dendritic cells in clusters",
                    "sub_points": [
                      "Vascular proliferation, increased FDCs",
                      "Increased plasmacytoid dendritic cells in clusters"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Unicentric Mixed/Plasmacytic Variant Castleman Disease": {
            "name": "Unicentric Mixed/Plasmacytic Variant Castleman Disease",
            "url": "https://app.pathprimer.com/document/5dc47f7c-d942-48c3-ab1d-ca055355c1ef/lesson/1ca98c4c-c6e6-4862-8c12-8cba7a24c075",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Unicentric Castleman disease (CD) is benign disorder that involves single lymph node or group of lymph nodes in same lymph node station"
                  },
                  {
                    "text": "Mixed/plasmacytic variant (MP)-CD shows morphologically distinctive reaction pattern characterized byMarked interfollicular plasmacytosisVariable follicular hyperplasiaRegressive changes in subset of follicles",
                    "sub_points": [
                      "Marked interfollicular plasmacytosis",
                      "Variable follicular hyperplasia",
                      "Regressive changes in subset of follicles"
                    ]
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "Dysregulation of IL-6 likely involved in pathogenesis"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "~ 20-30% of localized/unicentric cases of CD"
                  },
                  {
                    "text": "Broad age range; median: 3rd-4th decades"
                  },
                  {
                    "text": "Most patients present with lymphadenopathy without systemic symptoms~ 10-20% of patients have systemic symptoms &/or laboratory abnormalities",
                    "sub_points": [
                      "~ 10-20% of patients have systemic symptoms &/or laboratory abnormalities"
                    ]
                  },
                  {
                    "text": "Usually cured by surgical excision"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Preserved lymph node architecture; patent sinuses"
                  },
                  {
                    "text": "Marked plasmacytosis in interfollicular areas"
                  },
                  {
                    "text": "Lymphoid follicles show variable follicular hyperplasiaRegressive changes in subset of folliclesMantle zones are usually well defined; can be expanded",
                    "sub_points": [
                      "Regressive changes in subset of follicles",
                      "Mantle zones are usually well defined; can be expanded"
                    ]
                  },
                  {
                    "text": "Vascularity in interfollicular areas can be prominent"
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "Plasma cells usually express polytypic Ig light chainsPlasma cells monotypic in 10-20% of cases",
                    "sub_points": [
                      "Plasma cells monotypic in 10-20% of cases"
                    ]
                  },
                  {
                    "text": "Follicles composed of polytypic B cells and T cells; human herpesvirus 8 (HHV8)(-)"
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "Multicentric CD, idiopathic or HHV8(+)"
                  },
                  {
                    "text": "Unicentric CD, hyaline-vascular variant"
                  },
                  {
                    "text": "Autoimmune diseases"
                  },
                  {
                    "text": "Infectious etiologies"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Mixed/plasmacytic variant of Castleman disease (MP-CD)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Unicentric CD, plasma cell variant"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Benign lymphoproliferative disorder that involves single lymph node or group of lymph nodes in same lymph node station"
                  },
                  {
                    "text": "MP-CD shows morphologically distinctive reaction pattern characterized byMarked interfollicular plasmacytosisVariable follicular hyperplasiaRegressive [hyaline-vascular (HV)] changes in subset of follicles in most cases",
                    "sub_points": [
                      "Marked interfollicular plasmacytosis",
                      "Variable follicular hyperplasia",
                      "Regressive [hyaline-vascular (HV)] changes in subset of follicles in most cases"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Unknown": [
                  {
                    "text": "Data supporting role for dysregulation of interleukin-6 (IL-6) in pathogenesisLymphocytes in MP-CD express IL-6B cells express IL-6 receptor (CD126)Autocrine or paracrine mechanisms may be involvedIn mice, forced expression of IL-6 in bone marrow cells causes syndrome that resembles MP-CD",
                    "sub_points": [
                      "Lymphocytes in MP-CD express IL-6",
                      "B cells express IL-6 receptor (CD126)Autocrine or paracrine mechanisms may be involved",
                      "Autocrine or paracrine mechanisms may be involved",
                      "In mice, forced expression of IL-6 in bone marrow cells causes syndrome that resembles MP-CD"
                    ]
                  },
                  {
                    "text": "Immune dysregulation also may be involved"
                  },
                  {
                    "text": "There is no evidence of human herpesvirus 8 (HHV8) infection"
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "Accounts for 20-30% of unicentric cases of CD"
                  },
                  {
                    "text": "4-5 per million persons in USA1,000-1,500 new patients per year",
                    "sub_points": [
                      "1,000-1,500 new patients per year"
                    ]
                  }
                ],
                "Age": [
                  {
                    "text": "Broad range; median: 3rd-4th decades"
                  }
                ],
                "Sex": [
                  {
                    "text": "Some studies suggest mild female predominance"
                  }
                ],
                "Site": [
                  {
                    "text": "Peripheral lymph nodes most common"
                  },
                  {
                    "text": "Mediastinal involvement less common (than unicentric HV-CD)"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Most patients present with lymphadenopathy without systemic symptoms"
                  },
                  {
                    "text": "10-20% of patients reported in literature had systemic symptomsFever, night sweats, weight loss, malaise",
                    "sub_points": [
                      "Fever, night sweats, weight loss, malaise"
                    ]
                  },
                  {
                    "text": "AA-type amyloidosis in small patient subset"
                  }
                ],
                "Laboratory Tests": [
                  {
                    "text": "Many patients lack laboratory abnormalities"
                  },
                  {
                    "text": "Subset of patients (~ 20-30%) have associated abnormalitiesSerum IL-6 levels can be increasedCytopenias: Anemia and thrombocytopeniaHepatosplenomegaly, edema, pleural effusionsHypoalbuminemia, polyclonal hypergammaglobulinemia",
                    "sub_points": [
                      "Serum IL-6 levels can be increased",
                      "Cytopenias: Anemia and thrombocytopenia",
                      "Hepatosplenomegaly, edema, pleural effusions",
                      "Hypoalbuminemia, polyclonal hypergammaglobulinemia"
                    ]
                  }
                ],
                "Treatment": [],
                "Surgical approaches": [
                  {
                    "text": "Usually cured by excision"
                  },
                  {
                    "text": "Siltuximab is helpful for patients with inflammatory-type symptomsFDA-approved chimeric monoclonal antibody that targets IL-6",
                    "sub_points": [
                      "FDA-approved chimeric monoclonal antibody that targets IL-6"
                    ]
                  },
                  {
                    "text": "Tocilizumab (anti-IL-6 receptor) also may be helpful for symptomatic patients"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Excellent after surgical excision"
                  },
                  {
                    "text": "Inflammatory-type symptoms often resolveSmall subset of patients require siltuximab or immunochemotherapy",
                    "sub_points": [
                      "Small subset of patients require siltuximab or immunochemotherapy"
                    ]
                  }
                ]
              },
              "IMAGING": {
                "Radiographic Findings": [
                  {
                    "text": "Lymphadenopathy1 or few enlarged lymph nodes in single lymph node station",
                    "sub_points": [
                      "1 or few enlarged lymph nodes in single lymph node station"
                    ]
                  },
                  {
                    "text": "Plain films and CT show mass"
                  },
                  {
                    "text": "PET shows increased FDG uptake (SUV < 6)"
                  }
                ]
              },
              "MACROSCOPIC": {
                "Size": [
                  {
                    "text": "Usually lymphadenopathy is of modest size"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Overall preserved lymph node architecture"
                  },
                  {
                    "text": "Sinuses usually patent"
                  },
                  {
                    "text": "Marked plasmacytosis in interfollicular areasSome plasma cells can be binucleated",
                    "sub_points": [
                      "Some plasma cells can be binucleated"
                    ]
                  },
                  {
                    "text": "Vascularity in interfollicular areas can be prominent"
                  },
                  {
                    "text": "Lymphoid follicles show variable follicular hyperplasiaSubset of follicles show regressive changesSome follicles can resemble HV lesionsUsually less well developed than are seen in unicentric HV-CDAtretic follicles are usually present",
                    "sub_points": [
                      "Subset of follicles show regressive changesSome follicles can resemble HV lesionsUsually less well developed than are seen in unicentric HV-CD",
                      "Some follicles can resemble HV lesionsUsually less well developed than are seen in unicentric HV-CD",
                      "Usually less well developed than are seen in unicentric HV-CD",
                      "Atretic follicles are usually present"
                    ]
                  },
                  {
                    "text": "Mantle zones are usually well defined and can be expandedPlasmablasts are absent in mantle zones",
                    "sub_points": [
                      "Plasmablasts are absent in mantle zones"
                    ]
                  }
                ],
                "Cytologic Features": [
                  {
                    "text": "Very challenging to establish diagnosis of unicentric MP-CD by fine-needle aspirationPlasma cells are cytologically normal without atypiaLymphocytes show range in cell size",
                    "sub_points": [
                      "Plasma cells are cytologically normal without atypia",
                      "Lymphocytes show range in cell size"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "Interfollicular plasma cells usually express polytypic Ig light chainsIn 10-20% of cases, plasma cells express monotypic cytoplasmic IgMost cases are lambda (+)",
                    "sub_points": [
                      "In 10-20% of cases, plasma cells express monotypic cytoplasmic IgMost cases are lambda (+)",
                      "Most cases are lambda (+)"
                    ]
                  },
                  {
                    "text": "Follicles composed of polytypic B cells and T cellsAtretic follicles show increased follicular dendritic cellsCD21(+), CD23(+), CD35(+)Germinal centers (GCs) have decreased GC B cellsCD10(+), BCL-6(+), BCL-2(-)",
                    "sub_points": [
                      "Atretic follicles show increased follicular dendritic cellsCD21(+), CD23(+), CD35(+)",
                      "CD21(+), CD23(+), CD35(+)",
                      "Germinal centers (GCs) have decreased GC B cellsCD10(+), BCL-6(+), BCL-2(-)",
                      "CD10(+), BCL-6(+), BCL-2(-)"
                    ]
                  },
                  {
                    "text": "HHV8 latency nuclear antigen (LANA) is (-)"
                  }
                ],
                "Flow Cytometry": [
                  {
                    "text": "Polytypic B cells and normal T cells"
                  },
                  {
                    "text": "Specific diagnosis cannot be suggested based on immunophenotype"
                  }
                ],
                "In Situ Hybridization": [
                  {
                    "text": "Epstein-Barr virus-encoded RNA (EBER) is (-)"
                  }
                ],
                "PCR": [
                  {
                    "text": "No evidence of clonalIGH,TRG, orTRBin most casesSmall subset of cases carry clonalIGHrearrangements",
                    "sub_points": [
                      "Small subset of cases carry clonalIGHrearrangements"
                    ]
                  },
                  {
                    "text": "Human androgen receptor assay (HUMARA)Monoclonal pattern in few cases",
                    "sub_points": [
                      "Monoclonal pattern in few cases"
                    ]
                  }
                ],
                "Genetic Testing": [
                  {
                    "text": "Very few cases studied"
                  },
                  {
                    "text": "No specific and recurrent chromosomal translocations"
                  },
                  {
                    "text": "Gene mutations are reported in unicentric CDPDGFRB10-15%Mutations in MAPK signaling pathway < 10%Mutations in chromatin remodeling genes < 10%",
                    "sub_points": [
                      "PDGFRB10-15%",
                      "Mutations in MAPK signaling pathway < 10%",
                      "Mutations in chromatin remodeling genes < 10%"
                    ]
                  }
                ],
                "Associated Lymphoid Neoplasms": [
                  {
                    "text": "Small subset of MP-CD can be associated with lymphomaClassic Hodgkin lymphoma (HL) is most commonMixed cellularity typeCD changes can obscure large Reed-Sternberg and Hodgkin (RS+H) cellsNon-HLs (NHL) also occurDiffuse large B-cell lymphomaMantle cell lymphomaPeripheral T-cell lymphoma",
                    "sub_points": [
                      "Classic Hodgkin lymphoma (HL) is most commonMixed cellularity typeCD changes can obscure large Reed-Sternberg and Hodgkin (RS+H) cells",
                      "Mixed cellularity type",
                      "CD changes can obscure large Reed-Sternberg and Hodgkin (RS+H) cells",
                      "Non-HLs (NHL) also occurDiffuse large B-cell lymphomaMantle cell lymphomaPeripheral T-cell lymphoma",
                      "Diffuse large B-cell lymphoma",
                      "Mantle cell lymphoma",
                      "Peripheral T-cell lymphoma"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Multicentric Castleman Disease, Idiopathic": [
                  {
                    "text": "2 or more lymph nodes in 2 or more lymph node stations"
                  },
                  {
                    "text": "Constitutional symptoms and laboratory abnormalities are commonCytopenias, hypoalbuminemia, elevated ESRElevated serum IL-6, polyclonal hypergammaglobulinemia",
                    "sub_points": [
                      "Cytopenias, hypoalbuminemia, elevated ESR",
                      "Elevated serum IL-6, polyclonal hypergammaglobulinemia"
                    ]
                  },
                  {
                    "text": "Hepatosplenomegaly, pleural effusions, edema"
                  },
                  {
                    "text": "No evidence of HHV8 infection"
                  },
                  {
                    "text": "Grading system for morphologic changes in idiopathic multicentric CD (MCD) has been proposed5 morphologic features graded from 0-3+Regressed GCsFollicular dendritic cell prominenceVascularityHyperplastic GCsPlasmacytosis2-3+ regressive GCs and 2-3+ plasmacytosis are minimum requirement to establish diagnosis of MCD",
                    "sub_points": [
                      "5 morphologic features graded from 0-3+Regressed GCsFollicular dendritic cell prominenceVascularityHyperplastic GCsPlasmacytosis",
                      "Regressed GCs",
                      "Follicular dendritic cell prominence",
                      "Vascularity",
                      "Hyperplastic GCs",
                      "Plasmacytosis",
                      "2-3+ regressive GCs and 2-3+ plasmacytosis are minimum requirement to establish diagnosis of MCD"
                    ]
                  }
                ],
                "Multicentric Castleman Disease, HHV8(+)": [
                  {
                    "text": "2 or more lymph nodes in 2 or more lymph node stations"
                  },
                  {
                    "text": "High association with HIV infection in USAPatients usually have very low CD4(+) counts",
                    "sub_points": [
                      "Patients usually have very low CD4(+) counts"
                    ]
                  },
                  {
                    "text": "Clinically aggressive disease"
                  },
                  {
                    "text": "Constitutional symptoms and laboratory abnormalities are commonCytopenias, hypoalbuminemia, elevated ESRElevated serum IL-6, polyclonal hypergammaglobulinemia",
                    "sub_points": [
                      "Cytopenias, hypoalbuminemia, elevated ESR",
                      "Elevated serum IL-6, polyclonal hypergammaglobulinemia"
                    ]
                  },
                  {
                    "text": "Hepatosplenomegaly, pleural effusions, edema"
                  },
                  {
                    "text": "Morphologic findings resemble, in part, unicentric MP-CDKey differences includeBlurred boundaries between GCs and mantle zonesHHV8(+) plasmablasts in mantle zonesGreater degree of lymphocyte depletion (compared with idiopathic MCD)",
                    "sub_points": [
                      "Key differences includeBlurred boundaries between GCs and mantle zonesHHV8(+) plasmablasts in mantle zonesGreater degree of lymphocyte depletion (compared with idiopathic MCD)",
                      "Blurred boundaries between GCs and mantle zones",
                      "HHV8(+) plasmablasts in mantle zones",
                      "Greater degree of lymphocyte depletion (compared with idiopathic MCD)"
                    ]
                  },
                  {
                    "text": "Plasmablasts can be present in clusters and are monotypic lambda (+)Known as microlymphomaNo impact on prognosis",
                    "sub_points": [
                      "Known as microlymphoma",
                      "No impact on prognosis"
                    ]
                  }
                ],
                "Multicentric Castleman Disease Associated With POEMS Syndrome": [
                  {
                    "text": "POEMS = polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes"
                  },
                  {
                    "text": "MCD occurs in ~ 50% of patients"
                  },
                  {
                    "text": "Morphologic findings resemble, in part, unicentric MP-CDIn particular, fit traditional description of plasma cell variant of CD",
                    "sub_points": [
                      "In particular, fit traditional description of plasma cell variant of CD"
                    ]
                  }
                ],
                "Unicentric Castleman Disease Associated With HHV8 Infection": [
                  {
                    "text": "Rare unicentric cases, usually with features of MP-CD, are HHV8(+)"
                  },
                  {
                    "text": "Must exclude MCD, HHV8(+)"
                  },
                  {
                    "text": "Even if unicentric, better to consider as multicentric for treatment purposes"
                  }
                ],
                "Unicentric Castleman Disease, Hyaline-Vascular Variant": [
                  {
                    "text": "Usually presents as unicentric mass; often above diaphragm"
                  },
                  {
                    "text": "Lymph nodes showLarge follicles with prominent HV (lollipop) lesionsLinear (onion skin) mantle zonesInterfollicular stroma; no plasmacytosis",
                    "sub_points": [
                      "Large follicles with prominent HV (lollipop) lesions",
                      "Linear (onion skin) mantle zones",
                      "Interfollicular stroma; no plasmacytosis"
                    ]
                  },
                  {
                    "text": "No association with HHV8 infection"
                  },
                  {
                    "text": "Surgical excision is curative"
                  }
                ],
                "Unicentric Castleman Disease Associated With Classic Hodgkin Lymphoma": [
                  {
                    "text": "Rare entity with < 50 cases reported"
                  },
                  {
                    "text": "Unicentric CD of MP typeHHV8(-)",
                    "sub_points": [
                      "HHV8(-)"
                    ]
                  },
                  {
                    "text": "Classic HL usually has interfollicular patternRS+H cells presentCD15(+/-), CD30(+), pax-5 (dim +), CD45/LCA(-)",
                    "sub_points": [
                      "RS+H cells presentCD15(+/-), CD30(+), pax-5 (dim +), CD45/LCA(-)",
                      "CD15(+/-), CD30(+), pax-5 (dim +), CD45/LCA(-)"
                    ]
                  }
                ],
                "Autoimmune Diseases": [
                  {
                    "text": "Lymph nodes show florid interfollicular plasmacytosis and follicular hyperplasiaDiseases that need to be excludedRheumatoid arthritisSerologic studies helpful to establish diagnosis (e.g., anti-CCP)Systemic lupus erythematosusSerologic studies helpful to establish diagnosis (e.g., anti-dsDNA)IgG4-related disease5 patterns in lymph nodes have been describedElevated IgG4 serum level",
                    "sub_points": [
                      "Diseases that need to be excludedRheumatoid arthritisSerologic studies helpful to establish diagnosis (e.g., anti-CCP)Systemic lupus erythematosusSerologic studies helpful to establish diagnosis (e.g., anti-dsDNA)IgG4-related disease5 patterns in lymph nodes have been describedElevated IgG4 serum level",
                      "Rheumatoid arthritisSerologic studies helpful to establish diagnosis (e.g., anti-CCP)",
                      "Serologic studies helpful to establish diagnosis (e.g., anti-CCP)",
                      "Systemic lupus erythematosusSerologic studies helpful to establish diagnosis (e.g., anti-dsDNA)",
                      "Serologic studies helpful to establish diagnosis (e.g., anti-dsDNA)",
                      "IgG4-related disease5 patterns in lymph nodes have been describedElevated IgG4 serum level",
                      "5 patterns in lymph nodes have been described",
                      "Elevated IgG4 serum level"
                    ]
                  }
                ],
                "Infectious Etiologies": [
                  {
                    "text": "Some infectious diseases can cause marked plasmacytosis and follicular hyperplasiaLuetic lymphadenitis (syphilis)HIV infection",
                    "sub_points": [
                      "Luetic lymphadenitis (syphilis)",
                      "HIV infection"
                    ]
                  },
                  {
                    "text": "Must be excluded before diagnosis of unicentric MP-CD can be established"
                  }
                ],
                "Marginal Zone B-Cell Lymphoma With Marked Plasmacytic Differentiation": [
                  {
                    "text": "Follicular hyperplasia and sheets of plasma cells can be prominent in some cases"
                  },
                  {
                    "text": "Nodal architecture is usually replaced by lymphomaNeoplastic B cells often with monocytoid featuresMonotypic Ig expression; monoclonalIGHrearrangements",
                    "sub_points": [
                      "Neoplastic B cells often with monocytoid features",
                      "Monotypic Ig expression; monoclonalIGHrearrangements"
                    ]
                  }
                ],
                "Plasmacytoma": [
                  {
                    "text": "Plasma cells form sheets that replace lymph node architecturePlasma cells are cytologically atypicalResidual follicles are usually small and overtaken by neoplastic cell proliferationNeoplasm may extend into perinodal adipose tissue",
                    "sub_points": [
                      "Plasma cells are cytologically atypical",
                      "Residual follicles are usually small and overtaken by neoplastic cell proliferation",
                      "Neoplasm may extend into perinodal adipose tissue"
                    ]
                  },
                  {
                    "text": "Plasma cells are monotypic and monoclonal"
                  }
                ],
                "Angioimmunoblastic T-Cell Lymphoma": [
                  {
                    "text": "Regressive changes in residual GCs are commonUsually no HV lesions",
                    "sub_points": [
                      "Usually no HV lesions"
                    ]
                  },
                  {
                    "text": "Some angioimmunoblastic T-cell lymphoma (AITL) cases have marked plasmacytosis"
                  },
                  {
                    "text": "Lymph node architecture is replacedPolymorphous cell population, including cells with pale/clear cytoplasm",
                    "sub_points": [
                      "Polymorphous cell population, including cells with pale/clear cytoplasm"
                    ]
                  },
                  {
                    "text": "Aberrant T-cell population with TFH immunophenotypeCD10, BCL-6, CXCL13, or PD-1 in many cases",
                    "sub_points": [
                      "CD10, BCL-6, CXCL13, or PD-1 in many cases"
                    ]
                  },
                  {
                    "text": "Monoclonal T-cell receptor rearrangements"
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Clinically Relevant Pathologic Features": [
                  {
                    "text": "Enlarged lymph node(s) involving single lymph node station"
                  },
                  {
                    "text": "Patients with unicentric/localized MP-CDHave variable clinical presentation associated with lymphadenopathyMost patients lack systemic symptoms or laboratory abnormalitiesSmall subset of patients can have inflammatory-type symptoms or laboratory abnormalities",
                    "sub_points": [
                      "Have variable clinical presentation associated with lymphadenopathy",
                      "Most patients lack systemic symptoms or laboratory abnormalities",
                      "Small subset of patients can have inflammatory-type symptoms or laboratory abnormalities"
                    ]
                  },
                  {
                    "text": "Many other conditions can mimic MP-CD and must be excludedAutoimmune diseases, such as rheumatoid arthritis",
                    "sub_points": [
                      "Autoimmune diseases, such as rheumatoid arthritis"
                    ]
                  }
                ],
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "Marked interfollicular polytypic plasmacytosis"
                  },
                  {
                    "text": "Variably hyperplastic follicles, some with regressive changes"
                  },
                  {
                    "text": "Histologic features are not specific and can be observed in other conditions"
                  },
                  {
                    "text": "No evidence of HHV8 infection"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Multicentric Castleman Disease, Idiopathic": {
            "name": "Multicentric Castleman Disease, Idiopathic",
            "url": "https://app.pathprimer.com/document/3f950822-21a8-48b2-99ba-a38a4d688814/lesson/1ca98c4c-c6e6-4862-8c12-8cba7a24c075",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Idiopathic multicentric Castleman disease (iMCD)2 typesThrombocytopenia,anasarca, reticulinfibrosis of bone marrow,renal dysfunction,organomegaly (TAFRO)Not otherwise specified (NOS)",
                    "sub_points": [
                      "2 typesThrombocytopenia,anasarca, reticulinfibrosis of bone marrow,renal dysfunction,organomegaly (TAFRO)Not otherwise specified (NOS)",
                      "Thrombocytopenia,anasarca, reticulinfibrosis of bone marrow,renal dysfunction,organomegaly (TAFRO)",
                      "Not otherwise specified (NOS)"
                    ]
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "Attributable to cytokine dysregulation (\"storm\")"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Disease at presentation can be mild or severeLymphadenopathy: Peripheral &/or abdominalB-type symptoms, splenomegaly, hepatomegalyAnemia, elevated erythrocyte sedimentation rate (ESR), lactate dehydrogenase (LDH), B2MElevated serum levels of IL-6, VEGF, IL-2R, IgA, IgEThrombocytopenia and normal Ig levels in iMCD-TAFROThrombocytosis and polyclonal hypergammaglobulinemia in iMCD-NOS",
                    "sub_points": [
                      "Lymphadenopathy: Peripheral &/or abdominal",
                      "B-type symptoms, splenomegaly, hepatomegaly",
                      "Anemia, elevated erythrocyte sedimentation rate (ESR), lactate dehydrogenase (LDH), B2M",
                      "Elevated serum levels of IL-6, VEGF, IL-2R, IgA, IgE",
                      "Thrombocytopenia and normal Ig levels in iMCD-TAFRO",
                      "Thrombocytosis and polyclonal hypergammaglobulinemia in iMCD-NOS"
                    ]
                  },
                  {
                    "text": "Skin rash, neurologic changes, edema, body cavity effusions"
                  },
                  {
                    "text": "1st-line therapy: Anti-IL-6 antibody (siltuximab)"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "5 components occur but are not specific for iMCDRegressed germinal centers (GCs), FDC prominence, vascularity, hyperplastic GCs, plasmacytosis",
                    "sub_points": [
                      "Regressed germinal centers (GCs), FDC prominence, vascularity, hyperplastic GCs, plasmacytosis"
                    ]
                  },
                  {
                    "text": "2-3+ regressed GCs and plasmacytosis required for diagnosis of iMCD"
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "Increased FDCs in GCs: CD21(+), CD23(+)"
                  },
                  {
                    "text": "Wide mantle zones: IgD(+), BCL-2(+), CD10(-), BCL-6(-)"
                  },
                  {
                    "text": "Interfollicular areas show polytypic plasma cells"
                  },
                  {
                    "text": "No evidence of clonality in most cases"
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "MCD, HHV8(+)"
                  },
                  {
                    "text": "MCD in POEMS syndrome"
                  },
                  {
                    "text": "Unicentric CD"
                  },
                  {
                    "text": "Lymphadenopathy associated with infectious and autoimmune diseases, malignant neoplasms"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Idiopathic multicentric Castleman disease (iMCD)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Systemic lymphoproliferative disorder involving 2 or more lymph node stations attributable to cytokine dysregulationAssociated with wide spectrum of symptoms, physical findings, and laboratory abnormalities",
                    "sub_points": [
                      "Associated with wide spectrum of symptoms, physical findings, and laboratory abnormalities"
                    ]
                  },
                  {
                    "text": "2 subtypes of iMCDTAFROThrombocytopenia,anasarca, reticulinfibrosis of bone marrow,renal dysfunction,organomegalyNot otherwise specified (NOS)",
                    "sub_points": [
                      "TAFROThrombocytopenia,anasarca, reticulinfibrosis of bone marrow,renal dysfunction,organomegaly",
                      "Thrombocytopenia,anasarca, reticulinfibrosis of bone marrow,renal dysfunction,organomegaly",
                      "Not otherwise specified (NOS)"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Unknown Etiology: 3 Hypotheses": [
                  {
                    "text": "AutoimmunePathologic autoantibodies or germline genomic alterations",
                    "sub_points": [
                      "Pathologic autoantibodies or germline genomic alterations"
                    ]
                  },
                  {
                    "text": "ParaneoplasticSomatic mutations in clonal cells",
                    "sub_points": [
                      "Somatic mutations in clonal cells"
                    ]
                  },
                  {
                    "text": "Infection with virus other than HHV8"
                  }
                ],
                "Pathogenesis": [
                  {
                    "text": "Cytokine dysregulation or \"storm\"Elevated levels of interleukin-6 (IL-6)Correlate with disease severity of disease \"flares\"Elevated levels of vascular endothelial growth factor (VEGF)IL-1, IL-2R, tumor necrosis factor-α",
                    "sub_points": [
                      "Elevated levels of interleukin-6 (IL-6)Correlate with disease severity of disease \"flares\"",
                      "Correlate with disease severity of disease \"flares\"",
                      "Elevated levels of vascular endothelial growth factor (VEGF)",
                      "IL-1, IL-2R, tumor necrosis factor-α"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "MCD represents 1,600-1,700 cases per year in USA"
                  },
                  {
                    "text": "33-50% are idiopathic; remainder are HHV8(+)"
                  }
                ],
                "Age": [
                  {
                    "text": "iMCD-TAFRO: Median age: 6th decade"
                  },
                  {
                    "text": "iMCD-NOS: 4th-5th decades"
                  },
                  {
                    "text": "Wide range: 2-80 years"
                  }
                ],
                "Sex": [
                  {
                    "text": "No obvious preference"
                  }
                ],
                "Ethnicity": [
                  {
                    "text": "No association with ethnic group or geographic region"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Highly heterogeneous: Can be mild or severeFever, night sweats, weight loss in ~ 80%Lymphadenopathy: Peripheral &/or abdominalSplenomegaly in ~ 75%; hepatomegaly in ~ 50%Skin rash, neurologic changesEdema, body cavity effusionsSevere in iMCD-TAFROLess prominent or absent in iMCD-NOS",
                    "sub_points": [
                      "Fever, night sweats, weight loss in ~ 80%",
                      "Lymphadenopathy: Peripheral &/or abdominal",
                      "Splenomegaly in ~ 75%; hepatomegaly in ~ 50%",
                      "Skin rash, neurologic changes",
                      "Edema, body cavity effusionsSevere in iMCD-TAFROLess prominent or absent in iMCD-NOS",
                      "Severe in iMCD-TAFRO",
                      "Less prominent or absent in iMCD-NOS"
                    ]
                  },
                  {
                    "text": "Multiorgan dysfunctionMore common in iMCD-TAFRO patients",
                    "sub_points": [
                      "More common in iMCD-TAFRO patients"
                    ]
                  }
                ],
                "Laboratory Tests": [
                  {
                    "text": "Laboratory abnormalities are very commonAnemia, elevated erythrocyte sedimentation rate (ESR)Elevated serum IL-6, VEGF, IL-2R, IgA, IgEElevated serum lactate dehydrogenase (LDH), β-2-microglobulin (B2M)iMCD-TAFROThrombocytopenia and normal serum Ig levelsElevated alkaline phosphataseiMCD-NOSThrombocytosis and polyclonal hypergammaglobulinemia",
                    "sub_points": [
                      "Anemia, elevated erythrocyte sedimentation rate (ESR)",
                      "Elevated serum IL-6, VEGF, IL-2R, IgA, IgE",
                      "Elevated serum lactate dehydrogenase (LDH), β-2-microglobulin (B2M)",
                      "iMCD-TAFROThrombocytopenia and normal serum Ig levelsElevated alkaline phosphatase",
                      "Thrombocytopenia and normal serum Ig levels",
                      "Elevated alkaline phosphatase",
                      "iMCD-NOSThrombocytosis and polyclonal hypergammaglobulinemia",
                      "Thrombocytosis and polyclonal hypergammaglobulinemia"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "1st-line therapy: Anti-IL-6 antibody (siltuximab)~ 33% of iMCD patients respondRecent proteomics study showed 7-molecule signature predictive of good siltuximab response",
                    "sub_points": [
                      "~ 33% of iMCD patients respond",
                      "Recent proteomics study showed 7-molecule signature predictive of good siltuximab response"
                    ]
                  },
                  {
                    "text": "Anti-IL-6 receptor (tocilizumab) also may be used"
                  },
                  {
                    "text": "For nonrespondersSteroids, rituximab, or cytotoxic chemotherapyImmunomodulating agents (thalidomide), intravenous γ-globulinSome preclinical data suggest role for mTOR inhibitors",
                    "sub_points": [
                      "Steroids, rituximab, or cytotoxic chemotherapy",
                      "Immunomodulating agents (thalidomide), intravenous γ-globulin",
                      "Some preclinical data suggest role for mTOR inhibitors"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "5-year overall survival: 65%; 10-year overall survival: 40%"
                  },
                  {
                    "text": "Patients with iMCD-TAFRO have more aggressive clinical course; poorer outcome"
                  }
                ],
                "Risk of Malignancy": [
                  {
                    "text": "Patients with iMCD have 3x increased prevalence of malignant neoplasmsClassic Hodgkin lymphomaDiffuse large B-cell lymphomaMantle cell lymphoma, peripheral T-cell lymphoma NOS",
                    "sub_points": [
                      "Classic Hodgkin lymphoma",
                      "Diffuse large B-cell lymphoma",
                      "Mantle cell lymphoma, peripheral T-cell lymphoma NOS"
                    ]
                  }
                ]
              },
              "IMAGING": {
                "Radiographic Findings": [
                  {
                    "text": "Multicentric lymphadenopathy"
                  },
                  {
                    "text": "Hepatosplenomegaly"
                  }
                ]
              },
              "MACROSCOPIC": {
                "Size": [
                  {
                    "text": "By definition, lymph nodes in iMCD-NOS must be ≥ 1 cm in short-axis diameter"
                  },
                  {
                    "text": "iMCD-TAFRO lymph nodes tend to be smaller, < 1.5 cm"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "iMCD shows spectrum of histologic features"
                  },
                  {
                    "text": "5 components have been proposed as characteristic, but not specific, of iMCDRegressed germinal centers (GCs)Follicular dendritic cell (FDC) prominenceVascularityHyperplastic GCsPlasmacytosis",
                    "sub_points": [
                      "Regressed germinal centers (GCs)",
                      "Follicular dendritic cell (FDC) prominence",
                      "Vascularity",
                      "Hyperplastic GCs",
                      "Plasmacytosis"
                    ]
                  },
                  {
                    "text": "Grading system (0-3+) proposed for each of 5 components"
                  },
                  {
                    "text": "2-3+ regressed GCs and plasmacytosis are required for diagnosis"
                  },
                  {
                    "text": "iMCD-TAFROMixture of hyaline-vascular (hypervascular) and mixed/plasmacytic changes",
                    "sub_points": [
                      "Mixture of hyaline-vascular (hypervascular) and mixed/plasmacytic changes"
                    ]
                  },
                  {
                    "text": "iMCD-NOSOften shows well-developed mixed/plasmacytic changesHypervascular changes minimal or absent",
                    "sub_points": [
                      "Often shows well-developed mixed/plasmacytic changes",
                      "Hypervascular changes minimal or absent"
                    ]
                  }
                ],
                "Cytologic Features": [
                  {
                    "text": "Diagnosis by fine-needle aspiration is highly challengingGenerally not possible to establish specific diagnosis",
                    "sub_points": [
                      "Generally not possible to establish specific diagnosis"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "B cells and T cells in appropriate lymph node locations"
                  },
                  {
                    "text": "Follicles containCD10(+), BCL-6(+), BCL-2(-) GC B cellsIncreased FDCs: CD21(+)",
                    "sub_points": [
                      "CD10(+), BCL-6(+), BCL-2(-) GC B cells",
                      "Increased FDCs: CD21(+)"
                    ]
                  },
                  {
                    "text": "Mantle zone B cells: IgD(+), BCL-2(+), CD10(-), BCL-6(-)"
                  },
                  {
                    "text": "Plasma cells are polytypicIgM(+) more common around folliclesIgA(+) or IgG(+) common in interfollicular regionsIn ~ 10% of iMCD cases, plasma cells are monotypic",
                    "sub_points": [
                      "IgM(+) more common around follicles",
                      "IgA(+) or IgG(+) common in interfollicular regions",
                      "In ~ 10% of iMCD cases, plasma cells are monotypic"
                    ]
                  },
                  {
                    "text": "T cells have normal immunophenotype"
                  },
                  {
                    "text": "No HHV8(+) cells are present"
                  }
                ],
                "Flow Cytometry": [
                  {
                    "text": "Polytypic B cells and normal T cells"
                  },
                  {
                    "text": "Monotypic cytoplasmic light chain in small subset of cases"
                  }
                ],
                "PCR": [
                  {
                    "text": "Polyclonal antigen receptor genes in most cases~ 10% of cases carry clonalIGHandIGKrearrangements",
                    "sub_points": [
                      "~ 10% of cases carry clonalIGHandIGKrearrangements"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Multicentric Castleman Disease, HHV8(+)": [
                  {
                    "text": "Occurs in patients with immunodeficiencyHIV infection/AIDS is most common cause in USACD4(+) T cells are usually very low",
                    "sub_points": [
                      "HIV infection/AIDS is most common cause in USA",
                      "CD4(+) T cells are usually very low"
                    ]
                  },
                  {
                    "text": "Follicles show regressive changes and increased vascularity"
                  },
                  {
                    "text": "Interfollicular regions show plasmacytosis"
                  },
                  {
                    "text": "HHV8(+) plasmablasts are presentCommonly located at periphery of mantle zonesCan form small nodules (so-called microlymphomas)Likely precursors of HHV8(+) diffuse large B-cell lymphoma",
                    "sub_points": [
                      "Commonly located at periphery of mantle zones",
                      "Can form small nodules (so-called microlymphomas)Likely precursors of HHV8(+) diffuse large B-cell lymphoma",
                      "Likely precursors of HHV8(+) diffuse large B-cell lymphoma"
                    ]
                  }
                ],
                "Multicentric Castleman Disease in POEMS Syndrome": [
                  {
                    "text": "POEMS =peripheral neuropathy,organomegaly,endocrinopathy,monoclonal gammopathy,skin changes"
                  },
                  {
                    "text": "Lymph nodes show MCD in ~ 25% of patients"
                  },
                  {
                    "text": "Histologic findings closely resemble MCD-NOS"
                  },
                  {
                    "text": "Excluded from iMCD category (etiology known)Process is driven by monoclonal plasma cell neoplasm",
                    "sub_points": [
                      "Process is driven by monoclonal plasma cell neoplasm"
                    ]
                  }
                ],
                "Unicentric Castleman Disease": [
                  {
                    "text": "Single lymph node station is involvedExtranodal sites rarely involved",
                    "sub_points": [
                      "Extranodal sites rarely involved"
                    ]
                  },
                  {
                    "text": "Inflammatory-type symptoms are unusualMore common in mixed/plasmacytic variant",
                    "sub_points": [
                      "More common in mixed/plasmacytic variant"
                    ]
                  },
                  {
                    "text": "Unicentric mixed/plasmacytic variant resembles iMCD-NOS"
                  },
                  {
                    "text": "Hyaline-vascular variant shows overlap with iMCD-TAFRO"
                  }
                ],
                "Infectious Diseases": [
                  {
                    "text": "HHV8(+) lymphoproliferative disorders"
                  },
                  {
                    "text": "EBV(+) lymphoproliferative disordersInfectious mononucleosis, chronic active EBV infection",
                    "sub_points": [
                      "Infectious mononucleosis, chronic active EBV infection"
                    ]
                  },
                  {
                    "text": "Lymphadenopathy associated with uncontrolled infectionse.g., CMV, HIV, toxoplasmosis, tuberculosis",
                    "sub_points": [
                      "e.g., CMV, HIV, toxoplasmosis, tuberculosis"
                    ]
                  }
                ],
                "Autoimmune Diseases": [
                  {
                    "text": "Rheumatoid arthritisUsually lymph nodes in proximity to inflamed jointsLymph nodes morphologically often mimic iMCDInterfollicular sheets of plasma cells; hyperplastic folliclesSerologic studies are helpful to establish diagnosis",
                    "sub_points": [
                      "Usually lymph nodes in proximity to inflamed joints",
                      "Lymph nodes morphologically often mimic iMCDInterfollicular sheets of plasma cells; hyperplastic follicles",
                      "Interfollicular sheets of plasma cells; hyperplastic follicles",
                      "Serologic studies are helpful to establish diagnosis"
                    ]
                  },
                  {
                    "text": "Systemic lupus erythematosusInvolved lymph nodes can morphologically closely mimic iMCD10-30% of patientsSerologic studies are helpful to establish diagnosis",
                    "sub_points": [
                      "Involved lymph nodes can morphologically closely mimic iMCD10-30% of patients",
                      "10-30% of patients",
                      "Serologic studies are helpful to establish diagnosis"
                    ]
                  },
                  {
                    "text": "IgG4-related diseaseiMCD patients can have elevated serum IgG4 levelsIgG4(+) plasma cells can be increased in iMCD lymph nodesDiagnosis of iMCD supersedes diagnosis of IgG4-related disease",
                    "sub_points": [
                      "iMCD patients can have elevated serum IgG4 levels",
                      "IgG4(+) plasma cells can be increased in iMCD lymph nodes",
                      "Diagnosis of iMCD supersedes diagnosis of IgG4-related disease"
                    ]
                  },
                  {
                    "text": "Other autoimmune diseases that need to be excludedAdult-onset Still disease, juvenile idiopathic arthritisAutoimmune lymphoproliferative syndrome",
                    "sub_points": [
                      "Adult-onset Still disease, juvenile idiopathic arthritis",
                      "Autoimmune lymphoproliferative syndrome"
                    ]
                  }
                ],
                "Malignant Neoplasms": [
                  {
                    "text": "Castleman-like changes can occur with lymphomasClassic Hodgkin lymphoma (mixed cellularity, interfollicular)Various types of non-Hodgkin lymphomaAngioimmunoblastic T-cell lymphoma, follicular lymphoma, others",
                    "sub_points": [
                      "Classic Hodgkin lymphoma (mixed cellularity, interfollicular)",
                      "Various types of non-Hodgkin lymphomaAngioimmunoblastic T-cell lymphoma, follicular lymphoma, others",
                      "Angioimmunoblastic T-cell lymphoma, follicular lymphoma, others"
                    ]
                  },
                  {
                    "text": "Plasma cell myelomaPOEMS syndrome",
                    "sub_points": [
                      "POEMS syndrome"
                    ]
                  },
                  {
                    "text": "Primary plasmacytoma of lymph node"
                  },
                  {
                    "text": "FDC sarcoma"
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Clinically Relevant Pathologic Features": [
                  {
                    "text": "≥ 2 lymph node stations are required for diagnosis of iMCDUsually shown by radiologic imaging and biopsy",
                    "sub_points": [
                      "Usually shown by radiologic imaging and biopsy"
                    ]
                  },
                  {
                    "text": "Cytokine dysregulation leads to elevated IL-6, VEGF, IL-2R, IgA, IgE, others"
                  }
                ],
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "Pathologic findings are not specific for iMCDProposed criteria for diagnosis are designed to be sensitive, but they are not specific",
                    "sub_points": [
                      "Proposed criteria for diagnosis are designed to be sensitive, but they are not specific"
                    ]
                  },
                  {
                    "text": "Diagnosis of iMCD depends on integration of clinical, laboratory, and radiologic imaging results"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Multicentric Castleman Disease, HHV8 Associated": {
            "name": "Multicentric Castleman Disease, HHV8 Associated",
            "url": "https://app.pathprimer.com/document/c958a226-944c-46a2-88b2-46eb60d6fccb/lesson/1ca98c4c-c6e6-4862-8c12-8cba7a24c075",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Multicentric Castleman disease (MCD)"
                  },
                  {
                    "text": "Human herpesvirus 8 (HHV8) a.k.a. Kaposi sarcoma herpes virus"
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "HHV8 infection important in pathogenesisSeroprevalence of HHV8 ~ 25% in USAInfection is usually latentImmunodeficiency facilitates viral reactivationHIV/AIDS infection is most common causeHHV8 is thought to be major driver of this diseaseEncodes homologue of interleukin-6 (IL-6)Virus is pleiotropic; has many other effects",
                    "sub_points": [
                      "Seroprevalence of HHV8 ~ 25% in USAInfection is usually latentImmunodeficiency facilitates viral reactivationHIV/AIDS infection is most common cause",
                      "Infection is usually latent",
                      "Immunodeficiency facilitates viral reactivationHIV/AIDS infection is most common cause",
                      "HIV/AIDS infection is most common cause",
                      "HHV8 is thought to be major driver of this diseaseEncodes homologue of interleukin-6 (IL-6)Virus is pleiotropic; has many other effects",
                      "Encodes homologue of interleukin-6 (IL-6)",
                      "Virus is pleiotropic; has many other effects"
                    ]
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Lymphadenopathy constant; any lymph node group"
                  },
                  {
                    "text": "B symptoms in ~ 90% of patients"
                  },
                  {
                    "text": "Splenomegaly in ~ 75%; hepatomegaly in ~ 50%"
                  },
                  {
                    "text": "Patients with MCD-HHV8(+) often have other neoplasmsKaposi sarcoma, plasmablastic lymphoma",
                    "sub_points": [
                      "Kaposi sarcoma, plasmablastic lymphoma"
                    ]
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Sheets of plasma cells in interfollicular zones"
                  },
                  {
                    "text": "Extensive vascular proliferationHyaline-vascular lesions often present",
                    "sub_points": [
                      "Hyaline-vascular lesions often present"
                    ]
                  },
                  {
                    "text": "Blurring of boundary between mantle zones and interfollicular area"
                  },
                  {
                    "text": "Plasmablasts are present in mantle zones of follicles"
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "Immunohistochemistry for HHV8 latency-associated nuclear antigen 1 (LANA1)"
                  },
                  {
                    "text": "Epstein-Barr virus (EBV) is commonly present"
                  },
                  {
                    "text": "Plasma cells are monotypic in subset of casesClonalIGHrearrangements also present",
                    "sub_points": [
                      "ClonalIGHrearrangements also present"
                    ]
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "Other types of CD"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Multicentric Castleman disease (MCD)"
                  },
                  {
                    "text": "Human herpesvirus 8 (HHV8) a.k.a. Kaposi sarcoma herpes virus"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Plasmablastic MCD (obsolete)"
                  },
                  {
                    "text": "Plasmablastic variant of MCD (obsolete)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Systemic lymphoproliferative disorder that involves ≥ 2 or more lymph node stationsShares morphologic features of idiopathic MCD but is HHV8(+)",
                    "sub_points": [
                      "Shares morphologic features of idiopathic MCD but is HHV8(+)"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Infectious Agents": [
                  {
                    "text": "HHV8 infection is thought to drive MCD-HHV8(+)γ-herpesvirus with seroprevalence of ~ 25% in USAHHV8 infection is usually latentImmunodeficiency or immunodysregulation facilitates HHV8 reactivation",
                    "sub_points": [
                      "γ-herpesvirus with seroprevalence of ~ 25% in USAHHV8 infection is usually latent",
                      "HHV8 infection is usually latent",
                      "Immunodeficiency or immunodysregulation facilitates HHV8 reactivation"
                    ]
                  }
                ],
                "Pathogenesis": [
                  {
                    "text": "MCD-HHV8(+) manifestations related to hypercytokinemia and B-cell proliferation"
                  },
                  {
                    "text": "HHV8 encodes homologue of human interleukin-6 (IL-6)Viral IL-6 stimulates human cellular pathwaysHuman XBP-1 directly activates viral IL-6",
                    "sub_points": [
                      "Viral IL-6 stimulates human cellular pathways",
                      "Human XBP-1 directly activates viral IL-6"
                    ]
                  },
                  {
                    "text": "Human IL-6 is B-cell growth factor and has other functionsRegulates differentiation of B cells to plasma cellsRegulates T-cell function and induces C-reactive protein production by hepatocytes",
                    "sub_points": [
                      "Regulates differentiation of B cells to plasma cells",
                      "Regulates T-cell function and induces C-reactive protein production by hepatocytes"
                    ]
                  },
                  {
                    "text": "B cells in MCD-HHV8(+) overexpress IL-6 receptor (CD126)Cells within lymph nodes express high levels of IL-6Suggests paracrine or autocrine mechanisms for IL-6",
                    "sub_points": [
                      "Cells within lymph nodes express high levels of IL-6",
                      "Suggests paracrine or autocrine mechanisms for IL-6"
                    ]
                  },
                  {
                    "text": "Other HHV8 proteins play role in pathogenesisViral FLICE inhibitory protein (FLIP); viral microRNAsViral interferon regulatory factor 3 (vIRF3/LANA2)",
                    "sub_points": [
                      "Viral FLICE inhibitory protein (FLIP); viral microRNAs",
                      "Viral interferon regulatory factor 3 (vIRF3/LANA2)"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "There are 1,600-1,700 cases of MCD per year in USA50-67% of cases are MCD-HHV8(+)~ 80% of patients are HIV(+), and most have AIDS",
                    "sub_points": [
                      "50-67% of cases are MCD-HHV8(+)",
                      "~ 80% of patients are HIV(+), and most have AIDS"
                    ]
                  }
                ],
                "Age": [
                  {
                    "text": "Broad range; reflects HIV(+) population"
                  }
                ],
                "Sex": [
                  {
                    "text": "More common in men; reflects HIV(+)/AIDS population"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Diffuse lymphadenopathy is constant findingPeripheral, abdominal, or mediastinal lymphadenopathyAny lymph node group can be involved",
                    "sub_points": [
                      "Peripheral, abdominal, or mediastinal lymphadenopathy",
                      "Any lymph node group can be involved"
                    ]
                  },
                  {
                    "text": "Fever, night sweats, or weight loss in ~ 90%"
                  },
                  {
                    "text": "Splenomegaly in ~ 75%; hepatomegaly in ~ 50%"
                  },
                  {
                    "text": "Edema and body cavity effusions are common"
                  },
                  {
                    "text": "Central nervous system abnormalities in small subset"
                  },
                  {
                    "text": "Risk of coexistent chronic infections is increasedEpstein-Barr virus (EBV), hepatitis C, cytomegalovirus (CMV)",
                    "sub_points": [
                      "Epstein-Barr virus (EBV), hepatitis C, cytomegalovirus (CMV)"
                    ]
                  },
                  {
                    "text": "Kaposi sarcoma in 10-20% of patients"
                  }
                ],
                "Laboratory Tests": [
                  {
                    "text": "Virus load in peripheral blood mononuclear cells correlates with disease severity"
                  },
                  {
                    "text": "HematologicCytopenias: Anemia &/or thrombocytopenia",
                    "sub_points": [
                      "Cytopenias: Anemia &/or thrombocytopenia"
                    ]
                  },
                  {
                    "text": "Elevated serum IL-6 levels during symptomatic episodes"
                  },
                  {
                    "text": "Elevated ESR and LDH levels; hypergammaglobulinemia"
                  }
                ],
                "Treatment": [
                  {
                    "text": "Chemotherapy and steroids have been used for patients with MCDNot very effective for patients who are HIV(+) or who have peripheral neuropathy, organomegaly, endocrinopathy, monoclonal M protein, skin lesions (POEMS) syndrome",
                    "sub_points": [
                      "Not very effective for patients who are HIV(+) or who have peripheral neuropathy, organomegaly, endocrinopathy, monoclonal M protein, skin lesions (POEMS) syndrome"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Poor in patients with POEMS syndrome or HIV infectionPatients usually die within few months of diagnosis",
                    "sub_points": [
                      "Patients usually die within few months of diagnosis"
                    ]
                  }
                ],
                "Frequently Associated Neoplasms": [
                  {
                    "text": "HHV8(+) diffuse large B-cell lymphomaPlasmablastic morphologic featuresUsually involves lymph nodes &/or spleenLeukemic phase is rareCan affect HIV(-) patients in HHV8-endemic regionsAfrican and Mediterranean countries",
                    "sub_points": [
                      "Plasmablastic morphologic features",
                      "Usually involves lymph nodes &/or spleen",
                      "Leukemic phase is rare",
                      "Can affect HIV(-) patients in HHV8-endemic regionsAfrican and Mediterranean countries",
                      "African and Mediterranean countries"
                    ]
                  },
                  {
                    "text": "Kaposi sarcomaMore common in HIV/AIDS patients",
                    "sub_points": [
                      "More common in HIV/AIDS patients"
                    ]
                  },
                  {
                    "text": "Primary effusion lymphomaOccurs in HHV8(+) patientsUsually coinfected with EBV",
                    "sub_points": [
                      "Occurs in HHV8(+) patients",
                      "Usually coinfected with EBV"
                    ]
                  },
                  {
                    "text": "Increased frequency of various lymphomasClassic Hodgkin lymphomaMixed cellularity and interfollicular types are most commonDiffuse large B-cell lymphomaMantle cell lymphoma, peripheral T-cell lymphoma",
                    "sub_points": [
                      "Classic Hodgkin lymphomaMixed cellularity and interfollicular types are most common",
                      "Mixed cellularity and interfollicular types are most common",
                      "Diffuse large B-cell lymphoma",
                      "Mantle cell lymphoma, peripheral T-cell lymphoma"
                    ]
                  }
                ]
              },
              "IMAGING": {
                "Radiographic Findings": [
                  {
                    "text": "Lymphadenopathy and hepatosplenomegaly"
                  },
                  {
                    "text": "CT: Lesions enhance with IV contrast"
                  },
                  {
                    "text": "PET: ~ 50-60% of lesions have increased FDG uptake"
                  },
                  {
                    "text": "Radiographic findings are not specificBiopsy required for diagnosis",
                    "sub_points": [
                      "Biopsy required for diagnosis"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Lymph nodes in MCD-HHV8(+) are similar to mixed/plasmacytic unicentric CD (UCD) and idiopathic MCDSheets of polytypic plasma cells in interfollicular regionsExtensive vascular proliferationRegressed follicles are usually present; hyaline-vascular lesions (+/-)",
                    "sub_points": [
                      "Sheets of polytypic plasma cells in interfollicular regions",
                      "Extensive vascular proliferation",
                      "Regressed follicles are usually present; hyaline-vascular lesions (+/-)"
                    ]
                  },
                  {
                    "text": "Features of MCD-HHV8(+) that differ from mixed/plasmacytic UCD and idiopathic MCDGreater degree of lymphocyte depletionParticularly in HIV(+) patientsBlurred border between mantle zones and interfollicular areasAtypical plasma cells (plasmablasts) are present",
                    "sub_points": [
                      "Greater degree of lymphocyte depletionParticularly in HIV(+) patients",
                      "Particularly in HIV(+) patients",
                      "Blurred border between mantle zones and interfollicular areas",
                      "Atypical plasma cells (plasmablasts) are present"
                    ]
                  },
                  {
                    "text": "HHV8(+) cells can be small or large with features of plasmablastsUsually located in mantle zonesHHV8(+) cells can form small nodules or microlymphomasDuring early stage of disease, plasma cells are polytypic or monotypicDuring later stage of disease, plasma cells are monotypicUsually express monotypic lambda",
                    "sub_points": [
                      "Usually located in mantle zones",
                      "HHV8(+) cells can form small nodules or microlymphomasDuring early stage of disease, plasma cells are polytypic or monotypicDuring later stage of disease, plasma cells are monotypicUsually express monotypic lambda",
                      "During early stage of disease, plasma cells are polytypic or monotypic",
                      "During later stage of disease, plasma cells are monotypic",
                      "Usually express monotypic lambda"
                    ]
                  },
                  {
                    "text": "Bone marrow involvement by MCD-HHV8(+)Bland plasmacytosis is commonCan mimic plasma cell myelomaHHV8(+) cells can be identified in bone marrow",
                    "sub_points": [
                      "Bland plasmacytosis is commonCan mimic plasma cell myeloma",
                      "Can mimic plasma cell myeloma",
                      "HHV8(+) cells can be identified in bone marrow"
                    ]
                  }
                ],
                "Cytologic Features": [
                  {
                    "text": "MCD-HHV8(+)Touch imprints and smears show plasma cells, plasmablasts, and lymphocytes",
                    "sub_points": [
                      "Touch imprints and smears show plasma cells, plasmablasts, and lymphocytes"
                    ]
                  },
                  {
                    "text": "MCD with HHV8(+) diffuse large B-cell lymphomaMonotonous proliferation of large cells/plasmablasts",
                    "sub_points": [
                      "Monotonous proliferation of large cells/plasmablasts"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "Latency-associated nuclear antigen 1 (LANA1) antibodyDetects HHV8 with nuclear patternHHV8(+) cells can be small lymphocytes or large cells resembling immunoblasts or plasmablastsPlasmablasts are usually polytypic but can be monotypic; IgM(+)",
                    "sub_points": [
                      "Detects HHV8 with nuclear pattern",
                      "HHV8(+) cells can be small lymphocytes or large cells resembling immunoblasts or plasmablastsPlasmablasts are usually polytypic but can be monotypic; IgM(+)",
                      "Plasmablasts are usually polytypic but can be monotypic; IgM(+)"
                    ]
                  },
                  {
                    "text": "Follicles show B cells and increased CD21(+) follicular dendritic cells (FDCs)"
                  },
                  {
                    "text": "Plasma cells are usually polytypic but can be monotypic in subset of cases"
                  },
                  {
                    "text": "Interfollicular areas show T cells without aberrancy"
                  }
                ],
                "In Situ Hybridization": [
                  {
                    "text": "EBV-encoded RNA (EBER) present in most cases"
                  }
                ],
                "Genetic Testing": [
                  {
                    "text": "MonoclonalIGHrearrangements in subset of casesSupports concept that MCD-HHV8(+) is lymphoproliferative disorder",
                    "sub_points": [
                      "Supports concept that MCD-HHV8(+) is lymphoproliferative disorder"
                    ]
                  },
                  {
                    "text": "Monoclonal T-cell receptor gene rearrangements are uncommon"
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Multicentric Castleman Disease, Idiopathic": [
                  {
                    "text": "Involves 2 or more lymph node stations"
                  },
                  {
                    "text": "Attributable to cytokine dysregulation, particularly IL-6, but etiology unknown"
                  },
                  {
                    "text": "2 types of idiopathic MCD: Both HHV8(-)Thrombocytopenia, anasarca, reticulin fibrosis of bone marrow, renal dysfunction, organomegaly (TAFRO)Not otherwise specified (NOS)",
                    "sub_points": [
                      "Thrombocytopenia, anasarca, reticulin fibrosis of bone marrow, renal dysfunction, organomegaly (TAFRO)",
                      "Not otherwise specified (NOS)"
                    ]
                  },
                  {
                    "text": "5 morphologic features are present to a variable degreeRegressed germinal centers (GCs), FDC prominence, vascularity, hyperplastic GCs, plasmacytosisGrading system: 0-3+ has been proposed2-3+ regressed GCs and plasmacytosis required for diagnosis of idiopathic MCD",
                    "sub_points": [
                      "Regressed germinal centers (GCs), FDC prominence, vascularity, hyperplastic GCs, plasmacytosis",
                      "Grading system: 0-3+ has been proposed",
                      "2-3+ regressed GCs and plasmacytosis required for diagnosis of idiopathic MCD"
                    ]
                  }
                ],
                "Multicentric Castleman Disease Associated With POEMS Syndrome": [
                  {
                    "text": "POEMS syndromeDriven by monoclonal plasma cell populationOtherwise poorly understood; associated with cytokine dysregulation",
                    "sub_points": [
                      "Driven by monoclonal plasma cell population",
                      "Otherwise poorly understood; associated with cytokine dysregulation"
                    ]
                  }
                ],
                "Unicentric Castleman Disease, Mixed/Plasmacytic Variant": [
                  {
                    "text": "Single lymph node (or localized mass)"
                  },
                  {
                    "text": "Small subset of patients have inflammatory-type symptoms; most are asymptomatic"
                  },
                  {
                    "text": "Lacks blurring of mantle zone boundaries typically present in MCD-HHV8(+)"
                  },
                  {
                    "text": "HHV8(-), EBV(-), clonalIGHrearrangements uncommon"
                  }
                ],
                "Unicentric Castleman Disease, Hyaline-Vascular Variant": [
                  {
                    "text": "Single lymph node (or localized mass)"
                  },
                  {
                    "text": "Most patients are asymptomatic; compression-type symptoms can occur"
                  },
                  {
                    "text": "Large follicles with regressive changes, \"twinning,\" hyaline-vascular lesionsInterfollicular/stromal changes can be prominent (so-called stroma rich)",
                    "sub_points": [
                      "Interfollicular/stromal changes can be prominent (so-called stroma rich)"
                    ]
                  },
                  {
                    "text": "HHV8(-), EBV(-), no clonalIGHrearrangements"
                  }
                ],
                "Castleman-Like Changes in Lymph Nodes Involved by Lymphoma": [
                  {
                    "text": "Changes are usually focal and of no clinical significance"
                  },
                  {
                    "text": "Pathogenesis is unknown; possibly related to IL-6 dysregulation"
                  },
                  {
                    "text": "Regressed follicles can mimic UCD"
                  },
                  {
                    "text": "Can occur in classic Hodgkin lymphoma and nodular lymphocyte-predominant Hodgkin lymphoma"
                  },
                  {
                    "text": "Can occur in non-Hodgkin lymphomasAngioimmunoblastic T-cell lymphoma (AITL)Follicular lymphoma, other types",
                    "sub_points": [
                      "Angioimmunoblastic T-cell lymphoma (AITL)",
                      "Follicular lymphoma, other types"
                    ]
                  }
                ],
                "Autoimmune Diseases": [
                  {
                    "text": "Lymph nodes can histologically mimic MCD-HHV8(+)Active rheumatoid arthritis (RA) and 10-30% of systemic lupus erythematosus (SLE) cases",
                    "sub_points": [
                      "Active rheumatoid arthritis (RA) and 10-30% of systemic lupus erythematosus (SLE) cases"
                    ]
                  },
                  {
                    "text": "Features helpful to distinguish autoimmune diseases from MCD-HHV8(+)No history of symptoms and signs of RA or SLELaboratory studies to confirm RA or SLEHyaline-vascular follicles usually absent in RA and SLEHHV8(-), EBV(-)Plasma cells are polytypic; no clonalIGHrearrangements",
                    "sub_points": [
                      "No history of symptoms and signs of RA or SLE",
                      "Laboratory studies to confirm RA or SLE",
                      "Hyaline-vascular follicles usually absent in RA and SLE",
                      "HHV8(-), EBV(-)",
                      "Plasma cells are polytypic; no clonalIGHrearrangements"
                    ]
                  }
                ],
                "Angioimmunoblastic T-Cell Lymphoma": [
                  {
                    "text": "Follicles often show regressive changes that can mimic hyaline-vascular follicles"
                  },
                  {
                    "text": "Features of AITL that distinguish it from MCD-HHV8(+)Neoplastic T cells with clear cytoplasmEosinophils are present and can be numerousArborizing high endothelial venule networkImmunohistochemistry and geneticsT cells have follicular helper cell immunophenotypeCD10(+), BCL-6(+), CXCL13(+)PD-1/CD279(+), ICOS(+), othersDisrupted networks of FDCsCD21(+), CD23(+), CD35(+), clusterin (+)Monoclonal T-cell receptor gene rearrangements",
                    "sub_points": [
                      "Neoplastic T cells with clear cytoplasm",
                      "Eosinophils are present and can be numerous",
                      "Arborizing high endothelial venule network",
                      "Immunohistochemistry and geneticsT cells have follicular helper cell immunophenotypeCD10(+), BCL-6(+), CXCL13(+)PD-1/CD279(+), ICOS(+), othersDisrupted networks of FDCsCD21(+), CD23(+), CD35(+), clusterin (+)Monoclonal T-cell receptor gene rearrangements",
                      "T cells have follicular helper cell immunophenotypeCD10(+), BCL-6(+), CXCL13(+)PD-1/CD279(+), ICOS(+), others",
                      "CD10(+), BCL-6(+), CXCL13(+)",
                      "PD-1/CD279(+), ICOS(+), others",
                      "Disrupted networks of FDCsCD21(+), CD23(+), CD35(+), clusterin (+)",
                      "CD21(+), CD23(+), CD35(+), clusterin (+)",
                      "Monoclonal T-cell receptor gene rearrangements"
                    ]
                  },
                  {
                    "text": "EBV(+) is common; HHV8(-)"
                  }
                ],
                "Plasmacytoma of Lymph Node": [
                  {
                    "text": "Patients usually lack systemic abnormalities seen in MCD-HHV8(+)"
                  },
                  {
                    "text": "Often involves lymph nodes of head and neck"
                  },
                  {
                    "text": "Features of plasmacytoma that distinguish it from MCD-HHV8(+)Usually no hyaline-vascular folliclesLess vascularity in interfollicular regions in plasmacytomaPlasma cells form sheets that replace lymph node architecturePlasma cells are monotypic (kappa > lambda)HHV8(-), EBV(-)",
                    "sub_points": [
                      "Usually no hyaline-vascular follicles",
                      "Less vascularity in interfollicular regions in plasmacytoma",
                      "Plasma cells form sheets that replace lymph node architecture",
                      "Plasma cells are monotypic (kappa > lambda)",
                      "HHV8(-), EBV(-)"
                    ]
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Clinically Relevant Pathologic Features": [
                  {
                    "text": "Patients with MCD-HHV8(+) often haveFever, night sweats, &/or weight lossLymphadenopathy ± hepatosplenomegalyBody cavity effusions, edemaMany laboratory abnormalities",
                    "sub_points": [
                      "Fever, night sweats, &/or weight loss",
                      "Lymphadenopathy ± hepatosplenomegaly",
                      "Body cavity effusions, edema",
                      "Many laboratory abnormalities"
                    ]
                  },
                  {
                    "text": "Associated with immunodeficiency or immune dysregulation"
                  }
                ],
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "MCD-HHV8(+) resembles idiopathic MCD exceptGreater lymphocyte depletionFollicles show blurring of boundaries between mantle zones and interfollicular areasHHV8(+) cells in mantle zones",
                    "sub_points": [
                      "Greater lymphocyte depletion",
                      "Follicles show blurring of boundaries between mantle zones and interfollicular areas",
                      "HHV8(+) cells in mantle zones"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Rosai-Dorfman Disease": {
            "name": "Rosai-Dorfman Disease",
            "url": "https://app.pathprimer.com/document/a4b5af23-c22d-47a3-af09-3b0e50f3f21e/lesson/1ca98c4c-c6e6-4862-8c12-8cba7a24c075",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Rosai-Dorfman disease (RDD) or Rosai-Dorfman-Destombes diseaseSinus histiocytosis with massive lymphadenopathy is older term",
                    "sub_points": [
                      "Sinus histiocytosis with massive lymphadenopathy is older term"
                    ]
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "Likely multifactorial etiologyGene mutations in MAPK pathway in ~ 1/3 of cases",
                    "sub_points": [
                      "Gene mutations in MAPK pathway in ~ 1/3 of cases"
                    ]
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Some patients may regress over months or years"
                  },
                  {
                    "text": "Surgical excision is commonly required"
                  },
                  {
                    "text": "Systemic therapies needed"
                  }
                ],
                "Macroscopic": [
                  {
                    "text": "Mild to moderate lymphadenopathy (1-2 cm)Can be massiveOften matted with capsular fibrosis",
                    "sub_points": [
                      "Can be massive",
                      "Often matted with capsular fibrosis"
                    ]
                  },
                  {
                    "text": "Extranodal mass"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Lymph nodes show dilated sinuses"
                  },
                  {
                    "text": "RDD histiocytes characterized byAbundant eosinophilic cytoplasmVesicular nucleus; central nucleolusEmperipolesis",
                    "sub_points": [
                      "Abundant eosinophilic cytoplasm",
                      "Vesicular nucleus; central nucleolus",
                      "Emperipolesis"
                    ]
                  },
                  {
                    "text": "Associated with many lymphocytes and plasma cells"
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "ImmunohistochemistryS100(+), OCT-2(+), CD1a(-), CD207(-)",
                    "sub_points": [
                      "S100(+), OCT-2(+), CD1a(-), CD207(-)"
                    ]
                  },
                  {
                    "text": "~ 1/3 of RDD cases have increased IgG4(+) plasma cells"
                  },
                  {
                    "text": "SLC29A3gene is mutated in rare familial cases"
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "Langerhans cell histiocytosis"
                  },
                  {
                    "text": "Chronic granulomatous inflammation"
                  },
                  {
                    "text": "IgG4-related disease"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Rosai-Dorfman disease (RDD)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Rosai-Dorfman-Destombes disease"
                  },
                  {
                    "text": "Sinus histiocytosis with massive lymphadenopathy"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Proliferation of histiocytes with characteristic featuresLarge cells with abundant cytoplasmHistiocytes show emperipolesis (engulfment of lymphocytes)S100 protein (+)",
                    "sub_points": [
                      "Large cells with abundant cytoplasm",
                      "Histiocytes show emperipolesis (engulfment of lymphocytes)",
                      "S100 protein (+)"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Infectious Agents": [
                  {
                    "text": "Histologic similarities betweenSalmonellainfection and RDD have been observedNo culture evidence or other data to supportOther infectious agents are possible",
                    "sub_points": [
                      "No culture evidence or other data to support",
                      "Other infectious agents are possible"
                    ]
                  },
                  {
                    "text": "One study has reported SV40 polyomavirus in subset of cases of soft tissue-based RDDViral inclusions reported; study needs to be confirmed",
                    "sub_points": [
                      "Viral inclusions reported; study needs to be confirmed"
                    ]
                  }
                ],
                "Genetic": [
                  {
                    "text": "RDD has been reported in identical twins or families, suggesting genetic predisposition"
                  },
                  {
                    "text": "Rare familial forms of RDD have been reportedFaisalabad histiocytosisH syndromePigmentary hypertrichosis and nonautoimmune insulin-dependent diabetes mellitus (PHID) syndromeSLC29A3mutations have been identified",
                    "sub_points": [
                      "Faisalabad histiocytosis",
                      "H syndrome",
                      "Pigmentary hypertrichosis and nonautoimmune insulin-dependent diabetes mellitus (PHID) syndrome",
                      "SLC29A3mutations have been identified"
                    ]
                  }
                ],
                "Neoplastic": [
                  {
                    "text": "~ 1/3 of cases carry mutations in genes of MAPK pathwayKRASandMAP2K1are most often mutatedMAPK pathway is activatedRDD histiocytes express cyclin-D1 &/or pERK",
                    "sub_points": [
                      "KRASandMAP2K1are most often mutated",
                      "MAPK pathway is activatedRDD histiocytes express cyclin-D1 &/or pERK",
                      "RDD histiocytes express cyclin-D1 &/or pERK"
                    ]
                  }
                ],
                "Tumor-Associated Rosai-Dorfman Disease": [
                  {
                    "text": "RDD, typically focal, can be associated with lymphomas, most commonlyNodular lymphocyte-predominant Hodgkin lymphomaClassic Hodgkin lymphomaFollicular lymphoma",
                    "sub_points": [
                      "Nodular lymphocyte-predominant Hodgkin lymphoma",
                      "Classic Hodgkin lymphoma",
                      "Follicular lymphoma"
                    ]
                  }
                ],
                "Autoimmune": [
                  {
                    "text": "Autoimmune etiology has been suggestedSubset of RDD patients has autoimmune diseasesRheumatoid arthritis, Sjögren syndrome, systemic lupus erythematosusMultiple sclerosis, asthma, autoimmune hemolytic anemiaAssociation with autoimmune lymphoproliferative syndromeType Ia [mutations ofFAS(TNFRSF6)]",
                    "sub_points": [
                      "Subset of RDD patients has autoimmune diseasesRheumatoid arthritis, Sjögren syndrome, systemic lupus erythematosusMultiple sclerosis, asthma, autoimmune hemolytic anemia",
                      "Rheumatoid arthritis, Sjögren syndrome, systemic lupus erythematosus",
                      "Multiple sclerosis, asthma, autoimmune hemolytic anemia",
                      "Association with autoimmune lymphoproliferative syndromeType Ia [mutations ofFAS(TNFRSF6)]",
                      "Type Ia [mutations ofFAS(TNFRSF6)]"
                    ]
                  }
                ],
                "Possible Relationship With IgG4-Related Disease": [
                  {
                    "text": "40-50% of cases of RDD have increased IgG4(+) plasma cellsIncreased IgG4(+) plasma cells are not specificSerum levels of IgG4 elevated in subset of patients",
                    "sub_points": [
                      "Increased IgG4(+) plasma cells are not specific",
                      "Serum levels of IgG4 elevated in subset of patients"
                    ]
                  },
                  {
                    "text": "~ 15% of cases meet current criteria for IgG4-related diseaseImportance of overlap is currently unclearRDD and IgG4-related disease seem unlikely to be closely related",
                    "sub_points": [
                      "Importance of overlap is currently unclear",
                      "RDD and IgG4-related disease seem unlikely to be closely related"
                    ]
                  }
                ],
                "Idiopathic": [
                  {
                    "text": "Etiology of many RDD cases is unknown"
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "Rare; worldwide geographic distribution"
                  },
                  {
                    "text": "In USA~ 100 new cases of RDD per yearPrevalence is 1 in 200,000 persons",
                    "sub_points": [
                      "~ 100 new cases of RDD per year",
                      "Prevalence is 1 in 200,000 persons"
                    ]
                  }
                ],
                "Age": [
                  {
                    "text": "Wide rangeNewborn to ~ 80 yearsIn older studies, median age in 3rd decadeIn recent Mayo Clinic studyMedian age: 50 years (range: 2-79 years)",
                    "sub_points": [
                      "Newborn to ~ 80 years",
                      "In older studies, median age in 3rd decade",
                      "In recent Mayo Clinic studyMedian age: 50 years (range: 2-79 years)",
                      "Median age: 50 years (range: 2-79 years)"
                    ]
                  }
                ],
                "Sex": [
                  {
                    "text": "M:F = 3:2"
                  },
                  {
                    "text": "In recent Mayo Clinic study, M:F = 1:1.5"
                  }
                ],
                "Ethnicity": [
                  {
                    "text": "All races affected"
                  }
                ],
                "Site": [
                  {
                    "text": "Extranodal sites of disease are commonSkin and subcutaneous tissues most often involvedBones are commonly involved1 or multiple lytic lesionsHead and neck region commonUpper respiratory tractOther common sitesKidneys, breast, duraVirtually any extranodal site can be affected",
                    "sub_points": [
                      "Skin and subcutaneous tissues most often involved",
                      "Bones are commonly involved1 or multiple lytic lesions",
                      "1 or multiple lytic lesions",
                      "Head and neck region commonUpper respiratory tract",
                      "Upper respiratory tract",
                      "Other common sitesKidneys, breast, dura",
                      "Kidneys, breast, dura",
                      "Virtually any extranodal site can be affected"
                    ]
                  },
                  {
                    "text": "Lymph nodesTraditionally thought to be most common site2nd most common site in recent Mayo Clinic study",
                    "sub_points": [
                      "Traditionally thought to be most common site",
                      "2nd most common site in recent Mayo Clinic study"
                    ]
                  }
                ],
                "Presentation": [
                  {
                    "text": "Painless or painful subcutaneous mass"
                  },
                  {
                    "text": "Lymphadenopathy, often without any symptomsUnilateral or bilateralMild (1-2 cm) or, less often, massive enlargementCervical lymph nodes most often involvedSymptoms in ~ 10% of patientsGeneralized lymphadenopathy in ~ 10% of patients",
                    "sub_points": [
                      "Unilateral or bilateralMild (1-2 cm) or, less often, massive enlargement",
                      "Mild (1-2 cm) or, less often, massive enlargement",
                      "Cervical lymph nodes most often involved",
                      "Symptoms in ~ 10% of patients",
                      "Generalized lymphadenopathy in ~ 10% of patients"
                    ]
                  },
                  {
                    "text": "B symptoms are uncommon but can occurFever, night sweats can precede onset of mass",
                    "sub_points": [
                      "Fever, night sweats can precede onset of mass"
                    ]
                  },
                  {
                    "text": "Laboratory abnormalities in subset of patientsElevated serum C-reactive protein levelElevated erythrocyte sedimentation ratePolyclonal hypergammaglobulinemiaBlood lymphocytes with low CD4:CD8 ratio",
                    "sub_points": [
                      "Elevated serum C-reactive protein level",
                      "Elevated erythrocyte sedimentation rate",
                      "Polyclonal hypergammaglobulinemia",
                      "Blood lymphocytes with low CD4:CD8 ratio"
                    ]
                  },
                  {
                    "text": "5-10% of patients can have associated histiocytic diseasesLangerhans cell histiocytosis (LCH)Erdheim-Chester disease (ECD)",
                    "sub_points": [
                      "Langerhans cell histiocytosis (LCH)",
                      "Erdheim-Chester disease (ECD)"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "Subset of patients can be observed without therapySome patients may undergo regression after months or yearsMany patients eventually require therapy",
                    "sub_points": [
                      "Some patients may undergo regression after months or years",
                      "Many patients eventually require therapy"
                    ]
                  },
                  {
                    "text": "Surgical excisionOften 1st treatment approach~ 1/3 of patients relapse after excisionRequired for patients with obstruction-/compression-type symptoms",
                    "sub_points": [
                      "Often 1st treatment approach",
                      "~ 1/3 of patients relapse after excision",
                      "Required for patients with obstruction-/compression-type symptoms"
                    ]
                  },
                  {
                    "text": "Radiation therapyMay be used for patients with localized disease",
                    "sub_points": [
                      "May be used for patients with localized disease"
                    ]
                  },
                  {
                    "text": "Systemic therapiesCorticosteroidsPatients often respond rapidlyResponse can last months, but relapse is commonPatients with RDD rich in IgG4(+) plasma cells may respond betterRituximab (anti-CD20) has been used with good responseCladribine is often used with good response",
                    "sub_points": [
                      "CorticosteroidsPatients often respond rapidlyResponse can last months, but relapse is commonPatients with RDD rich in IgG4(+) plasma cells may respond better",
                      "Patients often respond rapidly",
                      "Response can last months, but relapse is common",
                      "Patients with RDD rich in IgG4(+) plasma cells may respond better",
                      "Rituximab (anti-CD20) has been used with good response",
                      "Cladribine is often used with good response"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Excellent for most affected patients"
                  },
                  {
                    "text": "Rare cases can be clinically aggressiveNo effective therapy for these rare aggressive casesFatalities can occur as result ofAccompanying immune dysregulationMass effect compromising vital organs",
                    "sub_points": [
                      "No effective therapy for these rare aggressive cases",
                      "Fatalities can occur as result ofAccompanying immune dysregulationMass effect compromising vital organs",
                      "Accompanying immune dysregulation",
                      "Mass effect compromising vital organs"
                    ]
                  }
                ]
              },
              "IMAGING": {
                "Radiographic Findings": [
                  {
                    "text": "Extranodal mass(es) &/or lymphadenopathy shown by various modalities"
                  },
                  {
                    "text": "FDG PET/CT: RDD can be FDG avid"
                  }
                ]
              },
              "MACROSCOPIC": {
                "General Features": [
                  {
                    "text": "Lymph nodesOften mild (1-2 cm) enlargementCan be massiveOften matted with capsular fibrosis",
                    "sub_points": [
                      "Often mild (1-2 cm) enlargementCan be massive",
                      "Can be massive",
                      "Often matted with capsular fibrosis"
                    ]
                  },
                  {
                    "text": "Extranodal sitesRDD forms mass",
                    "sub_points": [
                      "RDD forms mass"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Lymph nodesOverall lymph node architecture is intact but distortedMarked dilatation of sinusesFilled with RDD histiocytesAssociated with small lymphocytes and plasma cellsNeutrophils can be present in ~ 1/3 of casesEosinophils rare or absentRDD histiocytes show emperipolesisEngulfed cells are located in histiocyte cytoplasmSmall lymphocytes, plasma cells, neutrophils, or erythrocytesCells surrounded by intracytoplasmic vacuoles that appear as halosResult from formalin fixation in histologic sectionsEngulfed cells are usually viableOften marked plasmacytosis between sinusesSclerosis is common (~ 75% of cases)Reactive follicles often presentMitotic figures are uncommonAffected lymph nodes can undergo infarct",
                    "sub_points": [
                      "Overall lymph node architecture is intact but distorted",
                      "Marked dilatation of sinusesFilled with RDD histiocytesAssociated with small lymphocytes and plasma cellsNeutrophils can be present in ~ 1/3 of casesEosinophils rare or absent",
                      "Filled with RDD histiocytes",
                      "Associated with small lymphocytes and plasma cells",
                      "Neutrophils can be present in ~ 1/3 of casesEosinophils rare or absent",
                      "Eosinophils rare or absent",
                      "RDD histiocytes show emperipolesisEngulfed cells are located in histiocyte cytoplasmSmall lymphocytes, plasma cells, neutrophils, or erythrocytesCells surrounded by intracytoplasmic vacuoles that appear as halosResult from formalin fixation in histologic sectionsEngulfed cells are usually viable",
                      "Engulfed cells are located in histiocyte cytoplasm",
                      "Small lymphocytes, plasma cells, neutrophils, or erythrocytes",
                      "Cells surrounded by intracytoplasmic vacuoles that appear as halosResult from formalin fixation in histologic sections",
                      "Result from formalin fixation in histologic sections",
                      "Engulfed cells are usually viable",
                      "Often marked plasmacytosis between sinuses",
                      "Sclerosis is common (~ 75% of cases)",
                      "Reactive follicles often present",
                      "Mitotic figures are uncommon",
                      "Affected lymph nodes can undergo infarct"
                    ]
                  },
                  {
                    "text": "Extranodal sitesRDD histiocytes can be sparse in areasEmperipolesis can be absentSmall lymphocytes and plasma cells often numerousFibrosis can be prominent",
                    "sub_points": [
                      "RDD histiocytes can be sparse in areasEmperipolesis can be absent",
                      "Emperipolesis can be absent",
                      "Small lymphocytes and plasma cells often numerous",
                      "Fibrosis can be prominent"
                    ]
                  },
                  {
                    "text": "RDD can be associated with Hodgkin or non-Hodgkin lymphomasRDD is often small focus in this settingIncidental finding usually without impact on prognosis",
                    "sub_points": [
                      "RDD is often small focus in this setting",
                      "Incidental finding usually without impact on prognosis"
                    ]
                  }
                ],
                "Cytologic Features": [
                  {
                    "text": "RDD histiocytes are characterized byLarge size with abundant eosinophilic cytoplasmWell-defined cell bordersCentral, often round nucleusDistinct central nucleolusEmperipolesisCharacterized by cells within histiocyte cytoplasmUsually small lymphocytes in cytoplasmHalos around cells are not seen in cytologic preparations",
                    "sub_points": [
                      "Large size with abundant eosinophilic cytoplasmWell-defined cell borders",
                      "Well-defined cell borders",
                      "Central, often round nucleusDistinct central nucleolus",
                      "Distinct central nucleolus",
                      "EmperipolesisCharacterized by cells within histiocyte cytoplasmUsually small lymphocytes in cytoplasmHalos around cells are not seen in cytologic preparations",
                      "Characterized by cells within histiocyte cytoplasm",
                      "Usually small lymphocytes in cytoplasm",
                      "Halos around cells are not seen in cytologic preparations"
                    ]
                  },
                  {
                    "text": "Associated with many inflammatory cellsEarly lesions: Many small lymphocytes and immunoblastsLate lesions: More plasma cells; cytoplasmic globules (± Russell bodies)",
                    "sub_points": [
                      "Early lesions: Many small lymphocytes and immunoblasts",
                      "Late lesions: More plasma cells; cytoplasmic globules (± Russell bodies)"
                    ]
                  }
                ],
                "Predominant Pattern/Injury Type": [
                  {
                    "text": "Sinusoidal"
                  }
                ],
                "Predominant Cell/Compartment Type": [
                  {
                    "text": "Histiocyte"
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "RDD histiocytes areS100(+), OCT-2(+)Cyclin-D1 (+), pERK(+)Histiocyte markers are positiveCD14(+), CD64(+), CD68(+), CD163(+)CD15(+/-), CD4(-/+)Adhesion molecules are positiveCD11b(+), CD11c(+), CD18(+), CD31(+)CD31(+), CD103(+)Cathepsin-D (+), cathepsin-E (+)CD1a(-), langerin/CD207 (-)CD21(-), CD23(-), CD35(-)B-cell antigens (-), T-cell antigens (-)CD25(-), CD30(-), LMP1(-), Ki-67 lowHMB-45(-), MART-1(-)",
                    "sub_points": [
                      "S100(+), OCT-2(+)",
                      "Cyclin-D1 (+), pERK(+)",
                      "Histiocyte markers are positiveCD14(+), CD64(+), CD68(+), CD163(+)CD15(+/-), CD4(-/+)",
                      "CD14(+), CD64(+), CD68(+), CD163(+)",
                      "CD15(+/-), CD4(-/+)",
                      "Adhesion molecules are positiveCD11b(+), CD11c(+), CD18(+), CD31(+)CD31(+), CD103(+)",
                      "CD11b(+), CD11c(+), CD18(+), CD31(+)",
                      "CD31(+), CD103(+)",
                      "Cathepsin-D (+), cathepsin-E (+)",
                      "CD1a(-), langerin/CD207 (-)",
                      "CD21(-), CD23(-), CD35(-)",
                      "B-cell antigens (-), T-cell antigens (-)",
                      "CD25(-), CD30(-), LMP1(-), Ki-67 low",
                      "HMB-45(-), MART-1(-)"
                    ]
                  },
                  {
                    "text": "Lymphocytes within histiocyte cytoplasm (emperipolesis) include B and T cells"
                  },
                  {
                    "text": "Plasma cells are polytypic~ 1/3 of RDD cases have increased IgG4(+) plasma cellsMore common in extranodal lesions",
                    "sub_points": [
                      "~ 1/3 of RDD cases have increased IgG4(+) plasma cellsMore common in extranodal lesions",
                      "More common in extranodal lesions"
                    ]
                  },
                  {
                    "text": "Polytypic B cells and T cells with normal immunophenotypeIncreased FOXP3(+) Treg cells in subset of RDD",
                    "sub_points": [
                      "Increased FOXP3(+) Treg cells in subset of RDD"
                    ]
                  }
                ],
                "Flow Cytometry": [
                  {
                    "text": "Polytypic B cells and plasma cells"
                  },
                  {
                    "text": "T cells with normal immunophenotype"
                  }
                ],
                "In Situ Hybridization": [
                  {
                    "text": "Human herpesviruses are negativeEpstein-Barr virus (-)HHV6(-), HHV8(-), CMV(-)",
                    "sub_points": [
                      "Epstein-Barr virus (-)",
                      "HHV6(-), HHV8(-), CMV(-)"
                    ]
                  }
                ],
                "Genetic Testing": [
                  {
                    "text": "No characteristic cytogenetic abnormalities"
                  },
                  {
                    "text": "Gene mutations in MAPK pathway in ~ 1/3 of casesKRASandMAP2K1mutations most commonBRAFV600E mutation is rare",
                    "sub_points": [
                      "KRASandMAP2K1mutations most common",
                      "BRAFV600E mutation is rare"
                    ]
                  },
                  {
                    "text": "RDD histiocytes are polyclonalShown by X-linked polymorphic human androgen receptor assay (HUMARA)",
                    "sub_points": [
                      "Shown by X-linked polymorphic human androgen receptor assay (HUMARA)"
                    ]
                  },
                  {
                    "text": "No evidence of clonal immunoglobulin or T-cell receptor gene rearrangements"
                  },
                  {
                    "text": "SLC29A3gene is mutated in rare familial casesSLC29A3is located at chromosome 10q22.1Encodes for hENT3 (nucleoside transporter)SLC29A3is expressed in CNS, inner ear, and epithelium of mice",
                    "sub_points": [
                      "SLC29A3is located at chromosome 10q22.1",
                      "Encodes for hENT3 (nucleoside transporter)",
                      "SLC29A3is expressed in CNS, inner ear, and epithelium of mice"
                    ]
                  }
                ],
                "Electron Microscopy": [
                  {
                    "text": "3 types of histiocytes in RDDType I: Smooth cytoplasmic borders and moderate cytoplasmic lipidsType II: Complex cytoplasmic filopodia; most numerousType III: Large with abundant cytoplasmic lipids and myelin figures",
                    "sub_points": [
                      "Type I: Smooth cytoplasmic borders and moderate cytoplasmic lipids",
                      "Type II: Complex cytoplasmic filopodia; most numerous",
                      "Type III: Large with abundant cytoplasmic lipids and myelin figures"
                    ]
                  },
                  {
                    "text": "EmperipolesisSmall lymphocytes, plasma cells",
                    "sub_points": [
                      "Small lymphocytes, plasma cells"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Langerhans Cell Histiocytosis": [
                  {
                    "text": "LCH can be confined to lymph node sinusoids"
                  },
                  {
                    "text": "Eosinophils and necrosis are common"
                  },
                  {
                    "text": "LCH cells have twisted nuclei with nuclear groovesLess cytoplasm than RDD histiocytesNo emperipolesis",
                    "sub_points": [
                      "Less cytoplasm than RDD histiocytes",
                      "No emperipolesis"
                    ]
                  },
                  {
                    "text": "Birbeck granules present as shown by electron microscopy"
                  },
                  {
                    "text": "ImmunohistochemistryS100(+), CD1a(+), langerin/CD207 (+)Cyclin-D1 (+), OCT-2(-)",
                    "sub_points": [
                      "S100(+), CD1a(+), langerin/CD207 (+)",
                      "Cyclin-D1 (+), OCT-2(-)"
                    ]
                  },
                  {
                    "text": "LCH cells are monoclonalShown by HUMARA",
                    "sub_points": [
                      "Shown by HUMARA"
                    ]
                  },
                  {
                    "text": "Cases of coexistent LCH and RDD reported"
                  }
                ],
                "Erdheim-Chester Disease": [
                  {
                    "text": "Tends to involve extranodal sitesLong bones of legs in ~ 95% of patients",
                    "sub_points": [
                      "Long bones of legs in ~ 95% of patients"
                    ]
                  },
                  {
                    "text": "Histologic findingsHistiocytes, lymphocytes, plasma cellsTouton-like giant cells, fibrosisNo RDD histiocytes or emperipolesis",
                    "sub_points": [
                      "Histiocytes, lymphocytes, plasma cells",
                      "Touton-like giant cells, fibrosis",
                      "No RDD histiocytes or emperipolesis"
                    ]
                  },
                  {
                    "text": "Immunohistochemical findingsCD68(+), factor XIII(+)S100(-), CD1a(-), CD207(-), OCT-2(-)",
                    "sub_points": [
                      "CD68(+), factor XIII(+)",
                      "S100(-), CD1a(-), CD207(-), OCT-2(-)"
                    ]
                  },
                  {
                    "text": "Genetic findings50-60% of cases have mutations in MAPK pathwayBRAFV600E,MAP2K1most common",
                    "sub_points": [
                      "50-60% of cases have mutations in MAPK pathway",
                      "BRAFV600E,MAP2K1most common"
                    ]
                  },
                  {
                    "text": "Cases of coexistent ECD and RDD reported"
                  }
                ],
                "IgG4-Related Disease": [
                  {
                    "text": "Can show various patterns in lymph nodesFollicular hyperplasiaProgressive transformation of germinal centersInterfollicular expansion; infectious mononucleosis-likeMulticentric Castleman-likeInflammatory pseudotumor-like",
                    "sub_points": [
                      "Follicular hyperplasia",
                      "Progressive transformation of germinal centers",
                      "Interfollicular expansion; infectious mononucleosis-like",
                      "Multicentric Castleman-like",
                      "Inflammatory pseudotumor-like"
                    ]
                  },
                  {
                    "text": "Lymph nodes may show sclerosis and increased IgG4(+) plasma cellsTypical cutoffs: IgG4/IgG of 40% with > 100 IgG4(+) plasma cells/high-power field",
                    "sub_points": [
                      "Typical cutoffs: IgG4/IgG of 40% with > 100 IgG4(+) plasma cells/high-power field"
                    ]
                  },
                  {
                    "text": "Overlap between IgG4-related disease and RDDSubset of RDD cases have increased IgG4(+) plasma cellsNumbers of IgG4(+) plasma cells meet IgG4 cutoffsOverlap is more common at extranodal sitesNo RDD histiocytes in IgG4-related disease",
                    "sub_points": [
                      "Subset of RDD cases have increased IgG4(+) plasma cellsNumbers of IgG4(+) plasma cells meet IgG4 cutoffsOverlap is more common at extranodal sitesNo RDD histiocytes in IgG4-related disease",
                      "Numbers of IgG4(+) plasma cells meet IgG4 cutoffs",
                      "Overlap is more common at extranodal sites",
                      "No RDD histiocytes in IgG4-related disease"
                    ]
                  }
                ],
                "Chronic Granulomatous Inflammation": [
                  {
                    "text": "Usually not confined to lymph node sinuses"
                  },
                  {
                    "text": "Associated necrosis and acute and chronic inflammation"
                  },
                  {
                    "text": "Infectious agents identified commonly"
                  },
                  {
                    "text": "Epithelioid histiocytes and multinucleated cellsHistiocytes do not resemble RDD histiocytesS100 [(-/+) focal]",
                    "sub_points": [
                      "Histiocytes do not resemble RDD histiocytes",
                      "S100 [(-/+) focal]"
                    ]
                  }
                ],
                "Histiocytic Sarcoma": [
                  {
                    "text": "Typically replaces lymph node architecture, not sinusoidal"
                  },
                  {
                    "text": "Cytologic atypia and mitotic figures"
                  },
                  {
                    "text": "Phagocytosis by neoplastic histiocytes can occurUsually not prominent and no true emperipolesis",
                    "sub_points": [
                      "Usually not prominent and no true emperipolesis"
                    ]
                  },
                  {
                    "text": "Gene mutations in MAPK pathway are common"
                  }
                ],
                "SLC29A3Spectrum Disorder": [
                  {
                    "text": "Term suggested for rare familial syndromes in whichSLC29A3mutations are present"
                  },
                  {
                    "text": "Faisalabad histiocytosisAutosomal recessive; abnormal chromosome 11q25 locusChildren present with sensorineural deafness and joint contracturesHistiocytosis that histologically resembles RDD",
                    "sub_points": [
                      "Autosomal recessive; abnormal chromosome 11q25 locus",
                      "Children present with sensorineural deafness and joint contracturesHistiocytosis that histologically resembles RDD",
                      "Histiocytosis that histologically resembles RDD"
                    ]
                  },
                  {
                    "text": "H syndromeUsually childrenIndurated, hyperpigmented, hypertrichotic skin plaquesHepatomegaly, cardiac abnormalities, hearing loss, hypogonadismSkin lesions share many histologic features with RDD",
                    "sub_points": [
                      "Usually children",
                      "Indurated, hyperpigmented, hypertrichotic skin plaques",
                      "Hepatomegaly, cardiac abnormalities, hearing loss, hypogonadism",
                      "Skin lesions share many histologic features with RDD"
                    ]
                  },
                  {
                    "text": "PHID syndromeChildren present with pigmented hypertrichosis and insulin-dependent diabetes mellitusSkin lesions share histologic features with RDD, including emperipolesis",
                    "sub_points": [
                      "Children present with pigmented hypertrichosis and insulin-dependent diabetes mellitus",
                      "Skin lesions share histologic features with RDD, including emperipolesis"
                    ]
                  }
                ],
                "Metastatic Melanoma or Carcinoma": [
                  {
                    "text": "Clinical history of primary tumor"
                  },
                  {
                    "text": "Metastases to lymph node often involve sinuses"
                  },
                  {
                    "text": "Cytologic atypia present; mitoses common"
                  },
                  {
                    "text": "ImmunohistochemistryMelanoma: S100(+), HMB-45(+), MART-1(+)Carcinoma: Keratins (+), S100(-)",
                    "sub_points": [
                      "Melanoma: S100(+), HMB-45(+), MART-1(+)",
                      "Carcinoma: Keratins (+), S100(-)"
                    ]
                  }
                ],
                "Anaplastic Large Cell Lymphoma": [
                  {
                    "text": "Can selectively involve and expand lymph node sinuses"
                  },
                  {
                    "text": "Large neoplastic cells with horseshoe-shaped nuclei"
                  },
                  {
                    "text": "ImmunohistochemistryCD30(+), T-cell antigens (+/-)ALK1(+/-), S100(-)",
                    "sub_points": [
                      "CD30(+), T-cell antigens (+/-)",
                      "ALK1(+/-), S100(-)"
                    ]
                  },
                  {
                    "text": "Monoclonal T-cell receptor gene rearrangements (+/-)"
                  },
                  {
                    "text": "t(2;5)(p23;q35) ~ 75% of ALK(+) cases"
                  }
                ],
                "Classic Hodgkin Lymphoma": [
                  {
                    "text": "Can rarely be localized to lymph node sinuses"
                  },
                  {
                    "text": "Reed-Sternberg and Hodgkin cells are present"
                  },
                  {
                    "text": "Inflammatory background and eosinophils are common"
                  },
                  {
                    "text": "ImmunohistochemistryCD15(+/-), CD30(+), pax-5 (weak +)CD45/LCA(-), S100(-)",
                    "sub_points": [
                      "CD15(+/-), CD30(+), pax-5 (weak +)",
                      "CD45/LCA(-), S100(-)"
                    ]
                  }
                ],
                "ToxoplasmaLymphadenitis": [
                  {
                    "text": "Caused byToxoplasma gondiiinfection"
                  },
                  {
                    "text": "Diagnostic histologic triad includesSinusoidal expansion by monocytoid B cellsFollicular hyperplasiaEpithelioid histiocytes encroaching on reactive germinal centers",
                    "sub_points": [
                      "Sinusoidal expansion by monocytoid B cells",
                      "Follicular hyperplasia",
                      "Epithelioid histiocytes encroaching on reactive germinal centers"
                    ]
                  },
                  {
                    "text": "Immunohistochemistry withT. gondiiantibodies is helpful"
                  }
                ],
                "Sinus Histiocytosis": [
                  {
                    "text": "Nonspecific reaction pattern in lymph node sinuses"
                  },
                  {
                    "text": "Histiocytes do not cytologically resemble RDD histiocytesSmaller, less cytoplasm; no emperipolesis",
                    "sub_points": [
                      "Smaller, less cytoplasm; no emperipolesis"
                    ]
                  },
                  {
                    "text": "ImmunohistochemistryS100 [(-/+) focal]: Different pattern than RDD",
                    "sub_points": [
                      "S100 [(-/+) focal]: Different pattern than RDD"
                    ]
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Clinically Relevant Pathologic Features": [
                  {
                    "text": "Lymphadenopathy or extranodal massOften asymptomatic",
                    "sub_points": [
                      "Often asymptomatic"
                    ]
                  }
                ],
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "Lymph nodesSinusoidal distributionLarge histiocytes with abundant cytoplasmCentral vesicular nuclei; small, distinct nucleoliEmperipolesisAssociated small lymphocytes and plasma cellsImmunohistochemistryS100(+), OCT-2(+), CD1a(-), CD207(-)",
                    "sub_points": [
                      "Sinusoidal distribution",
                      "Large histiocytes with abundant cytoplasmCentral vesicular nuclei; small, distinct nucleoliEmperipolesis",
                      "Central vesicular nuclei; small, distinct nucleoli",
                      "Emperipolesis",
                      "Associated small lymphocytes and plasma cells",
                      "ImmunohistochemistryS100(+), OCT-2(+), CD1a(-), CD207(-)",
                      "S100(+), OCT-2(+), CD1a(-), CD207(-)"
                    ]
                  },
                  {
                    "text": "Extranodal sitesEmperipolesis can be minimal or absentCommon sitesSubcutaneous tissue, skin, bones, head and neck",
                    "sub_points": [
                      "Emperipolesis can be minimal or absent",
                      "Common sitesSubcutaneous tissue, skin, bones, head and neck",
                      "Subcutaneous tissue, skin, bones, head and neck"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Dermatopathic Lymphadenopathy": {
            "name": "Dermatopathic Lymphadenopathy",
            "url": "https://app.pathprimer.com/document/43ea5526-44ee-4b6a-a298-a86a893d32df/lesson/1ca98c4c-c6e6-4862-8c12-8cba7a24c075",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Paracortical hyperplasia characterized byInterdigitating dendritic cells (IDCs), Langerhans cells (LCs), and melanin-laden macrophagesMelanin pigment (variable); hemosiderin less frequent",
                    "sub_points": [
                      "Interdigitating dendritic cells (IDCs), Langerhans cells (LCs), and melanin-laden macrophages",
                      "Melanin pigment (variable); hemosiderin less frequent"
                    ]
                  },
                  {
                    "text": "Usually associated with skin disordersExfoliative or eczematoid dermatitisSubset of patients do not have skin disorders",
                    "sub_points": [
                      "Exfoliative or eczematoid dermatitis",
                      "Subset of patients do not have skin disorders"
                    ]
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "T-cell response to skin antigens processed and presented by IDCs and LCs"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Prognosis related to underlying skin disease or other associated systemic diseasesSpecific therapy not required for dermatopathic lymphadenopathy",
                    "sub_points": [
                      "Specific therapy not required for dermatopathic lymphadenopathy"
                    ]
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "ImmunohistochemistryIDCs and LCs are S100(+)LCs are CD1a(+) and langerin/CD207(+)Macrophages CD68(+); T cells CD3(+)",
                    "sub_points": [
                      "IDCs and LCs are S100(+)",
                      "LCs are CD1a(+) and langerin/CD207(+)",
                      "Macrophages CD68(+); T cells CD3(+)"
                    ]
                  },
                  {
                    "text": "Electron microscopyBirbeck granules only in LCs",
                    "sub_points": [
                      "Birbeck granules only in LCs"
                    ]
                  },
                  {
                    "text": "Flow cytometry immunophenotyping and T-cell receptor gene rearrangement analysisUseful to exclude T-cell clone and early involvement by mycosis fungoides/Sézary syndromePolyclonal pattern favors reactive process",
                    "sub_points": [
                      "Useful to exclude T-cell clone and early involvement by mycosis fungoides/Sézary syndrome",
                      "Polyclonal pattern favors reactive process"
                    ]
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "Langerhans cell histiocytosis"
                  },
                  {
                    "text": "Classic Hodgkin lymphoma"
                  },
                  {
                    "text": "Mycosis fungoides/Sézary syndrome"
                  },
                  {
                    "text": "Monocytic sarcoma"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Dermatopathic lymphadenopathy (DL)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Dermatopathic lymphadenitis"
                  },
                  {
                    "text": "Lipomelanosis reticularis of Pautrier"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Reactive lymphadenopathy characterized by paracortical hyperplasia that containsInterdigitating dendritic cells (IDCs), Langerhans cells (LCs), and melanin-laden histiocytes",
                    "sub_points": [
                      "Interdigitating dendritic cells (IDCs), Langerhans cells (LCs), and melanin-laden histiocytes"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Disease Associations": [
                  {
                    "text": "Usually associated with chronic skin disordersBenign or malignant",
                    "sub_points": [
                      "Benign or malignant"
                    ]
                  }
                ],
                "T-Cell Response to Skin Antigen Processing": [
                  {
                    "text": "Skin antigens processed and presented by LCs and IDCs"
                  },
                  {
                    "text": "LCs are specialized dendritic cells that reside in skinUpon activation, LCs migrate to lymph node",
                    "sub_points": [
                      "Upon activation, LCs migrate to lymph node"
                    ]
                  },
                  {
                    "text": "IDCs are specialized dendritic cells that reside in lymph node paracortexIDCs may be derived from LC",
                    "sub_points": [
                      "IDCs may be derived from LC"
                    ]
                  },
                  {
                    "text": "Both LCs and IDCs are derived from bone marrow precursor cells"
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Age": [
                  {
                    "text": "All ages but often occurs in middle-aged to older adult patients"
                  }
                ],
                "Sex": [
                  {
                    "text": "Males affected more frequently"
                  }
                ],
                "Ethnicity": [
                  {
                    "text": "No preference"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Lymphadenopathy; usually superficialMost often axillary, inguinal and cervical lymph nodes; commonly bilateralMulticompartmental or generalized lymphadenopathy is less commonUsually not tender adenopathy",
                    "sub_points": [
                      "Most often axillary, inguinal and cervical lymph nodes; commonly bilateral",
                      "Multicompartmental or generalized lymphadenopathy is less common",
                      "Usually not tender adenopathy"
                    ]
                  },
                  {
                    "text": "May occur in association with any chronic inflammatory skin disorderUsually generalized dermatitis, especially exfoliative and eczematoid dermatitisToxic shock syndrome, pemphigus, psoriasis, neurodermatitis, eczema, atrophia senilisLess common associations include squamous cell carcinoma, melanoma, post transplant, Still disease and othersSkin conditions may precede lymphadenopathy by months to yearsMild to moderate dermatopathic changes also can occur in patients without skin disease10-40% of patients do not have skin disease",
                    "sub_points": [
                      "Usually generalized dermatitis, especially exfoliative and eczematoid dermatitisToxic shock syndrome, pemphigus, psoriasis, neurodermatitis, eczema, atrophia senilisLess common associations include squamous cell carcinoma, melanoma, post transplant, Still disease and others",
                      "Toxic shock syndrome, pemphigus, psoriasis, neurodermatitis, eczema, atrophia senilis",
                      "Less common associations include squamous cell carcinoma, melanoma, post transplant, Still disease and others",
                      "Skin conditions may precede lymphadenopathy by months to years",
                      "Mild to moderate dermatopathic changes also can occur in patients without skin disease10-40% of patients do not have skin disease",
                      "10-40% of patients do not have skin disease"
                    ]
                  },
                  {
                    "text": "DL often associated with mycosis fungoides (MF) or Sézary syndrome (SS)~ 75% of patients with MF/SS present with lymphadenopathyLymphadenopathy in patients with MF/SS may or may not harbor lymphoma cellsNo lymphoma cells detected in DL at initial stagingLymphoma cells initially detected as small clusters, progressively as diffuse infiltration with effacement of nodal architectureDL, involvement by MF/SS, or both",
                    "sub_points": [
                      "~ 75% of patients with MF/SS present with lymphadenopathyLymphadenopathy in patients with MF/SS may or may not harbor lymphoma cellsNo lymphoma cells detected in DL at initial stagingLymphoma cells initially detected as small clusters, progressively as diffuse infiltration with effacement of nodal architectureDL, involvement by MF/SS, or both",
                      "Lymphadenopathy in patients with MF/SS may or may not harbor lymphoma cells",
                      "No lymphoma cells detected in DL at initial staging",
                      "Lymphoma cells initially detected as small clusters, progressively as diffuse infiltration with effacement of nodal architecture",
                      "DL, involvement by MF/SS, or both"
                    ]
                  }
                ],
                "Laboratory Tests": [
                  {
                    "text": "Increased erythrocyte sedimentation rate"
                  },
                  {
                    "text": "Occasional hypereosinophilia"
                  },
                  {
                    "text": "Autoimmune antibodies can be detected in some patients, related to skin conditions"
                  }
                ],
                "Treatment": [
                  {
                    "text": "No current guidelines exist on appropriate management of patients with DLBenign DL requires no specific therapyIf DL is associated with lymphoma, appropriate diagnosis and staging of lymphoma neededTherapy directed at lymphoma",
                    "sub_points": [
                      "Benign DL requires no specific therapy",
                      "If DL is associated with lymphoma, appropriate diagnosis and staging of lymphoma neededTherapy directed at lymphoma",
                      "Therapy directed at lymphoma"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "In benign DL, related to underlying cutaneous or systemic disease"
                  }
                ]
              },
              "MACROSCOPIC": {
                "General Features": [
                  {
                    "text": "Lymph node enlarged; 1-3.5 cm (median: 1.8 cm)"
                  },
                  {
                    "text": "Cut surface bulging, pale yellow"
                  },
                  {
                    "text": "In some extreme cases, black peripheral lines can be observed due to clumps of melanin pigment"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Continuum exists between early changes and fully developed DLEarly stage/mildAccumulation of IDCs, LCs, and macrophages in paracortical zonesScattered macrophages contain various amounts of melanin pigment in most casesHemosiderin and tattoo are coincidentally found in subset of casesFollicular hyperplasiaLymph node architecture generally preservedMiddle stage/moderateContinuous expansion of paracortical zones by IDCs, LCs, and macrophagesLymphoid follicles compressed, become atrophicLater stage/severeNodular or confluent expansion of paracortical zones with further accumulation of IDCs, LCs, and macrophagesRelative depletion of small lymphocytesAtrophic or compressed lymphoid follicles displaced by expanded paracortical nodulesPlasmacytosis in medullary cords can be prominentPlasma cells, eosinophils, and immunoblasts can be prominent",
                    "sub_points": [
                      "Early stage/mildAccumulation of IDCs, LCs, and macrophages in paracortical zonesScattered macrophages contain various amounts of melanin pigment in most casesHemosiderin and tattoo are coincidentally found in subset of casesFollicular hyperplasiaLymph node architecture generally preserved",
                      "Accumulation of IDCs, LCs, and macrophages in paracortical zones",
                      "Scattered macrophages contain various amounts of melanin pigment in most casesHemosiderin and tattoo are coincidentally found in subset of cases",
                      "Hemosiderin and tattoo are coincidentally found in subset of cases",
                      "Follicular hyperplasia",
                      "Lymph node architecture generally preserved",
                      "Middle stage/moderateContinuous expansion of paracortical zones by IDCs, LCs, and macrophagesLymphoid follicles compressed, become atrophic",
                      "Continuous expansion of paracortical zones by IDCs, LCs, and macrophages",
                      "Lymphoid follicles compressed, become atrophic",
                      "Later stage/severeNodular or confluent expansion of paracortical zones with further accumulation of IDCs, LCs, and macrophagesRelative depletion of small lymphocytesAtrophic or compressed lymphoid follicles displaced by expanded paracortical nodulesPlasmacytosis in medullary cords can be prominentPlasma cells, eosinophils, and immunoblasts can be prominent",
                      "Nodular or confluent expansion of paracortical zones with further accumulation of IDCs, LCs, and macrophages",
                      "Relative depletion of small lymphocytes",
                      "Atrophic or compressed lymphoid follicles displaced by expanded paracortical nodules",
                      "Plasmacytosis in medullary cords can be prominent",
                      "Plasma cells, eosinophils, and immunoblasts can be prominent"
                    ]
                  },
                  {
                    "text": "Vascular proliferation is often mild"
                  },
                  {
                    "text": "Difficult to distinguish DL alone from DL with early involvement by MF/SS using histologic criteriaLymph node involvement by MF/SS can be subtleAbsent cerebriform cells: LN0 in NCI classificationScattered cerebriform cells: LN1 in NCI classificationScattered, small cerebriform lymphocytes can be seen in DLAssociated with either MF/SS or benign skin diseasesSmall clusters of cerebriform cells: LN2 in NCI classification",
                    "sub_points": [
                      "Lymph node involvement by MF/SS can be subtleAbsent cerebriform cells: LN0 in NCI classificationScattered cerebriform cells: LN1 in NCI classification",
                      "Absent cerebriform cells: LN0 in NCI classification",
                      "Scattered cerebriform cells: LN1 in NCI classification",
                      "Scattered, small cerebriform lymphocytes can be seen in DLAssociated with either MF/SS or benign skin diseases",
                      "Associated with either MF/SS or benign skin diseases",
                      "Small clusters of cerebriform cells: LN2 in NCI classification"
                    ]
                  }
                ],
                "Cytologic Features": [
                  {
                    "text": "Clusters of IDCs and LCs present in paracortexIDCs and LCs are morphologically indistinguishable by light microscopyElongated convoluted nuclei with linear grooves (twisted towel appearance)Pale or eosinophilic cytoplasm and pseudonucleoli",
                    "sub_points": [
                      "IDCs and LCs are morphologically indistinguishable by light microscopyElongated convoluted nuclei with linear grooves (twisted towel appearance)Pale or eosinophilic cytoplasm and pseudonucleoli",
                      "Elongated convoluted nuclei with linear grooves (twisted towel appearance)",
                      "Pale or eosinophilic cytoplasm and pseudonucleoli"
                    ]
                  },
                  {
                    "text": "Macrophages with variable amount of pigmentMostly melanin but hemosiderin also can be presentHistiocytes can have cytoplasmic lipid droplets",
                    "sub_points": [
                      "Mostly melanin but hemosiderin also can be present",
                      "Histiocytes can have cytoplasmic lipid droplets"
                    ]
                  },
                  {
                    "text": "Absent or rare tingible body macrophages"
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "IDCs, LCs, and subset of macrophages express S100"
                  },
                  {
                    "text": "Only LCs are CD1a(+) and langerin/CD207(+)Langerin (+) cells are significantly less than S100(+) or CD1a(+) cellsLangerin highlights nonspecifically sinuses and cords of DL",
                    "sub_points": [
                      "Langerin (+) cells are significantly less than S100(+) or CD1a(+) cells",
                      "Langerin highlights nonspecifically sinuses and cords of DL"
                    ]
                  },
                  {
                    "text": "IDCs and LCs are CD4[(+) weak], CD68[(+) variable], and MUM1(+) and fascin (±)"
                  },
                  {
                    "text": "LCs can show variable lysozyme (+)"
                  },
                  {
                    "text": "IDCs and LCs are CD21(-), CD35(-), CD123(-), and CD163(-)"
                  },
                  {
                    "text": "Macrophages are CD68(+), and ~ 10% of sinus histiocytes are cyclin-D1 (+)"
                  },
                  {
                    "text": "Small lymphocytes express T-cell antigens"
                  },
                  {
                    "text": "Rare to scattered immunoblasts are highlighted with CD30"
                  },
                  {
                    "text": "Occasional loose clusters of plasmacytoid dendritic cells are positive for CD123"
                  },
                  {
                    "text": "If involvement by MF/SS suspected, assessment with CD3, CD4, CD7, and CD8 can be helpfulT-cell markers will highlight MF/SS cells and may show CD4 >> CD8 or loss/decreased CD7",
                    "sub_points": [
                      "T-cell markers will highlight MF/SS cells and may show CD4 >> CD8 or loss/decreased CD7"
                    ]
                  }
                ],
                "Genetic Testing": [
                  {
                    "text": "Assessment for T-cell receptor (TRB,TRG) rearrangements can be helpful if MF/SS suspectedDL shows polyclonalTRBandTRGNo monoclonalTRBorTRGrearrangements excludes MF/SS",
                    "sub_points": [
                      "DL shows polyclonalTRBandTRG",
                      "No monoclonalTRBorTRGrearrangements excludes MF/SS"
                    ]
                  },
                  {
                    "text": "TRBorTRGrearrangement analysis more sensitive than morphology to detect MF/SS"
                  },
                  {
                    "text": "No evidence of monoclonalIgrearrangements"
                  }
                ],
                "Electron Microscopy": [
                  {
                    "text": "Birbeck granules present in cytoplasm of LCs but not IDCsBoth LCs and IDCs have irregular nuclear contours and finger-like cytoplasmic projections",
                    "sub_points": [
                      "Both LCs and IDCs have irregular nuclear contours and finger-like cytoplasmic projections"
                    ]
                  }
                ],
                "Cytochemistry": [
                  {
                    "text": "Fontana silver: Melanin"
                  },
                  {
                    "text": "Prussian blue: Hemosiderin"
                  },
                  {
                    "text": "Oil red O: Lipid"
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Langerhans Cell Histiocytosis": [
                  {
                    "text": "Early involvement tends to be sinusoidal"
                  },
                  {
                    "text": "Partial or total effacement of lymph node with more extensive involvement"
                  },
                  {
                    "text": "LCs often associated with eosinophils &/or necrosis"
                  },
                  {
                    "text": "LCs are CD1a(+), langerin/CD207(+), and S100(+)Langerin marks nonspecifically sinuses and cords of DL",
                    "sub_points": [
                      "Langerin marks nonspecifically sinuses and cords of DL"
                    ]
                  },
                  {
                    "text": "Electron microscopy shows Birbeck granules"
                  },
                  {
                    "text": "Patients can have visceral involvement unlike DL patients"
                  }
                ],
                "Classic Hodgkin Lymphoma": [
                  {
                    "text": "Interfollicular pattern may mimic paracortical hyperplasia"
                  },
                  {
                    "text": "Reed-Sternberg and Hodgkin (RS+H) cells always present"
                  },
                  {
                    "text": "RS+H cells typically CD15(±), CD30(+), pax-5 (dim +)"
                  },
                  {
                    "text": "CD20(±), CD45/LCA(-)"
                  }
                ],
                "Mycosis Fungoides/Sézary Syndrome": [
                  {
                    "text": "Early lymph node involvement is almost identical to DLOnly interstitial or small clusters of cerebriform lymphocytes in paracortex",
                    "sub_points": [
                      "Only interstitial or small clusters of cerebriform lymphocytes in paracortex"
                    ]
                  },
                  {
                    "text": "Flow cytometry immunophenotyping is often more sensitiveAltered expression of CD2, CD3 (decreased), CD4, CD5, or CD7 (decreased)Decreased or absent CD26 expressionTCR Vβor TRBC2:TRBC1 ratio for clonality analysis helpfulPresence of clone supports MF/SS",
                    "sub_points": [
                      "Altered expression of CD2, CD3 (decreased), CD4, CD5, or CD7 (decreased)",
                      "Decreased or absent CD26 expression",
                      "TCR Vβor TRBC2:TRBC1 ratio for clonality analysis helpfulPresence of clone supports MF/SS",
                      "Presence of clone supports MF/SS"
                    ]
                  },
                  {
                    "text": "TRB&/orTRGrearrangement analysis helpful to identify minimal involvement by MF/SSIdentification of monoclonalTCRrearrangementSupports involvement by MF/SSCorrelates with poorer prognosis",
                    "sub_points": [
                      "Identification of monoclonalTCRrearrangementSupports involvement by MF/SSCorrelates with poorer prognosis",
                      "Supports involvement by MF/SS",
                      "Correlates with poorer prognosis"
                    ]
                  }
                ],
                "Monocytic Sarcoma": [
                  {
                    "text": "Paracortical expansion by leukemic cells with preservation of follicles"
                  },
                  {
                    "text": "Blasts/immature monocytes of medium to large size with delicate nuclear membranes and distinct cytoplasmic borders"
                  },
                  {
                    "text": "CD34(±), CD43(+), CD68(+), CD117(+), lysozyme (+), MPO usually (-)"
                  },
                  {
                    "text": "Patients usually have bone marrow and systemic disease (unlike DL)"
                  }
                ],
                "Metastatic Malignant Melanoma": [
                  {
                    "text": "In florid cases of DL, melanin pigment and S100(+) may suggest possibility of melanoma"
                  },
                  {
                    "text": "DL lacks nuclear atypia and increased mitoses of metastatic melanoma"
                  }
                ],
                "Lymph Nodes With Other Pigments": [
                  {
                    "text": "Drainage from tattoo; black pigment"
                  },
                  {
                    "text": "Hemosiderosis following blood transfusions"
                  },
                  {
                    "text": "Drainage after local trauma or surgery; hemosiderin"
                  },
                  {
                    "text": "Anthracotic pigment, particularly in mediastinal lymph nodes"
                  },
                  {
                    "text": "In most cases, IDCs and LCs are not markedly increased"
                  },
                  {
                    "text": "Dermatitis is not present"
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Clinically Relevant Pathologic Features": [
                  {
                    "text": "Often associated with skin disordersEspecially generalized and exfoliative dermatitis",
                    "sub_points": [
                      "Especially generalized and exfoliative dermatitis"
                    ]
                  }
                ],
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "Grossly enlarged lymph nodes; sometimes pigmented"
                  },
                  {
                    "text": "Paracortical hyperplasia withIDCs, LCs, and macrophages containing melanin pigment and lipid vacuoles",
                    "sub_points": [
                      "IDCs, LCs, and macrophages containing melanin pigment and lipid vacuoles"
                    ]
                  },
                  {
                    "text": "Histologic features of DL do not exclude early involvement by MF/SS"
                  },
                  {
                    "text": "Ancillary testing for clonality assessment can be helpfulFlow cytometry immunophenotype may reveal aberrant patterns of T lymphocytesPolyclonalTCRgene rearrangement favors reactive process",
                    "sub_points": [
                      "Flow cytometry immunophenotype may reveal aberrant patterns of T lymphocytes",
                      "PolyclonalTCRgene rearrangement favors reactive process"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Progressive Transformation of Germinal Centers": {
            "name": "Progressive Transformation of Germinal Centers",
            "url": "https://app.pathprimer.com/document/ff87bc6c-2a4e-4c50-a2df-0e9e39fb0cae/lesson/1ca98c4c-c6e6-4862-8c12-8cba7a24c075",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Progressive transformation of germinal centers (PTGC)"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Young adults most commonly affected"
                  },
                  {
                    "text": "Etiology unknown"
                  },
                  {
                    "text": "M > F are affected"
                  },
                  {
                    "text": "Asymptomatic localized lymphadenopathy in most patientsCervical lymph nodes in ~ 50%",
                    "sub_points": [
                      "Cervical lymph nodes in ~ 50%"
                    ]
                  },
                  {
                    "text": "Generalized lymphadenopathy occurs in subset of patients"
                  },
                  {
                    "text": "Can be incidental finding in lymphoma patientsNodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) most commonNo data to prove PTGC is precursor of NLPHLSimultaneous, preceding, or following lymphoma",
                    "sub_points": [
                      "Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) most common",
                      "No data to prove PTGC is precursor of NLPHL",
                      "Simultaneous, preceding, or following lymphoma"
                    ]
                  },
                  {
                    "text": "PTGC usually resolves spontaneouslyCan recur",
                    "sub_points": [
                      "Can recur"
                    ]
                  },
                  {
                    "text": "PTGC is not associated with HIV infection"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "PTGC is characterized byLarge (4-5x normal) follicles2-3 hyperplastic germinal centersMantle zone B cells migrate into and disrupt germinal centersNodules in PTGC are at different stages of development",
                    "sub_points": [
                      "Large (4-5x normal) follicles",
                      "2-3 hyperplastic germinal centers",
                      "Mantle zone B cells migrate into and disrupt germinal centers",
                      "Nodules in PTGC are at different stages of development"
                    ]
                  },
                  {
                    "text": "PTGC is associated with reactive follicular hyperplasia"
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "ImmunohistochemistryGerminal center cells: CD10(+), BCL-6(+), BCL-2(-)Mantle zone cells: IgD(+), BCL-2(+), CD10(-), BCL-6(-)IgG4(+) plasma cells in 30-40% of PTGC casesNo evidence of monotypic B-cell population",
                    "sub_points": [
                      "Germinal center cells: CD10(+), BCL-6(+), BCL-2(-)",
                      "Mantle zone cells: IgD(+), BCL-2(+), CD10(-), BCL-6(-)",
                      "IgG4(+) plasma cells in 30-40% of PTGC cases",
                      "No evidence of monotypic B-cell population"
                    ]
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "NLPHL"
                  },
                  {
                    "text": "Lymphocyte-rich classic Hodgkin lymphoma, nodular variant"
                  },
                  {
                    "text": "Follicular lymphoma, floral variant"
                  },
                  {
                    "text": "HIV-associated lymphadenopathy"
                  },
                  {
                    "text": "IgG4-related disease"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Progressive transformation of germinal centers (PTGC)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Progressively transformed germinal centers (GCs)"
                  },
                  {
                    "text": "Progressively transformed follicle centers"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Reactive hyperplasia of follicles characterized byLarge follicles (4-5x normal) with hyperplastic GCsDisruption of GCs due to infiltration by mantle zone B cellsTypically, affected follicles are at different stages",
                    "sub_points": [
                      "Large follicles (4-5x normal) with hyperplastic GCs",
                      "Disruption of GCs due to infiltration by mantle zone B cells",
                      "Typically, affected follicles are at different stages"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Unknown": [
                  {
                    "text": "Viral cause suspected"
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Presentation": [
                  {
                    "text": "Can occur at any age but is common in young adultsMedian age: 30-40 years~ 20% of cases occur in children",
                    "sub_points": [
                      "Median age: 30-40 years",
                      "~ 20% of cases occur in children"
                    ]
                  },
                  {
                    "text": "Male patients are more often affected than female patients"
                  },
                  {
                    "text": "Usually involves peripheral lymph nodesCervical lymph nodes are most commonly involved (~ 50%)Axillary and inguinal lymph nodes are less common",
                    "sub_points": [
                      "Cervical lymph nodes are most commonly involved (~ 50%)",
                      "Axillary and inguinal lymph nodes are less common"
                    ]
                  },
                  {
                    "text": "Can be predominant change in lymph nodes, prompting biopsy"
                  },
                  {
                    "text": "Patients with PTGC can present ± symptomsMost frequent presentation is asymptomatic and localized lymphadenopathyGeneralized lymphadenopathy can occur in subset of patientsAdolescents who present with viral-like illnessPatients with autoimmune diseasesPTGC can be incidental finding in patients with lymphomaPTGC detected at initial diagnosis or after therapyInterval between PTGC and lymphoma can be > 10 yearsPTGC can also rarely precede diagnosis of lymphoma",
                    "sub_points": [
                      "Most frequent presentation is asymptomatic and localized lymphadenopathy",
                      "Generalized lymphadenopathy can occur in subset of patientsAdolescents who present with viral-like illnessPatients with autoimmune diseases",
                      "Adolescents who present with viral-like illness",
                      "Patients with autoimmune diseases",
                      "PTGC can be incidental finding in patients with lymphomaPTGC detected at initial diagnosis or after therapyInterval between PTGC and lymphoma can be > 10 yearsPTGC can also rarely precede diagnosis of lymphoma",
                      "PTGC detected at initial diagnosis or after therapy",
                      "Interval between PTGC and lymphoma can be > 10 years",
                      "PTGC can also rarely precede diagnosis of lymphoma"
                    ]
                  },
                  {
                    "text": "Usually spontaneously resolves but can recurSame or different lymph nodesRecurrence occurs more often in children than adults",
                    "sub_points": [
                      "Same or different lymph nodes",
                      "Recurrence occurs more often in children than adults"
                    ]
                  },
                  {
                    "text": "Not associated with HIV infection"
                  }
                ],
                "Treatment": [
                  {
                    "text": "Observation"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Excellent"
                  }
                ]
              },
              "IMAGING": {
                "Radiographic Findings": [
                  {
                    "text": "Lymphadenopathy in subset of patients"
                  },
                  {
                    "text": "PET scan can be avid, and SUV can be high in some cases"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Follicles with PTGC are usually large4-5x size of normal reactive secondary follicles",
                    "sub_points": [
                      "4-5x size of normal reactive secondary follicles"
                    ]
                  },
                  {
                    "text": "Usually focal; involves only few follicles in lymph node"
                  },
                  {
                    "text": "Process of PTGC appears to proceed in stagesInitially, GCs become hyperplasticStarry-sky pattern can occur but unusual2-3 GCs per follicle fuse togetherMantle zone B cells infiltrate and disrupt GCsEventually, GCs disappearCentroblasts and follicular dendritic cells are scattered among small mantle zone B cells",
                    "sub_points": [
                      "Initially, GCs become hyperplasticStarry-sky pattern can occur but unusual",
                      "Starry-sky pattern can occur but unusual",
                      "2-3 GCs per follicle fuse together",
                      "Mantle zone B cells infiltrate and disrupt GCs",
                      "Eventually, GCs disappearCentroblasts and follicular dendritic cells are scattered among small mantle zone B cells",
                      "Centroblasts and follicular dendritic cells are scattered among small mantle zone B cells"
                    ]
                  },
                  {
                    "text": "Follicles involved by PTGC appear to be at different stages (i.e., asynchronous)"
                  },
                  {
                    "text": "Almost always accompanied by follicular hyperplasiaInterfollicular hyperplasia often present",
                    "sub_points": [
                      "Interfollicular hyperplasia often present"
                    ]
                  },
                  {
                    "text": "PTGC follicles can show Castleman-like changes; uncommon"
                  },
                  {
                    "text": "Clusters of epithelioid cells can surround PTGC follicles"
                  },
                  {
                    "text": "PTGC can coexist with Hodgkin or non-Hodgkin lymphomaNodular lymphocyte-predominant (LP) Hodgkin lymphoma (NLPHL) is most commonNo data to support PTGC as precursor of NLPHLOther lymphoma types uncommonly associated with PTGCClassic Hodgkin lymphoma, plasma cell myelomaMay involve same lymph node involved by lymphoma or different lymph node",
                    "sub_points": [
                      "Nodular lymphocyte-predominant (LP) Hodgkin lymphoma (NLPHL) is most commonNo data to support PTGC as precursor of NLPHL",
                      "No data to support PTGC as precursor of NLPHL",
                      "Other lymphoma types uncommonly associated with PTGCClassic Hodgkin lymphoma, plasma cell myeloma",
                      "Classic Hodgkin lymphoma, plasma cell myeloma",
                      "May involve same lymph node involved by lymphoma or different lymph node"
                    ]
                  },
                  {
                    "text": "In generalized cases of PTGC, histologic findings are more floridRarely associated with lymphoma",
                    "sub_points": [
                      "Rarely associated with lymphoma"
                    ]
                  }
                ],
                "Cytologic Features": [
                  {
                    "text": "Mixed population of small and large lymphocytesSmall, round lymphocytes are mantle zone B cells and reactive T cellsGC centrocytes and centroblasts",
                    "sub_points": [
                      "Small, round lymphocytes are mantle zone B cells and reactive T cells",
                      "GC centrocytes and centroblasts"
                    ]
                  },
                  {
                    "text": "No LP cells; no Reed-Sternberg or Hodgkin (RS+H) cells"
                  },
                  {
                    "text": "No plasma cells, neutrophils, or eosinophils"
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "Preserved B-cell and T-cell compartments of lymph nodeProminent follicular pattern",
                    "sub_points": [
                      "Prominent follicular pattern"
                    ]
                  },
                  {
                    "text": "In PTGC folliclesGCsB-cell antigens (+), CD10(+), BCL-6(+), BCL-2(-)Disruption of follicular dendritic cells that are CD21(+), CD23(+)IgG4(+) plasma cells in ~ 40-50% of PTGC casesMantle zonesB-cell antigens (+), IgD(+), BCL-2(+)CD10(-), BCL-6(-)",
                    "sub_points": [
                      "GCsB-cell antigens (+), CD10(+), BCL-6(+), BCL-2(-)Disruption of follicular dendritic cells that are CD21(+), CD23(+)IgG4(+) plasma cells in ~ 40-50% of PTGC cases",
                      "B-cell antigens (+), CD10(+), BCL-6(+), BCL-2(-)",
                      "Disruption of follicular dendritic cells that are CD21(+), CD23(+)",
                      "IgG4(+) plasma cells in ~ 40-50% of PTGC cases",
                      "Mantle zonesB-cell antigens (+), IgD(+), BCL-2(+)CD10(-), BCL-6(-)",
                      "B-cell antigens (+), IgD(+), BCL-2(+)",
                      "CD10(-), BCL-6(-)"
                    ]
                  },
                  {
                    "text": "T cells are relatively few in PTGC follicles"
                  }
                ],
                "Flow Cytometry": [
                  {
                    "text": "No evidence of monotypic B-cell population"
                  }
                ],
                "Genetic Testing": [
                  {
                    "text": "No evidence of monoclonalIGHrearrangements"
                  },
                  {
                    "text": "GC cells show somatic mutations similar to normal GCs"
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Nodular Lymphocyte-Predominant Hodgkin Lymphoma": [
                  {
                    "text": "Neoplastic nodules are more numerous and replace lymph node architecture"
                  },
                  {
                    "text": "Neoplastic nodules more irregular than those of PTGC"
                  },
                  {
                    "text": "LP cells are presentLarge with multilobated contours, clear nucleoplasm, and inconspicuous nucleoliCD20(+), CD45/LCA(+), CD15(-), CD30(-)BCL-6(+), IgD (~ 25%), BCL-2(-)T cells [PD-1(+)] form rosettes around LP cells",
                    "sub_points": [
                      "Large with multilobated contours, clear nucleoplasm, and inconspicuous nucleoli",
                      "CD20(+), CD45/LCA(+), CD15(-), CD30(-)",
                      "BCL-6(+), IgD (~ 25%), BCL-2(-)",
                      "T cells [PD-1(+)] form rosettes around LP cells"
                    ]
                  },
                  {
                    "text": "IgG4(+) plasma cells are absent or rare in nodules"
                  }
                ],
                "Lymphocyte-Rich Classic Hodgkin Lymphoma, Nodular Variant": [
                  {
                    "text": "Neoplastic nodules replace lymph node architecture"
                  },
                  {
                    "text": "Residual GCs are common within neoplastic nodules"
                  },
                  {
                    "text": "RS+H cells are presentLarge cells; usually 1-2 prominent nucleoliCD15(+/-), CD30(+), CD45/LCA(-)CD20(weak, -/+), BCL-2(+/-)",
                    "sub_points": [
                      "Large cells; usually 1-2 prominent nucleoli",
                      "CD15(+/-), CD30(+), CD45/LCA(-)",
                      "CD20(weak, -/+), BCL-2(+/-)"
                    ]
                  }
                ],
                "Follicular Lymphoma, Floral Variant": [
                  {
                    "text": "Many neoplastic follicles; back-to-back"
                  },
                  {
                    "text": "Composition of follicles is relatively homogeneousMixture of centrocytes and centroblasts; no LP cells",
                    "sub_points": [
                      "Mixture of centrocytes and centroblasts; no LP cells"
                    ]
                  },
                  {
                    "text": "Monotypic Ig(+), CD10(+), BCL-6(+), and BCL-2(+)"
                  }
                ],
                "HIV-Associated Lymphadenopathy": [
                  {
                    "text": "Follicle lysis is common in HIV(+) lymphadenopathyMost common in early stages of infection",
                    "sub_points": [
                      "Most common in early stages of infection"
                    ]
                  },
                  {
                    "text": "Follicle lysis superficially resembles PTGC, butFollicles are usually not enlarged (unlike PTGC)Hemorrhage is common in affected folliclesFollicles are infiltrated by T cells",
                    "sub_points": [
                      "Follicles are usually not enlarged (unlike PTGC)",
                      "Hemorrhage is common in affected follicles",
                      "Follicles are infiltrated by T cells"
                    ]
                  }
                ],
                "IgG4-Related Disease": [
                  {
                    "text": "PTGC can occur in patients with IgG4-related disease"
                  }
                ],
                "Reactive Follicular Hyperplasia": [
                  {
                    "text": "Follicles are smaller and of similar size"
                  },
                  {
                    "text": "Mantle zone B cells do not infiltrate into GCs"
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Clinically Relevant Pathologic Features": [
                  {
                    "text": "Young patients; M > F"
                  },
                  {
                    "text": "Usually asymptomatic; single enlarged lymph node"
                  },
                  {
                    "text": "Generalized lymphadenopathy with florid PTGC can occurAdolescents or patients with autoimmune diseases",
                    "sub_points": [
                      "Adolescents or patients with autoimmune diseases"
                    ]
                  },
                  {
                    "text": "Small number of cases are associated with lymphomaNLPHL is most commonPTGC may precede, coexist with, or follow lymphoma",
                    "sub_points": [
                      "NLPHL is most common",
                      "PTGC may precede, coexist with, or follow lymphoma"
                    ]
                  },
                  {
                    "text": "PTGC can occur in patients with IgG4-related diseaseIncreased IgG4(+) plasma cells in 30-40% of PTGC casesNot specific for IgG4-related disease",
                    "sub_points": [
                      "Increased IgG4(+) plasma cells in 30-40% of PTGC casesNot specific for IgG4-related disease",
                      "Not specific for IgG4-related disease"
                    ]
                  }
                ],
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "Large follicles with expanded mantle zones and disrupted GCs"
                  },
                  {
                    "text": "No LP or RS+H cells"
                  },
                  {
                    "text": "No evidence of monoclonal B-cell population"
                  }
                ]
              },
              "Selected References": {}
            }
          }
        }
      },
      "Lymph Node: Lymphoma": {
        "name": "Lymph Node: Lymphoma",
        "url": "https://app.pathprimer.com/lesson/1754477f-a4b1-4ec8-b223-cd1eb29cbd87",
        "topics": {
          "Lymphocyte-Rich Classic Hodgkin Lymphoma": {
            "name": "Lymphocyte-Rich Classic Hodgkin Lymphoma",
            "url": "https://app.pathprimer.com/document/8f83c82d-8ba8-469f-af85-e693736e59bd/lesson/1754477f-a4b1-4ec8-b223-cd1eb29cbd87",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Lymphocyte-rich classic Hodgkin lymphoma (LRCHL)"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Incidence: 0.2 per 100,000 persons per year"
                  },
                  {
                    "text": "4-5% of all classic Hodgkin lymphoma cases"
                  },
                  {
                    "text": "Most common in middle-aged persons (median: 43 years)"
                  },
                  {
                    "text": "B symptoms in ~ 10% of patients"
                  },
                  {
                    "text": "Peripheral lymph nodes usually involved"
                  },
                  {
                    "text": "Mediastinum involved ~ 15% of patients"
                  },
                  {
                    "text": "Visceral organs involved uncommonly"
                  },
                  {
                    "text": "Stage I or II disease"
                  },
                  {
                    "text": "Survival similar to patients with other types of CHLEarly relapses followed by plateau (implying cure)",
                    "sub_points": [
                      "Early relapses followed by plateau (implying cure)"
                    ]
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Nodular variant of LRCHL is most commonVague nodules replace architectureNodules are composed ofSmall lymphocytes and histiocytesNo granulocytes and plasma cells within nodules",
                    "sub_points": [
                      "Vague nodules replace architecture",
                      "Nodules are composed ofSmall lymphocytes and histiocytesNo granulocytes and plasma cells within nodules",
                      "Small lymphocytes and histiocytes",
                      "No granulocytes and plasma cells within nodules"
                    ]
                  },
                  {
                    "text": "Diffuse variant of LRCHL is uncommonDiffuse pattern; cytologic composition similar to nodular variant",
                    "sub_points": [
                      "Diffuse pattern; cytologic composition similar to nodular variant"
                    ]
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "RS+H cells have immunophenotype of CHLCD15(±), CD30(+), pax-5 (+ weak)MUM1/IRF4(+), CD20(±), CD45/LCA(-)Epstein-Barr virus (EBV) infection in ~ 40% of cases",
                    "sub_points": [
                      "CD15(±), CD30(+), pax-5 (+ weak)",
                      "MUM1/IRF4(+), CD20(±), CD45/LCA(-)",
                      "Epstein-Barr virus (EBV) infection in ~ 40% of cases"
                    ]
                  },
                  {
                    "text": "Small lymphocytes include many B cells and T cells"
                  },
                  {
                    "text": "Loose follicular dendritic cell meshworks in nodular variant"
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "Nodular lymphocyte-predominant HL"
                  },
                  {
                    "text": "Mixed cellularity HL"
                  },
                  {
                    "text": "Nodular sclerosis HL"
                  },
                  {
                    "text": "T-cell/histiocyte-rich large B-cell lymphoma"
                  },
                  {
                    "text": "Small B-cell lymphomas"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Lymphocyte-rich classic Hodgkin lymphoma (LRCHL)"
                  },
                  {
                    "text": "Reed-Sternberg and Hodgkin (RS+H) cells"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Follicular Hodgkin disease (lymphoma)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "LRCHL is composed of RS+H cells associated with numerous small lymphocytes and histiocytes2 variants: Nodular and diffuse",
                    "sub_points": [
                      "2 variants: Nodular and diffuse"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Tumorigenesis": [
                  {
                    "text": "RS+H cells arise from defective germinal center (GC) or post-GC B cellsClonal immunoglobulin (Ig) gene rearrangements shown by single-cell polymerase chain reaction (PCR)Carry somatic mutations of Ig variable region genesCrippling Ig gene mutations in subset of casesEpigenetic silencing (promoter hypermethylation) of Ig gene transcriptionImpaired transcription of transcription factors (e.g., OCT2, BOB.1)In LRCHL, B-cell transcription in RS+H cells is less abnormal than in other CHL typesIntermediate between nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) and CHLRS+H cells do not express surface Ig",
                    "sub_points": [
                      "Clonal immunoglobulin (Ig) gene rearrangements shown by single-cell polymerase chain reaction (PCR)Carry somatic mutations of Ig variable region genesCrippling Ig gene mutations in subset of cases",
                      "Carry somatic mutations of Ig variable region genes",
                      "Crippling Ig gene mutations in subset of cases",
                      "Epigenetic silencing (promoter hypermethylation) of Ig gene transcriptionImpaired transcription of transcription factors (e.g., OCT2, BOB.1)",
                      "Impaired transcription of transcription factors (e.g., OCT2, BOB.1)",
                      "In LRCHL, B-cell transcription in RS+H cells is less abnormal than in other CHL typesIntermediate between nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) and CHL",
                      "Intermediate between nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) and CHL",
                      "RS+H cells do not express surface Ig"
                    ]
                  },
                  {
                    "text": "Antiapoptotic mechanisms support RS+H cell survivalEpstein-Barr virus (EBV) infection in RS+H cellsMicroenvironment plays role on preventing apoptosis of RS+H cellsReactive cells are induced by RS+H cells and support RS+H cellsPlays role in preventing host immunosurveillance from attacking RS+H cells",
                    "sub_points": [
                      "Epstein-Barr virus (EBV) infection in RS+H cells",
                      "Microenvironment plays role on preventing apoptosis of RS+H cellsReactive cells are induced by RS+H cells and support RS+H cellsPlays role in preventing host immunosurveillance from attacking RS+H cells",
                      "Reactive cells are induced by RS+H cells and support RS+H cells",
                      "Plays role in preventing host immunosurveillance from attacking RS+H cells"
                    ]
                  },
                  {
                    "text": "NF-κB activated in RS+H cellsRELat chromosome 2p16 shows gains or amplification in subset of CHL casesRELencodes component of NK-κB pathwayc-Rel nuclear accumulation may play role in malignant transformation of RS+H cellsInactivating mutations in NF-κB inhibitor IκBα in 10-20% of CHL cases",
                    "sub_points": [
                      "RELat chromosome 2p16 shows gains or amplification in subset of CHL casesRELencodes component of NK-κB pathwayc-Rel nuclear accumulation may play role in malignant transformation of RS+H cells",
                      "RELencodes component of NK-κB pathway",
                      "c-Rel nuclear accumulation may play role in malignant transformation of RS+H cells",
                      "Inactivating mutations in NF-κB inhibitor IκBα in 10-20% of CHL cases"
                    ]
                  }
                ],
                "Postulated Normal Counterpart": [
                  {
                    "text": "LRCHL may be derived from B cells in outer zone of reactive GCsLarge cells in outer zone of reactive GCs have immunophenotype similar to RS+H cellsCD30(+), B-cell transcription factors (+)",
                    "sub_points": [
                      "Large cells in outer zone of reactive GCs have immunophenotype similar to RS+H cellsCD30(+), B-cell transcription factors (+)",
                      "CD30(+), B-cell transcription factors (+)"
                    ]
                  },
                  {
                    "text": "Large cells surrounded by T-cell rosettes that are PD-1(+), CD57(+)"
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "0.2 per 100,000 persons per year"
                  },
                  {
                    "text": "4-5% of all cases of HL"
                  }
                ],
                "Age": [
                  {
                    "text": "Most common in middle-aged persons (median: 43 years)"
                  }
                ],
                "Sex": [
                  {
                    "text": "M:F ~ 2:1"
                  }
                ],
                "Presentation": [
                  {
                    "text": "B symptoms in ~ 10% of patientsLess frequent compared with other types of CHL",
                    "sub_points": [
                      "Less frequent compared with other types of CHL"
                    ]
                  },
                  {
                    "text": "Stage I or II disease in ~ 70% of patients"
                  },
                  {
                    "text": "Peripheral lymph node involvement is typicalEspecially supradiaphragmatic lymph nodes",
                    "sub_points": [
                      "Especially supradiaphragmatic lymph nodes"
                    ]
                  },
                  {
                    "text": "Mediastinal involvement is uncommonIn ~ 15% of patients; typically not bulky",
                    "sub_points": [
                      "In ~ 15% of patients; typically not bulky"
                    ]
                  },
                  {
                    "text": "Visceral organ involvement is uncommonExtranodal sites include: Lungs (4%), bones (3%), bone marrow (2%), and liver (2%)",
                    "sub_points": [
                      "Extranodal sites include: Lungs (4%), bones (3%), bone marrow (2%), and liver (2%)"
                    ]
                  },
                  {
                    "text": "HL is rare in Waldeyer ring, but LRCHL is common type at this location"
                  }
                ],
                "Natural History": [
                  {
                    "text": "Survival curves of patients with LRCHL similar to patients with CHLEarly relapses followed by plateauUnlike patients with NLPHL, who have early and late relapses without plateau",
                    "sub_points": [
                      "Early relapses followed by plateau",
                      "Unlike patients with NLPHL, who have early and late relapses without plateau"
                    ]
                  }
                ],
                "Treatment": [],
                "Drugs": [
                  {
                    "text": "Various chemotherapy regimens have been used for patients with LRCHL; most common areABVD: Doxorubicin, bleomycin, vinblastine, and dacarbazine ± rituximabBEACOPP: Bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone",
                    "sub_points": [
                      "ABVD: Doxorubicin, bleomycin, vinblastine, and dacarbazine ± rituximab",
                      "BEACOPP: Bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone"
                    ]
                  }
                ],
                "Radiation": [
                  {
                    "text": "Patients with early- and intermediate-stage diseaseExtended-field or involved-field radiotherapy + chemotherapyRadiation alone for rare early localized disease",
                    "sub_points": [
                      "Extended-field or involved-field radiotherapy + chemotherapy",
                      "Radiation alone for rare early localized disease"
                    ]
                  },
                  {
                    "text": "Patients with advanced stage diseaseLocal radiotherapy to debulk tumor and for residual disease (in addition to chemotherapy)",
                    "sub_points": [
                      "Local radiotherapy to debulk tumor and for residual disease (in addition to chemotherapy)"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Good to excellent with current treatment regimens95% complete remission rate; 17% relapse rateHowever, not significantly better than other types of CHL that are stage comparable",
                    "sub_points": [
                      "95% complete remission rate; 17% relapse rate",
                      "However, not significantly better than other types of CHL that are stage comparable"
                    ]
                  },
                  {
                    "text": "Small subset of patients with LRCHL do poorly; fatalities due toRelapsed/progressive disease ~ 9%; 2nd malignancies ~ 4%",
                    "sub_points": [
                      "Relapsed/progressive disease ~ 9%; 2nd malignancies ~ 4%"
                    ]
                  }
                ]
              },
              "IMAGING": {
                "Radiographic Findings": [
                  {
                    "text": "Peripheral lymphadenopathy"
                  },
                  {
                    "text": "PET/CT useful for staging and helpful to assess therapeutic response"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Nodular variantVague and expansile nodules replace architectureNodules are composed of expanded mantle zone small lymphocytesSmall, compact, often eccentric GCs present in subset of casesHistiocytes present; relatively infrequent compared with lymphocytesPlasma cells uncommon or absent within nodulesNo eosinophils or neutrophils within nodulesLoose follicular dendritic cell (FDC) meshworks underlying nodulesHighlighted by FDC markers, such as CD21, CD23, and CD35RS+H cells scattered among small lymphocytesPredominantly found within expanded mantle zonesMost RS+H cells have classic cytologic featuresRS+H cells can resemble lymphocyte-predominant (LP) cells as seen in nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL)Eosinophils and neutrophils can be present around nodules; usually infrequent",
                    "sub_points": [
                      "Vague and expansile nodules replace architecture",
                      "Nodules are composed of expanded mantle zone small lymphocytesSmall, compact, often eccentric GCs present in subset of casesHistiocytes present; relatively infrequent compared with lymphocytesPlasma cells uncommon or absent within nodulesNo eosinophils or neutrophils within nodules",
                      "Small, compact, often eccentric GCs present in subset of cases",
                      "Histiocytes present; relatively infrequent compared with lymphocytes",
                      "Plasma cells uncommon or absent within nodules",
                      "No eosinophils or neutrophils within nodules",
                      "Loose follicular dendritic cell (FDC) meshworks underlying nodulesHighlighted by FDC markers, such as CD21, CD23, and CD35",
                      "Highlighted by FDC markers, such as CD21, CD23, and CD35",
                      "RS+H cells scattered among small lymphocytesPredominantly found within expanded mantle zonesMost RS+H cells have classic cytologic featuresRS+H cells can resemble lymphocyte-predominant (LP) cells as seen in nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL)",
                      "Predominantly found within expanded mantle zones",
                      "Most RS+H cells have classic cytologic features",
                      "RS+H cells can resemble lymphocyte-predominant (LP) cells as seen in nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL)",
                      "Eosinophils and neutrophils can be present around nodules; usually infrequent"
                    ]
                  },
                  {
                    "text": "Diffuse variantUncommon compared with nodular variantDiffuse replacement of lymph node architectureCytologic composition similar to that seen in nodular variant",
                    "sub_points": [
                      "Uncommon compared with nodular variant",
                      "Diffuse replacement of lymph node architecture",
                      "Cytologic composition similar to that seen in nodular variant"
                    ]
                  }
                ],
                "Cytologic Features": [
                  {
                    "text": "Fine-needle aspiration smears show small lymphocytes and RS+H cellsDiagnosis of CHL can be establishedDifficult to specifically recognize LRCHL by smear examination",
                    "sub_points": [
                      "Diagnosis of CHL can be established",
                      "Difficult to specifically recognize LRCHL by smear examination"
                    ]
                  },
                  {
                    "text": "Possible to diagnose specific type of LRCHL if clot specimen contains tissue fragments of adequate size"
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "RS+H cells have immunophenotype that supports CHLCD15(±), CD30(+), pax-5 (weak), MUM1/IRF4(+), CD45/LCA(-)",
                    "sub_points": [
                      "CD15(±), CD30(+), pax-5 (weak), MUM1/IRF4(+), CD45/LCA(-)"
                    ]
                  },
                  {
                    "text": "Small lymphocytes in background have immunophenotype of mantle zone B cellsCD19(+), CD20(+), pax-5(+), IgD(+), IgM(+)",
                    "sub_points": [
                      "CD19(+), CD20(+), pax-5(+), IgD(+), IgM(+)"
                    ]
                  },
                  {
                    "text": "LRCHL has features intermediate between CHL and NLPHLFeatures of RS+H cells closer in LP cells in NLPHL~ 50-60% of cases OCT1(+), OCT2(+), and BOB.1(+)Bright pax-5(±); CD20(-/+) ~ 30%; BCL-6(-/+) ~ 30%Features of RS+H cells closer to typical cells of CHLNuclear Rel(+), Rel-B(+), p50(+), and TRAF1(+), consistent with NF-κB activationEBV-LMP1(+) in ~ 40% of casesMicroenvironment of LRCHL similar to NLPHLNumerous small B cells in backgroundFDC networks in tumor nodulesT cells form rosettes around RS+H cells:Often PD-1(+), CD57(+), &/or CD3(+)",
                    "sub_points": [
                      "Features of RS+H cells closer in LP cells in NLPHL~ 50-60% of cases OCT1(+), OCT2(+), and BOB.1(+)Bright pax-5(±); CD20(-/+) ~ 30%; BCL-6(-/+) ~ 30%",
                      "~ 50-60% of cases OCT1(+), OCT2(+), and BOB.1(+)",
                      "Bright pax-5(±); CD20(-/+) ~ 30%; BCL-6(-/+) ~ 30%",
                      "Features of RS+H cells closer to typical cells of CHLNuclear Rel(+), Rel-B(+), p50(+), and TRAF1(+), consistent with NF-κB activationEBV-LMP1(+) in ~ 40% of cases",
                      "Nuclear Rel(+), Rel-B(+), p50(+), and TRAF1(+), consistent with NF-κB activation",
                      "EBV-LMP1(+) in ~ 40% of cases",
                      "Microenvironment of LRCHL similar to NLPHLNumerous small B cells in backgroundFDC networks in tumor nodulesT cells form rosettes around RS+H cells:Often PD-1(+), CD57(+), &/or CD3(+)",
                      "Numerous small B cells in background",
                      "FDC networks in tumor nodules",
                      "T cells form rosettes around RS+H cells:Often PD-1(+), CD57(+), &/or CD3(+)",
                      "Often PD-1(+), CD57(+), &/or CD3(+)"
                    ]
                  }
                ],
                "Flow Cytometry": [
                  {
                    "text": "Polytypic B cells and normal T cells"
                  },
                  {
                    "text": "Mature T cells with normal immunophenotype"
                  }
                ],
                "In Situ Hybridization": [
                  {
                    "text": "EBV-encoded RNA (EBER) (+) in RS+H cells in ~ 40% of cases"
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Nodular Lymphocyte-Predominant Hodgkin Lymphoma": [
                  {
                    "text": "NLPHL and LRCHL can closely resemble each otherImmunohistochemical analysis required to distinguishLP cells of NLPHL areCD45/LCA(+), CD20(+), BCL-6(+)pax-5(+), OCT2(+), BOB.1(+)CD30(-), CD15(-), EBER(-)T cells commonly form rosettes around LP cellsT cells have follicular T-helper cell immunophenotype",
                    "sub_points": [
                      "Immunohistochemical analysis required to distinguishLP cells of NLPHL areCD45/LCA(+), CD20(+), BCL-6(+)pax-5(+), OCT2(+), BOB.1(+)CD30(-), CD15(-), EBER(-)T cells commonly form rosettes around LP cellsT cells have follicular T-helper cell immunophenotype",
                      "LP cells of NLPHL areCD45/LCA(+), CD20(+), BCL-6(+)pax-5(+), OCT2(+), BOB.1(+)CD30(-), CD15(-), EBER(-)",
                      "CD45/LCA(+), CD20(+), BCL-6(+)",
                      "pax-5(+), OCT2(+), BOB.1(+)",
                      "CD30(-), CD15(-), EBER(-)",
                      "T cells commonly form rosettes around LP cellsT cells have follicular T-helper cell immunophenotype",
                      "T cells have follicular T-helper cell immunophenotype"
                    ]
                  }
                ],
                "Mixed Cellularity Hodgkin Lymphoma": [
                  {
                    "text": "Diffuse variant of LRCHL can resemble mixed cellularity HL"
                  },
                  {
                    "text": "Reactive cell background includes plasma cells and eosinophils"
                  },
                  {
                    "text": "EBV infection in ~ 75% of cases"
                  }
                ],
                "Nodular Sclerosis Hodgkin Lymphoma": [
                  {
                    "text": "Mediastinal mass in ~ 80% of patients"
                  },
                  {
                    "text": "Nodules surrounded by thick, fibrous bands"
                  },
                  {
                    "text": "Reactive cell background is more mixed: Plasma cells, eosinophils, neutrophils"
                  },
                  {
                    "text": "Some cases can exhibit prominent mantle zones with RS+H cells"
                  },
                  {
                    "text": "Some cases of LRCHL can relapse as this diagnosisSuggests that LRCHL category may include subset of early cases",
                    "sub_points": [
                      "Suggests that LRCHL category may include subset of early cases"
                    ]
                  }
                ],
                "T-Cell/Histiocyte-Rich Large B-Cell Lymphoma": [
                  {
                    "text": "Diffuse variant of LRCHL can resemble histologically"
                  },
                  {
                    "text": "Background infiltrate composed of abundant small T cells and histiocytesSmall B cells usually rare or absent",
                    "sub_points": [
                      "Small B cells usually rare or absent"
                    ]
                  },
                  {
                    "text": "Neoplastic cells CD45/LCA(+), CD20(+), CD15(-)"
                  }
                ],
                "Small B-Cell Lymphomas": [
                  {
                    "text": "LRCHL can mimic small B-cell lymphomasMantle cell lymphoma, nodal marginal zone lymphomaFollicular lymphoma, CLL/SLLChronic lymphocytic leukemia/small lymphocytic lymphoma",
                    "sub_points": [
                      "Mantle cell lymphoma, nodal marginal zone lymphoma",
                      "Follicular lymphoma, CLL/SLL",
                      "Chronic lymphocytic leukemia/small lymphocytic lymphoma"
                    ]
                  },
                  {
                    "text": "No RS+H cells in small B-cell lymphomas"
                  },
                  {
                    "text": "Immunophenotype helpful in differential diagnosisSmall B-cell lymphomas are monotypic Ig(+)CD5, CD10, CD23, Bcl-6, and cyclin D1 are useful for defining types",
                    "sub_points": [
                      "Small B-cell lymphomas are monotypic Ig(+)",
                      "CD5, CD10, CD23, Bcl-6, and cyclin D1 are useful for defining types"
                    ]
                  }
                ],
                "Reactive Paracortical Immunoblastic Hyperplasia": [
                  {
                    "text": "Can mimic diffuse variant of LRCHLImmunoblasts are CD30(+), CD45/LCA(+), CD15(-)",
                    "sub_points": [
                      "Immunoblasts are CD30(+), CD45/LCA(+), CD15(-)"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Nodular Lymphocyte-Predominant Hodgkin Lymphoma": {
            "name": "Nodular Lymphocyte-Predominant Hodgkin Lymphoma",
            "url": "https://app.pathprimer.com/document/be070e2d-785e-49a1-add8-e7d2a316cb60/lesson/1754477f-a4b1-4ec8-b223-cd1eb29cbd87",
            "content": {
              "KEY FACTS": {
                "Clinical Issues": [
                  {
                    "text": "Peak incidence in 4th decade but affects all ages"
                  },
                  {
                    "text": "Patients often present with stage I or II nodal-based diseaseCervical, axillary, or inguinal regions common",
                    "sub_points": [
                      "Cervical, axillary, or inguinal regions common"
                    ]
                  },
                  {
                    "text": "Slow progression and frequent relapses"
                  },
                  {
                    "text": "~ 10-15% of patients transform to large B-cell lymphoma"
                  },
                  {
                    "text": "With prolonged follow-up, ~ 15% of patients die of disease"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Nodular pattern pure or predominant in ~ 75% cases"
                  },
                  {
                    "text": "Few LP cells in sea of small lymphocytes and histiocytesMixture imparts moth-eaten pattern",
                    "sub_points": [
                      "Mixture imparts moth-eaten pattern"
                    ]
                  },
                  {
                    "text": "LP cells have vesicular chromatin, small nucleoli, and thin nuclear membranes"
                  },
                  {
                    "text": "No necrosis or thick, fibrous bands"
                  },
                  {
                    "text": "Various architectural patterns described, designated A-FTypical (patterns A and B)Variant patterns (C-F) associated with recurrenceLP cells outside B-cell nodules (pattern C)T-cell-rich nodules (pattern D)T-cell/histiocyte-rich large B-cell-like (pattern E)Diffuse pattern with increased small B-cells (pattern F)",
                    "sub_points": [
                      "Typical (patterns A and B)",
                      "Variant patterns (C-F) associated with recurrenceLP cells outside B-cell nodules (pattern C)T-cell-rich nodules (pattern D)T-cell/histiocyte-rich large B-cell-like (pattern E)Diffuse pattern with increased small B-cells (pattern F)",
                      "LP cells outside B-cell nodules (pattern C)",
                      "T-cell-rich nodules (pattern D)",
                      "T-cell/histiocyte-rich large B-cell-like (pattern E)",
                      "Diffuse pattern with increased small B-cells (pattern F)"
                    ]
                  },
                  {
                    "text": "Uninvolved lymph node shows follicular hyperplasia &/or PTGC"
                  },
                  {
                    "text": "Classic nodular pattern most common (pattern A)"
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "Immunophenotype of LP cellsCD20(+), CD45/LCA(+), BCL-6(+), pax-5(+)OCT-2(+), BOB1(+), MEF2B(+), IgD(±)CD3(-), CD15(-), CD30(-), EBV(-)",
                    "sub_points": [
                      "CD20(+), CD45/LCA(+), BCL-6(+), pax-5(+)",
                      "OCT-2(+), BOB1(+), MEF2B(+), IgD(±)",
                      "CD3(-), CD15(-), CD30(-), EBV(-)"
                    ]
                  },
                  {
                    "text": "Immunophenotype of background infiltrateB cells: CD20(+), CD79a(+), pax-5(+), OCT-2(+)T cells include many TFH cells: CD3(+), PD-1(+), ICOS(-)FDCs: CD21(+), CD23(+)",
                    "sub_points": [
                      "B cells: CD20(+), CD79a(+), pax-5(+), OCT-2(+)",
                      "T cells include many TFH cells: CD3(+), PD-1(+), ICOS(-)",
                      "FDCs: CD21(+), CD23(+)"
                    ]
                  },
                  {
                    "text": "ClonalIGHby single-cell PCR"
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "Lymphocyte-rich classic Hodgkin lymphoma"
                  },
                  {
                    "text": "T-cell/histiocyte-rich large B-cell lymphoma"
                  },
                  {
                    "text": "Angioimmunoblastic T-cell lymphoma"
                  },
                  {
                    "text": "Progressive transformation of germinal centers"
                  },
                  {
                    "text": "Follicular lymphoma"
                  },
                  {
                    "text": "Nodular sclerosis Hodgkin lymphoma"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Nodular lymphocyte-predominant Hodgkin disease (REAL, 1994)"
                  },
                  {
                    "text": "Lymphocyte-predominant Hodgkin disease (Rye, 1966)"
                  },
                  {
                    "text": "Lymphocytic- &/or histiocytic-predominant Hodgkin disease (Lukes and Butler, 1966)"
                  },
                  {
                    "text": "Paragranuloma (Jackson and Parker, 1944)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "B-cell neoplasm characterized by nodular ± diffuse proliferation of large neoplastic lymphocyte-predominant (LP) cells associated with small lymphocytes and histiocytesNeoplastic cells are designated as LP cellsa.k.a. popcorn cells because of their hyperlobated nuclei with vesicular chromatinFormerly called lymphocytic &/or histiocytic (L&H) cellsLP cells reside mostly within follicular dendritic cell meshworksBackground is composed of reactive small lymphocytes and histiocytesInflammatory cells greatly outnumber neoplastic LP cellsEosinophils and neutrophils are usually absent; plasma cells few",
                    "sub_points": [
                      "Neoplastic cells are designated as LP cellsa.k.a. popcorn cells because of their hyperlobated nuclei with vesicular chromatinFormerly called lymphocytic &/or histiocytic (L&H) cells",
                      "a.k.a. popcorn cells because of their hyperlobated nuclei with vesicular chromatin",
                      "Formerly called lymphocytic &/or histiocytic (L&H) cells",
                      "LP cells reside mostly within follicular dendritic cell meshworks",
                      "Background is composed of reactive small lymphocytes and histiocytesInflammatory cells greatly outnumber neoplastic LP cellsEosinophils and neutrophils are usually absent; plasma cells few",
                      "Inflammatory cells greatly outnumber neoplastic LP cells",
                      "Eosinophils and neutrophils are usually absent; plasma cells few"
                    ]
                  },
                  {
                    "text": "Diffuse form of NLPHLTerm derived from Lukes and Butler classificationMost cases in this category have been reclassified asT-cell/histiocyte-rich large B-cell lymphoma (THRLBCL)-like transformation of NLPHLNLPHL with diffuse THRLBCL-like areasClassic Hodgkin lymphoma (CHL)True cases of NLPHL with diffuse pattern likely exist but are truly rare",
                    "sub_points": [
                      "Term derived from Lukes and Butler classification",
                      "Most cases in this category have been reclassified asT-cell/histiocyte-rich large B-cell lymphoma (THRLBCL)-like transformation of NLPHLNLPHL with diffuse THRLBCL-like areasClassic Hodgkin lymphoma (CHL)",
                      "T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL)-like transformation of NLPHL",
                      "NLPHL with diffuse THRLBCL-like areas",
                      "Classic Hodgkin lymphoma (CHL)",
                      "True cases of NLPHL with diffuse pattern likely exist but are truly rare"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Environmental Exposure": [
                  {
                    "text": "Antigenic stimulation is likely involved in pathogenesisAssociated withMoraxella catarrhalisinfectionImmunologic synapses between LP cells and T cells forming rosettesSuggests chronic B-cell and T-cell stimulation",
                    "sub_points": [
                      "Associated withMoraxella catarrhalisinfection",
                      "Immunologic synapses between LP cells and T cells forming rosettes",
                      "Suggests chronic B-cell and T-cell stimulation"
                    ]
                  }
                ],
                "Infectious Agents": [
                  {
                    "text": "M. catarrhalisinfectionSpecifically associated with NLPHL cases with IgD(+) LP cells",
                    "sub_points": [
                      "Specifically associated with NLPHL cases with IgD(+) LP cells"
                    ]
                  }
                ],
                "Postulated Normal Counterpart": [
                  {
                    "text": "Germinal center B lymphocyte at centroblast stage of differentiation"
                  }
                ],
                "Associated Lesions": [
                  {
                    "text": "NLPHL is often associated withProgressive transformation of germinal centers (PTGC)Reactive follicular hyperplasia",
                    "sub_points": [
                      "Progressive transformation of germinal centers (PTGC)",
                      "Reactive follicular hyperplasia"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "0.1-0.2 per 100,000 per year"
                  },
                  {
                    "text": "5-6% of all HLs"
                  }
                ],
                "Age": [
                  {
                    "text": "Median: 35 years"
                  },
                  {
                    "text": "All age groups affected"
                  }
                ],
                "Sex": [
                  {
                    "text": "Male predominanceM:F = > 3:1",
                    "sub_points": [
                      "M:F = > 3:1"
                    ]
                  }
                ],
                "Site": [
                  {
                    "text": "Lymph nodes"
                  },
                  {
                    "text": "Most commonly affected groups include cervical, axillary, or inguinal lymph nodesParaaortic and iliac lymph nodes less often involved",
                    "sub_points": [
                      "Paraaortic and iliac lymph nodes less often involved"
                    ]
                  },
                  {
                    "text": "Liver &/or spleen involved in ~ 10% of cases"
                  },
                  {
                    "text": "Mediastinum involved in ~ 7% of cases"
                  },
                  {
                    "text": "Bone marrow rarely involved (~ 2%)Usually evidence of transformation to large B-cell lymphoma (LBCL)",
                    "sub_points": [
                      "Usually evidence of transformation to large B-cell lymphoma (LBCL)"
                    ]
                  }
                ],
                "Presentation": [
                  {
                    "text": "Peripheral lymphadenopathyStage I or II in ~ 80% of patients",
                    "sub_points": [
                      "Stage I or II in ~ 80% of patients"
                    ]
                  },
                  {
                    "text": "B symptoms uncommon (~ 10%)"
                  },
                  {
                    "text": "20% of patients present with advanced stage diseaseInvolvement of spleen and liverAbdominal lymphadenopathyB symptoms often (+)",
                    "sub_points": [
                      "Involvement of spleen and liver",
                      "Abdominal lymphadenopathy",
                      "B symptoms often (+)"
                    ]
                  }
                ],
                "Laboratory Tests": [
                  {
                    "text": "Normal complete blood count; no leukemic phase"
                  },
                  {
                    "text": "Usually unremarkable chemistry panelSerum LDH or β-2-microglobulin levels elevated in patients with high-stage disease",
                    "sub_points": [
                      "Serum LDH or β-2-microglobulin levels elevated in patients with high-stage disease"
                    ]
                  }
                ],
                "Natural History": [
                  {
                    "text": "Clinically indolent disease with frequent relapses"
                  },
                  {
                    "text": "Relapse-free survival curves show staircase patternNo plateau suggestive of cureEarly and late (> 10 years) relapses occurRisk of relapse independent of stage or therapy",
                    "sub_points": [
                      "No plateau suggestive of cure",
                      "Early and late (> 10 years) relapses occur",
                      "Risk of relapse independent of stage or therapy"
                    ]
                  },
                  {
                    "text": "~ 10-15% of NLPHL transform to LBCLLBCL typically follows NLPHL but can coexist with, or precede, NLPHLSubset of cases resembles diffuse LBCL (DLBCL)2nd subset resembles THRLBCL",
                    "sub_points": [
                      "LBCL typically follows NLPHL but can coexist with, or precede, NLPHLSubset of cases resembles diffuse LBCL (DLBCL)2nd subset resembles THRLBCL",
                      "Subset of cases resembles diffuse LBCL (DLBCL)",
                      "2nd subset resembles THRLBCL"
                    ]
                  },
                  {
                    "text": "With prolonged follow-up, ~ 15% of patients dieDeaths related to disease refractory to therapy or 2nd malignancies2nd malignancies represent ~ 4% of all deathsAcute leukemia (2%)Non-HL (1%)Solid organ tumors (1%)",
                    "sub_points": [
                      "Deaths related to disease refractory to therapy or 2nd malignancies",
                      "2nd malignancies represent ~ 4% of all deathsAcute leukemia (2%)Non-HL (1%)Solid organ tumors (1%)",
                      "Acute leukemia (2%)",
                      "Non-HL (1%)",
                      "Solid organ tumors (1%)"
                    ]
                  }
                ],
                "Treatment": [],
                "Options, risks, complications": [
                  {
                    "text": "Early or localized diseaseNo consensus for optimal therapeutic approachOptions includeActive surveillance/observation (particularly children)Involved field (or site) radiation therapyCombination chemotherapy advocated by some",
                    "sub_points": [
                      "No consensus for optimal therapeutic approach",
                      "Options includeActive surveillance/observation (particularly children)Involved field (or site) radiation therapyCombination chemotherapy advocated by some",
                      "Active surveillance/observation (particularly children)",
                      "Involved field (or site) radiation therapy",
                      "Combination chemotherapy advocated by some"
                    ]
                  },
                  {
                    "text": "Advanced stage diseaseCombination chemotherapyAdriamycin, (doxorubicin), bleomycin, vinblastine, dacarbazine (ABVD)Rituximab (R) may be combined with ABVDRecent data suggest that R-CHOP may be better than ABVDCHOP = cyclophosphamide, hydroxydaunorubicin (doxorubicin), oncovin (vincristine), prednisone",
                    "sub_points": [
                      "Combination chemotherapyAdriamycin, (doxorubicin), bleomycin, vinblastine, dacarbazine (ABVD)Rituximab (R) may be combined with ABVD",
                      "Adriamycin, (doxorubicin), bleomycin, vinblastine, dacarbazine (ABVD)",
                      "Rituximab (R) may be combined with ABVD",
                      "Recent data suggest that R-CHOP may be better than ABVDCHOP = cyclophosphamide, hydroxydaunorubicin (doxorubicin), oncovin (vincristine), prednisone",
                      "CHOP = cyclophosphamide, hydroxydaunorubicin (doxorubicin), oncovin (vincristine), prednisone"
                    ]
                  }
                ],
                "Drugs": [
                  {
                    "text": "Recommended regimen: ABVD"
                  },
                  {
                    "text": "Rituximab (anti-CD20) monoclonal antibody often usedAs part of upfront regimen or for refractory disease",
                    "sub_points": [
                      "As part of upfront regimen or for refractory disease"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "10-year survival > 80%Better survival for patients with low- vs. high-stage diseasePatients with NLPHL have better survival than patients with CHL",
                    "sub_points": [
                      "Better survival for patients with low- vs. high-stage disease",
                      "Patients with NLPHL have better survival than patients with CHL"
                    ]
                  },
                  {
                    "text": "Transformation to DLBCL or THRLBCL often associated with poor prognosisBone marrow involvement associated with aggressive clinical behaviorPrognosis may not be impacted if LBCL localized and treated appropriately",
                    "sub_points": [
                      "Bone marrow involvement associated with aggressive clinical behavior",
                      "Prognosis may not be impacted if LBCL localized and treated appropriately"
                    ]
                  }
                ]
              },
              "IMAGING": {
                "Radiographic Findings": [
                  {
                    "text": "Peripheral lymphadenopathy"
                  },
                  {
                    "text": "NLPHL lesions are not FDG-PET avid"
                  }
                ]
              },
              "MACROSCOPIC": {
                "General Features": [
                  {
                    "text": "When excised, lymph node often large and multinodular"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Complete or partial effacement of lymph node architectureNodular or nodular and diffuse patternExpansile nodules composed mainly of small lymphocytes and epithelioid histiocytesReactive germinal centers uncommon in nodules (~ 15%)Absent or rare centrocytes or centroblasts within nodulesNodules larger than usual reactive lymphoid follicles",
                    "sub_points": [
                      "Nodular or nodular and diffuse pattern",
                      "Expansile nodules composed mainly of small lymphocytes and epithelioid histiocytesReactive germinal centers uncommon in nodules (~ 15%)Absent or rare centrocytes or centroblasts within nodules",
                      "Reactive germinal centers uncommon in nodules (~ 15%)",
                      "Absent or rare centrocytes or centroblasts within nodules",
                      "Nodules larger than usual reactive lymphoid follicles"
                    ]
                  },
                  {
                    "text": "LP cells large and scattered amongst inflammatory infiltrateRepresent ~ 1-2% of all cellsLP cells have variety of appearancesMultilobated with vesicular chromatin and multiple small nucleoli (\"popcorn\" cells)Multinucleated or mummified cellsLP cells can be round without multilobation",
                    "sub_points": [
                      "Represent ~ 1-2% of all cells",
                      "LP cells have variety of appearancesMultilobated with vesicular chromatin and multiple small nucleoli (\"popcorn\" cells)Multinucleated or mummified cellsLP cells can be round without multilobation",
                      "Multilobated with vesicular chromatin and multiple small nucleoli (\"popcorn\" cells)",
                      "Multinucleated or mummified cells",
                      "LP cells can be round without multilobation"
                    ]
                  },
                  {
                    "text": "Various architectural patterns have been described, designated A-FClassic nodular pattern most common (pattern A)Serpiginous nodular pattern (pattern B)Confluent irregular nodulesNodular with extranodular LP cells (pattern C)LP cells located outside B-cell-rich nodulesNodular pattern with T-cell-rich background (pattern D)Very few small B cells identified in tumor nodulesTHRLBCL-like (pattern E)Always associated with at least 1 nodule of NLPHLDiffuse areas indistinguishable from primary THRLBCLMost background lymphocytes are T cells and histiocytesAbsence of underlying follicular dendritic cell meshworksAssociated with B symptoms and higher clinical stageDiffuse, B cell rich (pattern F)Uncommon pattern (< 5% of cases)Most background lymphocytes are B cellsUnderlying follicular dendritic cell meshworks (+)Variant patterns C-F correlate with greater risk of recurrence",
                    "sub_points": [
                      "Classic nodular pattern most common (pattern A)",
                      "Serpiginous nodular pattern (pattern B)Confluent irregular nodules",
                      "Confluent irregular nodules",
                      "Nodular with extranodular LP cells (pattern C)LP cells located outside B-cell-rich nodules",
                      "LP cells located outside B-cell-rich nodules",
                      "Nodular pattern with T-cell-rich background (pattern D)Very few small B cells identified in tumor nodules",
                      "Very few small B cells identified in tumor nodules",
                      "THRLBCL-like (pattern E)Always associated with at least 1 nodule of NLPHLDiffuse areas indistinguishable from primary THRLBCLMost background lymphocytes are T cells and histiocytesAbsence of underlying follicular dendritic cell meshworksAssociated with B symptoms and higher clinical stage",
                      "Always associated with at least 1 nodule of NLPHL",
                      "Diffuse areas indistinguishable from primary THRLBCL",
                      "Most background lymphocytes are T cells and histiocytes",
                      "Absence of underlying follicular dendritic cell meshworks",
                      "Associated with B symptoms and higher clinical stage",
                      "Diffuse, B cell rich (pattern F)Uncommon pattern (< 5% of cases)Most background lymphocytes are B cellsUnderlying follicular dendritic cell meshworks (+)",
                      "Uncommon pattern (< 5% of cases)",
                      "Most background lymphocytes are B cells",
                      "Underlying follicular dendritic cell meshworks (+)",
                      "Variant patterns C-F correlate with greater risk of recurrence"
                    ]
                  },
                  {
                    "text": "Histiocytes may be epithelioid &/or form small granulomasMay form \"wreath\" around neoplastic nodules",
                    "sub_points": [
                      "May form \"wreath\" around neoplastic nodules"
                    ]
                  },
                  {
                    "text": "Features common in CHL and usually absent in NLPHLEosinophils, neutrophils, and plasma cells are unusualReed-Sternberg or Hodgkin (RS+H) cells absent or rareNecrosis rare; no fibrous bands around nodules",
                    "sub_points": [
                      "Eosinophils, neutrophils, and plasma cells are unusual",
                      "Reed-Sternberg or Hodgkin (RS+H) cells absent or rare",
                      "Necrosis rare; no fibrous bands around nodules"
                    ]
                  },
                  {
                    "text": "Residual/uninvolved lymph node in biopsy specimens of NLPHLReactive follicular hyperplasia is usually presentPTGC commonly presentCompression of uninvolved lymph node tissue by expansile tumor nodules",
                    "sub_points": [
                      "Reactive follicular hyperplasia is usually present",
                      "PTGC commonly present",
                      "Compression of uninvolved lymph node tissue by expansile tumor nodules"
                    ]
                  },
                  {
                    "text": "Recurrent/relapsed NLPHLDepletion of small lymphocytes, increased histiocytesFibrosis in up to 40% of cases with recurrenceDiffuse areas present; often increased large cells",
                    "sub_points": [
                      "Depletion of small lymphocytes, increased histiocytes",
                      "Fibrosis in up to 40% of cases with recurrence",
                      "Diffuse areas present; often increased large cells"
                    ]
                  }
                ],
                "Cytologic Features": [
                  {
                    "text": "Diagnosis of NLPHL difficult to establish in fine-needle aspirate specimensNodular architecture difficult to appreciate in smearsSmall lymphocytes, histiocytes, follicular dendritic cells (FDCs) and LP cells presentNo granulocytes or plasma cells",
                    "sub_points": [
                      "Nodular architecture difficult to appreciate in smears",
                      "Small lymphocytes, histiocytes, follicular dendritic cells (FDCs) and LP cells present",
                      "No granulocytes or plasma cells"
                    ]
                  }
                ],
                "Transformation of NLPHL to Large Cell Lymphoma": [
                  {
                    "text": "Large cell lymphoma may coexist with or follow NLPHLLarge cells may form sheets similar to de novo DLBCLDiffuse pattern and scattered large cells similar to de novo THRLBCLIncreased background CD8(+) T cells and histiocytes",
                    "sub_points": [
                      "Large cells may form sheets similar to de novo DLBCL",
                      "Diffuse pattern and scattered large cells similar to de novo THRLBCLIncreased background CD8(+) T cells and histiocytes",
                      "Increased background CD8(+) T cells and histiocytes"
                    ]
                  },
                  {
                    "text": "WHO classification recommends term THRLBCL-like transformation of NLPHLPatient has history of NLPHLBiopsy specimen shows diffuse neoplasm without nodular areas",
                    "sub_points": [
                      "Patient has history of NLPHL",
                      "Biopsy specimen shows diffuse neoplasm without nodular areas"
                    ]
                  },
                  {
                    "text": "Patients with THRLBCL-like transformation of NLPHL often haveAdvanced stage disease, includingEvidence of hepatosplenomegaly or splenomegalyBone marrow involvementHigh serum LDH or β-2-microglobulin levelsLytic bone lesions",
                    "sub_points": [
                      "Advanced stage disease, includingEvidence of hepatosplenomegaly or splenomegalyBone marrow involvementHigh serum LDH or β-2-microglobulin levelsLytic bone lesions",
                      "Evidence of hepatosplenomegaly or splenomegaly",
                      "Bone marrow involvement",
                      "High serum LDH or β-2-microglobulin levels",
                      "Lytic bone lesions"
                    ]
                  },
                  {
                    "text": "Patients with THRLBCL-like transformation of NLPHL may have better prognosis than patients with de novo THRLBCL"
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "LP cellsCD19(+), CD20(+), CD22(+), CD79a(+)pax-5(+), OCT-2(+), BOB1(+), PU.1(+)Ig light chain (+) (often restricted), J chain (+)CD40(+), CDw75/LN1(+), CD80(+), CD86(+)BCL-6(+), MEF2B(+), AID(+)CD45/LCA(+), CD45RA(+), Ki-67 (proliferation) highEMA(+) in ~ 50%; IgD(+) in 25-50%; MUM1(-)Pan-T-cell antigens (-), CD10(-), BCL-2(-), TARC(-)CD15(-) and CD30(-)CD30(+) LP cells reported in ~ 10% of casesCD15(+) LP cells in ~ 5% of cases; often at relapseEpstein-Barr virus (EBV)-LMP1(-)Rare (< 1%) cases of NLPHL with EBV(+) LP cells reported in developed countries",
                    "sub_points": [
                      "CD19(+), CD20(+), CD22(+), CD79a(+)",
                      "pax-5(+), OCT-2(+), BOB1(+), PU.1(+)",
                      "Ig light chain (+) (often restricted), J chain (+)",
                      "CD40(+), CDw75/LN1(+), CD80(+), CD86(+)",
                      "BCL-6(+), MEF2B(+), AID(+)",
                      "CD45/LCA(+), CD45RA(+), Ki-67 (proliferation) high",
                      "EMA(+) in ~ 50%; IgD(+) in 25-50%; MUM1(-)",
                      "Pan-T-cell antigens (-), CD10(-), BCL-2(-), TARC(-)",
                      "CD15(-) and CD30(-)CD30(+) LP cells reported in ~ 10% of casesCD15(+) LP cells in ~ 5% of cases; often at relapse",
                      "CD30(+) LP cells reported in ~ 10% of cases",
                      "CD15(+) LP cells in ~ 5% of cases; often at relapse",
                      "Epstein-Barr virus (EBV)-LMP1(-)Rare (< 1%) cases of NLPHL with EBV(+) LP cells reported in developed countries",
                      "Rare (< 1%) cases of NLPHL with EBV(+) LP cells reported in developed countries"
                    ]
                  },
                  {
                    "text": "Background inflammatory infiltrateSmall lymphocytes are mixture of B and T cellsB cellsCD19(+), CD20(+), CD22(+), CD23(+), BCL-2(+)pax-5(+), OCT-2(+), IgM(+), IgD(+)CD21(±), CD38(+), CD71(+)CD10(-), BCL-6(-)T cellsCD2(+), CD3(+), CD5(+), CD7(+)CD45RO(+), CD69(+), BCL-2(+), CD38(-), CD71(-)T follicular helper (TFH) cells are increasedCD4(+), PD-1(+), CD57(+)CD10(+), BCL-6(+), ICOS(-)Form \"rosettes\" around LP cells in most casesFDC networks are present in nodular areasCD21(+), CD23(+), &/or CD35(+)HistiocytesCD68(+), CD163(+)ImmunoblastsCD30(+); common in NLPHL cases",
                    "sub_points": [
                      "Small lymphocytes are mixture of B and T cells",
                      "B cellsCD19(+), CD20(+), CD22(+), CD23(+), BCL-2(+)pax-5(+), OCT-2(+), IgM(+), IgD(+)CD21(±), CD38(+), CD71(+)CD10(-), BCL-6(-)",
                      "CD19(+), CD20(+), CD22(+), CD23(+), BCL-2(+)",
                      "pax-5(+), OCT-2(+), IgM(+), IgD(+)",
                      "CD21(±), CD38(+), CD71(+)",
                      "CD10(-), BCL-6(-)",
                      "T cellsCD2(+), CD3(+), CD5(+), CD7(+)CD45RO(+), CD69(+), BCL-2(+), CD38(-), CD71(-)",
                      "CD2(+), CD3(+), CD5(+), CD7(+)",
                      "CD45RO(+), CD69(+), BCL-2(+), CD38(-), CD71(-)",
                      "T follicular helper (TFH) cells are increasedCD4(+), PD-1(+), CD57(+)CD10(+), BCL-6(+), ICOS(-)Form \"rosettes\" around LP cells in most cases",
                      "CD4(+), PD-1(+), CD57(+)",
                      "CD10(+), BCL-6(+), ICOS(-)",
                      "Form \"rosettes\" around LP cells in most cases",
                      "FDC networks are present in nodular areasCD21(+), CD23(+), &/or CD35(+)",
                      "CD21(+), CD23(+), &/or CD35(+)",
                      "HistiocytesCD68(+), CD163(+)",
                      "CD68(+), CD163(+)",
                      "ImmunoblastsCD30(+); common in NLPHL cases",
                      "CD30(+); common in NLPHL cases"
                    ]
                  },
                  {
                    "text": "Recurrent/relapsed NLPHLDepletion of background small B cellsDecreased or absent FDCsIncreased numbers of background T cells and histiocytes",
                    "sub_points": [
                      "Depletion of background small B cells",
                      "Decreased or absent FDCs",
                      "Increased numbers of background T cells and histiocytes"
                    ]
                  }
                ],
                "Flow Cytometry": [
                  {
                    "text": "Polytypic B cells"
                  },
                  {
                    "text": "T cells with normal immunophenotypeCD4(+)/CD8(+) T cells ~ 1-2% in ~ 50% of cases",
                    "sub_points": [
                      "CD4(+)/CD8(+) T cells ~ 1-2% in ~ 50% of cases"
                    ]
                  },
                  {
                    "text": "Large neoplastic cells lost or overlooked in routine flow cytometric analysis"
                  }
                ],
                "In Situ Hybridization": [
                  {
                    "text": "EBV-encoded RNA EBER(-) in LP cells< 1% of NLPHL cases EBER(+) in Western countriesEBV may be more common in LP cells of NLPHL in developing countries",
                    "sub_points": [
                      "< 1% of NLPHL cases EBER(+) in Western countries",
                      "EBV may be more common in LP cells of NLPHL in developing countries"
                    ]
                  }
                ],
                "PCR": [
                  {
                    "text": "ClonalIGH,IGK, orIGLrearrangements when using single-cell PCR analysis"
                  },
                  {
                    "text": "Frequent somatic mutations ofIGHvariable regionEvidence of ongoing somatic mutations",
                    "sub_points": [
                      "Evidence of ongoing somatic mutations"
                    ]
                  },
                  {
                    "text": "Rearrangements not detectable using PCR or Southern blot methods and whole biopsy specimens"
                  }
                ],
                "Genetic Testing": [
                  {
                    "text": "Conventional cytogenetics/FISH analysis showComplex structural karyotypic aberrations are common3q27/BCL6rearrangements in ~ 50% of casesIGHmost common partnerOther partners: Chromosome loci 2q23; 5q31, 6q22, 9q22, and 17p21",
                    "sub_points": [
                      "Complex structural karyotypic aberrations are common",
                      "3q27/BCL6rearrangements in ~ 50% of casesIGHmost common partnerOther partners: Chromosome loci 2q23; 5q31, 6q22, 9q22, and 17p21",
                      "IGHmost common partner",
                      "Other partners: Chromosome loci 2q23; 5q31, 6q22, 9q22, and 17p21"
                    ]
                  }
                ],
                "Array Comparative Genomic Hybridization": [
                  {
                    "text": "30-60% of cases show gains or losses of chromosomesGains: Chromosomes 1, 2q, 3, 4q, 5q, 6, 8q, 11q, 12q, XGains ofREL,BCL6,JAK2Loss: Chromosome 17",
                    "sub_points": [
                      "Gains: Chromosomes 1, 2q, 3, 4q, 5q, 6, 8q, 11q, 12q, XGains ofREL,BCL6,JAK2",
                      "Gains ofREL,BCL6,JAK2",
                      "Loss: Chromosome 17"
                    ]
                  }
                ],
                "Gene Mutational Analysis": [
                  {
                    "text": "Cases of transformed NLPHL show mutations involvingPI3K pathway:SGK1,IL7R,PIK3R1,ZFP36L1,EIF3ANF-KB pathway:CARD11,JUNB,BCL10,NFKBIA,TNFAIP3Chromatin modifying genes:EP300,CREBBP,TET2NOTCH2mutations also common",
                    "sub_points": [
                      "PI3K pathway:SGK1,IL7R,PIK3R1,ZFP36L1,EIF3A",
                      "NF-KB pathway:CARD11,JUNB,BCL10,NFKBIA,TNFAIP3",
                      "Chromatin modifying genes:EP300,CREBBP,TET2",
                      "NOTCH2mutations also common"
                    ]
                  },
                  {
                    "text": "TP53and immune surveillance genes are rarely mutated"
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Lymphocyte-Rich Classic Hodgkin Lymphoma, Nodular Variant": [
                  {
                    "text": "Often, nodular pattern is prominent, mimicking NLPHL"
                  },
                  {
                    "text": "Nodules composed of prominent mantle zones with atrophic or absent germinal centers"
                  },
                  {
                    "text": "RS+H cells in mantle zones of enlarged lymphoid follicles"
                  },
                  {
                    "text": "Immunophenotype of RS+H cellsCD15(±), CD30(+), pax-5 (weak +), EBV(±), CD45/LCA(-)",
                    "sub_points": [
                      "CD15(±), CD30(+), pax-5 (weak +), EBV(±), CD45/LCA(-)"
                    ]
                  }
                ],
                "T-Cell/Histiocyte-Rich Large B-Cell Lymphoma": [
                  {
                    "text": "Affects older adult patients; rare in children and adolescents"
                  },
                  {
                    "text": "B symptoms, high stage, and elevated serum LDH levels"
                  },
                  {
                    "text": "Diffuse growth pattern"
                  },
                  {
                    "text": "Not associated with reactive follicular hyperplasia or PTGC"
                  },
                  {
                    "text": "Large neoplastic cells represent < 10% of all cells in specimen"
                  },
                  {
                    "text": "ImmunophenotypeLarge cells of B-cell lineagePan-B-cell antigens (+), CD45/LCA(+), CD30(±)CD10(±), BCL-2(±), BCL-6(±)Background reactive cells are T cells and histiocytesT cells can have a CD8(+) TIA1(+) cytotoxic phenotypeT-cells also can be CD4(+)Usually CD57(+)/BCL-6(+) T-cells are absent",
                    "sub_points": [
                      "Large cells of B-cell lineagePan-B-cell antigens (+), CD45/LCA(+), CD30(±)CD10(±), BCL-2(±), BCL-6(±)",
                      "Pan-B-cell antigens (+), CD45/LCA(+), CD30(±)",
                      "CD10(±), BCL-2(±), BCL-6(±)",
                      "Background reactive cells are T cells and histiocytesT cells can have a CD8(+) TIA1(+) cytotoxic phenotypeT-cells also can be CD4(+)Usually CD57(+)/BCL-6(+) T-cells are absent",
                      "T cells can have a CD8(+) TIA1(+) cytotoxic phenotype",
                      "T-cells also can be CD4(+)",
                      "Usually CD57(+)/BCL-6(+) T-cells are absent"
                    ]
                  }
                ],
                "Angioimmunoblastic T-Cell Lymphoma": [
                  {
                    "text": "Large number of TFH cells in NLPHL can mimic angioimmunoblastic T-cell lymphoma (AITL)"
                  },
                  {
                    "text": "Patients with AITL usually present withWidespread lymphadenopathy ± extranodal diseaseEvidence of immune dysregulation &/or autoimmunityAutoimmune hemolytic anemia, hypergammaglobulinemiaImmune complexes (+), rheumatoid factor (+), anti-smooth muscle antibodies (+)",
                    "sub_points": [
                      "Widespread lymphadenopathy ± extranodal disease",
                      "Evidence of immune dysregulation &/or autoimmunityAutoimmune hemolytic anemia, hypergammaglobulinemiaImmune complexes (+), rheumatoid factor (+), anti-smooth muscle antibodies (+)",
                      "Autoimmune hemolytic anemia, hypergammaglobulinemia",
                      "Immune complexes (+), rheumatoid factor (+), anti-smooth muscle antibodies (+)"
                    ]
                  },
                  {
                    "text": "Immunophenotypic analysis often shows an aberrant T-cell immunophenotypeCD10(+), surface CD3(-), CD4(+), CD8(-)",
                    "sub_points": [
                      "CD10(+), surface CD3(-), CD4(+), CD8(-)"
                    ]
                  },
                  {
                    "text": "Molecular studies show monoclonalTCRgene rearrangements"
                  }
                ],
                "Progressive Transformation of Germinal Centers": [
                  {
                    "text": "Rare patients can present with florid syndrome with generalized lymphadenopathy"
                  },
                  {
                    "text": "Lymph node architecture preserved"
                  },
                  {
                    "text": "Markedly enlarged lymphoid follicles (often 3-4x larger than typical reactive follicles)Follicles extensively colonized by mantle zone lymphocytesUnderlying FDC networks are distorted",
                    "sub_points": [
                      "Follicles extensively colonized by mantle zone lymphocytes",
                      "Underlying FDC networks are distorted"
                    ]
                  },
                  {
                    "text": "LP cells are absent"
                  },
                  {
                    "text": "CD4(+), CD8(+) T cells increased (similar to NLPHL)"
                  }
                ],
                "Follicular Lymphoma": [
                  {
                    "text": "Usually stage IV disease on presentation"
                  },
                  {
                    "text": "Neoplastic follicles are smaller than those seen in NLPHLNeoplastic follicles common in perinodal soft tissue",
                    "sub_points": [
                      "Neoplastic follicles common in perinodal soft tissue"
                    ]
                  },
                  {
                    "text": "Abundant neoplastic small and large centrocytes and large centroblasts"
                  },
                  {
                    "text": "ImmunophenotypeCD10(+), BCL-6(+), BCL-2(+)Flow cytometry demonstrates monotypic B lymphocytes, CD10(+)",
                    "sub_points": [
                      "CD10(+), BCL-6(+), BCL-2(+)",
                      "Flow cytometry demonstrates monotypic B lymphocytes, CD10(+)"
                    ]
                  }
                ],
                "Nodular Sclerosis Hodgkin Lymphoma": [
                  {
                    "text": "~ 20% of cases of NLPHL associated with fibrosisInguinal region common siteFibrosis more often present at time of relapse",
                    "sub_points": [
                      "Inguinal region common site",
                      "Fibrosis more often present at time of relapse"
                    ]
                  },
                  {
                    "text": "Fibrosis in NLPHL not birefringent/polarizableFibrous bands surrounding nodules not present",
                    "sub_points": [
                      "Fibrous bands surrounding nodules not present"
                    ]
                  },
                  {
                    "text": "ImmunophenotypeRS+H cells: CD15(±), CD30(+), EBV(±), CD45/LCA(-)",
                    "sub_points": [
                      "RS+H cells: CD15(±), CD30(+), EBV(±), CD45/LCA(-)"
                    ]
                  }
                ],
                "Reactive Follicular Hyperplasia": [
                  {
                    "text": "Lymph node architecture preserved"
                  },
                  {
                    "text": "Well-defined germinal centers with polarization and distinct mantle zonesSmall and large centrocytes and centroblastsTingible body macrophages usually abundant",
                    "sub_points": [
                      "Small and large centrocytes and centroblasts",
                      "Tingible body macrophages usually abundant"
                    ]
                  },
                  {
                    "text": "Reactive lymphoid follicles smaller than nodules of NLPHL"
                  }
                ],
                "Viral Lymphadenopathies": [
                  {
                    "text": "TFH cells can be increased similar to NLPHL"
                  },
                  {
                    "text": "Patients with viral illness usuallyAcute clinical symptomsOften young patientsUsually resolves without recurrence",
                    "sub_points": [
                      "Acute clinical symptoms",
                      "Often young patients",
                      "Usually resolves without recurrence"
                    ]
                  },
                  {
                    "text": "Follicles can be prominent; interfollicular areas also often expandedImmunoblasts can be numerous in interfollicular areas",
                    "sub_points": [
                      "Immunoblasts can be numerous in interfollicular areas"
                    ]
                  },
                  {
                    "text": "Large cells mark with T- and B-cell markers"
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "Expansile nodules with LP cells in reactive cellular backgroundNodules larger than reactive lymphoid folliclesLP cells represent 1-2% of all cells within nodulesBackground: Small lymphocytes, epithelioid histiocytes, and FDCsPattern can be purely nodular or nodular and diffuse",
                    "sub_points": [
                      "Nodules larger than reactive lymphoid folliclesLP cells represent 1-2% of all cells within nodulesBackground: Small lymphocytes, epithelioid histiocytes, and FDCs",
                      "LP cells represent 1-2% of all cells within nodules",
                      "Background: Small lymphocytes, epithelioid histiocytes, and FDCs",
                      "Pattern can be purely nodular or nodular and diffuse"
                    ]
                  },
                  {
                    "text": "Transformation to LBCL in 10-15% of cases"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Nodal Follicular Lymphoma": {
            "name": "Nodal Follicular Lymphoma",
            "url": "https://app.pathprimer.com/document/67dbb30e-8327-4468-8b1e-10a5a106b602/lesson/1754477f-a4b1-4ec8-b223-cd1eb29cbd87",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "B-cell neoplasm composed of germinal center B cells"
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "t(14;18)/IGH::BCL2is likely initiating event in FLOccurs in bone marrow as mistake in V-D-JBCL-2 is antiapoptotic and confers survival advantage",
                    "sub_points": [
                      "Occurs in bone marrow as mistake in V-D-J",
                      "BCL-2 is antiapoptotic and confers survival advantage"
                    ]
                  },
                  {
                    "text": "t(14;18) is insufficient to induce lymphomagenesis by itselfAdditional genetic hits occur in germinal centers due to mistakes inPhysiologic somatic hypermutationImmunoglobulin gene class switch recombinationResult in gene mutations",
                    "sub_points": [
                      "Additional genetic hits occur in germinal centers due to mistakes inPhysiologic somatic hypermutationImmunoglobulin gene class switch recombinationResult in gene mutations",
                      "Physiologic somatic hypermutation",
                      "Immunoglobulin gene class switch recombination",
                      "Result in gene mutations"
                    ]
                  },
                  {
                    "text": "End result is development of FL"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "~ 25% of non-Hodgkin lymphoma in USA and Europe"
                  },
                  {
                    "text": "Usually disseminated at presentationGeneralized lymphadenopathyLiver, spleen, bone marrow",
                    "sub_points": [
                      "Generalized lymphadenopathy",
                      "Liver, spleen, bone marrow"
                    ]
                  },
                  {
                    "text": "Overall 10-year survival is up to ~ 80%"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Partial or complete effacement of lymph node architectureClosely packed neoplastic folliclesFollicles fairly uniform in size and shape",
                    "sub_points": [
                      "Closely packed neoplastic follicles",
                      "Follicles fairly uniform in size and shape"
                    ]
                  },
                  {
                    "text": "Variable mixture of centrocytes and centroblastsGrade based on number of centroblasts per HPFGrade has prognostic and therapeutic importance",
                    "sub_points": [
                      "Grade based on number of centroblasts per HPF",
                      "Grade has prognostic and therapeutic importance"
                    ]
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "B-cell antigens (+), CD10(+), BCL-2(+), BCL-6(+)"
                  },
                  {
                    "text": "BCL-2(+) in 85-90% of FL grades 1-2; 50% in FL grade 3"
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "Reactive follicular hyperplasia"
                  },
                  {
                    "text": "Nodal marginal zone lymphoma"
                  },
                  {
                    "text": "Mantle cell lymphoma"
                  },
                  {
                    "text": "Nodular lymphocyte-predominant Hodgkin lymphoma"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Follicular lymphoma (FL)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Centroblastic/centrocytic lymphoma (Kiel classification)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "B-cell neoplasm composed of germinal center B cells (centrocytes and centroblasts)Follicular, follicular and diffuse, and diffuse growth patterns",
                    "sub_points": [
                      "Follicular, follicular and diffuse, and diffuse growth patterns"
                    ]
                  },
                  {
                    "text": "5th edition of World Health Organization encompassesClassic FL (cFL): BCL-2 rearranged; CD10(+)Grading G1, G2, and G3A considered nonmandatory in reportingQuestionable clinical significance and demonstrated lack of reproducibility of gradingFollicular large B-cell lymphoma (FLBL) replaces FL G3BBehavior closer to diffuse large B-cell lymphoma (DLBCL) than to cFLFL with uncommon featuresBlastoid or large centrocytic morphologyDiffuse FLIn situ follicular B-cell neoplasm (ISFN)Pediatric-type FLDuodenal-type FL",
                    "sub_points": [
                      "Classic FL (cFL): BCL-2 rearranged; CD10(+)Grading G1, G2, and G3A considered nonmandatory in reportingQuestionable clinical significance and demonstrated lack of reproducibility of grading",
                      "Grading G1, G2, and G3A considered nonmandatory in reportingQuestionable clinical significance and demonstrated lack of reproducibility of grading",
                      "Questionable clinical significance and demonstrated lack of reproducibility of grading",
                      "Follicular large B-cell lymphoma (FLBL) replaces FL G3BBehavior closer to diffuse large B-cell lymphoma (DLBCL) than to cFL",
                      "Behavior closer to diffuse large B-cell lymphoma (DLBCL) than to cFL",
                      "FL with uncommon featuresBlastoid or large centrocytic morphologyDiffuse FL",
                      "Blastoid or large centrocytic morphology",
                      "Diffuse FL",
                      "In situ follicular B-cell neoplasm (ISFN)",
                      "Pediatric-type FL",
                      "Duodenal-type FL"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "t(14;18)(q32;q21) Leads to Overexpression ofBCL2in Classic Follicular Lymphoma": [
                  {
                    "text": "t(14;18)/IGH::BCL2is likely initiating event in cFLOccurs in bone marrow as mistake in variable-diversity-joining (V-D-J)t(14;18) is insufficient to induce lymphomagenesis by itselfBCL-2 is antiapoptotic and confers survival advantageIGH::BCL2(+) cells in blood of ~ 50% of healthy individuals at very low levelsIGH::BCL2(+) cells circulate, entering and exiting germinal centersAdditional genetic hits occur in germinal centers as result of mistakes inPhysiologic hypermutation and class switch recombinationResult in gene mutations that eventually lead to cFLTranslocation results fromDouble-strand break at immunoglobulin-heavy locus due to defective RAG-mediated VDJ recombinationBreak atBCL2locus due to inherent fragility at CpG sites",
                    "sub_points": [
                      "Occurs in bone marrow as mistake in variable-diversity-joining (V-D-J)",
                      "t(14;18) is insufficient to induce lymphomagenesis by itselfBCL-2 is antiapoptotic and confers survival advantageIGH::BCL2(+) cells in blood of ~ 50% of healthy individuals at very low levels",
                      "BCL-2 is antiapoptotic and confers survival advantage",
                      "IGH::BCL2(+) cells in blood of ~ 50% of healthy individuals at very low levels",
                      "IGH::BCL2(+) cells circulate, entering and exiting germinal centers",
                      "Additional genetic hits occur in germinal centers as result of mistakes inPhysiologic hypermutation and class switch recombinationResult in gene mutations that eventually lead to cFL",
                      "Physiologic hypermutation and class switch recombination",
                      "Result in gene mutations that eventually lead to cFL",
                      "Translocation results fromDouble-strand break at immunoglobulin-heavy locus due to defective RAG-mediated VDJ recombinationBreak atBCL2locus due to inherent fragility at CpG sites",
                      "Double-strand break at immunoglobulin-heavy locus due to defective RAG-mediated VDJ recombination",
                      "Break atBCL2locus due to inherent fragility at CpG sites"
                    ]
                  }
                ],
                "Imbalance of Other Proteins Involved in Apoptosis": [
                  {
                    "text": "Overexpression of cell death-suppressor proteins BCL-xL and MCL1"
                  },
                  {
                    "text": "Decreased expression of cell death-promoting proteins BAX and BAD"
                  },
                  {
                    "text": "Overexpression of inhibitors of apoptosis proteins"
                  }
                ],
                "Multiple Genetic Mutations": [
                  {
                    "text": "Secondary abnormalities involved in development of FL"
                  },
                  {
                    "text": "Epigenetic mutations are commonMutations of methyltransferases or histone acetylasesKMT2D(MLL2),EZH2,EP300,MEF2B",
                    "sub_points": [
                      "Mutations of methyltransferases or histone acetylasesKMT2D(MLL2),EZH2,EP300,MEF2B",
                      "KMT2D(MLL2),EZH2,EP300,MEF2B"
                    ]
                  }
                ],
                "Tumor Microenvironment": [
                  {
                    "text": "Affects clinical behavior and prognosis of patients with FL"
                  },
                  {
                    "text": "CD40L(+) T cells in secondary follicles inhibit FL cell death"
                  },
                  {
                    "text": "Follicular dendritic cells, macrophages, and T-helper lymphocytes contribute to environment to support FL survival"
                  },
                  {
                    "text": "Cytokines IL-4, IL-21 provide growth and survival signaling"
                  },
                  {
                    "text": "Prognostic role of immune cells of tumor microenvironment is controversial"
                  }
                ],
                "Germline Susceptibility": [
                  {
                    "text": "Genotypic analysis has identified novel susceptibility locus at 6p21.3Contains single gene, chromosome 6 open reading frame 15 (C6orf15)",
                    "sub_points": [
                      "Contains single gene, chromosome 6 open reading frame 15 (C6orf15)"
                    ]
                  },
                  {
                    "text": "4x increased lymphoma risk in 1st-degree relatives of patients with FL"
                  },
                  {
                    "text": "Association of single nucleotide polymorphisms of estrogen receptor gene with reduced risk of FL"
                  }
                ],
                "Gene Expression Profiling": [
                  {
                    "text": "Initial study from Leukemia/Lymphoma Molecular Profiling Project showedHost response (microenvironment) in FLs has prognostic importance2 gene expression profiles: Immune response (IR)1 and IR2IR1: Good prognosis: Genes related to T cells and macrophagesIR2: Poor prognosis: Genes related to monocytes and dendritic cells",
                    "sub_points": [
                      "Host response (microenvironment) in FLs has prognostic importance",
                      "2 gene expression profiles: Immune response (IR)1 and IR2IR1: Good prognosis: Genes related to T cells and macrophagesIR2: Poor prognosis: Genes related to monocytes and dendritic cells",
                      "IR1: Good prognosis: Genes related to T cells and macrophages",
                      "IR2: Poor prognosis: Genes related to monocytes and dendritic cells"
                    ]
                  },
                  {
                    "text": "Recent studies have shown thatFL with t(14;18)(q32;q21) are enriched for germinal center B-cell genesFL without t(14;18)(q32;q21) are enriched for activated B-cell-like, NF-κB, and proliferation genes",
                    "sub_points": [
                      "FL with t(14;18)(q32;q21) are enriched for germinal center B-cell genes",
                      "FL without t(14;18)(q32;q21) are enriched for activated B-cell-like, NF-κB, and proliferation genes"
                    ]
                  },
                  {
                    "text": "Other groups have shown importance of host response but emphasize different gene signatures"
                  }
                ],
                "Occupational Exposure": [
                  {
                    "text": "Possible role of exposure to dichlorodiphenyldichloroethylene (DDE), polychlorinated biphenyls, and solvents"
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "~ 25% of non-Hodgkin lymphoma in USA and Europe2nd most common lymphoma diagnosed in USA",
                    "sub_points": [
                      "2nd most common lymphoma diagnosed in USA"
                    ]
                  },
                  {
                    "text": "Uncommon in Asia and resource-limited countries"
                  }
                ],
                "Age": [
                  {
                    "text": "Median: 59-65 years"
                  }
                ],
                "Sex": [
                  {
                    "text": "M:F = 1.0:1.7Pediatric cases occur mostly in boys",
                    "sub_points": [
                      "Pediatric cases occur mostly in boys"
                    ]
                  }
                ],
                "Site": [
                  {
                    "text": "Cervical and inguinal lymph nodes are more frequently affected"
                  },
                  {
                    "text": "Commonly affected extranodal sitesBone marrow, spleen, liver, and peripheral blood",
                    "sub_points": [
                      "Bone marrow, spleen, liver, and peripheral blood"
                    ]
                  },
                  {
                    "text": "FL uncommonly arises at extranodal sitesSkin, thyroid gland, duodenum, testis",
                    "sub_points": [
                      "Skin, thyroid gland, duodenum, testis"
                    ]
                  }
                ],
                "Presentation": [
                  {
                    "text": "Generalized lymphadenopathy is common"
                  },
                  {
                    "text": "Almost always disseminated (stages III-IV) at diagnosis"
                  },
                  {
                    "text": "Patients are often asymptomaticConstitutional symptoms are uncommon",
                    "sub_points": [
                      "Constitutional symptoms are uncommon"
                    ]
                  }
                ],
                "Natural History": [
                  {
                    "text": "Indolent clinical course but frequent relapses or refractory disease"
                  },
                  {
                    "text": "Some cases progress to DLBCL"
                  },
                  {
                    "text": "Cases of FL occurring in children rarely progress to higher stage or to DLBCL"
                  }
                ],
                "Treatment": [
                  {
                    "text": "\"Watch and wait\" for asymptomatic patients or patients with low tumor burdenRituximab as single agent is also optionHigh tumor burden is defined by presence of ≥ 1 of following criteriaLargest involved lymph node ≥ 7 cm in diameter3 nodes in 3 distinct areas with each lymph node ≥ 3 cm in diameterPresence of systemic symptomsSymptomatic splenomegalyAscites or pleural effusionCytopenias (neutrophil < 1 g/L or platelets < 100 g/L)Circulating lymphoma cells (> 5 g/L)",
                    "sub_points": [
                      "Rituximab as single agent is also option",
                      "High tumor burden is defined by presence of ≥ 1 of following criteriaLargest involved lymph node ≥ 7 cm in diameter3 nodes in 3 distinct areas with each lymph node ≥ 3 cm in diameterPresence of systemic symptomsSymptomatic splenomegalyAscites or pleural effusionCytopenias (neutrophil < 1 g/L or platelets < 100 g/L)Circulating lymphoma cells (> 5 g/L)",
                      "Largest involved lymph node ≥ 7 cm in diameter",
                      "3 nodes in 3 distinct areas with each lymph node ≥ 3 cm in diameter",
                      "Presence of systemic symptoms",
                      "Symptomatic splenomegaly",
                      "Ascites or pleural effusion",
                      "Cytopenias (neutrophil < 1 g/L or platelets < 100 g/L)",
                      "Circulating lymphoma cells (> 5 g/L)"
                    ]
                  },
                  {
                    "text": "Chemotherapy is currently used upfront more often for patients with stages III-IV diseaseRituximab, cyclophosphamide, Adriamycin (doxorubicin), vincristine, and prednisone (R-CHOP)Rituximab, cyclophosphamide, vincristine, and prednisone (R-CVP)Rituximab and lenalidomide (R2)",
                    "sub_points": [
                      "Rituximab, cyclophosphamide, Adriamycin (doxorubicin), vincristine, and prednisone (R-CHOP)",
                      "Rituximab, cyclophosphamide, vincristine, and prednisone (R-CVP)",
                      "Rituximab and lenalidomide (R2)"
                    ]
                  },
                  {
                    "text": "Radiation has value for subset of patients with stage I and II disease"
                  },
                  {
                    "text": "For patients with resistant disease, combination chemotherapy; stem cell transplant for subset of patients with good performance status"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "10-year overall survival (OS) is 60-80% for patients with cFL stage I or stage IIMedian OS: ~ 240 months",
                    "sub_points": [
                      "Median OS: ~ 240 months"
                    ]
                  },
                  {
                    "text": "Adverse prognostic factors are summarized in FL International Prognostic Index 2 (FLIPI-2)Low (0), intermediate (2), and high (≥ 3) riskAge > 60 yearsLargest involved lymph node > 6 cmBone marrow involvement (BMI)Hemoglobin < 12 g/dLHigh serum β-2-microglobulin",
                    "sub_points": [
                      "Low (0), intermediate (2), and high (≥ 3) riskAge > 60 yearsLargest involved lymph node > 6 cmBone marrow involvement (BMI)Hemoglobin < 12 g/dLHigh serum β-2-microglobulin",
                      "Age > 60 years",
                      "Largest involved lymph node > 6 cm",
                      "Bone marrow involvement (BMI)",
                      "Hemoglobin < 12 g/dL",
                      "High serum β-2-microglobulin"
                    ]
                  },
                  {
                    "text": "FLIPI-2 prognostic model stratifies patients into different prognostic risk groupsModel developed in era post rituximab using prospective analysis",
                    "sub_points": [
                      "Model developed in era post rituximab using prospective analysis"
                    ]
                  },
                  {
                    "text": "FLIPI-2 combined with gene mutations (m7-FLIPI) is promising"
                  },
                  {
                    "text": "Progression or relapse of FL within 2 years (POD24) after frontline chemoimmunotherapy is associated with poor outcomes in patients treated with R-CHOPRisk factors for POD24Male sexPoor performance statusHigh FLIPI scoreElevated β-2-microglobulin",
                    "sub_points": [
                      "Risk factors for POD24Male sexPoor performance statusHigh FLIPI scoreElevated β-2-microglobulin",
                      "Male sex",
                      "Poor performance status",
                      "High FLIPI score",
                      "Elevated β-2-microglobulin"
                    ]
                  },
                  {
                    "text": "PRIMA prognostic index (PRIMA-PI)Low risk: β-2-microglobulin < 3 mg/L and no BMIIntermediate risk: β-2-microglobulin < 3 mg/L and BMIHigh risk: β-2-microglobulin ≥ 3 mg/L",
                    "sub_points": [
                      "Low risk: β-2-microglobulin < 3 mg/L and no BMI",
                      "Intermediate risk: β-2-microglobulin < 3 mg/L and BMI",
                      "High risk: β-2-microglobulin ≥ 3 mg/L"
                    ]
                  },
                  {
                    "text": "Pathologic adverse prognostic factors includeHigh histologic grade and diffuse areas > 25% with predominance of large cells (DLBCL)High proliferation index",
                    "sub_points": [
                      "High histologic grade and diffuse areas > 25% with predominance of large cells (DLBCL)",
                      "High proliferation index"
                    ]
                  },
                  {
                    "text": "Cytogenetic adverse prognostic factors includeComplex karyotypeDel6q25-27; del17p and mutations ofTP53",
                    "sub_points": [
                      "Complex karyotype",
                      "Del6q25-27; del17p and mutations ofTP53"
                    ]
                  }
                ]
              },
              "IMAGING": {
                "General Features": [
                  {
                    "text": "Widespread lymphadenopathy; often small lymph nodes"
                  }
                ]
              },
              "MACROSCOPIC": {
                "General Features": [
                  {
                    "text": "Replacement of nodal parenchyma by \"fish-flesh\" tumor; ± nodularity"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Lymph node in cFLPartial or complete effacement of architectureClosely packed neoplastic follicles, fairly uniform in size and shapeDistributed in cortex, medulla, and perinodal fibroadipose tissueFollicles usually poorly circumscribed with faint or absent mantle zonesCracking artifact may surround neoplastic folliclesNeoplastic follicles are composed of centrocytes and centroblastsCells randomly distributed throughout individual follicles without polarityInfrequent mitoses and absent or scanty tingible body macrophagesCentrocytes: Small to large with angulated or twisted nuclei, dense chromatin, scant cytoplasmCentroblasts: Large cells with oval nuclei, vesicular chromatin, 1-3 nucleoli, and moderate cytoplasmDiffuse areas ± sclerosisMore frequent in mesenteric and retroperitoneal lymph nodesScattered interfollicular neoplastic lymphocytes are not considered diffuse growth patternFollicular dendritic cell meshworks are absent in diffuse areasRecommended nomenclature: DLBCL with FL",
                    "sub_points": [
                      "Partial or complete effacement of architecture",
                      "Closely packed neoplastic follicles, fairly uniform in size and shapeDistributed in cortex, medulla, and perinodal fibroadipose tissue",
                      "Distributed in cortex, medulla, and perinodal fibroadipose tissue",
                      "Follicles usually poorly circumscribed with faint or absent mantle zones",
                      "Cracking artifact may surround neoplastic follicles",
                      "Neoplastic follicles are composed of centrocytes and centroblastsCells randomly distributed throughout individual follicles without polarityInfrequent mitoses and absent or scanty tingible body macrophagesCentrocytes: Small to large with angulated or twisted nuclei, dense chromatin, scant cytoplasmCentroblasts: Large cells with oval nuclei, vesicular chromatin, 1-3 nucleoli, and moderate cytoplasm",
                      "Cells randomly distributed throughout individual follicles without polarity",
                      "Infrequent mitoses and absent or scanty tingible body macrophages",
                      "Centrocytes: Small to large with angulated or twisted nuclei, dense chromatin, scant cytoplasm",
                      "Centroblasts: Large cells with oval nuclei, vesicular chromatin, 1-3 nucleoli, and moderate cytoplasm",
                      "Diffuse areas ± sclerosisMore frequent in mesenteric and retroperitoneal lymph nodesScattered interfollicular neoplastic lymphocytes are not considered diffuse growth patternFollicular dendritic cell meshworks are absent in diffuse areasRecommended nomenclature: DLBCL with FL",
                      "More frequent in mesenteric and retroperitoneal lymph nodes",
                      "Scattered interfollicular neoplastic lymphocytes are not considered diffuse growth pattern",
                      "Follicular dendritic cell meshworks are absent in diffuse areas",
                      "Recommended nomenclature: DLBCL with FL"
                    ]
                  },
                  {
                    "text": "Bone marrowParatrabecular aggregates of centrocytes and, less frequently, centroblastsAspirate smears may have scant lymphoma cells or are negativeInterstitial &/or diffuse patterns in advanced disease",
                    "sub_points": [
                      "Paratrabecular aggregates of centrocytes and, less frequently, centroblastsAspirate smears may have scant lymphoma cells or are negative",
                      "Aspirate smears may have scant lymphoma cells or are negative",
                      "Interstitial &/or diffuse patterns in advanced disease"
                    ]
                  },
                  {
                    "text": "Peripheral bloodMarked leukemic involvement in 5-10% of patientsNeoplastic cells have highly indented nuclei and are known as buttock cellsLow-level involvement is detected by molecular methods in ~ 90% of patients",
                    "sub_points": [
                      "Marked leukemic involvement in 5-10% of patients",
                      "Neoplastic cells have highly indented nuclei and are known as buttock cells",
                      "Low-level involvement is detected by molecular methods in ~ 90% of patients"
                    ]
                  },
                  {
                    "text": "LiverPortal tracts are preferentially involvedLarge mass lesions usually indicate transformation to DLBCL",
                    "sub_points": [
                      "Portal tracts are preferentially involved",
                      "Large mass lesions usually indicate transformation to DLBCL"
                    ]
                  },
                  {
                    "text": "SpleenPreferential involvement of white pulp",
                    "sub_points": [
                      "Preferential involvement of white pulp"
                    ]
                  }
                ],
                "Cytologic Features": [
                  {
                    "text": "Diagnosis of FL can be established by fine-needle aspiration with ancillary supportIn smears, aggregates of cells bound by follicular dendritic cells and admixed with reactive small lymphocytesVariable mixture of centrocytes and centroblastsUsually, absence of tingible body macrophages",
                    "sub_points": [
                      "In smears, aggregates of cells bound by follicular dendritic cells and admixed with reactive small lymphocytes",
                      "Variable mixture of centrocytes and centroblasts",
                      "Usually, absence of tingible body macrophages"
                    ]
                  }
                ],
                "Grading of Classic Follicular Lymphoma": [
                  {
                    "text": "Grading is not considered mandatory in 5th edition of WHO classificationOverlapping clinical outcomes among G1, G2, and G3ASmall centrocytes with variable numbers of large centroblastsSystem is based on mean number of centroblasts per HPFCount 10 HPF and divide by 10Lack of reproducibility of histologic grading",
                    "sub_points": [
                      "Overlapping clinical outcomes among G1, G2, and G3ASmall centrocytes with variable numbers of large centroblasts",
                      "Small centrocytes with variable numbers of large centroblasts",
                      "System is based on mean number of centroblasts per HPFCount 10 HPF and divide by 10",
                      "Count 10 HPF and divide by 10",
                      "Lack of reproducibility of histologic grading"
                    ]
                  },
                  {
                    "text": "Most reliably performed on lymph node biopsy specimens"
                  },
                  {
                    "text": "Grade 1: 0-5 centroblasts/HPF"
                  },
                  {
                    "text": "Grade 2: 6-15 centroblasts/HPF"
                  },
                  {
                    "text": "Grade 3: > 15 centroblasts/HPFGrade 3A: Centrocytes admixed with centroblastsPrognostic importance of grade 3A is debatableMany cases treated as grade 1/2",
                    "sub_points": [
                      "Grade 3A: Centrocytes admixed with centroblastsPrognostic importance of grade 3A is debatableMany cases treated as grade 1/2",
                      "Prognostic importance of grade 3A is debatableMany cases treated as grade 1/2",
                      "Many cases treated as grade 1/2"
                    ]
                  },
                  {
                    "text": "FLBL (formerly grade 3B): Centroblasts only with rare or no centrocytes"
                  },
                  {
                    "text": "Remember: Cutoff values are based on 40x objective and 18-mm FOV ocularMany microscopes have larger FOV ocular20-mm FOV ocular: Divide by 10 HPF and count by 1222-mm FOV ocular: Divide by 10 HPF and count by 15",
                    "sub_points": [
                      "Many microscopes have larger FOV ocular20-mm FOV ocular: Divide by 10 HPF and count by 1222-mm FOV ocular: Divide by 10 HPF and count by 15",
                      "20-mm FOV ocular: Divide by 10 HPF and count by 12",
                      "22-mm FOV ocular: Divide by 10 HPF and count by 15"
                    ]
                  },
                  {
                    "text": "WHO classification recommends lumping cases of FL 1-2 together as low gradeMinimal differences in outcome between patients with FL grade 1 vs. 2",
                    "sub_points": [
                      "Minimal differences in outcome between patients with FL grade 1 vs. 2"
                    ]
                  },
                  {
                    "text": "There is controversy in classifying FL grade 3B since it appears more similar to DLBCL than to FL grade 3A"
                  }
                ],
                "Histologic Discordance (Discrepant Histology) in Patients With Classic Follicular Lymphoma": [
                  {
                    "text": "cFL involving different lymph node groups may show different gradesOccurs in up to 1/3 of patients; detected in past by staging laparotomy",
                    "sub_points": [
                      "Occurs in up to 1/3 of patients; detected in past by staging laparotomy"
                    ]
                  },
                  {
                    "text": "Lymph node can be involved by grade 3A FL or DLBCL with bone marrow showing grade 1 cFLOccurs in 10-20% of patients with grade 3A cFL or DLBCLLow-grade BMI does not affect prognosis",
                    "sub_points": [
                      "Occurs in 10-20% of patients with grade 3A cFL or DLBCL",
                      "Low-grade BMI does not affect prognosis"
                    ]
                  }
                ],
                "Reporting Pattern in Classic Follicular Lymphoma": [
                  {
                    "text": "Most reliably performed on lymph node excisional biopsies"
                  },
                  {
                    "text": "Follicular: > 75% follicular"
                  },
                  {
                    "text": "Follicular and diffuse: 25-75% follicular"
                  },
                  {
                    "text": "Focally follicular: 1-25% follicular"
                  }
                ],
                "In Situ Follicular B-Cell Neoplasm (Formerly In Situ Follicular Lymphoma)": [
                  {
                    "text": "Lymph node with normal-size, widely spaced follicles of which subset has BCL-2(+) germinal centersBCL-2 expression by germinal centers is characteristically brightBCL-2(+) follicles have immunophenotype of cFL and t(14;18)(q32;q21)Using histologic criteria alone, diagnosis of FL can be difficult or not possible",
                    "sub_points": [
                      "BCL-2 expression by germinal centers is characteristically bright",
                      "BCL-2(+) follicles have immunophenotype of cFL and t(14;18)(q32;q21)",
                      "Using histologic criteria alone, diagnosis of FL can be difficult or not possible"
                    ]
                  },
                  {
                    "text": "Patients with ISFN mayHave cFL elsewhere simultaneously or develop cFL subsequentlyHave other types of non-Hodgkin lymphoma or Hodgkin lymphoma simultaneously or subsequentlyNot develop lymphoma on clinical follow-up",
                    "sub_points": [
                      "Have cFL elsewhere simultaneously or develop cFL subsequently",
                      "Have other types of non-Hodgkin lymphoma or Hodgkin lymphoma simultaneously or subsequently",
                      "Not develop lymphoma on clinical follow-up"
                    ]
                  },
                  {
                    "text": "To be distinguished from cFL with partial involvement of lymph node"
                  }
                ],
                "Follicular Large B-Cell Lymphoma (Formerly Follicular Lymphoma Grade 3B)": [
                  {
                    "text": "Lymphoid follicles composed of large immunoblasts"
                  },
                  {
                    "text": "Absent (or few) centrocytes in backgroundAssociated with diffuse pattern (FL grade 3B + DLBCL)Closely related to DLBCL",
                    "sub_points": [
                      "Associated with diffuse pattern (FL grade 3B + DLBCL)Closely related to DLBCL",
                      "Closely related to DLBCL"
                    ]
                  },
                  {
                    "text": "To be distinguished from FL G3A with diffuse areasPure follicular pattern",
                    "sub_points": [
                      "Pure follicular pattern"
                    ]
                  },
                  {
                    "text": "Usually require therapy similar to DLBCL"
                  }
                ],
                "Diffuse Follicular Lymphoma": [
                  {
                    "text": "a.k.a. FL with del(1p36)/TNFRSF14"
                  },
                  {
                    "text": "Entirely diffuse growth of small centrocytes with few or absent centroblastsOften minor, small follicles with regressive changes",
                    "sub_points": [
                      "Often minor, small follicles with regressive changes"
                    ]
                  },
                  {
                    "text": "CD10(+), CD23(+), BCL-6(+), BCL-2(+/-);IGH::BCL2(-)"
                  },
                  {
                    "text": "STAT6mutations"
                  },
                  {
                    "text": "Rare diagnosis; more common in core needle biopsy specimensExtensive sampling may reveal focal follicular pattern",
                    "sub_points": [
                      "Extensive sampling may reveal focal follicular pattern"
                    ]
                  }
                ],
                "Follicular Lymphoma, Pediatric Type": [
                  {
                    "text": "Predominantly affects children but can occur in adults"
                  },
                  {
                    "text": "Usually localized disease that involves neck lymph nodes"
                  },
                  {
                    "text": "Usually grade 3 with large follicles"
                  },
                  {
                    "text": "Most cases are BCL-2(-) and lack t(14;18)(q32;q21)/IGH::BCL2"
                  },
                  {
                    "text": "Patients usually have good prognosis without disease progressionSurgical excision is adequate therapy",
                    "sub_points": [
                      "Surgical excision is adequate therapy"
                    ]
                  }
                ],
                "Follicular Lymphoma Associated WithIRF4Rearrangement": [
                  {
                    "text": "Falls in spectrum of large B-cell lymphoma withIRF4rearrangementDiffuse and follicular, and diffuse more common than follicular only",
                    "sub_points": [
                      "Diffuse and follicular, and diffuse more common than follicular only"
                    ]
                  },
                  {
                    "text": "Occurs most often in children but can occur in adults"
                  },
                  {
                    "text": "Usually involves head and neck region; Waldeyer ring common"
                  },
                  {
                    "text": "Usually grade 3"
                  },
                  {
                    "text": "t(6;14)(p25;q32)/IGH::IRF4and MUM1/IRF4(+)"
                  },
                  {
                    "text": "Most cases lack t(14;18)(q32;q21)/IGH::BCL2; BCL-2(+/-)"
                  }
                ],
                "Low-Grade Follicular Lymphoma Associated With High Proliferation Rate": [
                  {
                    "text": "Usually grade 1 FL with proliferation rate > 50%Appears to behave as FL G3A",
                    "sub_points": [
                      "Appears to behave as FL G3A"
                    ]
                  }
                ],
                "Transformation of Follicular Lymphoma": [
                  {
                    "text": "Transformation to clinically aggressive B-cell lymphoma occurs in ~ 30% of patientsAssociated with rapid progression lymphadenopathy, extranodal disease (besides bone marrow), B symptoms, hypercalcemia, elevated LDH, high FLIPI score, and nonresponse to initial therapyAssociated with resistance to therapy and median survival ~ 1 yearAccounts for many disease-related deaths in FL patients",
                    "sub_points": [
                      "Associated with rapid progression lymphadenopathy, extranodal disease (besides bone marrow), B symptoms, hypercalcemia, elevated LDH, high FLIPI score, and nonresponse to initial therapy",
                      "Associated with resistance to therapy and median survival ~ 1 year",
                      "Accounts for many disease-related deaths in FL patients"
                    ]
                  },
                  {
                    "text": "Morphologic features at time of transformation most often resemble DLBCLOther uncommon types includeBurkitt lymphoma, plasmablastic lymphomaHigh-grade B-cell lymphoma",
                    "sub_points": [
                      "Other uncommon types includeBurkitt lymphoma, plasmablastic lymphomaHigh-grade B-cell lymphoma",
                      "Burkitt lymphoma, plasmablastic lymphoma",
                      "High-grade B-cell lymphoma"
                    ]
                  },
                  {
                    "text": "Genetic studies show multiple pathways involved in transformatione.g., inactivation ofTP53orCDKN2A;MYCactivation",
                    "sub_points": [
                      "e.g., inactivation ofTP53orCDKN2A;MYCactivation"
                    ]
                  }
                ],
                "Epstein-Barr Virus (+) Follicular Lymphoma": [
                  {
                    "text": "~ 2-3% of FL casesMost common scenario in older adults, attributable to senescence",
                    "sub_points": [
                      "Most common scenario in older adults, attributable to senescence"
                    ]
                  },
                  {
                    "text": "Any grade, but more cases are grade 3"
                  },
                  {
                    "text": "Epstein-Barr virus (EBV) latency type II [EBER(+), LMP1(+), EBNA2(-)]"
                  },
                  {
                    "text": "EBV(+) FL associates with higher clinical stage"
                  }
                ],
                "Follicular Lymphoma WithMYCRearrangement": [
                  {
                    "text": "< 5% of FL cases"
                  },
                  {
                    "text": "Appears as subclones, thus only subset of lymphoma cells are MYC(+)"
                  },
                  {
                    "text": "Occasionally \"double hit\" withBCL2rearrangementNot as aggressive as high-grade B-cell lymphoma withMYC and BCL2rearrangement",
                    "sub_points": [
                      "Not as aggressive as high-grade B-cell lymphoma withMYC and BCL2rearrangement"
                    ]
                  }
                ],
                "Unusual Variants": [
                  {
                    "text": "FL with plasmacytic differentiationFocal plasmacytic differentiation can occur rarely in FL, intrafollicular or interfollicularExtreme degrees with intracytoplasmic inclusions can appear as signet-ring cells",
                    "sub_points": [
                      "Focal plasmacytic differentiation can occur rarely in FL, intrafollicular or interfollicular",
                      "Extreme degrees with intracytoplasmic inclusions can appear as signet-ring cells"
                    ]
                  },
                  {
                    "text": "FL with marginal zone differentiationMonocytoid cells with clear cytoplasm at periphery of neoplastic folliclesHas been correlated with poor prognosis",
                    "sub_points": [
                      "Monocytoid cells with clear cytoplasm at periphery of neoplastic follicles",
                      "Has been correlated with poor prognosis"
                    ]
                  },
                  {
                    "text": "Floral variantMantle zone lymphocytes penetrate into neoplastic follicles, imparting irregular shapesBetter highlighted with follicular dendritic cell markers, e.g., CD21Often grade 3 but also FL grade 1 or 2",
                    "sub_points": [
                      "Mantle zone lymphocytes penetrate into neoplastic follicles, imparting irregular shapes",
                      "Better highlighted with follicular dendritic cell markers, e.g., CD21",
                      "Often grade 3 but also FL grade 1 or 2"
                    ]
                  },
                  {
                    "text": "FL with Castleman-like featuresHistologically reminiscent of hyaline-vascular Castleman diseaseIncreased vascularity of interfollicular areasPhenotypically and prognostically similar to conventional (classic) nodal FL",
                    "sub_points": [
                      "Histologically reminiscent of hyaline-vascular Castleman disease",
                      "Increased vascularity of interfollicular areas",
                      "Phenotypically and prognostically similar to conventional (classic) nodal FL"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "Monotypic surface Ig(+); pan-B-cell markers (+)"
                  },
                  {
                    "text": "CD10(+), BCL-6(+), HGAL(+), LMO2(+)CD10 and BCL-6 more brightly expressed within follicles than in interfollicular regions",
                    "sub_points": [
                      "CD10 and BCL-6 more brightly expressed within follicles than in interfollicular regions"
                    ]
                  },
                  {
                    "text": "BCL-2(+) in 85-90% of FL grade 1 and grade 2; 50% in FL grade 3BCL-2(+) is useful to distinguish FL from reactive germinal centers that are BCL-2(-)",
                    "sub_points": [
                      "BCL-2(+) is useful to distinguish FL from reactive germinal centers that are BCL-2(-)"
                    ]
                  },
                  {
                    "text": "Ki-67 proliferation rate correlates with grading of FLUsually low proliferation rate in grade 1 FL and high in grade 3 FLProliferation rate not used for grading FL",
                    "sub_points": [
                      "Usually low proliferation rate in grade 1 FL and high in grade 3 FL",
                      "Proliferation rate not used for grading FL"
                    ]
                  },
                  {
                    "text": "Follicular dendritic cell meshworks are present in folliclesVariable expression of CD21, CD23, or CD35",
                    "sub_points": [
                      "Variable expression of CD21, CD23, or CD35"
                    ]
                  },
                  {
                    "text": "CD23(+/-), IRF-4/MUM1(-)"
                  },
                  {
                    "text": "FLs are usually CD5(-), CD43(-)Small subset (< 5%) can be CD5(+) or CD43(+)",
                    "sub_points": [
                      "Small subset (< 5%) can be CD5(+) or CD43(+)"
                    ]
                  },
                  {
                    "text": "CD2(-), CD3(-), CD4(-), CD7(-), CD8(-)"
                  },
                  {
                    "text": "Proliferation rate of FLs assessed by Ki-67Percentage of Ki-67(+) cells correlates with gradeMost low-grade FLs show low proliferation rate (< 20%)High-grade FLs show moderate to high proliferation rate (> 40%)~ 20% of low-grade FLs have moderate/high proliferation rate (> 40%)These FLs appear to behave more aggressively, similar to grade 3A FL",
                    "sub_points": [
                      "Percentage of Ki-67(+) cells correlates with gradeMost low-grade FLs show low proliferation rate (< 20%)High-grade FLs show moderate to high proliferation rate (> 40%)",
                      "Most low-grade FLs show low proliferation rate (< 20%)",
                      "High-grade FLs show moderate to high proliferation rate (> 40%)",
                      "~ 20% of low-grade FLs have moderate/high proliferation rate (> 40%)These FLs appear to behave more aggressively, similar to grade 3A FL",
                      "These FLs appear to behave more aggressively, similar to grade 3A FL"
                    ]
                  },
                  {
                    "text": "Grade 3 FLsCan be CD10(-), BCL-2(-), IRF-4/MUM1(+)",
                    "sub_points": [
                      "Can be CD10(-), BCL-2(-), IRF-4/MUM1(+)"
                    ]
                  }
                ],
                "In Situ Hybridization": [
                  {
                    "text": "FISH can detectIGH::BCL2in up to 90% of FL casesResults in overexpression of BCL-2Large probes can detect multiple breakpoints",
                    "sub_points": [
                      "Results in overexpression of BCL-2",
                      "Large probes can detect multiple breakpoints"
                    ]
                  }
                ],
                "PCR": [
                  {
                    "text": "Monoclonal immunoglobulin (Ig) heavy and light chain gene rearrangementsVariable regions of Ig genes undergo extensive mutationsMutations can cause false-negative results when using PCRMultiple primer sets are therefore required for analysis",
                    "sub_points": [
                      "Variable regions of Ig genes undergo extensive mutations",
                      "Mutations can cause false-negative results when using PCRMultiple primer sets are therefore required for analysis",
                      "Multiple primer sets are therefore required for analysis"
                    ]
                  },
                  {
                    "text": "There are multiple breakpoints inBCL2that must be individually assessed by PCRMajor breakpoint cluster region: ~ 50-60% of FLMinor breakpoint cluster region: ~ 5-10% of FLsIntermediate cluster region: ~ 10-15% of FL; 5' breakpoint region: ~ 5% of FLOther low-frequency breakpoints exist",
                    "sub_points": [
                      "Major breakpoint cluster region: ~ 50-60% of FL",
                      "Minor breakpoint cluster region: ~ 5-10% of FLs",
                      "Intermediate cluster region: ~ 10-15% of FL; 5' breakpoint region: ~ 5% of FL",
                      "Other low-frequency breakpoints exist"
                    ]
                  }
                ],
                "Genetic Testing": [
                  {
                    "text": "IGH::BCL2/t(14;18)(q32;q21) in 80-90% of FLJuxtaposesBCL2at 18q21 adjacent toIGHon derivative chromosome 14",
                    "sub_points": [
                      "JuxtaposesBCL2at 18q21 adjacent toIGHon derivative chromosome 14"
                    ]
                  },
                  {
                    "text": "BCL6/3q27 rearrangement in ~ 15% of FL"
                  },
                  {
                    "text": "Complex karyotype correlates with poorer prognosis"
                  },
                  {
                    "text": "Inactivation of tumor suppressor genesTP53,CDKN2AOccurs in FLs but more common at time of histologic transformation",
                    "sub_points": [
                      "Occurs in FLs but more common at time of histologic transformation"
                    ]
                  },
                  {
                    "text": "MYCrearrangement is often associated with transformation to DLBCL"
                  }
                ],
                "Cytogenetics": [
                  {
                    "text": "~ 90% of FLs have abnormalities detected by comparative genomic hybridizationGains: 1, 2p15, 6p, 7p, 7q, 8q, 12q, 18p, 18q, XLosses: 1p36, 3q, 6q, 9p, 10q, 11q, 13q, 17p",
                    "sub_points": [
                      "Gains: 1, 2p15, 6p, 7p, 7q, 8q, 12q, 18p, 18q, X",
                      "Losses: 1p36, 3q, 6q, 9p, 10q, 11q, 13q, 17p"
                    ]
                  },
                  {
                    "text": "Abnormalities associated with worse prognosisGain of chromosome XLoss of 6q or 9p21",
                    "sub_points": [
                      "Gain of chromosome X",
                      "Loss of 6q or 9p21"
                    ]
                  },
                  {
                    "text": "Abnormalities associated with transformation to DLBCLGains of 2, 3q, and 5",
                    "sub_points": [
                      "Gains of 2, 3q, and 5"
                    ]
                  },
                  {
                    "text": "Trisomy 21 is associated with shorter OS and PFS"
                  }
                ],
                "Gene Mutations": [
                  {
                    "text": "Common chromatin modifying gene mutationsKMT2D,CREBBP, andEZH2",
                    "sub_points": [
                      "KMT2D,CREBBP, andEZH2"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Reactive Follicular Hyperplasia": [
                  {
                    "text": "Children and young adults; patients with autoimmune disease"
                  },
                  {
                    "text": "Features that favor reactive follicular hyperplasia over FLLymph node architecture preserved with follicles mostly in cortexWidely spaced follicles that vary in size and shapePolarization of germinal centers into light and dark zonesFrequent mitoses and tingible body macrophages in germinal centersSharply demarcated mantle zonesNo evidence of monoclonality",
                    "sub_points": [
                      "Lymph node architecture preserved with follicles mostly in cortex",
                      "Widely spaced follicles that vary in size and shape",
                      "Polarization of germinal centers into light and dark zones",
                      "Frequent mitoses and tingible body macrophages in germinal centers",
                      "Sharply demarcated mantle zones",
                      "No evidence of monoclonality"
                    ]
                  }
                ],
                "Nodal Marginal Zone Lymphoma": [
                  {
                    "text": "Partial effacement of lymph node architecture with marginal zone expansion"
                  },
                  {
                    "text": "Neoplastic small lymphocytes, lymphocytes with monocytoid nuclei, and large cellsNeoplastic lymphocytes frequently colonize germinal centers",
                    "sub_points": [
                      "Neoplastic lymphocytes frequently colonize germinal centers"
                    ]
                  },
                  {
                    "text": "ImmunophenotypeNo evidence of t(14;18)(q32;q21)",
                    "sub_points": [
                      "No evidence of t(14;18)(q32;q21)"
                    ]
                  },
                  {
                    "text": "CD5(-), CD10(-), Cyclin-D1(+), BCL-6(-)"
                  },
                  {
                    "text": "Monotypic B-cell population; BCL-2(+)"
                  }
                ],
                "Mantle Cell Lymphoma": [
                  {
                    "text": "Nodular or mantle zone patterns of mantle cell lymphoma can resemble low-grade FL"
                  },
                  {
                    "text": "Mantle cell lymphoma (MCL) cells are small with irregular nuclear contours; no centroblasts"
                  },
                  {
                    "text": "Hyalinized blood vessels and histiocytes with eosinophilic cytoplasm are common"
                  },
                  {
                    "text": "ImmunophenotypeOccasional CD10 expression may mimic FL",
                    "sub_points": [
                      "Occasional CD10 expression may mimic FL"
                    ]
                  },
                  {
                    "text": "Monotypic B cell; CD5(+), CD43(+), Cyclin-D1(+)"
                  },
                  {
                    "text": "t(11;14)(q13;q32)/CCND1::IGH"
                  }
                ],
                "Nodular Lymphocyte-Predominant Hodgkin Lymphoma": [
                  {
                    "text": "Large, vaguely circumscribed nodules"
                  },
                  {
                    "text": "Most cells in nodules are small round lymphocytesAdmixed with fewer lymphocyte-predominant (LP) cells",
                    "sub_points": [
                      "Admixed with fewer lymphocyte-predominant (LP) cells"
                    ]
                  },
                  {
                    "text": "LP cells are CD20(+), CD45(+), CD10(-), BCL-2(-), OCT2(+)"
                  },
                  {
                    "text": "Small cells in tumor nodules are mostly reactive B lymphocytes"
                  },
                  {
                    "text": "CD4(+) and CD57(+) T cells commonly form rosettes around LP cells"
                  }
                ],
                "Progressive Transformation of Germinal Centers": [
                  {
                    "text": "Nodules are 3-5x larger than background reactive follicles"
                  },
                  {
                    "text": "Mantle zone small lymphocytes infiltrate and disrupt germinal centers"
                  },
                  {
                    "text": "No evidence of monoclonality"
                  }
                ],
                "Lymphocyte-Rich Classic Hodgkin Lymphoma": [
                  {
                    "text": "Large nodules with eccentric germinal centers"
                  },
                  {
                    "text": "Nodules are composed of small round lymphocytes and Reed-Sternberg and Hodgkin (RS+H) cellsRS+H cells are CD15(+/-), CD30(+), CD45/LCA(-)",
                    "sub_points": [
                      "RS+H cells are CD15(+/-), CD30(+), CD45/LCA(-)"
                    ]
                  },
                  {
                    "text": "No evidence of monoclonality"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Nodal Marginal Zone Lymphoma": {
            "name": "Nodal Marginal Zone Lymphoma",
            "url": "https://app.pathprimer.com/document/e70a56f5-a81c-4214-a5f8-6af0fa6c5126/lesson/1754477f-a4b1-4ec8-b223-cd1eb29cbd87",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "NMZL involves lymph nodesNo evidence of extranodal or splenic disease",
                    "sub_points": [
                      "No evidence of extranodal or splenic disease"
                    ]
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Median age: 60-70 years"
                  },
                  {
                    "text": "Lymphadenopathy, localized or widespreadPeripheral lymph nodes most often involved",
                    "sub_points": [
                      "Peripheral lymph nodes most often involved"
                    ]
                  },
                  {
                    "text": "Systemic B symptoms in 1/3 of patients"
                  },
                  {
                    "text": "Bone marrow involvement in 30-40%"
                  },
                  {
                    "text": "Elevated serum lactate dehydrogenase (LDH) in 15-50%; paraprotein in ~ 30%"
                  },
                  {
                    "text": "Leukemic involvement (leukocytosis) is uncommon"
                  },
                  {
                    "text": "Patients with NMZL usually have indolent clinical course"
                  },
                  {
                    "text": "No consensus for optimal therapeutic approach"
                  },
                  {
                    "text": "Transformation to diffuse large B-cell lymphoma can occur5-15% of patients; associated with poorer prognosis",
                    "sub_points": [
                      "5-15% of patients; associated with poorer prognosis"
                    ]
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Lymph nodes can be partially or completely effacedLymphoma can selectively involve marginal zones",
                    "sub_points": [
                      "Lymphoma can selectively involve marginal zones"
                    ]
                  },
                  {
                    "text": "Heterogeneous cellular compositionLymphoma composed of small cells and few large cellsSmall cells can be monocytoid or centrocyte-likePlasmacytic differentiation (+/-)",
                    "sub_points": [
                      "Lymphoma composed of small cells and few large cells",
                      "Small cells can be monocytoid or centrocyte-like",
                      "Plasmacytic differentiation (+/-)"
                    ]
                  },
                  {
                    "text": "Residual follicles often hyperplastic"
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "Monotypic Ig (bright +) and pan-B-cell markers (+)"
                  },
                  {
                    "text": "CD43(+) in ~ 50%; CD5(-) or, rarely, (dim +)"
                  },
                  {
                    "text": "CD10(-), BCL-6(-)"
                  },
                  {
                    "text": "MonoclonalIGHrearrangements"
                  },
                  {
                    "text": "KMT2D(MLL2),PTPRD,NOTCH2, andKLF2mutationsPTPRDmutations appear to be unique to NMZL",
                    "sub_points": [
                      "PTPRDmutations appear to be unique to NMZL"
                    ]
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "Extranodal MZL draining into lymph nodes"
                  },
                  {
                    "text": "Lymphoplasmacytic lymphoma/Waldenström macroglobulinemia"
                  },
                  {
                    "text": "Follicular lymphoma"
                  },
                  {
                    "text": "Mantle cell lymphoma"
                  }
                ],
                "Diagnostic Checklist": [
                  {
                    "text": "Often pale appearance at low-power magnification"
                  },
                  {
                    "text": "Residual germinal centers surrounded by mantle zones"
                  },
                  {
                    "text": "Centrocyte-like &/or monocytoid cellsPlasmacytoid differentiation (+/-)",
                    "sub_points": [
                      "Plasmacytoid differentiation (+/-)"
                    ]
                  },
                  {
                    "text": "Scattered large cells present"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Nodal marginal zone lymphoma (NMZL)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Monocytoid B-cell lymphoma"
                  },
                  {
                    "text": "Parafollicular B-cell lymphoma"
                  }
                ],
                "Definitions": [
                  {
                    "text": "NMZL involves lymph nodes and resembles MZLs involving extranodal sites or spleenNo evidence of extranodal or splenic disease",
                    "sub_points": [
                      "No evidence of extranodal or splenic disease"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Infectious Agents": [
                  {
                    "text": "There is association between hepatitis C infection and NMZLAssociation most common in Italy",
                    "sub_points": [
                      "Association most common in Italy"
                    ]
                  }
                ],
                "Multifactorial Pathogenesis With Genetic Abnormalities": [
                  {
                    "text": "Antigen drive is likely involved in pathogenesisBased on biased use of IGH variable region genes",
                    "sub_points": [
                      "Based on biased use of IGH variable region genes"
                    ]
                  },
                  {
                    "text": "Trisomies of chromosomes 7, 8, and 18"
                  },
                  {
                    "text": "Common gene mutations includeKMT2D(MLL2) (~ 33%),PTPRD(~ 20%),NOTCH2(~ 20%),KLF2(~ 15-20%)PTPRDmutations appear to be unique to NMZL",
                    "sub_points": [
                      "KMT2D(MLL2) (~ 33%),PTPRD(~ 20%),NOTCH2(~ 20%),KLF2(~ 15-20%)",
                      "PTPRDmutations appear to be unique to NMZL"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "0.8 cases per 100,000 adults per year"
                  },
                  {
                    "text": "Frequency: 1-2% of all non-Hodgkin lymphomas"
                  }
                ],
                "Age": [
                  {
                    "text": "Median: 60-70 yearsCan occur in children",
                    "sub_points": [
                      "Can occur in children"
                    ]
                  }
                ],
                "Sex": [
                  {
                    "text": "Slight male predominance"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Lymphadenopathy, localized or widespreadPeripheral lymph nodes most often involvedCervical, axillary, inguinal/femoral regionsIn patients with localized disease, head and neck region often affected",
                    "sub_points": [
                      "Peripheral lymph nodes most often involvedCervical, axillary, inguinal/femoral regions",
                      "Cervical, axillary, inguinal/femoral regions",
                      "In patients with localized disease, head and neck region often affected"
                    ]
                  },
                  {
                    "text": "Systemic B symptoms in 1/3 of patients"
                  },
                  {
                    "text": "Bone marrow involvement in 30-40% of patients"
                  },
                  {
                    "text": "Leukemic phase of disease (elevated WBC) is uncommon"
                  }
                ],
                "Laboratory Tests": [
                  {
                    "text": "Elevated serum LDH in 15-50% of patients"
                  },
                  {
                    "text": "Monoclonal paraprotein in up to 1/3 of patientsUsually IgM and low level",
                    "sub_points": [
                      "Usually IgM and low level"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "No consensus for optimal therapeutic approach"
                  },
                  {
                    "text": "Low stage: Watchful waiting if asymptomatic"
                  },
                  {
                    "text": "High stage or symptomatic: Combination chemotherapy"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Patients with NMZL usually have indolent clinical courseAffected children have excellent long-term survival",
                    "sub_points": [
                      "Affected children have excellent long-term survival"
                    ]
                  },
                  {
                    "text": "Patients can undergo transformation to diffuse large B-cell lymphomaOccurs in 5-15% of patients, associated with poorer prognosis",
                    "sub_points": [
                      "Occurs in 5-15% of patients, associated with poorer prognosis"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Lymph nodes can be partially or completely effacedMarginal zones can be selectively expanded",
                    "sub_points": [
                      "Marginal zones can be selectively expanded"
                    ]
                  },
                  {
                    "text": "Heterogeneous cellular compositionMost cells are small with variably irregular nuclear contours (centrocyte-like)Cells may have abundant pale (monocytoid) cytoplasmPlasmacytoid lymphocytes or plasma cells can be numerousLarge cells always present in variable numbers",
                    "sub_points": [
                      "Most cells are small with variably irregular nuclear contours (centrocyte-like)Cells may have abundant pale (monocytoid) cytoplasmPlasmacytoid lymphocytes or plasma cells can be numerous",
                      "Cells may have abundant pale (monocytoid) cytoplasm",
                      "Plasmacytoid lymphocytes or plasma cells can be numerous",
                      "Large cells always present in variable numbers"
                    ]
                  },
                  {
                    "text": "Reactive follicles with hyperplastic germinal centers (GCs) are commonGCs often surrounded by residual mantle zoneGCs can be colonized by lymphoma cells",
                    "sub_points": [
                      "GCs often surrounded by residual mantle zone",
                      "GCs can be colonized by lymphoma cells"
                    ]
                  },
                  {
                    "text": "Bone marrowParatrabecular &/or nonparatrabecular lymphoid aggregates",
                    "sub_points": [
                      "Paratrabecular &/or nonparatrabecular lymphoid aggregates"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "Pan-B-cell antigens (+)"
                  },
                  {
                    "text": "BCL-2(+), CD43(+/-), monotypic cytoplasmic Ig(+/-)"
                  },
                  {
                    "text": "IRTA1(+/-), MNDA(+/-)Neither marker sensitive nor specific for NMZL",
                    "sub_points": [
                      "Neither marker sensitive nor specific for NMZL"
                    ]
                  },
                  {
                    "text": "CD5(-/+), CD10(-), BCL-6(-), LMO2(-), cyclin-D1 (-)"
                  },
                  {
                    "text": "CD3(-), CD21(-), CD23(-), CD35(-)"
                  },
                  {
                    "text": "Ki-67 variable 10-40%, p53(-)"
                  }
                ],
                "Flow Cytometry": [
                  {
                    "text": "Monotypic surface Ig(+)"
                  },
                  {
                    "text": "pan-B-cell antigens (bright +)CD19, CD20, CD22, CD79A",
                    "sub_points": [
                      "CD19, CD20, CD22, CD79A"
                    ]
                  },
                  {
                    "text": "CD200(+), CD43(+/-), CD23(-/+)"
                  },
                  {
                    "text": "Small subset of cases CD5(dim +); CD10(-), T-cell antigens (-)"
                  }
                ],
                "PCR": [
                  {
                    "text": "MonoclonalIGHrearrangements (+)"
                  },
                  {
                    "text": "IGHvariable regions mutated in ~ 70% of cases"
                  },
                  {
                    "text": "No evidence ofCCND1::IGHorIGH::BCL2;MYCusually not rearranged"
                  },
                  {
                    "text": "MYD88mutations uncommon (~ 5%)"
                  }
                ],
                "Conventional Cytogenetics": [
                  {
                    "text": "Rearrangements of chromosomes 1 and 3 in up to 50%"
                  },
                  {
                    "text": "Trisomies of chromosomes 7, 8, and 18"
                  }
                ],
                "Fluorescence In Situ Hybridization": [
                  {
                    "text": "Trisomy 3 in 50-60%"
                  },
                  {
                    "text": "Trisomy 7 and 18 in 20-40% of cases"
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Extranodal Marginal Zone Lymphoma": [
                  {
                    "text": "Extranodal sites: GI tract, lungs, salivary glands, etc."
                  },
                  {
                    "text": "Morphologically can resemble NMZL in lymph nodes"
                  },
                  {
                    "text": "Chromosomal translocations reported in subset of MALT lymphomast(11;18)(q21;q21)/BIRC3::MALT1t(14;18)(q32;q21)/MALT1::IGHt(3;14)(p14.1;q32)/FOXP1::IGHt(1;14)(p22;q32)/BCL10::IGH",
                    "sub_points": [
                      "t(11;18)(q21;q21)/BIRC3::MALT1",
                      "t(14;18)(q32;q21)/MALT1::IGH",
                      "t(3;14)(p14.1;q32)/FOXP1::IGH",
                      "t(1;14)(p22;q32)/BCL10::IGH"
                    ]
                  }
                ],
                "Lymphoplasmacytic Lymphoma": [
                  {
                    "text": "Can morphologically resemble NMZL in lymph nodes"
                  },
                  {
                    "text": "Most patients with lymphoplasmacytic lymphoma (LPL) also have Waldenström macroglobulinemia (WM)WM: Serum IgM paraprotein (+) and bone marrow (+)",
                    "sub_points": [
                      "WM: Serum IgM paraprotein (+) and bone marrow (+)"
                    ]
                  },
                  {
                    "text": "Immunophenotype of NMZL and LPL/WM overlap"
                  },
                  {
                    "text": "MYD88L265P mutation in ~ 90% LPL/WM vs. ~ 5% in NMZL"
                  }
                ],
                "Follicular Lymphoma": [
                  {
                    "text": "Most cases show follicular pattern; centrocytes and centroblasts"
                  },
                  {
                    "text": "NMZL colonizing follicles can closely resemble follicular lymphoma (FL)"
                  },
                  {
                    "text": "Rare FL cases exhibit monocytoid differentiation"
                  },
                  {
                    "text": "CD10(+), BCL-6(+); t(14;18)(q32;q21)/IGH::BCL2(+)"
                  }
                ],
                "Mantle Cell Lymphoma": [
                  {
                    "text": "Lymphoma cells are small and uniform; large cells rare"
                  },
                  {
                    "text": "Epithelioid histiocytes in ~ 75% of cases (unlike NMZL)"
                  },
                  {
                    "text": "CD5(+), cyclin-D1 (+), SOX-11(+), CD10(-), CD200(-),"
                  },
                  {
                    "text": "t(11;14)(q13;q32)/CCND1::IGH(+)"
                  }
                ],
                "CLL/SLL": [
                  {
                    "text": "Bone marrow, blood and lymph nodes common"
                  },
                  {
                    "text": "Proliferation centers are characteristic; usually seen in lymph nodes"
                  },
                  {
                    "text": "CD5(+), CD20 (dim +), CD23(+), CD200(+)"
                  }
                ],
                "Peripheral T-Cell Lymphoma": [
                  {
                    "text": "Interfollicular pattern can mimic marginal zone pattern of NMZL"
                  },
                  {
                    "text": "Eosinophils and histiocytes may be abundant in peripheral T-cell lymphoma"
                  },
                  {
                    "text": "Neoplastic cells express T-cell markers"
                  },
                  {
                    "text": "Monoclonal TCR rearrangements"
                  }
                ],
                "Reactive Lymphoid Hyperplasia": [
                  {
                    "text": "Preserved overall lymph node architecture"
                  },
                  {
                    "text": "Spectrum of reactive lymphoid cells"
                  },
                  {
                    "text": "No evidence of monotypic Ig or monoclonalIGHrearrangements; no translocations"
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Clinically Relevant Pathologic Features": [
                  {
                    "text": "Lymphadenopathy without extranodal or splenic involvement"
                  }
                ],
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "Residual lymphoid follicles with hyperplastic GCs and mantle zones surrounded by lymphoma"
                  },
                  {
                    "text": "Lymphoma cells can be centrocyte-like or monocytoidLarge cells present in variable number",
                    "sub_points": [
                      "Large cells present in variable number"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT Lymphoma)": {
            "name": "Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT Lymphoma)",
            "url": "https://app.pathprimer.com/document/d54bb6b4-8742-40a4-80aa-0b7595b1c956/lesson/1754477f-a4b1-4ec8-b223-cd1eb29cbd87",
            "content": {
              "KEY FACTS": {
                "Etiology/Pathogenesis": [
                  {
                    "text": "Infectious agents are implicated in pathogenesis of extranodal marginal zone lymphoma (EMZL)Chlamydia psittaci: Ocular adnexaBorrelia burgdorferi: Skin (Europe)Helicobacter pylori: StomachCampylobacter jejuni: IntestineAchromobacter xylosoxidans: LungHepatitis C: Various sites",
                    "sub_points": [
                      "Chlamydia psittaci: Ocular adnexa",
                      "Borrelia burgdorferi: Skin (Europe)",
                      "Helicobacter pylori: Stomach",
                      "Campylobacter jejuni: Intestine",
                      "Achromobacter xylosoxidans: Lung",
                      "Hepatitis C: Various sites"
                    ]
                  },
                  {
                    "text": "Autoimmune diseases are implicated in pathogenesis of EMZLSjögren syndrome: Salivary glands and lungHashimoto thyroiditis: Thyroid gland",
                    "sub_points": [
                      "Sjögren syndrome: Salivary glands and lung",
                      "Hashimoto thyroiditis: Thyroid gland"
                    ]
                  }
                ],
                "Microscopic": [
                  {
                    "text": "EMZLs share common featuresMarginal zone pattern surrounding reactive folliclesHeterogeneous cell population± lymphoepithelial lesions",
                    "sub_points": [
                      "Marginal zone pattern surrounding reactive follicles",
                      "Heterogeneous cell population",
                      "± lymphoepithelial lesions"
                    ]
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "CD20(+), CD22(+), CD79a(+), pax-5(+)"
                  },
                  {
                    "text": "Monotypic Ig(+), BCL-2(+), CD43(+/-), Ki-67 low"
                  },
                  {
                    "text": "Recurrent translocations identified in 30-40% of EMZLs"
                  },
                  {
                    "text": "Many translocations identified; 4 well-known and most characteristic affected sitesBIRC3::MALT1/t(11;18)(q21;q21): LungIGH::MALT1/t(14;18)(q32;q21): StomachFOXP1::IGH/t(3;14)(p14.1;q32): ThyroidBCL10::IGH/t(1;14)(p22;q32): Stomach",
                    "sub_points": [
                      "BIRC3::MALT1/t(11;18)(q21;q21): Lung",
                      "IGH::MALT1/t(14;18)(q32;q21): Stomach",
                      "FOXP1::IGH/t(3;14)(p14.1;q32): Thyroid",
                      "BCL10::IGH/t(1;14)(p22;q32): Stomach"
                    ]
                  },
                  {
                    "text": "NF-κB pathway activation in various MALT lymphomas"
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "Reactive inflammatory diseases"
                  },
                  {
                    "text": "Lymphoepithelial/myoepithelial sialadenitis"
                  },
                  {
                    "text": "Follicular lymphoma"
                  },
                  {
                    "text": "Mantle cell lymphoma"
                  },
                  {
                    "text": "Plasmacytoma"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Extranodal marginal zone lymphoma (EMZL) of mucosa-associated lymphoid tissue (MALT)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Low-grade B-cell lymphoma of MALT"
                  },
                  {
                    "text": "MALToma"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Entities under umbrella of marginal zone lymphoma (MZL)Nodal MZLSplenic MZLExtranodal MZL of MALT (MALT lymphoma)",
                    "sub_points": [
                      "Nodal MZL",
                      "Splenic MZL",
                      "Extranodal MZL of MALT (MALT lymphoma)"
                    ]
                  },
                  {
                    "text": "First described by Drs. Peter Isaacson and Dennis Wright in 1983"
                  },
                  {
                    "text": "Listed as distinct entity in revised European-American classification of lymphoid neoplasms (REAL) of 1994"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Infectious Agents": [
                  {
                    "text": "Play important role in pathogenesis of some types of EMZL"
                  },
                  {
                    "text": "Borrelia burgdorferiPrimary cutaneous MZLMore common in Europe",
                    "sub_points": [
                      "Primary cutaneous MZL",
                      "More common in Europe"
                    ]
                  },
                  {
                    "text": "Helicobacter pyloriandHelicobacter heilmanniiGastric MZLRole of cytotoxin-associated gene A (CagA) proteinActivation of intratumoral T-cells and BCL-2 family pathwayUpregulation of cyclin-A2 andPTENloss",
                    "sub_points": [
                      "Gastric MZL",
                      "Role of cytotoxin-associated gene A (CagA) protein",
                      "Activation of intratumoral T-cells and BCL-2 family pathway",
                      "Upregulation of cyclin-A2 andPTENloss"
                    ]
                  },
                  {
                    "text": "Campylobacter jejuniImmunoproliferative small intestinal disease; a.k.a. α-heavy chain disease",
                    "sub_points": [
                      "Immunoproliferative small intestinal disease; a.k.a. α-heavy chain disease"
                    ]
                  },
                  {
                    "text": "Achromobacter xylosoxidansLung MZL",
                    "sub_points": [
                      "Lung MZL"
                    ]
                  },
                  {
                    "text": "Hepatitis CMultiple sites",
                    "sub_points": [
                      "Multiple sites"
                    ]
                  },
                  {
                    "text": "Chlamydia psittaciOcular adnexa MZL",
                    "sub_points": [
                      "Ocular adnexa MZL"
                    ]
                  }
                ],
                "Autoimmune Disorders": [
                  {
                    "text": "2 autoimmune diseases have been implicated in pathogenesis of MALT lymphomasSjögren syndromeEMZLs of parotid gland, lung, and thymusHashimoto thyroiditisThyroid EMZL",
                    "sub_points": [
                      "Sjögren syndromeEMZLs of parotid gland, lung, and thymus",
                      "EMZLs of parotid gland, lung, and thymus",
                      "Hashimoto thyroiditisThyroid EMZL",
                      "Thyroid EMZL"
                    ]
                  }
                ],
                "Chromosomal Translocations and Somatic Hypermutations": [
                  {
                    "text": "Chromosomal translocationsIdentified in 30-40% of EMZLsResult in NF-κB pathway activationEnhanced cell survival, proliferation, and impaired apoptosis",
                    "sub_points": [
                      "Identified in 30-40% of EMZLs",
                      "Result in NF-κB pathway activationEnhanced cell survival, proliferation, and impaired apoptosis",
                      "Enhanced cell survival, proliferation, and impaired apoptosis"
                    ]
                  },
                  {
                    "text": "Somatic hypermutations and rearrangements of immunoglobulin VH (IGHV) genesDifferent mutated IGVH familiesVH1: Skin and salivary glandVH3: Stomach and lungVH4: Ocular adnexa, skin, and lungRecurrentCCR6somatic mutationsUsually associated with chronic antigen stimulation via infection or autoimmune diseaseCanonical and noncanonical activation of NF-κB",
                    "sub_points": [
                      "Different mutated IGVH familiesVH1: Skin and salivary glandVH3: Stomach and lungVH4: Ocular adnexa, skin, and lung",
                      "VH1: Skin and salivary gland",
                      "VH3: Stomach and lung",
                      "VH4: Ocular adnexa, skin, and lung",
                      "RecurrentCCR6somatic mutationsUsually associated with chronic antigen stimulation via infection or autoimmune disease",
                      "Usually associated with chronic antigen stimulation via infection or autoimmune disease",
                      "Canonical and noncanonical activation of NF-κB"
                    ]
                  }
                ],
                "EMZL Without Chromosomal Translocations": [
                  {
                    "text": "Possible role for antigen driveChronic antigen stimulation via infection or autoimmune diseaseLeads to accumulation of extranodal lymphoid tissuePolyclonal B cells evolve to oligoclonal and then monoclonal B-cell populations",
                    "sub_points": [
                      "Chronic antigen stimulation via infection or autoimmune diseaseLeads to accumulation of extranodal lymphoid tissuePolyclonal B cells evolve to oligoclonal and then monoclonal B-cell populations",
                      "Leads to accumulation of extranodal lymphoid tissue",
                      "Polyclonal B cells evolve to oligoclonal and then monoclonal B-cell populations"
                    ]
                  },
                  {
                    "text": "No central role for NF-κB activation"
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "7-8% of all B-cell non-Hodgkin lymphomas"
                  },
                  {
                    "text": "3rd most common type of non-Hodgkin lymphoma"
                  },
                  {
                    "text": "Most common type of MZL (~ 80% of all MZLs)"
                  }
                ],
                "Age": [
                  {
                    "text": "Median: ~ 60 years"
                  }
                ],
                "Sex": [
                  {
                    "text": "Slight female predominance"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Subset of patients are asymptomatic"
                  },
                  {
                    "text": "Indolent clinical course and symptoms are related to organ involved"
                  },
                  {
                    "text": "Usually present at early stage"
                  },
                  {
                    "text": "B symptoms are rare"
                  },
                  {
                    "text": "Distant lymphadenopathy and dissemination to other extranodal sites in ~ 25% of cases"
                  },
                  {
                    "text": "Orbit and ocular adnexaSwelling due to nodular or mass lesions usually located at lacrimal gland, conjunctiva, and orbital regionRare cases with bilateral involvement (< 20%)",
                    "sub_points": [
                      "Swelling due to nodular or mass lesions usually located at lacrimal gland, conjunctiva, and orbital region",
                      "Rare cases with bilateral involvement (< 20%)"
                    ]
                  },
                  {
                    "text": "Salivary glandsSwelling due to nodular or mass lesionsSymptoms related to Sjögren disease",
                    "sub_points": [
                      "Swelling due to nodular or mass lesions",
                      "Symptoms related to Sjögren disease"
                    ]
                  },
                  {
                    "text": "ThyroidSymptoms related to hypothyroidismPainless nodular or mass lesionsShortness of breath due to extrinsic compressionMay be associated with thyroid carcinoma",
                    "sub_points": [
                      "Symptoms related to hypothyroidism",
                      "Painless nodular or mass lesionsShortness of breath due to extrinsic compression",
                      "Shortness of breath due to extrinsic compression",
                      "May be associated with thyroid carcinoma"
                    ]
                  },
                  {
                    "text": "SkinSolitary or multifocal small nodulesUsually located at arms or trunkDisease should be confined to skin at diagnosis",
                    "sub_points": [
                      "Solitary or multifocal small nodulesUsually located at arms or trunk",
                      "Usually located at arms or trunk",
                      "Disease should be confined to skin at diagnosis"
                    ]
                  },
                  {
                    "text": "BreastAsymptomatic; usually detected at screening mammogramPalpable lesion",
                    "sub_points": [
                      "Asymptomatic; usually detected at screening mammogram",
                      "Palpable lesion"
                    ]
                  },
                  {
                    "text": "LungsAsymptomatic or presenting with cough and dyspneaSingle or multiple consolidations or nodules with no lobe predominanceLymph node involvement and pleural effusion are uncommon",
                    "sub_points": [
                      "Asymptomatic or presenting with cough and dyspnea",
                      "Single or multiple consolidations or nodules with no lobe predominance",
                      "Lymph node involvement and pleural effusion are uncommon"
                    ]
                  },
                  {
                    "text": "StomachAsymptomatic or presenting with anemia, bleeding, weight loss, and pain is commonComplications are rare at initial clinical presentationObstruction or perforation",
                    "sub_points": [
                      "Asymptomatic or presenting with anemia, bleeding, weight loss, and pain is common",
                      "Complications are rare at initial clinical presentationObstruction or perforation",
                      "Obstruction or perforation"
                    ]
                  },
                  {
                    "text": "IntestineDuodenal involvementAsymptomatic or dyspepsiaPolyp, flat depression, ulcer, or subepithelial lesionComplications in up to ~ 40% of casesColonic involvementAbdominal pain, weight loss, and mucoid stoolDiarrhea or constipationPolypoid, flat, or elevated single or multiple lesions",
                    "sub_points": [
                      "Duodenal involvementAsymptomatic or dyspepsiaPolyp, flat depression, ulcer, or subepithelial lesionComplications in up to ~ 40% of cases",
                      "Asymptomatic or dyspepsia",
                      "Polyp, flat depression, ulcer, or subepithelial lesion",
                      "Complications in up to ~ 40% of cases",
                      "Colonic involvementAbdominal pain, weight loss, and mucoid stoolDiarrhea or constipationPolypoid, flat, or elevated single or multiple lesions",
                      "Abdominal pain, weight loss, and mucoid stool",
                      "Diarrhea or constipation",
                      "Polypoid, flat, or elevated single or multiple lesions"
                    ]
                  }
                ],
                "Laboratory Tests": [
                  {
                    "text": "Changes in serum laboratory work in up to ~ 30% of cases↑ β-2-microglobulin, lactate dehydrogenase (LDH), or immunoglobulin paraproteinMonoclonal gammopathyAnemiaRelated to iron deficiency",
                    "sub_points": [
                      "↑ β-2-microglobulin, lactate dehydrogenase (LDH), or immunoglobulin paraprotein",
                      "Monoclonal gammopathy",
                      "AnemiaRelated to iron deficiency",
                      "Related to iron deficiency"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "Watch and wait strategyUsed for cases with single lesions in which excisional biopsy for diagnosis had negative marginsUsually not recommended for gastric cases",
                    "sub_points": [
                      "Used for cases with single lesions in which excisional biopsy for diagnosis had negative margins",
                      "Usually not recommended for gastric cases"
                    ]
                  },
                  {
                    "text": "Surgical excision ± radiation therapy ± chemotherapyInvolved field radiation therapy can be used on recurrent localized casesSingle agents for cases with low-grade histologyRituximab, lenalidomide, or fludarabineSystemic chemotherapyNo standard consensusIndicated for cases with evidence of disease progression or transformationR-CHOP: Rituximab combined with cyclophosphamide, doxorubicin, vincristine, and prednisoneIbrutinib, chimeric antigen receptor (CAR) T cells in relapsed or refractory cases",
                    "sub_points": [
                      "Involved field radiation therapy can be used on recurrent localized cases",
                      "Single agents for cases with low-grade histologyRituximab, lenalidomide, or fludarabine",
                      "Rituximab, lenalidomide, or fludarabine",
                      "Systemic chemotherapyNo standard consensusIndicated for cases with evidence of disease progression or transformationR-CHOP: Rituximab combined with cyclophosphamide, doxorubicin, vincristine, and prednisone",
                      "No standard consensus",
                      "Indicated for cases with evidence of disease progression or transformationR-CHOP: Rituximab combined with cyclophosphamide, doxorubicin, vincristine, and prednisone",
                      "R-CHOP: Rituximab combined with cyclophosphamide, doxorubicin, vincristine, and prednisone",
                      "Ibrutinib, chimeric antigen receptor (CAR) T cells in relapsed or refractory cases"
                    ]
                  },
                  {
                    "text": "Specific treatment according to siteOrbit and ocular adnexaAntibiotics to eradicateC. psittaciMay be considered upfront strategyMALT lymphoma often stage IE and is treated by radiation alone or combined with surgerySkinControversial use of antibioticsCeftriaxoneSurgical excisionIntralesional rituximab and interferon-αLungsWatch and wait strategyLocal therapy (surgical excision and radiation therapy)Chemotherapy upon clinical or histologic transformationStomachAntibiotics to eradicateH. pyloriAssociated with long-term remissionCan be considered as initial strategy even in cases with no laboratory confirmation ofHelicobacterspp.infectionChemotherapy ± radiation if transformed to large B-cell lymphoma or disseminated diseaseIntestineControversial use of antibioticsTetracycline, metronidazole, and ampicillinSurgical excision ± radiation therapy",
                    "sub_points": [
                      "Orbit and ocular adnexaAntibiotics to eradicateC. psittaciMay be considered upfront strategyMALT lymphoma often stage IE and is treated by radiation alone or combined with surgery",
                      "Antibiotics to eradicateC. psittaciMay be considered upfront strategy",
                      "May be considered upfront strategy",
                      "MALT lymphoma often stage IE and is treated by radiation alone or combined with surgery",
                      "SkinControversial use of antibioticsCeftriaxoneSurgical excisionIntralesional rituximab and interferon-α",
                      "Controversial use of antibioticsCeftriaxone",
                      "Ceftriaxone",
                      "Surgical excision",
                      "Intralesional rituximab and interferon-α",
                      "LungsWatch and wait strategyLocal therapy (surgical excision and radiation therapy)Chemotherapy upon clinical or histologic transformation",
                      "Watch and wait strategy",
                      "Local therapy (surgical excision and radiation therapy)",
                      "Chemotherapy upon clinical or histologic transformation",
                      "StomachAntibiotics to eradicateH. pyloriAssociated with long-term remissionCan be considered as initial strategy even in cases with no laboratory confirmation ofHelicobacterspp.infectionChemotherapy ± radiation if transformed to large B-cell lymphoma or disseminated disease",
                      "Antibiotics to eradicateH. pyloriAssociated with long-term remissionCan be considered as initial strategy even in cases with no laboratory confirmation ofHelicobacterspp.infection",
                      "Associated with long-term remission",
                      "Can be considered as initial strategy even in cases with no laboratory confirmation ofHelicobacterspp.infection",
                      "Chemotherapy ± radiation if transformed to large B-cell lymphoma or disseminated disease",
                      "IntestineControversial use of antibioticsTetracycline, metronidazole, and ampicillinSurgical excision ± radiation therapy",
                      "Controversial use of antibioticsTetracycline, metronidazole, and ampicillinSurgical excision ± radiation therapy",
                      "Tetracycline, metronidazole, and ampicillin",
                      "Surgical excision ± radiation therapy"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Use of MALT Lymphoma International Prognostic Index (MALT-IPI)Advanced age (≥ 70 years)Elevated LDHAdvanced Ann Arbor stage (III/IV)Low risk (0 point), intermediate risk (1 point), high risk (≥ 2 points)",
                    "sub_points": [
                      "Advanced age (≥ 70 years)",
                      "Elevated LDH",
                      "Advanced Ann Arbor stage (III/IV)",
                      "Low risk (0 point), intermediate risk (1 point), high risk (≥ 2 points)"
                    ]
                  },
                  {
                    "text": "Groupe d'Etude des Lymphomes Folliculaires (GELF) criteria: To determine patients with high tumor burden and need for immediate therapyNode or mass > 7 cm, > 3 nodal sites (each > 3 cm), B symptoms, marked splenomegaly, pleural or peritoneal effusionLeukemic phase > 5 x 10⁹/L, leukopenia < 1 x 10⁹/L, thrombocytopenia < 100 x 10⁹/L",
                    "sub_points": [
                      "Node or mass > 7 cm, > 3 nodal sites (each > 3 cm), B symptoms, marked splenomegaly, pleural or peritoneal effusion",
                      "Leukemic phase > 5 x 10⁹/L, leukopenia < 1 x 10⁹/L, thrombocytopenia < 100 x 10⁹/L"
                    ]
                  },
                  {
                    "text": "Transformation to diffuse large B-cell lymphoma (DLBCL) is associated with worse prognosisB symptoms, high clinical stage, high (> 13) SUV using F-18 FDG PET, failure of 1st-line therapyHigh LDH, bone marrow failure: Anemia, leukopenia, or thrombocytopeniaCorrelates with histologic transformationOverall survival (OS) of extranodal MZL at 5 years after diagnosis of transformation is 72%",
                    "sub_points": [
                      "B symptoms, high clinical stage, high (> 13) SUV using F-18 FDG PET, failure of 1st-line therapy",
                      "High LDH, bone marrow failure: Anemia, leukopenia, or thrombocytopenia",
                      "Correlates with histologic transformation",
                      "Overall survival (OS) of extranodal MZL at 5 years after diagnosis of transformation is 72%"
                    ]
                  },
                  {
                    "text": "5-year OS according to siteOrbit and ocular adnexa: 84%Salivary glands: 88%Thyroid: 95%Skin: 91-100%Breast: 79%Lungs: 77-90%Stomach: 71%Lymphoma can regress after eradication ofH. pyloriby antibiotics in ~ 75% of casest(11;18)(q21;q21) is associated with resistance to antibiotics< 10% of cases transform to DLBCL25-35% relapse rate in stomach or other extranodal sitesIntestine: 72%",
                    "sub_points": [
                      "Orbit and ocular adnexa: 84%",
                      "Salivary glands: 88%",
                      "Thyroid: 95%",
                      "Skin: 91-100%",
                      "Breast: 79%",
                      "Lungs: 77-90%",
                      "Stomach: 71%Lymphoma can regress after eradication ofH. pyloriby antibiotics in ~ 75% of casest(11;18)(q21;q21) is associated with resistance to antibiotics< 10% of cases transform to DLBCL25-35% relapse rate in stomach or other extranodal sites",
                      "Lymphoma can regress after eradication ofH. pyloriby antibiotics in ~ 75% of cases",
                      "t(11;18)(q21;q21) is associated with resistance to antibiotics",
                      "< 10% of cases transform to DLBCL",
                      "25-35% relapse rate in stomach or other extranodal sites",
                      "Intestine: 72%"
                    ]
                  },
                  {
                    "text": "Development of 2nd malignancy (occurs in 24% of extranodal MZL) conveys poor prognosis"
                  }
                ]
              },
              "IMAGING": {
                "Radiographic Findings": [
                  {
                    "text": "Single or multiple masses"
                  },
                  {
                    "text": "Lung(s) involved by MALT lymphoma ± consolidation"
                  },
                  {
                    "text": "Controversial value of F-18 FDG PET"
                  }
                ],
                "Endoscopic Findings": [
                  {
                    "text": "Gastric or intestinal MZL: ± mass, ulcer, bleedingRecommended minimum of 10 biopsies of visible lesion for diagnosisEndoscopic follow-up every 3-6 months for first 2 years after initial diagnosis",
                    "sub_points": [
                      "Recommended minimum of 10 biopsies of visible lesion for diagnosis",
                      "Endoscopic follow-up every 3-6 months for first 2 years after initial diagnosis"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Diffuse or nodular pattern of growth"
                  },
                  {
                    "text": "Expansion of marginal zone by cytologically heterogeneous cell populationPredominantly centrocyte-like cells with small, irregular nucleiMonocytoid appearance with distinct rim of clear cytoplasmScattered large cells (centroblasts or immunoblasts) are present; up to 10% of all cells± plasmacytoid differentiation; ± Dutcher bodies",
                    "sub_points": [
                      "Predominantly centrocyte-like cells with small, irregular nuclei",
                      "Monocytoid appearance with distinct rim of clear cytoplasm",
                      "Scattered large cells (centroblasts or immunoblasts) are present; up to 10% of all cells",
                      "± plasmacytoid differentiation; ± Dutcher bodies"
                    ]
                  },
                  {
                    "text": "Hyperplastic lymphoid follicles are common± colonized by lymphoma imparting nodular pattern",
                    "sub_points": [
                      "± colonized by lymphoma imparting nodular pattern"
                    ]
                  },
                  {
                    "text": "Lymphoepithelial lesions are common in epithelial tissues involved by EMZLInfiltration and distortion of epithelial structures by ≥ 3 neoplastic lymphocytesEpithelial degeneration and glandular structure destructionMost prominent in thyroid and parotid glandsEosinophilic degeneration",
                    "sub_points": [
                      "Infiltration and distortion of epithelial structures by ≥ 3 neoplastic lymphocytes",
                      "Epithelial degeneration and glandular structure destruction",
                      "Most prominent in thyroid and parotid glands",
                      "Eosinophilic degeneration"
                    ]
                  },
                  {
                    "text": "Multifocal disease~ 25% of patients have > 1 extranodal site of involvement",
                    "sub_points": [
                      "~ 25% of patients have > 1 extranodal site of involvement"
                    ]
                  }
                ],
                "Cytologic Features": [
                  {
                    "text": "FNA smears show polymorphous cell populationSmall, round, or irregular lymphocytes; variable numbers of large cells &/or plasma cells",
                    "sub_points": [
                      "Small, round, or irregular lymphocytes; variable numbers of large cells &/or plasma cells"
                    ]
                  }
                ],
                "Orbit and Ocular Adnexa": [
                  {
                    "text": "Nodular or diffuse polymorphic infiltrate in orbital soft tissue, conjunctiva, and lacrimal gland"
                  }
                ],
                "Salivary Glands": [
                  {
                    "text": "Arises in background of myoepithelial sialadenitis (MESA)"
                  },
                  {
                    "text": "Lymphoepithelial lesions (epithelial-myoepithelial islands) common in EMZL and MESA"
                  },
                  {
                    "text": "Concentric and confluent zones of monocytoid cells around ducts favor EMZL over MESABeware that MESA can have monotypic and monoclonal B-cell populations",
                    "sub_points": [
                      "Beware that MESA can have monotypic and monoclonal B-cell populations"
                    ]
                  }
                ],
                "Thyroid Gland": [
                  {
                    "text": "Arises in background of Hashimoto thyroiditis"
                  },
                  {
                    "text": "Lymphoepithelial lesions occur in both EMZL and Hashimoto thyroiditis"
                  },
                  {
                    "text": "Lymphoma cells within follicles tend to be centrocyte-like cells and contained within thyroid follicles"
                  },
                  {
                    "text": "Lymphoma cells outside follicles are often extremely plasmacytic"
                  }
                ],
                "Skin": [
                  {
                    "text": "Most common B-cell lymphoma of skin"
                  },
                  {
                    "text": "Follicular colonization can be prominent; these lesions closely mimic follicular lymphoma (primary or secondary)"
                  }
                ],
                "Breast": [
                  {
                    "text": "Lymphoepithelial lesions are uncommon at this site"
                  },
                  {
                    "text": "Can arise in or be disseminated to breast"
                  }
                ],
                "Lungs": [
                  {
                    "text": "Lymphoepithelial lesions common in EMZL and lymphocytic interstitial pneumonitis"
                  },
                  {
                    "text": "Lymphangitic pattern"
                  },
                  {
                    "text": "Circumscribed mass supports diagnosis of EMZL"
                  }
                ],
                "Stomach": [
                  {
                    "text": "Intense lymphoid infiltrate in lamina propria"
                  },
                  {
                    "text": "Common lymphoepithelial lesions"
                  },
                  {
                    "text": "H. pylorican be identified in normal surface epithelium"
                  }
                ],
                "Intestine": [
                  {
                    "text": "Intense lymphoid infiltrate in lamina propria"
                  },
                  {
                    "text": "Uncommon lymphoepithelial lesions"
                  }
                ],
                "Other Sites of Extranodal Marginal Zone Lymphoma": [
                  {
                    "text": "Very wide range of body sites can be involvedDura mater, soft tissues, thymus, gallbladder, kidney, bladder",
                    "sub_points": [
                      "Dura mater, soft tissues, thymus, gallbladder, kidney, bladder"
                    ]
                  }
                ],
                "Lymph Nodes": [
                  {
                    "text": "Involvement is indistinguishable from nodal MZLCases with early-stage MALT lymphoma have similar outcomes of cases with early-stage nodal MZL",
                    "sub_points": [
                      "Cases with early-stage MALT lymphoma have similar outcomes of cases with early-stage nodal MZL"
                    ]
                  },
                  {
                    "text": "Usually lymph nodes draining primary site of disease are involved"
                  },
                  {
                    "text": "Distant lymph nodes involved in < 10% of patients"
                  }
                ],
                "Bone Marrow": [
                  {
                    "text": "10-20% of patients with EMZL have bone marrow involvement at staging"
                  },
                  {
                    "text": "Paratrabecular &/or nonparatrabecular aggregatesFollicular dendritic cells commonly present in aggregates",
                    "sub_points": [
                      "Follicular dendritic cells commonly present in aggregates"
                    ]
                  },
                  {
                    "text": "Sinusoidal pattern in ~ 20-25% of cases"
                  }
                ],
                "Histologic Transformation to Diffuse Large B-Cell Lymphoma": [
                  {
                    "text": "May coexist with low-grade EMZL at initial presentation"
                  },
                  {
                    "text": "Occurs in 11-19% of cases with median of 23-36 months after diagnosis"
                  },
                  {
                    "text": "Large cells form sheets or large clusters of > 20 cells or represent > 50% of cellsUsually high proliferation rate (40-80%) as determined by Ki-67 proliferation markerFrequent mitoses, necrosis, and karyorrhexis can be detected",
                    "sub_points": [
                      "Usually high proliferation rate (40-80%) as determined by Ki-67 proliferation marker",
                      "Frequent mitoses, necrosis, and karyorrhexis can be detected"
                    ]
                  },
                  {
                    "text": "Excisional biopsy is better than needle biopsies or FNA to detect transformation"
                  },
                  {
                    "text": "Correlates with clinical or imaging features of progression or transformation of disease"
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "CD19(+), CD20(+), CD22(+), CD79a(+), pax-5(+)"
                  },
                  {
                    "text": "IgM(+) > IgA(+) > IgG(+)"
                  },
                  {
                    "text": "IgD(-) but demonstrates intact follicular IgD(+) mantle zones"
                  },
                  {
                    "text": "Monotypic Ig light chain (+); best seen in plasmacytoid cells"
                  },
                  {
                    "text": "BCL-2(+), CD35(+), CD43(+/-), BCL-10(+/-)"
                  },
                  {
                    "text": "Ki-67 (MIB-1) is low, although may be focally high in residual reactive germinal centers"
                  },
                  {
                    "text": "CD21 highlights follicular dendritic cell meshworks in folliclesMeshworks are disrupted by follicular colonization",
                    "sub_points": [
                      "Meshworks are disrupted by follicular colonization"
                    ]
                  },
                  {
                    "text": "FOXP1, CD10, BCL-6, and p53 expression in transformed cases"
                  },
                  {
                    "text": "Cytokeratin (-); useful for highlighting lymphoepithelial lesions"
                  },
                  {
                    "text": "κ- or λ-light chain restriction"
                  },
                  {
                    "text": "CD10(-), BCL-6(-), cyclin-D1 (-)"
                  },
                  {
                    "text": "CD2(-), CD3(-), CD7(-), MUM1(-), EBV-LMP1(-)"
                  },
                  {
                    "text": "CD5 usually (-)~ 5% of cases are CD5(+); correlates with dissemination",
                    "sub_points": [
                      "~ 5% of cases are CD5(+); correlates with dissemination"
                    ]
                  }
                ],
                "Flow Cytometry": [
                  {
                    "text": "Monotypic surface Ig light chain (+)"
                  },
                  {
                    "text": "FMC7(+), CD11c(+/-), CD23(-/+), CD25(-), CD103(-)"
                  },
                  {
                    "text": "T-cell antigens (-)CD5(+) is unusual and often (dim +)",
                    "sub_points": [
                      "CD5(+) is unusual and often (dim +)"
                    ]
                  }
                ],
                "In Situ Hybridization": [
                  {
                    "text": "Can be used to detect MALT lymphoma-associated translocationsMALT1 probe commercially available",
                    "sub_points": [
                      "MALT1 probe commercially available"
                    ]
                  },
                  {
                    "text": "EBER(-)"
                  }
                ],
                "PCR": [
                  {
                    "text": "MonoclonalIGHrearrangementsRearrangements can persist after therapy and complete clinical remission",
                    "sub_points": [
                      "Rearrangements can persist after therapy and complete clinical remission"
                    ]
                  },
                  {
                    "text": "RT-PCR and PCR assays developed to detect translocations"
                  }
                ],
                "Genetic Testing": [
                  {
                    "text": "Inactivating mutations ofTNFAIP3(6p23)~ 20% of EMZLsMutations also occur in other types of MZL",
                    "sub_points": [
                      "~ 20% of EMZLs",
                      "Mutations also occur in other types of MZL"
                    ]
                  },
                  {
                    "text": "Recurrent translocations have been identified in 30-40% of EMZLsGenerally specific for MALT lymphomasTranslocations are mutually exclusive with each otherTranslocations correlate with anatomic site of EMZLFrequency of translocations shows geographic variationBIRC3::MALT1/t(11;18)(q21;q21)Most common in stomach, lungs, and intestineIGH::MALT1/t(14;18)(q32;q21)Most common in ocular adnexa, skin, salivary glands, and liverFOXP1::IGH/t(3;14)(p14.1;q32)Most common in ocular adnexa, thyroid gland, and skinBCL10::IGH/t(1;14)(p22;q32)Rare overall frequency; more common in intestine, salivary glands, and lungBCL6rearrangements in subset of EMZL in transformation to large cell lymphomaRecent studies have identified 5-6 more translocationsSome are currently poorly definedGenes not cloned for subset of translocations",
                    "sub_points": [
                      "Generally specific for MALT lymphomas",
                      "Translocations are mutually exclusive with each other",
                      "Translocations correlate with anatomic site of EMZL",
                      "Frequency of translocations shows geographic variation",
                      "BIRC3::MALT1/t(11;18)(q21;q21)Most common in stomach, lungs, and intestine",
                      "Most common in stomach, lungs, and intestine",
                      "IGH::MALT1/t(14;18)(q32;q21)Most common in ocular adnexa, skin, salivary glands, and liver",
                      "Most common in ocular adnexa, skin, salivary glands, and liver",
                      "FOXP1::IGH/t(3;14)(p14.1;q32)Most common in ocular adnexa, thyroid gland, and skin",
                      "Most common in ocular adnexa, thyroid gland, and skin",
                      "BCL10::IGH/t(1;14)(p22;q32)Rare overall frequency; more common in intestine, salivary glands, and lung",
                      "Rare overall frequency; more common in intestine, salivary glands, and lung",
                      "BCL6rearrangements in subset of EMZL in transformation to large cell lymphoma",
                      "Recent studies have identified 5-6 more translocationsSome are currently poorly definedGenes not cloned for subset of translocations",
                      "Some are currently poorly definedGenes not cloned for subset of translocations",
                      "Genes not cloned for subset of translocations"
                    ]
                  },
                  {
                    "text": "Trisomies 3 and 18 are frequently present in EMZL at various sites but are nonspecific"
                  },
                  {
                    "text": "Somatic mutations &/or deletionsPIK3CD,CREBBP,KMTDC,SPEN,TET2, andTNFRSF14",
                    "sub_points": [
                      "PIK3CD,CREBBP,KMTDC,SPEN,TET2, andTNFRSF14"
                    ]
                  }
                ],
                "Gene Expression Profiling": [
                  {
                    "text": "NF-κB pathway activation is shared feature of many MALT lymphomas"
                  },
                  {
                    "text": "2nd distinct subset of EMZLsT-cell or memory B-cell signature reported in one studyPlasma cell gene signature identified in another studyNo NF-κB pathway activation",
                    "sub_points": [
                      "T-cell or memory B-cell signature reported in one study",
                      "Plasma cell gene signature identified in another study",
                      "No NF-κB pathway activation"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Reactive Inflammatory Diseases": [
                  {
                    "text": "Lymphoepithelial lesions can occur inFlorid gastritis or inflammatory lung diseasesSjögren syndrome or Hashimoto thyroiditis",
                    "sub_points": [
                      "Florid gastritis or inflammatory lung diseases",
                      "Sjögren syndrome or Hashimoto thyroiditis"
                    ]
                  },
                  {
                    "text": "Do not form expansile destructive mass, as observed in EMZL"
                  },
                  {
                    "text": "Plasma cells are polytypic; B cells may express CD43(+)"
                  }
                ],
                "Lymphoepithelial/Myoepithelial Sialadenitis": [
                  {
                    "text": "Occurs as result of autoimmune process or is HIV relatede.g., Sjögren syndrome",
                    "sub_points": [
                      "e.g., Sjögren syndrome"
                    ]
                  },
                  {
                    "text": "Nests of ductal epithelial cells infiltrated by small lymphoid cells"
                  },
                  {
                    "text": "No concentric rings of monocytoid cells around ducts"
                  },
                  {
                    "text": "No evidence of monotypic or monoclonal B-cell population"
                  }
                ],
                "Follicular Lymphoma": [
                  {
                    "text": "At extranodal sites, can mimic MALT lymphoma with colonization of follicles"
                  },
                  {
                    "text": "Duodenal typeIncidental findingMultifocal involvement of polypoid lesionsCD10(+), BCL-2 (strong +), BCL-6(+);IGH::BCL2/t(14;18)(q32;q21)",
                    "sub_points": [
                      "Incidental finding",
                      "Multifocal involvement of polypoid lesions",
                      "CD10(+), BCL-2 (strong +), BCL-6(+);IGH::BCL2/t(14;18)(q32;q21)"
                    ]
                  },
                  {
                    "text": "Primary cutaneous follicle center lymphomaSolitary or multiple plaques &/or tumorsCommon in head and neckNeoplastic follicles present with centrocytes and scattered centroblastsCD20(+), CD10(+/-), BCL-6(+), BCL-2(-)",
                    "sub_points": [
                      "Solitary or multiple plaques &/or tumors",
                      "Common in head and neck",
                      "Neoplastic follicles present with centrocytes and scattered centroblasts",
                      "CD20(+), CD10(+/-), BCL-6(+), BCL-2(-)"
                    ]
                  }
                ],
                "Mantle Cell Lymphoma": [
                  {
                    "text": "Has tropism for gastrointestinal tract; can involve other extranodal sites"
                  },
                  {
                    "text": "Monotonous neoplastic cells without intermixed large cells or plasma cells"
                  },
                  {
                    "text": "± mantle zone pattern; no follicular colonization"
                  },
                  {
                    "text": "Cyclin-D1 (+);CCND1::IGH/t(11;14)(q13;q32)B-cell antigens (+), CD5(+)",
                    "sub_points": [
                      "B-cell antigens (+), CD5(+)"
                    ]
                  }
                ],
                "Plasmacytoma": [
                  {
                    "text": "Plasmacytoma at extranodal sites may be related to EMZLPatients may present with plasmacytoma and relapse as EMZL or as EMZL and relapse as plasmacytomaExtranodal plasmacytoma is also clinically indolent",
                    "sub_points": [
                      "Patients may present with plasmacytoma and relapse as EMZL or as EMZL and relapse as plasmacytoma",
                      "Extranodal plasmacytoma is also clinically indolent"
                    ]
                  },
                  {
                    "text": "No neoplastic B lymphocytes in plasmacytomaUsually IgA(+) or IgG(+)",
                    "sub_points": [
                      "Usually IgA(+) or IgG(+)"
                    ]
                  },
                  {
                    "text": "CD20(-), CD38(+), CD138(+), MUM1(+)"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Mantle Cell Lymphoma": {
            "name": "Mantle Cell Lymphoma",
            "url": "https://app.pathprimer.com/document/9f3977e5-bc74-4c66-a7b0-bd288e5dc307/lesson/1754477f-a4b1-4ec8-b223-cd1eb29cbd87",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Mantle cell lymphoma (MCL)"
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "t(11;14) results inCCND1at 11q13 being juxtaposed withIGHat 14q32Facilitates cell cycle progression from G1 to S phase",
                    "sub_points": [
                      "Facilitates cell cycle progression from G1 to S phase"
                    ]
                  },
                  {
                    "text": "Many other genetic lesions occur in MCL"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Median age: 6th-7th decades; male predominance"
                  },
                  {
                    "text": "Lymphadenopathy in ~ 90%; B symptoms in ~ 30-40%"
                  },
                  {
                    "text": "Extranodal sites of involvement are commonGastrointestinal tract, bone marrow, spleenWaldeyer ring, peripheral blood",
                    "sub_points": [
                      "Gastrointestinal tract, bone marrow, spleen",
                      "Waldeyer ring, peripheral blood"
                    ]
                  },
                  {
                    "text": "Most patients have clinical stage III/IV disease"
                  },
                  {
                    "text": "MCL is incurable but variable clinical course and prognosis"
                  },
                  {
                    "text": "Prognostic assessment based on symptoms, clinical risk factors, and tumor burden"
                  },
                  {
                    "text": "In recent years, approach to therapy is more tailored"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Architectural effacement by lymphoma with nodular, diffuse, or mantle-zone pattern"
                  },
                  {
                    "text": "Monotonous population of small/medium-size cells"
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "ImmunophenotypeCD5(+), CD19(+), CD20(+), FMC-7(+), CD10(-), CD23(-/+)Cyclin-D1 (+), SOX11(+), Ki-67 variable",
                    "sub_points": [
                      "CD5(+), CD19(+), CD20(+), FMC-7(+), CD10(-), CD23(-/+)",
                      "Cyclin-D1 (+), SOX11(+), Ki-67 variable"
                    ]
                  },
                  {
                    "text": "Cytogenetics or FISH: t(11;14)(q13;q32) orCCND1::IGH"
                  },
                  {
                    "text": "Gene expression profilingUnique profileProliferation signature predicts prognosis",
                    "sub_points": [
                      "Unique profile",
                      "Proliferation signature predicts prognosis"
                    ]
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "Chronic lymphocytic leukemia/small lymphocytic lymphoma"
                  },
                  {
                    "text": "Follicular lymphoma"
                  },
                  {
                    "text": "Nodal marginal zone B-cell lymphoma"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Mantle cell lymphoma (MCL)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Centrocytic lymphomaTerm used in original description by Karl Lennert",
                    "sub_points": [
                      "Term used in original description by Karl Lennert"
                    ]
                  },
                  {
                    "text": "Lymphocytic lymphoma, intermediate grade of differentiation"
                  },
                  {
                    "text": "Intermediate lymphocytic lymphoma"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Clinically aggressive B-cell lymphoma usually composed of monomorphic small- to medium-size cellsAssociated with t(11;14)(q13;q32) and cyclin-D1 overexpression",
                    "sub_points": [
                      "Associated with t(11;14)(q13;q32) and cyclin-D1 overexpression"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "t(11;14)(q13;q32)": [
                  {
                    "text": "CCND1at 11q13 is juxtaposed withIGHat 14q32 on derivative chromosome 14Results in cyclin-D1 overexpression, Rb phosphorylation, and release of E2FFacilitates cell cycle progression from G1 to S phase",
                    "sub_points": [
                      "Results in cyclin-D1 overexpression, Rb phosphorylation, and release of E2F",
                      "Facilitates cell cycle progression from G1 to S phase"
                    ]
                  },
                  {
                    "text": "Many other genetic lesions occur in MCL"
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Presentation": [
                  {
                    "text": "Median age: 6th-7th decades; male predominance"
                  },
                  {
                    "text": "Most patients present with clinical stage III/IV disease; B symptoms in 40-50%"
                  },
                  {
                    "text": "Generalized lymphadenopathy"
                  },
                  {
                    "text": "Extranodal sites of involvement are commonGastrointestinal tract, spleen, liver, tonsilsBone marrow, Waldeyer ringPeripheral bloodOvert leukemia in ~ 10% of patientsOccasional MCL cells in blood in > 75% of patients",
                    "sub_points": [
                      "Gastrointestinal tract, spleen, liver, tonsils",
                      "Bone marrow, Waldeyer ring",
                      "Peripheral bloodOvert leukemia in ~ 10% of patientsOccasional MCL cells in blood in > 75% of patients",
                      "Overt leukemia in ~ 10% of patients",
                      "Occasional MCL cells in blood in > 75% of patients"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "In recent years, more tailored approach to MCL therapy has been used"
                  },
                  {
                    "text": "Young patients with widespread lymphadenopathy and symptoms (high risk)Aggressive chemotherapyHyper-CVAD chemotherapy regimen used at many medical centersOther regimens &/or stem cell transplantation may be used",
                    "sub_points": [
                      "Aggressive chemotherapyHyper-CVAD chemotherapy regimen used at many medical centersOther regimens &/or stem cell transplantation may be used",
                      "Hyper-CVAD chemotherapy regimen used at many medical centers",
                      "Other regimens &/or stem cell transplantation may be used"
                    ]
                  },
                  {
                    "text": "Older patients may be treated with more standard therapiesRituximab (R)-CHOP or R-bendamustine",
                    "sub_points": [
                      "Rituximab (R)-CHOP or R-bendamustine"
                    ]
                  },
                  {
                    "text": "New biologic agents: Targeted therapiesIbrutinib (Bruton tyrosine kinase inhibitor), idelalisib (phosphoinositide-3 kinase inhibitor)66% response rate, 26% overall survival in patients with refractory diseaseLenalidomide (immunomodulatory)ABT-199/venetoclax [B-cell lymphoma 2 (BCL-2) inhibitor]May be used in combination: Anti-CD20, venetoclax, and IbrutinibChimeric antigen receptor (CAR) T cells offers durable and high rate of remission",
                    "sub_points": [
                      "Ibrutinib (Bruton tyrosine kinase inhibitor), idelalisib (phosphoinositide-3 kinase inhibitor)66% response rate, 26% overall survival in patients with refractory disease",
                      "66% response rate, 26% overall survival in patients with refractory disease",
                      "Lenalidomide (immunomodulatory)",
                      "ABT-199/venetoclax [B-cell lymphoma 2 (BCL-2) inhibitor]",
                      "May be used in combination: Anti-CD20, venetoclax, and Ibrutinib",
                      "Chimeric antigen receptor (CAR) T cells offers durable and high rate of remission"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Disease is incurable; patients with aggressive disease have very poor prognosis"
                  },
                  {
                    "text": "Prognostic assessment based on symptoms, clinical risk factors, and tumor burdenMantle Cell Lymphoma International Prognostic Index (MIPI)Age, performance status, serum lactate dehydrogenase, leukocyte count",
                    "sub_points": [
                      "Mantle Cell Lymphoma International Prognostic Index (MIPI)Age, performance status, serum lactate dehydrogenase, leukocyte count",
                      "Age, performance status, serum lactate dehydrogenase, leukocyte count"
                    ]
                  },
                  {
                    "text": "Factors associated with poor prognosisKi-67 immunohistochemistry (IHC) > 30%Blastoid and pleomorphic variantsComplex karyotype,MYCrearrangement,TP53mutation, EZH2 expression",
                    "sub_points": [
                      "Ki-67 immunohistochemistry (IHC) > 30%",
                      "Blastoid and pleomorphic variants",
                      "Complex karyotype,MYCrearrangement,TP53mutation, EZH2 expression"
                    ]
                  }
                ],
                "Smoldering Mantle Cell Lymphoma": [
                  {
                    "text": "In patients with indolent disease, \"watch and wait\" may be recommended"
                  },
                  {
                    "text": "Features that predict indolent diseaseAbsence of B symptomsNormal LDH and β-2-microglobulinLow MIPI scoreSpleen < 20 cm; lymph nodes < 3 cm, SUV < 6No blastoid or pleomorphic morphologyKi-67 < 30%Phenotype: CD5(-), CD23(+), CD38(-), CD200(+)MYC(-),TP53(-),NOTCH1/2(-)",
                    "sub_points": [
                      "Absence of B symptoms",
                      "Normal LDH and β-2-microglobulin",
                      "Low MIPI score",
                      "Spleen < 20 cm; lymph nodes < 3 cm, SUV < 6",
                      "No blastoid or pleomorphic morphology",
                      "Ki-67 < 30%",
                      "Phenotype: CD5(-), CD23(+), CD38(-), CD200(+)",
                      "MYC(-),TP53(-),NOTCH1/2(-)"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Monotonous population of small- to medium-size lymphocytesVariably irregular nuclear contours, condensed chromatin, and scant cytoplasmNo centroblasts or other large cells",
                    "sub_points": [
                      "Variably irregular nuclear contours, condensed chromatin, and scant cytoplasm",
                      "No centroblasts or other large cells"
                    ]
                  },
                  {
                    "text": "Other common histologic featuresBenign histiocytes with eosinophilic cytoplasmHyalinized blood vesselsGerminal centers without mantle zones (\"naked\")",
                    "sub_points": [
                      "Benign histiocytes with eosinophilic cytoplasm",
                      "Hyalinized blood vessels",
                      "Germinal centers without mantle zones (\"naked\")"
                    ]
                  },
                  {
                    "text": "2 aggressive variants of MCL are recognized by WHO classificationBlastoid: Cells with immature chromatin and high mitotic rate (≥ 10/10 HPF)Cells resemble lymphoblastsPleomorphic: Heterogeneous population of cells, including cells with nucleoli and high mitotic rateCells similar to cells of diffuse large B-cell lymphoma",
                    "sub_points": [
                      "Blastoid: Cells with immature chromatin and high mitotic rate (≥ 10/10 HPF)Cells resemble lymphoblasts",
                      "Cells resemble lymphoblasts",
                      "Pleomorphic: Heterogeneous population of cells, including cells with nucleoli and high mitotic rateCells similar to cells of diffuse large B-cell lymphoma",
                      "Cells similar to cells of diffuse large B-cell lymphoma"
                    ]
                  },
                  {
                    "text": "Liver: MCL preferentially involves portal tracts"
                  },
                  {
                    "text": "Spleen: MCL preferentially replaces white pulp, secondarily red pulp"
                  },
                  {
                    "text": "Bone marrow: MCL often has nonparatrabecular and paratrabecular pattern"
                  },
                  {
                    "text": "Peripheral bloodClassic: Small cells with high nuclear:cytoplasm ratioSome variation from cell to cellProlymphocytoid: Cells resemble prolymphocytesRare; associated with poorer prognosis",
                    "sub_points": [
                      "Classic: Small cells with high nuclear:cytoplasm ratioSome variation from cell to cell",
                      "Some variation from cell to cell",
                      "Prolymphocytoid: Cells resemble prolymphocytesRare; associated with poorer prognosis",
                      "Rare; associated with poorer prognosis"
                    ]
                  }
                ],
                "In Situ Mantle Cell Neoplasm": [
                  {
                    "text": "Lymphoma cells are confined to thin layer of mantle zones around reactive germinal centers"
                  },
                  {
                    "text": "Overall architecture is normalNeed immunohistochemical analysis to recognize",
                    "sub_points": [
                      "Need immunohistochemical analysis to recognize"
                    ]
                  },
                  {
                    "text": "Immunophenotype: Cyclin-D1 (+), SOX11(+), CD5(+), CD20(+)"
                  },
                  {
                    "text": "Usually incidentally found5% of patients have overt MCL at other sites",
                    "sub_points": [
                      "5% of patients have overt MCL at other sites"
                    ]
                  }
                ],
                "Leukemic Nonnodal Mantle Cell Lymphoma": [
                  {
                    "text": "Blood and bone marrow involvement without significant lymphadenopathyImaging studies can show lymph nodes < 2 cm in largest diameter",
                    "sub_points": [
                      "Imaging studies can show lymph nodes < 2 cm in largest diameter"
                    ]
                  },
                  {
                    "text": "Leukemic lymphocytes are small, round, and resemble CLL/SLL lymphocytes"
                  },
                  {
                    "text": "May show CD5(-), CD23(+)dim, CD200(+), and SOX11(-)"
                  },
                  {
                    "text": "Indolent course, but over time, subset may develop aggressive disease"
                  }
                ],
                "Cyclin-D1(-) MCL": [
                  {
                    "text": "Histology, immunophenotype similar to MCL but without t(11;14)(q13;q32) and cyclin-D1 (-)"
                  },
                  {
                    "text": "Cyclin-D2 and cyclin-D3 rearrangements"
                  },
                  {
                    "text": "Represent ~ 1-2% of MCL cases"
                  }
                ],
                "MCL With Marginal Zone Differentiation": [
                  {
                    "text": "Most MCL cells show moderately abundant clear cytoplasm"
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "Cyclin-D1 overexpression in almost all cases of MCL"
                  },
                  {
                    "text": "CD19(+), CD20(+), CD22(+)"
                  },
                  {
                    "text": "CD5(+) and SOX11(+) in most cases"
                  },
                  {
                    "text": "Ki-67 is variable and has prognostic importance"
                  }
                ],
                "Flow Cytometry": [
                  {
                    "text": "CD5(+), CD19(+), CD20(+), CD22(+), CD79b(+), FMC-7(+), and monotypic Ig"
                  },
                  {
                    "text": "CD3(-), CD10(-), CD23(-), CD43(+/-), CD11c(+/-)"
                  },
                  {
                    "text": "Rare cases have atypical immunophenotypeCD5(-), CD10(+), CD23(+) (dim ~ 10%), or CD200(+)",
                    "sub_points": [
                      "CD5(-), CD10(+), CD23(+) (dim ~ 10%), or CD200(+)"
                    ]
                  }
                ],
                "Genetic Testing": [
                  {
                    "text": "Numerous methods can be used for demonstrating t(11;14)(q13;q32)FISH is convenient because it can be performed on fixed tissue sectionsConventional cytogenetics if fresh material availablePCR assay detects 1 major breakpoint region in MCLMajor translocation cluster; 30-50% of cases",
                    "sub_points": [
                      "FISH is convenient because it can be performed on fixed tissue sections",
                      "Conventional cytogenetics if fresh material available",
                      "PCR assay detects 1 major breakpoint region in MCLMajor translocation cluster; 30-50% of cases",
                      "Major translocation cluster; 30-50% of cases"
                    ]
                  },
                  {
                    "text": "Cyclin-D2 rearrangements by FISH in cyclin-D1 (-) cases"
                  },
                  {
                    "text": "Aggressive variants of MCLTP53or p16 mutations are commonMYCrearrangements in small subset of cases",
                    "sub_points": [
                      "TP53or p16 mutations are common",
                      "MYCrearrangements in small subset of cases"
                    ]
                  }
                ],
                "Gene Expression Profiling": [
                  {
                    "text": "MCL has distinctive proliferation signatureCan divide patients into 4 prognostic subgroupsKi-67 IHC can function as surrogate",
                    "sub_points": [
                      "Can divide patients into 4 prognostic subgroups",
                      "Ki-67 IHC can function as surrogate"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma": [
                  {
                    "text": "Proliferation centers; mixture of small lymphocytes, prolymphocytes, and paraimmunoblasts"
                  },
                  {
                    "text": "Cells express dim surface Ig, CD5, CD23, and LEF1"
                  },
                  {
                    "text": "SOX11(-); cyclin-D1 weak in proliferation centers"
                  }
                ],
                "Follicular Lymphoma": [
                  {
                    "text": "Sharply circumscribed nodules composed of centrocytes and centroblasts"
                  },
                  {
                    "text": "CD10(+) and BCL-6(+)"
                  }
                ],
                "Nodal Marginal Zone B-Cell Lymphoma": [
                  {
                    "text": "Neoplastic B cells ± monocytoid cytoplasm"
                  },
                  {
                    "text": "Reactive germinal centers are common"
                  },
                  {
                    "text": "CD5(-) and cyclin-D1 (-)"
                  }
                ],
                "Lymphoblastic Lymphoma": [
                  {
                    "text": "Mimics blastoid variant of MCL"
                  },
                  {
                    "text": "Younger patients; TdT(+) and cyclin-D1 (-)"
                  }
                ],
                "Diffuse Large B-Cell Lymphoma": [
                  {
                    "text": "Mimics pleomorphic variant of MCL"
                  },
                  {
                    "text": "CD5(-) and cyclin-D1 (-)"
                  }
                ],
                "Reactive Follicular Hyperplasia": [
                  {
                    "text": "Thinner mantle zones composed of small, round, mature lymphocytes surrounding prominent germinal centers"
                  },
                  {
                    "text": "No evidence of monoclonality"
                  }
                ],
                "Castleman Disease, Hyaline Vascular Type": [
                  {
                    "text": "Large localized mass in young person"
                  },
                  {
                    "text": "Architecture not entirely effaced"
                  },
                  {
                    "text": "Hyaline-vascular follicles, \"onion skin\" lymphocytes concentrically layered around germinal centers"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma": {
            "name": "Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma",
            "url": "https://app.pathprimer.com/document/b6726756-990d-4bad-8a86-7c4a0e4649b2/lesson/1754477f-a4b1-4ec8-b223-cd1eb29cbd87",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Neoplasm of monomorphic, small round B cells in peripheral blood (PB), bone marrow (BM), lymph nodes (LNs), and spleen"
                  },
                  {
                    "text": "CLL: Monotypic B-cells ≥ 5x 109/L in PB and LNs > 1.5 cm"
                  },
                  {
                    "text": "SLL: Nonleukemic tissue infiltrate that otherwise resembles CLL"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "5-year survival, 90% with immunotherapy"
                  },
                  {
                    "text": "Clinical staging systems: Rai (0-IV) and Binet (A-C) are best predictors of survival"
                  },
                  {
                    "text": "BM infiltration may lead to anemia, thrombocytopenia, and neutropenia"
                  },
                  {
                    "text": "Autoimmunity frequently seen in CLL/SLL"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "MBL: < 5 x 10⁹/L CLL cells in blood"
                  },
                  {
                    "text": "Lymph nodes with vaguely nodular pattern with dark zones of mature CLL cells and light zones (proliferation centers)MBL in LNs < 1.5 cm in diameter; usually interfollicular",
                    "sub_points": [
                      "MBL in LNs < 1.5 cm in diameter; usually interfollicular"
                    ]
                  },
                  {
                    "text": "PB diagnosis requires persistent (> 1-month) lymphocytosis > 5 x 10⁹ CLL cells/L"
                  },
                  {
                    "text": "Accelerated phase: Increased large proliferation centers with high Ki-67"
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "Dim expression of sIg (IgM or IgM and IgD or, rarely, IgG) with κ- or λ-light chain restriction"
                  },
                  {
                    "text": "CD20 (dim +), CD19(+), CD5(+), CD23(+), LEF1(+)"
                  },
                  {
                    "text": "Expression of T-cell-associated antigen ZAP70 is associated with unmutatedIGHgene variable region"
                  },
                  {
                    "text": "ZAP70(+) on > 30% of cells by flow cytometry associates with worse prognosis than ZAP70(-) cases"
                  },
                  {
                    "text": "~ 50% of cases have abnormal karyotypes"
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "Mantle cell lymphoma"
                  },
                  {
                    "text": "Marginal zone lymphoma"
                  },
                  {
                    "text": "Follicular lymphoma"
                  },
                  {
                    "text": "Hairy cell leukemia"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Monoclonal B-cell lymphocytosis (MBL)"
                  },
                  {
                    "text": "Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Preneoplastic and neoplastic small lymphocytic proliferationsUmbrella term introduced in 5th edition of WHO classification",
                    "sub_points": [
                      "Umbrella term introduced in 5th edition of WHO classification"
                    ]
                  },
                  {
                    "text": "2 entities are recognized: MBL and CLL/SLL"
                  },
                  {
                    "text": "MBLMonotypic B cells in blood < 5 x 10⁹/L and no other features of lymphoproliferative disorder (LPD)3 subtypes are recognizedLow-count MBL: < 0.5 x 10⁹/L and no other features of LPDCLL/SLL type MBL: CLL/SLL phenotype; B-cell count 0.5 < 5 x 10⁹/L and no features of CLL/SLLNon-CLL/SLL-type MBL: Monotypic non-CLL/SLL expansion and no other B cell lymphoma",
                    "sub_points": [
                      "Monotypic B cells in blood < 5 x 10⁹/L and no other features of lymphoproliferative disorder (LPD)",
                      "3 subtypes are recognizedLow-count MBL: < 0.5 x 10⁹/L and no other features of LPDCLL/SLL type MBL: CLL/SLL phenotype; B-cell count 0.5 < 5 x 10⁹/L and no features of CLL/SLLNon-CLL/SLL-type MBL: Monotypic non-CLL/SLL expansion and no other B cell lymphoma",
                      "Low-count MBL: < 0.5 x 10⁹/L and no other features of LPD",
                      "CLL/SLL type MBL: CLL/SLL phenotype; B-cell count 0.5 < 5 x 10⁹/L and no features of CLL/SLL",
                      "Non-CLL/SLL-type MBL: Monotypic non-CLL/SLL expansion and no other B cell lymphoma"
                    ]
                  },
                  {
                    "text": "CLL/SLLMonomorphic, small round B cells in peripheral blood (PB), bone marrow (BM), lymph nodes, and spleenCLL/SLL cells usually coexpress CD5 and CD23SLL terminology is used for nonleukemic cases in which tissue infiltrates have morphology and immunophenotype of CLLProlymphocytes and paraimmunoblasts form proliferation centers in tissues",
                    "sub_points": [
                      "Monomorphic, small round B cells in peripheral blood (PB), bone marrow (BM), lymph nodes, and spleen",
                      "CLL/SLL cells usually coexpress CD5 and CD23",
                      "SLL terminology is used for nonleukemic cases in which tissue infiltrates have morphology and immunophenotype of CLL",
                      "Prolymphocytes and paraimmunoblasts form proliferation centers in tissues"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Etiology": [
                  {
                    "text": "Genetic predisposition to CLL/SLL and CLL/SLL-type MBL identified in families that share multiple single-nucleotide polymorphisms"
                  },
                  {
                    "text": "Inherited, but not environmental, factors associated with risk to develop MBL"
                  }
                ],
                "Pathogenesis": [
                  {
                    "text": "Similar stereotyped B-cell receptors are found in both CLL/SLL-type MBL and CLL/SLL"
                  },
                  {
                    "text": "MYD88mutations can be found in non-CLL/SLL-type MBL"
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [
                  {
                    "text": "MBL~ 5% in adults 40-50 years of age~ 5-25% of adults 65-80 years of age; 50-75% of adults > 90 years of ageMedian age of patients with CLL/SLL-type MBL: 75 yearsMore frequent in Hispanic and White than in African, Eastern Mediterranean, and Western Pacific patients",
                    "sub_points": [
                      "~ 5% in adults 40-50 years of age",
                      "~ 5-25% of adults 65-80 years of age; 50-75% of adults > 90 years of age",
                      "Median age of patients with CLL/SLL-type MBL: 75 years",
                      "More frequent in Hispanic and White than in African, Eastern Mediterranean, and Western Pacific patients"
                    ]
                  },
                  {
                    "text": "CLL/SLLIs most common adult leukemia in USA; uncommon in AsiaAffected patients usually in 6th decade of life; rare < 3rd decade of lifeMore common in White patients than in Black patientsMore common in 1st-degree relatives of affected patients than general populationAssociated with HLA-DRB4 haplotype among White and Hispanic populations",
                    "sub_points": [
                      "Is most common adult leukemia in USA; uncommon in Asia",
                      "Affected patients usually in 6th decade of life; rare < 3rd decade of life",
                      "More common in White patients than in Black patients",
                      "More common in 1st-degree relatives of affected patients than general population",
                      "Associated with HLA-DRB4 haplotype among White and Hispanic populations"
                    ]
                  }
                ],
                "Presentation": [
                  {
                    "text": "MBLIncidentally found; rarely symptomaticDecreased response to vaccinesLymphadenopathy can occur, but nodes are always < 1.5 cm in largest diameterIt is considered marker of immune senescence and potential precursor of B cell malignancy",
                    "sub_points": [
                      "Incidentally found; rarely symptomatic",
                      "Decreased response to vaccines",
                      "Lymphadenopathy can occur, but nodes are always < 1.5 cm in largest diameter",
                      "It is considered marker of immune senescence and potential precursor of B cell malignancy"
                    ]
                  },
                  {
                    "text": "CLL/SLLLymphadenopathy, generalizedOccurs primarily in adults > 50 years of ageMost patients are asymptomaticPatients with SLL present with lymphadenopathy and often develop lymphocytosisPatients with CLL present with lymphocytosis and may develop lymphadenopathySplenomegaly may be result of infiltration that leads to hypersplenism and peripheral cytopeniasBM infiltration may lead to anemia, thrombocytopenia, and neutropeniaPatients with CLL/SLL have significantly impaired immunologic activityAutoimmunity frequently seen in CLL/SLLUp to 25% of patients develop Coombs (+) autoimmune hemolytic anemiaRed cell aplasia occurs rarelySerum monoclonal paraprotein present in ~ 20% of patients",
                    "sub_points": [
                      "Lymphadenopathy, generalizedOccurs primarily in adults > 50 years of ageMost patients are asymptomaticPatients with SLL present with lymphadenopathy and often develop lymphocytosisPatients with CLL present with lymphocytosis and may develop lymphadenopathy",
                      "Occurs primarily in adults > 50 years of age",
                      "Most patients are asymptomatic",
                      "Patients with SLL present with lymphadenopathy and often develop lymphocytosis",
                      "Patients with CLL present with lymphocytosis and may develop lymphadenopathy",
                      "Splenomegaly may be result of infiltration that leads to hypersplenism and peripheral cytopenias",
                      "BM infiltration may lead to anemia, thrombocytopenia, and neutropenia",
                      "Patients with CLL/SLL have significantly impaired immunologic activity",
                      "Autoimmunity frequently seen in CLL/SLLUp to 25% of patients develop Coombs (+) autoimmune hemolytic anemia",
                      "Up to 25% of patients develop Coombs (+) autoimmune hemolytic anemia",
                      "Red cell aplasia occurs rarely",
                      "Serum monoclonal paraprotein present in ~ 20% of patients"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "MBL: No therapy is indicated"
                  },
                  {
                    "text": "CLL/SLLNot considered to be curable with available therapyVariable therapies, according to risk stratificationWatch and wait for patients with low risk of progressionChemoimmunotherapy combination of fludarabine, cyclophosphamide, and rituximab results in complete response rate of 72%5-year overall survival is 88% for patients receiving immunotherapy according recent estimatesBruton tyrosine kinase (BTK) inhibitor ibrutinib can be useful in refractory or relapsed diseaseCombination of obinutuzumab (anti-CD20), ibrutinib (anti-BTK), and venetoclax (anti-BCL2) is recommended for high-risk patientsPatients with del17(p) orTP53mutationPatients with refractory diseasePotential on chimeric antigen receptor (CAR) T-cell therapy",
                    "sub_points": [
                      "Not considered to be curable with available therapy",
                      "Variable therapies, according to risk stratificationWatch and wait for patients with low risk of progression",
                      "Watch and wait for patients with low risk of progression",
                      "Chemoimmunotherapy combination of fludarabine, cyclophosphamide, and rituximab results in complete response rate of 72%5-year overall survival is 88% for patients receiving immunotherapy according recent estimates",
                      "5-year overall survival is 88% for patients receiving immunotherapy according recent estimates",
                      "Bruton tyrosine kinase (BTK) inhibitor ibrutinib can be useful in refractory or relapsed disease",
                      "Combination of obinutuzumab (anti-CD20), ibrutinib (anti-BTK), and venetoclax (anti-BCL2) is recommended for high-risk patientsPatients with del17(p) orTP53mutationPatients with refractory disease",
                      "Patients with del17(p) orTP53mutation",
                      "Patients with refractory disease",
                      "Potential on chimeric antigen receptor (CAR) T-cell therapy"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "MBL may progress to CLL/SLL at a rate of 1-2% per yearHigher risk of progression if aberrant lymphocyte count is > 3 x 10⁹/LHigher risk of progression if IGHV is unmutated and β2-microglobulin is elevated",
                    "sub_points": [
                      "Higher risk of progression if aberrant lymphocyte count is > 3 x 10⁹/L",
                      "Higher risk of progression if IGHV is unmutated and β2-microglobulin is elevated"
                    ]
                  },
                  {
                    "text": "Median survival: 7.5 years for CLL/SLL5-year survival: 85%10-year survival: < 30%",
                    "sub_points": [
                      "5-year survival: 85%",
                      "10-year survival: < 30%"
                    ]
                  },
                  {
                    "text": "Clinical staging systems: Rai (0-IV) and Binet (A-C) are best predictors of survival"
                  },
                  {
                    "text": "CLL-International Prognostic Index (CLLIPI): Establishes risk score"
                  },
                  {
                    "text": "Adverse prognosis: Unmutated IGHV, as well as mutations ofPT53,NOTCH1, andSF3B1Complex karyotype affects adversely outcome",
                    "sub_points": [
                      "Complex karyotype affects adversely outcome"
                    ]
                  },
                  {
                    "text": "Secondary immunodeficiency in patients with CLL/SLLCellular and immune immunodeficiency is common in patients subjected to chemotherapy or secondary effects of the disease itselfIncreased mortality due to COVID-19 infection found among previously treated CLL patients",
                    "sub_points": [
                      "Cellular and immune immunodeficiency is common in patients subjected to chemotherapy or secondary effects of the disease itself",
                      "Increased mortality due to COVID-19 infection found among previously treated CLL patients"
                    ]
                  }
                ]
              },
              "MACROSCOPIC": {
                "Lymph Node Features": [
                  {
                    "text": "Lymph nodes are enlarged, and cut surface usually shows diffuse replacement"
                  },
                  {
                    "text": "Necrosis is rare"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Lymph nodes"
                  }
                ],
                "Predominant Pattern/Injury Type": [
                  {
                    "text": "Diffuse"
                  }
                ],
                "Predominant Cell/Compartment Type": [
                  {
                    "text": "Hematopoietic, lymphoid"
                  }
                ],
                "Monoclonal B-Cell Lymphocytosis": [
                  {
                    "text": "Healthy adults who have absolute increase in circulating monoclonal B lymphocytes"
                  },
                  {
                    "text": "< 5 x 10⁹/L B lymphocytes in PBSubset < 0.5 x 10⁹/L lymphocytes: Unlikely CLL/SLL will developSubset 1 to < 5 x10⁹/L lymphocytes: Likely to develop CLL/SLL",
                    "sub_points": [
                      "Subset < 0.5 x 10⁹/L lymphocytes: Unlikely CLL/SLL will develop",
                      "Subset 1 to < 5 x10⁹/L lymphocytes: Likely to develop CLL/SLL"
                    ]
                  },
                  {
                    "text": "Absence of lymphadenopathy or organomegaly, cytopenias, or disease-related symptomsNodal MBL in incidentally found < 1.5-cm nodes",
                    "sub_points": [
                      "Nodal MBL in incidentally found < 1.5-cm nodes"
                    ]
                  },
                  {
                    "text": "Histologically lymph nodes may show partial interfollicular, perifollicular, or diffuse lymphocytes with CLL/SLL phenotypeNo proliferation centers in MBL",
                    "sub_points": [
                      "No proliferation centers in MBL"
                    ]
                  },
                  {
                    "text": "BM involvement in MBL can be as lymphoid aggregates or interstitial lymphocytosisMay represent up to 30% of BM cells, and this burden does not qualify for CLL/SLL in BMDiagnosis of CLL/SLL requires ≥ 5 x 10⁹/L monotypic lymphocytes or lymphadenopathy > 1.5 cm",
                    "sub_points": [
                      "May represent up to 30% of BM cells, and this burden does not qualify for CLL/SLL in BMDiagnosis of CLL/SLL requires ≥ 5 x 10⁹/L monotypic lymphocytes or lymphadenopathy > 1.5 cm",
                      "Diagnosis of CLL/SLL requires ≥ 5 x 10⁹/L monotypic lymphocytes or lymphadenopathy > 1.5 cm"
                    ]
                  },
                  {
                    "text": "Cases with non-CLL increase with aging"
                  }
                ],
                "Peripheral Blood in CLL/SLL": [
                  {
                    "text": "Diagnosis requires persistent (> 1-month) PB lymphocytosis (> 5 x 10⁹ cells/L) of mature-appearing lymphocytes"
                  },
                  {
                    "text": "Mature-appearing lymphocytes with scant agranular cytoplasm and condensed chromatin without nucleoli"
                  },
                  {
                    "text": "Characteristic soccer ball chromatin pattern and numerous smudge cellsAlbumin prevents smudge cells formation",
                    "sub_points": [
                      "Albumin prevents smudge cells formation"
                    ]
                  },
                  {
                    "text": "Proportion of prolymphocytes (larger cells with prominent nucleoli) in blood films usually < 3%"
                  },
                  {
                    "text": "Increased numbers of prolymphocytes correlate with more aggressive disease course"
                  },
                  {
                    "text": "Variant CLL with increased prolymphocytes is defined by > 15% but < 55% prolymphocytes"
                  },
                  {
                    "text": "Circulating lymphocytes with CLL immunophenotype"
                  }
                ],
                "Bone Marrow in CLL/SLL": [
                  {
                    "text": "Involvement may be interstitial, nodular, or diffuse"
                  },
                  {
                    "text": "Proliferation centers can be found with extensive involvementLess common in BM than in lymph nodes",
                    "sub_points": [
                      "Less common in BM than in lymph nodes"
                    ]
                  },
                  {
                    "text": "Paratrabecular aggregates can occur but are not characteristic of CLL/SLL"
                  },
                  {
                    "text": "Advanced disease and BM failure are associated with diffuse pattern of infiltration"
                  },
                  {
                    "text": "Examination of BM is essential for staging and helpful to monitor response to therapy"
                  }
                ],
                "Lymph Node in CLL/SLL": [
                  {
                    "text": "Diffuse effacement of architecture with characteristic proliferation centersVaguely nodular areas that appear lighter compared with surrounding darker zonesDarker zones contain mainly small mature lymphocytes",
                    "sub_points": [
                      "Vaguely nodular areas that appear lighter compared with surrounding darker zones",
                      "Darker zones contain mainly small mature lymphocytes"
                    ]
                  },
                  {
                    "text": "Lighter areas contain scattered prolymphocytes and paraimmunoblasts admixed with small lymphocytesProlymphocytes: Medium-size cells with dispersed chromatin and small nucleoliParaimmunoblasts: Medium to large cells with round to oval nuclei, dispersed chromatin, central eosinophilic nucleoli",
                    "sub_points": [
                      "Prolymphocytes: Medium-size cells with dispersed chromatin and small nucleoli",
                      "Paraimmunoblasts: Medium to large cells with round to oval nuclei, dispersed chromatin, central eosinophilic nucleoli"
                    ]
                  },
                  {
                    "text": "Predominant cell is small lymphocyte with clumped chromatin, usually round nucleus, and occasionally small nucleolus"
                  },
                  {
                    "text": "In some cases, cells show moderate nuclear irregularity (atypical cytology)"
                  },
                  {
                    "text": "Mitotic activity usually very lowCLL/SLL can involve lymph nodes with interfollicular pattern, surrounding reactive folliclesOccasional cases show plasmacytoid differentiation",
                    "sub_points": [
                      "CLL/SLL can involve lymph nodes with interfollicular pattern, surrounding reactive follicles",
                      "Occasional cases show plasmacytoid differentiation"
                    ]
                  }
                ],
                "Accelerated Phase": [
                  {
                    "text": "Nodal or extranodal disease with features more aggressive than usual CLL/SLL but not as full blown as diffuse large B-cell lymphoma (DLBCL)"
                  },
                  {
                    "text": "Increased proliferation rate (Ki-67 > 40%)"
                  },
                  {
                    "text": "Increased proliferation centers that may be confluentProliferation centers > 200x magnification field",
                    "sub_points": [
                      "Proliferation centers > 200x magnification field"
                    ]
                  },
                  {
                    "text": "> 2.4 mitoses per proliferation center"
                  }
                ],
                "Prolymphocytoid Transformation": [
                  {
                    "text": "Increased prolymphocytes in PBProlymphocytoid transformation: > 15% prolymphocytes in patients with underlying CLL/SLLProlymphocytes 15-55% are denominated atypical CLL by some authors",
                    "sub_points": [
                      "Prolymphocytoid transformation: > 15% prolymphocytes in patients with underlying CLL/SLLProlymphocytes 15-55% are denominated atypical CLL by some authors",
                      "Prolymphocytes 15-55% are denominated atypical CLL by some authors"
                    ]
                  },
                  {
                    "text": "Associated with clinical signs of progression"
                  },
                  {
                    "text": "B-cell prolymphocytic leukemia requires > 55% circulating prolymphocytesTerm restricted to those cases without underlying CLL/SLLNeeds to be distinguished from leukemic mantle cell lymphoma",
                    "sub_points": [
                      "Term restricted to those cases without underlying CLL/SLL",
                      "Needs to be distinguished from leukemic mantle cell lymphoma"
                    ]
                  }
                ],
                "Large Cell Transformation: Richter Transformation": [
                  {
                    "text": "Nodal or extranodal disease with manifestations of progression: B-symptoms, bulky adenopathy, hepatosplenomegaly."
                  },
                  {
                    "text": "Histologically indistinguishable from DLBCLLymphoma cells appear as centroblastsLess frequently, may appear as T-cell/histiocyte-rich large B-cell lymphoma (THRBCL) or classic Hodgkin lymphomaAlso: High-grade B-cell lymphoma or plasmablastic lymphoma",
                    "sub_points": [
                      "Lymphoma cells appear as centroblasts",
                      "Less frequently, may appear as T-cell/histiocyte-rich large B-cell lymphoma (THRBCL) or classic Hodgkin lymphomaAlso: High-grade B-cell lymphoma or plasmablastic lymphoma",
                      "Also: High-grade B-cell lymphoma or plasmablastic lymphoma"
                    ]
                  },
                  {
                    "text": "PET/CT shows high standardized uptake value (SUV)"
                  },
                  {
                    "text": "In ~ 70% of cases, Richter and underlying CLL/SLL are clonality related"
                  },
                  {
                    "text": "In ~ 30% of cases, Richter and underlying CLL/SLL are not clonally relatedBetter outcomes than those clonally related",
                    "sub_points": [
                      "Better outcomes than those clonally related"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "B-cell antigens (CD20, CD79a, and pax-5) are (+), but CD20 expression can be weak (dim)"
                  },
                  {
                    "text": "CD5, CD23, and LEF1 (+)"
                  },
                  {
                    "text": "CD23 is useful in distinguishing CLL/SLL from mantle cell lymphomaShould be evaluated in every case, if possible",
                    "sub_points": [
                      "Should be evaluated in every case, if possible"
                    ]
                  },
                  {
                    "text": "Some cases of CLL express CD23 only weakly or partially; some cases of mantle cell lymphoma can be dimly CD23(+)"
                  },
                  {
                    "text": "Cyclin-D1 is weakly (+) in proliferation centers"
                  },
                  {
                    "text": "p53 is expressed in ~ 10% of cases"
                  },
                  {
                    "text": "CD10(-), Ki-67 low"
                  }
                ],
                "Flow Cytometry": [
                  {
                    "text": "Dim expression of sIg (IgM or IgM and IgD or, rarely, IgG) with κ- or λ-light chain restriction"
                  },
                  {
                    "text": "Expression of CD19, CD20 (dim), and CD79b"
                  },
                  {
                    "text": "CD5(+), CD23(+), CD43(+), and CD200(+)"
                  },
                  {
                    "text": "CD11c(±), CD10(-), FMC7(-) or (+ dim)"
                  },
                  {
                    "text": "Expression of CD38 on > 30% of cells is seen in ~ 1/2 of cases and reported to be associated with worse prognosis"
                  },
                  {
                    "text": "Expression of T-cell-associated antigen ZAP70 is associated with unmutatedIGHvariable genes"
                  },
                  {
                    "text": "Cases with ZAP70(+) in > 30% of cells by flow cytometry have worse prognosis than ZAP70(-) cases"
                  },
                  {
                    "text": "Flow cytometry used to determine minimal residual disease (MRD) at 0.01%Favorable prognosis when negative for MRDReceptor tyrosine kinase-like orphan receptor 1 (ROR1) has limit of detection of 0.001%Consistently expressed in CLL and MBL and used to assess MRD",
                    "sub_points": [
                      "Favorable prognosis when negative for MRD",
                      "Receptor tyrosine kinase-like orphan receptor 1 (ROR1) has limit of detection of 0.001%Consistently expressed in CLL and MBL and used to assess MRD",
                      "Consistently expressed in CLL and MBL and used to assess MRD"
                    ]
                  },
                  {
                    "text": "Most cases of MBL show CLL phenotype, while minority shows CD5(-) phenotype (non-CLL phenotype)"
                  }
                ],
                "Genetic Testing": [
                  {
                    "text": "~ 50% of cases have abnormal karyotypes (conventional methods); FISH is more often abnormal"
                  },
                  {
                    "text": "Most laboratories perform FISH for assessment of specific abnormalities as part of diagnostic work-up of CLL/SLLDel(13q14), trisomy 12, del(11q22-23)/ATM, del(17p13)/TP53, and del(6q21)",
                    "sub_points": [
                      "Del(13q14), trisomy 12, del(11q22-23)/ATM, del(17p13)/TP53, and del(6q21)"
                    ]
                  },
                  {
                    "text": "Trisomy 12 reported in 1/3 of cases with cytogenetic abnormalitiesCorrelates with atypical histology and aggressive clinical courseCases with trisomy 12 have predominantly unmutatedIGHvariable region genes",
                    "sub_points": [
                      "Correlates with atypical histology and aggressive clinical course",
                      "Cases with trisomy 12 have predominantly unmutatedIGHvariable region genes"
                    ]
                  },
                  {
                    "text": "Abnormalities of 13q (miR-15a/miR-16-1) reported in up to 25% of cases; associated with longer survivalThose with 13q14 abnormalities more often haveIGHmutations",
                    "sub_points": [
                      "Those with 13q14 abnormalities more often haveIGHmutations"
                    ]
                  },
                  {
                    "text": "Abnormalities of 11q23 (ATM) found in small subset of cases; associated with lymphadenopathy and aggressive course"
                  },
                  {
                    "text": "Deletions of 6q21 or 17p13 (TP53locus) seen in 5% and 10% of cases, respectivelyTP53mutations or deletions are associated with worse prognosis regardless ofIGHmutational status",
                    "sub_points": [
                      "TP53mutations or deletions are associated with worse prognosis regardless ofIGHmutational status"
                    ]
                  },
                  {
                    "text": "Translocations are uncommon in CLL/SLLt(14;19)(q32;q13)/IGH::BCL3t(2;14)(p13;q32)/IGH::BCL11At(8;14)(q24;q32)/IGH::MYC",
                    "sub_points": [
                      "t(14;19)(q32;q13)/IGH::BCL3",
                      "t(2;14)(p13;q32)/IGH::BCL11A",
                      "t(8;14)(q24;q32)/IGH::MYC"
                    ]
                  },
                  {
                    "text": "MBL abnormalities overlap with CLL/SLL or CD5(-)/CD10(-) lymphomas"
                  }
                ],
                "Molecular Testing": [
                  {
                    "text": "All cases of CLL/SLL carryIGHrearrangement and almost always lackTRBandTRGrearrangements"
                  },
                  {
                    "text": "Mutational status of IGH variable region has prognostic valueMutated (≥ 2% variability from germline): Better prognosisUnmutated (< 2% variability from germline): Associated with aggressive clinical course",
                    "sub_points": [
                      "Mutated (≥ 2% variability from germline): Better prognosis",
                      "Unmutated (< 2% variability from germline): Associated with aggressive clinical course"
                    ]
                  },
                  {
                    "text": "Gene expression profile shows memory B-cell pattern"
                  },
                  {
                    "text": "Gene mutations with prognostic valueTP53: Predictive of poor prognosisSF3B1,ATM, andNOTCH1associated with shorter time of disease progressionBIRC3andMYD88",
                    "sub_points": [
                      "TP53: Predictive of poor prognosis",
                      "SF3B1,ATM, andNOTCH1associated with shorter time of disease progression",
                      "BIRC3andMYD88"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Mantle Cell Lymphoma": [
                  {
                    "text": "Lymphocytes intermediate in size with irregular nuclear contoursCD5(+), CD19(+), CD20(+), CD22(+), and CD43(+); moderate monoclonal sIgCD10(-), CD23(-/+), CD200(-)",
                    "sub_points": [
                      "CD5(+), CD19(+), CD20(+), CD22(+), and CD43(+); moderate monoclonal sIg",
                      "CD10(-), CD23(-/+), CD200(-)"
                    ]
                  },
                  {
                    "text": "Cyclin-D1 (+), SOX11(+)"
                  },
                  {
                    "text": "t(11;14)(q13;q32)(+) by conventional cytogenetics or FISH"
                  }
                ],
                "Marginal Zone B-Cell Lymphoma": [
                  {
                    "text": "Can affect nodal or extranodal sites"
                  },
                  {
                    "text": "Can present with PB lymphocytosis"
                  },
                  {
                    "text": "Common BM involvement"
                  },
                  {
                    "text": "B-cell markers CD19(+), CD20(+), CD22(+), CD79b(+)"
                  },
                  {
                    "text": "Dim CD5 in 20% of cases"
                  }
                ],
                "Follicular Lymphoma": [
                  {
                    "text": "Low magnification with neoplastic follicles"
                  },
                  {
                    "text": "Histologically may have small, ill-defined follicles, reminiscent of proliferation centers"
                  },
                  {
                    "text": "Neoplastic lymphocytes are centrocytes and centroblastsCD10, CD19, CD20, and CD22 (+); bright monoclonal sIgBCL-6(+), LMO2(+)CD5(-), CD11c(-), CD43(-)",
                    "sub_points": [
                      "CD10, CD19, CD20, and CD22 (+); bright monoclonal sIg",
                      "BCL-6(+), LMO2(+)",
                      "CD5(-), CD11c(-), CD43(-)"
                    ]
                  }
                ],
                "Hairy Cell Leukemia": [
                  {
                    "text": "Patients present with splenomegaly and pancytopenia"
                  },
                  {
                    "text": "Indented nuclei with abundant clear cytoplasm"
                  },
                  {
                    "text": "CD11c (bright +), CD19(+), CD20(+), CD22(bright +), CD25(+), and CD103(+)"
                  },
                  {
                    "text": "Faint reactivity for cyclin-D1"
                  },
                  {
                    "text": "CD5(-), CD10(-), CD23(-)"
                  },
                  {
                    "text": "TRAP stain is strongly (+) in hairy cellsCytochemical stain is specific in contrast with immunohistochemical testing for TRAP",
                    "sub_points": [
                      "Cytochemical stain is specific in contrast with immunohistochemical testing for TRAP"
                    ]
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "Dimming light with light microscopy is helpful for appreciating proliferation centers in histologic sectionsAtypical immunophenotype occurs in ~ 10-20% of casesCD23(-) or dim, bright surface Ig, CD20 (bright), CD22 (bright)",
                    "sub_points": [
                      "Atypical immunophenotype occurs in ~ 10-20% of casesCD23(-) or dim, bright surface Ig, CD20 (bright), CD22 (bright)",
                      "CD23(-) or dim, bright surface Ig, CD20 (bright), CD22 (bright)"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Diffuse Large B-Cell Lymphoma, Not Otherwise Specified": {
            "name": "Diffuse Large B-Cell Lymphoma, Not Otherwise Specified",
            "url": "https://app.pathprimer.com/document/fb8fc7d3-886a-48f2-839e-71941c0f0f47/lesson/1754477f-a4b1-4ec8-b223-cd1eb29cbd87",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Diffuse proliferation of neoplastic B cells with nuclei ≥ benign histiocyte nuclei or 2x size of small lymphocyte nuclei"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Clinically aggressive lymphoma that requires chemotherapyR-CHOP is currently standard frontline therapy30-40% of patients fail R-CHOP",
                    "sub_points": [
                      "R-CHOP is currently standard frontline therapy",
                      "30-40% of patients fail R-CHOP"
                    ]
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Diffuse growth pattern"
                  },
                  {
                    "text": "Many mitotic figures and apoptotic cells"
                  },
                  {
                    "text": "Centroblastic variant: ~ 85% of casesCells 10-14 μm, vesicular chromatin, 2-3 small nucleoli",
                    "sub_points": [
                      "Cells 10-14 μm, vesicular chromatin, 2-3 small nucleoli"
                    ]
                  },
                  {
                    "text": "Immunoblastic variant: ~ 10% of casesCells 15-20 μm, prominent central nucleolus, few centroblasts",
                    "sub_points": [
                      "Cells 15-20 μm, prominent central nucleolus, few centroblasts"
                    ]
                  },
                  {
                    "text": "Anaplastic variant: ~ 3% of casesLarge and bizarre nuclei; Reed-Sternberg-like (+/-)",
                    "sub_points": [
                      "Large and bizarre nuclei; Reed-Sternberg-like (+/-)"
                    ]
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "Pan-B-cell markers (+); Ki-67 often high"
                  },
                  {
                    "text": "Double-expressor lymphoma: MYC(+) and BCL-2(+)Correlates with poorer prognosis",
                    "sub_points": [
                      "Correlates with poorer prognosis"
                    ]
                  },
                  {
                    "text": "Common chromosomal translocations3q27/BCL6(~ 30%); t(14;18) (~ 20%); 8q24/MYC(~ 10%)Poorer prognosis associated withMYCtranslocationsMYCandBCL2translocations (double-hit lymphoma)",
                    "sub_points": [
                      "3q27/BCL6(~ 30%); t(14;18) (~ 20%); 8q24/MYC(~ 10%)",
                      "Poorer prognosis associated withMYCtranslocationsMYCandBCL2translocations (double-hit lymphoma)",
                      "MYCtranslocations",
                      "MYCandBCL2translocations (double-hit lymphoma)"
                    ]
                  },
                  {
                    "text": "Many gene mutations in DLBCL~ 150 genes can be mutated; 5-15 mutations per case",
                    "sub_points": [
                      "~ 150 genes can be mutated; 5-15 mutations per case"
                    ]
                  },
                  {
                    "text": "Gene expression profiling shows 2 groups: GCB and ABCThis binary model is insufficiently granular to guide targeted therapyRecent studies suggest 6 or more types of DLBCL",
                    "sub_points": [
                      "This binary model is insufficiently granular to guide targeted therapy",
                      "Recent studies suggest 6 or more types of DLBCL"
                    ]
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "Other specific types of large B-cell lymphoma"
                  },
                  {
                    "text": "Burkitt lymphoma"
                  },
                  {
                    "text": "Follicular lymphoma (grade 3B)"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Diffuse large B-cell lymphoma, not otherwise specified (DLBCL-NOS)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Diffuse proliferation of neoplastic B cells with nuclei ≥ benign histiocyte nuclei or 2x size of small lymphocyte nuclei"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Infectious Agents": [
                  {
                    "text": "Infection plays role in pathogenesis of DLBCLEpstein-Barr virus (EBV) and human herpesvirus 8 (HHV8) are involved in specific typesIncreased risk associated with HIV infectionAttributable primarily to immunodeficiencySome data suggest that virus has direct effectsChronic antigenic stimulation is likely involvedHepatitis C infection is risk factorLikely attributable to chronic antigenic stimulation",
                    "sub_points": [
                      "Epstein-Barr virus (EBV) and human herpesvirus 8 (HHV8) are involved in specific types",
                      "Increased risk associated with HIV infectionAttributable primarily to immunodeficiencySome data suggest that virus has direct effectsChronic antigenic stimulation is likely involved",
                      "Attributable primarily to immunodeficiency",
                      "Some data suggest that virus has direct effects",
                      "Chronic antigenic stimulation is likely involved",
                      "Hepatitis C infection is risk factorLikely attributable to chronic antigenic stimulation",
                      "Likely attributable to chronic antigenic stimulation"
                    ]
                  },
                  {
                    "text": "Chronic infection at extranodal sites can precede DLBCLHelicobacter pyloriinfection in stomach",
                    "sub_points": [
                      "Helicobacter pyloriinfection in stomach"
                    ]
                  }
                ],
                "Other Factors Involved in Pathogenesis": [
                  {
                    "text": "Immunodeficiency is risk factor for DLBCL"
                  },
                  {
                    "text": "Diseases associated with chronic B-cell antigenic stimulation increase riskAutoimmune diseasesRheumatoid arthritisHashimoto thyroiditisInfections can induce chronic B-cell antigenic stimulation",
                    "sub_points": [
                      "Autoimmune diseasesRheumatoid arthritisHashimoto thyroiditis",
                      "Rheumatoid arthritis",
                      "Hashimoto thyroiditis",
                      "Infections can induce chronic B-cell antigenic stimulation"
                    ]
                  },
                  {
                    "text": "Genetic predisposition is involvedSusceptibility loci have been linked to immune function pathways",
                    "sub_points": [
                      "Susceptibility loci have been linked to immune function pathways"
                    ]
                  }
                ],
                "Transformation of Low-Grade B-Cell Lymphomas": [
                  {
                    "text": "Low-grade B-cell lymphoma can undergo transformation to DLBCLFollicular lymphoma is most common; risk ~ 1% per yearChronic lymphocytic leukemia can progress to DLBCL (Richter syndrome)Marginal zone lymphomas and lymphoplasmacytic lymphomaLower risk of transformation than follicular lymphoma",
                    "sub_points": [
                      "Follicular lymphoma is most common; risk ~ 1% per year",
                      "Chronic lymphocytic leukemia can progress to DLBCL (Richter syndrome)",
                      "Marginal zone lymphomas and lymphoplasmacytic lymphomaLower risk of transformation than follicular lymphoma",
                      "Lower risk of transformation than follicular lymphoma"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "DLBCL is most common type of non-Hodgkin lymphoma worldwide150,000 cases per year",
                    "sub_points": [
                      "150,000 cases per year"
                    ]
                  }
                ],
                "Age": [
                  {
                    "text": "Predominantly disease of adults, especially older adultsSubset of cases in children and young adults",
                    "sub_points": [
                      "Subset of cases in children and young adults"
                    ]
                  }
                ],
                "Sex": [
                  {
                    "text": "Slightly more common in male patients"
                  }
                ],
                "Site": [
                  {
                    "text": "Lymph nodes are involved in 60-70% of patientsExtranodal sites also can be present",
                    "sub_points": [
                      "Extranodal sites also can be present"
                    ]
                  },
                  {
                    "text": "DLBCL can arise at extranodal sites in 30-40% of patientsGastrointestinal tract, head and neck region are most common",
                    "sub_points": [
                      "Gastrointestinal tract, head and neck region are most common"
                    ]
                  }
                ],
                "Presentation": [
                  {
                    "text": "Enlarging mass in nodal &/or extranodal sites"
                  },
                  {
                    "text": "Systemic B-type symptoms in 30-40% of patients"
                  },
                  {
                    "text": "Stage IV in at least 1/3 of patients"
                  },
                  {
                    "text": "Bone marrow involvement in 10-20% of patients"
                  }
                ],
                "Laboratory Tests": [
                  {
                    "text": "Patients commonly have elevated serum lactate dehydrogenase (LDH) and β-2-microglobulin levels"
                  }
                ],
                "Treatment": [
                  {
                    "text": "Standard immunochemotherapy regimen is R-CHOPRituximab, cyclophosphamide, doxorubicin, vincristine, prednisone~ 30% of patients relapse~ 10% of patients refractory to therapy",
                    "sub_points": [
                      "Rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone~ 30% of patients relapse~ 10% of patients refractory to therapy",
                      "~ 30% of patients relapse",
                      "~ 10% of patients refractory to therapy"
                    ]
                  },
                  {
                    "text": "For patients who fail R-CHOP therapySalvage includes high-dose chemotherapy and stem cell transplantation (SCT)Novel/experimental agents if SCT fails",
                    "sub_points": [
                      "Salvage includes high-dose chemotherapy and stem cell transplantation (SCT)",
                      "Novel/experimental agents if SCT fails"
                    ]
                  },
                  {
                    "text": "R-EPOCH regimen has been suggested for patients with poor prognostic featuresRituximab + etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin",
                    "sub_points": [
                      "Rituximab + etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "5-year survival: 60-70% overallPrognosis substantially poorer for those who fail R-CHOP",
                    "sub_points": [
                      "Prognosis substantially poorer for those who fail R-CHOP"
                    ]
                  },
                  {
                    "text": "Prognostic factorsInternational Prognostic Index (IPI)5 variables (1 point each) that are added (maximum score of 5)Prognosis according to IPI scoreGood (0-1), intermediate (2-3), and poor (4-5)MorphologyImmunoblastic variant associated with poorer prognosisMay be attributable to higher frequency ofMYCtranslocationsImmunophenotypeCD5 expression has been correlated with poorer prognosisDouble-expressor lymphoma associated with poorer prognosisExpression of MYC (> 40%) and BCL-2 (> 50%) by IHCCytogeneticsMYCtranslocations impart poorer prognosisParticularly whenMYCpartner is immunoglobulin geneMYCandBCL2translocations (double-hit lymphoma)MYC,BCL2,BCL6translocations known as triple-hit lymphomaImparts poorer prognosisMost cases resemble DLBCLSmaller subset of cases has Burkitt-like or small blastoid morphologyTP53mutations correlate with poorer prognosisGene expression profile (GEP)Activated B-cell (ABC) type has poorer survival than germinal center (GC) B-cell type (GCB)IHC algorithms are used as surrogates for GEPDisagreement with GEP data in 10-20% of cases",
                    "sub_points": [
                      "International Prognostic Index (IPI)5 variables (1 point each) that are added (maximum score of 5)Prognosis according to IPI scoreGood (0-1), intermediate (2-3), and poor (4-5)",
                      "5 variables (1 point each) that are added (maximum score of 5)",
                      "Prognosis according to IPI scoreGood (0-1), intermediate (2-3), and poor (4-5)",
                      "Good (0-1), intermediate (2-3), and poor (4-5)",
                      "MorphologyImmunoblastic variant associated with poorer prognosisMay be attributable to higher frequency ofMYCtranslocations",
                      "Immunoblastic variant associated with poorer prognosisMay be attributable to higher frequency ofMYCtranslocations",
                      "May be attributable to higher frequency ofMYCtranslocations",
                      "ImmunophenotypeCD5 expression has been correlated with poorer prognosisDouble-expressor lymphoma associated with poorer prognosisExpression of MYC (> 40%) and BCL-2 (> 50%) by IHC",
                      "CD5 expression has been correlated with poorer prognosis",
                      "Double-expressor lymphoma associated with poorer prognosisExpression of MYC (> 40%) and BCL-2 (> 50%) by IHC",
                      "Expression of MYC (> 40%) and BCL-2 (> 50%) by IHC",
                      "CytogeneticsMYCtranslocations impart poorer prognosisParticularly whenMYCpartner is immunoglobulin geneMYCandBCL2translocations (double-hit lymphoma)MYC,BCL2,BCL6translocations known as triple-hit lymphomaImparts poorer prognosisMost cases resemble DLBCLSmaller subset of cases has Burkitt-like or small blastoid morphology",
                      "MYCtranslocations impart poorer prognosisParticularly whenMYCpartner is immunoglobulin gene",
                      "Particularly whenMYCpartner is immunoglobulin gene",
                      "MYCandBCL2translocations (double-hit lymphoma)MYC,BCL2,BCL6translocations known as triple-hit lymphomaImparts poorer prognosisMost cases resemble DLBCLSmaller subset of cases has Burkitt-like or small blastoid morphology",
                      "MYC,BCL2,BCL6translocations known as triple-hit lymphoma",
                      "Imparts poorer prognosis",
                      "Most cases resemble DLBCL",
                      "Smaller subset of cases has Burkitt-like or small blastoid morphology",
                      "TP53mutations correlate with poorer prognosis",
                      "Gene expression profile (GEP)Activated B-cell (ABC) type has poorer survival than germinal center (GC) B-cell type (GCB)IHC algorithms are used as surrogates for GEPDisagreement with GEP data in 10-20% of cases",
                      "Activated B-cell (ABC) type has poorer survival than germinal center (GC) B-cell type (GCB)",
                      "IHC algorithms are used as surrogates for GEPDisagreement with GEP data in 10-20% of cases",
                      "Disagreement with GEP data in 10-20% of cases"
                    ]
                  }
                ]
              },
              "IMAGING": {
                "Radiographic Findings": [
                  {
                    "text": "Enlarged lymph nodes or extranodal mass by CT or MR"
                  },
                  {
                    "text": "PET/CT shows increased F-18 FDG uptakeReported as standardized uptake value (SUV)",
                    "sub_points": [
                      "Reported as standardized uptake value (SUV)"
                    ]
                  }
                ]
              },
              "MACROSCOPIC": {
                "Size": [
                  {
                    "text": "Can be small or form large mass, especially at extranodal sitesNecrosis common in large masses",
                    "sub_points": [
                      "Necrosis common in large masses"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Diffuse growth patternReplacement of normal architecture by dense infiltrate of lymphoma cellsSclerosis frequent, particularly in extranodal sitesCan be fine or coarseCan impart vaguely nodular appearanceMitotic figures and apoptotic cells often numerous",
                    "sub_points": [
                      "Replacement of normal architecture by dense infiltrate of lymphoma cells",
                      "Sclerosis frequent, particularly in extranodal sitesCan be fine or coarseCan impart vaguely nodular appearance",
                      "Can be fine or coarse",
                      "Can impart vaguely nodular appearance",
                      "Mitotic figures and apoptotic cells often numerous"
                    ]
                  },
                  {
                    "text": "Centroblastic variant: ~ 85% of casesComposed predominantly of centroblasts (large noncleaved cells)Medium-size to large cells (10-14 μm) with vesicular chromatin2-3 nucleoli apposed to nuclear membrane and scant to moderate cytoplasmMultilobated: Lymphoma cells have multilobated nuclear contoursMore common at extranodal sites, e.g., bonesPolymorphous: Mix of centroblasts, immunoblasts, and cells with overlapping features",
                    "sub_points": [
                      "Composed predominantly of centroblasts (large noncleaved cells)Medium-size to large cells (10-14 μm) with vesicular chromatin2-3 nucleoli apposed to nuclear membrane and scant to moderate cytoplasm",
                      "Medium-size to large cells (10-14 μm) with vesicular chromatin2-3 nucleoli apposed to nuclear membrane and scant to moderate cytoplasm",
                      "2-3 nucleoli apposed to nuclear membrane and scant to moderate cytoplasm",
                      "Multilobated: Lymphoma cells have multilobated nuclear contoursMore common at extranodal sites, e.g., bones",
                      "More common at extranodal sites, e.g., bones",
                      "Polymorphous: Mix of centroblasts, immunoblasts, and cells with overlapping features"
                    ]
                  },
                  {
                    "text": "Immunoblastic variant: ~ 10% of casesImmunoblasts are large with prominent central nucleoliOften strands of chromatin attach nucleolus to nuclear membrane (\"spider legs\")± plasmacytoid differentiationTraditional definition: > 90% immunoblastsAlternative definition proposed: < 10% centroblasts",
                    "sub_points": [
                      "Immunoblasts are large with prominent central nucleoliOften strands of chromatin attach nucleolus to nuclear membrane (\"spider legs\")± plasmacytoid differentiation",
                      "Often strands of chromatin attach nucleolus to nuclear membrane (\"spider legs\")",
                      "± plasmacytoid differentiation",
                      "Traditional definition: > 90% immunoblasts",
                      "Alternative definition proposed: < 10% centroblasts"
                    ]
                  },
                  {
                    "text": "Anaplastic variant: ~ 3% of casesCells have anaplastic nuclei; often Hodgkin or Reed-Sternberg cell-like",
                    "sub_points": [
                      "Cells have anaplastic nuclei; often Hodgkin or Reed-Sternberg cell-like"
                    ]
                  },
                  {
                    "text": "Other rare (< 1%) morphologic variants of DLBCL-NOS reportedSinusoidal, signet ring, myxoid, spindle cell, rosette-like",
                    "sub_points": [
                      "Sinusoidal, signet ring, myxoid, spindle cell, rosette-like"
                    ]
                  }
                ],
                "More Specific Types of Large B-Cell Lymphoma in WHO Classification": [
                  {
                    "text": "T-cell/histiocyte-rich large B-cell lymphomaLymphoma cells usually < 10%; many T cells &/or histiocytes",
                    "sub_points": [
                      "Lymphoma cells usually < 10%; many T cells &/or histiocytes"
                    ]
                  },
                  {
                    "text": "DLBCL/high-grade B-cell lymphoma with double-hit geneticsMYCandBCL2translocations",
                    "sub_points": [
                      "MYCandBCL2translocations"
                    ]
                  },
                  {
                    "text": "ALK(+) large B-cell lymphomaALKabnormalities; plasmablastic immunophenotype",
                    "sub_points": [
                      "ALKabnormalities; plasmablastic immunophenotype"
                    ]
                  },
                  {
                    "text": "Large B-cell lymphoma withIRF4rearrangementStrongly MUM1/IRF4(+);IGH::IFR4(+)",
                    "sub_points": [
                      "Strongly MUM1/IRF4(+);IGH::IFR4(+)"
                    ]
                  },
                  {
                    "text": "High-grade B-cell lymphoma with 11q aberrationsOften resembles Burkitt lymphoma but noMYCtranslocation",
                    "sub_points": [
                      "Often resembles Burkitt lymphoma but noMYCtranslocation"
                    ]
                  },
                  {
                    "text": "Lymphomatoid granulomatosisLungs in > 95% of patients; bilateral; angiocentric; EBV(+)",
                    "sub_points": [
                      "Lungs in > 95% of patients; bilateral; angiocentric; EBV(+)"
                    ]
                  },
                  {
                    "text": "EBV(+) DLBCLOften but not exclusively occurs in older adult patientsNo known immunodeficiency",
                    "sub_points": [
                      "Often but not exclusively occurs in older adult patients",
                      "No known immunodeficiency"
                    ]
                  },
                  {
                    "text": "DLBCL associated with chronic inflammationRare; associated with hypoxic microenvironment; usually EBV(+)",
                    "sub_points": [
                      "Rare; associated with hypoxic microenvironment; usually EBV(+)"
                    ]
                  },
                  {
                    "text": "Fibrin-associated LBCLMinute; associated with hypoxic microenvironment; EBV(+)Therapy for DLBCL may not be required",
                    "sub_points": [
                      "Minute; associated with hypoxic microenvironment; EBV(+)",
                      "Therapy for DLBCL may not be required"
                    ]
                  },
                  {
                    "text": "Fluid overload-associated LBCLPatients often have heart failure; HHV8(-)",
                    "sub_points": [
                      "Patients often have heart failure; HHV8(-)"
                    ]
                  },
                  {
                    "text": "Plasmablastic lymphomaCD138(+), CD20(-); EBV often (+)",
                    "sub_points": [
                      "CD138(+), CD20(-); EBV often (+)"
                    ]
                  },
                  {
                    "text": "Primary cutaneous DLBCL, leg typeArises in skin; often on lower legs of older patients",
                    "sub_points": [
                      "Arises in skin; often on lower legs of older patients"
                    ]
                  },
                  {
                    "text": "Primary LBCL of immune-privileged sitesPrimary DLBCL of central nervous systemIncludes intraocular LBCLPrimary DLBCL of testis",
                    "sub_points": [
                      "Primary DLBCL of central nervous systemIncludes intraocular LBCL",
                      "Includes intraocular LBCL",
                      "Primary DLBCL of testis"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "Pan-B-cell antigens (+)"
                  },
                  {
                    "text": "GC markers positive in subsetCD10(+), BCL-6(+), LM02(+)Centerin/GCET1(+), HGAL/GCET2(+)",
                    "sub_points": [
                      "CD10(+), BCL-6(+), LM02(+)",
                      "Centerin/GCET1(+), HGAL/GCET2(+)"
                    ]
                  },
                  {
                    "text": "BCL-2(+/-), CD30(-/+)"
                  },
                  {
                    "text": "Proliferation fraction (Ki-67) usually high (> 40%)"
                  },
                  {
                    "text": "Various IHC algorithms proposed as surrogates for GCB and ABC typesKnown in this context as GCB vs. non-GCBHans et al algorithm best knownOthers: Choi et al, Meyer et al, Visco-Young et al",
                    "sub_points": [
                      "Known in this context as GCB vs. non-GCB",
                      "Hans et al algorithm best knownOthers: Choi et al, Meyer et al, Visco-Young et al",
                      "Others: Choi et al, Meyer et al, Visco-Young et al"
                    ]
                  },
                  {
                    "text": "CD5(+) in ~ 5% of cases; usually ABC type"
                  },
                  {
                    "text": "Double-expressor lymphoma with MYC(+) and BCL-2(+)Common cutoffs: 40% for MYC and 50% for BCL-2",
                    "sub_points": [
                      "Common cutoffs: 40% for MYC and 50% for BCL-2"
                    ]
                  }
                ],
                "Genetic Testing": [
                  {
                    "text": "Most common chromosomal translocations in DLBCLTranslocations involving 3q27/BCL6in ~ 30%t(14;18)(q32;q21)/IGH::BCL2in ~ 20%Translocations involving 8q24/MYCin ~ 10%",
                    "sub_points": [
                      "Translocations involving 3q27/BCL6in ~ 30%",
                      "t(14;18)(q32;q21)/IGH::BCL2in ~ 20%",
                      "Translocations involving 8q24/MYCin ~ 10%"
                    ]
                  },
                  {
                    "text": "TP53mutations in ~ 20%"
                  }
                ],
                "Gene Expression Profiling": [
                  {
                    "text": "Expression microarray studies have established 2 major groups of DLBCLGCB: GEP similar to GC B cellsABC: GEP similar to activated B cells",
                    "sub_points": [
                      "GCB: GEP similar to GC B cells",
                      "ABC: GEP similar to activated B cells"
                    ]
                  }
                ],
                "Gene Mutation Analysis": [
                  {
                    "text": "Wide variety and number of gene mutations in DLBCLIn GCB typeGenes involved in DNA acetylation or histone modificationCREBBP,EP300,EZH2,KMT2D(MLL2)In ABC typeCARD11,MYD88,CD79A/CD79BMALT1,BCL10,TNFAIP3In both GCB and ABCImmune surveillance genes:CD58,B2M,TNFRSF14,CIITATP53",
                    "sub_points": [
                      "In GCB typeGenes involved in DNA acetylation or histone modificationCREBBP,EP300,EZH2,KMT2D(MLL2)",
                      "Genes involved in DNA acetylation or histone modificationCREBBP,EP300,EZH2,KMT2D(MLL2)",
                      "CREBBP,EP300,EZH2,KMT2D(MLL2)",
                      "In ABC typeCARD11,MYD88,CD79A/CD79BMALT1,BCL10,TNFAIP3",
                      "CARD11,MYD88,CD79A/CD79B",
                      "MALT1,BCL10,TNFAIP3",
                      "In both GCB and ABCImmune surveillance genes:CD58,B2M,TNFRSF14,CIITATP53",
                      "Immune surveillance genes:CD58,B2M,TNFRSF14,CIITA",
                      "TP53"
                    ]
                  },
                  {
                    "text": "Mutated genes potential targets for therapyParticularly inhibitors of oncogenes that cause activatione.g., ibrutinib (inhibitor of Bruton tyrosine kinase)",
                    "sub_points": [
                      "Particularly inhibitors of oncogenes that cause activatione.g., ibrutinib (inhibitor of Bruton tyrosine kinase)",
                      "e.g., ibrutinib (inhibitor of Bruton tyrosine kinase)"
                    ]
                  },
                  {
                    "text": "3 genetic studies show that GCB vs. ABC model is insufficiently granularAt least 6 genetic types of DLBCL-NOSAlso subtypes among these 6 groupsMuch consensus between studies",
                    "sub_points": [
                      "At least 6 genetic types of DLBCL-NOSAlso subtypes among these 6 groupsMuch consensus between studies",
                      "Also subtypes among these 6 groups",
                      "Much consensus between studies"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Burkitt Lymphoma": [
                  {
                    "text": "Monomorphic, medium-size cells with multiple small nucleoli"
                  },
                  {
                    "text": "Numerous mitoses and starry-sky pattern"
                  },
                  {
                    "text": "CD10(+), CD20(+), BCL-6 (+), BCL-2(-), Ki-67 ~ 100%"
                  },
                  {
                    "text": "MYCtranslocations with immunoglobulin loci are characteristic"
                  }
                ],
                "DLBCL/High-Grade B-Cell Lymphoma WithMYCandBCL2Translocations": [
                  {
                    "text": "a.k.a. double-hit lymphoma"
                  },
                  {
                    "text": "Can morphologically resemble DLBCL, Burkitt-like, or small blastoid cell"
                  }
                ],
                "High-Grade B-Cell Lymphoma, Not Otherwise Specified": [
                  {
                    "text": "Morphology: High-grade, Burkitt-like featuresStarry-sky pattern common; high mitotic rate; high apoptosis",
                    "sub_points": [
                      "Starry-sky pattern common; high mitotic rate; high apoptosis"
                    ]
                  }
                ],
                "Follicular Large B-Cell Lymphoma": [
                  {
                    "text": "Follicular architecture required; can be associated with diffuse areas"
                  },
                  {
                    "text": "CD21, CD23, or CD35 highlights follicular dendritic cells in follicular areas"
                  }
                ],
                "Primary Mediastinal Large B-Cell Lymphoma": [
                  {
                    "text": "Confined to mediastinum; likely thymic origin"
                  },
                  {
                    "text": "Morphologically resembles DLBCL"
                  },
                  {
                    "text": "Pan-B-cell antigens (+), CD30(+) in ~ 75%, CD23(+) in ~ 70%"
                  }
                ],
                "Plasmablastic Lymphoma": [
                  {
                    "text": "Large, neoplastic cells that can resemble plasmablasts or immunoblastsPlasmablasts can have eccentrically located nuclei and abundant purple, plasmacytoid cytoplasmCD38(+), CD138(+), MUM1/IRF4(+), CD20(-), pax-5(-)",
                    "sub_points": [
                      "Plasmablasts can have eccentrically located nuclei and abundant purple, plasmacytoid cytoplasm",
                      "CD38(+), CD138(+), MUM1/IRF4(+), CD20(-), pax-5(-)"
                    ]
                  }
                ],
                "ALK(+) Large B-Cell Lymphoma": [
                  {
                    "text": "Large neoplastic cells often resemble plasmablasts"
                  },
                  {
                    "text": "ALK(+) with cytoplasmic or cytoplasmic and nuclear pattern"
                  },
                  {
                    "text": "t(2;17)(p23;q23/ALK::CLTCmost common; 7 other translocations"
                  }
                ],
                "Intravascular Large B-Cell Lymphoma": [
                  {
                    "text": "Exclusively intravascular location of lymphoma cells"
                  },
                  {
                    "text": "Lymphoma cells usually resemble centroblasts"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "ALK(+) Anaplastic Large Cell Lymphoma": {
            "name": "ALK(+) Anaplastic Large Cell Lymphoma",
            "url": "https://app.pathprimer.com/document/b1f5c405-683d-4b63-9f04-76c2cbebda99/lesson/1754477f-a4b1-4ec8-b223-cd1eb29cbd87",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "ALK(+) ALCL is systemic T-cell neoplasm usually composed of large and anaplastic cells associated with translocations involvingALKand overexpression of ALK"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Most common in children and younger adults"
                  },
                  {
                    "text": "M:F ~ 2:1"
                  },
                  {
                    "text": "B symptoms common, especially fever"
                  },
                  {
                    "text": "~ 75% of patients present with clinical stage III/IV disease"
                  },
                  {
                    "text": "Extranodal involvement common in 40-60% of patientsSpleen (~ 15%), lungs (~ 10%)Skin (~ 10%), soft tissue (~ 5%), liver (~ 5%)Bone marrow (+) in 10-30%",
                    "sub_points": [
                      "Spleen (~ 15%), lungs (~ 10%)",
                      "Skin (~ 10%), soft tissue (~ 5%), liver (~ 5%)",
                      "Bone marrow (+) in 10-30%"
                    ]
                  },
                  {
                    "text": "International Prognostic Index often high"
                  },
                  {
                    "text": "Very good response to chemotherapy5-year survival: ~ 80%",
                    "sub_points": [
                      "5-year survival: ~ 80%"
                    ]
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Lymph node sinusoids often involved"
                  },
                  {
                    "text": "Paracortical or diffuse replacement"
                  },
                  {
                    "text": "Neoplastic cells are usually large, irregular, and pleomorphicHallmark cells are commonEccentric horseshoe- or kidney-shaped nucleusProminent eosinophilic, paranuclear (Golgi) region",
                    "sub_points": [
                      "Hallmark cells are commonEccentric horseshoe- or kidney-shaped nucleusProminent eosinophilic, paranuclear (Golgi) region",
                      "Eccentric horseshoe- or kidney-shaped nucleus",
                      "Prominent eosinophilic, paranuclear (Golgi) region"
                    ]
                  },
                  {
                    "text": "Histologic variantsCommon or classic: ~ 80%Lymphohistiocytic: ~ 5-10%Small cell: ~ 5-10%Hodgkin-like: < 5%",
                    "sub_points": [
                      "Common or classic: ~ 80%",
                      "Lymphohistiocytic: ~ 5-10%",
                      "Small cell: ~ 5-10%",
                      "Hodgkin-like: < 5%"
                    ]
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "Immunophenotypic studies needed to confirm diagnosisALK(+), CD30(+)",
                    "sub_points": [
                      "ALK(+), CD30(+)"
                    ]
                  },
                  {
                    "text": "All cases associated withALKrearrangementst(2;5)(p23;q35)/NPM1::ALKdetected in ~ 75%",
                    "sub_points": [
                      "t(2;5)(p23;q35)/NPM1::ALKdetected in ~ 75%"
                    ]
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "ALK(-) ALCL"
                  },
                  {
                    "text": "Primary cutaneous ALCL"
                  },
                  {
                    "text": "Classic Hodgkin lymphoma"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Anaplastic large cell lymphoma (ALCL)"
                  },
                  {
                    "text": "Anaplastic lymphoma kinase (ALK)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "ALK(+) ALCL is systemic T-cell neoplasm usually composed of large and anaplastic cells associated with translocations involvingALKand overexpression of ALK"
                  },
                  {
                    "text": "Current World Health Organization distinguishes 4 types of ALCLALK(+) ALCLALK(-) ALCLBreast implant-associated ALCLPrimary cutaneous ALCL",
                    "sub_points": [
                      "ALK(+) ALCL",
                      "ALK(-) ALCL",
                      "Breast implant-associated ALCL",
                      "Primary cutaneous ALCL"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Genetic Abnormalities": [
                  {
                    "text": "ALKtranslocations and ALK overexpression are essential but insufficient to induce lymphomagenesis"
                  },
                  {
                    "text": "Many cellular pathways are activatedJAK-STATPhosphorylation of STAT3 plays major role in maintaining neoplastic phenotypeUpregulates CAAT/enhance binding protein beta (C/EBPβ)Phospholipase C-gammamTOR, PI3K/AKTRAS/ERK/MAPKCdc42/Rac1, JNK/c-Jun",
                    "sub_points": [
                      "JAK-STATPhosphorylation of STAT3 plays major role in maintaining neoplastic phenotypeUpregulates CAAT/enhance binding protein beta (C/EBPβ)",
                      "Phosphorylation of STAT3 plays major role in maintaining neoplastic phenotypeUpregulates CAAT/enhance binding protein beta (C/EBPβ)",
                      "Upregulates CAAT/enhance binding protein beta (C/EBPβ)",
                      "Phospholipase C-gamma",
                      "mTOR, PI3K/AKT",
                      "RAS/ERK/MAPK",
                      "Cdc42/Rac1, JNK/c-Jun"
                    ]
                  },
                  {
                    "text": "Gene expression profilingDistinctive signature enriched for HIF-1α, IL10, and RAS pathway genesALK(+) and ALK(-) ALCL cases share similar profiles",
                    "sub_points": [
                      "Distinctive signature enriched for HIF-1α, IL10, and RAS pathway genes",
                      "ALK(+) and ALK(-) ALCL cases share similar profiles"
                    ]
                  },
                  {
                    "text": "Gene mutations also occur in ALK(+) ALCLLRP1B(~ 20%),TP53(~ 10%)Chromatin modifying genesKMT2D,KMT2C,TET2,EP300",
                    "sub_points": [
                      "LRP1B(~ 20%),TP53(~ 10%)",
                      "Chromatin modifying genesKMT2D,KMT2C,TET2,EP300",
                      "KMT2D,KMT2C,TET2,EP300"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "0.25 per 100,000 person years"
                  }
                ],
                "Age": [
                  {
                    "text": "Most common in children and younger adults"
                  }
                ],
                "Sex": [
                  {
                    "text": "Male predominance (M:F ~ 2:1)"
                  }
                ],
                "Ethnicity": [
                  {
                    "text": "Incidence higher in White than in Black or Asian populations"
                  }
                ],
                "Presentation": [
                  {
                    "text": "B symptoms, especially fever"
                  },
                  {
                    "text": "~ 75% of patients present with clinical stage III/IV disease"
                  },
                  {
                    "text": "Extranodal involvement common in 40-60% of patientsSpleen (~ 15%), lungs (~ 10%)Skin (~ 10%), soft tissue (~ 5%), liver (~ 5%)Involvement of central nervous system is rare",
                    "sub_points": [
                      "Spleen (~ 15%), lungs (~ 10%)",
                      "Skin (~ 10%), soft tissue (~ 5%), liver (~ 5%)",
                      "Involvement of central nervous system is rare"
                    ]
                  },
                  {
                    "text": "Bone marrow involvement reported to be 10-30%Immunohistochemistry for ALK &/or CD30 increases frequency of detection",
                    "sub_points": [
                      "Immunohistochemistry for ALK &/or CD30 increases frequency of detection"
                    ]
                  },
                  {
                    "text": "International Prognostic Index (IPI) is often high"
                  }
                ],
                "Treatment": [
                  {
                    "text": "Intensive chemotherapy, doxorubicin-based regimens"
                  },
                  {
                    "text": "Brentuximab vedotin (anti-CD30 drug conjugate)"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "5-year overall survival: ~ 80%; 5-year progression-free survival: ~ 70%"
                  },
                  {
                    "text": "Markers of poorer prognosis> 1 extranodal site involved and high IPILeukemic involvement",
                    "sub_points": [
                      "> 1 extranodal site involved and high IPI",
                      "Leukemic involvement"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Sinusoids often involved; paracortical or diffuse replacement"
                  },
                  {
                    "text": "Neoplastic cells tend to aggregate around blood vessels"
                  },
                  {
                    "text": "Prominent starry-sky pattern can be present"
                  },
                  {
                    "text": "Neoplastic cells are usually large, irregular, and pleomorphicVariability in cell sizeHallmark cells are common",
                    "sub_points": [
                      "Variability in cell size",
                      "Hallmark cells are common"
                    ]
                  },
                  {
                    "text": "Hallmark cellLarge with eccentric horseshoe- or kidney-shaped nucleusHas prominent eosinophilic, paranuclear (Golgi) region",
                    "sub_points": [
                      "Large with eccentric horseshoe- or kidney-shaped nucleus",
                      "Has prominent eosinophilic, paranuclear (Golgi) region"
                    ]
                  },
                  {
                    "text": "There are many histologic variants of ALK(+) ALCL4 variants recognized in WHO classificationCommon or classic: ~ 80%Lymphohistiocytic: ~ 5-10%Numerous histiocytes can obscure neoplastic cellsSmall cell: ~ 5-10%Neoplastic cells are small; rare hallmark cellsHodgkin-likeNodular; often with fibrous bandsOther rare variants of ALK(+) ALCL includeMonomorphic: ~ 2-3%Sarcomatoid: ~ 1%Giant cell rich, signet-ring cell-likeNeutrophil rich, eosinophil richMyxomatous or granulation tissue-like",
                    "sub_points": [
                      "4 variants recognized in WHO classificationCommon or classic: ~ 80%Lymphohistiocytic: ~ 5-10%Numerous histiocytes can obscure neoplastic cellsSmall cell: ~ 5-10%Neoplastic cells are small; rare hallmark cellsHodgkin-likeNodular; often with fibrous bands",
                      "Common or classic: ~ 80%",
                      "Lymphohistiocytic: ~ 5-10%Numerous histiocytes can obscure neoplastic cells",
                      "Numerous histiocytes can obscure neoplastic cells",
                      "Small cell: ~ 5-10%Neoplastic cells are small; rare hallmark cells",
                      "Neoplastic cells are small; rare hallmark cells",
                      "Hodgkin-likeNodular; often with fibrous bands",
                      "Nodular; often with fibrous bands",
                      "Other rare variants of ALK(+) ALCL includeMonomorphic: ~ 2-3%Sarcomatoid: ~ 1%Giant cell rich, signet-ring cell-likeNeutrophil rich, eosinophil richMyxomatous or granulation tissue-like",
                      "Monomorphic: ~ 2-3%",
                      "Sarcomatoid: ~ 1%",
                      "Giant cell rich, signet-ring cell-like",
                      "Neutrophil rich, eosinophil rich",
                      "Myxomatous or granulation tissue-like"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "CD30(+); strong and uniformMembranous and paranuclear (target-like) pattern",
                    "sub_points": [
                      "Membranous and paranuclear (target-like) pattern"
                    ]
                  },
                  {
                    "text": "ALK(+) and pattern correlates with underlying genetic abnormalityt(2;5)(p23;q35): ALK is nuclear and cytoplasmicMost other abnormalities: ALK is cytoplasmict(2;17)(p23;q25): ALK is cytoplasmic and granular (or \"fluffy\")t(X;2)(q11-12;p23): ALK is membranous",
                    "sub_points": [
                      "t(2;5)(p23;q35): ALK is nuclear and cytoplasmic",
                      "Most other abnormalities: ALK is cytoplasmic",
                      "t(2;17)(p23;q25): ALK is cytoplasmic and granular (or \"fluffy\")",
                      "t(X;2)(q11-12;p23): ALK is membranous"
                    ]
                  },
                  {
                    "text": "Cytotoxic molecules (+), clusterin (+)"
                  },
                  {
                    "text": "EMA(+/-), CD45/LCA(+/-), p53(+/-)"
                  },
                  {
                    "text": "BCL-2(-), Epstein-Barr virus LMP1 (-), B-cell antigens (-)"
                  }
                ],
                "Flow Cytometry": [
                  {
                    "text": "ALCL can be of T-cell (~ 90%) lineage or null cell (~ 10%)"
                  },
                  {
                    "text": "T-cell cases often show an aberrant immunophenotypeMost cases are CD2(+), CD43(+), CD45(+)CD3(-/+), CD5(-/+), CD7(-/+), T-cell receptors (-/+)",
                    "sub_points": [
                      "Most cases are CD2(+), CD43(+), CD45(+)",
                      "CD3(-/+), CD5(-/+), CD7(-/+), T-cell receptors (-/+)"
                    ]
                  },
                  {
                    "text": "Null-cell cases lack all T-cell antigens"
                  },
                  {
                    "text": "Neoplastic cells are often found in monocyte gate"
                  }
                ],
                "In Situ Hybridization": [
                  {
                    "text": "EBER(-)"
                  }
                ],
                "PCR": [
                  {
                    "text": "ClonalTRGandTRBrearrangements in ~ 90% of cases"
                  }
                ],
                "Genetic Testing": [
                  {
                    "text": "ALK(+) ALCL characterized by chromosomal translocations involvingALKgene at 2p23"
                  },
                  {
                    "text": "Methods used for demonstratingALKabnormalitiesConventional cytogenetics, FISHFISH, long-range PCR",
                    "sub_points": [
                      "Conventional cytogenetics, FISH",
                      "FISH, long-range PCR"
                    ]
                  },
                  {
                    "text": "Chromosomal translocationst(2;5)(p23;q35) in 75-80% of casest(2;5) juxtaposes nucleophosmin gene at 5q35 withALKgene at 2p23Variant chromosomal abnormalities in ~ 25% of cases",
                    "sub_points": [
                      "t(2;5)(p23;q35) in 75-80% of casest(2;5) juxtaposes nucleophosmin gene at 5q35 withALKgene at 2p23",
                      "t(2;5) juxtaposes nucleophosmin gene at 5q35 withALKgene at 2p23",
                      "Variant chromosomal abnormalities in ~ 25% of cases"
                    ]
                  },
                  {
                    "text": "Gene expression and microRNA profiles of ALK(+) ALCL are distinctiveShare some features with ALK(-) ALCL",
                    "sub_points": [
                      "Share some features with ALK(-) ALCL"
                    ]
                  },
                  {
                    "text": "Comparative genomic hybridizationMean of 4 chromosomal imbalancesCommon gains: 2q, 7p, 17p, 17qCommon losses: 4q, 11q, 13q",
                    "sub_points": [
                      "Mean of 4 chromosomal imbalancesCommon gains: 2q, 7p, 17p, 17qCommon losses: 4q, 11q, 13q",
                      "Common gains: 2q, 7p, 17p, 17q",
                      "Common losses: 4q, 11q, 13q"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "ALK(-) ALCL": [
                  {
                    "text": "Morphologically resembles ALK(+) ALCLStrong, uniform CD30(+) but ALK(-)",
                    "sub_points": [
                      "Strong, uniform CD30(+) but ALK(-)"
                    ]
                  },
                  {
                    "text": "ALK(-) ALCL is clinically and genetically heterogeneousCases withTP63rearrangements: Poor prognosisCases withDUSP22rearrangements: Good prognosis3rd group is negative for both: Intermediate prognosis",
                    "sub_points": [
                      "Cases withTP63rearrangements: Poor prognosis",
                      "Cases withDUSP22rearrangements: Good prognosis",
                      "3rd group is negative for both: Intermediate prognosis"
                    ]
                  }
                ],
                "Classic Hodgkin Lymphoma": [
                  {
                    "text": "Hodgkin and Reed-Sternberg (HRS) cells in inflammatory cell background"
                  },
                  {
                    "text": "HRS cells are CD15(+/-), CD30(+), pax-5 (weak +)ALK(-), CD45(-)",
                    "sub_points": [
                      "ALK(-), CD45(-)"
                    ]
                  }
                ],
                "Diffuse Large B-Cell Lymphoma": [
                  {
                    "text": "10-15% of diffuse large B-cell lymphoma (DLBCL) cases are CD30(+)"
                  },
                  {
                    "text": "3-5% of DLBCL cases have anaplastic morphologic features"
                  },
                  {
                    "text": "CD20(+), pax-5(+), ALK(-), T-cell antigens (-)"
                  }
                ],
                "ALK(+) Large B-Cell Lymphoma": [
                  {
                    "text": "Unique subset of DLBCL that carries t(2;17) or rarely t(2;5)Plasmablastic morphologyCD138(+), IgA(+) CD4(+/-), CD79a(-/+), CD30(-)",
                    "sub_points": [
                      "Plasmablastic morphology",
                      "CD138(+), IgA(+) CD4(+/-), CD79a(-/+), CD30(-)"
                    ]
                  }
                ],
                "Peripheral T-Cell Lymphoma, Not Otherwise Specified": [
                  {
                    "text": "Distribution of neoplastic cells is rarely sinusoidal"
                  },
                  {
                    "text": "Cytologic features are not anaplastic"
                  },
                  {
                    "text": "CD3(+), CD5(+), CD30(-/+), T-cell receptor (+)"
                  }
                ],
                "Cutaneous CD30(+) Lymphoproliferative Disorders": [
                  {
                    "text": "Spectrum of neoplasmsLymphomatoid papulosis (LyP)Primary cutaneous ALCL",
                    "sub_points": [
                      "Lymphomatoid papulosis (LyP)",
                      "Primary cutaneous ALCL"
                    ]
                  },
                  {
                    "text": "Diagnosis depends on correlation of clinical and histologic findings"
                  },
                  {
                    "text": "LyP: Grouped or disseminated papules that regress spontaneously after few weeksMany histologic subtypes",
                    "sub_points": [
                      "Many histologic subtypes"
                    ]
                  },
                  {
                    "text": "Primary cutaneous ALCL usually presents as solitary nodule that rapidly grows and often ulceratesCD30(+), CD2(+), CD4(+)Rare (~ 2%) cases are ALK(+)Often CD3(-), CD5(-), EMA(-)",
                    "sub_points": [
                      "CD30(+), CD2(+), CD4(+)",
                      "Rare (~ 2%) cases are ALK(+)",
                      "Often CD3(-), CD5(-), EMA(-)"
                    ]
                  }
                ],
                "Others Tumors Expressing ALK Protein": [
                  {
                    "text": "ALK fusion genes &/or expression occurs in solid cancersAdenocarcinoma of lung~ 6% of all non-small cell carcinomas; younger patientsMucinous > solid > papillary > acinar > lepidicInflammatory myofibroblastic tumor",
                    "sub_points": [
                      "Adenocarcinoma of lung~ 6% of all non-small cell carcinomas; younger patientsMucinous > solid > papillary > acinar > lepidic",
                      "~ 6% of all non-small cell carcinomas; younger patients",
                      "Mucinous > solid > papillary > acinar > lepidic",
                      "Inflammatory myofibroblastic tumor"
                    ]
                  },
                  {
                    "text": "Expression of ALK proteins also observed inNeuroblastoma, glioblastoma, alveolar rhabdomyosarcomaALK is often full length and inactive",
                    "sub_points": [
                      "Neuroblastoma, glioblastoma, alveolar rhabdomyosarcoma",
                      "ALK is often full length and inactive"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "ALK(-) Anaplastic Large Cell Lymphoma": {
            "name": "ALK(-) Anaplastic Large Cell Lymphoma",
            "url": "https://app.pathprimer.com/document/447a9f96-5aef-475b-af6a-1ef1c8684693/lesson/1754477f-a4b1-4ec8-b223-cd1eb29cbd87",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Systemic T-cell neoplasm composed of large, anaplastic cells that closely resembles ALK(+) ALCLNo evidence ofALKtranslocations or ALK overexpression",
                    "sub_points": [
                      "No evidence ofALKtranslocations or ALK overexpression"
                    ]
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Median age: 6th decade"
                  },
                  {
                    "text": "Most patients present with nodal disease"
                  },
                  {
                    "text": "~ 70% of patients have stage III/IV disease"
                  },
                  {
                    "text": "ALK(-) ALCL is heterogeneous with at least 3 subsets~ 30% withDUSP22translocations~ 8% withTP63translocations: Poor prognosis50-60% double negative: Intermediate prognosis",
                    "sub_points": [
                      "~ 30% withDUSP22translocations",
                      "~ 8% withTP63translocations: Poor prognosis",
                      "50-60% double negative: Intermediate prognosis"
                    ]
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Closely mimics classic variant of ALK(+) ALCLCohesive growth pattern; often sinusoidal involvementOften more cytologically anaplastic with less hallmark cells than ALK(+) ALCLDUSP22rearranged cases showSheet-like growth, more monomorphic than other ALK(-) ALCL cases; doughnut cells common",
                    "sub_points": [
                      "Cohesive growth pattern; often sinusoidal involvement",
                      "Often more cytologically anaplastic with less hallmark cells than ALK(+) ALCL",
                      "DUSP22rearranged cases showSheet-like growth, more monomorphic than other ALK(-) ALCL cases; doughnut cells common",
                      "Sheet-like growth, more monomorphic than other ALK(-) ALCL cases; doughnut cells common"
                    ]
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "CD30 strongly and uniformly (+), ALK(-)"
                  },
                  {
                    "text": "Aberrant T-cell immunophenotypes common"
                  },
                  {
                    "text": "Clusterin (+), PD-L1 often (+), cytotoxic molecules often (+)"
                  },
                  {
                    "text": "JAK-STAT and PI3K pathways activated"
                  },
                  {
                    "text": "DUSP22rearranged cases differPD-L1(-), Cytotoxic molecules (-)JAK-STAT pathway not activated",
                    "sub_points": [
                      "PD-L1(-), Cytotoxic molecules (-)",
                      "JAK-STAT pathway not activated"
                    ]
                  },
                  {
                    "text": "Monoclonal T-cell receptor gene rearrangements"
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "ALK(+) anaplastic large cell lymphoma"
                  },
                  {
                    "text": "Peripheral T-cell lymphoma, not otherwise specified"
                  },
                  {
                    "text": "Diffuse large B-cell lymphoma, anaplastic variant"
                  },
                  {
                    "text": "Classic Hodgkin lymphoma"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Anaplastic large cell lymphoma (ALCL)"
                  },
                  {
                    "text": "Anaplastic lymphoma kinase (ALK)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Systemic T-cell neoplasm composed of large, anaplastic cells that closely resembles ALK(+) ALCLNo evidence ofALKtranslocations or ALK overexpression",
                    "sub_points": [
                      "No evidence ofALKtranslocations or ALK overexpression"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "ALK(-) ALCL is Genetically Heterogeneous": [
                  {
                    "text": "~ 30% carryDUSP22/6p25.3 translocationImmunogenic neoplasmUpregulation of cancer-testis antigenUpregulation of immune surveillance genes: CD58, HLA class II,Marked DNA hypomethylationMinimal expression of PD-L1Lacks JAK-STAT pathway activation",
                    "sub_points": [
                      "Immunogenic neoplasmUpregulation of cancer-testis antigenUpregulation of immune surveillance genes: CD58, HLA class II,Marked DNA hypomethylationMinimal expression of PD-L1Lacks JAK-STAT pathway activation",
                      "Upregulation of cancer-testis antigen",
                      "Upregulation of immune surveillance genes: CD58, HLA class II,",
                      "Marked DNA hypomethylation",
                      "Minimal expression of PD-L1",
                      "Lacks JAK-STAT pathway activation"
                    ]
                  },
                  {
                    "text": "~ 8% carryTP63/3q28 translocation"
                  },
                  {
                    "text": "50-60% of cases lack known translocationsJAK-STAT pathway activationMutations ofJAK1orSTAT3Activation of PI3K signaling pathwayOverexpression ofTNFRSF8,GATA3,TMOD1Mutations ofTP53,PRDM1,TET2,FAS,STIM2",
                    "sub_points": [
                      "JAK-STAT pathway activationMutations ofJAK1orSTAT3",
                      "Mutations ofJAK1orSTAT3",
                      "Activation of PI3K signaling pathwayOverexpression ofTNFRSF8,GATA3,TMOD1",
                      "Overexpression ofTNFRSF8,GATA3,TMOD1",
                      "Mutations ofTP53,PRDM1,TET2,FAS,STIM2"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Age": [
                  {
                    "text": "Median: 6th decade"
                  }
                ],
                "Sex": [
                  {
                    "text": "M:F = 1.6"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Most patients present with nodal disease"
                  },
                  {
                    "text": "Extranodal involvement can be seenSkin, liver, and lungs involved most often",
                    "sub_points": [
                      "Skin, liver, and lungs involved most often"
                    ]
                  },
                  {
                    "text": "~ 70% of patients have stage III/IV disease"
                  },
                  {
                    "text": "International Prognostic Index: 0-1 in ~ 70% of patients"
                  },
                  {
                    "text": "Bone marrow involvement 5-15%"
                  },
                  {
                    "text": "Small subset of patients can present in leukemic phaseDefined as > 10% lymphoma cells in blood",
                    "sub_points": [
                      "Defined as > 10% lymphoma cells in blood"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "Doxorubicin-based chemotherapy regimensEtoposide improves prognosisA-CHP is more efficacious than traditional CHOP therapyA-CHP = Adcetris (brentuximab vedotin), cyclophosphamide, doxorubicin, prednisone",
                    "sub_points": [
                      "Etoposide improves prognosis",
                      "A-CHP is more efficacious than traditional CHOP therapyA-CHP = Adcetris (brentuximab vedotin), cyclophosphamide, doxorubicin, prednisone",
                      "A-CHP = Adcetris (brentuximab vedotin), cyclophosphamide, doxorubicin, prednisone"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Prognosis is variable depending on molecular findingsCases withDUSP22rearrangement have good prognosisCases withTP63rearrangement have very poor prognosisRemaining cases have intermediate prognosis",
                    "sub_points": [
                      "Cases withDUSP22rearrangement have good prognosis",
                      "Cases withTP63rearrangement have very poor prognosis",
                      "Remaining cases have intermediate prognosis"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Common variant closely mimics classic ALK(+) ALCLLarge neoplastic cells, including hallmark cellsCohesive growth pattern and sinusoidal involvement commonOften high mitotic rate; necrosis (+/-)",
                    "sub_points": [
                      "Large neoplastic cells, including hallmark cells",
                      "Cohesive growth pattern and sinusoidal involvement common",
                      "Often high mitotic rate; necrosis (+/-)"
                    ]
                  },
                  {
                    "text": "Degree of anaplasia often greater in ALK(-) ALCL than in ALK(+) ALCL"
                  },
                  {
                    "text": "DUSP22rearranged cases of ALK(-) ALCL showSheet-like growth patternLess pleomorphismDoughnut cells are common",
                    "sub_points": [
                      "Sheet-like growth pattern",
                      "Less pleomorphism",
                      "Doughnut cells are common"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "CD30(+), strong and uniform"
                  },
                  {
                    "text": "T-cell lineageCD4 and CD43 usually (+)CD2(+/-), CD7(+/-)CD45RO(+/-), CD3(-/+)CD5(-/+), T-cell receptors (-/+)",
                    "sub_points": [
                      "CD4 and CD43 usually (+)",
                      "CD2(+/-), CD7(+/-)",
                      "CD45RO(+/-), CD3(-/+)",
                      "CD5(-/+), T-cell receptors (-/+)"
                    ]
                  },
                  {
                    "text": "Aberrant T-cell immunophenotypes are very common"
                  },
                  {
                    "text": "Rare (< 5%) cases lack all T-cell antigensSo-called null cell type",
                    "sub_points": [
                      "So-called null cell type"
                    ]
                  },
                  {
                    "text": "Clusterin (+) in most cases"
                  },
                  {
                    "text": "CD45/LCA(+) and MUM1/IRF4(+) in most casesCD45 can be negative by immunohistochemistry; flow cytometry (+)",
                    "sub_points": [
                      "CD45 can be negative by immunohistochemistry; flow cytometry (+)"
                    ]
                  },
                  {
                    "text": "PD-L1(+) in 60-70% of casesOften (-) inDUSP22rearranged cases",
                    "sub_points": [
                      "Often (-) inDUSP22rearranged cases"
                    ]
                  },
                  {
                    "text": "Expression of cytotoxic molecules in 60-70% of casesTIA1, granzyme-B, perforinDUSP22rearranged cases often lack cytotoxic markers",
                    "sub_points": [
                      "TIA1, granzyme-B, perforin",
                      "DUSP22rearranged cases often lack cytotoxic markers"
                    ]
                  },
                  {
                    "text": "EMA/MUC1(+) in ~50% of cases; LEF-1(+/-)"
                  },
                  {
                    "text": "ERBB4(+) in ~ 25% of casesAssociated with truncated ERBB4 transcripts",
                    "sub_points": [
                      "Associated with truncated ERBB4 transcripts"
                    ]
                  },
                  {
                    "text": "Ki-67 usually high; p53(+/-) usually weak"
                  },
                  {
                    "text": "BCL-2(+/-), BCL-6(-/+), CD15(-/+)"
                  },
                  {
                    "text": "Epstein-Barr virus (EBV) latent membrane protein 1 (LMP1) (-)"
                  },
                  {
                    "text": "ALK(-), HHV8(-), CD117(-)"
                  },
                  {
                    "text": "B-cell antigens (-)CD19(-), CD20(-), CD22(-), CD79a (-)Rare cases pax-5(+); often patchy when present",
                    "sub_points": [
                      "CD19(-), CD20(-), CD22(-), CD79a (-)",
                      "Rare cases pax-5(+); often patchy when present"
                    ]
                  }
                ],
                "In Situ Hybridization": [
                  {
                    "text": "FISH testing is helpful~ 30% of ALK- ALCL carryDUSP22/IRF4translocation~ 8% haveTP63/3q28 translocation50-60% of cases negative",
                    "sub_points": [
                      "~ 30% of ALK- ALCL carryDUSP22/IRF4translocation",
                      "~ 8% haveTP63/3q28 translocation",
                      "50-60% of cases negative"
                    ]
                  },
                  {
                    "text": "Colorimetric in situ hybridizationEBV-encoded small RNA (EBER) (-)",
                    "sub_points": [
                      "EBV-encoded small RNA (EBER) (-)"
                    ]
                  }
                ],
                "PCR": [
                  {
                    "text": "Monoclonal T-cell receptor gene rearrangements"
                  }
                ],
                "Genetic Testing": [
                  {
                    "text": "Next-generation sequencing shows mutations in ~ 20% of casesMutation data not yet incorporated into routine patient management",
                    "sub_points": [
                      "Mutation data not yet incorporated into routine patient management"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "ALK(+) ALCL": [
                  {
                    "text": "Histologically, ALK(+) ALCL and ALK(-) ALCL are often indistinguishableALK(+) ALCL has a small cell variantNot recognized in ALK(-) ALCL",
                    "sub_points": [
                      "ALK(+) ALCL has a small cell variantNot recognized in ALK(-) ALCL",
                      "Not recognized in ALK(-) ALCL"
                    ]
                  },
                  {
                    "text": "Immunophenotypically, ALK(+) ALCL shares many features with ALK(-) ALCLCommon featuresFrequent aberrant T-cell immunophenotypesCD30(+) (strong and uniform), clusterin (+)Cytotoxic molecules expressed in most casesDifferencesALK(+)Various patterns; most often nuclear and cytoplasmicEBV(-) in virtually all cases in developed nationsBCL-2(-) by immunohistochemistry; CD15(-)",
                    "sub_points": [
                      "Common featuresFrequent aberrant T-cell immunophenotypesCD30(+) (strong and uniform), clusterin (+)Cytotoxic molecules expressed in most cases",
                      "Frequent aberrant T-cell immunophenotypes",
                      "CD30(+) (strong and uniform), clusterin (+)",
                      "Cytotoxic molecules expressed in most cases",
                      "DifferencesALK(+)Various patterns; most often nuclear and cytoplasmicEBV(-) in virtually all cases in developed nationsBCL-2(-) by immunohistochemistry; CD15(-)",
                      "ALK(+)Various patterns; most often nuclear and cytoplasmic",
                      "Various patterns; most often nuclear and cytoplasmic",
                      "EBV(-) in virtually all cases in developed nations",
                      "BCL-2(-) by immunohistochemistry; CD15(-)"
                    ]
                  },
                  {
                    "text": "ALK alterations are present in all casest(2;5)(p23;q35)/NPM1::ALKis most common",
                    "sub_points": [
                      "t(2;5)(p23;q35)/NPM1::ALKis most common"
                    ]
                  }
                ],
                "Peripheral T-Cell Lymphoma, Not Otherwise Specified": [
                  {
                    "text": "Sinusoidal pattern of infiltration is infrequent"
                  },
                  {
                    "text": "Hallmark cells usually absent"
                  },
                  {
                    "text": "CD30(-/+); usually expressed variably"
                  },
                  {
                    "text": "Usually CD3(+), CD5(+), and T-cell receptors (+)ALK(-) ALCL usually lose 1 or several T-cell antigens",
                    "sub_points": [
                      "ALK(-) ALCL usually lose 1 or several T-cell antigens"
                    ]
                  },
                  {
                    "text": "Cytotoxic molecules often (-), clusterin (-)"
                  }
                ],
                "Classic Hodgkin Lymphoma": [
                  {
                    "text": "Cases of syncytial variant nodular sclerosis can mimic ALK(-) ALCLNumerous Hodgkin-Reed-Sternberg (HRS) cells in sheetsOften associated with eosinophils",
                    "sub_points": [
                      "Numerous Hodgkin-Reed-Sternberg (HRS) cells in sheets",
                      "Often associated with eosinophils"
                    ]
                  },
                  {
                    "text": "HRS cells are of B-cell lineagepax-5(+) weak, CD15(+) ~ 70%, CD30(+), MUM1/IRF4(+)CD45/LCA(-), clusterin (-), EMA/MUC1(-)",
                    "sub_points": [
                      "pax-5(+) weak, CD15(+) ~ 70%, CD30(+), MUM1/IRF4(+)",
                      "CD45/LCA(-), clusterin (-), EMA/MUC1(-)"
                    ]
                  }
                ],
                "Diffuse Large B-Cell Lymphoma, Anaplastic Variant": [
                  {
                    "text": "Subset of cases (~ 3%) of DLBCL hasAnaplastic cytologic features ± sinusoidal involvement",
                    "sub_points": [
                      "Anaplastic cytologic features ± sinusoidal involvement"
                    ]
                  },
                  {
                    "text": "CD30 often (+); pattern usually less uniform than in ALCL"
                  },
                  {
                    "text": "B-cell antigens (+); monoclonalIGHrearrangements"
                  }
                ],
                "Primary Cutaneous ALCL": [
                  {
                    "text": "Disease confined to skinClinical and radiologic staging studies needed to establish diagnosisSmall subset of cases regress spontaneously",
                    "sub_points": [
                      "Clinical and radiologic staging studies needed to establish diagnosis",
                      "Small subset of cases regress spontaneously"
                    ]
                  },
                  {
                    "text": "Up to 20% of patients with systemic ALCL can have skin disease"
                  },
                  {
                    "text": "CD30(+) strong and uniform"
                  },
                  {
                    "text": "ALK(-) in ~ 97% of cases; EMA/MUC1 usually (-)"
                  },
                  {
                    "text": "DUSP22rearrangements occur in ~ 15% of casesMore monomorphic; doughnut cells presentCytotoxic molecules usually negative",
                    "sub_points": [
                      "More monomorphic; doughnut cells present",
                      "Cytotoxic molecules usually negative"
                    ]
                  }
                ],
                "Breast Implant-Associated ALCL": [
                  {
                    "text": "Lymphoma surrounds textured breast implantDevelops median of 9 years after implant placement",
                    "sub_points": [
                      "Develops median of 9 years after implant placement"
                    ]
                  },
                  {
                    "text": "Most patients have localized disease; confined to breast capsuleUsually present with periimplant effusion",
                    "sub_points": [
                      "Usually present with periimplant effusion"
                    ]
                  },
                  {
                    "text": "A subset of patients has more extensive diseasePresent with tumor mass in capsule surrounding implantRegional lymphadenopathy in ~ 20% of patientsRare patients develop widespread dissemination",
                    "sub_points": [
                      "Present with tumor mass in capsule surrounding implant",
                      "Regional lymphadenopathy in ~ 20% of patients",
                      "Rare patients develop widespread dissemination"
                    ]
                  },
                  {
                    "text": "CD30(+) strong and uniform; ALK(-)"
                  },
                  {
                    "text": "Aberrant T-cell immunophenotypes are common"
                  }
                ],
                "ALK(+) Large B-cell Lymphoma": [
                  {
                    "text": "Often plasmablastic or immunoblastic features"
                  },
                  {
                    "text": "Sinusoidal involvement can be prominent"
                  },
                  {
                    "text": "CD138(+), MUM1/IRF4(+), CD20(-)"
                  },
                  {
                    "text": "CD30(-), T-cell antigens usually (-)"
                  },
                  {
                    "text": "ALKalterations presentt(2;17)(p23;q23)/CLTC::ALKis most common",
                    "sub_points": [
                      "t(2;17)(p23;q23)/CLTC::ALKis most common"
                    ]
                  }
                ],
                "Metastatic Solid Tumors in Lymph Node": [
                  {
                    "text": "Metastatic carcinoma or melanoma in lymph nodes can mimic ALK(-) ALCLSinusoidal pattern; cohesive appearance",
                    "sub_points": [
                      "Sinusoidal pattern; cohesive appearance"
                    ]
                  },
                  {
                    "text": "Immunohistochemistry is helpfulCarcinoma: cytokeratins (+), EMA/MUC1(+)Melanoma: S100(+), HMB-45(+), other melanoma-associated markers",
                    "sub_points": [
                      "Carcinoma: cytokeratins (+), EMA/MUC1(+)",
                      "Melanoma: S100(+), HMB-45(+), other melanoma-associated markers"
                    ]
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Clinically Relevant Pathologic Features": [
                  {
                    "text": "ALK(-) ALCL is a genetically heterogeneous entityDUSP22rearrangement: associated with standard prognosisTP63rearrangement: associated with very poor prognosisRemaining cases have an intermediate prognosisThis subset is likely also heterogeneous",
                    "sub_points": [
                      "DUSP22rearrangement: associated with standard prognosis",
                      "TP63rearrangement: associated with very poor prognosis",
                      "Remaining cases have an intermediate prognosisThis subset is likely also heterogeneous",
                      "This subset is likely also heterogeneous"
                    ]
                  },
                  {
                    "text": "Current patient management relies mostly on traditional CHOP type chemotherapyManagement strategies are evolving",
                    "sub_points": [
                      "Management strategies are evolving"
                    ]
                  }
                ],
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "ALK(-) ALCL resembles common variant of ALK(+) ALCLSinusoidal pattern of infiltration is commonHallmark cells are presentCD30(+) strong and uniform; clusterin (+)Commonly (+) for cytotoxic proteins: TIA1, granzyme B, perforin",
                    "sub_points": [
                      "Sinusoidal pattern of infiltration is common",
                      "Hallmark cells are present",
                      "CD30(+) strong and uniform; clusterin (+)",
                      "Commonly (+) for cytotoxic proteins: TIA1, granzyme B, perforin"
                    ]
                  },
                  {
                    "text": "Cases of ALK(-) ALCL with DUSP22 rearrangement are differentMore monomorphic; doughnut cellsOften negative for cytotoxic molecules",
                    "sub_points": [
                      "More monomorphic; doughnut cells",
                      "Often negative for cytotoxic molecules"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Angioimmunoblastic T-Cell Lymphoma": {
            "name": "Angioimmunoblastic T-Cell Lymphoma",
            "url": "https://app.pathprimer.com/document/bb2e7b52-89be-44a0-8352-0070eb6e7ee0/lesson/1754477f-a4b1-4ec8-b223-cd1eb29cbd87",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Peripheral T-cell lymphoma derived from CD4(+) T follicular helper (TFH) cells characterized byLymphadenopathy, systemic disease, and, usually, immunodysregulation and immunodeficiency",
                    "sub_points": [
                      "Lymphadenopathy, systemic disease, and, usually, immunodysregulation and immunodeficiency"
                    ]
                  },
                  {
                    "text": "nTFHL-AI is 1 of 3 entities under umbrella term of nodal T-follicular helper cell lymphomas"
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "Somatic mutations of epigenetic modifiersTET2,IDH2, andDNMT3Aas well asRHOA, small GTPase protein"
                  },
                  {
                    "text": "EBV(+) B cells detected in most cases of nTFHL-AI"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Advanced stage with generalized lymphadenopathy, hepatomegaly, &/or splenomegaly"
                  },
                  {
                    "text": "Aggressive with median survival of < 3 years"
                  },
                  {
                    "text": "Anemia, hypereosinophilia, polyclonal hypergammaglobulinemia"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Partial or complete effacement of nodal architecture"
                  },
                  {
                    "text": "Neoplastic T cells with clear/pale cytoplasm"
                  },
                  {
                    "text": "Proliferation of follicular dendritic cells"
                  },
                  {
                    "text": "Proliferation of arborizing high endothelial venules"
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "CD2(+), CD3(+), CD4(+), CD5(+), TCR-αβ(+)"
                  },
                  {
                    "text": "CD10(+/-), BCL-6(+/-), CXCL13(+/-), PD-1(+/-)"
                  },
                  {
                    "text": "B immunoblasts (+) in variable numbers"
                  },
                  {
                    "text": "MonoclonalTRBorTRGrearrangements"
                  },
                  {
                    "text": "EBER(+) in ~ 80-90% of cases"
                  },
                  {
                    "text": "Neoplastic cells have gene expression profile of follicular helper T cells"
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "Drug reaction and viral lymphadenitis"
                  },
                  {
                    "text": "Classic Hodgkin lymphoma"
                  },
                  {
                    "text": "Kimura disease"
                  },
                  {
                    "text": "T-cell/histiocyte-rich large B-cell lymphoma"
                  },
                  {
                    "text": "Peripheral T-cell lymphoma, not otherwise specified"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Angioimmunoblastic T-cell lymphoma (AITL)"
                  },
                  {
                    "text": "Nodal T follicular helper lymphoma, angioimmunoblastic type (nTFHL-AI)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Angioimmunoblastic lymphadenopathy with dysproteinemia (AILD)AILD-like (type) T-cell lymphoma",
                    "sub_points": [
                      "AILD-like (type) T-cell lymphoma"
                    ]
                  },
                  {
                    "text": "Immunoblastic lymphadenopathy"
                  },
                  {
                    "text": "Lymphogranulomatosis X"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Peripheral T-cell lymphoma (PTCL) derived from CD4(+) T follicular helper cells characterized byLymphadenopathy, systemic disease, and, usually, immunodysregulation and immunodeficiency",
                    "sub_points": [
                      "Lymphadenopathy, systemic disease, and, usually, immunodysregulation and immunodeficiency"
                    ]
                  },
                  {
                    "text": "AITL is currently 1 of 3 entities under umbrella term of nodal T-follicular helper cell lymphomas in WHO 5th editionnTFHL angioimmunoblastic type (nTFHL-AI)nTFHL follicular type (nTFHL-F)nTFHL not otherwise specified (nTFHL-NOS)Primary cutaneous CD4(+) small/medium T-cell lymphoproliferative disorder (provisional entity)",
                    "sub_points": [
                      "nTFHL angioimmunoblastic type (nTFHL-AI)",
                      "nTFHL follicular type (nTFHL-F)",
                      "nTFHL not otherwise specified (nTFHL-NOS)",
                      "Primary cutaneous CD4(+) small/medium T-cell lymphoproliferative disorder (provisional entity)"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Hemaotpoietic Cells and Somatic Mutations": [
                  {
                    "text": "Hematopoietic cell mutations of epigenetic modifiers in both nTFHL-NOS and nTFHL-AIMutations in 50%TET2, 20%IDH2, 33%DNMT3A",
                    "sub_points": [
                      "Mutations in 50%TET2, 20%IDH2, 33%DNMT3A"
                    ]
                  },
                  {
                    "text": "Concurrent somatic mutations occur in lymphoma cells in ~ 50% of nTFHL-AI cases have p.Gly17Val mutation inRHOA(small GTPase protein of RAS family)Mutation is at GTP-binding domain and leads to loss of GTP binding activity and drives cell proliferationMutation is less common in nTFHL-NOS and NK/T-cell lymphomas, and not detected in B-cell lymphomas",
                    "sub_points": [
                      "Mutation is at GTP-binding domain and leads to loss of GTP binding activity and drives cell proliferation",
                      "Mutation is less common in nTFHL-NOS and NK/T-cell lymphomas, and not detected in B-cell lymphomas"
                    ]
                  },
                  {
                    "text": "Somatic mutations in other genes at very low frequency detected; uncertain significanceJAK2(V617F and G571S),ARIDIA,CCND3,FAS,CD58,PRDM1,TNFSF9,TP53, andETV6",
                    "sub_points": [
                      "JAK2(V617F and G571S),ARIDIA,CCND3,FAS,CD58,PRDM1,TNFSF9,TP53, andETV6"
                    ]
                  }
                ],
                "Immunodysregulation": [
                  {
                    "text": "nTFHL-AI is tumor of follicular helper T cellsEssential checkpoint for B-cell activation and differentiationFollicular helper T cells upregulate CXCR5 and CXCL13CXCL13 promotes B-cell recruitment through adherence of B cells on high endothelial venules (HEV)CD21(+) follicular dendritic cells expand around HEVLeads to B-cell expansion, plasmacytic differentiation, and hypergammaglobulinemia",
                    "sub_points": [
                      "Essential checkpoint for B-cell activation and differentiationFollicular helper T cells upregulate CXCR5 and CXCL13CXCL13 promotes B-cell recruitment through adherence of B cells on high endothelial venules (HEV)CD21(+) follicular dendritic cells expand around HEVLeads to B-cell expansion, plasmacytic differentiation, and hypergammaglobulinemia",
                      "Follicular helper T cells upregulate CXCR5 and CXCL13CXCL13 promotes B-cell recruitment through adherence of B cells on high endothelial venules (HEV)CD21(+) follicular dendritic cells expand around HEVLeads to B-cell expansion, plasmacytic differentiation, and hypergammaglobulinemia",
                      "CXCL13 promotes B-cell recruitment through adherence of B cells on high endothelial venules (HEV)",
                      "CD21(+) follicular dendritic cells expand around HEV",
                      "Leads to B-cell expansion, plasmacytic differentiation, and hypergammaglobulinemia"
                    ]
                  }
                ],
                "Viral Infection": [
                  {
                    "text": "EBV(+) B cells detected in most cases of nTFHL-AIMost likely secondary event as result of host immunocompromise",
                    "sub_points": [
                      "Most likely secondary event as result of host immunocompromise"
                    ]
                  },
                  {
                    "text": "HHV-6B also detected by PCR in almost 1/2 of nTFHL-AI cases"
                  },
                  {
                    "text": "EBV and potentially HHV-6B mayModulate secretion of cytokines and chemokines or expression of membrane receptorsInfluence development of tumor microenvironment, favoring disease progression",
                    "sub_points": [
                      "Modulate secretion of cytokines and chemokines or expression of membrane receptors",
                      "Influence development of tumor microenvironment, favoring disease progression"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "Rate: 0.5 per 100,000 person-years in USA"
                  },
                  {
                    "text": "Represents 1.2% of all non-Hodgkin lymphomas and 18% of all PTCLs"
                  },
                  {
                    "text": "More common in White than in Black or Asian American populations"
                  },
                  {
                    "text": "nTFHL-AI is more common in Europe than in North America or Asia"
                  }
                ],
                "Age": [
                  {
                    "text": "Median: 59-65 years in various studies"
                  }
                ],
                "Sex": [
                  {
                    "text": "Slight male predominance (but varies in different studies)"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Subacute or acute systemic illness"
                  },
                  {
                    "text": "Advanced stage (III/IV) with generalized lymphadenopathy, hepatomegaly, &/or splenomegaly"
                  },
                  {
                    "text": "B symptoms in 50-80% of casesFever, weight loss, night sweats",
                    "sub_points": [
                      "Fever, weight loss, night sweats"
                    ]
                  },
                  {
                    "text": "Skin rash in > 50% of patientsGeneralized or predominantly truncal maculopapular eruption mimicking inflammatory dermatosisNodular lesions, plaques, infiltrated purpura, erythroderma, macupapular eruption, Quincke edema, annular rash, tumor, and urticarial lesions also have been observedPrior to, concurrent with, or following initial diagnosis of AITL",
                    "sub_points": [
                      "Generalized or predominantly truncal maculopapular eruption mimicking inflammatory dermatosis",
                      "Nodular lesions, plaques, infiltrated purpura, erythroderma, macupapular eruption, Quincke edema, annular rash, tumor, and urticarial lesions also have been observed",
                      "Prior to, concurrent with, or following initial diagnosis of AITL"
                    ]
                  },
                  {
                    "text": "Other systemic manifestationsArthralgias or arthritisPleural effusions, ascites, &/or edema (~ 40%)Lung, neurologic, or gastrointestinal involvement",
                    "sub_points": [
                      "Arthralgias or arthritis",
                      "Pleural effusions, ascites, &/or edema (~ 40%)",
                      "Lung, neurologic, or gastrointestinal involvement"
                    ]
                  },
                  {
                    "text": "Cases of nTFHL-AI reported after administration of antibioticsMost likely, patients with undetected AITL predisposed to infection requiring antibiotic therapy",
                    "sub_points": [
                      "Most likely, patients with undetected AITL predisposed to infection requiring antibiotic therapy"
                    ]
                  }
                ],
                "Laboratory Tests": [
                  {
                    "text": "Complete blood cell countAnemiaCryoglobulins or cold agglutininsPositive Coombs test in many patientsHypereosinophiliaLymphopenia (lymphocytosis is rare)Thrombocytopenia",
                    "sub_points": [
                      "AnemiaCryoglobulins or cold agglutininsPositive Coombs test in many patients",
                      "Cryoglobulins or cold agglutinins",
                      "Positive Coombs test in many patients",
                      "Hypereosinophilia",
                      "Lymphopenia (lymphocytosis is rare)",
                      "Thrombocytopenia"
                    ]
                  },
                  {
                    "text": "Polyclonal hypergammaglobulinemiaMonoclonal gammopathy in ~ 10% of casesHypoalbuminemia",
                    "sub_points": [
                      "Monoclonal gammopathy in ~ 10% of cases",
                      "Hypoalbuminemia"
                    ]
                  },
                  {
                    "text": "± autoantibodiesRheumatoid factor, antinuclear factor, antismooth muscle",
                    "sub_points": [
                      "Rheumatoid factor, antinuclear factor, antismooth muscle"
                    ]
                  },
                  {
                    "text": "Elevated erythrocyte sedimentation rate"
                  },
                  {
                    "text": "Elevated serum lactate dehydrogenase and β2-microglobulin levels"
                  }
                ],
                "Treatment": [
                  {
                    "text": "For medically eligible patients, combined chemotherapy followed by autologous hematopoietic cell transplantationGood response but short remissionChemotherapy is usually anthracycline-based regimen",
                    "sub_points": [
                      "Good response but short remission",
                      "Chemotherapy is usually anthracycline-based regimen"
                    ]
                  },
                  {
                    "text": "For nontransplant candidates, combined chemotherapy only"
                  },
                  {
                    "text": "Single-agent oral therapy used in relapsed/refractory scenario"
                  },
                  {
                    "text": "Steroids have role for patients who are not candidates for chemotherapy"
                  },
                  {
                    "text": "Novel, investigational therapies needed for patients with AITL"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Aggressive disease with median survival of < 3 years~ 30% of patients are long-term survivors",
                    "sub_points": [
                      "~ 30% of patients are long-term survivors"
                    ]
                  },
                  {
                    "text": "Adverse prognostic factorsAdvanced age, Easter Cooperative Oncology Group (ECOG) performance status > 2, involvement of extranodal sites, B symptoms, and thrombocytopenia (< 150 x 10⁹/L)",
                    "sub_points": [
                      "Advanced age, Easter Cooperative Oncology Group (ECOG) performance status > 2, involvement of extranodal sites, B symptoms, and thrombocytopenia (< 150 x 10⁹/L)"
                    ]
                  },
                  {
                    "text": "Histological features of nTFHL-AI do not correlate with prognosis"
                  },
                  {
                    "text": "May be associated or progress to EBV(+) B-cell lymphomas"
                  }
                ]
              },
              "IMAGING": {
                "Radiographic Findings": [
                  {
                    "text": "Generalized lymphadenopathy, organ involvement, body effusionsCannot distinguish AITL from other lymphoma types with disseminated disease",
                    "sub_points": [
                      "Cannot distinguish AITL from other lymphoma types with disseminated disease"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Lymph nodePartial or complete effacement of architecture; perinodal infiltration commonParacortical distribution of neoplasmSubcapsular sinuses often patentNeoplastic cells are small- to medium-sized with clear to pale cytoplasm, distinct cell membranes, and minimal atypiaTumor cells often form small clusters around follicles and HEVPolymorphous background cells in variable numbersSmall reactive lymphocytes, plasma cells, eosinophils, and histiocytes± immunoblasts of B-cell lineage; can be prominent± Reed-Sternberg + Hodgkin (RS+H)-like cells of B-cell lineage; usually EBV(+)Marked proliferation of arborizing HEVIncreased proliferation of follicular dendritic cells (FDC), usually around HEV3 patterns in lymph node have been describedI: Architecture partially preserved and hyperplastic, or normal follicles are presentII: Architecture mostly effaced with residual follicles present ± follicles disrupted or irregularIII: Architecture completely replaced ± few regressed (\"burned-out\") follicles",
                    "sub_points": [
                      "Partial or complete effacement of architecture; perinodal infiltration commonParacortical distribution of neoplasmSubcapsular sinuses often patent",
                      "Paracortical distribution of neoplasm",
                      "Subcapsular sinuses often patent",
                      "Neoplastic cells are small- to medium-sized with clear to pale cytoplasm, distinct cell membranes, and minimal atypiaTumor cells often form small clusters around follicles and HEV",
                      "Tumor cells often form small clusters around follicles and HEV",
                      "Polymorphous background cells in variable numbersSmall reactive lymphocytes, plasma cells, eosinophils, and histiocytes± immunoblasts of B-cell lineage; can be prominent± Reed-Sternberg + Hodgkin (RS+H)-like cells of B-cell lineage; usually EBV(+)",
                      "Small reactive lymphocytes, plasma cells, eosinophils, and histiocytes",
                      "± immunoblasts of B-cell lineage; can be prominent",
                      "± Reed-Sternberg + Hodgkin (RS+H)-like cells of B-cell lineage; usually EBV(+)",
                      "Marked proliferation of arborizing HEV",
                      "Increased proliferation of follicular dendritic cells (FDC), usually around HEV",
                      "3 patterns in lymph node have been describedI: Architecture partially preserved and hyperplastic, or normal follicles are presentII: Architecture mostly effaced with residual follicles present ± follicles disrupted or irregularIII: Architecture completely replaced ± few regressed (\"burned-out\") follicles",
                      "I: Architecture partially preserved and hyperplastic, or normal follicles are present",
                      "II: Architecture mostly effaced with residual follicles present ± follicles disrupted or irregular",
                      "III: Architecture completely replaced ± few regressed (\"burned-out\") follicles"
                    ]
                  },
                  {
                    "text": "Bone marrowNodular or interstitial aggregates in paratrabecular or nonparatrabecular distributionNeoplastic cells often small ± clear cytoplasm; can be difficult to identifyReactive cells include B cells, plasma cells, eosinophils, and histiocytesAggregates associated with blood vessel proliferation± EBV(+) cellsUninvolved bone marrow ± reactive changes associated with nTFHL-AIErythroid hyperplasia, polyclonal plasmacytosis, eosinophilia, fibrosis, or hemophagocytosis",
                    "sub_points": [
                      "Nodular or interstitial aggregates in paratrabecular or nonparatrabecular distributionNeoplastic cells often small ± clear cytoplasm; can be difficult to identifyReactive cells include B cells, plasma cells, eosinophils, and histiocytesAggregates associated with blood vessel proliferation± EBV(+) cells",
                      "Neoplastic cells often small ± clear cytoplasm; can be difficult to identify",
                      "Reactive cells include B cells, plasma cells, eosinophils, and histiocytes",
                      "Aggregates associated with blood vessel proliferation",
                      "± EBV(+) cells",
                      "Uninvolved bone marrow ± reactive changes associated with nTFHL-AIErythroid hyperplasia, polyclonal plasmacytosis, eosinophilia, fibrosis, or hemophagocytosis",
                      "Erythroid hyperplasia, polyclonal plasmacytosis, eosinophilia, fibrosis, or hemophagocytosis"
                    ]
                  },
                  {
                    "text": "Peripheral bloodLymphocytosis uncommon± atypical lymphocytes or activated lymphocytes (so-called immunocytes)CD10(+) T cells have been shown in many patients by flow cytometric immunophenotyping",
                    "sub_points": [
                      "Lymphocytosis uncommon",
                      "± atypical lymphocytes or activated lymphocytes (so-called immunocytes)",
                      "CD10(+) T cells have been shown in many patients by flow cytometric immunophenotyping"
                    ]
                  },
                  {
                    "text": "SkinChanges variable, may not always result from direct tumor infiltrationChanges can range from nonspecific, mild perivascular dermal lymphocytic infiltrate to, less frequently, overt lymphoma",
                    "sub_points": [
                      "Changes variable, may not always result from direct tumor infiltrationChanges can range from nonspecific, mild perivascular dermal lymphocytic infiltrate to, less frequently, overt lymphoma",
                      "Changes can range from nonspecific, mild perivascular dermal lymphocytic infiltrate to, less frequently, overt lymphoma"
                    ]
                  },
                  {
                    "text": "Body effusionsNonneoplastic in nature; cause poorly understoodMixture of small lymphocytes and histiocytes ± eosinophils",
                    "sub_points": [
                      "Nonneoplastic in nature; cause poorly understood",
                      "Mixture of small lymphocytes and histiocytes ± eosinophils"
                    ]
                  },
                  {
                    "text": "Morphological variants of nTFHL-AIEpithelioid cell-rich variantHigh content of epithelioid histiocytes in small, poorly defined clusters (Lennert-like reaction)Clear cell-rich variantOvert lymphomatous proliferation with clusters or sheets of neoplastic cells with clear/pale cytoplasmFollicular T-cell lymphomaTumor cell-rich variantMonomorphic rather than polymorphous appearanceMost neoplastic cells express follicular helper T-cell markers and show disrupted FDC meshworksPlasma cell-rich variantPlasma cells numerous; can resemble plasma cell neoplasmPlasma cells lack cytologic atypia, usually EBV(-)B cell-rich variantBackground lymphocytes can be composed of numerous small B lymphocytesEBV(+/-)",
                    "sub_points": [
                      "Epithelioid cell-rich variantHigh content of epithelioid histiocytes in small, poorly defined clusters (Lennert-like reaction)",
                      "High content of epithelioid histiocytes in small, poorly defined clusters (Lennert-like reaction)",
                      "Clear cell-rich variantOvert lymphomatous proliferation with clusters or sheets of neoplastic cells with clear/pale cytoplasm",
                      "Overt lymphomatous proliferation with clusters or sheets of neoplastic cells with clear/pale cytoplasm",
                      "Follicular T-cell lymphoma",
                      "Tumor cell-rich variantMonomorphic rather than polymorphous appearanceMost neoplastic cells express follicular helper T-cell markers and show disrupted FDC meshworks",
                      "Monomorphic rather than polymorphous appearance",
                      "Most neoplastic cells express follicular helper T-cell markers and show disrupted FDC meshworks",
                      "Plasma cell-rich variantPlasma cells numerous; can resemble plasma cell neoplasmPlasma cells lack cytologic atypia, usually EBV(-)",
                      "Plasma cells numerous; can resemble plasma cell neoplasm",
                      "Plasma cells lack cytologic atypia, usually EBV(-)",
                      "B cell-rich variantBackground lymphocytes can be composed of numerous small B lymphocytesEBV(+/-)",
                      "Background lymphocytes can be composed of numerous small B lymphocytes",
                      "EBV(+/-)"
                    ]
                  },
                  {
                    "text": "2ndlymphomas in patients withnTFHL-AIPatients with AITL have increased risk of developing another lymphomaDiffuse large B-cell lymphoma (DLBCL) is most commonUsually EBV(+)EBV(+) DLBCL can precede diagnosis of nTFHL-AIPatients can develop classic Hodgkin lymphomaUsually EBV(+)Small B-cell lymphomas and plasmacytomas have been reportedUsually EBV(-)",
                    "sub_points": [
                      "Patients with AITL have increased risk of developing another lymphoma",
                      "Diffuse large B-cell lymphoma (DLBCL) is most commonUsually EBV(+)EBV(+) DLBCL can precede diagnosis of nTFHL-AI",
                      "Usually EBV(+)",
                      "EBV(+) DLBCL can precede diagnosis of nTFHL-AI",
                      "Patients can develop classic Hodgkin lymphomaUsually EBV(+)",
                      "Usually EBV(+)",
                      "Small B-cell lymphomas and plasmacytomas have been reportedUsually EBV(-)",
                      "Usually EBV(-)"
                    ]
                  }
                ],
                "Cytologic Features": [
                  {
                    "text": "Diagnosis of AITL can be difficult to establish by fine-needle aspiration because of polymorphous cell compositionAbnormal proliferation of follicular dendritic cells and branched capillariesCorrelation with clinical features and ancillary studies to assess immunophenotype or clonality are necessary",
                    "sub_points": [
                      "Abnormal proliferation of follicular dendritic cells and branched capillaries",
                      "Correlation with clinical features and ancillary studies to assess immunophenotype or clonality are necessary"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "CD2(+), CD3(+), CD5(+), βF1/TCR-αβ(+)"
                  },
                  {
                    "text": "± aberrant loss or reduced expression of CD7"
                  },
                  {
                    "text": "Usually CD4(+) and CD8(-)"
                  },
                  {
                    "text": "T cells have follicular helper T-cell immunophenotype in most casesCD10(+), BCL-6(+), CXCL13(+), CXCR5(+), ICOS(+), &/or PD-1(+)",
                    "sub_points": [
                      "CD10(+), BCL-6(+), CXCL13(+), CXCR5(+), ICOS(+), &/or PD-1(+)"
                    ]
                  },
                  {
                    "text": "FDC proliferation around HEVHighlighted by FDC-associated markers, such as CD21, CD23, CD35, and clusterin",
                    "sub_points": [
                      "Highlighted by FDC-associated markers, such as CD21, CD23, CD35, and clusterin"
                    ]
                  },
                  {
                    "text": "B-immunoblasts present in variable numberCD19(+), CD20(+), pax-5(+), CD79a(+)Commonly EBER(+); subset LMP1(+/-)",
                    "sub_points": [
                      "CD19(+), CD20(+), pax-5(+), CD79a(+)",
                      "Commonly EBER(+); subset LMP1(+/-)"
                    ]
                  },
                  {
                    "text": "CD30(+) in ~20% of the cases"
                  }
                ],
                "Flow Cytometry": [
                  {
                    "text": "Normal CD4:CD8 ratio is commonDue to reactive T cells that outnumber neoplastic T cells",
                    "sub_points": [
                      "Due to reactive T cells that outnumber neoplastic T cells"
                    ]
                  },
                  {
                    "text": "± decreased expression or loss of CD7 &/or CD26"
                  },
                  {
                    "text": "Decrease or loss of sCD3 in peripheral blood or bone marrow as opposed to mycosis fungoides"
                  },
                  {
                    "text": "± coexpression of CD10 by subset of T cells mainly in lymph nodes with nTFHL-AI< 5% of normal CD3(+)/CD4(+) lymphocytes can express CD10",
                    "sub_points": [
                      "< 5% of normal CD3(+)/CD4(+) lymphocytes can express CD10"
                    ]
                  },
                  {
                    "text": "Monotypic B-cell population can be detected in ~ 15% of cases"
                  }
                ],
                "In Situ Hybridization": [
                  {
                    "text": "EBER(+) in ~ 80-90% of cases"
                  }
                ],
                "PCR": [
                  {
                    "text": "MonoclonalTRBorTRGrearrangements in 75-90% of cases"
                  },
                  {
                    "text": "MonoclonalIGHrearrangements in ~ 25% of cases"
                  }
                ],
                "Genetic Testing": [
                  {
                    "text": "Most common recurrent abnormalities: Trisomies of chromosomes 3, 5, and 21, gain of X, and loss of 6q"
                  }
                ],
                "Array CGH": [
                  {
                    "text": "Gains of 11q13, 19 and 22q, 19"
                  },
                  {
                    "text": "Loss of 13q"
                  }
                ],
                "Gene Expression Profiling": [
                  {
                    "text": "These studies have shown 2 general components in biopsy specimens involved by nTFHL-AINeoplastic T cells have expression profile of follicular helper T cellsExpression ofCD10,BCL6,CXCL13,PD1, (CD279),ICOS,SAP, orCCR5Other gene signature consistent with reactive inflammatory and stromal cells",
                    "sub_points": [
                      "Neoplastic T cells have expression profile of follicular helper T cellsExpression ofCD10,BCL6,CXCL13,PD1, (CD279),ICOS,SAP, orCCR5",
                      "Expression ofCD10,BCL6,CXCL13,PD1, (CD279),ICOS,SAP, orCCR5",
                      "Other gene signature consistent with reactive inflammatory and stromal cells"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Drug Reaction": [
                  {
                    "text": "Patients with drug reaction can develop B symptoms, generalized lymphadenopathy, and effusions mimicking nTFHL-AI"
                  },
                  {
                    "text": "Histologic findings in drug reaction also can mimic nTFHL-AIParacortical expansion by polymorphous infiltrateProliferation of HEVOligoclonal or monoclonalTRBorTRGrearrangements",
                    "sub_points": [
                      "Paracortical expansion by polymorphous infiltrate",
                      "Proliferation of HEV",
                      "Oligoclonal or monoclonalTRBorTRGrearrangements"
                    ]
                  },
                  {
                    "text": "Usually atypical clear cells are absent"
                  },
                  {
                    "text": "No immunophenotypic evidence of follicular T-helper cell immunophenotype"
                  },
                  {
                    "text": "Clinical history is extremely helpful for establishing diagnosis"
                  }
                ],
                "Reactive Hyperplasia as Result of Viral Infection or Immunodysregulation": [
                  {
                    "text": "These diseases can overlap with early involvement by nTFHL-AI (pattern I)"
                  },
                  {
                    "text": "Absence of atypical clear T cells that are positive for CD10 or follicular T-helper cell markers"
                  },
                  {
                    "text": "No FDC expansion"
                  },
                  {
                    "text": "Features that favor reactive hyperplasia over nTFHL-AIUniform CD10 expression in germinal center cellsLower proliferative rate in interfollicular areas",
                    "sub_points": [
                      "Uniform CD10 expression in germinal center cells",
                      "Lower proliferative rate in interfollicular areas"
                    ]
                  },
                  {
                    "text": "Vasculature can be increased; often not HEV"
                  },
                  {
                    "text": "Often CD8(+) T cells are predominant (especially in viral infection)"
                  },
                  {
                    "text": "EBV(-) with exception of EBV(+) infectious mononucleosis"
                  },
                  {
                    "text": "Presence of monoclonalTRBorTRGgene rearrangements can be misleading"
                  }
                ],
                "Classic Hodgkin Lymphoma, Mixed Cellularity Type": [
                  {
                    "text": "In some cases of AITL, RS+H-like cells can be present; EBV(+); B-cell antigens (+)"
                  },
                  {
                    "text": "Classic Hodgkin lymphoma lacks neoplastic T cells with clear cytoplasm; no increase in HEV or FDC"
                  },
                  {
                    "text": "No evidence of aberrant T-cell immunophenotype or monoclonalTRBorTRGrearrangements"
                  }
                ],
                "Kimura Disease": [
                  {
                    "text": "Subcutaneous mass of head and neck (including salivary glands); associated with regional lymphadenopathy"
                  },
                  {
                    "text": "Germinal center hyperplasiaWith polykaryocytes, fibrosis, and proteinaceous material in germinal centers; also folliculolysis",
                    "sub_points": [
                      "With polykaryocytes, fibrosis, and proteinaceous material in germinal centers; also folliculolysis"
                    ]
                  },
                  {
                    "text": "Interfollicular eosinophils and eosinophilic abscesses"
                  },
                  {
                    "text": "Increased paracortical plasma cells; variably hyalinized vessels"
                  }
                ],
                "Angiolymphoid Hyperplasia With Eosinophilia/Epithelioid Hemangioma": [
                  {
                    "text": "Can be associated with marked polymorphous inflammatory infiltrate mimicking AITL"
                  },
                  {
                    "text": "Typically extranodal; no evidence of systemic symptoms or disease"
                  },
                  {
                    "text": "No evidence of aberrant T-cell immunophenotype or T-cell clonality"
                  }
                ],
                "T-Cell/Histiocyte-Rich Large B-Cell Lymphoma": [
                  {
                    "text": "Features that support diagnosis of T-cell/histiocyte-rich large B-cell lymphoma over AITLB cells (tumor cells) are large; in AITL, there are many small B cells as well as B immunoblastsT cells lack atypia; no FDC proliferation; EBV(-)MonoclonalIGHrearrangements",
                    "sub_points": [
                      "B cells (tumor cells) are large; in AITL, there are many small B cells as well as B immunoblasts",
                      "T cells lack atypia; no FDC proliferation; EBV(-)",
                      "MonoclonalIGHrearrangements"
                    ]
                  }
                ],
                "Peripheral T-Cell Lymphoma, Not Otherwise Specified": [
                  {
                    "text": "Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) lacks features that allow diagnosis of AITLNo proliferation of FDC ± increased HEVMarkedly reduced B cells; most cases are EBV(-)",
                    "sub_points": [
                      "No proliferation of FDC ± increased HEV",
                      "Markedly reduced B cells; most cases are EBV(-)"
                    ]
                  },
                  {
                    "text": "Gene expression profiling has shown that subset of PTCL-NOS has follicular helper T-cell profileSuggests that some cases of early AITL are included within current PTCL-NOS category",
                    "sub_points": [
                      "Suggests that some cases of early AITL are included within current PTCL-NOS category"
                    ]
                  }
                ],
                "Primary Cutaneous CD4(+) Small/Medium T-Cell Lymphoproliferative Disorder": [
                  {
                    "text": "Currently provisional entity in WHO classification and not considered as lymphoma"
                  },
                  {
                    "text": "Presents as localized, solitary skin lesion; no patches or plaques that may suggest mycosis fungoides"
                  },
                  {
                    "text": "Lesions usually asymptomatic, mainly in head and neck or upper trunk"
                  },
                  {
                    "text": "Express markers of follicular helper T cells"
                  },
                  {
                    "text": "AITL is favored in presence of systemic features, hypergammaglobulinemia or lymphadenopathy"
                  }
                ],
                "EBV(+) Diffuse Large B-Cell Lymphoma, Not Otherwise Specified": [
                  {
                    "text": "Polymorphous subtype can mimic AITL"
                  },
                  {
                    "text": "Features that support EBV(+) DLBCL over AITLNo proliferation of FDCEBV(+) large B cells, often markedly increased and forming sheetsNo evidence of aberrant T-cell immunophenotype or monoclonalTRBorTRGrearrangements",
                    "sub_points": [
                      "No proliferation of FDC",
                      "EBV(+) large B cells, often markedly increased and forming sheets",
                      "No evidence of aberrant T-cell immunophenotype or monoclonalTRBorTRGrearrangements"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Extranodal NK-/T-Cell Lymphoma": {
            "name": "Extranodal NK-/T-Cell Lymphoma",
            "url": "https://app.pathprimer.com/document/3794ba4b-41f2-4fad-8fbd-def39ed3cdf9/lesson/1754477f-a4b1-4ec8-b223-cd1eb29cbd87",
            "content": {
              "KEY FACTS": {
                "Etiology/Pathogenesis": [
                  {
                    "text": "Epstein-Barr virus (EBV) is constant finding and likely involved in pathogenesis"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Nasal cases are usually defined as neoplasm involving upper aerodigestive tractNasal cavity, nasopharynx, paranasal sinuses, palateRegional lymphadenopathy occurs in 10-20% of patients",
                    "sub_points": [
                      "Nasal cavity, nasopharynx, paranasal sinuses, palate",
                      "Regional lymphadenopathy occurs in 10-20% of patients"
                    ]
                  },
                  {
                    "text": "Extranasal cases are defined as neoplasm involving any site other than nasalSkin is most common extranasal site",
                    "sub_points": [
                      "Skin is most common extranasal site"
                    ]
                  },
                  {
                    "text": "Staging bone marrow of patients with nasal or extranasal disease can be positive10-20% of patients",
                    "sub_points": [
                      "10-20% of patients"
                    ]
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Cytologic spectrum of extranodal NK-/T-cell lymphoma is wideSmall cell neoplasms can be misinterpreted as chronic inflammation",
                    "sub_points": [
                      "Small cell neoplasms can be misinterpreted as chronic inflammation"
                    ]
                  },
                  {
                    "text": "Necrosis and superimposed acute and chronic inflammation can lead to incorrect diagnosis"
                  },
                  {
                    "text": "Angiocentricity and angiodestruction are helpful findings but are not constantMost likely to be absent in small biopsy specimens",
                    "sub_points": [
                      "Most likely to be absent in small biopsy specimens"
                    ]
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "All tumors are positive for cytotoxic proteins and EBV"
                  },
                  {
                    "text": "~ 2/3 of tumors are of NK-cell lineage"
                  },
                  {
                    "text": "~ 1/3 of tumors are of cytotoxic T-cell lineage"
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "Aggressive NK-cell leukemia"
                  },
                  {
                    "text": "Nodal EBV(+) NK-/T-cell lymphoma"
                  },
                  {
                    "text": "Indolent NK-cell lymphoproliferative disorder of gastrointestinal tract"
                  },
                  {
                    "text": "Peripheral T-cell lymphoma, not otherwise specified"
                  },
                  {
                    "text": "Intestinal NK-/T-cell lymphoma"
                  },
                  {
                    "text": "Wegener granulomatosis"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Synonyms": [
                  {
                    "text": "Extranodal NK-/T-cell lymphoma, nasal type (WHO classification, 4th edition)"
                  },
                  {
                    "text": "Polymorphic reticulosis"
                  },
                  {
                    "text": "Malignant midline reticulosis"
                  },
                  {
                    "text": "Angiocentric T-cell lymphoma"
                  },
                  {
                    "text": "Lethal midline granuloma"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Predominantly extranodal lymphoma of either NK- or T-cell lineageCharacterized by necrosis, cytotoxic immunophenotype, and Epstein-Barr virus (EBV) infection",
                    "sub_points": [
                      "Characterized by necrosis, cytotoxic immunophenotype, and Epstein-Barr virus (EBV) infection"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Infectious Agents": [
                  {
                    "text": "EBV is consistently present in these neoplasms, suggesting its pathogenic rolePresent as episome in neoplastic cells; monoclonalThereby, EBV is present before clonal expansion, implicating virus in pathogenesisUsually type AType I or, more often, type II latency pattern of infectionLMP1(+), LMP2(+), and EBNA1(+)EBV plays key role as epigenetic driver in EBV-associated cancerEBV(+) NK cells secrete IL-2 and IL-9Involved in autocrine NK-cell activation and proliferation and initially cause chronic active EBV infectionLater acquire mutations of tumor suppressor genes and activation of oncogenic genes, such asSTAT3, that triggers lymphomaSubset of cases shows higher level of lytic geneBALF3, which is associated with DNA damage and genomic instabilityAnother subset of cases has mutations of epigenetic modifiers and activation of NF-kB and TCR signaling pathwaysMutations ofEBNA3andBPLF1loci in EBV extranodal NK-/T-cell lymphoma",
                    "sub_points": [
                      "Present as episome in neoplastic cells; monoclonalThereby, EBV is present before clonal expansion, implicating virus in pathogenesis",
                      "Thereby, EBV is present before clonal expansion, implicating virus in pathogenesis",
                      "Usually type A",
                      "Type I or, more often, type II latency pattern of infectionLMP1(+), LMP2(+), and EBNA1(+)",
                      "LMP1(+), LMP2(+), and EBNA1(+)",
                      "EBV plays key role as epigenetic driver in EBV-associated cancer",
                      "EBV(+) NK cells secrete IL-2 and IL-9Involved in autocrine NK-cell activation and proliferation and initially cause chronic active EBV infectionLater acquire mutations of tumor suppressor genes and activation of oncogenic genes, such asSTAT3, that triggers lymphoma",
                      "Involved in autocrine NK-cell activation and proliferation and initially cause chronic active EBV infection",
                      "Later acquire mutations of tumor suppressor genes and activation of oncogenic genes, such asSTAT3, that triggers lymphoma",
                      "Subset of cases shows higher level of lytic geneBALF3, which is associated with DNA damage and genomic instability",
                      "Another subset of cases has mutations of epigenetic modifiers and activation of NF-kB and TCR signaling pathways",
                      "Mutations ofEBNA3andBPLF1loci in EBV extranodal NK-/T-cell lymphoma"
                    ]
                  }
                ],
                "Epidemiology": [
                  {
                    "text": "Common in Southeast Asia and Native Americans of Central and South AmericaHLA-DPB1 postulated as susceptibility gene predisposing to extranodal NK-/T-cell lymphoma",
                    "sub_points": [
                      "HLA-DPB1 postulated as susceptibility gene predisposing to extranodal NK-/T-cell lymphoma"
                    ]
                  },
                  {
                    "text": "Rare in USA, but incidence has been risingPatients with immunosuppression (e.g., post transplant) are susceptible",
                    "sub_points": [
                      "Patients with immunosuppression (e.g., post transplant) are susceptible"
                    ]
                  }
                ],
                "Gene Expression Profiling": [
                  {
                    "text": "Distinctive gene expression profilePRDM1deletion andSTAT3mutant cooperatively promote NK-cell growth",
                    "sub_points": [
                      "PRDM1deletion andSTAT3mutant cooperatively promote NK-cell growth"
                    ]
                  },
                  {
                    "text": "Overexpression of genes related toAngiogenesis, genotoxic stress, proliferation, EBV",
                    "sub_points": [
                      "Angiogenesis, genotoxic stress, proliferation, EBV"
                    ]
                  },
                  {
                    "text": "Activation of JAK/STAT3, AKT and decreased inhibition of NF-κBActivation of STAT3 contributes to PD-L1 expression and immune evasion",
                    "sub_points": [
                      "Activation of STAT3 contributes to PD-L1 expression and immune evasion"
                    ]
                  },
                  {
                    "text": "Mutations of tumor suppressor genes (48%) and chromatin modifiers (45%)"
                  },
                  {
                    "text": "Mutations ofSTAT3(21%),DDX3X,KMT2D, andTP53(11%)"
                  },
                  {
                    "text": "Alterations of genes associated with epigenomic regulation"
                  },
                  {
                    "text": "PDGFAis overexpressed"
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Presentation": [
                  {
                    "text": "Nasal presentationNasal cavity, nasopharynx, paranasal sinuses, palatePatients suffer fromNasal obstruction, epistaxisFacial swelling, proptosis, impaired extraocular movementMidline destructive lesionRegional lymphadenopathy occurs in 10-20% of patients",
                    "sub_points": [
                      "Nasal cavity, nasopharynx, paranasal sinuses, palate",
                      "Patients suffer fromNasal obstruction, epistaxisFacial swelling, proptosis, impaired extraocular movementMidline destructive lesion",
                      "Nasal obstruction, epistaxis",
                      "Facial swelling, proptosis, impaired extraocular movement",
                      "Midline destructive lesion",
                      "Regional lymphadenopathy occurs in 10-20% of patients"
                    ]
                  },
                  {
                    "text": "Extranasal presentationNeoplasms primarily involving any nonnasal siteSkin and intestines are most common sitesOther sites: Testes, kidneys, salivary glandsSubset of patients may be found to also have nasal disease",
                    "sub_points": [
                      "Neoplasms primarily involving any nonnasal site",
                      "Skin and intestines are most common sites",
                      "Other sites: Testes, kidneys, salivary glands",
                      "Subset of patients may be found to also have nasal disease"
                    ]
                  },
                  {
                    "text": "Staging bone marrow is positive in 10-15% of patients"
                  }
                ],
                "Natural History": [
                  {
                    "text": "Can disseminate to virtually any anatomic site; leukemic phase can occur"
                  }
                ],
                "Treatment": [],
                "Options, risks, complications": [
                  {
                    "text": "Nasal: Radiation therapy and combination chemotherapy"
                  },
                  {
                    "text": "Extranasal or stage III/IV disease: Combination chemotherapySteroid,methotrexate,ifosfamide,L-asparaginase,etoposide (SMILE)Checkpoint inhibitors or CAR T cells for refractory disease",
                    "sub_points": [
                      "Steroid,methotrexate,ifosfamide,L-asparaginase,etoposide (SMILE)",
                      "Checkpoint inhibitors or CAR T cells for refractory disease"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Patients with localized nasal disease can be cured with therapyFactors associated with poorer prognosis for patients with nasal disease includeHigh International Prognostic Index (IPI) or Korean NK-/T-cell prognostic scoreHepatomegalyLarge cells > 40% and Ki-67 (proliferation rate) > 50%Elevated C-reactive protein, anemia (< 11 g/dL), or thrombocytopenia (less than normal)Detection of EBV in bloodMutations ofDDX3XandTP53",
                    "sub_points": [
                      "Factors associated with poorer prognosis for patients with nasal disease includeHigh International Prognostic Index (IPI) or Korean NK-/T-cell prognostic scoreHepatomegalyLarge cells > 40% and Ki-67 (proliferation rate) > 50%Elevated C-reactive protein, anemia (< 11 g/dL), or thrombocytopenia (less than normal)Detection of EBV in bloodMutations ofDDX3XandTP53",
                      "High International Prognostic Index (IPI) or Korean NK-/T-cell prognostic score",
                      "Hepatomegaly",
                      "Large cells > 40% and Ki-67 (proliferation rate) > 50%",
                      "Elevated C-reactive protein, anemia (< 11 g/dL), or thrombocytopenia (less than normal)",
                      "Detection of EBV in blood",
                      "Mutations ofDDX3XandTP53"
                    ]
                  },
                  {
                    "text": "Patients with extranasal tumors have poor prognosis"
                  },
                  {
                    "text": "Korean NK-/T-cell prognostic score is based onB symptoms, stage, serum LDH, and regional lymph nodes",
                    "sub_points": [
                      "B symptoms, stage, serum LDH, and regional lymph nodes"
                    ]
                  }
                ]
              },
              "IMAGING": {
                "General Features": [],
                "Location": [
                  {
                    "text": "Nasal: Usually seen as mass that can distort midline, displace adjacent organs, and destroy bone"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Extranodal NK-/T-cell lymphoma has diffuse pattern; commonly associated with coagulative necrosisCell size is variable, ranging from small to largeMitotic figures are usually identifiedIn touch imprints, neoplastic cells can have azurophilic cytoplasmic granulesAngiocentricity and angiodestruction are common but not invariableLess common in small biopsy specimensUlcer and superimposed inflammation at mucosal sitesOverlying epithelium can show pseudoepitheliomatous hyperplasia",
                    "sub_points": [
                      "Cell size is variable, ranging from small to large",
                      "Mitotic figures are usually identified",
                      "In touch imprints, neoplastic cells can have azurophilic cytoplasmic granules",
                      "Angiocentricity and angiodestruction are common but not invariableLess common in small biopsy specimens",
                      "Less common in small biopsy specimens",
                      "Ulcer and superimposed inflammation at mucosal sites",
                      "Overlying epithelium can show pseudoepitheliomatous hyperplasia"
                    ]
                  },
                  {
                    "text": "Bone marrowInterstitial infiltrate without discrete aggregatesIn situ hybridization for EBER helpful to detect disease",
                    "sub_points": [
                      "Interstitial infiltrate without discrete aggregates",
                      "In situ hybridization for EBER helpful to detect disease"
                    ]
                  },
                  {
                    "text": "Lymph nodesRegional lymph node involvement is uncommonInterfollicular expansion by lymphomaCytologic features similar to primary tumor",
                    "sub_points": [
                      "Regional lymph node involvement is uncommonInterfollicular expansion by lymphomaCytologic features similar to primary tumor",
                      "Interfollicular expansion by lymphoma",
                      "Cytologic features similar to primary tumor"
                    ]
                  },
                  {
                    "text": "IntestinesSmall &/or large intestineUsually presents as perforated ulcer surrounded by dense and transmural lymphoid infiltratePolymorphous infiltrate composed of cells with irregular nuclei and scant cytoplasmFrequent mitoses, necrosis, and vascular congestionMesenteric lymph nodes may be involved",
                    "sub_points": [
                      "Small &/or large intestine",
                      "Usually presents as perforated ulcer surrounded by dense and transmural lymphoid infiltratePolymorphous infiltrate composed of cells with irregular nuclei and scant cytoplasmFrequent mitoses, necrosis, and vascular congestion",
                      "Polymorphous infiltrate composed of cells with irregular nuclei and scant cytoplasm",
                      "Frequent mitoses, necrosis, and vascular congestion",
                      "Mesenteric lymph nodes may be involved"
                    ]
                  }
                ],
                "Cytologic Features": [
                  {
                    "text": "Primary site of extranodal NK-/T-cell lymphoma is rarely assessed by fine-needle aspiration (FNA)"
                  },
                  {
                    "text": "FNA more often used to assess regional lymphadenopathy"
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "NK-cell lineage in ~ 65-75% of casesCD2(+), cytoplasmic CD3-ε(+), CD94(+)Both T and NK cells express CD3-εTIA1(+), GZM-B(+), perforin (+), CD56(+/-)CD4(-), CD5(-), CD8(-), TCR-β (BF1)(-)< 5% of cases express CD20 or CD79bAssociates with advanced disease and poor prognosisCD30(+) in 30-50% of casesPD-L1(+) in 40-100% of cases",
                    "sub_points": [
                      "CD2(+), cytoplasmic CD3-ε(+), CD94(+)Both T and NK cells express CD3-ε",
                      "Both T and NK cells express CD3-ε",
                      "TIA1(+), GZM-B(+), perforin (+), CD56(+/-)",
                      "CD4(-), CD5(-), CD8(-), TCR-β (BF1)(-)",
                      "< 5% of cases express CD20 or CD79bAssociates with advanced disease and poor prognosis",
                      "Associates with advanced disease and poor prognosis",
                      "CD30(+) in 30-50% of cases",
                      "PD-L1(+) in 40-100% of cases"
                    ]
                  },
                  {
                    "text": "True T-cell lineage in ~ 25-35% of casesCD2(+), CD3-ε(+), CD5(+), CD8(+/-), TCR-β (βF1)(+)TIA1(+), GZM-B(+), perforin (+), CD56(-/+)",
                    "sub_points": [
                      "CD2(+), CD3-ε(+), CD5(+), CD8(+/-), TCR-β (βF1)(+)",
                      "TIA1(+), GZM-B(+), perforin (+), CD56(-/+)"
                    ]
                  },
                  {
                    "text": "Both NK- and T-cell neoplasms are positive for EBVCan be shown by variety of molecular methods (Southern blotting, in situ hybridization)In situ hybridization for EBER is convenient and sensitiveEBV-LMP is variably expressed (usually many fewer cells than EBER)",
                    "sub_points": [
                      "Can be shown by variety of molecular methods (Southern blotting, in situ hybridization)In situ hybridization for EBER is convenient and sensitive",
                      "In situ hybridization for EBER is convenient and sensitive",
                      "EBV-LMP is variably expressed (usually many fewer cells than EBER)"
                    ]
                  }
                ],
                "PCR": [
                  {
                    "text": "T-cell neoplasms carry clonal TCR gene rearrangements"
                  },
                  {
                    "text": "NK-cell tumors negative for clonal TCR gene rearrangements"
                  }
                ],
                "Genetic Testing": [
                  {
                    "text": "Various gene deletions or mutations identified in extranodal NK-/T-cell lymphomaJAK3mutations in ~ 1/3 of casesResults inSTAT3phosphorylation (activation)Mutations ofTP53,CTNNB1,KRAS,KIT,KMT2D,ARID1AMore common in large cell tumorsCDKN2B(TP15) andCDKN2A(TP16) often inactivated by methylation",
                    "sub_points": [
                      "JAK3mutations in ~ 1/3 of casesResults inSTAT3phosphorylation (activation)",
                      "Results inSTAT3phosphorylation (activation)",
                      "Mutations ofTP53,CTNNB1,KRAS,KIT,KMT2D,ARID1A",
                      "More common in large cell tumors",
                      "CDKN2B(TP15) andCDKN2A(TP16) often inactivated by methylation"
                    ]
                  },
                  {
                    "text": "Circulating viral DNA can be used for monitoring activity of disease"
                  }
                ],
                "Array Comparative Genomic Hybridization": [
                  {
                    "text": "Comparative genomic hybridization studies have shown multiple gains and lossesCommon gains: 1q21-q44, 2q13-q14, 2q31-q32, 6p25-p11, 7q11-q34, 7q35-36, 17q21, 20q11Common losses: 6q16-q25, 11q23, 11q24-q25, 13q14, 17p13Loss of 6q16-q25 in 30-50% of casesCandidate tumor suppressor genes:PRDM1,HACE1,FOXO3",
                    "sub_points": [
                      "Common gains: 1q21-q44, 2q13-q14, 2q31-q32, 6p25-p11, 7q11-q34, 7q35-36, 17q21, 20q11",
                      "Common losses: 6q16-q25, 11q23, 11q24-q25, 13q14, 17p13Loss of 6q16-q25 in 30-50% of casesCandidate tumor suppressor genes:PRDM1,HACE1,FOXO3",
                      "Loss of 6q16-q25 in 30-50% of cases",
                      "Candidate tumor suppressor genes:PRDM1,HACE1,FOXO3"
                    ]
                  }
                ],
                "MicroRNA Profiling": [
                  {
                    "text": "Upregulation: miR-155 and miR-21"
                  },
                  {
                    "text": "Downregulation: miR-342-5p, miR-26b, miR-363, miR-150, and miR-28-5p"
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Aggressive NK-Cell Leukemia": [
                  {
                    "text": "Aggressive leukemia often associated with EBV infectionSubset of patients have chronic active EBV infection",
                    "sub_points": [
                      "Subset of patients have chronic active EBV infection"
                    ]
                  },
                  {
                    "text": "Overlaps with extranodal NK-/T-cell lymphoma when there is multiorgan involvementAlso considered leukemic counterpart of extranodal NK-/T-cell lymphoma",
                    "sub_points": [
                      "Also considered leukemic counterpart of extranodal NK-/T-cell lymphoma"
                    ]
                  },
                  {
                    "text": "Preferential geographic distribution: Asia"
                  },
                  {
                    "text": "Variable number and percentage of circulating leukemic lymphocytes"
                  },
                  {
                    "text": "Hepatosplenomegaly and lymphadenopathy are common"
                  },
                  {
                    "text": "Pancytopenia is common"
                  },
                  {
                    "text": "Leukemic cells range from small, mature-appearing lymphocytes to large pleomorphic cellsHemophagocytosis can be detected",
                    "sub_points": [
                      "Hemophagocytosis can be detected"
                    ]
                  },
                  {
                    "text": "Bone marrow involvement can be focal or diffuse"
                  },
                  {
                    "text": "Phenotype: CD2(+), surface CD3(-), cytoplasmic CD3-ε(+), CD5(-), CD56(+), CD57(-)"
                  },
                  {
                    "text": "Fatal outcome within few months after diagnosisFactors include hemophagocytosis and multiorgan failure",
                    "sub_points": [
                      "Factors include hemophagocytosis and multiorgan failure"
                    ]
                  }
                ],
                "Nodal EBV(+) T-/NK-Cell Lymphoma": [
                  {
                    "text": "This neoplasm arises in lymph nodesDistinct from secondary lymph node involvement by extranodal NK-/T-cell lymphomaUsed to be considered variant of peripheral T-cell lymphoma, not otherwise specified",
                    "sub_points": [
                      "Distinct from secondary lymph node involvement by extranodal NK-/T-cell lymphoma",
                      "Used to be considered variant of peripheral T-cell lymphoma, not otherwise specified"
                    ]
                  },
                  {
                    "text": "These neoplasms are commonly composed of large cells; necrosis (+/-)"
                  },
                  {
                    "text": "Most tumors (~ 85%) are of T-cell lineage; type 2 EBV latency"
                  },
                  {
                    "text": "Upregulation of NF-kB and immune-related pathways"
                  },
                  {
                    "text": "Mutations ofSTAT3,TET2,PIK3CDare common"
                  }
                ],
                "Indolent NK-Cell Lymphoproliferative Disorder of Gastrointestinal Tract": [
                  {
                    "text": "Formerly known as lymphomatoid gastropathy or NK-cell enteropathy"
                  },
                  {
                    "text": "Has benign course with spontaneous remission; some cases can persist for years"
                  },
                  {
                    "text": "NK-cell markers (+); EBV(-)"
                  },
                  {
                    "text": "JAK3mutations (+); activation of JAK-STAT pathway"
                  }
                ],
                "Peripheral T-Cell Lymphoma, Not Otherwise Specified, Involving Upper Aerodigestive Tract": [
                  {
                    "text": "Histologic features can mimic extranodal NK-/T-cell lymphomaNecrosis and involvement of vessels",
                    "sub_points": [
                      "Necrosis and involvement of vessels"
                    ]
                  },
                  {
                    "text": "T-cell markers (+); CD56(-/+), EBV(-)"
                  },
                  {
                    "text": "Molecular testing reveals clonal TCR gene rearrangements"
                  }
                ],
                "Granulomatosis With Polyangiitis": [
                  {
                    "text": "Previously known as Wegener granulomatosis"
                  },
                  {
                    "text": "Typically, patients also have lung and kidney disease"
                  },
                  {
                    "text": "Classic histologic triad is uncommon (< 25% of cases)Vasculitis, granulomatous inflammation, and geographic necrosis",
                    "sub_points": [
                      "Vasculitis, granulomatous inflammation, and geographic necrosis"
                    ]
                  },
                  {
                    "text": "Inflammatory infiltrate is mixedGranulocytes (including eosinophils), lymphocytes, histiocytes and multinucleated giant cells, and plasma cells are presentWegener granulomatosis is not lymphocyte rich",
                    "sub_points": [
                      "Granulocytes (including eosinophils), lymphocytes, histiocytes and multinucleated giant cells, and plasma cells are present",
                      "Wegener granulomatosis is not lymphocyte rich"
                    ]
                  },
                  {
                    "text": "Epithelial ulceration is common"
                  }
                ],
                "B-Cell Lymphomas Involving Upper Aerodigestive Tract": [
                  {
                    "text": "Most often diffuse large B-cell lymphoma"
                  },
                  {
                    "text": "Blood vessel involvement is less common"
                  },
                  {
                    "text": "Superimposed inflammation is also less common"
                  },
                  {
                    "text": "Immunophenotype: Pan-B-cell antigens (+), CD3(-), EBV(-)"
                  },
                  {
                    "text": "Molecular studies show clonalIGHrearrangements"
                  }
                ],
                "Infections": [
                  {
                    "text": "Number of infectious organisms can involve nasal region"
                  },
                  {
                    "text": "Mixed inflammatory infiltrate with granulocytes"
                  },
                  {
                    "text": "No evidence of monoclonality, EBV(-)"
                  }
                ],
                "Lethal Midline Granuloma": [
                  {
                    "text": "Term for clinical syndrome that includes nasal-type extranodal NK-/T-cell lymphoma as well asAggressive variants of granulomatosis with polyangiitisInfections, cocaine abuse (usually marked inflammation without vasculitis)",
                    "sub_points": [
                      "Aggressive variants of granulomatosis with polyangiitis",
                      "Infections, cocaine abuse (usually marked inflammation without vasculitis)"
                    ]
                  }
                ]
              },
              "STAGING": {
                "Staging": [
                  {
                    "text": "Ann Arbor staging is not ideal for nasal-type extranodal NK-/T-cell lymphoma3-tier system for staging has been suggested in KoreaLimited stage upper aerodigestive tract disease without local invasionAdvanced stage upper aerodigestive tract disease or limited stage with extensive local invasionInvolvement of nonnasal sites",
                    "sub_points": [
                      "3-tier system for staging has been suggested in KoreaLimited stage upper aerodigestive tract disease without local invasionAdvanced stage upper aerodigestive tract disease or limited stage with extensive local invasionInvolvement of nonnasal sites",
                      "Limited stage upper aerodigestive tract disease without local invasion",
                      "Advanced stage upper aerodigestive tract disease or limited stage with extensive local invasion",
                      "Involvement of nonnasal sites"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Posttransplant Lymphoproliferative Disorders, Nondestructive Lesions and Polymorphic": {
            "name": "Posttransplant Lymphoproliferative Disorders, Nondestructive Lesions and Polymorphic",
            "url": "https://app.pathprimer.com/document/c00259dd-c143-4a18-aed8-935c74da2546/lesson/1754477f-a4b1-4ec8-b223-cd1eb29cbd87",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Nondestructive PTLD: Mass lesion with preserved tissue architecture arising after transplant3 types of nondestructive lesions are recognizedPlasmacytic hyperplasiaInfectious mononucleosis (IM)-like hyperplasiaFollicular hyperplasia",
                    "sub_points": [
                      "3 types of nondestructive lesions are recognizedPlasmacytic hyperplasiaInfectious mononucleosis (IM)-like hyperplasiaFollicular hyperplasia",
                      "Plasmacytic hyperplasia",
                      "Infectious mononucleosis (IM)-like hyperplasia",
                      "Follicular hyperplasia"
                    ]
                  },
                  {
                    "text": "Polymorphic PTLD: Mass lesion with effaced/destroyed tissue architecture arising after transplantThese lesions do not meet criteria for lymphoma",
                    "sub_points": [
                      "These lesions do not meet criteria for lymphoma"
                    ]
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "Impaired host immunosurveillance"
                  },
                  {
                    "text": "Epstein-Barr virus (EBV) infectionPresent in most nondestructive and polymorphic PTLDs",
                    "sub_points": [
                      "Present in most nondestructive and polymorphic PTLDs"
                    ]
                  },
                  {
                    "text": "Risk factors for developing PTLDDegree of overall immunosuppressionType of immunosuppression; type of transplantEBV seronegativity before transplant; young patient age",
                    "sub_points": [
                      "Degree of overall immunosuppression",
                      "Type of immunosuppression; type of transplant",
                      "EBV seronegativity before transplant; young patient age"
                    ]
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Therapy1st step: Reduction of immunosuppression by ~ 50%Next steps: Rituximab ± cytotoxic chemotherapy",
                    "sub_points": [
                      "1st step: Reduction of immunosuppression by ~ 50%",
                      "Next steps: Rituximab ± cytotoxic chemotherapy"
                    ]
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Plasmacytic hyperplasiaMedullary and interfollicular plasma cells, lymphocytes",
                    "sub_points": [
                      "Medullary and interfollicular plasma cells, lymphocytes"
                    ]
                  },
                  {
                    "text": "IM-like hyperplasiaParacortical expansion by CD30(+) immunoblasts",
                    "sub_points": [
                      "Paracortical expansion by CD30(+) immunoblasts"
                    ]
                  },
                  {
                    "text": "Follicular hyperplasiaWidely spaced, reactive follicles",
                    "sub_points": [
                      "Widely spaced, reactive follicles"
                    ]
                  },
                  {
                    "text": "Polymorphic PTLDEffacement by variable-size lymphocytes, immunoblasts, histiocytes, and plasma cells",
                    "sub_points": [
                      "Effacement by variable-size lymphocytes, immunoblasts, histiocytes, and plasma cells"
                    ]
                  },
                  {
                    "text": "Ancillary dataNondestructive lesions: PolyclonalPolymorphic PTLD: ~ 60% monoclonalCytogenetic abnormalities in ~ 33%",
                    "sub_points": [
                      "Nondestructive lesions: Polyclonal",
                      "Polymorphic PTLD: ~ 60% monoclonalCytogenetic abnormalities in ~ 33%",
                      "Cytogenetic abnormalities in ~ 33%"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Posttransplant lymphoproliferative disorder (PTLD)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Nondestructive (early) lesions: Mass-forming hyperplasias with preservation of tissue architecture that occur following transplantation3 types are recognizedPlasmacytic hyperplasiaInfectious mononucleosis (IM)-like hyperplasiaFollicular hyperplasia",
                    "sub_points": [
                      "3 types are recognizedPlasmacytic hyperplasiaInfectious mononucleosis (IM)-like hyperplasiaFollicular hyperplasia",
                      "Plasmacytic hyperplasia",
                      "Infectious mononucleosis (IM)-like hyperplasia",
                      "Follicular hyperplasia"
                    ]
                  },
                  {
                    "text": "Polymorphic PTLD: Mass-forming lesions that efface/destroy tissue architecture and occur following transplantationThese lesions do not fulfill criteria for any known lymphoma type",
                    "sub_points": [
                      "These lesions do not fulfill criteria for any known lymphoma type"
                    ]
                  },
                  {
                    "text": "5th edition of WHO classification emphasizesPTLDs share features with lesions arising in context of other immunodeficiency settingsTraditional PTLD classification has clinical utility",
                    "sub_points": [
                      "PTLDs share features with lesions arising in context of other immunodeficiency settings",
                      "Traditional PTLD classification has clinical utility"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Infectious Agents": [
                  {
                    "text": "Epstein-Barr virus (EBV) plays important role in pathogenesisMost nondestructive and polymorphic PTLDs are EBV(+)Serum EBV antibody titers and blood EBV DNA load increase prior to onset of PTLDNumber of EBV(+) cytotoxic T cells drops prior to onset of PTLDTreatment with EBV-specific T cells induces remission or responses in some patientsAnalysis of EBV terminal repeat regions by Southern blot analysisNondestructive lesions: EBV usually polyclonalPolymorphic PTLDs: EBV often monoclonalIndicates EBV is present before monoclonal expansion beginsEBV can transform B cellsEBV infection extends half-life of B cellsIncreases likelihood of acquiring additional molecular aberrations that confer growth advantageEBV can coopt host cell B-cell signaling and miRNA programs leading to proliferationEBV infection has a latency type III patternEBERs(+), LMPs(+), all EBV nuclear antigens (+)",
                    "sub_points": [
                      "Most nondestructive and polymorphic PTLDs are EBV(+)",
                      "Serum EBV antibody titers and blood EBV DNA load increase prior to onset of PTLD",
                      "Number of EBV(+) cytotoxic T cells drops prior to onset of PTLD",
                      "Treatment with EBV-specific T cells induces remission or responses in some patients",
                      "Analysis of EBV terminal repeat regions by Southern blot analysisNondestructive lesions: EBV usually polyclonalPolymorphic PTLDs: EBV often monoclonalIndicates EBV is present before monoclonal expansion begins",
                      "Nondestructive lesions: EBV usually polyclonal",
                      "Polymorphic PTLDs: EBV often monoclonalIndicates EBV is present before monoclonal expansion begins",
                      "Indicates EBV is present before monoclonal expansion begins",
                      "EBV can transform B cellsEBV infection extends half-life of B cellsIncreases likelihood of acquiring additional molecular aberrations that confer growth advantageEBV can coopt host cell B-cell signaling and miRNA programs leading to proliferation",
                      "EBV infection extends half-life of B cellsIncreases likelihood of acquiring additional molecular aberrations that confer growth advantage",
                      "Increases likelihood of acquiring additional molecular aberrations that confer growth advantage",
                      "EBV can coopt host cell B-cell signaling and miRNA programs leading to proliferation",
                      "EBV infection has a latency type III patternEBERs(+), LMPs(+), all EBV nuclear antigens (+)",
                      "EBERs(+), LMPs(+), all EBV nuclear antigens (+)"
                    ]
                  }
                ],
                "Pathogenesis": [
                  {
                    "text": "Factors involved in pathogenesis of all nondestructive and polymorphic PTLDsDecreased host immunosurveillance (related to immunosuppression)EBV infectionAdults: Likely reactivation of EBV attributable to decreased immunosurveillanceChildren and some adults: Primary EBV infectionPossibly some patients are genetically more susceptible",
                    "sub_points": [
                      "Decreased host immunosurveillance (related to immunosuppression)",
                      "EBV infectionAdults: Likely reactivation of EBV attributable to decreased immunosurveillanceChildren and some adults: Primary EBV infection",
                      "Adults: Likely reactivation of EBV attributable to decreased immunosurveillance",
                      "Children and some adults: Primary EBV infection",
                      "Possibly some patients are genetically more susceptible"
                    ]
                  }
                ],
                "General Risk Factors for Posttransplant Lymphoproliferative Disorder": [
                  {
                    "text": "Type of transplantRisk likely related to immunosuppressive regimens &/or degree of immunosuppression",
                    "sub_points": [
                      "Risk likely related to immunosuppressive regimens &/or degree of immunosuppression"
                    ]
                  },
                  {
                    "text": "Degree of overall immunosuppression"
                  },
                  {
                    "text": "Type of immunosuppressionHigher risk: Tacrolimus, OKT3 monoclonal antibody, or antithymocyte globulin",
                    "sub_points": [
                      "Higher risk: Tacrolimus, OKT3 monoclonal antibody, or antithymocyte globulin"
                    ]
                  },
                  {
                    "text": "EBV seronegativity before transplant"
                  },
                  {
                    "text": "AgePediatric patients have higher incidence of PTLDLikely related to EBV seronegativity prior to transplant",
                    "sub_points": [
                      "Pediatric patients have higher incidence of PTLD",
                      "Likely related to EBV seronegativity prior to transplant"
                    ]
                  },
                  {
                    "text": "Men have higher risk than women"
                  },
                  {
                    "text": "Additional risk factors for hematopoietic stem cell transplantHLA-mismatched allograftT-cell-depleted allograftImmunosuppressive therapy for graft-vs.-host disease",
                    "sub_points": [
                      "HLA-mismatched allograft",
                      "T-cell-depleted allograft",
                      "Immunosuppressive therapy for graft-vs.-host disease"
                    ]
                  }
                ],
                "Cell of Origin of Posttransplant Lymphoproliferative Disorder": [
                  {
                    "text": "Cell of originSolid organ allograft recipients: Most PTLDs reported to be of host originHematopoietic stem cell allograft recipients: Most PTLDs reported to be of donor origin",
                    "sub_points": [
                      "Solid organ allograft recipients: Most PTLDs reported to be of host origin",
                      "Hematopoietic stem cell allograft recipients: Most PTLDs reported to be of donor origin"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "~ 115,000 transplants (all types) performed each year worldwide"
                  },
                  {
                    "text": "Frequency of lymphoma in transplant patients is 20-120% higher than general population"
                  },
                  {
                    "text": "Frequency of PTLD is related to type of transplant and associated immunosuppressionMultiple organ transplants: ~ 10% of transplant patientsSmall intestine: ~ 10% (or higher) of transplant patientsHeart: 5-6% of transplants patientsLungs: 3-4% of transplant patientsLiver: 2-3% of transplant patientsPancreas: 2-3% of transplant patientsKidney: 0.5-1% of transplant patientsHematopoietic stem cell transplant: < 1% of transplant patients",
                    "sub_points": [
                      "Multiple organ transplants: ~ 10% of transplant patients",
                      "Small intestine: ~ 10% (or higher) of transplant patients",
                      "Heart: 5-6% of transplants patients",
                      "Lungs: 3-4% of transplant patients",
                      "Liver: 2-3% of transplant patients",
                      "Pancreas: 2-3% of transplant patients",
                      "Kidney: 0.5-1% of transplant patients",
                      "Hematopoietic stem cell transplant: < 1% of transplant patients"
                    ]
                  }
                ],
                "Site": [
                  {
                    "text": "Early lesionsLymph nodes are most often involvedUsually localized; can be disseminatedWaldeyer ring and bone marrow are most common extranodal sites",
                    "sub_points": [
                      "Lymph nodes are most often involvedUsually localized; can be disseminated",
                      "Usually localized; can be disseminated",
                      "Waldeyer ring and bone marrow are most common extranodal sites"
                    ]
                  },
                  {
                    "text": "Polymorphic PTLDLymph nodes ± extranodal sitesLymphadenopathy alone in ~ 30% of patientsCommon extranodal sites of diseaseGastrointestinal tract, lungs, liver, skin, brain",
                    "sub_points": [
                      "Lymph nodes ± extranodal sitesLymphadenopathy alone in ~ 30% of patients",
                      "Lymphadenopathy alone in ~ 30% of patients",
                      "Common extranodal sites of diseaseGastrointestinal tract, lungs, liver, skin, brain",
                      "Gastrointestinal tract, lungs, liver, skin, brain"
                    ]
                  }
                ],
                "Presentation": [
                  {
                    "text": "Highly variable± nonspecific findings: Weight loss, fever, lethargy, or malaise",
                    "sub_points": [
                      "± nonspecific findings: Weight loss, fever, lethargy, or malaise"
                    ]
                  },
                  {
                    "text": "Nondestructive lesionsLymphadenopathy, enlarged tonsils, or adenoids± obstructive symptomsFew patients develop IM-like clinical syndrome",
                    "sub_points": [
                      "Lymphadenopathy, enlarged tonsils, or adenoids± obstructive symptoms",
                      "± obstructive symptoms",
                      "Few patients develop IM-like clinical syndrome"
                    ]
                  },
                  {
                    "text": "Polymorphic lesionsLymphadenopathy or extranodal mass± organ-specific compromise",
                    "sub_points": [
                      "Lymphadenopathy or extranodal mass± organ-specific compromise",
                      "± organ-specific compromise"
                    ]
                  }
                ],
                "Natural History": [
                  {
                    "text": "Nondestructive lesionsMore common in pediatric patientsUsually regress; either spontaneously or after reduction of immunosuppressionRare patients with IM-like lesion have aggressive courseFew patients subsequently develop polymorphic or monomorphic PTLD",
                    "sub_points": [
                      "More common in pediatric patients",
                      "Usually regress; either spontaneously or after reduction of immunosuppression",
                      "Rare patients with IM-like lesion have aggressive course",
                      "Few patients subsequently develop polymorphic or monomorphic PTLD"
                    ]
                  },
                  {
                    "text": "Polymorphic PTLDSubset of cases regresses after reduction of immunosuppressionOther patients have progressive disease and require chemotherapy",
                    "sub_points": [
                      "Subset of cases regresses after reduction of immunosuppression",
                      "Other patients have progressive disease and require chemotherapy"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "No established consensus for treatment of PTLDs due toClinical and pathologic heterogeneity of these lesionsGeneral lack of prospective, randomized studies",
                    "sub_points": [
                      "Clinical and pathologic heterogeneity of these lesions",
                      "General lack of prospective, randomized studies"
                    ]
                  },
                  {
                    "text": "3-step approach is often taken in treating patients with PTLDsReduction of immunosuppressionTypically, dose is reduced by ~ 50%Single-agent rituximab (anti-CD20)Rituximab and cytotoxic chemotherapy with CHOP regimenCHOP = cyclophosphamide, doxorubicin, vincristine, and prednisone",
                    "sub_points": [
                      "Reduction of immunosuppressionTypically, dose is reduced by ~ 50%",
                      "Typically, dose is reduced by ~ 50%",
                      "Single-agent rituximab (anti-CD20)",
                      "Rituximab and cytotoxic chemotherapy with CHOP regimenCHOP = cyclophosphamide, doxorubicin, vincristine, and prednisone",
                      "CHOP = cyclophosphamide, doxorubicin, vincristine, and prednisone"
                    ]
                  },
                  {
                    "text": "Nondestructive lesions often require only 1st step in management"
                  },
                  {
                    "text": "Other therapeutic approachesInfusion of EBV-specific cytotoxic T lymphocytesRadiation therapy has potential role for localized and bulky disease",
                    "sub_points": [
                      "Infusion of EBV-specific cytotoxic T lymphocytes",
                      "Radiation therapy has potential role for localized and bulky disease"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "In general, pediatric patients or patients with localized disease have best prognosis"
                  },
                  {
                    "text": "Nondestructive lesionsPrognosis usually excellentMost cases regress",
                    "sub_points": [
                      "Prognosis usually excellent",
                      "Most cases regress"
                    ]
                  },
                  {
                    "text": "Polymorphic PTLDPatients have variable prognosisSubset of polymorphic PTLD cases regresses after reduction of immunosuppressionMany polymorphic PTLD persist and require rituximab + chemotherapySubset of these patients does poorlyAdverse risk factorsOlder age, B symptoms (+), advanced stageSerum lactate dehydrogenase high, serum albumin lowInvolvement of brain or bone marrow",
                    "sub_points": [
                      "Patients have variable prognosis",
                      "Subset of polymorphic PTLD cases regresses after reduction of immunosuppression",
                      "Many polymorphic PTLD persist and require rituximab + chemotherapySubset of these patients does poorlyAdverse risk factorsOlder age, B symptoms (+), advanced stageSerum lactate dehydrogenase high, serum albumin lowInvolvement of brain or bone marrow",
                      "Subset of these patients does poorly",
                      "Adverse risk factorsOlder age, B symptoms (+), advanced stageSerum lactate dehydrogenase high, serum albumin lowInvolvement of brain or bone marrow",
                      "Older age, B symptoms (+), advanced stage",
                      "Serum lactate dehydrogenase high, serum albumin low",
                      "Involvement of brain or bone marrow"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "3 types of nondestructive lesions recognized in WHO classification scheme of PTLDsPlasmacytic hyperplasiaIM-like lesionsFollicular hyperplasia",
                    "sub_points": [
                      "Plasmacytic hyperplasia",
                      "IM-like lesions",
                      "Follicular hyperplasia"
                    ]
                  },
                  {
                    "text": "Plasmacytic hyperplasiaPreserved architectureExpansion of medullary cords and interfollicular regionsSheets or aggregates of plasma cells, small lymphocytes ± hyperplastic follicles",
                    "sub_points": [
                      "Preserved architecture",
                      "Expansion of medullary cords and interfollicular regions",
                      "Sheets or aggregates of plasma cells, small lymphocytes ± hyperplastic follicles"
                    ]
                  },
                  {
                    "text": "IM-like hyperplasiaProminent paracortical expansionProliferation of mixed population of EBV(+) B cells and reactive T cellsNumerous immunoblastsFollicles can be hyperplastic or small",
                    "sub_points": [
                      "Prominent paracortical expansion",
                      "Proliferation of mixed population of EBV(+) B cells and reactive T cells",
                      "Numerous immunoblasts",
                      "Follicles can be hyperplastic or small"
                    ]
                  },
                  {
                    "text": "Reactive follicular hyperplasia (RFH)Floridly reactive follicles with prominent germinal centers (GCs)Morphologically indistinguishable from RFH in nontransplant patients",
                    "sub_points": [
                      "Floridly reactive follicles with prominent germinal centers (GCs)",
                      "Morphologically indistinguishable from RFH in nontransplant patients"
                    ]
                  },
                  {
                    "text": "Polymorphic PTLDPartial or complete effacement of normal architecture of involved organMixed population of variable-size lymphocytes, immunoblasts, histiocytes and plasma cells± Reed-Sternberg and Hodgkin (RS+H)-like cellsMitotic figures easily identified and can be numerous± focal or confluent areas of necrosisSheets of large cells should not be seen (if present supports monomorphic PTLD)",
                    "sub_points": [
                      "Partial or complete effacement of normal architecture of involved organ",
                      "Mixed population of variable-size lymphocytes, immunoblasts, histiocytes and plasma cells± Reed-Sternberg and Hodgkin (RS+H)-like cells",
                      "± Reed-Sternberg and Hodgkin (RS+H)-like cells",
                      "Mitotic figures easily identified and can be numerous",
                      "± focal or confluent areas of necrosis",
                      "Sheets of large cells should not be seen (if present supports monomorphic PTLD)"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "Nondestructive lesionsPlasmacytic hyperplasiaPolytypic plasma cells that are CD38(+), CD138(+)Fewer small CD20(+) B cells and CD3(+) T cells; EBV LMP1(+/-)Usually EBER(+); EBV LMP1(+/-)IM-like hyperplasiaMany CD30(+) immunoblasts; mixture of B and T lymphocytesUsually EBER(+); EBV LMP1(+/-)Follicular hyperplasiaPolytypic B cells; BCL-2(-) GCs; EBV LMP1(+/-)Evidence of EBV infection in 40-50%",
                    "sub_points": [
                      "Plasmacytic hyperplasiaPolytypic plasma cells that are CD38(+), CD138(+)Fewer small CD20(+) B cells and CD3(+) T cells; EBV LMP1(+/-)Usually EBER(+); EBV LMP1(+/-)",
                      "Polytypic plasma cells that are CD38(+), CD138(+)",
                      "Fewer small CD20(+) B cells and CD3(+) T cells; EBV LMP1(+/-)",
                      "Usually EBER(+); EBV LMP1(+/-)",
                      "IM-like hyperplasiaMany CD30(+) immunoblasts; mixture of B and T lymphocytesUsually EBER(+); EBV LMP1(+/-)",
                      "Many CD30(+) immunoblasts; mixture of B and T lymphocytes",
                      "Usually EBER(+); EBV LMP1(+/-)",
                      "Follicular hyperplasiaPolytypic B cells; BCL-2(-) GCs; EBV LMP1(+/-)Evidence of EBV infection in 40-50%",
                      "Polytypic B cells; BCL-2(-) GCs; EBV LMP1(+/-)",
                      "Evidence of EBV infection in 40-50%"
                    ]
                  },
                  {
                    "text": "Polymorphic PTLD~ 50% cytoplasmic monotypic immunoglobulin (+)Many B cells CD20(+), CD79a(+), pax-5(+)Usually EBER(+); EBV LMP1(+/-)Plasma cells and plasmacytic lymphocytes: CD38(+), CD138(+)Many histiocytes and plasmacytoid dendritic cells: CD68(+), CD123(+), CD163(+)T cells: CD3(+), CD5(+)Proliferation rate by MIB-1/Ki-67 can be high",
                    "sub_points": [
                      "~ 50% cytoplasmic monotypic immunoglobulin (+)",
                      "Many B cells CD20(+), CD79a(+), pax-5(+)Usually EBER(+); EBV LMP1(+/-)",
                      "Usually EBER(+); EBV LMP1(+/-)",
                      "Plasma cells and plasmacytic lymphocytes: CD38(+), CD138(+)",
                      "Many histiocytes and plasmacytoid dendritic cells: CD68(+), CD123(+), CD163(+)",
                      "T cells: CD3(+), CD5(+)",
                      "Proliferation rate by MIB-1/Ki-67 can be high"
                    ]
                  }
                ],
                "Flow Cytometry": [
                  {
                    "text": "Nondestructive lesions are polytypic"
                  },
                  {
                    "text": "Polymorphic PTLD are monotypic in 50-60% of cases"
                  },
                  {
                    "text": "T cells show no immunophenotypic aberrancies"
                  }
                ],
                "In Situ Hybridization": [
                  {
                    "text": "Most nondestructive lesions and polymorphic PTLDs are EBER(+)"
                  },
                  {
                    "text": "Follicular hyperplasia: EBER(+) in 40-50%EBER is often localized to reactive GCs",
                    "sub_points": [
                      "EBER is often localized to reactive GCs"
                    ]
                  }
                ],
                "Genetic Testing": [
                  {
                    "text": "Nondestructive lesionsPlasmacytic hyperplasiaNo evidence of monoclonalIGHrearrangementsNo cytogenetic abnormalitiesIM-like hyperplasiaSmall monoclonal or oligoclonalIGHrearrangements~ 10% of cases have simple clonal karyotypic abnormalitiesFollicular hyperplasiaSmall monoclonal or oligoclonalIGHrearrangements~ 10% of cases have simple clonal karyotypic abnormalitiesNo translocations or oncogene mutations",
                    "sub_points": [
                      "Plasmacytic hyperplasiaNo evidence of monoclonalIGHrearrangementsNo cytogenetic abnormalities",
                      "No evidence of monoclonalIGHrearrangements",
                      "No cytogenetic abnormalities",
                      "IM-like hyperplasiaSmall monoclonal or oligoclonalIGHrearrangements~ 10% of cases have simple clonal karyotypic abnormalities",
                      "Small monoclonal or oligoclonalIGHrearrangements",
                      "~ 10% of cases have simple clonal karyotypic abnormalities",
                      "Follicular hyperplasiaSmall monoclonal or oligoclonalIGHrearrangements~ 10% of cases have simple clonal karyotypic abnormalities",
                      "Small monoclonal or oligoclonalIGHrearrangements",
                      "~ 10% of cases have simple clonal karyotypic abnormalities",
                      "No translocations or oncogene mutations"
                    ]
                  },
                  {
                    "text": "Polymorphic PTLD50-60% of cases carry monoclonalIGHrearrangementsSomatic mutations of Ig variable region genes in ~ 75% of casesBCL6mutations or aberrant methylation in subset of casesCytogenetic abnormalities in ~ 1/3 of casesChromosomal translocation are uncommon",
                    "sub_points": [
                      "50-60% of cases carry monoclonalIGHrearrangements",
                      "Somatic mutations of Ig variable region genes in ~ 75% of cases",
                      "BCL6mutations or aberrant methylation in subset of cases",
                      "Cytogenetic abnormalities in ~ 1/3 of casesChromosomal translocation are uncommon",
                      "Chromosomal translocation are uncommon"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Plasma Cell Neoplasms": [
                  {
                    "text": "Plasmacytic hyperplasia can have some resemblance to plasma cell neoplasm"
                  },
                  {
                    "text": "Features that support plasma cell neoplasmNo history of transplantationEffacement of architectureEBV(-)",
                    "sub_points": [
                      "No history of transplantation",
                      "Effacement of architecture",
                      "EBV(-)"
                    ]
                  }
                ],
                "Follicular Lymphoma": [
                  {
                    "text": "Numerous follicles that are closely spaced"
                  },
                  {
                    "text": "BCL-2(+) follicles; monotypic B-cell population by flow cytometry"
                  },
                  {
                    "text": "MonoclonalIGHrearrangements"
                  },
                  {
                    "text": "t(14;18)(q32;q21)/IGH::BCL2in ~ 85% of cases"
                  }
                ],
                "Anaplastic Large Cell Lymphoma": [
                  {
                    "text": "Cases of IM-like hyperplasia may resemble anaplastic large cell lymphoma (ALCL)"
                  },
                  {
                    "text": "Features that support IM-like hyperplasia over ALCLHistory of transplantOften localized massMany immunoblasts of B-cell lineageNo evidence of monoclonal T-cell receptor (TCR) gene rearrangements",
                    "sub_points": [
                      "History of transplant",
                      "Often localized mass",
                      "Many immunoblasts of B-cell lineage",
                      "No evidence of monoclonal T-cell receptor (TCR) gene rearrangements"
                    ]
                  },
                  {
                    "text": "Features that support ALCL over PTLDDisseminated diseaseALCL cells are of T-cell lineageCytotoxic markers (+); often ALK(+)Monoclonal TCR gene rearrangementsALKtranslocations in ALK(+) ALCL cases",
                    "sub_points": [
                      "Disseminated disease",
                      "ALCL cells are of T-cell lineage",
                      "Cytotoxic markers (+); often ALK(+)",
                      "Monoclonal TCR gene rearrangements",
                      "ALKtranslocations in ALK(+) ALCL cases"
                    ]
                  }
                ],
                "Classic Hodgkin Lymphoma": [
                  {
                    "text": "Cases of IM-like hyperplasia and polymorphic PTLD may resemble classic Hodgkin lymphoma (CHL)"
                  },
                  {
                    "text": "Features that distinguish IM-like hyperplasia from CHLImmunoblasts: CD30(+), CD45/LCA (+/-), CD15(-)",
                    "sub_points": [
                      "Immunoblasts: CD30(+), CD45/LCA (+/-), CD15(-)"
                    ]
                  },
                  {
                    "text": "Features that support polymorphic PTLD over CHLHistory of transplantRS+H-like cells in polymorphic PTLDCD30(+), CD20(+), CD15(-)~ 50% of polymorphic PTLDs are monoclonal",
                    "sub_points": [
                      "History of transplant",
                      "RS+H-like cells in polymorphic PTLDCD30(+), CD20(+), CD15(-)",
                      "CD30(+), CD20(+), CD15(-)",
                      "~ 50% of polymorphic PTLDs are monoclonal"
                    ]
                  },
                  {
                    "text": "Features that support CHL over polymorphic PTLDNo history of transplantTypical morphologic features of CHLRS+H cells in CHLCD45/LCA(-), CD15(+), CD30(+), pax-5 (dim +)",
                    "sub_points": [
                      "No history of transplant",
                      "Typical morphologic features of CHL",
                      "RS+H cells in CHLCD45/LCA(-), CD15(+), CD30(+), pax-5 (dim +)",
                      "CD45/LCA(-), CD15(+), CD30(+), pax-5 (dim +)"
                    ]
                  }
                ],
                "EBV(+) Diffuse Large B-Cell Lymphoma": [
                  {
                    "text": "IM-like or polymorphic PTLD can resemble, in part, EBV(+) diffuse large B-cell lymphoma (DLBCL)"
                  },
                  {
                    "text": "Features that support EBV(+) DLBCL over IM-like PTLDNo history of transplantEffacement of architecture by sheets of large cellsLarge cells are of B-cell lineage and monoclonal",
                    "sub_points": [
                      "No history of transplant",
                      "Effacement of architecture by sheets of large cells",
                      "Large cells are of B-cell lineage and monoclonal"
                    ]
                  },
                  {
                    "text": "Features supporting EBV(+) DLBCL over polymorphic PTLDNo history of transplantSheets of large cells",
                    "sub_points": [
                      "No history of transplant",
                      "Sheets of large cells"
                    ]
                  },
                  {
                    "text": "Subsets of polymorphic PTLD are EBV(-) or polyclonal"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Primary Effusion Lymphoma and Solid Variant of Primary Effusion Lymphoma": {
            "name": "Primary Effusion Lymphoma and Solid Variant of Primary Effusion Lymphoma",
            "url": "https://app.pathprimer.com/document/f0f9e4dc-e881-4f23-abac-91e139e867c1/lesson/1754477f-a4b1-4ec8-b223-cd1eb29cbd87",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Primary effusion lymphoma (PEL) is human herpesvirus 8 (HHV8)-associated large B-cell lymphoma2 forms of PEL: Classic and extracavitary/solid",
                    "sub_points": [
                      "2 forms of PEL: Classic and extracavitary/solid"
                    ]
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "HHV8 virus is essential for diagnosisγ herpes double-stranded DNA lymphotropic virusTransmitted by body fluids, especially salivaInfection endemic in regions of Africa and South America5-20% seroprevalence bordering Mediterranean Sea< 5% seroprevalence in North America, Northern Europe, and Asia",
                    "sub_points": [
                      "γ herpes double-stranded DNA lymphotropic virus",
                      "Transmitted by body fluids, especially saliva",
                      "Infection endemic in regions of Africa and South America",
                      "5-20% seroprevalence bordering Mediterranean Sea",
                      "< 5% seroprevalence in North America, Northern Europe, and Asia"
                    ]
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "PEL is associated with clinical and laboratory findings of severe immunosuppression (usually HIV infection)"
                  },
                  {
                    "text": "Classic form of PELLymphoma cells grow in pleural, peritoneal, &/or pericardial effusionsIntracavitary mass in ~ 25% of patients",
                    "sub_points": [
                      "Lymphoma cells grow in pleural, peritoneal, &/or pericardial effusions",
                      "Intracavitary mass in ~ 25% of patients"
                    ]
                  },
                  {
                    "text": "Extracavitary or solid variant of PELPatients present with extracavitary mass",
                    "sub_points": [
                      "Patients present with extracavitary mass"
                    ]
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Classic form of PEL in cytologic preparations of effusionLarge cells with round to irregular nuclei, prominent nucleoli, and abundant cytoplasm",
                    "sub_points": [
                      "Large cells with round to irregular nuclei, prominent nucleoli, and abundant cytoplasm"
                    ]
                  },
                  {
                    "text": "Extracavitary/solid variant of PEL in tissue specimensDiffuse pattern; starry sky common; high mitotic activity",
                    "sub_points": [
                      "Diffuse pattern; starry sky common; high mitotic activity"
                    ]
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "HHV8(+) is essential for diagnosis"
                  },
                  {
                    "text": "Plasma cell-associated markers (+); pan-B cell (-)"
                  },
                  {
                    "text": "No rearrangements ofMYC,BCL2,BCL6,CCND1"
                  },
                  {
                    "text": "TP53andRASgenes are rarely mutated"
                  },
                  {
                    "text": "Gene expression profileFeatures of plasma cells and EBV-transformed lymphocytes",
                    "sub_points": [
                      "Features of plasma cells and EBV-transformed lymphocytes"
                    ]
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "Diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS)"
                  },
                  {
                    "text": "Plasmablastic lymphoma"
                  },
                  {
                    "text": "DLBCL associated with chronic inflammation"
                  },
                  {
                    "text": "Plasmablastic plasma cell myeloma"
                  },
                  {
                    "text": "ALK(+) Large B-cell Lymphoma"
                  },
                  {
                    "text": "EBV(+) DLBCL, NOS"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Primary effusion lymphoma (PEL)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Body cavity-based lymphoma"
                  },
                  {
                    "text": "Kaposi sarcoma-associated herpesvirus-associated lymphoma"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Human herpesvirus 8 (HHV8)-associated large B-cell neoplasm most often involving body cavitiesPleural, pericardial, or peritoneal cavity",
                    "sub_points": [
                      "Pleural, pericardial, or peritoneal cavity"
                    ]
                  },
                  {
                    "text": "HHV8(+) lymphomas indistinguishable from PEL rarely present as solid tumor massDesignated as extracavitary or solid variant of PEL",
                    "sub_points": [
                      "Designated as extracavitary or solid variant of PEL"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Infectious Agents": [
                  {
                    "text": "PEL arises from HHV8infected B cells with \"plasmablastic\" differentiationMigration of neoplastic cells or recruitment in cavities by local stimulusHypoxia due fluid accumulationHypoxia-inducible factor-1 production and HHV8 replicationEBV is virtually constant in setting of HIV infectionMay enhance the lymphomagenesis",
                    "sub_points": [
                      "Migration of neoplastic cells or recruitment in cavities by local stimulusHypoxia due fluid accumulationHypoxia-inducible factor-1 production and HHV8 replication",
                      "Hypoxia due fluid accumulationHypoxia-inducible factor-1 production and HHV8 replication",
                      "Hypoxia-inducible factor-1 production and HHV8 replication",
                      "EBV is virtually constant in setting of HIV infectionMay enhance the lymphomagenesis",
                      "May enhance the lymphomagenesis"
                    ]
                  },
                  {
                    "text": "HHV8 virus (a.k.a. Kaposi sarcoma herpesvirus)γ herpes double-stranded DNA lymphotropic virusTransmitted by body fluids, especially salivaEncodes number of homologues of cellular genesInvolved in cell proliferation and apoptosisNF-κB activationSeroprevalence of HHV8 worldwideEndemic; up to 50% in sub-Saharan Africa and Amazon region of South America5-20% in nations bordering Mediterranean Sea1-5% in Asia, Europe, and North AmericaHHV8 evades host cytotoxic T-cell immunosurveillance by infecting B cellsLifelong and latent infectionT-cell mediated immunoregulationHyperactivation of T-helper 2 (Th2) and downregulation of T-helper 1 (Th1) of hostVirally encoded cytokines and viral chemokinesViral interleukin 6 (vIL-6) and viral interferon regulatory factor 3 (vIRF3 or LANA2)cCCL1, vCCL2, and vCCL3; CD200HHV8 is also associated withKaposi sarcomaMulticentric Castleman disease (MCD)MCD-associated plasmablastic/large B-cell lymphoma",
                    "sub_points": [
                      "γ herpes double-stranded DNA lymphotropic virus",
                      "Transmitted by body fluids, especially saliva",
                      "Encodes number of homologues of cellular genesInvolved in cell proliferation and apoptosisNF-κB activation",
                      "Involved in cell proliferation and apoptosis",
                      "NF-κB activation",
                      "Seroprevalence of HHV8 worldwideEndemic; up to 50% in sub-Saharan Africa and Amazon region of South America5-20% in nations bordering Mediterranean Sea1-5% in Asia, Europe, and North America",
                      "Endemic; up to 50% in sub-Saharan Africa and Amazon region of South America",
                      "5-20% in nations bordering Mediterranean Sea",
                      "1-5% in Asia, Europe, and North America",
                      "HHV8 evades host cytotoxic T-cell immunosurveillance by infecting B cellsLifelong and latent infectionT-cell mediated immunoregulationHyperactivation of T-helper 2 (Th2) and downregulation of T-helper 1 (Th1) of host",
                      "Lifelong and latent infection",
                      "T-cell mediated immunoregulationHyperactivation of T-helper 2 (Th2) and downregulation of T-helper 1 (Th1) of host",
                      "Hyperactivation of T-helper 2 (Th2) and downregulation of T-helper 1 (Th1) of host",
                      "Virally encoded cytokines and viral chemokinesViral interleukin 6 (vIL-6) and viral interferon regulatory factor 3 (vIRF3 or LANA2)cCCL1, vCCL2, and vCCL3; CD200",
                      "Viral interleukin 6 (vIL-6) and viral interferon regulatory factor 3 (vIRF3 or LANA2)",
                      "cCCL1, vCCL2, and vCCL3; CD200",
                      "HHV8 is also associated withKaposi sarcomaMulticentric Castleman disease (MCD)MCD-associated plasmablastic/large B-cell lymphoma",
                      "Kaposi sarcoma",
                      "Multicentric Castleman disease (MCD)",
                      "MCD-associated plasmablastic/large B-cell lymphoma"
                    ]
                  }
                ],
                "Clinical Associations": [
                  {
                    "text": "HIV infection or other severe acquired immunodeficienciesPreexisting AIDS is very common~ 60% of cases are related to HIV infectionRare cases related to transplant setting",
                    "sub_points": [
                      "Preexisting AIDS is very common~ 60% of cases are related to HIV infection",
                      "~ 60% of cases are related to HIV infection",
                      "Rare cases related to transplant setting"
                    ]
                  },
                  {
                    "text": "PEL also can occur in patients without immunodeficiencyOlder adult patients in 8th-9th decades in HHV8 endemic areasUsually these tumors are EBV(-)",
                    "sub_points": [
                      "Older adult patients in 8th-9th decades in HHV8 endemic areasUsually these tumors are EBV(-)",
                      "Usually these tumors are EBV(-)"
                    ]
                  },
                  {
                    "text": "Rare cases of PEL are associated with hepatitis C &/or B"
                  }
                ],
                "Pathogenesis": [
                  {
                    "text": "In PEL, B-cell differentiation program is blockedIn part due to overexpression of activated B-cell factor 1 (ABF-1) and inhibitor of differentiation 2 (ID2)These molecules inhibit TCF3/E2A (B-cell transcription factor)TCF3/E2A inhibition downregulates B-cell-specific genesRestoration of TCF3/E2Aactivity in PEL induces apoptosis of tumor cells",
                    "sub_points": [
                      "In part due to overexpression of activated B-cell factor 1 (ABF-1) and inhibitor of differentiation 2 (ID2)These molecules inhibit TCF3/E2A (B-cell transcription factor)TCF3/E2A inhibition downregulates B-cell-specific genes",
                      "These molecules inhibit TCF3/E2A (B-cell transcription factor)",
                      "TCF3/E2A inhibition downregulates B-cell-specific genes",
                      "Restoration of TCF3/E2Aactivity in PEL induces apoptosis of tumor cells"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "Rare< 0.5% of all aggressive lymphomas in HIV(-) patients~ 4% of all HIV-related non-Hodgkin lymphomasM:F rate is 8.5:1More common in Whites",
                    "sub_points": [
                      "< 0.5% of all aggressive lymphomas in HIV(-) patients",
                      "~ 4% of all HIV-related non-Hodgkin lymphomas",
                      "M:F rate is 8.5:1",
                      "More common in Whites"
                    ]
                  }
                ],
                "Presentation": [
                  {
                    "text": "PEL is associated with clinical and laboratory findings of severe immunosuppression (e.g., HIV)Marked depletion of CD4(+) T cellsUsually < 200 cells/μL",
                    "sub_points": [
                      "Marked depletion of CD4(+) T cellsUsually < 200 cells/μL",
                      "Usually < 200 cells/μL"
                    ]
                  },
                  {
                    "text": "Rare cases in HIV(-) patientsUsually in older ages, no association with EBV, and lower risk of extracavitary involvement",
                    "sub_points": [
                      "Usually in older ages, no association with EBV, and lower risk of extracavitary involvement"
                    ]
                  },
                  {
                    "text": "Aggressive clinical course"
                  },
                  {
                    "text": "Classic form of PELLymphoma cells grow in pleural, peritoneal, pericardial, subarachnoid spacesPleural involvement is common presentationIntracavitary mass can be present in ~ 25% of patientsMulticavitary involvement in up to 30% of casesUsually no distinct extracavitary tumor masses &/or organomegalyFrequent B symptomsSymptoms commonly result from massive malignant effusionDyspnea, chest pain, heart failure, cardiac tamponade, and abdominal distensionCompression from pleural, pericardial &/or abdominal volume overloadSystemic dissemination can occur during course of diseaseLymph nodes, extranodal sites, and, rarely, bone marrow",
                    "sub_points": [
                      "Lymphoma cells grow in pleural, peritoneal, pericardial, subarachnoid spacesPleural involvement is common presentationIntracavitary mass can be present in ~ 25% of patientsMulticavitary involvement in up to 30% of cases",
                      "Pleural involvement is common presentation",
                      "Intracavitary mass can be present in ~ 25% of patients",
                      "Multicavitary involvement in up to 30% of cases",
                      "Usually no distinct extracavitary tumor masses &/or organomegaly",
                      "Frequent B symptoms",
                      "Symptoms commonly result from massive malignant effusionDyspnea, chest pain, heart failure, cardiac tamponade, and abdominal distensionCompression from pleural, pericardial &/or abdominal volume overload",
                      "Dyspnea, chest pain, heart failure, cardiac tamponade, and abdominal distensionCompression from pleural, pericardial &/or abdominal volume overload",
                      "Compression from pleural, pericardial &/or abdominal volume overload",
                      "Systemic dissemination can occur during course of diseaseLymph nodes, extranodal sites, and, rarely, bone marrow",
                      "Lymph nodes, extranodal sites, and, rarely, bone marrow"
                    ]
                  },
                  {
                    "text": "Extracavitary or solid variant of PELPatients present with extracavitary massOften develop malignant effusion over disease courseGastrointestinal tract and lymph nodes most frequently involved",
                    "sub_points": [
                      "Patients present with extracavitary massOften develop malignant effusion over disease course",
                      "Often develop malignant effusion over disease course",
                      "Gastrointestinal tract and lymph nodes most frequently involved"
                    ]
                  },
                  {
                    "text": "Involvement of central nervous system is rareCase reports of involvement of cerebrospinal fluid",
                    "sub_points": [
                      "Case reports of involvement of cerebrospinal fluid"
                    ]
                  },
                  {
                    "text": "Standard Ann Arbor staging is not useful as, by definition, all PEL cases are stage IV"
                  },
                  {
                    "text": "Patients can have coexistent or prior history of Kaposi sarcoma in up to 75% of cases"
                  }
                ],
                "Treatment": [
                  {
                    "text": "Antiretroviral therapy improves prognosis and should be maintainedLopinavir and azidothymidine",
                    "sub_points": [
                      "Lopinavir and azidothymidine"
                    ]
                  },
                  {
                    "text": "Intracavitary cidofovir (antiviral agent that inhibits replication of HHV8) with interferon-α"
                  },
                  {
                    "text": "No consensus regarding optimal therapyCyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP)Dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (DA-EPOCH)Rituximab probably has no role in patients with PEL [CD20 is usually (-)]Limited data about bortezomib, proteosome inhibitor that inhibits NF-kB pathwayAxicabtagene ciloleucel/uCAR-T cell may be used",
                    "sub_points": [
                      "Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP)",
                      "Dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (DA-EPOCH)",
                      "Rituximab probably has no role in patients with PEL [CD20 is usually (-)]",
                      "Limited data about bortezomib, proteosome inhibitor that inhibits NF-kB pathway",
                      "Axicabtagene ciloleucel/uCAR-T cell may be used"
                    ]
                  },
                  {
                    "text": "Relapsed/refractory settingAntivirals (valganciclovir)Autologous stem cell transplantationRadiation",
                    "sub_points": [
                      "Antivirals (valganciclovir)",
                      "Autologous stem cell transplantation",
                      "Radiation"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Usually poor; median survival < 6 months1-, 3-, and 5-year overall survival (OS): 30%, 18%, and 17%",
                    "sub_points": [
                      "1-, 3-, and 5-year overall survival (OS): 30%, 18%, and 17%"
                    ]
                  },
                  {
                    "text": "Peritoneal involvement and elevated lactate dehydrogenase (LDH) seems to be associated with higher risk of death while pericardial involvement with lower risk of death"
                  }
                ]
              },
              "IMAGING": {
                "Radiographic Findings": [
                  {
                    "text": "Bilateral or unilateral pleural effusion"
                  },
                  {
                    "text": "Pericardial effusion, peritoneal effusion"
                  },
                  {
                    "text": "Slight thickening of parietal pleura, pericardium, or peritoneum"
                  },
                  {
                    "text": "Absence of solid tumor masses, parenchymal abnormalities, or mediastinal enlargementIf mass is present with effusion, diagnosis is unlikely",
                    "sub_points": [
                      "If mass is present with effusion, diagnosis is unlikely"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Classic form of PELDiagnosis is usually established on cytologic preparations of effusion fluidBiopsy specimens may show neoplastic cells adherent to mesothelial surfaces",
                    "sub_points": [
                      "Diagnosis is usually established on cytologic preparations of effusion fluid",
                      "Biopsy specimens may show neoplastic cells adherent to mesothelial surfaces"
                    ]
                  },
                  {
                    "text": "Extracavitary/solid variant of PELSheets of large cells in diffuse patternStarry-sky pattern common; high mitotic activityNecrosis and mitosis can be presentLarge lymphoid cells with round to irregular nuclei, prominent nucleoli, and abundant cytoplasm; often spectrumImmunoblastic: Round nuclei and prominent central nucleoliPlasmablastic: Eccentric nuclei with abundant cytoplasm, ± perinuclear hofAnaplastic: Multinucleated and Reed-Sternberg-like cells",
                    "sub_points": [
                      "Sheets of large cells in diffuse pattern",
                      "Starry-sky pattern common; high mitotic activity",
                      "Necrosis and mitosis can be present",
                      "Large lymphoid cells with round to irregular nuclei, prominent nucleoli, and abundant cytoplasm; often spectrumImmunoblastic: Round nuclei and prominent central nucleoliPlasmablastic: Eccentric nuclei with abundant cytoplasm, ± perinuclear hofAnaplastic: Multinucleated and Reed-Sternberg-like cells",
                      "Immunoblastic: Round nuclei and prominent central nucleoli",
                      "Plasmablastic: Eccentric nuclei with abundant cytoplasm, ± perinuclear hof",
                      "Anaplastic: Multinucleated and Reed-Sternberg-like cells"
                    ]
                  }
                ],
                "Cytologic Features": [
                  {
                    "text": "CytospinDyscohesive pattern of large atypical cells, many with irregular nuclear contours, fine chromatin, prominent nucleoli, and abundant basophilic cytoplasm (± vacuolated, ± pale Golgi zone)Cytomorphologic appearance: Immunoblastic, plasmablastic, or anaplasticAnaplastic morphology can mimic carcinomaOccasional Reed-Sternberg-like cellsAbundant erythrocytes in background",
                    "sub_points": [
                      "Dyscohesive pattern of large atypical cells, many with irregular nuclear contours, fine chromatin, prominent nucleoli, and abundant basophilic cytoplasm (± vacuolated, ± pale Golgi zone)",
                      "Cytomorphologic appearance: Immunoblastic, plasmablastic, or anaplasticAnaplastic morphology can mimic carcinoma",
                      "Anaplastic morphology can mimic carcinoma",
                      "Occasional Reed-Sternberg-like cells",
                      "Abundant erythrocytes in background"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "HHV-8(+) is essential for diagnosis"
                  },
                  {
                    "text": "Classic form of PELPlasma cell-associated markers (+)CD138, VS38c, IRF4/MUM1CD38, BLIMP1, EMA (+/-)CD45/LCA(+/-), CD71(+), HLA-DR(+)CD30(+/-), surface Ig(-), cytoplasmic Ig(+/-)Notch (+) in most casesNuclear and cytoplasmic pattern of expressionPan-B-cell markers (-)CD19, CD20, CD79a, pax-5CD10(-), CD15(-), BCL-6(-), LMP1(-)Aberrant expression of T-cell antigensCD3, CD4, CD7, CD45RORare cases with aberrant expression of cytokeratinHigh Ki-67 proliferation indexUsually > 80%",
                    "sub_points": [
                      "Plasma cell-associated markers (+)CD138, VS38c, IRF4/MUM1CD38, BLIMP1, EMA (+/-)",
                      "CD138, VS38c, IRF4/MUM1",
                      "CD38, BLIMP1, EMA (+/-)",
                      "CD45/LCA(+/-), CD71(+), HLA-DR(+)",
                      "CD30(+/-), surface Ig(-), cytoplasmic Ig(+/-)",
                      "Notch (+) in most casesNuclear and cytoplasmic pattern of expression",
                      "Nuclear and cytoplasmic pattern of expression",
                      "Pan-B-cell markers (-)CD19, CD20, CD79a, pax-5",
                      "CD19, CD20, CD79a, pax-5",
                      "CD10(-), CD15(-), BCL-6(-), LMP1(-)",
                      "Aberrant expression of T-cell antigensCD3, CD4, CD7, CD45RO",
                      "CD3, CD4, CD7, CD45RO",
                      "Rare cases with aberrant expression of cytokeratin",
                      "High Ki-67 proliferation indexUsually > 80%",
                      "Usually > 80%"
                    ]
                  },
                  {
                    "text": "Extracavitary/solid variant of PELSimilar immunophenotype to classic PEL exceptLess often CD45/LCA(+) or CD138(+)~ 20% CD20(+) &/or CD79a(+)",
                    "sub_points": [
                      "Similar immunophenotype to classic PEL exceptLess often CD45/LCA(+) or CD138(+)~ 20% CD20(+) &/or CD79a(+)",
                      "Less often CD45/LCA(+) or CD138(+)",
                      "~ 20% CD20(+) &/or CD79a(+)"
                    ]
                  }
                ],
                "Flow Cytometry": [
                  {
                    "text": "Classic PEL: Similar immunophenotype to that observed by immunohistochemistry"
                  },
                  {
                    "text": "ResultsIntermediate to high side scatteredCD45/LCA(+/-), CD71(+)HLA-DR(+); CD23(+) in ~ 20%Surface Ig light chain expression is rareCD19(-), CD20(-), CD22(-)~ 10% of cases have dim CD20 expressionCD2(-), CD3(-), CD10(-), FMC7(-)Aberrant T-cell markers are (+) in subset of casesCD45RO (~ 90%), CD7 (~ 30%), CD4 (~ 20%)",
                    "sub_points": [
                      "Intermediate to high side scattered",
                      "CD45/LCA(+/-), CD71(+)",
                      "HLA-DR(+); CD23(+) in ~ 20%",
                      "Surface Ig light chain expression is rare",
                      "CD19(-), CD20(-), CD22(-)~ 10% of cases have dim CD20 expression",
                      "~ 10% of cases have dim CD20 expression",
                      "CD2(-), CD3(-), CD10(-), FMC7(-)",
                      "Aberrant T-cell markers are (+) in subset of casesCD45RO (~ 90%), CD7 (~ 30%), CD4 (~ 20%)",
                      "CD45RO (~ 90%), CD7 (~ 30%), CD4 (~ 20%)"
                    ]
                  }
                ],
                "In Situ Hybridization": [
                  {
                    "text": "EBER(+) in ~ 80% of casesVirtually 100% of HIV(+) patients> 90% of all casesLatency pattern I: EBER(+), LMP-1(-), EBNA2(-)",
                    "sub_points": [
                      "Virtually 100% of HIV(+) patients> 90% of all cases",
                      "> 90% of all cases",
                      "Latency pattern I: EBER(+), LMP-1(-), EBNA2(-)"
                    ]
                  }
                ],
                "Genetic Testing": [
                  {
                    "text": "MonoclonalIGHrearrangementsFrequent somatic hypermutation ofIGHvariable regions",
                    "sub_points": [
                      "Frequent somatic hypermutation ofIGHvariable regions"
                    ]
                  },
                  {
                    "text": "Monoclonal T-cell receptor gene rearrangements in subset"
                  },
                  {
                    "text": "Usually complex karyotype"
                  },
                  {
                    "text": "No recurrent chromosomal abnormalities identified"
                  },
                  {
                    "text": "No rearrangements ofMYC, BCL2, BCL6, CCND1Mutations ofBCL6in subset of cases",
                    "sub_points": [
                      "Mutations ofBCL6in subset of cases"
                    ]
                  },
                  {
                    "text": "TP53andRASgenes are rarely mutated"
                  }
                ],
                "Array Comparative Genomic Hybridization": [
                  {
                    "text": "Gains of Iq21-41, 4q28-35, 7q, 8q, 11, 12, 17q, 19p, 20q"
                  },
                  {
                    "text": "Losses of 4q, 11q25, 14q32Amplification of selectin-P ligand (12q24.11)",
                    "sub_points": [
                      "Amplification of selectin-P ligand (12q24.11)"
                    ]
                  }
                ],
                "Gene Expression Profiling": [
                  {
                    "text": "PEL in HIV(+) patients has been assessedProfile is distinctiveFeatures of plasma cells and EBV-transformed lymphocytes",
                    "sub_points": [
                      "Profile is distinctiveFeatures of plasma cells and EBV-transformed lymphocytes",
                      "Features of plasma cells and EBV-transformed lymphocytes"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Diffuse Large B-Cell Lymphoma, Not Otherwise Specified": [
                  {
                    "text": "Patients can present with or subsequently develop body cavity involvement"
                  },
                  {
                    "text": "Any systemic lymphoma may involve any serosal cavitiesMost frequent type is diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS)Pleural involvement can be unilateral or bilateralUnilateral involvement is more common on left side",
                    "sub_points": [
                      "Most frequent type is diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS)",
                      "Pleural involvement can be unilateral or bilateralUnilateral involvement is more common on left side",
                      "Unilateral involvement is more common on left side"
                    ]
                  },
                  {
                    "text": "Usually no history of immunosuppression"
                  }
                ],
                "Plasmablastic Lymphoma": [
                  {
                    "text": "Oral and nonoral types"
                  },
                  {
                    "text": "Associated with HIV(+) and EBV(+)"
                  },
                  {
                    "text": "Plasmablastic lymphoma exhibits cytologic spectrumImmunoblasticMore common in oral cavity and in HIV(+) patientsPlasmablasticMore common in nonoral sites",
                    "sub_points": [
                      "ImmunoblasticMore common in oral cavity and in HIV(+) patients",
                      "More common in oral cavity and in HIV(+) patients",
                      "PlasmablasticMore common in nonoral sites",
                      "More common in nonoral sites"
                    ]
                  },
                  {
                    "text": "Plasma cell-associated markers strongly (+)IRF4/MUM1, CD38, CD138, VS38/p63",
                    "sub_points": [
                      "IRF4/MUM1, CD38, CD138, VS38/p63"
                    ]
                  },
                  {
                    "text": "Cytoplasmic Ig(+) ~ 60-70%; CD79a(+) ~ 70-80%"
                  },
                  {
                    "text": "CD45/LCA(-) or weakly (+); CD20(-); HHV8(-)"
                  }
                ],
                "Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation": [
                  {
                    "text": "Lymphoma occurring in setting of longstanding chronic inflammation"
                  },
                  {
                    "text": "a.k.a. pyothorax-associated lymphomaHistory of chronic pleural inflammationMycobacterium tuberculosisinfection &/or pyothoraxArtificial pneumothorax as part of therapy",
                    "sub_points": [
                      "History of chronic pleural inflammationMycobacterium tuberculosisinfection &/or pyothoraxArtificial pneumothorax as part of therapy",
                      "Mycobacterium tuberculosisinfection &/or pyothorax",
                      "Artificial pneumothorax as part of therapy"
                    ]
                  },
                  {
                    "text": "More common in Japan; usually in older adult men"
                  },
                  {
                    "text": "Usually presents as large pleural massDirect invasion of adjacent structures and organs",
                    "sub_points": [
                      "Direct invasion of adjacent structures and organs"
                    ]
                  },
                  {
                    "text": "Immunoblastic morphology is most common"
                  },
                  {
                    "text": "CD20(+), CD79a(+)Small subset of cases exhibits plasmacytoid differentiationCD20(-) or CD79a(-)IRF4/MUM1(+) or CD138(+)",
                    "sub_points": [
                      "Small subset of cases exhibits plasmacytoid differentiationCD20(-) or CD79a(-)IRF4/MUM1(+) or CD138(+)",
                      "CD20(-) or CD79a(-)",
                      "IRF4/MUM1(+) or CD138(+)"
                    ]
                  },
                  {
                    "text": "EBER(+), LMP1(+), HHV8(-)"
                  },
                  {
                    "text": "TP53mutations in ~ 70%"
                  }
                ],
                "ALK(+) Large B-Cell Lymphoma": [
                  {
                    "text": "No association with underlying conditions"
                  },
                  {
                    "text": "Preference for nodal sites"
                  },
                  {
                    "text": "Plasmablastic morphology"
                  },
                  {
                    "text": "CD138(+), IRF4/MUM-1(+), CD20(-), ALK(+)"
                  },
                  {
                    "text": "EBER(-), HHV8(-)"
                  },
                  {
                    "text": "Poor prognosis"
                  }
                ],
                "EBV(+) Diffuse Large B-Cell Lymphoma, Not Otherwise Specified": [
                  {
                    "text": "Advanced age"
                  },
                  {
                    "text": "Related to immunosenescence"
                  },
                  {
                    "text": "Occur in nodal or extranodal sites"
                  },
                  {
                    "text": "Centroblastic, immunoblastic, or plasmablastic morphology"
                  },
                  {
                    "text": "CD20(+), CD10(-), BCL-6(+/-), IRF4/MUM-1(+)"
                  },
                  {
                    "text": "Poor prognosis"
                  }
                ],
                "HHV8(+) Diffuse Large B-Cell Lymphoma, Not Otherwise Specified": [
                  {
                    "text": "Association with multicentric Castleman Disease"
                  },
                  {
                    "text": "More common in nodal sites"
                  },
                  {
                    "text": "Plasmablastic morphology"
                  },
                  {
                    "text": "LANA-1(+), cIgM lambda restriction, CD20(+/-), CD138(-)"
                  }
                ],
                "Burkitt Lymphoma": [
                  {
                    "text": "Burkitt lymphoma (BL) and PEL can share extranodal location and high proliferation rate"
                  },
                  {
                    "text": "BL can occur in HIV(+) patients but rarely shows plasmacytoid differentiation"
                  },
                  {
                    "text": "Pan-B-cell antigens (+); CD10(+), BCL-6(+)"
                  },
                  {
                    "text": "MIB-1/Ki-67 high (~ 100%); BCL-2(-)"
                  },
                  {
                    "text": "MYC-associated translocations with immunoglobulin partner"
                  }
                ],
                "Plasmablastic Plasma Cell Myeloma": [
                  {
                    "text": "Evidence of plasma cell myeloma is usually presentParaprotein in blood &/or excess light chains (Bence Jones protein) in urineBone marrow involved; lytic bone lesions present",
                    "sub_points": [
                      "Paraprotein in blood &/or excess light chains (Bence Jones protein) in urine",
                      "Bone marrow involved; lytic bone lesions present"
                    ]
                  },
                  {
                    "text": "Presence of atypical plasma cells; EBER(-)"
                  }
                ],
                "Anaplastic Large Cell Lymphoma": [
                  {
                    "text": "Anaplastic morphology with \"hallmark\" cells"
                  },
                  {
                    "text": "CD30(+), T-cell markers (+), HHV8(-)"
                  }
                ],
                "Malignant Melanoma": [
                  {
                    "text": "Melanoma cells can have abundant eosinophilic cytoplasm resembling plasmacytoid differentiation"
                  },
                  {
                    "text": "S100(+), HMB-45(+), Melan-A (+)"
                  },
                  {
                    "text": "Electron microscopy (EM) may show melanosomes"
                  }
                ],
                "Poorly Differentiated or Undifferentiated Carcinoma": [
                  {
                    "text": "Carcinomas can be CD138(+)"
                  },
                  {
                    "text": "Cytokeratin (+), CD38(-), IRF4/MUM1(-)"
                  },
                  {
                    "text": "EM often shows desmosomes or cellular junctions"
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "Diagnosis is usually based on cytological examination of body fluids"
                  },
                  {
                    "text": "Many lymphomas, mostly aggressive types, can present with neoplastic serous effusion"
                  },
                  {
                    "text": "PEL is associated with immunodeficiency and hasEvidence of HHV8 infection",
                    "sub_points": [
                      "Evidence of HHV8 infection"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          }
        }
      },
      "Spleen: Nonneoplastic Lesions": {
        "name": "Spleen: Nonneoplastic Lesions",
        "url": "https://app.pathprimer.com/lesson/b0cb4bb8-512f-4a17-8214-1343aaeb2eac",
        "topics": {
          "Epithelial Cyst": {
            "name": "Epithelial Cyst",
            "url": "https://app.pathprimer.com/document/eb307b6e-9bed-4c5a-885d-d41bd4c5d6f4/lesson/b0cb4bb8-512f-4a17-8214-1343aaeb2eac",
            "content": {
              "Key Facts": {
                "Terminology": [
                  {
                    "text": "Defined by presence of epithelial lining"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "30% asymptomatic"
                  },
                  {
                    "text": "Other symptoms related to pressure of cyst on other organs"
                  },
                  {
                    "text": "No treatment is needed if < 5 cm, otherwise surgical treatment is required"
                  }
                ],
                "Macroscopic Features": [
                  {
                    "text": "Usually large unilocular cysts"
                  },
                  {
                    "text": "Shiny lining with fibrous trabeculations"
                  },
                  {
                    "text": "Filled with fluid"
                  }
                ],
                "Microscopic Features": [
                  {
                    "text": "Cyst wall composed of fibrous tissue"
                  },
                  {
                    "text": "Lined by columnar, cuboidal, or flattened epithelium"
                  },
                  {
                    "text": "Positive for cytokeratins or mesothelioma markers"
                  }
                ]
              },
              "Terminology": {
                "Synonyms": [
                  {
                    "text": "True cysts"
                  },
                  {
                    "text": "Primary cysts"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Cyst with inner cellular liningStratified squamous epithelium = epidermoidLow cuboidal to low columnar epithelium = mesothelialSkin appendages = dermoid",
                    "sub_points": [
                      "Stratified squamous epithelium = epidermoid",
                      "Low cuboidal to low columnar epithelium = mesothelial",
                      "Skin appendages = dermoid"
                    ]
                  }
                ]
              },
              "Etiology/Pathogenesis": {
                "Controversial": [
                  {
                    "text": "Developmental displacement of fetal epithelial tissue vs.Origin from peritoneal mesotheliumTeratomatous origin",
                    "sub_points": [
                      "Origin from peritoneal mesothelium",
                      "Teratomatous origin"
                    ]
                  },
                  {
                    "text": "Possibly distinct origins for mesothelial vs. epidermoid/dermoid cysts"
                  }
                ]
              },
              "Clinical Issues": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "0.07% in a review of 42,327 autopsies"
                  },
                  {
                    "text": "20% of splenic nonparasitic cysts"
                  }
                ],
                "Age": [
                  {
                    "text": "2nd-3rd decade of life"
                  }
                ],
                "Gender": [
                  {
                    "text": "No gender predilection"
                  }
                ],
                "Presentation": [
                  {
                    "text": "30% asymptomatic"
                  },
                  {
                    "text": "Palpable splenomegalyLeft upper quadrant discomfort/pain",
                    "sub_points": [
                      "Left upper quadrant discomfort/pain"
                    ]
                  },
                  {
                    "text": "Symptoms related to pressure of cyst on other organsStomachEpigastric painEarly satietyDysphagiaDiaphragmCoughingPain in left shoulderLeft kidney/renal arteryHydronephrosisArterial hypertension",
                    "sub_points": [
                      "StomachEpigastric painEarly satietyDysphagia",
                      "Epigastric pain",
                      "Early satiety",
                      "Dysphagia",
                      "DiaphragmCoughingPain in left shoulder",
                      "Coughing",
                      "Pain in left shoulder",
                      "Left kidney/renal arteryHydronephrosisArterial hypertension",
                      "Hydronephrosis",
                      "Arterial hypertension"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "No treatment needed if < 5 cm"
                  }
                ],
                "Surgical approaches": [
                  {
                    "text": "Complete or partial splenectomy"
                  },
                  {
                    "text": "Cystectomy"
                  },
                  {
                    "text": "Splenic decapsulation"
                  }
                ],
                "Complications": [
                  {
                    "text": "Rupture"
                  },
                  {
                    "text": "Infection"
                  },
                  {
                    "text": "Intracystic hemorrhage"
                  }
                ]
              },
              "Image Findings": {
                "Ultrasonographic Findings": [
                  {
                    "text": "Cystic lesions with good through-transmission and low-level internal echoes scattered throughout"
                  }
                ],
                "CT Findings": [
                  {
                    "text": "Homogeneous low-density lesions without enhancement"
                  }
                ]
              },
              "Macroscopic Features": {
                "General Features": [
                  {
                    "text": "Usually large (averaging 8-10 cm) single cyst"
                  },
                  {
                    "text": "Most commonly unilocular but can be multilocular"
                  },
                  {
                    "text": "White/gray, shiny lining with fibrous trabeculations"
                  },
                  {
                    "text": "Variable fluid contents ranging in consistency (serous to viscous) and color (clear, yellow, green, or brown)"
                  }
                ]
              },
              "Microscopic Pathology": {
                "Histologic Features": [
                  {
                    "text": "Cyst wall composed of fibrous tissue"
                  },
                  {
                    "text": "Lined byStratified squamous epithelium, which may be keratinizedKeratin positive, including CEA and CA19-9Columnar, cuboidal, or flattened epithelium (mesothelial lining)Mesothelial markers positive, including calretininTransitional epithelium with mucinous cells",
                    "sub_points": [
                      "Stratified squamous epithelium, which may be keratinizedKeratin positive, including CEA and CA19-9",
                      "Keratin positive, including CEA and CA19-9",
                      "Columnar, cuboidal, or flattened epithelium (mesothelial lining)Mesothelial markers positive, including calretinin",
                      "Mesothelial markers positive, including calretinin",
                      "Transitional epithelium with mucinous cells"
                    ]
                  },
                  {
                    "text": "Focal calcifications may be present"
                  }
                ]
              },
              "Differential Diagnosis": {
                "Pseudocyst": [
                  {
                    "text": "Lacks epithelial lining"
                  }
                ],
                "Parasitic (Echinococcal) Cyst": [
                  {
                    "text": "Multilocular"
                  },
                  {
                    "text": "Concurrent cysts in liver"
                  },
                  {
                    "text": "Outer cyst with multiple daughter cysts"
                  },
                  {
                    "text": "Hooklets and scolices in cyst wall"
                  }
                ],
                "Cystic Hemangioma or Lymphangioma": [
                  {
                    "text": "Endothelial lining"
                  }
                ]
              },
              "Diagnostic Checklist": {
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "Epithelial lining may be partially denudedMultiple histologic sections should be evaluated",
                    "sub_points": [
                      "Multiple histologic sections should be evaluated"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "False Cyst": {
            "name": "False Cyst",
            "url": "https://app.pathprimer.com/document/70ffc662-b470-4b28-86c7-620eea55a9ad/lesson/b0cb4bb8-512f-4a17-8214-1343aaeb2eac",
            "content": {
              "Key Facts": {
                "Etiology/Pathogenesis": [
                  {
                    "text": "History of trauma"
                  },
                  {
                    "text": "Degradation of intrasplenic hematoma or infarct"
                  }
                ],
                "Macroscopic Features": [
                  {
                    "text": "Usually unilocular with raggedy and hemorrhagic luminal surface"
                  },
                  {
                    "text": "Filled with brown/green fluid or mixture of solid and liquid components"
                  }
                ],
                "Microscopic Features": [
                  {
                    "text": "Dense fibrous wall with central calcified areas, hemosiderin, and cholesterol clefts"
                  },
                  {
                    "text": "Internal contents consist of blood and necrotic debris"
                  }
                ],
                "Diagnostic Checklist": [
                  {
                    "text": "Cyst wall must be adequately sampled to confirm absence of epithelial lining prior to making diagnosis of pseudocyst"
                  }
                ]
              },
              "Terminology": {
                "Synonyms": [
                  {
                    "text": "Pseudocyst"
                  },
                  {
                    "text": "Traumatic cyst"
                  },
                  {
                    "text": "Nonparasitic splenic cyst"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Cyst in spleen with absence of epithelial lining"
                  }
                ]
              },
              "Etiology/Pathogenesis": {
                "History of Trauma": [
                  {
                    "text": "Majority result from degeneration of post-traumatic splenic hematoma"
                  },
                  {
                    "text": "Can also form due to degeneration of splenic infarction"
                  }
                ]
              },
              "Clinical Issues": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "Uncommon"
                  },
                  {
                    "text": "True incidence unknown"
                  }
                ],
                "Age": [
                  {
                    "text": "Young adults (mean: 30 years)On average, false cysts tend to occur at older age than true cysts",
                    "sub_points": [
                      "On average, false cysts tend to occur at older age than true cysts"
                    ]
                  }
                ],
                "Presentation": [
                  {
                    "text": "Most commonly asymptomatic"
                  }
                ],
                "Larger cysts have nonspecific findings such as": [
                  {
                    "text": "Splenomegaly"
                  },
                  {
                    "text": "Symptoms related to adjacent organ compressionEpigastric pain and early satietyLeft lower lobe pneumoniaHypertension due to renal artery compression",
                    "sub_points": [
                      "Epigastric pain and early satiety",
                      "Left lower lobe pneumonia",
                      "Hypertension due to renal artery compression"
                    ]
                  }
                ],
                "Natural History": [
                  {
                    "text": "Varies depending on size and location of cyst"
                  },
                  {
                    "text": "Small cysts may be reabsorbed"
                  },
                  {
                    "text": "Large cysts may be complicated by rupture, torsion, or infection"
                  }
                ],
                "Treatment": [
                  {
                    "text": "No therapy is required for small cysts (< 5 cm)"
                  },
                  {
                    "text": "Surgical approaches for symptomatic cystsTotal splenectomyCyst resectionCyst aspiration or marsupializationNot recommended due to high risk of recurrence",
                    "sub_points": [
                      "Total splenectomy",
                      "Cyst resection",
                      "Cyst aspiration or marsupializationNot recommended due to high risk of recurrence",
                      "Not recommended due to high risk of recurrence"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Excellent"
                  }
                ]
              },
              "Image Findings": {
                "Ultrasonographic Findings": [
                  {
                    "text": "Distinct masses with thick walls"
                  },
                  {
                    "text": "Peripheral brightly echogenic foci with distal shadowing due to calcifications"
                  },
                  {
                    "text": "Internal echoes from debris"
                  }
                ],
                "CT Findings": [
                  {
                    "text": "Well-defined masses with density close to that of water"
                  },
                  {
                    "text": "Internal higher density zones corresponding to organizing hematomas can be present"
                  }
                ]
              },
              "Macroscopic Features": {
                "General Features": [
                  {
                    "text": "Usually unilocular cyst"
                  },
                  {
                    "text": "Luminal surface is usually raggedy and hemorrhagicCan be smooth and shinyTrabeculations are more characteristic of true cysts",
                    "sub_points": [
                      "Can be smooth and shinyTrabeculations are more characteristic of true cysts",
                      "Trabeculations are more characteristic of true cysts"
                    ]
                  },
                  {
                    "text": "Cysts are either filled with opaque brown or green fluid or contain mixed solid and liquid components consistent with organizing hematoma"
                  }
                ]
              },
              "Microscopic Pathology": {
                "Histologic Features": [
                  {
                    "text": "Pseudocyst wall consists of dense fibrous tissueCalcified areas frequently found within fibrous wallHemosiderin and hemosiderin-laden macrophagesCholesterol clefts",
                    "sub_points": [
                      "Calcified areas frequently found within fibrous wall",
                      "Hemosiderin and hemosiderin-laden macrophages",
                      "Cholesterol clefts"
                    ]
                  },
                  {
                    "text": "Cyst contentsBlood and necrotic debris with hemosiderin and cholesterol clefts",
                    "sub_points": [
                      "Blood and necrotic debris with hemosiderin and cholesterol clefts"
                    ]
                  },
                  {
                    "text": "Epithelial lining is absent"
                  }
                ]
              },
              "Ancillary Tests": {
                "Immunohistochemistry": [
                  {
                    "text": "Pan-cytokeratin staining can be performed to confirm absence of epithelial lining"
                  }
                ]
              },
              "Differential Diagnosis": {
                "True Cyst": [
                  {
                    "text": "Luminal surface lined by epithelium"
                  }
                ],
                "Parasitic (Echinococcal) Cyst": [
                  {
                    "text": "Multilocular"
                  },
                  {
                    "text": "Concurrent cysts in liver"
                  },
                  {
                    "text": "Outer cyst with multiple daughter cysts and laminated membrane"
                  },
                  {
                    "text": "Hooklets and scolices"
                  }
                ]
              },
              "Diagnostic Checklist": {
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "True cysts with denuded epithelial lining can be misdiagnosed as pseudocysts"
                  },
                  {
                    "text": "Cyst wall must be adequately sampled to confirm absence of epithelial lining prior to making diagnosis of pseudocyst"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Peliosis": {
            "name": "Peliosis",
            "url": "https://app.pathprimer.com/document/56c92c13-8d91-4549-9fd7-c233675d71eb/lesson/b0cb4bb8-512f-4a17-8214-1343aaeb2eac",
            "content": {
              "Key Facts": {
                "Terminology": [
                  {
                    "text": "Nonneoplastic blood-filled cavities in spleen, liver, and (less commonly) other organs"
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "Unknown, possibly vascular malformation"
                  },
                  {
                    "text": "Associated with chronic infections, drugs (oral contraceptives, anabolic steroids), hematologic disorders, and some chronic conditions"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Fatal peritoneal hemorrhage due to cyst rupture is major complication"
                  },
                  {
                    "text": "Isolated splenic peliosis is very rare  (< 100 cases reported)"
                  }
                ],
                "Microscopic Features": [
                  {
                    "text": "Round to irregular blood-filled cavities, often localized to parafollicular areas"
                  },
                  {
                    "text": "Blood-filled spaces ± endothelial lining"
                  }
                ]
              },
              "Terminology": {
                "Synonyms": [
                  {
                    "text": "Peliosis lienis"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Nonneoplastic blood-filled cavities in spleen, liver, and (less commonly) other organs"
                  },
                  {
                    "text": "Name originates from \"pelios\" (Greek for blue/black or purple)"
                  }
                ]
              },
              "Etiology/Pathogenesis": {
                "Etiology": [
                  {
                    "text": "Unknown, possibly vascular malformationAlterations in vascular pressure could lead to vascular malformation",
                    "sub_points": [
                      "Alterations in vascular pressure could lead to vascular malformation"
                    ]
                  },
                  {
                    "text": "Associated withChronic infectionsTuberculosis, HIV,Bartonella henselaeDrugs or toxinsOral contraceptives, anabolic steroids, intravenous drug abuse, alcoholHematologic disordersHodgkin lymphoma, myeloid neoplasms, aplastic anemiaOther chronic conditionsRenal failure, cirrhosis",
                    "sub_points": [
                      "Chronic infectionsTuberculosis, HIV,Bartonella henselae",
                      "Tuberculosis, HIV,Bartonella henselae",
                      "Drugs or toxinsOral contraceptives, anabolic steroids, intravenous drug abuse, alcohol",
                      "Oral contraceptives, anabolic steroids, intravenous drug abuse, alcohol",
                      "Hematologic disordersHodgkin lymphoma, myeloid neoplasms, aplastic anemia",
                      "Hodgkin lymphoma, myeloid neoplasms, aplastic anemia",
                      "Other chronic conditionsRenal failure, cirrhosis",
                      "Renal failure, cirrhosis"
                    ]
                  }
                ]
              },
              "Clinical Issues": {
                "Epidemiology": [
                  {
                    "text": "Isolated splenic peliosis is very rare  (< 100 cases reported)"
                  },
                  {
                    "text": "Usually occurs together with peliosis hepatis"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Usually incidental finding on imaging or at autopsy"
                  },
                  {
                    "text": "Can present with splenomegaly"
                  },
                  {
                    "text": "Can present with symptoms related to massive peritoneal hemorrhage due to rupture of peliotic spleen"
                  }
                ],
                "Treatment": [
                  {
                    "text": "Medical management of associated disordersTreatment of infectionDiscontinuation of steroids/oral contraceptives",
                    "sub_points": [
                      "Treatment of infection",
                      "Discontinuation of steroids/oral contraceptives"
                    ]
                  },
                  {
                    "text": "Splenectomy is definitive treatment"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "May resolve with management of associated condition"
                  },
                  {
                    "text": "Rupture can be fatal"
                  }
                ]
              },
              "Image Findings": {
                "Ultrasonographic Findings": [
                  {
                    "text": "Normally sized or enlarged spleen with heterogeneous echotexture and multiple fluid-filled and echogenic areas"
                  }
                ],
                "CT Findings": [
                  {
                    "text": "Multiple small, well-defined hypoattenuating lesions on non-contrast-enhanced CT"
                  },
                  {
                    "text": "Introduction of contrast reveals slow centripetal enhancement of lesions"
                  }
                ]
              },
              "Macroscopic Features": {
                "General Features": [
                  {
                    "text": "Usually, normal-sized spleen, but can be enlarged"
                  },
                  {
                    "text": "Purple subcapsular nodules on surface of spleen"
                  },
                  {
                    "text": "Splenic cut surface with multiple, round to oval or irregular, well-demarcated blood-filled spaces that can be present in clusters or distributed throughout red pulpBlood within cavities can be liquid and clottedCan also form thrombi",
                    "sub_points": [
                      "Blood within cavities can be liquid and clottedCan also form thrombi",
                      "Can also form thrombi"
                    ]
                  }
                ]
              },
              "Microscopic Pathology": {
                "Histologic Features": [
                  {
                    "text": "Round to irregular blood-filled cavities of varying caliber haphazardly scattered throughout red pulp"
                  },
                  {
                    "text": "Well demarcated from splenic parenchyma"
                  },
                  {
                    "text": "Often localized in parafollicular areas, adjacent to periarteriolar lymphoid sheaths, and may surround white pulp"
                  },
                  {
                    "text": "Blood-filled spaces generally lack endothelial lining (directly abut splenic parenchyma)Flattened endothelial cells can sometimes be present",
                    "sub_points": [
                      "Flattened endothelial cells can sometimes be present"
                    ]
                  },
                  {
                    "text": "White pulp is attenuated"
                  },
                  {
                    "text": "Cysts contain RBCs and inflammatory cells"
                  }
                ]
              },
              "Ancillary Tests": {
                "Immunohistochemistry": [
                  {
                    "text": "Vascular markers (CD31, CD34, and factor VIII) are positive if there is endothelial lining and negative if there is no lining"
                  },
                  {
                    "text": "CD8 and D240 are negative"
                  }
                ]
              },
              "Differential Diagnosis": {
                "Hemangioma": [
                  {
                    "text": "Proliferation of endothelium-lined vascular channels"
                  },
                  {
                    "text": "Always positive for vascular markers (unlike peliosis)"
                  }
                ],
                "Lymphangiectasia": [
                  {
                    "text": "Dilated lymphatic vessels filled with proteinaceous fluid"
                  },
                  {
                    "text": "Positive for D240 (unlike peliosis)"
                  }
                ],
                "Hairy Cell Leukemia": [
                  {
                    "text": "Formation of blood lakes"
                  },
                  {
                    "text": "Red pulp involved by proliferation of neoplastic B cells with round nuclei and moderate amount of cytoplasm"
                  }
                ],
                "Chronic Passive Congestion": [
                  {
                    "text": "Diffuse red pulp process, not just parafollicular lesion like peliosis"
                  }
                ]
              },
              "Diagnostic Checklist": {
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "Blood-filled spaces haphazardly distributed throughout red pulp with predilection for parafollicular involvement"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Florid Follicular Hyperplasia": {
            "name": "Florid Follicular Hyperplasia",
            "url": "https://app.pathprimer.com/document/5773806a-916b-4b22-8b00-9f14a69e5091/lesson/b0cb4bb8-512f-4a17-8214-1343aaeb2eac",
            "content": {
              "Key Facts": {
                "Terminology": [
                  {
                    "text": "Expansion of splenic white pulp follicles in response to humoral immune reaction that involves stimulation and proliferation of B cells"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Hypersplenism"
                  },
                  {
                    "text": "Often has accompanying cytopenia"
                  },
                  {
                    "text": "Relatively common incidental finding"
                  }
                ],
                "Macroscopic Features": [
                  {
                    "text": "Prominent and diffusely scattered white nodules"
                  }
                ],
                "Microscopic Features": [
                  {
                    "text": "Numerous variably sized and shaped reactive germinal centers"
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "Follicular lymphoma"
                  },
                  {
                    "text": "Normal histologic finding"
                  }
                ]
              },
              "Terminology": {
                "Abbreviations": [
                  {
                    "text": "Florid follicular hyperplasia (FFH)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "White pulp hyperplasia"
                  },
                  {
                    "text": "Lymphoid hyperplasia"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Expansion of splenic white pulp follicles in response to humoral immune reaction that involves stimulation and proliferation of B cells"
                  }
                ]
              },
              "Etiology/Pathogenesis": {
                "Immune-Mediated Reaction": [
                  {
                    "text": "Manifestation of an antigenic stimulusMay occur in response toOpsonized pathogensEncapsulated bacteriaAntibody-coated erythrocytes, granulocytes, &/or plateletsObserved during acute or chronic infections",
                    "sub_points": [
                      "May occur in response toOpsonized pathogensEncapsulated bacteriaAntibody-coated erythrocytes, granulocytes, &/or platelets",
                      "Opsonized pathogens",
                      "Encapsulated bacteria",
                      "Antibody-coated erythrocytes, granulocytes, &/or platelets",
                      "Observed during acute or chronic infections"
                    ]
                  }
                ]
              },
              "Clinical Issues": {
                "Presentation": [
                  {
                    "text": "HypersplenismOften has accompanying cytopenia",
                    "sub_points": [
                      "Often has accompanying cytopenia"
                    ]
                  },
                  {
                    "text": "Relatively common incidental findingNormal finding in children and adolescentsNot uncommonly encountered in adult spleen",
                    "sub_points": [
                      "Normal finding in children and adolescents",
                      "Not uncommonly encountered in adult spleen"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Benign hyperplasia"
                  },
                  {
                    "text": "Not considered a condition predisposing to lymphoma"
                  }
                ]
              },
              "Macroscopic Features": {
                "General Features": [
                  {
                    "text": "Enlarged spleen (> 500 g)"
                  },
                  {
                    "text": "Prominent and diffusely scattered white nodules throughout spleen in a miliary pattern"
                  },
                  {
                    "text": "Focal aggregation of follicles can result in formation of prominent solitary nodules that may simulate lymphoma"
                  }
                ]
              },
              "Microscopic Pathology": {
                "Histologic Features": [
                  {
                    "text": "Features are similar to those found in other reactive lymphoid tissues (e.g., lymph nodes, tonsils)Numerous follicles that may vary in size or shape with some coalescence of folliclesGerminal center surrounded by peripheral, sharply demarcated mantle zone and outer marginal zone",
                    "sub_points": [
                      "Numerous follicles that may vary in size or shape with some coalescence of follicles",
                      "Germinal center surrounded by peripheral, sharply demarcated mantle zone and outer marginal zone"
                    ]
                  },
                  {
                    "text": "Germinal centerContains a complement of centrocytes (cleaved cells), centroblasts (noncleaved cells), follicular dendritic cells, T cells, and macrophages (tingible body macrophages)Displays polarization (dark and light zones)",
                    "sub_points": [
                      "Contains a complement of centrocytes (cleaved cells), centroblasts (noncleaved cells), follicular dendritic cells, T cells, and macrophages (tingible body macrophages)",
                      "Displays polarization (dark and light zones)"
                    ]
                  },
                  {
                    "text": "Red pulpMay demonstrate increase in small mature lymphocytes, plasma cells, and immunoblastsReflection of antigenic stimulation",
                    "sub_points": [
                      "May demonstrate increase in small mature lymphocytes, plasma cells, and immunoblastsReflection of antigenic stimulation",
                      "Reflection of antigenic stimulation"
                    ]
                  }
                ]
              },
              "Ancillary Tests": {
                "Immunohistochemistry": [
                  {
                    "text": "Germinal centerExpresses pan-B-cell antigens (e.g., CD20, CD79-a, pax-5), CD10, and Bcl-6Bcl-2 negative",
                    "sub_points": [
                      "Expresses pan-B-cell antigens (e.g., CD20, CD79-a, pax-5), CD10, and Bcl-6",
                      "Bcl-2 negative"
                    ]
                  },
                  {
                    "text": "Mantle zoneExpresses pan-B-cell antigens in addition to IgD, CD5, and Bcl-2CD10 negative",
                    "sub_points": [
                      "Expresses pan-B-cell antigens in addition to IgD, CD5, and Bcl-2",
                      "CD10 negative"
                    ]
                  },
                  {
                    "text": "Marginal zoneExpresses pan-B-cell antigens and Bcl-2CD5 and CD10 negative",
                    "sub_points": [
                      "Expresses pan-B-cell antigens and Bcl-2",
                      "CD5 and CD10 negative"
                    ]
                  }
                ],
                "Flow Cytometry": [
                  {
                    "text": "Polytypic B-cell population with subset expressing CD10"
                  }
                ],
                "PCR": [
                  {
                    "text": "No monoclonal immunoglobulin heavy-chain gene rearrangement by PCR"
                  },
                  {
                    "text": "No evidence of t(14;18)(q32;q21) orIGH-BCL2fusion sequences"
                  }
                ]
              },
              "Differential Diagnosis": {
                "Follicular Lymphoma": [
                  {
                    "text": "Germinal centers lack polarization and tingible body macrophages"
                  },
                  {
                    "text": "Follicles lack variation in size and shape"
                  },
                  {
                    "text": "Monoclonal immunoglobulin heavy-chain gene rearrangement by PCR and t(14:18)(q32;q31)"
                  }
                ],
                "Normal Histologic Finding": [
                  {
                    "text": "Children and adolescents often show increased white pulp"
                  }
                ],
                "Disease States Associated With FFH and Hypersplenism": [
                  {
                    "text": "Idiopathic/immune thrombocytopenic purpura"
                  },
                  {
                    "text": "Felty syndrome; acquired hemolytic anemia"
                  },
                  {
                    "text": "Hemodialysis; idiopathic antigen stimulation"
                  },
                  {
                    "text": "Acquired immunodeficiency syndrome (AIDS)"
                  }
                ],
                "Multicentric Castleman Disease, Hyaline Vascular Type": [
                  {
                    "text": "Striking form of splenic white pulp hyperplasia"
                  },
                  {
                    "text": "> 1 germinal center per follicle"
                  },
                  {
                    "text": "Germinal centers may have regressive/atretic changes"
                  },
                  {
                    "text": "Well-defined and often expanded mantle zones"
                  }
                ]
              },
              "Diagnostic Checklist": {
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "Poorly fixed &/or sectioned specimens may result in artifactual conditions resembling follicular lymphoma"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Autoimmune Disease": {
            "name": "Autoimmune Disease",
            "url": "https://app.pathprimer.com/document/7e2ae597-ca9d-470f-a203-a8e16866c06c/lesson/b0cb4bb8-512f-4a17-8214-1343aaeb2eac",
            "content": {
              "Key Facts": {
                "Terminology": [
                  {
                    "text": "Systemic autoimmune disease affecting white pulp or vessels of spleen"
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "Autoantibodies against cell surface, cytoplasm, nuclear envelope, or nucleus (SLE, RA)"
                  },
                  {
                    "text": "Immune complex deposits, direct autoantibody binding to vessels or neutrophils, and cell-mediated inflammation (WG, PAN)"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Moderately enlarged spleen"
                  },
                  {
                    "text": "Rupture may occurCan be spontaneous or delayed after minor trauma",
                    "sub_points": [
                      "Can be spontaneous or delayed after minor trauma"
                    ]
                  },
                  {
                    "text": "Immunosuppressive drugs can remit cytopenias"
                  },
                  {
                    "text": "Splenectomy is controversial because it can exacerbate some symptoms, particularly in SLE"
                  },
                  {
                    "text": "Vasculitides are often found post mortem or incidentally as aneurysms on image studies"
                  }
                ],
                "Microscopic Features": [
                  {
                    "text": "White pulp hyperplasia and histiocytic necrosisIn RA and SLE",
                    "sub_points": [
                      "In RA and SLE"
                    ]
                  },
                  {
                    "text": "Necrosis, infarction, vasculitis, and fibrin in vesselsSeen in WG and PAN",
                    "sub_points": [
                      "Seen in WG and PAN"
                    ]
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "InfectionExcluded by special stains",
                    "sub_points": [
                      "Excluded by special stains"
                    ]
                  },
                  {
                    "text": "Trauma"
                  },
                  {
                    "text": "Hematopoietic malignancy"
                  },
                  {
                    "text": "TTP and ITP"
                  }
                ]
              },
              "Terminology": {
                "Abbreviations": [
                  {
                    "text": "Systemic lupus erythematosus (SLE)"
                  },
                  {
                    "text": "Rheumatoid arthritis (RA)"
                  },
                  {
                    "text": "Mixed connective tissue disorders (MCD)"
                  },
                  {
                    "text": "Polyarteritis nodosa (PAN)"
                  },
                  {
                    "text": "Wegener granulomatosis (WG)"
                  },
                  {
                    "text": "Immune thrombocytopenic purpura (ITP)"
                  },
                  {
                    "text": "Thrombotic thrombocytopenic purpura (TTP)"
                  },
                  {
                    "text": "Juvenile rheumatoid arthritis (JRA)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Lupus splenitis"
                  },
                  {
                    "text": "Autoimmune splenitis"
                  },
                  {
                    "text": "Rheumatoid splenitis"
                  },
                  {
                    "text": "Idiopathic systemic necrotizing vasculitis"
                  },
                  {
                    "text": "Still disease (JRA)"
                  },
                  {
                    "text": "Felty syndrome"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Systemic autoimmune disease secondarily involving spleen, primarily affecting white pulp or, rarely, vessels"
                  }
                ]
              },
              "Etiology/Pathogenesis": {
                "Disorders With Autoantibodies": [
                  {
                    "text": "Autoantibodies are directed against cell surface, cytoplasm, nuclear envelope, or nucleus"
                  },
                  {
                    "text": "Mixed connective tissue/rheumatologic disorders with antinuclear antibodies (ANAs) includeRA and SLEMost commonly described disorders affecting spleen due to their chronicity and incidenceDrug-related SLECaused by drugs such as procainamideBehçet disease, Sjögren syndrome, and JRARarely described in relation to spleenOverlap syndromesCriteria: ≥ 2 connective tissue diseases presenting at same or different timesExample: SLE and RA overlap (known as rupus)Other rheumatoid autoimmune diseases are not usually described in relation to spleen",
                    "sub_points": [
                      "RA and SLEMost commonly described disorders affecting spleen due to their chronicity and incidence",
                      "Most commonly described disorders affecting spleen due to their chronicity and incidence",
                      "Drug-related SLECaused by drugs such as procainamide",
                      "Caused by drugs such as procainamide",
                      "Behçet disease, Sjögren syndrome, and JRARarely described in relation to spleen",
                      "Rarely described in relation to spleen",
                      "Overlap syndromesCriteria: ≥ 2 connective tissue diseases presenting at same or different timesExample: SLE and RA overlap (known as rupus)",
                      "Criteria: ≥ 2 connective tissue diseases presenting at same or different times",
                      "Example: SLE and RA overlap (known as rupus)",
                      "Other rheumatoid autoimmune diseases are not usually described in relation to spleen"
                    ]
                  }
                ],
                "Disorders With Immune Complex Deposits": [
                  {
                    "text": "Direct autoantibody binding to vessels or neutrophils and cell-mediated inflammation"
                  },
                  {
                    "text": "WG and PANPrimary systemic vasculitides with immune complex deposits involving spleenWG produces cytoplasmic antineutrophil cytoplasmic antibodies (c-ANCAs)T-cell response, granuloma formation, basophilic necrosis, and vasculitisPAN deposits immune complexes in vessels",
                    "sub_points": [
                      "Primary systemic vasculitides with immune complex deposits involving spleen",
                      "WG produces cytoplasmic antineutrophil cytoplasmic antibodies (c-ANCAs)T-cell response, granuloma formation, basophilic necrosis, and vasculitis",
                      "T-cell response, granuloma formation, basophilic necrosis, and vasculitis",
                      "PAN deposits immune complexes in vessels"
                    ]
                  },
                  {
                    "text": "No widely accepted standard classification system for idiopathic vasculitides"
                  },
                  {
                    "text": "Other vasculitides are not commonly diagnosed in spleen"
                  }
                ]
              },
              "Clinical Issues": {
                "Presentation": [
                  {
                    "text": "SplenomegalyUsually moderate, rarely massiveSeen in SLE, RA, WG, PAN, and JRA",
                    "sub_points": [
                      "Usually moderate, rarely massive",
                      "Seen in SLE, RA, WG, PAN, and JRA"
                    ]
                  },
                  {
                    "text": "Spontaneous splenic ruptureSeen in WG and PAN, rarely in RA and SLE",
                    "sub_points": [
                      "Seen in WG and PAN, rarely in RA and SLE"
                    ]
                  },
                  {
                    "text": "Post-traumatic splenic ruptureMay be delayed days after traumaFound in RA and SLE",
                    "sub_points": [
                      "May be delayed days after traumaFound in RA and SLE",
                      "Found in RA and SLE"
                    ]
                  },
                  {
                    "text": "Impaired spleen functionThrombocytopenia, anemia, neutropeniaSLE, RA, WG, PAN, and Felty syndrome (RA with neutropenia)Etiology for cytopenias is not clear (may involve immune complexes or decreased circulating time)Spleen size may not correlate with dysfunctionFunctional aspleniaMay fluctuate with disease activity",
                    "sub_points": [
                      "Thrombocytopenia, anemia, neutropeniaSLE, RA, WG, PAN, and Felty syndrome (RA with neutropenia)Etiology for cytopenias is not clear (may involve immune complexes or decreased circulating time)Spleen size may not correlate with dysfunction",
                      "SLE, RA, WG, PAN, and Felty syndrome (RA with neutropenia)",
                      "Etiology for cytopenias is not clear (may involve immune complexes or decreased circulating time)",
                      "Spleen size may not correlate with dysfunction",
                      "Functional aspleniaMay fluctuate with disease activity",
                      "May fluctuate with disease activity"
                    ]
                  },
                  {
                    "text": "Infarct"
                  },
                  {
                    "text": "Hematoma"
                  },
                  {
                    "text": "Splenic atrophyHowell-Jolly bodies, Pappenheimer bodies, spherocytes, target cells seen in peripheral bloodCommon in rheumatologic disease due to chronicityNoted in RA and SLE",
                    "sub_points": [
                      "Howell-Jolly bodies, Pappenheimer bodies, spherocytes, target cells seen in peripheral blood",
                      "Common in rheumatologic disease due to chronicity",
                      "Noted in RA and SLE"
                    ]
                  },
                  {
                    "text": "Splenic calcificationsNoted in RACan be multiple",
                    "sub_points": [
                      "Noted in RA",
                      "Can be multiple"
                    ]
                  },
                  {
                    "text": "AneurysmsRarely found in WG and PAN",
                    "sub_points": [
                      "Rarely found in WG and PAN"
                    ]
                  },
                  {
                    "text": "Systemic symptoms of underlying autoimmune processVary according to each autoimmune diseaseFindings in drug-related SLE are similar to those in idiopathic SLE",
                    "sub_points": [
                      "Vary according to each autoimmune disease",
                      "Findings in drug-related SLE are similar to those in idiopathic SLE"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "Steroids and immune suppressionFunctional asplenia can reverse with immune suppression",
                    "sub_points": [
                      "Functional asplenia can reverse with immune suppression"
                    ]
                  },
                  {
                    "text": "SplenectomyControversial, may increase symptoms in SLEOccasionally, symptoms of autoimmune disease remit after splenectomyBlood counts can return to normal after splenectomyPneumococcal vaccine is necessary",
                    "sub_points": [
                      "Controversial, may increase symptoms in SLE",
                      "Occasionally, symptoms of autoimmune disease remit after splenectomy",
                      "Blood counts can return to normal after splenectomy",
                      "Pneumococcal vaccine is necessary"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Prognosis post splenectomy depends on underlying autoimmune processPrognosis is good for SLE and RA",
                    "sub_points": [
                      "Prognosis is good for SLE and RA"
                    ]
                  },
                  {
                    "text": "Postsplenectomy infection is possible complication"
                  },
                  {
                    "text": "Hyposplenism can occur with late hypoplasia, cytopenias, and infection"
                  },
                  {
                    "text": "Vasculitides are often found post mortem"
                  }
                ]
              },
              "Image Findings": {
                "CT Findings": [
                  {
                    "text": "Moderate splenomegaly"
                  },
                  {
                    "text": "Lymphoid hyperplasia"
                  },
                  {
                    "text": "Infarction sometimes segmental"
                  },
                  {
                    "text": "Diffuse microcalcificationsCan be seen in longstanding SLE",
                    "sub_points": [
                      "Can be seen in longstanding SLE"
                    ]
                  },
                  {
                    "text": "Hematoma/rupture"
                  },
                  {
                    "text": "Hyposplenism"
                  }
                ]
              },
              "Macroscopic Features": {
                "Size": [
                  {
                    "text": "Spleen can be moderately enlargedMassive enlargement is rare",
                    "sub_points": [
                      "Massive enlargement is rare"
                    ]
                  }
                ],
                "General Description": [
                  {
                    "text": "Hemorrhage and capsular disruption if rupture occurs"
                  },
                  {
                    "text": "Irregular, bumpy capsular surfaceNoted in RA and SLE",
                    "sub_points": [
                      "Noted in RA and SLE"
                    ]
                  },
                  {
                    "text": "Infarction"
                  }
                ]
              },
              "Microscopic Pathology": {
                "Histologic Features": [
                  {
                    "text": "White pulp hyperplasia with hyperplastic germinal centersIn RA and SLE",
                    "sub_points": [
                      "In RA and SLE"
                    ]
                  },
                  {
                    "text": "Focal histiocytic collections with apoptotic debris, necrosis (SLE, RA)"
                  },
                  {
                    "text": "Granulomatous inflammation (WG; rarely SLE, RA)"
                  },
                  {
                    "text": "Vascular fibrosis"
                  },
                  {
                    "text": "\"Onion skinning\" of lymphocytes around vessels (SLE)"
                  }
                ],
                "Cytologic Features": [
                  {
                    "text": "Necrosis shows apoptotic debris and few inflammatory cells (RA, SLE)"
                  },
                  {
                    "text": "Fibrin and platelet plugs in vessels (WG, PAN)"
                  },
                  {
                    "text": "Acute inflammation in vessels (PAN)"
                  }
                ]
              },
              "Ancillary Tests": {
                "Serologic Testing": [
                  {
                    "text": "Intracellular and nuclear antigens must be detected in rheumatologic diseasePresence, quantity, and immunologic specificity must be identified for diagnosisImmunofluorescence microscopy and immunoenzyme tests are used for screening for intracellular autoantibodiesImmunodiffusion, immunoprecipitation, particle agglutination, enzyme-linked immunosorbent assay, immunoblotting, and radioimmunoassay are all used for definitive identification of autoantibodies",
                    "sub_points": [
                      "Presence, quantity, and immunologic specificity must be identified for diagnosis",
                      "Immunofluorescence microscopy and immunoenzyme tests are used for screening for intracellular autoantibodies",
                      "Immunodiffusion, immunoprecipitation, particle agglutination, enzyme-linked immunosorbent assay, immunoblotting, and radioimmunoassay are all used for definitive identification of autoantibodies"
                    ]
                  },
                  {
                    "text": "Vasculitis has many etiologies and no widely standardized classification systemc-ANCA testsMajor diagnostic tool for necrotizing systemic vasculitisOften positive in WGc-ANCA immunofluorescence should be confirmed by ELISA assayPerinuclear antineutrophil cytoplasmic antibodies (p-ANCAs) are not specificNo definitive laboratory tests exist for systemic necrotizing vasculitis",
                    "sub_points": [
                      "c-ANCA testsMajor diagnostic tool for necrotizing systemic vasculitisOften positive in WGc-ANCA immunofluorescence should be confirmed by ELISA assay",
                      "Major diagnostic tool for necrotizing systemic vasculitis",
                      "Often positive in WG",
                      "c-ANCA immunofluorescence should be confirmed by ELISA assay",
                      "Perinuclear antineutrophil cytoplasmic antibodies (p-ANCAs) are not specific",
                      "No definitive laboratory tests exist for systemic necrotizing vasculitis"
                    ]
                  }
                ]
              },
              "Differential Diagnosis": {
                "Infection": [
                  {
                    "text": "Granulomas ± necrosis are typical"
                  },
                  {
                    "text": "Patients with autoimmune disease are immunocompromised and predisposed to infection"
                  },
                  {
                    "text": "Serum studies or special bacterial stains can exclude infection"
                  },
                  {
                    "text": "Clinical history is often similar for infection and autoimmune disorder"
                  }
                ],
                "Hematologic Abnormalities": [
                  {
                    "text": "LymphomaPredisposition created byImmune compromise of underlying disorderImmunosuppressive drugs (e.g., methotrexate) used to treat underlying autoimmune processExcluded based on morphology, immunohistochemistry, and ancillary studies",
                    "sub_points": [
                      "Predisposition created byImmune compromise of underlying disorderImmunosuppressive drugs (e.g., methotrexate) used to treat underlying autoimmune process",
                      "Immune compromise of underlying disorder",
                      "Immunosuppressive drugs (e.g., methotrexate) used to treat underlying autoimmune process",
                      "Excluded based on morphology, immunohistochemistry, and ancillary studies"
                    ]
                  },
                  {
                    "text": "Bone marrow malignanciesMyelodysplastic syndromes and myeloproliferative disorders are diagnosed by examination of peripheral blood and bone marrow",
                    "sub_points": [
                      "Myelodysplastic syndromes and myeloproliferative disorders are diagnosed by examination of peripheral blood and bone marrow"
                    ]
                  },
                  {
                    "text": "Hemolytic anemiasDiagnosed by examination of peripheral smear and by ancillary studies",
                    "sub_points": [
                      "Diagnosed by examination of peripheral smear and by ancillary studies"
                    ]
                  }
                ],
                "Trauma": [
                  {
                    "text": "History distinguishes trauma from more chronic diseases"
                  },
                  {
                    "text": "Rupture may occur immediately or be delayed"
                  },
                  {
                    "text": "Examination of splenic histology should exclude underlying disease process as cause for rupture"
                  }
                ],
                "Immune Thrombocytopenic Purpura": [
                  {
                    "text": "Clinical history of thrombocytopenia"
                  },
                  {
                    "text": "Spleen is not enlarged"
                  },
                  {
                    "text": "Spleen is often histologically normal"
                  },
                  {
                    "text": "Lipogranulomas can be seen"
                  },
                  {
                    "text": "Foamy histocytes are sometimes seen in red pulp"
                  },
                  {
                    "text": "Neutrophil clusters are rarely seen"
                  },
                  {
                    "text": "Vascular lesions are not seen"
                  },
                  {
                    "text": "May be primary or secondaryITP may occur secondary to connective tissue disorders but should not be the sole finding",
                    "sub_points": [
                      "ITP may occur secondary to connective tissue disorders but should not be the sole finding"
                    ]
                  },
                  {
                    "text": "Etiology: Increased platelet clearance caused by IgG antiplatelet autoantibodies against platelet membrane glycoproteins"
                  }
                ],
                "Thrombotic Thrombocytopenic Purpura": [
                  {
                    "text": "Clinical presentation can be similar to that of SLE, but neurologic symptoms can help distinguish"
                  },
                  {
                    "text": "History is important to exclude hemolytic uremic syndrome"
                  },
                  {
                    "text": "Spleen can be moderately enlarged"
                  },
                  {
                    "text": "Platelet-rich thrombi are present in vessels without inflammation"
                  },
                  {
                    "text": "Hyperplasia of white pulp is present"
                  },
                  {
                    "text": "Infarcts are not common"
                  },
                  {
                    "text": "Etiology: Deficient activity of ADAMTS 13 plasma metalloproteinase"
                  }
                ]
              },
              "Diagnostic Checklist": {
                "Clinically Relevant Pathologic Features": [
                  {
                    "text": "SLE and RA are often found after rupture or removal of spleen for symptomatic relief of cytopenias"
                  },
                  {
                    "text": "Findings of WG and PAN are often found at postmortem examination"
                  }
                ],
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "White pulp hyperplasia is seen often"
                  },
                  {
                    "text": "Necrosis with histiocytes and apoptotic debris reminiscent of Kikuchi-Fujimoto disease"
                  },
                  {
                    "text": "Vasculitis or vascular fibrosis can be seen"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Marginal Zone Hyperplasia": {
            "name": "Marginal Zone Hyperplasia",
            "url": "https://app.pathprimer.com/document/10df8ee3-a2e7-4ae7-84e9-344091a1a995/lesson/b0cb4bb8-512f-4a17-8214-1343aaeb2eac",
            "content": {
              "Key Facts": {
                "Terminology": [
                  {
                    "text": "Expansion of marginal zone (outer 3rd layer of splenic follicle structure)"
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "Manifestation of an antigenic stimulus"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Hypersplenism"
                  },
                  {
                    "text": "± cytopenias"
                  }
                ],
                "Microscopic Features": [
                  {
                    "text": "Retention of marginal zone, mantle zone, and germinal center"
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "Expresses pan-B-cell markers in addition to Bcl-2"
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "Splenic marginal zone lymphoma"
                  },
                  {
                    "text": "Other small B-cell/white pulp lymphomas"
                  }
                ]
              },
              "Terminology": {
                "Synonyms": [
                  {
                    "text": "White pulp hyperplasia, lymphoid hyperplasia"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Expansion of marginal zone (outer 3rd layer of splenic follicle structure) often in response to a humoral immune or autoimmune reaction that involves stimulation and proliferation of B cells"
                  },
                  {
                    "text": "Expansion/hyperplasia is defined as > 12 cells in thickness"
                  }
                ]
              },
              "Etiology/Pathogenesis": {
                "Immune-Mediated Process": [
                  {
                    "text": "Manifestation of an antigenic stimulusMay occur in response to opsonized pathogens, encapsulated bacteria, and antibody-coated erythrocytes, granulocytes, &/or plateletsUsually associated with autoimmune processes, immunodeficiency, or idiopathic thrombocytopenic purpuraCommonly associated with autoimmune hemolytic anemias; also seen post vaccination",
                    "sub_points": [
                      "May occur in response to opsonized pathogens, encapsulated bacteria, and antibody-coated erythrocytes, granulocytes, &/or platelets",
                      "Usually associated with autoimmune processes, immunodeficiency, or idiopathic thrombocytopenic purpura",
                      "Commonly associated with autoimmune hemolytic anemias; also seen post vaccination"
                    ]
                  }
                ],
                "Idiopathic": [
                  {
                    "text": "Can also occur as isolated finding without identified etiology"
                  }
                ]
              },
              "Clinical Issues": {
                "Presentation": [
                  {
                    "text": "Hypersplenism ± cytopenias"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Benign lesion; not considered a precursor to lymphoma"
                  }
                ]
              },
              "Macroscopic Features": {
                "General Features": [
                  {
                    "text": "Spleen may be of normal size or enlarged, weighing up to 1,000 g"
                  },
                  {
                    "text": "Prominent and diffusely scattered white nodules"
                  },
                  {
                    "text": "Focal aggregation of follicles can result in the formation of prominent solitary nodules that may simulate lymphoma"
                  }
                ]
              },
              "Microscopic Pathology": {
                "Histologic Features": [
                  {
                    "text": "Expansion of marginal zoneSmall mature lymphocytes with moderate amounts of clear cytoplasmOccasional plasma cells, plasmacytoid lymphocytes, &/or larger transformed lymphocytes",
                    "sub_points": [
                      "Small mature lymphocytes with moderate amounts of clear cytoplasm",
                      "Occasional plasma cells, plasmacytoid lymphocytes, &/or larger transformed lymphocytes"
                    ]
                  },
                  {
                    "text": "Retention of white pulp/splenic follicle architectureTriphasic patternMarginal zone, mantle zone, and germinal centerBiphasic patternMay be present in cases/follicles without germinal center formation",
                    "sub_points": [
                      "Triphasic patternMarginal zone, mantle zone, and germinal center",
                      "Marginal zone, mantle zone, and germinal center",
                      "Biphasic patternMay be present in cases/follicles without germinal center formation",
                      "May be present in cases/follicles without germinal center formation"
                    ]
                  },
                  {
                    "text": "Preserved red pulp with only rare lymphocytes in sinuses or splenic cords"
                  },
                  {
                    "text": "No disruption of germinal centers by infiltrating marginal zone lymphocytes (follicular colonization)"
                  }
                ]
              },
              "Ancillary Tests": {
                "Immunohistochemistry": [
                  {
                    "text": "Express pan-B-cell markers in addition to Bcl-2"
                  },
                  {
                    "text": "CD43 negative"
                  },
                  {
                    "text": "Stains to highlight/assess follicular architecture: CD10, CD20, CD21, Bcl-2, Bcl-6, and Ki-67CD21 will highlight follicular dendritic meshwork, assess follicular colonizationBcl-6 and CD10 will highlight germinal center (GC) cellsBcl-2 will show negative staining in GC and positive staining in mantle and marginal zonesKi-67 shows high proliferation index (often polarized) in GC",
                    "sub_points": [
                      "CD21 will highlight follicular dendritic meshwork, assess follicular colonization",
                      "Bcl-6 and CD10 will highlight germinal center (GC) cells",
                      "Bcl-2 will show negative staining in GC and positive staining in mantle and marginal zones",
                      "Ki-67 shows high proliferation index (often polarized) in GC"
                    ]
                  },
                  {
                    "text": "IgM-positive phenotype"
                  }
                ],
                "Flow Cytometry": [
                  {
                    "text": "Polyclonal B cells that lack CD5 and CD10"
                  },
                  {
                    "text": "Subset of CD10-positive B cells (follicle center cells) may be noted if GCs are presentCD20 is often slightly brighter in this subset",
                    "sub_points": [
                      "CD20 is often slightly brighter in this subset"
                    ]
                  }
                ],
                "PCR": [
                  {
                    "text": "Lack of monoclonal immunoglobulin heavy-chain gene rearrangement by PCR"
                  }
                ]
              },
              "Differential Diagnosis": {
                "Splenic Marginal Zone Lymphoma": [
                  {
                    "text": "Expansion of white pulp with clusters of B cells in red pulpBiphasic pattern of splenic marginal zoneOften shows clusters of B cells in red pulp",
                    "sub_points": [
                      "Biphasic pattern of splenic marginal zone",
                      "Often shows clusters of B cells in red pulp"
                    ]
                  },
                  {
                    "text": "Mantle zone and GC are usually effaced"
                  },
                  {
                    "text": "GCs show infiltration by marginal zone lymphocytes (follicular colonization)"
                  },
                  {
                    "text": "Numerous B cells present in T-cell-rich periarteriolar lymphoid sheath"
                  },
                  {
                    "text": "Monoclonal B cells and low Ki-67 proliferation index"
                  }
                ],
                "Other Small B-Cell/White Pulp Lymphomas": [
                  {
                    "text": "Follicular lymphomaUniformly sized follicles that lack polarization and tingible body macrophagesExpresses pan-B-cell markers in addition to CD10, Bcl-6, and Bcl-2",
                    "sub_points": [
                      "Uniformly sized follicles that lack polarization and tingible body macrophages",
                      "Expresses pan-B-cell markers in addition to CD10, Bcl-6, and Bcl-2"
                    ]
                  },
                  {
                    "text": "Mantle cell lymphomaDistinct immunophenotype: CD19(+), CD20(+), CD5(+), cyclin-D1(+), CD23(-)",
                    "sub_points": [
                      "Distinct immunophenotype: CD19(+), CD20(+), CD5(+), cyclin-D1(+), CD23(-)"
                    ]
                  },
                  {
                    "text": "Small lymphocytic lymphomaLack of monocytoid appearanceDistinct immunophenotype: CD19(+), CD20 (dim +), CD5(+), CD23(+), cyclin-D1(-)",
                    "sub_points": [
                      "Lack of monocytoid appearance",
                      "Distinct immunophenotype: CD19(+), CD20 (dim +), CD5(+), CD23(+), cyclin-D1(-)"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          }
        }
      },
      "Spleen: Neoplasms": {
        "name": "Spleen: Neoplasms",
        "url": "https://app.pathprimer.com/lesson/4659bf0d-8055-4c33-9e2a-78e6f233a411",
        "topics": {
          "Introduction to Lymphoma": {
            "name": "Introduction to Lymphoma",
            "url": "https://app.pathprimer.com/document/14b26b38-13b0-464f-b06d-034aaf8808fd/lesson/4659bf0d-8055-4c33-9e2a-78e6f233a411",
            "content": {
              "Terminology": {
                "Primary Lymphomas of Spleen": [
                  {
                    "text": "Lymphomas with involvement limited to spleen or spleen and hilar lymph nodes (as per stringent criteria)"
                  },
                  {
                    "text": "Comprise about 1% of all lymphomasMost are non-HodgkinMost are B-cell lineagePrimary Hodgkin lymphoma of spleen is very rare",
                    "sub_points": [
                      "Most are non-Hodgkin",
                      "Most are B-cell lineage",
                      "Primary Hodgkin lymphoma of spleen is very rare"
                    ]
                  },
                  {
                    "text": "Some primary splenic lymphomas presenting with high stage are missed using these strict criteria"
                  }
                ],
                "Distinct Non-Hodgkin Lymphomas With Prominent Splenomegaly": [
                  {
                    "text": "Hairy cell leukemia"
                  },
                  {
                    "text": "Splenic marginal zone lymphoma"
                  },
                  {
                    "text": "Splenic B-cell lymphoma/leukemia, unclassifiableSplenic diffuse red pulp small B-cell lymphoma (2008 WHO provisional entity)Hairy cell leukemia variant (2008 WHO provisional entity)",
                    "sub_points": [
                      "Splenic diffuse red pulp small B-cell lymphoma (2008 WHO provisional entity)",
                      "Hairy cell leukemia variant (2008 WHO provisional entity)"
                    ]
                  },
                  {
                    "text": "Hepatosplenic T-cell lymphoma"
                  },
                  {
                    "text": "Lymphoplasmacytic lymphoma"
                  }
                ],
                "Secondary Lymphomas of Spleen": [
                  {
                    "text": "Non-Hodgkin lymphomasLarge B-cell lymphomaSmall B-cell lymphoma typesSmall lymphocytic lymphoma/chronic lymphocytic leukemia (SLL/CLL)Mantle cell lymphomaFollicular lymphomaLymphoplasmacytic lymphoma",
                    "sub_points": [
                      "Large B-cell lymphoma",
                      "Small B-cell lymphoma typesSmall lymphocytic lymphoma/chronic lymphocytic leukemia (SLL/CLL)Mantle cell lymphomaFollicular lymphomaLymphoplasmacytic lymphoma",
                      "Small lymphocytic lymphoma/chronic lymphocytic leukemia (SLL/CLL)",
                      "Mantle cell lymphoma",
                      "Follicular lymphoma",
                      "Lymphoplasmacytic lymphoma"
                    ]
                  },
                  {
                    "text": "T-cell lymphoproliferative disordersHepatosplenic T-cell lymphomaAggressive NK-cell lymphoma/leukemiaAdult T-cell leukemia/lymphomaT-cell prolymphocytic leukemiaAngioimmunoblastic T-cell lymphomaPeripheral T-cell lymphoma, not otherwise specifiedAnaplastic large cell lymphoma",
                    "sub_points": [
                      "Hepatosplenic T-cell lymphoma",
                      "Aggressive NK-cell lymphoma/leukemia",
                      "Adult T-cell leukemia/lymphoma",
                      "T-cell prolymphocytic leukemia",
                      "Angioimmunoblastic T-cell lymphoma",
                      "Peripheral T-cell lymphoma, not otherwise specified",
                      "Anaplastic large cell lymphoma"
                    ]
                  },
                  {
                    "text": "Hodgkin lymphomaMost are subtypes of classic Hodgkin lymphomaSplenic involvement by nodular lymphocyte-predominant Hodgkin lymphoma is extremely rare",
                    "sub_points": [
                      "Most are subtypes of classic Hodgkin lymphoma",
                      "Splenic involvement by nodular lymphocyte-predominant Hodgkin lymphoma is extremely rare"
                    ]
                  }
                ]
              },
              "Epidemiology": {
                "Incidence": [
                  {
                    "text": "Variable depending on lymphoma subtype"
                  },
                  {
                    "text": "Frequency in splenectomy specimens involved by non-Hodgkin lymphomaLarge B-cell lymphoma: ~ 33% of all splenic lymphomasSLL/CLL: ~ 20%Follicular lymphoma: ~ 13%Lymphoplasmacytic lymphoma: ~ 9%Splenic marginal zone lymphoma: ~ 8%Mantle cell lymphoma: ~ 7%All T-cell lymphomas combined: ~ 3%",
                    "sub_points": [
                      "Large B-cell lymphoma: ~ 33% of all splenic lymphomas",
                      "SLL/CLL: ~ 20%",
                      "Follicular lymphoma: ~ 13%",
                      "Lymphoplasmacytic lymphoma: ~ 9%",
                      "Splenic marginal zone lymphoma: ~ 8%",
                      "Mantle cell lymphoma: ~ 7%",
                      "All T-cell lymphomas combined: ~ 3%"
                    ]
                  }
                ],
                "Age Range": [
                  {
                    "text": "ALK-positive anaplastic large cell lymphomaCommon in children",
                    "sub_points": [
                      "Common in children"
                    ]
                  },
                  {
                    "text": "Classic Hodgkin lymphomaBimodal age distribution1st peak at 15-35 years of age2nd peak at older age",
                    "sub_points": [
                      "Bimodal age distribution1st peak at 15-35 years of age2nd peak at older age",
                      "1st peak at 15-35 years of age",
                      "2nd peak at older age"
                    ]
                  },
                  {
                    "text": "Hepatosplenic T-cell lymphomaAdolescents and young adults",
                    "sub_points": [
                      "Adolescents and young adults"
                    ]
                  },
                  {
                    "text": "Most other lymphomasPredominantly in adults",
                    "sub_points": [
                      "Predominantly in adults"
                    ]
                  }
                ],
                "Gender": [
                  {
                    "text": "ALK-positive anaplastic large cell lymphoma: M > F"
                  },
                  {
                    "text": "Hepatosplenic T-cell lymphoma: M > > F"
                  },
                  {
                    "text": "Hairy cell leukemia: M > F"
                  }
                ],
                "Ethnicity Relationship": [
                  {
                    "text": "Aggressive NK/T-cell lymphoma shows predilection for Asians and Native Americans"
                  },
                  {
                    "text": "Adult T-cell leukemia/lymphoma is prevalent in Southwestern Japan, Caribbean, and central Africa"
                  }
                ]
              },
              "Etiology/Pathogenesis": {
                "Unclear in Most Subtypes of Lymphomas": [
                  {
                    "text": "Viruses linked to some subtypes of lymphomasEpstein-Barr virus (EBV) in aggressive NK/T-cell lymphomaEBV plays a role in pathogenesis of subset of classic Hodgkin lymphomaHuman T-cell leukemia virus in adult T-cell leukemia/lymphoma",
                    "sub_points": [
                      "Epstein-Barr virus (EBV) in aggressive NK/T-cell lymphoma",
                      "EBV plays a role in pathogenesis of subset of classic Hodgkin lymphoma",
                      "Human T-cell leukemia virus in adult T-cell leukemia/lymphoma"
                    ]
                  },
                  {
                    "text": "Deregulation of oncogenesBCL1/cyclin D1(CCND1) gene in mantle cell lymphomaBCL2in follicular lymphomaALKgene in ALK-positive anaplastic large cell lymphomaTCL1gene in T-cell prolymphocytic leukemia (T-PLL)MTCP1in subset of T-PLL",
                    "sub_points": [
                      "BCL1/cyclin D1(CCND1) gene in mantle cell lymphoma",
                      "BCL2in follicular lymphoma",
                      "ALKgene in ALK-positive anaplastic large cell lymphoma",
                      "TCL1gene in T-cell prolymphocytic leukemia (T-PLL)",
                      "MTCP1in subset of T-PLL"
                    ]
                  },
                  {
                    "text": "Genes and microRNA deregulationBRAFV600E mutations in hairy cell leukemiaIDH2mutations in angioimmunoblastic T-cell lymphomaMicroRNA mutations in SLL/CLL",
                    "sub_points": [
                      "BRAFV600E mutations in hairy cell leukemia",
                      "IDH2mutations in angioimmunoblastic T-cell lymphoma",
                      "MicroRNA mutations in SLL/CLL"
                    ]
                  }
                ]
              },
              "Macroscopic Findings": {
                "Gross Appearance of Spleen Involved by Lymphoma": [
                  {
                    "text": "Diffuse miliary small white nodulesFollicular lymphomaMantle cell lymphomaSplenic marginal zone lymphomaSLL/CLLRarely classic Hodgkin lymphoma, particularly in HIV-positive patients",
                    "sub_points": [
                      "Follicular lymphoma",
                      "Mantle cell lymphoma",
                      "Splenic marginal zone lymphoma",
                      "SLL/CLL",
                      "Rarely classic Hodgkin lymphoma, particularly in HIV-positive patients"
                    ]
                  },
                  {
                    "text": "Solitary or multiple large nodulesDiffuse large B-cell lymphomaGrade 3 follicular lymphomaClassic Hodgkin lymphoma",
                    "sub_points": [
                      "Diffuse large B-cell lymphoma",
                      "Grade 3 follicular lymphoma",
                      "Classic Hodgkin lymphoma"
                    ]
                  },
                  {
                    "text": "Homogeneous, beefy-red cut surfaceHairy cell leukemiaHairy cell leukemia variantSplenic diffuse red pulp small B-cell lymphomaHepatosplenic T-cell lymphomaT-cell prolymphocytic leukemiaPeripheral T-cell lymphoma, not otherwise specified",
                    "sub_points": [
                      "Hairy cell leukemia",
                      "Hairy cell leukemia variant",
                      "Splenic diffuse red pulp small B-cell lymphoma",
                      "Hepatosplenic T-cell lymphoma",
                      "T-cell prolymphocytic leukemia",
                      "Peripheral T-cell lymphoma, not otherwise specified"
                    ]
                  }
                ]
              },
              "Microscopic Findings": {
                "White Pulp-Predominant Nodular Proliferations": [
                  {
                    "text": "Follicular lymphomaUniform involvement of white pulpResidual mantle and marginal zone cells can be seenPredominance of centrocytes and lack of tingible bodies in grade 1Mixed centrocytes and centroblasts in grade 2 or 3A may mimic reactive follicles",
                    "sub_points": [
                      "Uniform involvement of white pulp",
                      "Residual mantle and marginal zone cells can be seen",
                      "Predominance of centrocytes and lack of tingible bodies in grade 1",
                      "Mixed centrocytes and centroblasts in grade 2 or 3A may mimic reactive follicles"
                    ]
                  },
                  {
                    "text": "Mantle cell lymphomaNeoplastic cells expand around residual germinal centers of white pulpMay invade and replace germinal centersResidual marginal zone cells may be seenMay mimic grade 1 follicular lymphoma",
                    "sub_points": [
                      "Neoplastic cells expand around residual germinal centers of white pulp",
                      "May invade and replace germinal centers",
                      "Residual marginal zone cells may be seen",
                      "May mimic grade 1 follicular lymphoma"
                    ]
                  },
                  {
                    "text": "SLL/CLLInvolved white pulp is typically not well defined compared with follicular lymphomaPatchy or diffuse infiltration of red pulp is always presentProlymphocytes and paraimmunoblasts are typically present among small, round SLL/CLL cells",
                    "sub_points": [
                      "Involved white pulp is typically not well defined compared with follicular lymphoma",
                      "Patchy or diffuse infiltration of red pulp is always present",
                      "Prolymphocytes and paraimmunoblasts are typically present among small, round SLL/CLL cells"
                    ]
                  },
                  {
                    "text": "Splenic marginal zone lymphomaInvolved white pulp shows biphasic pattern of dark inner zone and pale outer zoneBiphasic pattern may mimic mantle and marginal zones of normal white pulpGerminal centers are usually effaced but may be present in rare casesRed pulp is infiltrated with diffuse involvement of splenic sinusesSplenic hilar lymph nodes are usually involved without complete effacement of nodal architecture",
                    "sub_points": [
                      "Involved white pulp shows biphasic pattern of dark inner zone and pale outer zoneBiphasic pattern may mimic mantle and marginal zones of normal white pulp",
                      "Biphasic pattern may mimic mantle and marginal zones of normal white pulp",
                      "Germinal centers are usually effaced but may be present in rare cases",
                      "Red pulp is infiltrated with diffuse involvement of splenic sinuses",
                      "Splenic hilar lymph nodes are usually involved without complete effacement of nodal architecture"
                    ]
                  },
                  {
                    "text": "Lymphoplasmacytic lymphomaNeoplastic cells can be localized mainly in mantle zone of white pulpBiphasic zonal distribution also occurSmall lymphocytes in the inner zoneLymphoplasmacytic and plasma cells in mantle and marginal zonesMay mimic marginal zone lymphoma with plasmacytic differentiation",
                    "sub_points": [
                      "Neoplastic cells can be localized mainly in mantle zone of white pulp",
                      "Biphasic zonal distribution also occurSmall lymphocytes in the inner zoneLymphoplasmacytic and plasma cells in mantle and marginal zones",
                      "Small lymphocytes in the inner zone",
                      "Lymphoplasmacytic and plasma cells in mantle and marginal zones",
                      "May mimic marginal zone lymphoma with plasmacytic differentiation"
                    ]
                  }
                ],
                "Red Pulp-Predominant Proliferations": [
                  {
                    "text": "Hairy cell leukemiaHeavy infiltration of red pulp with virtual absence of white pulpHairy cells typically contain round or bean-shaped nuclei and abundant cytoplasmBlood lakes surrounded by hairy cells are typically present",
                    "sub_points": [
                      "Heavy infiltration of red pulp with virtual absence of white pulp",
                      "Hairy cells typically contain round or bean-shaped nuclei and abundant cytoplasm",
                      "Blood lakes surrounded by hairy cells are typically present"
                    ]
                  },
                  {
                    "text": "Splenic B-cell lymphoma/leukemia, unclassifiableExtensive involvement of red pulp with atrophic to absent white pulpBlood lakes may be presentMorphologic distinction from hairy cell leukemia can be very difficult",
                    "sub_points": [
                      "Extensive involvement of red pulp with atrophic to absent white pulp",
                      "Blood lakes may be present",
                      "Morphologic distinction from hairy cell leukemia can be very difficult"
                    ]
                  },
                  {
                    "text": "Hepatosplenic T-cell lymphomaSplenic sinuses and cords are infiltratedWhite pulp is atrophicPredominantly sinusoidal distribution in liver and bone marrow",
                    "sub_points": [
                      "Splenic sinuses and cords are infiltrated",
                      "White pulp is atrophic",
                      "Predominantly sinusoidal distribution in liver and bone marrow"
                    ]
                  },
                  {
                    "text": "T-cell large granular lymphocytic leukemiaSplenic white pulp architecture is preservedRed pulp sinuses and cords are involvedLesser involvement compared with T-PLL",
                    "sub_points": [
                      "Splenic white pulp architecture is preserved",
                      "Red pulp sinuses and cords are involved",
                      "Lesser involvement compared with T-PLL"
                    ]
                  },
                  {
                    "text": "T-PLLDiffuse red pulp infiltrate with involvement of splenic sinuses and cordsWhite pulp involvement is also commonAngioinvasion and infiltration into fibrous trabeculaeSplenic capsular invasion and extension to splenic hilum",
                    "sub_points": [
                      "Diffuse red pulp infiltrate with involvement of splenic sinuses and cords",
                      "White pulp involvement is also common",
                      "Angioinvasion and infiltration into fibrous trabeculae",
                      "Splenic capsular invasion and extension to splenic hilum"
                    ]
                  },
                  {
                    "text": "Aggressive NK/T-cell lymphoma/leukemiaMedium to large cells infiltrate splenic red pulp and sinuses of liverAssociated hemophagocytic syndromeCan mimic hepatosplenic T-cell lymphomaBlood vessel walls are typically infiltrated",
                    "sub_points": [
                      "Medium to large cells infiltrate splenic red pulp and sinuses of liver",
                      "Associated hemophagocytic syndrome",
                      "Can mimic hepatosplenic T-cell lymphoma",
                      "Blood vessel walls are typically infiltrated"
                    ]
                  }
                ],
                "Solitary or Multiple Large Nodular Proliferations": [
                  {
                    "text": "Diffuse large B-cell lymphomaSheets of large lymphoma cellsIntervening splenic tissue is intactSplenic cords and sinuses can be involved in primary diffuse large B-cell lymphoma",
                    "sub_points": [
                      "Sheets of large lymphoma cells",
                      "Intervening splenic tissue is intact",
                      "Splenic cords and sinuses can be involved in primary diffuse large B-cell lymphoma"
                    ]
                  },
                  {
                    "text": "Grade 3 follicular lymphomaLarge coalescent nodulesPredominance of large centroblastic cells",
                    "sub_points": [
                      "Large coalescent nodules",
                      "Predominance of large centroblastic cells"
                    ]
                  },
                  {
                    "text": "Classic Hodgkin lymphomaAll types can involve spleenNodular proliferations can be solitary or multipleMiliary small nodules involving entire spleen are occasionally seen",
                    "sub_points": [
                      "All types can involve spleen",
                      "Nodular proliferations can be solitary or multiple",
                      "Miliary small nodules involving entire spleen are occasionally seen"
                    ]
                  }
                ]
              },
              "Differential Diagnosis of Large Nodules in Spleen": {
                "Nonhematopoietic Tumors": [
                  {
                    "text": "Primary or metastatic nonhematopoietic tumors"
                  },
                  {
                    "text": "Inflammatory pseudotumor"
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Flow Cytometry": [
                  {
                    "text": "Detects lineage and B-cell clonality"
                  },
                  {
                    "text": "Identifies aberrant NK/T-cell population"
                  },
                  {
                    "text": "Can diagnose lymphoid neoplasms with known specific antigen profileCD25 and CD103 coexpression in hairy cell leukemiaCD5 and CD23 coexpression in SLL/CLL",
                    "sub_points": [
                      "CD25 and CD103 coexpression in hairy cell leukemia",
                      "CD5 and CD23 coexpression in SLL/CLL"
                    ]
                  }
                ],
                "Immunohistochemistry/EBER": [
                  {
                    "text": "Assessment of B- and T-cell associated antigens is critical in most cases"
                  },
                  {
                    "text": "Inclusion of additional antibodies needed to arrive at specific diagnosisAnnexin-A1 in hairy cell leukemiaCD5 and cyclin-D1 in mantle cell lymphomaCD5 and CD23 in SLL/CLLTCL1 in T-PLLEBER in NK-cell lymphoma and other EBV-associated lymphoid neoplasms",
                    "sub_points": [
                      "Annexin-A1 in hairy cell leukemia",
                      "CD5 and cyclin-D1 in mantle cell lymphoma",
                      "CD5 and CD23 in SLL/CLL",
                      "TCL1 in T-PLL",
                      "EBER in NK-cell lymphoma and other EBV-associated lymphoid neoplasms"
                    ]
                  }
                ],
                "FISH/Cytogenetics": [
                  {
                    "text": "Detects cytogenetic abnormalities linked to specific entitiesBCL2/IGHin follicular lymphomaCCND1/IGHin mantle cell lymphomainv14/t(14;14) in T-PLLIsochromosome 7q in hepatosplenic T-cell lymphoma in appropriate setting",
                    "sub_points": [
                      "BCL2/IGHin follicular lymphoma",
                      "CCND1/IGHin mantle cell lymphoma",
                      "inv14/t(14;14) in T-PLL",
                      "Isochromosome 7q in hepatosplenic T-cell lymphoma in appropriate setting"
                    ]
                  }
                ],
                "Molecular Testings": [
                  {
                    "text": "PCR for assessment of clonality"
                  },
                  {
                    "text": "Southern blot assessment of EBV DNA terminal repeatsDetermines clonality in NK proliferations",
                    "sub_points": [
                      "Determines clonality in NK proliferations"
                    ]
                  },
                  {
                    "text": "Mutational analysis as indicatedBRAFV600E mutations in hairy cell leukemiaIDH2mutations in subset of angioimmunoblastic T-cell lymphoma",
                    "sub_points": [
                      "BRAFV600E mutations in hairy cell leukemia",
                      "IDH2mutations in subset of angioimmunoblastic T-cell lymphoma"
                    ]
                  }
                ]
              },
              "Diagnostic Checklist": {
                "Pathology Tips": [
                  {
                    "text": "Obtain clinical information upfrontEssential in planning appropriate processing of spleen",
                    "sub_points": [
                      "Essential in planning appropriate processing of spleen"
                    ]
                  },
                  {
                    "text": "Cut thin slices of spleen, and sample any suspicious lesion/nodule"
                  },
                  {
                    "text": "Process all hilar lymph nodes"
                  },
                  {
                    "text": "Examine Diff-Quick-stained touch imprint of suspicious lesionCan help to decide if flow cytometry &/or cytogenetics is needed",
                    "sub_points": [
                      "Can help to decide if flow cytometry &/or cytogenetics is needed"
                    ]
                  },
                  {
                    "text": "Adequate fixation is crucial in interpreting histologyAssess pattern and extent of involvementCarefully examine white pulp and splenic cords and sinusesSome lymphoid neoplasms may have low level of involvementExamine cytologic features of neoplastic cellsIntegrate clinical, histomorphologic, immunophenotypic, and molecular genetic findings (if any) in diagnostic interpretation",
                    "sub_points": [
                      "Assess pattern and extent of involvement",
                      "Carefully examine white pulp and splenic cords and sinuses",
                      "Some lymphoid neoplasms may have low level of involvement",
                      "Examine cytologic features of neoplastic cells",
                      "Integrate clinical, histomorphologic, immunophenotypic, and molecular genetic findings (if any) in diagnostic interpretation"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Hepatosplenic T-Cell Lymphoma": {
            "name": "Hepatosplenic T-Cell Lymphoma",
            "url": "https://app.pathprimer.com/document/2498c60c-67bd-4815-b2eb-3eda9d41e73a/lesson/4659bf0d-8055-4c33-9e2a-78e6f233a411",
            "content": {
              "Key Facts": {
                "Terminology": [
                  {
                    "text": "Clinically aggressive extranodal and systemic T-cell lymphoma"
                  },
                  {
                    "text": "Spleen, liver, and bone marrow involvement"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Rare< 1% of all non-Hodgkin lymphomas",
                    "sub_points": [
                      "< 1% of all non-Hodgkin lymphomas"
                    ]
                  },
                  {
                    "text": "Young adultsMedian age: 35 years",
                    "sub_points": [
                      "Median age: 35 years"
                    ]
                  },
                  {
                    "text": "B symptoms and poor prognosis"
                  },
                  {
                    "text": "Marked splenomegaly, common hepatomegaly"
                  },
                  {
                    "text": "Minimal or absent lymphadenopathy"
                  }
                ],
                "Microscopic Features": [
                  {
                    "text": "Spleen: Red pulp cords and sinuses infiltration"
                  },
                  {
                    "text": "Bone marrow and liver: Sinusoidal infiltration"
                  },
                  {
                    "text": "Clear cytoplasm, devoid of azurophilic granules"
                  },
                  {
                    "text": "Occasional cases with blastic cells with prominent nucleoli that mimic acute leukemia"
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "Typical immunophenotype: CD3(+), CD4(-)/CD8(-/+), CD5(-), CD56(+), TCR-γδ(+)Nonactivated cytotoxic cells: TIA1(+), granzyme B(-)",
                    "sub_points": [
                      "Nonactivated cytotoxic cells: TIA1(+), granzyme B(-)"
                    ]
                  },
                  {
                    "text": "Subset of cases express TCR-αβSimilar clinicopathologic and cytogenetic features to TCR-γδ(+) cases",
                    "sub_points": [
                      "Similar clinicopathologic and cytogenetic features to TCR-γδ(+) cases"
                    ]
                  },
                  {
                    "text": "Isochromosome 7q is consistent cytogenetic abnormality"
                  },
                  {
                    "text": "Trisomy 8 in subset of cases"
                  }
                ]
              },
              "Terminology": {
                "Abbreviations": [
                  {
                    "text": "Hepatosplenic T-cell lymphoma (HSTCL)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Historical term: Erythrophagocytic T-gamma lymphoma"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Aggressive extranodal, systemic T-cell lymphoma; usually TCR-γδ(+)Spleen, liver, and bone marrow involvementNonactivated cytotoxic immunophenotype",
                    "sub_points": [
                      "Spleen, liver, and bone marrow involvement",
                      "Nonactivated cytotoxic immunophenotype"
                    ]
                  }
                ]
              },
              "Etiology/Pathogenesis": {
                "Etiology": [
                  {
                    "text": "Unknown in 80% of patients"
                  }
                ],
                "Association With Chronic Immunosuppression": [
                  {
                    "text": "20% of patients"
                  },
                  {
                    "text": "Solid organ transplant recipients"
                  },
                  {
                    "text": "Patients with inflammatory bowel disease on long-term therapy with tumor necrosis factor alpha antagonists or thiopurines"
                  }
                ]
              },
              "Clinical Issues": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "< 1% of all non-Hodgkin lymphomas"
                  }
                ],
                "Age": [
                  {
                    "text": "Young adultsMedian age: 35 years",
                    "sub_points": [
                      "Median age: 35 years"
                    ]
                  }
                ],
                "Gender": [
                  {
                    "text": "M > F"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Systemic (B-type) symptoms"
                  },
                  {
                    "text": "Marked splenomegaly is commonly used to define diseaseHepatomegaly in ~ 50% of patients",
                    "sub_points": [
                      "Hepatomegaly in ~ 50% of patients"
                    ]
                  },
                  {
                    "text": "Minimal or absent lymphadenopathy"
                  },
                  {
                    "text": "Cytopenias are commonThrombocytopenia is almost constantSeverity correlates with progressionLeukemic phase is unlikely at presentationCan occur during course of disease",
                    "sub_points": [
                      "Thrombocytopenia is almost constantSeverity correlates with progression",
                      "Severity correlates with progression",
                      "Leukemic phase is unlikely at presentationCan occur during course of disease",
                      "Can occur during course of disease"
                    ]
                  },
                  {
                    "text": "High serum lactate dehydrogenase level"
                  }
                ],
                "Treatment": [
                  {
                    "text": "Standard anthracycline-containing chemotherapy regimens are not effective"
                  },
                  {
                    "text": "Platinum-cytarabine regimens and 2'- deoxycoformycin (pentostatin) are often used"
                  },
                  {
                    "text": "Promise for cure after stem cell transplantation"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "PoorMedian survival: ~ 12 monthsNo clinical features or biomarkers predict prognosis",
                    "sub_points": [
                      "Median survival: ~ 12 months",
                      "No clinical features or biomarkers predict prognosis"
                    ]
                  }
                ]
              },
              "Macroscopic Features": {
                "General Features": [
                  {
                    "text": "SpleenDiffuse enlargement; no discrete gross lesionsCommonly > 1,000 gHomogeneous and diffusely red-purple parenchyma",
                    "sub_points": [
                      "Diffuse enlargement; no discrete gross lesions",
                      "Commonly > 1,000 g",
                      "Homogeneous and diffusely red-purple parenchyma"
                    ]
                  },
                  {
                    "text": "LiverDiffuse enlargement; no discrete gross lesions",
                    "sub_points": [
                      "Diffuse enlargement; no discrete gross lesions"
                    ]
                  },
                  {
                    "text": "Lymph nodesUsually not enlarged",
                    "sub_points": [
                      "Usually not enlarged"
                    ]
                  }
                ]
              },
              "Microscopic Pathology": {
                "Histologic Features": [
                  {
                    "text": "SpleenRed pulp sinuses and cords are infiltrated by T cellsWhite pulp is atrophicHemophagocytosis can be observed",
                    "sub_points": [
                      "Red pulp sinuses and cords are infiltrated by T cellsWhite pulp is atrophic",
                      "White pulp is atrophic",
                      "Hemophagocytosis can be observed"
                    ]
                  },
                  {
                    "text": "LiverSinusoidal pattern of infiltrationMild portal and periportal infiltrate can be seen",
                    "sub_points": [
                      "Sinusoidal pattern of infiltration",
                      "Mild portal and periportal infiltrate can be seen"
                    ]
                  },
                  {
                    "text": "Lymph nodesEnlarged splenic hilar nodes in ~ 10% of casesNeoplastic infiltration usually confined to sinuses",
                    "sub_points": [
                      "Enlarged splenic hilar nodes in ~ 10% of cases",
                      "Neoplastic infiltration usually confined to sinuses"
                    ]
                  },
                  {
                    "text": "Bone marrowFeatures are often characteristic, and splenectomy may not be required for diagnosisHypercellular bone marrow with trilineage hematopoiesisPattern of infiltrationPattern can be subtle and difficult to recognize in routine H&E-stained sectionsImmunohistochemistry for T-cell markers is useful to assess extent and pattern of infiltrationSinusoidal pattern is commonInterstitial or diffuse pattern may occur in advanced disease",
                    "sub_points": [
                      "Features are often characteristic, and splenectomy may not be required for diagnosis",
                      "Hypercellular bone marrow with trilineage hematopoiesis",
                      "Pattern of infiltrationPattern can be subtle and difficult to recognize in routine H&E-stained sectionsImmunohistochemistry for T-cell markers is useful to assess extent and pattern of infiltrationSinusoidal pattern is commonInterstitial or diffuse pattern may occur in advanced disease",
                      "Pattern can be subtle and difficult to recognize in routine H&E-stained sections",
                      "Immunohistochemistry for T-cell markers is useful to assess extent and pattern of infiltration",
                      "Sinusoidal pattern is common",
                      "Interstitial or diffuse pattern may occur in advanced disease"
                    ]
                  }
                ],
                "Cytologic Features": [
                  {
                    "text": "Early-stage diseaseRelatively monotonous tumor cells, small to intermediate in size with irregular nuclear contoursNuclear chromatin loosely condensed with small nucleoliClear cytoplasm, devoid of azurophilic granules",
                    "sub_points": [
                      "Relatively monotonous tumor cells, small to intermediate in size with irregular nuclear contoursNuclear chromatin loosely condensed with small nucleoliClear cytoplasm, devoid of azurophilic granules",
                      "Nuclear chromatin loosely condensed with small nucleoli",
                      "Clear cytoplasm, devoid of azurophilic granules"
                    ]
                  },
                  {
                    "text": "Late-stage diseaseMedium to large cells with prominent nucleoli that resemble blastsCan mimic myelodysplastic syndrome or myeloproliferative neoplasm",
                    "sub_points": [
                      "Medium to large cells with prominent nucleoli that resemble blasts",
                      "Can mimic myelodysplastic syndrome or myeloproliferative neoplasm"
                    ]
                  }
                ]
              },
              "Ancillary Tests": {
                "Immunohistochemistry": [
                  {
                    "text": "Antibody specific for TCR-γδ useful in paraffin tissue sections has become available recentlyLess commonly, loss of TCR-γδ expression (TCR silent) can occur during disease progression",
                    "sub_points": [
                      "Less commonly, loss of TCR-γδ expression (TCR silent) can occur during disease progression"
                    ]
                  },
                  {
                    "text": "TCR-βF1 antibody reacting with epitope of framework of α/β TCR receptor is usually (-)"
                  },
                  {
                    "text": "CD3(+), CD5(-), CD7(+), CD56(+/-)"
                  },
                  {
                    "text": "Nonactivated cytotoxic immunophenotypeTIA1(+), granzyme M(+), granzyme B(-), and perforin (-)",
                    "sub_points": [
                      "TIA1(+), granzyme M(+), granzyme B(-), and perforin (-)"
                    ]
                  },
                  {
                    "text": "CD19(-), CD20(-), CD25(-), CD30(-)"
                  }
                ],
                "Flow Cytometry": [
                  {
                    "text": "Extremely helpful for characterizing immunophenotype of HSTCL cells"
                  },
                  {
                    "text": "Most cases are TCR-γδ(+)TCR-γδ(+) is most reliably determined by flow cytometry",
                    "sub_points": [
                      "TCR-γδ(+) is most reliably determined by flow cytometry"
                    ]
                  },
                  {
                    "text": "Few cases express TCR-αβClinicopathologic and cytogenetic features similar to TCR-γδ(+) casesMore common in women",
                    "sub_points": [
                      "Clinicopathologic and cytogenetic features similar to TCR-γδ(+) cases",
                      "More common in women"
                    ]
                  },
                  {
                    "text": "CD2(+), CD3(+), CD7(+), CD16(-/+), CD56(+/-)"
                  },
                  {
                    "text": "KIR(+), CD94 (dim + or -)"
                  },
                  {
                    "text": "CD4(-), CD5(-), CD8(-/+), CD57(-)Unusual variations include CD5 expression",
                    "sub_points": [
                      "Unusual variations include CD5 expression"
                    ]
                  },
                  {
                    "text": "B-cell antigens (-), myeloid antigens (-)"
                  }
                ],
                "Cytogenetics": [
                  {
                    "text": "Isochromosome 7q is common abnormality (but not specific)Also detected in nasal-type extranodal NK/T-cell lymphoma and ALK(-) anaplastic large cell lymphoma",
                    "sub_points": [
                      "Also detected in nasal-type extranodal NK/T-cell lymphoma and ALK(-) anaplastic large cell lymphoma"
                    ]
                  },
                  {
                    "text": "Trisomy 8 or loss of Y chromosome in subset of cases"
                  }
                ],
                "Molecular Genetics": [
                  {
                    "text": "Monoclonal rearrangements ofTCRγgene is common"
                  },
                  {
                    "text": "Monoclonal rearrangements ofTCRβgene is also detected"
                  }
                ]
              },
              "Differential Diagnosis": {
                "T-Cell Large Granular Lymphocytic (T-LGL) Leukemia": [
                  {
                    "text": "Older patients with indolent clinical course"
                  },
                  {
                    "text": "Peripheral blood: Increased number of large granular lymphocytes"
                  },
                  {
                    "text": "Spleen: Expansion of red pulp cords and sinusoids"
                  },
                  {
                    "text": "Bone marrow, usually interstitial pattern, but sinusoidal pattern can also seen"
                  },
                  {
                    "text": "Typical immunophenotype: CD8(+), CD57(+), TCR-αβ(+)Activated cytotoxic immunophenotype: TIA1(+), granzyme B(+), perforin (+)CD5 (dim +), CD16(+), CD56(-)",
                    "sub_points": [
                      "Activated cytotoxic immunophenotype: TIA1(+), granzyme B(+), perforin (+)",
                      "CD5 (dim +), CD16(+), CD56(-)"
                    ]
                  },
                  {
                    "text": "Distinction between HSTCL and T-LGL leukemia can be difficult in some patientsNeoplastic lymphocytes with azurophilic granules favors T-LGL leukemiaTCR-αβ(+), CD8(+), CD57(+) favors T-LGL leukemia",
                    "sub_points": [
                      "Neoplastic lymphocytes with azurophilic granules favors T-LGL leukemia",
                      "TCR-αβ(+), CD8(+), CD57(+) favors T-LGL leukemia"
                    ]
                  }
                ],
                "T-Cell Prolymphocytic Leukemia": [
                  {
                    "text": "Extremely high white blood cell count, usually > 100 x 10⁹/L"
                  },
                  {
                    "text": "Lymphocytes with prominent nucleoli"
                  },
                  {
                    "text": "Hepatosplenomegaly; generalized lymphadenopathy in subset"
                  },
                  {
                    "text": "Spleen: Red pulp infiltrate with atrophy of white pulp"
                  },
                  {
                    "text": "T-cell markers (+), CD52 (bright +), TCL1(+/-)"
                  },
                  {
                    "text": "Karyotype: inv14q or t(14;14)(q11;q32)"
                  }
                ],
                "Aggressive NK-Cell Leukemia/Lymphoma": [
                  {
                    "text": "Patients with hepatosplenomegaly, B-symptoms, and aggressive course"
                  },
                  {
                    "text": "Cytoplasmic azurophilic granules"
                  },
                  {
                    "text": "Bone marrow infiltration is interstitial and diffuse; not sinusoidal"
                  },
                  {
                    "text": "NK-cell markers (+), surface CD3(-), TCR(-), and EBV(+)"
                  },
                  {
                    "text": "Express-activated cytotoxic immunophenotype: TIA1(+), granzyme B(+), perforin (+)"
                  },
                  {
                    "text": "Negative forTCRgene rearrangements"
                  }
                ],
                "Nonsplenic Cytotoxic T-Cell Lymphoma With γδ(+) Phenotype": [
                  {
                    "text": "T-cell lymphomas with cytotoxic phenotype and TCR-γδ expression but no hepatomegaly or splenomegaly"
                  },
                  {
                    "text": "Designated in skin as primary cutaneous γδ T-cell lymphoma and is aggressive"
                  },
                  {
                    "text": "Rare cases of enteropathy-associated T-cell lymphoma are TCR-γδ(+)"
                  }
                ],
                "T-Cell Lymphoblastic Leukemia/Lymphoma": [
                  {
                    "text": "Shares some clinicopathologic features of HSTCL"
                  },
                  {
                    "text": "Older children and adolescents"
                  },
                  {
                    "text": "Mediastinal mass is common"
                  },
                  {
                    "text": "Blasts are T cells and TdT(+), CD1a(+), and CD99(+)"
                  }
                ],
                "Peripheral T- or NK-Cell Lymphomas With Intravascular Pattern": [
                  {
                    "text": "Rare cases of T-cell lymphoma or NK-cell lymphoma can be intravascular"
                  },
                  {
                    "text": "Most cases are not evaluated for TCR expression"
                  },
                  {
                    "text": "Some reported intravascular T-cell lymphomas may be HSTCL"
                  }
                ],
                "Myelodysplastic Syndrome": [
                  {
                    "text": "Cytopenias and blastic cells can resemble late-stage HSTCL"
                  },
                  {
                    "text": "Blasts in myelodysplastic syndrome are usually myeloperoxidase (+), nonspecific esterase (+), and myeloid antigens (+)"
                  }
                ],
                "Splenic Marginal Zone Lymphoma": [
                  {
                    "text": "Spleen: Infiltration of white pulp and red pulp"
                  },
                  {
                    "text": "Small neoplastic cells with abundant pale cytoplasm"
                  },
                  {
                    "text": "Villous lymphocytes in peripheral blood smear"
                  },
                  {
                    "text": "CD3(-), CD19(+), CD20(+), CD22(+), and pax-5(+)"
                  },
                  {
                    "text": "Allelic loss of chromosome 7q22-36 (40%)"
                  }
                ],
                "Hairy Cell Leukemia": [
                  {
                    "text": "Older patients and indolent clinical course"
                  },
                  {
                    "text": "Red pulp infiltrate with atrophy of white pulp"
                  },
                  {
                    "text": "Red blood cell lakes"
                  },
                  {
                    "text": "Hairy cells in peripheral blood smear"
                  },
                  {
                    "text": "Interstitial pattern of bone marrow infiltration"
                  },
                  {
                    "text": "CD3(-), CD19(+), CD20(+), CD25(+), CD103(+), annexin-A1 (+), and pax-5(+)"
                  }
                ],
                "Intravascular Large B-Cell Lymphoma": [
                  {
                    "text": "Neurologic and dermatologic manifestations"
                  },
                  {
                    "text": "Large cells filling splenic sinusoids and systemic small vessels (capillaries)"
                  },
                  {
                    "text": "CD3(-), CD19(+), CD20(+), and pax-5(+)"
                  }
                ],
                "B-Cell Prolymphocytic Leukemia": [
                  {
                    "text": "Extremely high white blood cell count"
                  },
                  {
                    "text": "Spleen: Infiltration of white pulp and red pulp"
                  },
                  {
                    "text": "Intermediate to large cells with prominent central nucleoli"
                  },
                  {
                    "text": "CD3(-), CD19(+), CD20(+), and pax-5(+)"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Langerhans Cell Histiocytosis": {
            "name": "Langerhans Cell Histiocytosis",
            "url": "https://app.pathprimer.com/document/2b3b0c7d-f15e-43ed-9e80-b04e3f278f60/lesson/4659bf0d-8055-4c33-9e2a-78e6f233a411",
            "content": {
              "Key Facts": {
                "Terminology": [
                  {
                    "text": "Clonal proliferation of Langerhans cells with expression of CD1a, langerin, and S100 protein and recurrent genetic abnormalities"
                  },
                  {
                    "text": "Langerhans cell histiocytosis (LCH)"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Most cases occur in childrenRarely seen in older adults",
                    "sub_points": [
                      "Rarely seen in older adults"
                    ]
                  },
                  {
                    "text": "M:F = 3:1"
                  },
                  {
                    "text": "3 major overlapping variantsSolitary eosinophilic granuloma (unifocal disease that occurs in older children or adults)Hand-Schüller-Christian disease (multifocal unisystem disease that occurs in young children)Letterer-Siwe disease (disseminated disease with multisystem involvement that occurs in infants)",
                    "sub_points": [
                      "Solitary eosinophilic granuloma (unifocal disease that occurs in older children or adults)",
                      "Hand-Schüller-Christian disease (multifocal unisystem disease that occurs in young children)",
                      "Letterer-Siwe disease (disseminated disease with multisystem involvement that occurs in infants)"
                    ]
                  },
                  {
                    "text": "Treatment options are based on disease severity and organ system involvement"
                  }
                ],
                "Microscopic Features": [
                  {
                    "text": "Morphological features of Langerhans cellOval-shaped, ~ 10-15 μm in diameterAbundant eosinophilic cytoplasmCoffee bean-shaped, indented, or lobulated nuclei with linear grooves and inconspicuous nucleoli",
                    "sub_points": [
                      "Oval-shaped, ~ 10-15 μm in diameter",
                      "Abundant eosinophilic cytoplasm",
                      "Coffee bean-shaped, indented, or lobulated nuclei with linear grooves and inconspicuous nucleoli"
                    ]
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "CD1a, langerin, S100 protein, CD68 (weakly), and vimentin are positive"
                  },
                  {
                    "text": "Activating mutationBRAFV600E is positive"
                  },
                  {
                    "text": "Cytoplasmic Birbeck granules on electron microscopy"
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "Langerhans cell sarcoma, Rosai-Dorfman disease"
                  }
                ]
              },
              "Terminology": {
                "Abbreviations": [
                  {
                    "text": "Langerhans cell histiocytosis (LCH)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Histiocytosis X"
                  },
                  {
                    "text": "Eosinophilic granuloma"
                  },
                  {
                    "text": "Hand–Schüller–Christian disease"
                  },
                  {
                    "text": "Letterer-Siwe disease"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Clonal proliferation of Langerhans cells with expression of CD1a, langerin (CD207), and S100 protein and recurrent genetic abnormalities"
                  }
                ]
              },
              "Etiology/Pathogenesis": {
                "Etiology": [
                  {
                    "text": "Idiopathic"
                  },
                  {
                    "text": "Clonal X-linked androgen receptor gene assay proves that LCH is a clonal disorder"
                  },
                  {
                    "text": "BRAFV600Emutations (in 57% of patients) supports that LCH is neoplastic"
                  }
                ]
              },
              "Clinical Issues": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "~ 5 per 1 million"
                  }
                ],
                "Age": [
                  {
                    "text": "Most cases occur in children, rarely  in older adults"
                  }
                ],
                "Gender": [
                  {
                    "text": "M:F = 3:1"
                  }
                ],
                "Ethnicity": [
                  {
                    "text": "Most common in whites and rare in blacks"
                  }
                ],
                "Site": [
                  {
                    "text": "Bone and skin are most common sites"
                  },
                  {
                    "text": "Spleen in ~ 13% of cases"
                  },
                  {
                    "text": "Other organs involvedLymph nodeLiverOral mucosaLungCentral nervous system",
                    "sub_points": [
                      "Lymph node",
                      "Liver",
                      "Oral mucosa",
                      "Lung",
                      "Central nervous system"
                    ]
                  }
                ],
                "Presentation": [],
                "3 major overlapping variants": [
                  {
                    "text": "Solitary eosinophilic granuloma(variant of unifocal)Usually a unifocal disease, often involving bone, less commonly seen in lymph node, skin, or lungPatients are usually older children or adultsLytic bone lesions are most common presentation",
                    "sub_points": [
                      "Usually a unifocal disease, often involving bone, less commonly seen in lymph node, skin, or lung",
                      "Patients are usually older children or adults",
                      "Lytic bone lesions are most common presentation"
                    ]
                  },
                  {
                    "text": "Hand-Schüller-Christian disease(variant of multifocal/unisystem)Multifocal diseasePatients are usually young childrenAssociated with triad of exophthalmos, lytic bone lesions (often in skull), and diabetes insipidus (from pituitary stalk infiltration)",
                    "sub_points": [
                      "Multifocal disease",
                      "Patients are usually young children",
                      "Associated with triad of exophthalmos, lytic bone lesions (often in skull), and diabetes insipidus (from pituitary stalk infiltration)"
                    ]
                  },
                  {
                    "text": "Letterer-Siwe disease(variant of multifocal/multisystem)Disseminated disease with multisystem involvement (skin, bone, liver, spleen, and bone marrow)Patients are usually infantsCommon presentation includes fever, hepatosplenomegaly, lymphadenopathy, and cutaneous lesions",
                    "sub_points": [
                      "Disseminated disease with multisystem involvement (skin, bone, liver, spleen, and bone marrow)",
                      "Patients are usually infants",
                      "Common presentation includes fever, hepatosplenomegaly, lymphadenopathy, and cutaneous lesions"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "Possible future treatments designed to inhibit the activity of mutant BRAF protein (V600E)"
                  }
                ],
                "Surgical approaches": [
                  {
                    "text": "Curettage or excision for solitary bone lesions"
                  },
                  {
                    "text": "Splenectomy is usually not performed"
                  }
                ],
                "Drugs": [
                  {
                    "text": "Topical steroids for localized skin disease"
                  },
                  {
                    "text": "Systemic chemotherapy for multisystem involvement"
                  }
                ],
                "Radiation": [
                  {
                    "text": "For inaccessible sites or vital structures"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Poor if multisystem involvement including splenic disease and if younger age at diagnosisSurvival rate: ~ 80%",
                    "sub_points": [
                      "Survival rate: ~ 80%"
                    ]
                  },
                  {
                    "text": "Favorable if isolated bone lesion or skin lesionSurvival rate: ~ 99%",
                    "sub_points": [
                      "Survival rate: ~ 99%"
                    ]
                  }
                ]
              },
              "Image Findings": {
                "Radiographic Findings": [
                  {
                    "text": "Discrete, punched-out, lytic bone lesions"
                  },
                  {
                    "text": "Splenomegaly with ≥ 1 discrete lesion"
                  }
                ]
              },
              "Macroscopic Features": {
                "General Features": [
                  {
                    "text": "Splenomegaly with ≥ 1 nodular lesion"
                  }
                ]
              },
              "Microscopic Pathology": {
                "Histologic Features": [
                  {
                    "text": "Pathologic features vary depending on anatomic site"
                  },
                  {
                    "text": "SpleenAggregates of Langerhans cells, mostly in red pulpSecondary white pulp involvement can occurEosinophils, neutrophils, small lymphocytes, plasma cells, macrophages, and histiocytes are often present",
                    "sub_points": [
                      "Aggregates of Langerhans cells, mostly in red pulp",
                      "Secondary white pulp involvement can occur",
                      "Eosinophils, neutrophils, small lymphocytes, plasma cells, macrophages, and histiocytes are often present"
                    ]
                  },
                  {
                    "text": "Lymph nodeLangerhans cells infiltrate sinus and paracortex",
                    "sub_points": [
                      "Langerhans cells infiltrate sinus and paracortex"
                    ]
                  },
                  {
                    "text": "LiverLangerhans cells infiltrate sinusoidal spaces and intrahepatic biliary systemProgressive intrahepatic sclerosing cholangitis can occur",
                    "sub_points": [
                      "Langerhans cells infiltrate sinusoidal spaces and intrahepatic biliary system",
                      "Progressive intrahepatic sclerosing cholangitis can occur"
                    ]
                  },
                  {
                    "text": "LungsInterstitial infiltrate of Langerhans cells with abundant eosinophils, often subpleural in location",
                    "sub_points": [
                      "Interstitial infiltrate of Langerhans cells with abundant eosinophils, often subpleural in location"
                    ]
                  },
                  {
                    "text": "SkinLangerhans cells infiltrate dermis and subcutis tissue and extend throughout epidermis",
                    "sub_points": [
                      "Langerhans cells infiltrate dermis and subcutis tissue and extend throughout epidermis"
                    ]
                  }
                ],
                "Cytologic Features": [
                  {
                    "text": "Oval cells, ~ 10-15 μm in diameter"
                  },
                  {
                    "text": "Coffee bean-shaped, indented, or lobulated nuclei with linear grooves and inconspicuous nucleoli"
                  },
                  {
                    "text": "Abundant eosinophilic cytoplasm"
                  }
                ]
              },
              "Ancillary Tests": {
                "Immunohistochemistry": [
                  {
                    "text": "CD1a and langerin are specific for Langerhans cells"
                  },
                  {
                    "text": "S100 protein is positive but not specificBoth cytoplasmic and nuclear staining in Langerhans cells",
                    "sub_points": [
                      "Both cytoplasmic and nuclear staining in Langerhans cells"
                    ]
                  },
                  {
                    "text": "Also positive for vimentin, CD4, and CD68 (weak)"
                  },
                  {
                    "text": "Negative immunostains include CD1c, B-cell markers, T-cell markers, CD30, and CD23"
                  }
                ],
                "Molecular Genetics": [
                  {
                    "text": "BRAFV600E activating mutation"
                  }
                ],
                "Electron Microscopy": [
                  {
                    "text": "Birbeck granulesPentilaminar cytoplasmic bodies with terminal oval protrusion (tennis racket-shaped)",
                    "sub_points": [
                      "Pentilaminar cytoplasmic bodies with terminal oval protrusion (tennis racket-shaped)"
                    ]
                  }
                ]
              },
              "Differential Diagnosis": {
                "Langerhans Cell Sarcoma": [
                  {
                    "text": "High-grade neoplasm of Langerhans cell with overtly malignant cytologic features"
                  },
                  {
                    "text": "Multiorgan involvement and aggressive clinical course"
                  },
                  {
                    "text": "High mitotic activity and fewer eosinophils than LCH"
                  },
                  {
                    "text": "Adults with median age of 39 years"
                  },
                  {
                    "text": "Same phenotype as LCHPositive for CD1a, langerin, and S100",
                    "sub_points": [
                      "Positive for CD1a, langerin, and S100"
                    ]
                  },
                  {
                    "text": "Ultrastructural Birbeck granules confirm diagnosis"
                  },
                  {
                    "text": "Skin and soft tissue are most commonly involved"
                  }
                ],
                "Rosai-Dorfman Disease": [
                  {
                    "text": "Proliferation of non-Langerhans cell histiocytes, a.k.a. sinus histiocytosis with massive lymphadenopathy"
                  },
                  {
                    "text": "Patients are often 10-20 years old"
                  },
                  {
                    "text": "Commonly presents with enlargement of lymph nodes in neck"
                  },
                  {
                    "text": "Spleen is usually not involved"
                  },
                  {
                    "text": "Emperipolesis is the hallmark lesion"
                  },
                  {
                    "text": "Typically intact lymphocytes are seen in histiocyte cytoplasm"
                  },
                  {
                    "text": "Positive for S100 protein"
                  },
                  {
                    "text": "Negative for CD1a and langerin"
                  }
                ],
                "Familial Hemophagocytic Lymphohistiocytosis": [
                  {
                    "text": "Overproduction of activated lymphocytes (B and T cells), natural killer cells, and histiocytes with systemic manifestations, fulminant clinical course, and high mortality rate"
                  },
                  {
                    "text": "Splenic red pulp with phagocytic histiocytes, which can contain red cells (erythrophagocytosis), white blood cells, or plateletsPositive for CD68Negative for CD1a, langerin, and S100 protein",
                    "sub_points": [
                      "Positive for CD68",
                      "Negative for CD1a, langerin, and S100 protein"
                    ]
                  },
                  {
                    "text": "~ 40-60% have mutations inPRF1orUNC13Dgenes"
                  },
                  {
                    "text": "Occurs in ~ 1 per 50,000 individuals worldwide"
                  },
                  {
                    "text": "Infants from birth to 18 months of age"
                  }
                ],
                "Histiocytic Sarcoma": [
                  {
                    "text": "Malignant histiocytic neoplasm"
                  },
                  {
                    "text": "Morphology ranges from benign appearing to overtly malignant"
                  },
                  {
                    "text": "Positive for CD68, CD163, lysozyme, and S100 (variable)"
                  },
                  {
                    "text": "Negative for CD20, CD3, langerin, and CD1a"
                  }
                ],
                "Interdigitating Dendritic Cell Sarcoma": [
                  {
                    "text": "Rare neoplasm with splenic red pulp involvement"
                  },
                  {
                    "text": "Large neoplastic cells forming fascicles or storiform pattern"
                  },
                  {
                    "text": "Positive for S100, vimentin, CD68 (weak), lysozyme, and CD45"
                  },
                  {
                    "text": "Negative for CD1a and langerin"
                  }
                ],
                "Lymphoma/Leukemia": [
                  {
                    "text": "Often has more cytologic atypia than LCH"
                  },
                  {
                    "text": "Different immunophenotype than LCHPositive for hematopoietic markers (i.e., CD45, CD20, CD3)Usually negative for CD1a, langerin, and S100",
                    "sub_points": [
                      "Positive for hematopoietic markers (i.e., CD45, CD20, CD3)",
                      "Usually negative for CD1a, langerin, and S100"
                    ]
                  },
                  {
                    "text": "Look for molecular findings not seen in LCHSuch as t(14;18) in follicular lymphoma",
                    "sub_points": [
                      "Such as t(14;18) in follicular lymphoma"
                    ]
                  }
                ],
                "Chronic Granulomatous Disease": [
                  {
                    "text": "Splenomegaly and granulomas with necrotic abscess and bacterial and fungal infection"
                  },
                  {
                    "text": "Enzymatic defect of granulocytes and monocytesPresent in 1 of 4 components of nicotinamide adenine dinucleotide phosphate",
                    "sub_points": [
                      "Present in 1 of 4 components of nicotinamide adenine dinucleotide phosphate"
                    ]
                  },
                  {
                    "text": "Negative for CD1a, langerin, and S100"
                  }
                ],
                "Noninfectious Granulomas": [
                  {
                    "text": "Examples include sarcoid and epithelioid histiocytes in hematopoietic disorders"
                  },
                  {
                    "text": "May lead to splenomegaly"
                  },
                  {
                    "text": "Negative for CD1a, langerin, and S100"
                  }
                ],
                "Gaucher Disease": [
                  {
                    "text": "Autosomal recessive inherited lipid storage disease, caused by deficiency of glucocerebrosidase"
                  },
                  {
                    "text": "Clusters of Gaucher cells can look similar to Langerhans cells"
                  },
                  {
                    "text": "Gaucher cells have small nuclei and wrinkled silk- or granular-looking cytoplasm"
                  },
                  {
                    "text": "Gaucher cells are result of deposition of glucocerebroside in cells of macrophage-monocyte system"
                  },
                  {
                    "text": "PhenotypePAS positiveNegative for CD1a, langerin, and S100",
                    "sub_points": [
                      "PAS positive",
                      "Negative for CD1a, langerin, and S100"
                    ]
                  },
                  {
                    "text": "Negative forBRAFV600E activating mutation"
                  }
                ]
              },
              "Diagnostic Checklist": {
                "Clinically Relevant Pathologic Features": [
                  {
                    "text": "Combination of lytic bone lesions and skin lesions points to LCH"
                  }
                ],
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "Langerhans cells have coffee bean-shaped nuclei and linear grooves"
                  },
                  {
                    "text": "Phenotype: Positive for CD1a, langerin, and S100"
                  },
                  {
                    "text": "Birbeck granules have tennis racket shape on electron microscopy"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma": {
            "name": "Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma",
            "url": "https://app.pathprimer.com/document/f1f811e0-cdd6-4722-a1b5-466dbab22abd/lesson/4659bf0d-8055-4c33-9e2a-78e6f233a411",
            "content": {
              "Key Facts": {
                "Terminology": [
                  {
                    "text": "CLL/SLL: Neoplasm of small B lymphocytesTypically involves peripheral blood (PB), bone marrow (BM), lymph nodes, and spleen",
                    "sub_points": [
                      "Typically involves peripheral blood (PB), bone marrow (BM), lymph nodes, and spleen"
                    ]
                  },
                  {
                    "text": "CLL: Disease involving PB or BM (leukemic)"
                  },
                  {
                    "text": "SLL: Disease restricted to lymph nodes or other tissue sites (nonleukemic)"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "CLL is most common leukemia in Western hemisphere"
                  },
                  {
                    "text": "Splenic involvement by CLL/SLL is typically detected by radiologic imaging"
                  },
                  {
                    "text": "At time of CLL/SLL diagnosis, splenic involvement is often asymptomatic"
                  },
                  {
                    "text": "Splenectomy can be performed to alleviate symptoms or refractory cytopenias"
                  }
                ],
                "Microscopic Features": [
                  {
                    "text": "White pulp-predominant infiltrate forming uniform nodules"
                  },
                  {
                    "text": "Red pulp involvement as small aggregates or diffuse in cords and sinuses"
                  },
                  {
                    "text": "Lymphocytes are round to slightly irregular with clumped chromatin and scant cytoplasm"
                  },
                  {
                    "text": "Proliferation centers (pseudofollicles) can be observed"
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "Surface Ig (dim +), CD19(+), CD20 (dim +)"
                  },
                  {
                    "text": "CD5(+), CD23(+), Ki-67 (low), CD22 (dim/-)"
                  },
                  {
                    "text": "UnmutatedIGHvariable region genes predict poorer prognosisZAP70 or CD38 expression correlates with unmutatedIGHvariable region genes",
                    "sub_points": [
                      "ZAP70 or CD38 expression correlates with unmutatedIGHvariable region genes"
                    ]
                  }
                ]
              },
              "Terminology": {
                "Abbreviations": [
                  {
                    "text": "Chronic lymphocytic leukemia (CLL)"
                  },
                  {
                    "text": "Small lymphocytic lymphoma (SLL)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "CLL and SLL are used as synonyms, but these terms convey slightly different meaningsCLL is used for disease involving peripheral blood or bone marrow (leukemic)SLL is used for disease restricted to lymph nodes or other extramedullary sites (nonleukemic)",
                    "sub_points": [
                      "CLL is used for disease involving peripheral blood or bone marrow (leukemic)",
                      "SLL is used for disease restricted to lymph nodes or other extramedullary sites (nonleukemic)"
                    ]
                  }
                ],
                "Definitions": [
                  {
                    "text": "CLL/SLL is a neoplasm of small B lymphocytes that usually involves blood, bone marrow, lymph nodes, and spleen"
                  },
                  {
                    "text": "CLL/SLL cells have characteristic immunophenotypeSurface Ig (dim +), pan B cell (+), CD5(+), CD23(+)",
                    "sub_points": [
                      "Surface Ig (dim +), pan B cell (+), CD5(+), CD23(+)"
                    ]
                  }
                ]
              },
              "Clinical Issues": {
                "Epidemiology": [
                  {
                    "text": "PathogenesisGenetic, not environmental, factors play roleGenetic polymorphisms have been identifiedCLL/SLL shows genetic and familial predisposition~ 5-10% of casesMonoclonal B-cell lymphocytosis can precede CLL/SLLEarly involvement by CLL/SLL vs. distinct precursor lesion",
                    "sub_points": [
                      "Genetic, not environmental, factors play roleGenetic polymorphisms have been identified",
                      "Genetic polymorphisms have been identified",
                      "CLL/SLL shows genetic and familial predisposition~ 5-10% of cases",
                      "~ 5-10% of cases",
                      "Monoclonal B-cell lymphocytosis can precede CLL/SLLEarly involvement by CLL/SLL vs. distinct precursor lesion",
                      "Early involvement by CLL/SLL vs. distinct precursor lesion"
                    ]
                  }
                ],
                "Incidence": [
                  {
                    "text": "CLL is the most common type of leukemia in Western hemisphereUncommon or rare in Eastern hemisphere and Africa",
                    "sub_points": [
                      "Uncommon or rare in Eastern hemisphere and Africa"
                    ]
                  }
                ],
                "Age": [
                  {
                    "text": "Range: 30-82 years (median: 65 years)"
                  }
                ],
                "Gender": [
                  {
                    "text": "M:F = 1.5:1"
                  }
                ],
                "Site": [
                  {
                    "text": "Splenomegaly is detected by physical examination in 30-50% of patientsBiopsy of spleen is rare",
                    "sub_points": [
                      "Biopsy of spleen is rare"
                    ]
                  },
                  {
                    "text": "Diagnosis of CLL/SLL is usually established by examination of blood and bone marrowCommonly (~ 30%) detected incidentally as leukocytosisLymph node biopsy is performed in nonleukemic cases",
                    "sub_points": [
                      "Commonly (~ 30%) detected incidentally as leukocytosis",
                      "Lymph node biopsy is performed in nonleukemic cases"
                    ]
                  }
                ],
                "Presentation": [
                  {
                    "text": "At time of CLL/SLL diagnosis, splenic involvement is often asymptomatic"
                  },
                  {
                    "text": "30% of patients present with autoimmune manifestationsHemolytic anemia, red cell aplasia, agranulocytosis, or thrombocytopenia",
                    "sub_points": [
                      "Hemolytic anemia, red cell aplasia, agranulocytosis, or thrombocytopenia"
                    ]
                  },
                  {
                    "text": "Subset of patients present with immunodeficiency"
                  }
                ],
                "Laboratory Tests": [
                  {
                    "text": "Persistent peripheral blood monotypic B-cell lymphocytosis ≥ 5 x 10⁹/LIf  < 5 x 10⁹/L lymphocytosis, it is usually designated as monoclonal B-cell lymphocytosis but can be CLL if cytopenia(s), disease-related symptoms, or tissue (lymph node) involvement is/are present",
                    "sub_points": [
                      "If  < 5 x 10⁹/L lymphocytosis, it is usually designated as monoclonal B-cell lymphocytosis but can be CLL if cytopenia(s), disease-related symptoms, or tissue (lymph node) involvement is/are present"
                    ]
                  }
                ],
                "Natural History": [
                  {
                    "text": "Most patients have indolent clinical course~ 33% of patients progress to more aggressive disease",
                    "sub_points": [
                      "~ 33% of patients progress to more aggressive disease"
                    ]
                  },
                  {
                    "text": "In general, patients with splenomegaly &/or cytopenias have high-stage disease and shorter survival span"
                  },
                  {
                    "text": "Subset of patients develop higher grade, clinically aggressive disease (Richter syndrome)Diffuse large B-cell lymphoma (DLBCL) is most commonOften discrete mass with necrosisClassic Hodgkin lymphomaUsually, Epstein-Barr virus (EBV)(+)",
                    "sub_points": [
                      "Diffuse large B-cell lymphoma (DLBCL) is most commonOften discrete mass with necrosis",
                      "Often discrete mass with necrosis",
                      "Classic Hodgkin lymphomaUsually, Epstein-Barr virus (EBV)(+)",
                      "Usually, Epstein-Barr virus (EBV)(+)"
                    ]
                  },
                  {
                    "text": "Subset of patients develop prolymphocytoid transformation of CLLClosely related to, or variant of, Richter syndromeIncreased (often > 55%) prolymphocytes in peripheral bloodExtensive involvement of bone marrow and usually marked splenomegaly",
                    "sub_points": [
                      "Closely related to, or variant of, Richter syndrome",
                      "Increased (often > 55%) prolymphocytes in peripheral blood",
                      "Extensive involvement of bone marrow and usually marked splenomegaly"
                    ]
                  },
                  {
                    "text": "Herpes simplex virus (HSV) infection/reactivation is common in CLL/SLL patientsCan clinically or histologically mimic transformation to large cell lymphomaCommonly found incidentally",
                    "sub_points": [
                      "Can clinically or histologically mimic transformation to large cell lymphoma",
                      "Commonly found incidentally"
                    ]
                  }
                ],
                "Treatment": [],
                "Options, risks, complications": [
                  {
                    "text": "Watch and wait with low-stage, asymptomatic disease"
                  }
                ],
                "Surgical approaches": [
                  {
                    "text": "Splenectomy is usually performed for refractory cytopeniasLeads to significant hematologic benefits in most patients",
                    "sub_points": [
                      "Leads to significant hematologic benefits in most patients"
                    ]
                  }
                ],
                "Adjuvant therapy": [
                  {
                    "text": "No uniform scheme; variable with stage of disease and manifestations"
                  },
                  {
                    "text": "Fludarabine, cyclophosphamide, and rituximab (FCR regimen) are recommendedRecommended for patients who require chemotherapyImprove overall survival and progression-free survivalFludarabine is immunosuppressive, and patients are predisposed to infections",
                    "sub_points": [
                      "Recommended for patients who require chemotherapy",
                      "Improve overall survival and progression-free survival",
                      "Fludarabine is immunosuppressive, and patients are predisposed to infections"
                    ]
                  },
                  {
                    "text": "Many other chemotherapy regimens can be used for CLL/SLL patientsInhibitors of B-cell receptor pathway for refractory disease",
                    "sub_points": [
                      "Inhibitors of B-cell receptor pathway for refractory disease"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Rai and Binet clinical staging systems are used to assess prognosis"
                  },
                  {
                    "text": "5-year overall survival rate: 50%"
                  },
                  {
                    "text": "Great interest in biologic markers to assess prognosisMarkers associated with poor prognosisUnmutatedIGHvariable region genesCD38 or ZAP70 expressionChromosomal abnormalities: del(11q22-23), del(17p)/TP53, del(6q)Markers associated with better prognosisdel(13q14.3)",
                    "sub_points": [
                      "Markers associated with poor prognosisUnmutatedIGHvariable region genesCD38 or ZAP70 expressionChromosomal abnormalities: del(11q22-23), del(17p)/TP53, del(6q)",
                      "UnmutatedIGHvariable region genes",
                      "CD38 or ZAP70 expression",
                      "Chromosomal abnormalities: del(11q22-23), del(17p)/TP53, del(6q)",
                      "Markers associated with better prognosisdel(13q14.3)",
                      "del(13q14.3)"
                    ]
                  }
                ]
              },
              "Image Findings": {
                "Radiographic Findings": [
                  {
                    "text": "Various modalities show splenomegaly"
                  },
                  {
                    "text": "FDG PET scan is usually negative"
                  }
                ]
              },
              "Macroscopic Features": {
                "General Features": [
                  {
                    "text": "Median weight: 1,400 g (range: 200-7,100 g)"
                  },
                  {
                    "text": "Cut surface shows diffuse/miliary growth patternDiscrete tumor mass can less often occur, especially in cases of large cell transformation",
                    "sub_points": [
                      "Discrete tumor mass can less often occur, especially in cases of large cell transformation"
                    ]
                  }
                ]
              },
              "Microscopic Pathology": {
                "Histologic Features": [
                  {
                    "text": "CLL/SLL preferentially involves white pulpWhite pulp nodules are expandedWhite pulp is often not well defined compared with follicular lymphomaInvolvement rarely can mimic marginal zone pattern",
                    "sub_points": [
                      "White pulp nodules are expanded",
                      "White pulp is often not well defined compared with follicular lymphoma",
                      "Involvement rarely can mimic marginal zone pattern"
                    ]
                  },
                  {
                    "text": "Red pulp is always involved as small aggregates or diffuse replacement of cords and sinuses"
                  },
                  {
                    "text": "Proliferation centers (pseudofollicles) can be observed in spleenPresence correlates with more extensive involvement",
                    "sub_points": [
                      "Presence correlates with more extensive involvement"
                    ]
                  },
                  {
                    "text": "CLL/SLL can surround reactive germinal centers without mantle zonesSo-called naked germinal centers",
                    "sub_points": [
                      "So-called naked germinal centers"
                    ]
                  },
                  {
                    "text": "Splenic hilar lymph nodesOften involved by CLL/SLLPartial or total architectural replacementPatent sinuses in cases with partial involvementProliferation centers (+/-)",
                    "sub_points": [
                      "Often involved by CLL/SLLPartial or total architectural replacementPatent sinuses in cases with partial involvementProliferation centers (+/-)",
                      "Partial or total architectural replacement",
                      "Patent sinuses in cases with partial involvement",
                      "Proliferation centers (+/-)"
                    ]
                  },
                  {
                    "text": "Bone marrow is commonly involved3 patterns: Diffuse, interstitial, and nodularNodular pattern is uncommon if spleen is extensively involved",
                    "sub_points": [
                      "3 patterns: Diffuse, interstitial, and nodular",
                      "Nodular pattern is uncommon if spleen is extensively involved"
                    ]
                  },
                  {
                    "text": "Richter syndrome occurs in 2-8% of CLL patientsHistologically, most cases are similar to diffuse large B-cell lymphomaSheets of large B cells can replace both white and red pulpMitotic figures are increased; necrosis is commonHigh proliferation rate (Ki-67 or MIB1 proliferation-associated markers)~ 50-60% of DLBCL are clonally related to underlying CLL/SLLClassic Hodgkin lymphoma is uncommon (~1%)Reed-Sternberg and Hodgkin cellsBackground inflammatory cellsNecrosis is common; usually EBV(+)Much less common than DLBCLOther rare histologic forms occur in Richter syndromeB-cell lymphoblastic lymphoma/leukemiaBurkitt lymphomaT-cell lymphomas",
                    "sub_points": [
                      "Histologically, most cases are similar to diffuse large B-cell lymphomaSheets of large B cells can replace both white and red pulpMitotic figures are increased; necrosis is commonHigh proliferation rate (Ki-67 or MIB1 proliferation-associated markers)~ 50-60% of DLBCL are clonally related to underlying CLL/SLL",
                      "Sheets of large B cells can replace both white and red pulp",
                      "Mitotic figures are increased; necrosis is common",
                      "High proliferation rate (Ki-67 or MIB1 proliferation-associated markers)",
                      "~ 50-60% of DLBCL are clonally related to underlying CLL/SLL",
                      "Classic Hodgkin lymphoma is uncommon (~1%)Reed-Sternberg and Hodgkin cellsBackground inflammatory cellsNecrosis is common; usually EBV(+)Much less common than DLBCL",
                      "Reed-Sternberg and Hodgkin cells",
                      "Background inflammatory cells",
                      "Necrosis is common; usually EBV(+)",
                      "Much less common than DLBCL",
                      "Other rare histologic forms occur in Richter syndromeB-cell lymphoblastic lymphoma/leukemiaBurkitt lymphomaT-cell lymphomas",
                      "B-cell lymphoblastic lymphoma/leukemia",
                      "Burkitt lymphoma",
                      "T-cell lymphomas"
                    ]
                  }
                ],
                "Cytologic Features": [
                  {
                    "text": "Tumor cells are predominantly small with round nuclear contours, clumped chromatin, and scant cytoplasmScattered prolymphocytes or paraimmunoblasts are present among smaller round lymphocytesLarger lymphocytes with moderately abundant cytoplasm and nucleus with single nucleolusIn some cases, CLL/SLL cells can show plasmacytoid differentiationCan be associated with serum paraprotein; usually low level",
                    "sub_points": [
                      "Scattered prolymphocytes or paraimmunoblasts are present among smaller round lymphocytesLarger lymphocytes with moderately abundant cytoplasm and nucleus with single nucleolus",
                      "Larger lymphocytes with moderately abundant cytoplasm and nucleus with single nucleolus",
                      "In some cases, CLL/SLL cells can show plasmacytoid differentiationCan be associated with serum paraprotein; usually low level",
                      "Can be associated with serum paraprotein; usually low level"
                    ]
                  },
                  {
                    "text": "Subset of CLL/SLL cases show atypical cytologic featuresMore irregular nuclear contours or increased large cell populationAssociation with trisomy 12",
                    "sub_points": [
                      "More irregular nuclear contours or increased large cell population",
                      "Association with trisomy 12"
                    ]
                  }
                ]
              },
              "Ancillary Tests": {
                "Immunohistochemistry": [
                  {
                    "text": "CD19(+), CD20(+), CD79-a(+), pax-5(+)"
                  },
                  {
                    "text": "CD5(+), CD23(+), Bcl-2(+), Tbet(+)"
                  },
                  {
                    "text": "Usually low proliferation rate: < 10% (Ki-67)"
                  },
                  {
                    "text": "CD10(-), Bcl-6(-), cyclin-D1(-)"
                  },
                  {
                    "text": "ZAP70 or CD38 expressionSurrogate for unmutatedIGHvariable region genesDiscordance between ZAP70 or CD38 and molecular analysis in ~ 20% of casesCan be assessed by immunohistochemistry or flow cytometry",
                    "sub_points": [
                      "Surrogate for unmutatedIGHvariable region genes",
                      "Discordance between ZAP70 or CD38 and molecular analysis in ~ 20% of cases",
                      "Can be assessed by immunohistochemistry or flow cytometry"
                    ]
                  }
                ],
                "Flow Cytometry": [
                  {
                    "text": "Surface Ig (dim +), CD19(+), CD20 (dim +)"
                  },
                  {
                    "text": "IgM(+), IgD(+)"
                  },
                  {
                    "text": "CD5(+), CD23(+), CD43(+), CD200(+)~ 5% of CLL/SLL cases are CD23(-)",
                    "sub_points": [
                      "~ 5% of CLL/SLL cases are CD23(-)"
                    ]
                  },
                  {
                    "text": "CD3(-), CD10(-), CD22 (dim/-), CD79-b(-), FMC7 (dim/-)"
                  },
                  {
                    "text": "Atypical immunophenotypes occur in ~ 10-20% of CLL/SLLBright surface Ig(+), CD20(+), CD22(+), CD79-b(+), or FMC7(+)",
                    "sub_points": [
                      "Bright surface Ig(+), CD20(+), CD22(+), CD79-b(+), or FMC7(+)"
                    ]
                  }
                ],
                "Cytogenetics": [
                  {
                    "text": "Usually performed on blood or bone marrow specimens"
                  },
                  {
                    "text": "Abnormal karyotypes in ~ 25% of casesCLL/SLL cells grow poorly in culture",
                    "sub_points": [
                      "CLL/SLL cells grow poorly in culture"
                    ]
                  },
                  {
                    "text": "Trisomy 12 occurs in ~ 20% of CLL/SLL cases with abnormal karyotypeCorrelates with atypical morphologic or immunophenotypic features",
                    "sub_points": [
                      "Correlates with atypical morphologic or immunophenotypic features"
                    ]
                  },
                  {
                    "text": "< 5% of CLL/SLL cases have chromosomal translocations"
                  }
                ],
                "In Situ Hybridization": [
                  {
                    "text": "FISH can detect cytogenetic abnormalities in ~ 80% of cases"
                  },
                  {
                    "text": "Panel has been designed to detect most common abnormalitiesProbes for 13q14, 11q22, +12, 17p13, and 6q21Target genesdel(13q14.3): Possibly micro-RNA genesmiR-16andmiR-15adel(11q22): Ataxia-telangiectasia mutated (ATM)Trisomy 12: Unknowndel(17p13):TP53del(6q21): Unknown",
                    "sub_points": [
                      "Probes for 13q14, 11q22, +12, 17p13, and 6q21",
                      "Target genesdel(13q14.3): Possibly micro-RNA genesmiR-16andmiR-15adel(11q22): Ataxia-telangiectasia mutated (ATM)Trisomy 12: Unknowndel(17p13):TP53del(6q21): Unknown",
                      "del(13q14.3): Possibly micro-RNA genesmiR-16andmiR-15a",
                      "del(11q22): Ataxia-telangiectasia mutated (ATM)",
                      "Trisomy 12: Unknown",
                      "del(17p13):TP53",
                      "del(6q21): Unknown"
                    ]
                  },
                  {
                    "text": "Small subset (< 5%) of CLL/SLL cases have chromosomal translocationsIGH-BCL3/t(14;19)(q32;q13)IGH-BCL2/t(14;18)(q32;q21)IGH-BCL11A/t(2;14) (p16;q32)",
                    "sub_points": [
                      "IGH-BCL3/t(14;19)(q32;q13)",
                      "IGH-BCL2/t(14;18)(q32;q21)",
                      "IGH-BCL11A/t(2;14) (p16;q32)"
                    ]
                  }
                ],
                "Molecular Genetics": [
                  {
                    "text": "MonoclonalIGHgene rearrangements"
                  },
                  {
                    "text": "No evidence of monoclonal T-cell receptor gene rearrangements"
                  },
                  {
                    "text": "Somatic hypermutation ofIGHvariable region genes in ~ 50% of casesCorrelates with better prognosis; CD38(-), ZAP70(-)Consistent with antigen experienced lymphocytes",
                    "sub_points": [
                      "Correlates with better prognosis; CD38(-), ZAP70(-)",
                      "Consistent with antigen experienced lymphocytes"
                    ]
                  },
                  {
                    "text": "MicroRNA mutations"
                  }
                ],
                "Gene Expression Profiling": [
                  {
                    "text": "Signature of CLL/SLL is distinct from other low-grade B-cell lymphomas that involve spleen"
                  }
                ]
              },
              "Differential Diagnosis": {
                "Mantle Cell Lymphoma": [
                  {
                    "text": "Splenomegaly (common)Manifestation of systemic disease",
                    "sub_points": [
                      "Manifestation of systemic disease"
                    ]
                  },
                  {
                    "text": "Few patients present with marked splenomegaly and minimal lymphadenopathySo-called splenomegalic form of mantle cell lymphoma",
                    "sub_points": [
                      "So-called splenomegalic form of mantle cell lymphoma"
                    ]
                  },
                  {
                    "text": "In rare cases, transforms to high-grade neoplasm that resembles B-cell prolymphocytic leukemiaNumerous prolymphocytes in blood and bone marrowVery prominent splenomegaly",
                    "sub_points": [
                      "Numerous prolymphocytes in blood and bone marrow",
                      "Very prominent splenomegaly"
                    ]
                  },
                  {
                    "text": "Histologic features of spleenEnlarged white pulp nodules that frequently are coalescentMonotonous lymphocytes of intermediate size with irregular nuclear contoursNeoplastic cells may expand around residual germinal centers of white pulp",
                    "sub_points": [
                      "Enlarged white pulp nodules that frequently are coalescent",
                      "Monotonous lymphocytes of intermediate size with irregular nuclear contours",
                      "Neoplastic cells may expand around residual germinal centers of white pulp"
                    ]
                  },
                  {
                    "text": "Immunophenotype differs from that of CLL/SLLSurface Ig (moderate +), CD19(+), and CD20 (moderate +)CD5(+), CD23(- ), CD200(-)CD79-b(+), FMC7(+), cyclin-D1(+)",
                    "sub_points": [
                      "Surface Ig (moderate +), CD19(+), and CD20 (moderate +)",
                      "CD5(+), CD23(- ), CD200(-)",
                      "CD79-b(+), FMC7(+), cyclin-D1(+)"
                    ]
                  },
                  {
                    "text": "CCND1-IGH/t(11;14)(q13;q32) by FISH, RT-PCR, or cytogenetics"
                  }
                ],
                "Splenic Marginal Zone Lymphoma": [
                  {
                    "text": "Biphasic pattern at low-power magnification"
                  },
                  {
                    "text": "Center of nodules shows round to oval, uniform lymphocytes"
                  },
                  {
                    "text": "Marginal zone shows mixture of small and large lymphocytes, some with prominent nucleoli"
                  },
                  {
                    "text": "May present with plasmacytic differentiation and paraproteinemia"
                  },
                  {
                    "text": "Peripheral blood lymphocytes may show unipolar cytoplasmic projectionsCorresponds to entity designated \"splenic lymphoma with villous lymphocytes\"",
                    "sub_points": [
                      "Corresponds to entity designated \"splenic lymphoma with villous lymphocytes\""
                    ]
                  },
                  {
                    "text": "Bone marrow infiltrate with residual dendritic cell meshworks and occasional sinusoidal pattern"
                  },
                  {
                    "text": "ImmunophenotypeDBA.44(+), CD5(-/+), CD23(-/+)",
                    "sub_points": [
                      "DBA.44(+), CD5(-/+), CD23(-/+)"
                    ]
                  }
                ],
                "Lymphoplasmacytic Lymphoma": [
                  {
                    "text": "Involves white pulp and red pulp of spleenTumor cells show plasmacytic differentiation",
                    "sub_points": [
                      "Tumor cells show plasmacytic differentiation"
                    ]
                  },
                  {
                    "text": "Serum paraprotein is commonly present; peak usually > 3 g/dLIgM in patients with Waldenström macroglobulinemia",
                    "sub_points": [
                      "IgM in patients with Waldenström macroglobulinemia"
                    ]
                  },
                  {
                    "text": "Immunophenotype differs from that of CLL/SLLUsually CD5(-), CD43(-/+), cytoplasmic Ig(+)",
                    "sub_points": [
                      "Usually CD5(-), CD43(-/+), cytoplasmic Ig(+)"
                    ]
                  }
                ],
                "B-Cell Prolymphocytic Leukemia": [
                  {
                    "text": "Excludes CLL in prolymphocytoid transformation~ 50% of cases once classified as B-cell prolymphocytic leukemia are prolymphocytoid transformation of CLLOther subsets are derived from mantle cell lymphoma and splenic marginal zone lymphoma",
                    "sub_points": [
                      "~ 50% of cases once classified as B-cell prolymphocytic leukemia are prolymphocytoid transformation of CLL",
                      "Other subsets are derived from mantle cell lymphoma and splenic marginal zone lymphoma"
                    ]
                  },
                  {
                    "text": "Patients present with massive splenomegaly and marked lymphocytosis"
                  },
                  {
                    "text": "Red pulp expansion with indistinct white pulp involvement"
                  },
                  {
                    "text": "Peripheral blood shows that > 55% of lymphocytes are of intermediate sizeLymphocytes show central nucleoli and perinuclear accentuation",
                    "sub_points": [
                      "Lymphocytes show central nucleoli and perinuclear accentuation"
                    ]
                  }
                ],
                "Hairy Cell Leukemia": [
                  {
                    "text": "Peripheral blood usually shows pancytopenia and low monocyte count"
                  },
                  {
                    "text": "Predominantly red pulp infiltration with white pulp atrophy"
                  },
                  {
                    "text": "Blood lakes in red pulp (+/-)"
                  },
                  {
                    "text": "Monotonous population of small to intermediate-size lymphoid cells with central nuclei without nucleoliVillous cytoplasmic projections (\"hairs\") are not seen in sections of spleen",
                    "sub_points": [
                      "Villous cytoplasmic projections (\"hairs\") are not seen in sections of spleen"
                    ]
                  },
                  {
                    "text": "Immunophenotype: CD11c(+), CD25(+), CD103(+), annexin-A1(+)"
                  }
                ],
                "Hairy Cell Leukemia Variant": [
                  {
                    "text": "Predominantly red pulp infiltration with white pulp atrophy"
                  },
                  {
                    "text": "Splenic histology similar to that of hairy cell leukemia"
                  },
                  {
                    "text": "Peripheral blood lymphocytosis and normal monocyte countLymphocytes may have distinct nucleoli and moderately abundant cytoplasm",
                    "sub_points": [
                      "Lymphocytes may have distinct nucleoli and moderately abundant cytoplasm"
                    ]
                  },
                  {
                    "text": "Immunophenotype: CD11c(+), CD25(-), CD103(+/-)"
                  }
                ]
              },
              "Diagnostic Checklist": {
                "Clinically Relevant Pathologic Features": [
                  {
                    "text": "Patients with spleen involved by CLL/SLL usually have systemic diseaseBlood, bone marrow, lymph nodes, and liver",
                    "sub_points": [
                      "Blood, bone marrow, lymph nodes, and liver"
                    ]
                  },
                  {
                    "text": "Splenectomy is usually performed to relieve local symptoms or cytopenias"
                  }
                ],
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "Touch imprints of spleen are helpful for assessing cytologic features"
                  },
                  {
                    "text": "CLL/SLL expands white pulp, forming uniform nodules"
                  },
                  {
                    "text": "Immunophenotype of CLL/SLL is characteristicSurface Ig (dim), IgM(+), IgD(+), CD19(+), and CD20 (dim)CD5(+), CD23(+), and CD22 (dim/-)",
                    "sub_points": [
                      "Surface Ig (dim), IgM(+), IgD(+), CD19(+), and CD20 (dim)",
                      "CD5(+), CD23(+), and CD22 (dim/-)"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Hairy Cell Leukemia": {
            "name": "Hairy Cell Leukemia",
            "url": "https://app.pathprimer.com/document/36d56825-e1a2-4378-ba22-0c96e4db7446/lesson/4659bf0d-8055-4c33-9e2a-78e6f233a411",
            "content": {
              "Key Facts": {
                "Terminology": [
                  {
                    "text": "Mature B-cell leukemia of lymphocytes with cytoplasmic projections"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Weakness, fatigue, and left abdominal pain"
                  },
                  {
                    "text": "Pancytopenia with monocytopenia"
                  },
                  {
                    "text": "Now often detected at early stageLess monocytopeniaLess massive splenomegaly",
                    "sub_points": [
                      "Less monocytopenia",
                      "Less massive splenomegaly"
                    ]
                  },
                  {
                    "text": "Excellent prognosis with cladribine treatment"
                  },
                  {
                    "text": "Homogeneous beefy-red cut surface"
                  }
                ],
                "Microscopic Features": [
                  {
                    "text": "Blood with scattered hairy cells that have cytoplasmic projections"
                  },
                  {
                    "text": "Spleen shows primarily red pulp involvement with atrophic or effaced white pulp"
                  },
                  {
                    "text": "Bone marrow shows malignant B cells with \"fried egg\" appearance or spindling and reticulin fibrosis"
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "Characteristic immunophenotype by flow cytometryBright surface Ig(+), pan B(+), CD11c(+), CD22(+)CD25(+), CD103(+), CD123(+)CD5(-), CD10(-)",
                    "sub_points": [
                      "Bright surface Ig(+), pan B(+), CD11c(+), CD22(+)",
                      "CD25(+), CD103(+), CD123(+)",
                      "CD5(-), CD10(-)"
                    ]
                  },
                  {
                    "text": "ImmunohistochemistryDBA.44 (CD76)(+), annexin-A1(+), T-bet(+), mutation-specific BRAF V600E(+)",
                    "sub_points": [
                      "DBA.44 (CD76)(+), annexin-A1(+), T-bet(+), mutation-specific BRAF V600E(+)"
                    ]
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "Hairy cell leukemia variant"
                  },
                  {
                    "text": "Splenic diffuse red pulp small B-cell lymphoma"
                  },
                  {
                    "text": "Splenic marginal zone lymphoma/splenic lymphoma with villous lymphocytes"
                  }
                ]
              },
              "Terminology": {
                "Abbreviations": [
                  {
                    "text": "Hairy cell leukemia (HCL)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Leukemic reticuloendotheliosis (no longer used)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "B-cell neoplasm of small to intermediate-sized lymphocytes with oval nuclei and abundant cytoplasm with \"hairy\" projections"
                  },
                  {
                    "text": "Primarily involves blood, bone marrow, and spleen"
                  }
                ]
              },
              "Etiology/Pathogenesis": {
                "Etiology": [
                  {
                    "text": "Unknown; risk associated with genetic features and exposure to agricultural pesticides"
                  }
                ],
                "Cell of Origin": [
                  {
                    "text": "Mature memory B cell arising at post-germinal center cell stage of maturation"
                  }
                ],
                "Pathogenesis": [
                  {
                    "text": "Mitogen-activated protein kinases regulate tumor growth"
                  },
                  {
                    "text": "Hairy cells overexpress an isoform of β-actin that supports \"hairy\" cytoplasmic projections"
                  },
                  {
                    "text": "TNF-α has antiapoptotic effect"
                  },
                  {
                    "text": "Leukemic cells overexpress integrins that bind to splenic red pulp and sinusoids"
                  },
                  {
                    "text": "BRAFV600E mutations are present in almost all casesPathogenic role ofBRAFmutations not yet defined",
                    "sub_points": [
                      "Pathogenic role ofBRAFmutations not yet defined"
                    ]
                  }
                ]
              },
              "Clinical Issues": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "Uncommon (~ 2% of lymphoid leukemias)"
                  }
                ],
                "Age": [
                  {
                    "text": "Middle-aged or elderly adults (median age: 52 years)Uncommon in young adultsExceptionally rare in children",
                    "sub_points": [
                      "Uncommon in young adults",
                      "Exceptionally rare in children"
                    ]
                  }
                ],
                "Gender": [
                  {
                    "text": "M:F = 5:1"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Weakness and fatigue"
                  },
                  {
                    "text": "Left abdominal pain due to splenomegaly"
                  },
                  {
                    "text": "Fever secondary to neutropenia and recurrent opportunistic infectionsMore common in advanced disease",
                    "sub_points": [
                      "More common in advanced disease"
                    ]
                  },
                  {
                    "text": "Bleeding secondary to thrombocytopenia"
                  },
                  {
                    "text": "Massive splenomegaly used to be common but is rather uncommon nowadaysSmaller spleen size is related to earlier detection of disease",
                    "sub_points": [
                      "Smaller spleen size is related to earlier detection of disease"
                    ]
                  },
                  {
                    "text": "Hepatomegaly"
                  },
                  {
                    "text": "Lymph node involvement is uncommon and often minimalMore common 20-30 years ago (due to late disease detection)",
                    "sub_points": [
                      "More common 20-30 years ago (due to late disease detection)"
                    ]
                  }
                ],
                "Laboratory Tests": [
                  {
                    "text": "CBC and peripheral blood smearPancytopenia is typicalMonocytopenia is characteristic of HCLCirculating hairy cells are identified, usually in small numbersHairy cells are small to intermediate in size, with moderately abundant pale cytoplasmCytoplasmic projections (\"hairs\") are typically circumferentialCentral oval to bean-shaped nucleus with uniform chromatin; no nucleolusCytoplasmic vacuoles or inclusions that represent ribosomal-lamellar complexes",
                    "sub_points": [
                      "Pancytopenia is typical",
                      "Monocytopenia is characteristic of HCL",
                      "Circulating hairy cells are identified, usually in small numbersHairy cells are small to intermediate in size, with moderately abundant pale cytoplasmCytoplasmic projections (\"hairs\") are typically circumferentialCentral oval to bean-shaped nucleus with uniform chromatin; no nucleolusCytoplasmic vacuoles or inclusions that represent ribosomal-lamellar complexes",
                      "Hairy cells are small to intermediate in size, with moderately abundant pale cytoplasm",
                      "Cytoplasmic projections (\"hairs\") are typically circumferential",
                      "Central oval to bean-shaped nucleus with uniform chromatin; no nucleolus",
                      "Cytoplasmic vacuoles or inclusions that represent ribosomal-lamellar complexes"
                    ]
                  },
                  {
                    "text": "Bone marrow biopsyHCL involves bone marrow in interstitial or diffuse patternReticulin fibrosis is commonAspiration is often \"dry tap\" due to fibrosis",
                    "sub_points": [
                      "HCL involves bone marrow in interstitial or diffuse patternReticulin fibrosis is common",
                      "Reticulin fibrosis is common",
                      "Aspiration is often \"dry tap\" due to fibrosis"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "Current therapy: Cladribine or pentostatin (purine analogs) administered as single agents> 80% of patients achieve complete remissionRelapse rate at 10 years: ~ 40%",
                    "sub_points": [
                      "> 80% of patients achieve complete remission",
                      "Relapse rate at 10 years: ~ 40%"
                    ]
                  },
                  {
                    "text": "Rituximab may be useful for patients with refractory or recurrent diseaseAnti-CD22 and anti-CD25 monoclonal antibodies are experimentalPromise for BRAF inhibitors, such as vemurafenib, for patients with refractory disease",
                    "sub_points": [
                      "Anti-CD22 and anti-CD25 monoclonal antibodies are experimental",
                      "Promise for BRAF inhibitors, such as vemurafenib, for patients with refractory disease"
                    ]
                  },
                  {
                    "text": "Splenectomy or IFN-α was used in the pastRelapse occurred in ~ 30% of patients",
                    "sub_points": [
                      "Relapse occurred in ~ 30% of patients"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Excellent, with 10-year survival rate of ~ 90%Median survival: > 12 years",
                    "sub_points": [
                      "Median survival: > 12 years"
                    ]
                  },
                  {
                    "text": "High risk of 2nd malignant neoplasmUp to 30% of long-term survivorsHodgkin lymphoma, non-Hodgkin lymphomaMany different types of solid tumors",
                    "sub_points": [
                      "Up to 30% of long-term survivors",
                      "Hodgkin lymphoma, non-Hodgkin lymphoma",
                      "Many different types of solid tumors"
                    ]
                  }
                ]
              },
              "Macroscopic Features": {
                "General Features": [
                  {
                    "text": "Enlarged spleen with homogeneous beefy-red surfaceWhite pulp absent or inconspicuousRed pulp may appear hemorrhagic in areas of blood lakesNecrosis is unusual (unless secondary infarct)",
                    "sub_points": [
                      "White pulp absent or inconspicuous",
                      "Red pulp may appear hemorrhagic in areas of blood lakes",
                      "Necrosis is unusual (unless secondary infarct)"
                    ]
                  }
                ]
              },
              "Microscopic Pathology": {
                "Histologic Features": [
                  {
                    "text": "Diffuse effacement of red pulp (cords and sinuses)"
                  },
                  {
                    "text": "Red cell lakes and pseudosinusesRange from microscopic to grossly visibleConsequence of disruption of normal blood flow to red pulpBlood lakes are surrounded by hairy cells without endothelial lining",
                    "sub_points": [
                      "Range from microscopic to grossly visible",
                      "Consequence of disruption of normal blood flow to red pulp",
                      "Blood lakes are surrounded by hairy cells without endothelial lining"
                    ]
                  },
                  {
                    "text": "White pulp is absent or atrophic"
                  },
                  {
                    "text": "Cytologic featuresHairy cells have oval to bean-shaped nuclei and abundant clear cytoplasmNonoverlapping, widely spaced nuclei and pale cytoplasm (\"fried egg\" appearance)Mitotic figures are rare or absent",
                    "sub_points": [
                      "Hairy cells have oval to bean-shaped nuclei and abundant clear cytoplasm",
                      "Nonoverlapping, widely spaced nuclei and pale cytoplasm (\"fried egg\" appearance)",
                      "Mitotic figures are rare or absent"
                    ]
                  },
                  {
                    "text": "Rare cases of blastic HCL are reportedLarge cells with atypia, numerous mitotic figures, and sometimes necrosisTypical immunophenotypeSome patients have history of typical HCL",
                    "sub_points": [
                      "Large cells with atypia, numerous mitotic figures, and sometimes necrosis",
                      "Typical immunophenotype",
                      "Some patients have history of typical HCL"
                    ]
                  }
                ],
                "Lymph Nodes": [
                  {
                    "text": "Typically involves paracortical regions of lymph nodeFollicles are spared; sinuses are usually patent",
                    "sub_points": [
                      "Follicles are spared; sinuses are usually patent"
                    ]
                  }
                ]
              },
              "Ancillary Tests": {
                "Immunohistochemistry": [
                  {
                    "text": "Pan-B-cell antigens (+), pan-T-cell antigens (-)"
                  },
                  {
                    "text": "DBA.44 (CD76)(+), CD25(+), CD103(+), CD123(+), T-bet(+), TRAP(+)"
                  },
                  {
                    "text": "Annexin-A1 is specific for HCL among B-cell lymphoid neoplasmsAlso (+) in granulocytes and T cellsCan be difficult to use in partially involved bone marrow specimens",
                    "sub_points": [
                      "Also (+) in granulocytes and T cells",
                      "Can be difficult to use in partially involved bone marrow specimens"
                    ]
                  },
                  {
                    "text": "Bcl-2(+), CD45/LCA(+); CD10(-), Bcl-6(-)"
                  },
                  {
                    "text": "Cyclin-D1 weakly (+) in subset of cells"
                  },
                  {
                    "text": "Associated T-lymphocytes are cytotoxic: CD3(+), CD8(+), CD57(+)"
                  },
                  {
                    "text": "Mutation-specific BRAF V600E antibody is (+) in > 80% of HCL casesMonoclonal antibody raised against the most frequent point mutationCytoplasmic pattern of reactivity",
                    "sub_points": [
                      "Monoclonal antibody raised against the most frequent point mutation",
                      "Cytoplasmic pattern of reactivity"
                    ]
                  }
                ],
                "Flow Cytometry": [
                  {
                    "text": "Immunophenotype of HCL is characteristic"
                  },
                  {
                    "text": "Bright surface Ig light chain (lambda > kappa),HCL can express surface IgM, IgD, or IgGRarely, 2 Ig heavy chains are expressed",
                    "sub_points": [
                      "HCL can express surface IgM, IgD, or IgG",
                      "Rarely, 2 Ig heavy chains are expressed"
                    ]
                  },
                  {
                    "text": "CD19(+), CD20(+), and bright CD11c(+) and CD22(+)"
                  },
                  {
                    "text": "CD25(+), CD103(+), CD123(+), CD200/OX2(+), and FMC7(+)"
                  },
                  {
                    "text": "Negative for CD5, CD10, and CD23Rare cases reported positive for CD5 or CD10",
                    "sub_points": [
                      "Rare cases reported positive for CD5 or CD10"
                    ]
                  }
                ],
                "Cytogenetics": [
                  {
                    "text": "No recurrent structural or numerical cytogenetic abnormalities"
                  }
                ],
                "Molecular Genetics": [
                  {
                    "text": "Monoclonal Ig gene rearrangements"
                  },
                  {
                    "text": "Most cases show somatic hypermutation in IgH variable region genesConsistent with post-germinal center cell stage of maturationUnmutatedIGHVgenes correlate with aggressive course",
                    "sub_points": [
                      "Consistent with post-germinal center cell stage of maturation",
                      "UnmutatedIGHVgenes correlate with aggressive course"
                    ]
                  },
                  {
                    "text": "BRAFV600E mutation detected in ~ 100% of HCL casesHot spots in exons 11 (codon 468) and 15 (codons 595-600)Only ~ 1% of other B-cell lymphoproliferative disorders carry the mutation",
                    "sub_points": [
                      "Hot spots in exons 11 (codon 468) and 15 (codons 595-600)",
                      "Only ~ 1% of other B-cell lymphoproliferative disorders carry the mutation"
                    ]
                  },
                  {
                    "text": "Gene expression profiling shows upregulation of cytokines and adhesion molecules"
                  },
                  {
                    "text": "Array-based comparative genomic hybridization: HCL has stable genome"
                  },
                  {
                    "text": "Associated T-lymphocytes can show monoclonal or oligoclonal T-cell receptor gene rearrangements"
                  }
                ],
                "Electron Microscopy": [
                  {
                    "text": "Ribosome-lamellar bodies are characteristic but not specific"
                  }
                ],
                "Cytochemistry": [
                  {
                    "text": "Tartrate-resistant acid phosphatase (TRAP) shows cytoplasmic granules in HCL cellsAcid phosphatase often appears brighter in HCL cells after tartrate treatment",
                    "sub_points": [
                      "Acid phosphatase often appears brighter in HCL cells after tartrate treatment"
                    ]
                  }
                ]
              },
              "Differential Diagnosis": {
                "Hairy Cell Leukemia Variant": [
                  {
                    "text": "Uncommon compared with HCL"
                  },
                  {
                    "text": "Diffuse splenic red pulp involvement similar to HCL"
                  },
                  {
                    "text": "Peripheral blood shows lymphocytosis (often high WBC) and normal monocyte count"
                  },
                  {
                    "text": "Cytologic features of cells differ from those of HCL cellsNuclei have distinct (but not large) nucleoliCytoplasm is clear to basophilic and often has fewer cytoplasmic projections",
                    "sub_points": [
                      "Nuclei have distinct (but not large) nucleoli",
                      "Cytoplasm is clear to basophilic and often has fewer cytoplasmic projections"
                    ]
                  },
                  {
                    "text": "TRAP cytochemistry is typically negative (or weakly positive)"
                  },
                  {
                    "text": "Immunophenotype: Bright sIg(+), CD11c(+), DBA.44(+), CD103(+/-)Annexin-A1(-/+), CD25(-), CD123(-)",
                    "sub_points": [
                      "Annexin-A1(-/+), CD25(-), CD123(-)"
                    ]
                  },
                  {
                    "text": "Considered provisional entity in 2008 WHO classification"
                  }
                ],
                "Splenic Diffuse Red Pulp Small B-Cell Lymphoma": [
                  {
                    "text": "Predominant red pulp involvement with effacement of white pulp, similar to HCL"
                  },
                  {
                    "text": "Peripheral blood lymphocytes may show villous cytoplasmic projections"
                  },
                  {
                    "text": "Bone marrow involvement commonly has sinusoidal pattern"
                  },
                  {
                    "text": "Immunophenotype: IgM(+), IgD(-), CD5(-), CD11c(+), CD25(-), CD103(-/+), CD123(-)"
                  },
                  {
                    "text": "Relationship of this entity to HCL variant is unclear since both frequently overlap"
                  },
                  {
                    "text": "Currently considered provisional entity in 2008 WHO classification"
                  }
                ],
                "Splenic Marginal Zone Lymphoma/Splenic Lymphoma With Villous Lymphocytes": [
                  {
                    "text": "Marked expansion of white pulp with biphasic patternCenters composed of small lymphocytes (darker) surrounded by larger marginal zone cells with pale cytoplasm",
                    "sub_points": [
                      "Centers composed of small lymphocytes (darker) surrounded by larger marginal zone cells with pale cytoplasm"
                    ]
                  },
                  {
                    "text": "Secondary involvement of red pulp by nodules"
                  },
                  {
                    "text": "TRAP cytochemistry often weakly positive"
                  },
                  {
                    "text": "Immunophenotype: Bright sIg(+), pan-B-cell antigens (+)CD10(-), CD5 (dim -/+), CD23 (dim -/+)",
                    "sub_points": [
                      "CD10(-), CD5 (dim -/+), CD23 (dim -/+)"
                    ]
                  },
                  {
                    "text": "Conventional cytogenetics: del(7q) in ~ 40-50%"
                  }
                ],
                "Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma": [
                  {
                    "text": "Expansion of white pulp forming uniform nodulesRed pulp commonly involvedProliferation centers can be observed when involvement is extensive",
                    "sub_points": [
                      "Red pulp commonly involvedProliferation centers can be observed when involvement is extensive",
                      "Proliferation centers can be observed when involvement is extensive"
                    ]
                  },
                  {
                    "text": "Lymphocytes are round to oval with clumped chromatin and scant cytoplasm"
                  },
                  {
                    "text": "Immunophenotype is distinctiveDim surface Ig light chain (kappa > lambda), IgD(+/-), CD19(+), CD20 (dim +)CD5(+), CD23(+), CD11c(+/-), CD22(-), CD25(-), CD103(-)Annexin-A1(-), T-bet(+)",
                    "sub_points": [
                      "Dim surface Ig light chain (kappa > lambda), IgD(+/-), CD19(+), CD20 (dim +)",
                      "CD5(+), CD23(+), CD11c(+/-), CD22(-), CD25(-), CD103(-)",
                      "Annexin-A1(-), T-bet(+)"
                    ]
                  },
                  {
                    "text": "Trisomy 12, del(13q14), del(11q23), del(17p) common"
                  }
                ],
                "Mantle Cell Lymphoma": [
                  {
                    "text": "Expansion of white pulp forming large nodules with frequent coalescence of nodules"
                  },
                  {
                    "text": "Red pulp involvement as lymphoid aggregates"
                  },
                  {
                    "text": "Lymphocytes are intermediate in size with round to irregular nuclear contoursLarge lymphoid cells are rare or absent (unless blastoid or pleomorphic variants)",
                    "sub_points": [
                      "Large lymphoid cells are rare or absent (unless blastoid or pleomorphic variants)"
                    ]
                  },
                  {
                    "text": "Immunophenotype: CD5(+), CD10(-), CD23(-), sIg(+), pan-B-cell antigens (+)Cyclin-D1 is bright (+)By contrast, HCL is cyclin-D1 (dim +) in ~ 50% of cases~ 10% can be CD23 (dim +); < 5% can be CD5(-)",
                    "sub_points": [
                      "Cyclin-D1 is bright (+)By contrast, HCL is cyclin-D1 (dim +) in ~ 50% of cases",
                      "By contrast, HCL is cyclin-D1 (dim +) in ~ 50% of cases",
                      "~ 10% can be CD23 (dim +); < 5% can be CD5(-)"
                    ]
                  },
                  {
                    "text": "Conventional cytogenetics/FISH: t(11;14)(q13;q32)/CCND1-IGH"
                  }
                ],
                "Systemic Mastocytosis": [
                  {
                    "text": "Mast cells with pale cytoplasm can mimic HCL or marginal zone lymphoma cells"
                  },
                  {
                    "text": "Disease can involve white pulp, red pulp, or both"
                  },
                  {
                    "text": "Aggregates are often associated with eosinophils or granulomas"
                  },
                  {
                    "text": "Perivascular involvement is typical"
                  },
                  {
                    "text": "Air-dried touch preps stained for Giemsa are helpful"
                  },
                  {
                    "text": "Immunophenotype: CD2(+/-), CD25(+/-), CD43(+), CD68(+), CD117(+), tryptase(+)"
                  },
                  {
                    "text": "KITmutation (D816V) in subset of cases"
                  }
                ],
                "Acute Myeloid Leukemia/Myeloid Sarcoma": [
                  {
                    "text": "Acute myeloid leukemia can involve red pulp (alone or preferentially)"
                  },
                  {
                    "text": "Myeloid sarcoma forms mass that often replaces red and white pulp"
                  },
                  {
                    "text": "Cytologic features are helpful: Eosinophilic myelocytes (+/-), cytoplasmic granules (+/-)"
                  },
                  {
                    "text": "Air-dried touch imprints for cytochemistry are helpful"
                  },
                  {
                    "text": "Immunophenotype: MPO(+), CD13(+), CD33(+), CD34(+), CD117(+)"
                  }
                ]
              },
              "Diagnostic Checklist": {
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "Pancytopenia with monocytopenia"
                  },
                  {
                    "text": "Few HCL cells in peripheral blood smear"
                  },
                  {
                    "text": "Interstitial or diffuse pattern in bone marrow\"Fried egg\" appearance at low power",
                    "sub_points": [
                      "\"Fried egg\" appearance at low power"
                    ]
                  },
                  {
                    "text": "Diffuse involvement of red pulp of spleen with effacement of white pulp nodularity"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Hemangioma": {
            "name": "Hemangioma",
            "url": "https://app.pathprimer.com/document/2f8337a9-6976-480a-8e5a-917b9ba43c70/lesson/4659bf0d-8055-4c33-9e2a-78e6f233a411",
            "content": {
              "Key Facts": {
                "Terminology": [
                  {
                    "text": "Benign vascular tumor in the spleen consisting of variably sized blood vessels with flat to plump endothelial cells and no atypia"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Commonly incidental but may present with cytopenias"
                  },
                  {
                    "text": "May be associated with underlying syndromes"
                  }
                ],
                "Macroscopic Features": [
                  {
                    "text": "Normal to massive splenomegaly"
                  },
                  {
                    "text": "Single or multiple lesions"
                  },
                  {
                    "text": "Usually well-defined borders"
                  }
                ],
                "Microscopic Features": [
                  {
                    "text": "Multiple thin-walled vessels"
                  },
                  {
                    "text": "No atypia or mitoses"
                  },
                  {
                    "text": "No necrosis"
                  },
                  {
                    "text": "Extramedullary hematopoiesis is common"
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "AngiosarcomaAtypia, mitoses, necrosis, and irregular boarder",
                    "sub_points": [
                      "Atypia, mitoses, necrosis, and irregular boarder"
                    ]
                  },
                  {
                    "text": "HamartomaDevelopmental lesion consisting exclusively of red pulp",
                    "sub_points": [
                      "Developmental lesion consisting exclusively of red pulp"
                    ]
                  },
                  {
                    "text": "Littoral cell angiomaDistinctive type of angioma with tall and flat endothelial cells",
                    "sub_points": [
                      "Distinctive type of angioma with tall and flat endothelial cells"
                    ]
                  },
                  {
                    "text": "Sclerosing angiomatous nodular tumorSclerosing angiomatous lesion of uncertain etiology",
                    "sub_points": [
                      "Sclerosing angiomatous lesion of uncertain etiology"
                    ]
                  },
                  {
                    "text": "LymphangiomaVacular neoplasm composed of lymphatics",
                    "sub_points": [
                      "Vacular neoplasm composed of lymphatics"
                    ]
                  }
                ]
              },
              "Terminology": {
                "Definitions": [
                  {
                    "text": "Benign vascular tumor consisting of variably sized, interconnected blood vessels with flat to plump endothelial cells and no atypia"
                  }
                ]
              },
              "Clinical Issues": {
                "Presentation": [
                  {
                    "text": "Most common benign neoplasm in spleen"
                  },
                  {
                    "text": "Affects all ages; most commonly seen in adults"
                  },
                  {
                    "text": "Mostly small and incidental"
                  },
                  {
                    "text": "Rarely multifocal"
                  },
                  {
                    "text": "May cause hypersplenism and cytopenias"
                  },
                  {
                    "text": "Rupture can rarely occur"
                  },
                  {
                    "text": "May be associated with syndromes such as Proteus, Kasabach-Merritt, or Klippel-Trenaunay-Weber"
                  }
                ],
                "Treatment": [
                  {
                    "text": "Splenectomy is curative"
                  },
                  {
                    "text": "Partial splenectomy has been successful"
                  },
                  {
                    "text": "Radiofrequency ablation has been used with success"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Symptoms and cytopenias are eliminated with removal"
                  }
                ]
              },
              "Image Findings": {
                "General Features": [
                  {
                    "text": "Imaging studies show a mass with cystic spaces"
                  },
                  {
                    "text": "Multiple small punctate or peripherally curvilinear calcifications may be present"
                  },
                  {
                    "text": "Hemorrhage, infarction, and thrombosis may be present"
                  },
                  {
                    "text": "Isoechogenicity to spleen parenchyma in all phases"
                  }
                ]
              },
              "Macroscopic Features": {
                "General Features": [
                  {
                    "text": "Size of spleen is normal to massively enlarged"
                  },
                  {
                    "text": "Solitary to multiple masses"
                  },
                  {
                    "text": "Well demarcated from surrounding spleen but not encapsulatedOccasional irregular borders",
                    "sub_points": [
                      "Occasional irregular borders"
                    ]
                  },
                  {
                    "text": "Cut surface often shows a dark-red/purple spongy mass"
                  },
                  {
                    "text": "Rarely, diffuse hemangiomatosis with innumerable lesions throughout spleen is seen"
                  }
                ]
              },
              "Microscopic Pathology": {
                "Histologic Features": [
                  {
                    "text": "Dilated variably sized vascular spaces"
                  },
                  {
                    "text": "Thin-walled vessels with lumina filled with red blood cells"
                  },
                  {
                    "text": "Flat to plump endothelial cells without atypia"
                  },
                  {
                    "text": "Mitoses are absent to rare"
                  },
                  {
                    "text": "No necrosis"
                  },
                  {
                    "text": "Solid areas should not be present"
                  },
                  {
                    "text": "Extramedullary hematopoiesis is commonly seen"
                  },
                  {
                    "text": "Connective tissue septaeFibrous bands of variable widthVariable amounts of fibrosis and myxoid change",
                    "sub_points": [
                      "Fibrous bands of variable width",
                      "Variable amounts of fibrosis and myxoid change"
                    ]
                  },
                  {
                    "text": "May undergo changes such as infarction, cystic degeneration, and fibrosisThrombosis, hyalinization, calcification, ossification",
                    "sub_points": [
                      "Thrombosis, hyalinization, calcification, ossification"
                    ]
                  }
                ],
                "Cytologic Features": [
                  {
                    "text": "Variants have been describedCavernousCapillaryPericytic differentiationMyoid differentiationSclerotic",
                    "sub_points": [
                      "Cavernous",
                      "Capillary",
                      "Pericytic differentiation",
                      "Myoid differentiation",
                      "Sclerotic"
                    ]
                  }
                ]
              },
              "Ancillary Tests": {
                "Immunohistochemistry": [
                  {
                    "text": "Positive with vascular markers (CD34, CD31, and factor VIII)"
                  },
                  {
                    "text": "Negative with CD8"
                  }
                ]
              },
              "Differential Diagnosis": {
                "Angiosarcoma": [
                  {
                    "text": "Primary diagnostic differentialMalignant vascular neoplasmSlight to massive splenomegalyAtypical endothelial cellsMitosesNecrosisPapillary focallySolid sarcomatous focally",
                    "sub_points": [
                      "Malignant vascular neoplasm",
                      "Slight to massive splenomegaly",
                      "Atypical endothelial cells",
                      "Mitoses",
                      "Necrosis",
                      "Papillary focally",
                      "Solid sarcomatous focally"
                    ]
                  },
                  {
                    "text": "Types of angiosarcomaKaposi sarcoma; HHV8(+)Littoral cell angiosarcomaRare malignant counterpart to littoral cell angiomaStains similarly to littoral cell angiomaHemangioendothelioma; borderline behavior",
                    "sub_points": [
                      "Kaposi sarcoma; HHV8(+)",
                      "Littoral cell angiosarcomaRare malignant counterpart to littoral cell angiomaStains similarly to littoral cell angioma",
                      "Rare malignant counterpart to littoral cell angioma",
                      "Stains similarly to littoral cell angioma",
                      "Hemangioendothelioma; borderline behavior"
                    ]
                  }
                ],
                "Littoral Cell Angioma": [
                  {
                    "text": "Benign vascular lesion with irregular vascular channels"
                  },
                  {
                    "text": "Vessels lined with tall and basal lining cellsTall lining cells are histocytic: CD31(-), CD34(+), CD68(+), CD163(+)Basilar lining cells are endothelial: CD31(+), CD34(+), factor VIII (+)",
                    "sub_points": [
                      "Tall lining cells are histocytic: CD31(-), CD34(+), CD68(+), CD163(+)",
                      "Basilar lining cells are endothelial: CD31(+), CD34(+), factor VIII (+)"
                    ]
                  }
                ],
                "Sclerosing Angiomatous Nodular Tumor": [
                  {
                    "text": "Nodular benign angiomatous lesion"
                  },
                  {
                    "text": "Single lesion composed of multiple nodules and surrounding sclerosis"
                  },
                  {
                    "text": "Entrapped sinuses are CD8(+)"
                  },
                  {
                    "text": "Entrapped vessels are CD34(+) and CD31(+)"
                  },
                  {
                    "text": "Possibly a form of sclerosing hemangioma"
                  }
                ],
                "Hamartoma": [
                  {
                    "text": "Well defined grossly; difficult to see microscopically"
                  },
                  {
                    "text": "Benign developmental lesion"
                  },
                  {
                    "text": "Composed exclusively of red pulp"
                  },
                  {
                    "text": "Sinuses are CD8(+), CD31(+), CD34(-), factor VIII (-)"
                  }
                ],
                "Lymphangioma": [
                  {
                    "text": "Benign vascular neoplasm composed of lymphatic vessels"
                  },
                  {
                    "text": "Subcapsular"
                  },
                  {
                    "text": "D2-40(+), variable with CD34, CD31, and factor VIII"
                  },
                  {
                    "text": "Commonly large single lesions unless associated with syndromes such as Klippel-Trenaunay-Weber"
                  }
                ],
                "Peliosis": [
                  {
                    "text": "Benign dilation of sinuses near white pulp peripheryMay be extensive",
                    "sub_points": [
                      "May be extensive"
                    ]
                  },
                  {
                    "text": "Sinuses are CD8(+); background vessels are CD34(+)"
                  },
                  {
                    "text": "Etiology is unknown but is associated with steroid use"
                  }
                ],
                "Infection": [
                  {
                    "text": "May be diffuse or focal"
                  },
                  {
                    "text": "Histocytic"
                  },
                  {
                    "text": "Special stains for organisms are positive"
                  }
                ],
                "Metastasis": [
                  {
                    "text": "Single or multiple"
                  },
                  {
                    "text": "Histology of underlying primary neoplasm dictates morphology"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Littoral Cell Angioma": {
            "name": "Littoral Cell Angioma",
            "url": "https://app.pathprimer.com/document/4b0cbb3a-c558-44bb-9831-bc2b4b649c6b/lesson/4659bf0d-8055-4c33-9e2a-78e6f233a411",
            "content": {
              "Key Facts": {
                "Etiology": [
                  {
                    "text": "Benign vascular neoplasm of red pulp lining cells"
                  },
                  {
                    "text": "Lining cells have features of histiocytes and endothelial cells"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Commonly an incidental finding"
                  },
                  {
                    "text": "Occasionally causes sequestration of peripheral blood cells"
                  }
                ],
                "Macroscopic Features": [
                  {
                    "text": "Multiple lesions with spongy appearance"
                  }
                ],
                "Microscopic Features": [
                  {
                    "text": "Vascular spaces filled with blood"
                  },
                  {
                    "text": "Flat and tall lining cellsTall lining cells have histiocytic featuresFlat lining cells have endothelial features",
                    "sub_points": [
                      "Tall lining cells have histiocytic features",
                      "Flat lining cells have endothelial features"
                    ]
                  },
                  {
                    "text": "Extramedullary hematopoiesis is commonly present"
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "ImmunohistochemistryFlat lining cells: CD34(+), factor VIII (+)Tall lining cells: CD68(+), CD163(+), CD21(+)",
                    "sub_points": [
                      "Flat lining cells: CD34(+), factor VIII (+)",
                      "Tall lining cells: CD68(+), CD163(+), CD21(+)"
                    ]
                  },
                  {
                    "text": "Iron stainCommonly positive in histocytes from engulfing erythroid cells",
                    "sub_points": [
                      "Commonly positive in histocytes from engulfing erythroid cells"
                    ]
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "Hemangioma"
                  },
                  {
                    "text": "Angiosarcoma"
                  },
                  {
                    "text": "Hamartoma"
                  },
                  {
                    "text": "Lymphangioma"
                  },
                  {
                    "text": "Sclerosing angiomatous nodular tumor"
                  }
                ]
              },
              "Terminology": {
                "Abbreviations": [
                  {
                    "text": "Littoral cell angioma (LCA)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Relatively rare benign splenic vascular neoplasm thought to arise from red pulp sinus lining cellsShows histiocytic and vascular differentiation",
                    "sub_points": [
                      "Shows histiocytic and vascular differentiation"
                    ]
                  }
                ]
              },
              "Clinical Issues": {
                "Site": [
                  {
                    "text": "Only in spleen; no similar lesion in soft tissueMay occur in accessory spleen",
                    "sub_points": [
                      "May occur in accessory spleen"
                    ]
                  }
                ],
                "Presentation": [
                  {
                    "text": "Multiple lesions, only rarely solitary"
                  },
                  {
                    "text": "Often incidental finding, but may present with hypersplenism and cytopenias"
                  },
                  {
                    "text": "Seen in all age groups"
                  },
                  {
                    "text": "M = F"
                  }
                ],
                "Treatment": [
                  {
                    "text": "Surgical excision (splenectomy) is curative"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Excellent; only rare instances of metastasis are reported, and most likely these are cases of angiosarcoma and not LCA"
                  }
                ]
              },
              "Image Findings": {
                "General Features": [
                  {
                    "text": "Multiple variably sized blood-filled nodules, often throughout entire spleen"
                  },
                  {
                    "text": "Hypodense nodules in a patient with splenomegaly and hypersplenism on CT and MR"
                  }
                ]
              },
              "Macroscopic Features": {
                "General Features": [
                  {
                    "text": "Multiple spongy vascular lesions throughout spleen"
                  },
                  {
                    "text": "Slight to massive splenomegaly"
                  }
                ]
              },
              "Microscopic Pathology": {
                "Histologic Features": [
                  {
                    "text": "Multiple irregular cystic vascular channels in red pulp"
                  },
                  {
                    "text": "Tall lining cellsLCA endothelial cells are often plumpIntracytoplasmic eosinophilic (PAS[+]) globules may be seenPapillary projections into vascular spaces may be presentVascular lumina contain desquamated littoral cells and macrophagesErythrophagocytosis may occur in these cellsTall lining cells are more histocytic in differentiation: CD68(+), CD163(+)",
                    "sub_points": [
                      "LCA endothelial cells are often plump",
                      "Intracytoplasmic eosinophilic (PAS[+]) globules may be seen",
                      "Papillary projections into vascular spaces may be present",
                      "Vascular lumina contain desquamated littoral cells and macrophagesErythrophagocytosis may occur in these cells",
                      "Erythrophagocytosis may occur in these cells",
                      "Tall lining cells are more histocytic in differentiation: CD68(+), CD163(+)"
                    ]
                  },
                  {
                    "text": "Flat lining cellsBasal in locationFlat lining cells are more endothelial in differentiation: CD34(+), CD31(+)",
                    "sub_points": [
                      "Basal in location",
                      "Flat lining cells are more endothelial in differentiation: CD34(+), CD31(+)"
                    ]
                  },
                  {
                    "text": "Extramedullary hematopoiesis is common"
                  }
                ],
                "Cytologic Features": [
                  {
                    "text": "Lining cells have both histocytic and endothelial features"
                  }
                ]
              },
              "Ancillary Tests": {
                "Immunohistochemistry": [
                  {
                    "text": "Tall lining cells: CD68(+), CD163(+), factor VIII (+), CD34(-), CD31(-), focal S100(+), CD21(+)"
                  },
                  {
                    "text": "Flat basal lining cells: CD31(+), CD34(+/-), CD8(-), CD163(-), CD68(-), factor VIII (+)"
                  },
                  {
                    "text": "CD8 is often negative but can be positive"
                  }
                ]
              },
              "Differential Diagnosis": {
                "Hemangioma": [
                  {
                    "text": "Thin-walled vascular neoplasm without atypia"
                  },
                  {
                    "text": "Endothelial lining cells are positive with vascular stains (CD34, CD31, and factor VIII)"
                  },
                  {
                    "text": "No histiocytic features, i.e., CD68(-), CD163(-)"
                  }
                ],
                "Angiosarcoma": [
                  {
                    "text": "Malignant vascular neoplasm"
                  },
                  {
                    "text": "More atypia, interanastomosing vascular channels, necrosis, and mitoses than in LCA"
                  },
                  {
                    "text": "Endothelial lining cells are CD34(+), CD31(+), and factor VIII (+)Littoral cell angiosarcomaVery rare but describedCytology similar to that of LCA, but lining cells are atypical",
                    "sub_points": [
                      "Littoral cell angiosarcomaVery rare but describedCytology similar to that of LCA, but lining cells are atypical",
                      "Very rare but described",
                      "Cytology similar to that of LCA, but lining cells are atypical"
                    ]
                  }
                ],
                "Hemangioendothelioma": [
                  {
                    "text": "Borderline malignant"
                  },
                  {
                    "text": "More atypia than LCA"
                  }
                ],
                "Kaposi Sarcoma": [
                  {
                    "text": "Associated with HIV and human herpesvirus 8"
                  },
                  {
                    "text": "Spindled flat malignant endothelial cells"
                  },
                  {
                    "text": "Eosinophilic globules"
                  }
                ],
                "Hamartoma": [
                  {
                    "text": "Benign tumor; most likely developmental"
                  },
                  {
                    "text": "Spleen with exclusively red pulp componentsCD8 highlights the red pulp sinusesCD34, CD31, and factor VIII are negative except in incidental vessels",
                    "sub_points": [
                      "CD8 highlights the red pulp sinuses",
                      "CD34, CD31, and factor VIII are negative except in incidental vessels"
                    ]
                  },
                  {
                    "text": "Most are asymptomatic and incidental"
                  }
                ],
                "Lymphangioma": [
                  {
                    "text": "Benign vascular tumor composed of lymphatic vessels"
                  },
                  {
                    "text": "Thin-walled cysts containing clear gross fluid and eosinophilic material microscopically"
                  },
                  {
                    "text": "Lymphatic endothelial cells are immunoreactive with D2-40; variable with CD31, CD34, and factor VIII"
                  }
                ],
                "Sclerosing Angiomatous Nodular Tumor": [
                  {
                    "text": "Sclerotic vascular lesion"
                  },
                  {
                    "text": "Commonly an incidental finding"
                  },
                  {
                    "text": "Possible sclerotic capillary hemangioma"
                  },
                  {
                    "text": "Single multilobated nodule with multiple angiomatous nodules surrounded by sclerotic fibrous tissue"
                  },
                  {
                    "text": "Vessels are small, showing CD31(+) and CD34(+)"
                  },
                  {
                    "text": "Entrapped sinuses are CD8(+)"
                  }
                ],
                "Metastasis": [
                  {
                    "text": "Primary neoplasm dictates morphology and immunophenotype"
                  }
                ],
                "Infection": [
                  {
                    "text": "Histiocytes may be increased in number"
                  },
                  {
                    "text": "No vascular channels"
                  },
                  {
                    "text": "Organisms may be present"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Angiosarcoma": {
            "name": "Angiosarcoma",
            "url": "https://app.pathprimer.com/document/6620af2f-649f-4dc5-9d32-c158606c0a0f/lesson/4659bf0d-8055-4c33-9e2a-78e6f233a411",
            "content": {
              "Key Facts": {
                "Terminology": [
                  {
                    "text": "Malignant vascular neoplasm"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Moderate to massive splenomegaly"
                  },
                  {
                    "text": "Rupture can cause hemoperitoneum"
                  },
                  {
                    "text": "Cytopenias, particularly anemia"
                  }
                ],
                "Macroscopic Features": [
                  {
                    "text": "Large spleen"
                  },
                  {
                    "text": "Cut sections are heterogeneousNodular, necrotic, spongy, hemorrhagic",
                    "sub_points": [
                      "Nodular, necrotic, spongy, hemorrhagic"
                    ]
                  },
                  {
                    "text": "Occasional dominant mass"
                  }
                ],
                "Microscopic Features": [
                  {
                    "text": "Variably pleomorphic endothelial tumor cells"
                  },
                  {
                    "text": "Irregular, anastomosing vascular spaces"
                  },
                  {
                    "text": "Variable histology, sometimes deceptively bland"
                  },
                  {
                    "text": "Often nodular mass"
                  },
                  {
                    "text": "Papillary or solid patterns"
                  },
                  {
                    "text": "Cells range from benign appearing to pleomorphic"
                  },
                  {
                    "text": "Necrosis, hemorrhage, mitoses"
                  },
                  {
                    "text": "Infiltrates into normal spleen"
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "HemangiomaCan be particularly hard to distinguish from angiosarcoma; both are treated with splenectomy",
                    "sub_points": [
                      "Can be particularly hard to distinguish from angiosarcoma; both are treated with splenectomy"
                    ]
                  },
                  {
                    "text": "Littoral cell angioma/littoral cell angiosarcomaDistinctive appearance both grossly and microscopicallyTall and basilar lining cells",
                    "sub_points": [
                      "Distinctive appearance both grossly and microscopically",
                      "Tall and basilar lining cells"
                    ]
                  },
                  {
                    "text": "Lymphangioma/lymphangiosarcomaVacular neoplasms composed of lymphatic vesselsSubcapsular and benign appearing",
                    "sub_points": [
                      "Vacular neoplasms composed of lymphatic vessels",
                      "Subcapsular and benign appearing"
                    ]
                  }
                ]
              },
              "Terminology": {
                "Synonyms": [
                  {
                    "text": "Hemangiosarcoma"
                  },
                  {
                    "text": "Hemangioblastoma"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Malignant vascular neoplasm of spleen composed of neoplastic endothelial cells"
                  }
                ]
              },
              "Clinical Issues": {
                "Presentation": [
                  {
                    "text": "Splenomegaly~ 50% with massive splenomegaly (> 1,000 g)",
                    "sub_points": [
                      "~ 50% with massive splenomegaly (> 1,000 g)"
                    ]
                  },
                  {
                    "text": "Cytopenias (primarily anemia)"
                  },
                  {
                    "text": "Rupture and resulting hemoperitoneum may rarely occur"
                  },
                  {
                    "text": "Incidental presentation is uncommon"
                  }
                ],
                "Treatment": [
                  {
                    "text": "Splenectomy"
                  },
                  {
                    "text": "Adjuvant chemotherapy also may be given"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Poor, since this is an aggressive malignant neoplasmMean life expectancy: < 12 monthsAggressive clinical course with wide metastasisPoor prognosis irrespective of treatment",
                    "sub_points": [
                      "Mean life expectancy: < 12 months",
                      "Aggressive clinical course with wide metastasis",
                      "Poor prognosis irrespective of treatment"
                    ]
                  }
                ]
              },
              "Image Findings": {
                "General Features": [
                  {
                    "text": "Moderate to massive splenomegaly"
                  },
                  {
                    "text": "Single or multiple masses"
                  },
                  {
                    "text": "Hypodense, inhomogeneous and heterogeneous"
                  }
                ]
              },
              "Macroscopic Features": {
                "General Features": [
                  {
                    "text": "Often massively enlarged spleen"
                  },
                  {
                    "text": "Cut section heterogeneous in appearanceHemorrhagic, nodular, necrotic, spongy, cystic",
                    "sub_points": [
                      "Hemorrhagic, nodular, necrotic, spongy, cystic"
                    ]
                  },
                  {
                    "text": "Well circumscribed to poorly demarcated and infiltrative"
                  },
                  {
                    "text": "Occasionally a single dominant mass can be seen"
                  }
                ]
              },
              "Microscopic Pathology": {
                "Histologic Features": [
                  {
                    "text": "Variable morphology, both within same case and among cases"
                  },
                  {
                    "text": "Pleomorphic endothelial cells, often forming nodular massesMalignant endothelial cells range from benign appearing to bizarre and pleomorphicCan have solid or papillary growth patternsEndothelial multilayering, sometimes spindle cell morphology",
                    "sub_points": [
                      "Malignant endothelial cells range from benign appearing to bizarre and pleomorphic",
                      "Can have solid or papillary growth patterns",
                      "Endothelial multilayering, sometimes spindle cell morphology"
                    ]
                  },
                  {
                    "text": "Irregular infiltrating vascular spacesVacular spaces can be slit-like, honeycomb-like, cavernous, anastomosing, or capillaryNo relationship to preexisting benign vessels",
                    "sub_points": [
                      "Vacular spaces can be slit-like, honeycomb-like, cavernous, anastomosing, or capillary",
                      "No relationship to preexisting benign vessels"
                    ]
                  },
                  {
                    "text": "Hemophagocytosis and necrosis can be present"
                  },
                  {
                    "text": "Hemorrhage, hemosiderin, fibrosis, and calcification can be seen"
                  },
                  {
                    "text": "Increased mitotic figures"
                  },
                  {
                    "text": "Hyaline globules are sometime seen with PAS (particularly in Kaposi-like angiosarcoma)"
                  },
                  {
                    "text": "Tumor infiltrates normal spleen, which is often seen at periphery"
                  }
                ]
              },
              "Ancillary Tests": {
                "Immunohistochemistry": [
                  {
                    "text": "Malignant endothelial cells are positive with at least 1 vascular marker (CD34, CD31, FLI-1, factor VIII)"
                  },
                  {
                    "text": "CD8(-)"
                  }
                ]
              },
              "Differential Diagnosis": {
                "Hemangioma": [
                  {
                    "text": "Primary differential for angiosarcoma"
                  },
                  {
                    "text": "Benign vascular neoplasm"
                  },
                  {
                    "text": "Well-formed vascular structures"
                  },
                  {
                    "text": "No atypia, necrosis, or infiltration"
                  },
                  {
                    "text": "Immunohistochemistry is positive for vascular markers (CD34, CD31, and factor VIII)"
                  },
                  {
                    "text": "Lobular architecture"
                  },
                  {
                    "text": "No multilayered endothelial cells or papillary areas"
                  },
                  {
                    "text": "Only rare mitotic figures"
                  }
                ],
                "Littoral Cell Angioma/Littoral Cell Angiosarcoma": [
                  {
                    "text": "Vascular neoplasms composed of splenic littoral cells"
                  },
                  {
                    "text": "Distinctive appearance with spongy cut surface"
                  },
                  {
                    "text": "Tall and flat lining cellsTall lining cells exhibit histiocytic qualitiesCD68(+), CD163(+), and factor VIII (+/-)Basilar lining cells exhibit endothelial qualitiesCD34(+), CD31(+), and factor VIII (+)",
                    "sub_points": [
                      "Tall lining cells exhibit histiocytic qualitiesCD68(+), CD163(+), and factor VIII (+/-)",
                      "CD68(+), CD163(+), and factor VIII (+/-)",
                      "Basilar lining cells exhibit endothelial qualitiesCD34(+), CD31(+), and factor VIII (+)",
                      "CD34(+), CD31(+), and factor VIII (+)"
                    ]
                  },
                  {
                    "text": "Littoral cell angiosarcoma is similar to littoral cell angioma but has malignant endothelial cells"
                  }
                ],
                "Hamartoma": [
                  {
                    "text": "Benign lesion of uncertain etiology"
                  },
                  {
                    "text": "Composed of red pulp without white pulp"
                  },
                  {
                    "text": "Rarely shows bizarre stromal cells"
                  },
                  {
                    "text": "Immunohistochemistry shows disorganized pattern of splenic sinuses reactive with CD8"
                  }
                ],
                "Lymphangioma/Lymphangiosarcoma": [
                  {
                    "text": "Neoplasms composed of lymphatic vessels"
                  },
                  {
                    "text": "Endothelial cells are variably immunoreactive with CD34, CD31, and factor VIII but strongly positive with D2-40"
                  },
                  {
                    "text": "Lymphangiosarcoma are malignant vascular neoplasms composed of lymphatic vesselsSimilar phenotype to lymphangioma",
                    "sub_points": [
                      "Similar phenotype to lymphangioma"
                    ]
                  }
                ],
                "Sclerosing Angiomatoid Nodular Transformation": [
                  {
                    "text": "Benign vascular lesion of unknown etiology"
                  },
                  {
                    "text": "Often solitary lesion composed of micronodules with a central scar"
                  },
                  {
                    "text": "Surrounded by sclerosis"
                  },
                  {
                    "text": "No atypia or necrosis"
                  },
                  {
                    "text": "3 cell typesCapillaries: CD34(+), CD31(+), CD8(-)Sinuses: CD8(+), CD31(+), CD34(-)Small veins: CD31(+), CD8(-), CD34(-)",
                    "sub_points": [
                      "Capillaries: CD34(+), CD31(+), CD8(-)",
                      "Sinuses: CD8(+), CD31(+), CD34(-)",
                      "Small veins: CD31(+), CD8(-), CD34(-)"
                    ]
                  }
                ],
                "Peliosis": [
                  {
                    "text": "Benign dilation of red pulp sinuses, which may be extensive"
                  },
                  {
                    "text": "Sinuses are CD8(+)"
                  }
                ],
                "Metastasis": [
                  {
                    "text": "Malignant collection of cells"
                  },
                  {
                    "text": "Primary neoplasm presupposes the staining characteristics"
                  }
                ]
              },
              "Selected References": {}
            }
          }
        }
      }
    }
  }
}